0000885725-24-000046.txt : 20240501 0000885725-24-000046.hdr.sgml : 20240501 20240501160548 ACCESSION NUMBER: 0000885725-24-000046 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 78 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240501 DATE AS OF CHANGE: 20240501 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 24902938 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 10-Q 1 bsx-20240331.htm 10-Q bsx-20240331
000088572512/312024Q1false31531434135925400008857252024-01-012024-03-310000885725us-gaap:CommonStockMember2024-01-012024-03-310000885725bsx:SeniorNotedue2027Member2024-01-012024-03-31iso4217:USDxbrli:shares00008857252024-04-29xbrli:sharesiso4217:USD00008857252023-01-012023-03-3100008857252024-03-3100008857252023-12-310000885725us-gaap:CommonStockMember2024-03-310000885725us-gaap:PreferredStockMember2023-12-310000885725us-gaap:PreferredStockMember2022-12-310000885725us-gaap:PreferredStockMember2024-01-012024-03-310000885725us-gaap:PreferredStockMember2023-01-012023-03-310000885725us-gaap:PreferredStockMember2024-03-310000885725us-gaap:PreferredStockMember2023-03-310000885725us-gaap:CommonStockMember2023-12-310000885725us-gaap:CommonStockMember2022-12-310000885725us-gaap:CommonStockMember2024-01-012024-03-310000885725us-gaap:CommonStockMember2023-01-012023-03-310000885725us-gaap:CommonStockMember2023-03-310000885725us-gaap:TreasuryStockCommonMember2023-12-310000885725us-gaap:TreasuryStockCommonMember2022-12-310000885725us-gaap:TreasuryStockCommonMember2024-01-012024-03-310000885725us-gaap:TreasuryStockCommonMember2023-01-012023-03-310000885725us-gaap:TreasuryStockCommonMember2024-03-310000885725us-gaap:TreasuryStockCommonMember2023-03-310000885725us-gaap:AdditionalPaidInCapitalMember2023-12-310000885725us-gaap:AdditionalPaidInCapitalMember2022-12-310000885725us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000885725us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000885725us-gaap:AdditionalPaidInCapitalMember2024-03-310000885725us-gaap:AdditionalPaidInCapitalMember2023-03-310000885725us-gaap:RetainedEarningsMember2023-12-310000885725us-gaap:RetainedEarningsMember2022-12-310000885725us-gaap:RetainedEarningsMember2024-01-012024-03-310000885725us-gaap:RetainedEarningsMember2023-01-012023-03-310000885725us-gaap:RetainedEarningsMember2024-03-310000885725us-gaap:RetainedEarningsMember2023-03-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100008857252023-03-310000885725us-gaap:NoncontrollingInterestMember2023-12-310000885725us-gaap:NoncontrollingInterestMember2022-12-310000885725us-gaap:NoncontrollingInterestMember2024-01-012024-03-310000885725us-gaap:NoncontrollingInterestMember2023-01-012023-03-310000885725us-gaap:NoncontrollingInterestMember2024-03-310000885725us-gaap:NoncontrollingInterestMember2023-03-3100008857252022-12-310000885725bsx:AxonicsMember2024-01-08xbrli:pure0000885725bsx:AxonicsMember2024-01-082024-01-080000885725bsx:AcotecMember2023-02-200000885725bsx:AcotecMember2023-02-202023-02-20iso4217:HKD0000885725bsx:AcotecMember2024-01-012024-03-310000885725bsx:AcotecMember2024-03-310000885725bsx:AcotecMember2023-02-200000885725bsx:AcotecMemberus-gaap:TechnologyBasedIntangibleAssetsMember2024-03-310000885725bsx:AcotecMemberus-gaap:TechnologyBasedIntangibleAssetsMember2024-01-012024-03-310000885725srt:WeightedAverageMemberbsx:AcotecMemberus-gaap:TechnologyBasedIntangibleAssetsMember2024-03-310000885725bsx:AcotecMemberus-gaap:CustomerRelationshipsMember2024-03-310000885725bsx:AcotecMemberus-gaap:CustomerRelationshipsMember2024-01-012024-03-310000885725srt:WeightedAverageMemberbsx:AcotecMemberus-gaap:CustomerRelationshipsMember2024-03-310000885725us-gaap:OtherIntangibleAssetsMemberbsx:AcotecMember2024-03-310000885725us-gaap:OtherIntangibleAssetsMemberbsx:AcotecMember2024-01-012024-03-310000885725us-gaap:OtherIntangibleAssetsMembersrt:WeightedAverageMemberbsx:AcotecMember2024-03-310000885725bsx:AllBusinessAcquisitionsMember2024-03-310000885725bsx:RevenueBasedPaymentsMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-03-310000885725srt:MinimumMemberbsx:RevenueBasedPaymentsMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-03-31utr:Rate0000885725srt:MaximumMemberbsx:RevenueBasedPaymentsMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-03-310000885725srt:WeightedAverageMemberbsx:RevenueBasedPaymentsMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-03-310000885725us-gaap:TechnologyBasedIntangibleAssetsMember2024-03-310000885725us-gaap:TechnologyBasedIntangibleAssetsMember2023-12-310000885725us-gaap:PatentsMember2024-03-310000885725us-gaap:PatentsMember2023-12-310000885725us-gaap:OtherIntangibleAssetsMember2024-03-310000885725us-gaap:OtherIntangibleAssetsMember2023-12-310000885725us-gaap:GoodwillMember2024-03-310000885725us-gaap:GoodwillMember2023-12-310000885725us-gaap:InProcessResearchAndDevelopmentMember2024-03-310000885725us-gaap:InProcessResearchAndDevelopmentMember2023-12-310000885725us-gaap:TechnologyBasedIntangibleAssetsMember2024-03-310000885725us-gaap:TechnologyBasedIntangibleAssetsMember2023-12-310000885725bsx:MedsurgMember2023-12-310000885725bsx:CardiovascularMember2023-12-310000885725bsx:MedsurgMember2024-01-012024-03-310000885725bsx:CardiovascularMember2024-01-012024-03-310000885725bsx:MedsurgMember2024-03-310000885725bsx:CardiovascularMember2024-03-310000885725bsx:December2027NotesMember2024-03-31iso4217:EUR0000885725bsx:December2027NotesMember2023-12-310000885725us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2024-01-012024-03-310000885725us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-31bsx:derivative_instrument0000885725us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000885725us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2024-03-310000885725us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2023-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMember2024-03-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMember2023-12-310000885725bsx:ForeigncurrencydenominatedindebtMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2024-03-310000885725bsx:ForeigncurrencydenominatedindebtMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2023-12-310000885725us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2024-03-310000885725us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2023-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2024-03-31bsx:units0000885725us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2024-03-310000885725us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMember2024-01-012024-03-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:InterestExpenseMemberus-gaap:ForeignExchangeContractMember2024-01-012024-03-310000885725bsx:ForeigncurrencydenominatedindebtMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:InterestExpenseMember2024-01-012024-03-310000885725us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMemberus-gaap:InterestRateContractMember2024-01-012024-03-310000885725us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMember2023-01-012023-03-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:InterestExpenseMemberus-gaap:ForeignExchangeContractMember2023-01-012023-03-310000885725bsx:ForeigncurrencydenominatedindebtMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:InterestExpenseMember2023-01-012023-03-310000885725us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMemberus-gaap:InterestRateContractMember2023-01-012023-03-310000885725us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-03-310000885725us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-03-310000885725us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMember2024-03-310000885725us-gaap:NetInvestmentHedgingMemberus-gaap:InterestExpenseMemberus-gaap:ForeignExchangeContractMember2024-03-310000885725us-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMemberus-gaap:InterestRateContractMember2024-03-310000885725us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NondesignatedMember2024-01-012024-03-310000885725us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NondesignatedMember2023-01-012023-03-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-03-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:ForeignExchangeContractMember2024-03-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:ForeignExchangeContractMember2023-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000885725us-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000885725us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-03-310000885725us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMember2024-03-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMember2023-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-03-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-03-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-12-310000885725us-gaap:NondesignatedMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMember2024-03-310000885725us-gaap:NondesignatedMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMember2023-12-310000885725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-03-310000885725us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000885725us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000885725us-gaap:FairValueMeasurementsRecurringMember2024-03-310000885725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310000885725us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000885725us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000885725us-gaap:FairValueMeasurementsRecurringMember2023-12-310000885725us-gaap:FairValueInputsLevel3Member2024-03-310000885725bsx:LicensingarrangementassetsMember2024-03-310000885725bsx:LicensingarrangementassetsMembersrt:WeightedAverageMember2024-03-310000885725bsx:LicensingarrangementliabilitiesMembersrt:MinimumMember2024-03-310000885725srt:MaximumMemberbsx:LicensingarrangementliabilitiesMember2024-03-310000885725bsx:LicensingarrangementliabilitiesMembersrt:WeightedAverageMember2024-03-310000885725bsx:LicensingarrangementassetsMember2024-01-012024-03-310000885725bsx:LicensingarrangementliabilitiesMember2024-01-012024-03-310000885725bsx:March2025NotesMember2024-03-310000885725bsx:March2025NotesMember2023-12-310000885725bsx:June2025NotesMember2024-03-310000885725bsx:June2025NotesMember2023-12-310000885725bsx:March2026NotesMember2024-03-310000885725bsx:March2026NotesMember2023-12-310000885725bsx:March2028SeniorNotesMember2024-03-310000885725bsx:March2028SeniorNotesMember2023-12-310000885725bsx:March2028NotesMember2024-03-310000885725bsx:March2028NotesMember2023-12-310000885725bsx:March2029NotesMember2024-03-310000885725bsx:March2029NotesMember2023-12-310000885725bsx:March2029EuroSeniorNotesMember2024-03-310000885725bsx:March2029EuroSeniorNotesMember2023-12-310000885725bsx:June2030NotesMember2024-03-310000885725bsx:June2030NotesMember2023-12-310000885725bsx:March2031NotesMember2024-03-310000885725bsx:March2031NotesMember2023-12-310000885725bsx:March2032EuroSeniorNotesMember2024-03-310000885725bsx:March2032EuroSeniorNotesMember2023-12-310000885725bsx:March2034NotesMember2024-03-310000885725bsx:March2034NotesMember2023-12-310000885725bsx:November2035NotesMember2024-03-310000885725bsx:November2035NotesMember2023-12-310000885725bsx:March2039NotesMember2024-03-310000885725bsx:March2039NotesMember2023-12-310000885725bsx:January2040NotesMember2024-03-310000885725bsx:January2040NotesMember2023-12-310000885725bsx:March2049NotesMember2024-03-310000885725bsx:March2049NotesMember2023-12-310000885725us-gaap:SeniorNotesMember2024-03-310000885725us-gaap:SeniorNotesMember2023-12-310000885725us-gaap:CapitalLeaseObligationsMember2024-03-310000885725us-gaap:CapitalLeaseObligationsMember2023-12-310000885725bsx:CreditRatingAOrA3OrHigherMemberbsx:November2035NotesMember2024-03-310000885725us-gaap:RevolvingCreditFacilityMember2021-05-100000885725us-gaap:RevolvingCreditFacilityMember2021-05-102021-05-100000885725us-gaap:RevolvingCreditFacilityMember2024-03-310000885725us-gaap:RevolvingCreditFacilityMember2023-12-310000885725bsx:CurrentRequirementMember2024-03-310000885725bsx:ActualCovenantMember2024-03-310000885725bsx:RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember2024-03-310000885725bsx:RequirementFourSucceedingQuartersFollowingQualifiedAcquisitionMember2024-03-310000885725bsx:RequirementfifthquarterfollowingqualifiedacquisitionMember2024-03-310000885725bsx:RequirementSixthQuarterFollowingQualifiedAcquisitionMember2024-03-310000885725bsx:RequirementSeventhQuarterFollowingQualifiedAcquisitionMember2024-03-310000885725bsx:RequirementEighthQuarterFollowingQualifiedAcquisitionAndThroughRemainingTermOfFacilityMember2024-03-310000885725us-gaap:CommercialPaperMember2023-12-310000885725us-gaap:CommercialPaperMember2024-03-310000885725bsx:TheOfferingAggregatePrincipalAmountMember2024-02-220000885725bsx:March2029EuroSeniorNotesMember2024-02-220000885725bsx:March2032EuroSeniorNotesMember2024-02-220000885725bsx:March2024NotesMember2024-03-310000885725bsx:AMSEuropeMember2024-01-012024-03-310000885725bsx:EuroDenominatedFactoringArrangementsMember2024-03-310000885725bsx:EuroDenominatedFactoringArrangementsMember2024-01-012024-03-310000885725bsx:EuroDenominatedFactoringArrangementsMember2023-12-310000885725bsx:EuroDenominatedFactoringArrangementsMember2023-01-012023-12-310000885725bsx:YenDenominatedFactoringArrangementsMember2024-03-310000885725bsx:YenDenominatedFactoringArrangementsMember2024-01-012024-03-310000885725bsx:YenDenominatedFactoringArrangementsMember2023-12-310000885725bsx:YenDenominatedFactoringArrangementsMember2023-01-012023-12-310000885725bsx:RenminbiDenominatedFactoringArrangementsMember2024-03-310000885725bsx:RenminbiDenominatedFactoringArrangementsMember2024-01-012024-03-310000885725bsx:RenminbiDenominatedFactoringArrangementsMember2023-12-310000885725bsx:RenminbiDenominatedFactoringArrangementsMember2023-01-012023-12-3100008857252023-01-312023-01-310000885725bsx:A550MCPSSeriesAMember2020-05-270000885725bsx:A550MCPSSeriesAMember2020-05-272020-05-270000885725bsx:A550MCPSSeriesAMember2023-06-010000885725us-gaap:EmployeeStockOptionMember2024-01-012024-03-310000885725us-gaap:EmployeeStockOptionMember2023-01-012023-03-310000885725bsx:A550MCPSSeriesAMember2024-01-012024-03-310000885725bsx:A550MCPSSeriesAMember2023-01-012023-03-3100008857252020-12-14bsx:reportablesegments0000885725bsx:MedsurgMember2023-01-012023-03-310000885725bsx:CardiovascularMember2023-01-012023-03-310000885725bsx:BSXReportableSegmentsMember2024-01-012024-03-310000885725bsx:BSXReportableSegmentsMember2023-01-012023-03-310000885725bsx:TotalAllocatedToReportableSegmentsMember2024-01-012024-03-310000885725bsx:TotalAllocatedToReportableSegmentsMember2023-01-012023-03-310000885725bsx:CorporateExpensesincludinghedgingactivitiesMember2024-01-012024-03-310000885725bsx:CorporateExpensesincludinghedgingactivitiesMember2023-01-012023-03-310000885725bsx:SpecialChargesMember2024-01-012024-03-310000885725bsx:SpecialChargesMember2023-01-012023-03-31bsx:business0000885725country:USbsx:GlobalEndoscopyEndoReportingUnitMember2024-01-012024-03-310000885725us-gaap:NonUsMemberbsx:GlobalEndoscopyEndoReportingUnitMember2024-01-012024-03-310000885725bsx:GlobalEndoscopyEndoReportingUnitMember2024-01-012024-03-310000885725country:USbsx:GlobalEndoscopyEndoReportingUnitMember2023-01-012023-03-310000885725us-gaap:NonUsMemberbsx:GlobalEndoscopyEndoReportingUnitMember2023-01-012023-03-310000885725bsx:GlobalEndoscopyEndoReportingUnitMember2023-01-012023-03-310000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMembercountry:US2024-01-012024-03-310000885725us-gaap:NonUsMemberbsx:GlobalUrologyandPelvicHealthReportingUnitMember2024-01-012024-03-310000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMember2024-01-012024-03-310000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMembercountry:US2023-01-012023-03-310000885725us-gaap:NonUsMemberbsx:GlobalUrologyandPelvicHealthReportingUnitMember2023-01-012023-03-310000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMember2023-01-012023-03-310000885725bsx:GlobalNeuromodulationNmReportingUnitMembercountry:US2024-01-012024-03-310000885725us-gaap:NonUsMemberbsx:GlobalNeuromodulationNmReportingUnitMember2024-01-012024-03-310000885725bsx:GlobalNeuromodulationNmReportingUnitMember2024-01-012024-03-310000885725bsx:GlobalNeuromodulationNmReportingUnitMembercountry:US2023-01-012023-03-310000885725us-gaap:NonUsMemberbsx:GlobalNeuromodulationNmReportingUnitMember2023-01-012023-03-310000885725bsx:GlobalNeuromodulationNmReportingUnitMember2023-01-012023-03-310000885725bsx:MedsurgMembercountry:US2024-01-012024-03-310000885725us-gaap:NonUsMemberbsx:MedsurgMember2024-01-012024-03-310000885725bsx:MedsurgMembercountry:US2023-01-012023-03-310000885725us-gaap:NonUsMemberbsx:MedsurgMember2023-01-012023-03-310000885725bsx:InterventionalCardiologyTherapiesMembercountry:US2024-01-012024-03-310000885725us-gaap:NonUsMemberbsx:InterventionalCardiologyTherapiesMember2024-01-012024-03-310000885725bsx:InterventionalCardiologyTherapiesMember2024-01-012024-03-310000885725bsx:InterventionalCardiologyTherapiesMembercountry:US2023-01-012023-03-310000885725us-gaap:NonUsMemberbsx:InterventionalCardiologyTherapiesMember2023-01-012023-03-310000885725bsx:InterventionalCardiologyTherapiesMember2023-01-012023-03-310000885725bsx:WatchmanMembercountry:US2024-01-012024-03-310000885725us-gaap:NonUsMemberbsx:WatchmanMember2024-01-012024-03-310000885725bsx:WatchmanMember2024-01-012024-03-310000885725bsx:WatchmanMembercountry:US2023-01-012023-03-310000885725us-gaap:NonUsMemberbsx:WatchmanMember2023-01-012023-03-310000885725bsx:WatchmanMember2023-01-012023-03-310000885725bsx:CardiacRhythmManagementMembercountry:US2024-01-012024-03-310000885725us-gaap:NonUsMemberbsx:CardiacRhythmManagementMember2024-01-012024-03-310000885725bsx:CardiacRhythmManagementMember2024-01-012024-03-310000885725bsx:CardiacRhythmManagementMembercountry:US2023-01-012023-03-310000885725us-gaap:NonUsMemberbsx:CardiacRhythmManagementMember2023-01-012023-03-310000885725bsx:CardiacRhythmManagementMember2023-01-012023-03-310000885725bsx:ElectrophysiologyEPMembercountry:US2024-01-012024-03-310000885725us-gaap:NonUsMemberbsx:ElectrophysiologyEPMember2024-01-012024-03-310000885725bsx:ElectrophysiologyEPMember2024-01-012024-03-310000885725bsx:ElectrophysiologyEPMembercountry:US2023-01-012023-03-310000885725us-gaap:NonUsMemberbsx:ElectrophysiologyEPMember2023-01-012023-03-310000885725bsx:ElectrophysiologyEPMember2023-01-012023-03-310000885725bsx:GlobalCardiologyReportingUnitMembercountry:US2024-01-012024-03-310000885725us-gaap:NonUsMemberbsx:GlobalCardiologyReportingUnitMember2024-01-012024-03-310000885725bsx:GlobalCardiologyReportingUnitMember2024-01-012024-03-310000885725bsx:GlobalCardiologyReportingUnitMembercountry:US2023-01-012023-03-310000885725us-gaap:NonUsMemberbsx:GlobalCardiologyReportingUnitMember2023-01-012023-03-310000885725bsx:GlobalCardiologyReportingUnitMember2023-01-012023-03-310000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMembercountry:US2024-01-012024-03-310000885725us-gaap:NonUsMemberbsx:GlobalPeripheralInterventionsPiReportingUnitMember2024-01-012024-03-310000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMember2024-01-012024-03-310000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMembercountry:US2023-01-012023-03-310000885725us-gaap:NonUsMemberbsx:GlobalPeripheralInterventionsPiReportingUnitMember2023-01-012023-03-310000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMember2023-01-012023-03-310000885725bsx:CardiovascularMembercountry:US2024-01-012024-03-310000885725us-gaap:NonUsMemberbsx:CardiovascularMember2024-01-012024-03-310000885725bsx:CardiovascularMembercountry:US2023-01-012023-03-310000885725us-gaap:NonUsMemberbsx:CardiovascularMember2023-01-012023-03-310000885725country:US2024-01-012024-03-310000885725us-gaap:NonUsMember2024-01-012024-03-310000885725country:US2023-01-012023-03-310000885725us-gaap:NonUsMember2023-01-012023-03-310000885725bsx:BSXReportableSegmentsMembercountry:US2024-01-012024-03-310000885725bsx:BSXReportableSegmentsMembercountry:US2023-01-012023-03-310000885725bsx:BSXReportableSegmentsMemberus-gaap:EMEAMember2024-01-012024-03-310000885725bsx:BSXReportableSegmentsMemberus-gaap:EMEAMember2023-01-012023-03-310000885725bsx:BSXReportableSegmentsMembersrt:AsiaPacificMember2024-01-012024-03-310000885725bsx:BSXReportableSegmentsMembersrt:AsiaPacificMember2023-01-012023-03-310000885725bsx:LatinAmericaandCanadaMemberbsx:BSXReportableSegmentsMember2024-01-012024-03-310000885725bsx:LatinAmericaandCanadaMemberbsx:BSXReportableSegmentsMember2023-01-012023-03-310000885725bsx:EmergingMarketsMember2024-01-012024-03-310000885725bsx:EmergingMarketsMember2023-01-012023-03-310000885725us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000885725us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310000885725us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310000885725us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-03-310000885725us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-03-310000885725us-gaap:AccumulatedTranslationAdjustmentMember2024-03-310000885725us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-03-310000885725us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-03-310000885725us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000885725us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310000885725us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000885725us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-03-310000885725us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-03-310000885725us-gaap:AccumulatedTranslationAdjustmentMember2023-03-310000885725us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-03-310000885725us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-03-310000885725bsx:VanceRBrownMember2024-01-012024-03-310000885725bsx:VanceRBrownMember2024-03-310000885725bsx:DanielBrennanMember2024-01-012024-03-310000885725bsx:DanielBrennanMemberbsx:DanielBrennanRuleTradingArrangementCommonStockMember2024-03-310000885725bsx:DanielBrennanMemberbsx:DanielBrennanRuleTradingArrangementStockOptionsMember2024-03-310000885725bsx:JonathanMonsonMember2024-01-012024-03-310000885725bsx:JonathanMonsonMemberbsx:JonathanMonsonRuleTradingArrangementCommonStockMember2024-03-310000885725bsx:JonathanMonsonMemberbsx:JonathanMonsonRuleTradingArrangementStockOptionsMember2024-03-310000885725bsx:JeffreyBMirvissMember2024-01-012024-03-310000885725bsx:JeffreyBMirvissMemberbsx:JeffreyB.MirvissRuleTradingArrangementCommonStockMember2024-03-310000885725bsx:JeffreyB.MirvissRuleTradingArrangementVestingOfPerformanceUnitsAndRestrictedUnitsMemberbsx:JeffreyBMirvissMember2024-03-310000885725bsx:JeffreyBMirvissMemberbsx:JeffreyB.MirvissRuleTradingArrangementStockOptionsMember2024-03-310000885725bsx:MichaelF.MahoneyMember2024-01-012024-03-310000885725bsx:MichaelF.MahoneyMemberbsx:MichaelF.MahoneyRuleTradingArrangementCommonStockMember2024-03-310000885725bsx:MichaelF.MahoneyMemberbsx:MichaelF.MahoneyRuleTradingArrangementStockOptionsMember2024-03-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2024
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File No. 1-11083
BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)
Delaware04-2695240
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
    300 Boston Scientific Way, Marlborough, Massachusetts                    01752-1234
        (Address of Principal Executive Offices)                         (Zip Code)
508 683-4000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareBSXNew York Stock Exchange
0.625% Senior Notes due 2027BSX27New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No
The number of shares outstanding of Common Stock, $0.01 par value per share, as of April 29, 2024 was 1,470,179,843.


TABLE OF CONTENTS
  Page No.
 
   
   
 
   
 
   
 
   
 
   
   
   
   
   
   
 
2

PART I
FINANCIAL INFORMATION

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

Three Months Ended
March 31,
(in millions, except per share data)20242023
Net sales$3,856 $3,389 
Cost of products sold1,209 1,040 
Gross profit2,648 2,349 
Operating expenses:
Selling, general and administrative expenses1,364 1,215 
Research and development expenses366 337 
Royalty expense10 11 
Amortization expense214 203 
Contingent consideration net expense (benefit)17 12 
Restructuring net charges (credits)3 20 
 1,973 1,797 
Operating income (loss)675 552 
Other income (expense):
Interest expense(69)(65)
Other, net2 (43)
Income (loss) before income taxes608 444 
Income tax expense (benefit)115 131 
Net income (loss)493 314 
Preferred stock dividends (14)
Net income (loss) attributable to noncontrolling interests(1) 
Net income (loss) attributable to Boston Scientific common stockholders$495 $300 
Net income (loss) per common share — basic$0.34 $0.21 
Net income (loss) per common share — diluted$0.33 $0.21 
Weighted-average shares outstanding
Basic1,468.4 1,435.8 
Diluted1,481.7 1,446.0 

Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.
3

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)

Three Months Ended
March 31,
(in millions)20242023
Net income (loss)$493 $314 
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment57 (42)
Net change in derivative financial instruments22 (43)
Net change in defined benefit pensions and other items(0)(5)
Other comprehensive income (loss)78 (91)
Comprehensive income (loss)$572 $223 
Comprehensive income (loss) attributable to noncontrolling interests(6) 
Comprehensive income attributable to Boston Scientific common stockholders$578 $223 





































Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.
4

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS (UNAUDITED)
 As of
(in millions, except share and per share data)March 31, 2024December 31, 2023
ASSETS  
Current assets:  
Cash and cash equivalents$2,329 $865 
Trade accounts receivable, net2,304 2,228 
Inventories2,561 2,484 
Prepaid income taxes319 315 
Other current assets671 621 
Total current assets8,185 6,514 
Property, plant and equipment, net2,897 2,859 
Goodwill14,361 14,387 
Other intangible assets, net5,839 6,003 
Deferred tax assets3,792 3,841 
Other long-term assets1,596 1,531 
TOTAL ASSETS$36,669 $35,136 
LIABILITIES AND STOCKHOLDERS’ EQUITY  
Current liabilities:  
Current debt obligations$1,085 $531 
Accounts payable921 942 
Accrued expenses2,083 2,646 
Other current liabilities827 814 
Total current liabilities4,916 4,933 
Long-term debt9,534 8,571 
Deferred income taxes132 134 
Other long-term liabilities1,919 1,967 
Commitments and contingencies
Stockholders’ equity  
Preferred stock, $0.01 par value - authorized 50,000,000 shares - 0 shares issued as of March 31, 2024 and December 31, 2023
  
Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,733,293,885 shares as of March 31, 2024 and 1,729,000,224 shares as of December 31, 2023
17 17 
Treasury stock, at cost - 263,289,848 shares as of March 31, 2024 and December 31, 2023
(2,251)(2,251)
Additional paid-in capital20,713 20,647 
Retained earnings1,314 819 
Accumulated other comprehensive income (loss), net of tax132 49 
Total stockholders’ equity19,926 19,282 
Noncontrolling interests242 248 
Total equity20,168 19,530 
TOTAL LIABILITIES AND EQUITY$36,669 $35,136 



Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.
5

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)
Three Months Ended
March 31,
(in millions, except share data)20242023
Preferred stock shares issued
   Beginning 10,062,500 
Preferred stock issuance  
   Ending 10,062,500 
Common stock shares issued
   Beginning1,729,000,224 1,696,633,993 
Impact of stock-based compensation plans4,293,661 4,194,880 
   Ending1,733,293,885 1,700,828,873 
Preferred stock
   Beginning$ $0 
Preferred stock issuance  
   Ending$ $0 
Common stock
   Beginning$17 $17 
Impact of stock-based compensation plans0 0 
   Ending$17 $17 
Treasury stock
Beginning$(2,251)$(2,251)
Repurchase of common stock  
Ending$(2,251)$(2,251)
Additional paid-in capital
Beginning$20,647 $20,289 
Impact of stock-based compensation plans66 68 
Ending$20,713 $20,356 
Retained earnings/(Accumulated deficit)
Beginning$819 $(750)
Net income (loss)493 314 
Net (income) loss attributable to noncontrolling interests1  
Preferred stock dividends (14)
Ending$1,314 $(450)
Accumulated other comprehensive income (loss), net of tax
Beginning$49 $269 
Changes in other comprehensive income (loss)83 (91)
Ending$132 $178 
Total stockholders' equity$19,926 $17,850 
Noncontrolling interests
Beginning$248 $ 
Net income (loss) attributable to noncontrolling interests(1) 
Changes in other comprehensive income (loss)(5) 
Changes to noncontrolling ownership interest 259 
Ending$242 $259 
Total equity$20,168 $18,109 



Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.
6

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

Three Months Ended March 31,
(in millions)20242023
Net income (loss)$493 $314 
Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities
Depreciation and amortization304 285 
Deferred and prepaid income taxes31 19 
Stock-based compensation expense63 55 
Net loss (gain) on investments and notes receivable2 31 
Contingent consideration net expense (benefit)17 12 
Other, net(4)(2)
Increase (decrease) in operating assets and liabilities, excluding purchase accounting:
Trade accounts receivable(114)(86)
Inventories(124)(185)
Other assets(55)(41)
Accounts payable, accrued expenses and other liabilities(450)(211)
Cash provided by (used for) operating activities164 190 
Investing activities:  
Purchases of property, plant and equipment and internal use software(179)(111)
Proceeds from sale of property, plant and equipment1 3 
Payments for acquisitions of businesses, net of cash acquired(47)(375)
Payments for investments and acquisitions of certain technologies, net of investment proceeds(66)(10)
Proceeds from royalty rights7 9 
Cash provided by (used for) investing activities(285)(484)
Financing activities:  
Payment of contingent consideration previously established in purchase accounting(34)(34)
Payments for royalty rights(15)(34)
Payments for finance leases(25) 
Payments on short-term borrowings(504) 
Proceeds from long-term borrowings, net of debt issuance costs2,145  
Cash dividends paid on preferred stock (14)
Cash used to net share settle employee equity awards(78)(50)
Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans80 63 
Cash provided by (used for) financing activities1,569 (69)
Effect of foreign exchange rates on cash(7) 
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents1,441 (363)
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period1,055 1,126 
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period$2,496 $763 





Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.
7

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(SUPPLEMENTAL INFORMATION)

Three Months Ended March 31,
(in millions)20242023
Supplemental Information
Stock-based compensation expense$63 $55 
Non-cash impact of transferred royalty rights(7)(9)

As of March 31,
Reconciliation to amounts within the unaudited consolidated balance sheets:20242023
Cash and cash equivalents$2,329 $570 
Restricted cash and restricted cash equivalents included in Other current assets
93 135 
Restricted cash equivalents included in Other long-term assets
74 57 
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period$2,496 $763 
























Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.
8

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE A – BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements of Boston Scientific Corporation have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and with the instructions to Form 10-Q and Article 10 of Regulation S-X, and they do not include all of the information and footnotes required by GAAP for complete financial statements. When used in this report, the terms, "we," "us," "our," and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for fair presentation have been included. Operating results for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. Accordingly, our unaudited consolidated financial statements and footnotes thereto should be read in conjunction with our audited consolidated financial statements and footnotes thereto included in Item 8 of our most recent Annual Report on Form 10-K.

The accompanying unaudited consolidated financial statements include the accounts of the Company's wholly owned- subsidiaries and entities for which the Company has a controlling financial interest. All intercompany balances and transactions have been eliminated in consolidation.

Amounts reported in millions within this Quarterly Report on Form 10-Q are computed based on the amounts in thousands. As a result, the sum of the components may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.
Subsequent Events
We evaluate events occurring after the date of our accompanying unaudited consolidated balance sheet for potential recognition or disclosure within our financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly.
Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note H – Commitments and Contingencies for further details.

NOTE B – ACQUISITIONS AND STRATEGIC INVESTMENTS

Our accompanying unaudited consolidated financial statements include the operating results for acquired entities from the respective dates of acquisition. We have not presented supplemental pro forma financial information for completed acquisitions or divestitures given their results are not material to our accompanying unaudited consolidated financial statements. Further, transaction costs were immaterial to our accompanying unaudited consolidated financial statements and were expensed as incurred.

On January 8, 2024, we announced our entry into a definitive agreement to acquire 100 percent of Axonics, Inc. (Axonics), a publicly traded medical technology company primarily focused on the development and commercialization of devices to treat urinary and bowel dysfunction. The purchase price is $71.00 in cash per share, or approximately $3.670 billion for 100% of the fully diluted equity. On April 3, 2024, we and Axonics each received a request for additional information (Second Request) from the United States Federal Trade Commission (FTC) in connection with the FTC's review of the transaction. The issuance of the Second Request extends the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR Act), until 30 days after both we and Axonics have substantially complied with the Second Request, unless the waiting period is extended voluntarily by the parties or terminated earlier by the FTC. We and Axonics expect to promptly respond to the Second Request and to continue to work cooperatively with the FTC in its review. The transaction is expected to be completed in the second half of 2024, subject to the expiration or termination of the waiting period under the HSR Act and the satisfaction (or waiver) of other customary closing conditions. The Axonics business will be integrated into our Urology division.

2023 Acquisition

On February 20, 2023, we completed the acquisition of a majority stake investment in Acotec Scientific Holdings Limited (Acotec), a publicly traded Chinese manufacturer of drug-coated balloons and other products used in the treatment of vascular and other diseases. We consolidated this majority stake investment in Acotec based on the conclusion we control the entity, and
9

recorded a noncontrolling interest for the portion we do not own. We acquired approximately 65 percent of the outstanding shares of Acotec, for an upfront cash payment of HK$20.00 per share, or $519 million at foreign currency exchange rates at closing. The Acotec portfolio complements our existing Peripheral Interventions portfolio.

Purchase Price Allocation

We accounted for our majority stake investment in Acotec as a business combination in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 805, Business Combinations (FASB ASC Topic 805). The final purchase price was comprised of the amount presented below:

(in millions)
Acotec(1)
Payment for majority stake investment$381 
$381 
(1) Excludes approximately $140 million of cash on hand at the closing of the transaction

We recorded the assets acquired, liabilities assumed and the noncontrolling interest at their respective fair values as of the closing date of the transaction. The final purchase price allocation was comprised of the components presented below, with the excess of the purchase price over the fair value of net assets acquired recorded to goodwill:

(in millions)Acotec
Goodwill$337 
Amortizable intangible assets334 
Other assets acquired93 
Liabilities assumed(48)
Net deferred tax liabilities(76)
Fair value of noncontrolling interest(259)
$381 

The fair value of Acotec's noncontrolling interest was based on the publicly traded market value of the remaining 35 percent of the outstanding shares we did not acquire as of the transaction date and is presented in Stockholders' equity within our accompanying unaudited consolidated balance sheets. Goodwill was primarily established for Acotec due to opportunities for collaboration in research and development, manufacturing and commercial strategies and was not deductible for tax purposes.

We allocated a portion of the purchase price to the specific intangible asset categories as follows:

Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
Technology-related$308 1114%
Customer relationships15 1114%
Other intangible assets11 1314%
$334 
10

Contingent Consideration
Changes in the fair value of our contingent consideration liability during the first quarter of 2024 associated with prior period acquisitions were as follows:

(in millions)
Balance as of December 31, 2023$404 
Contingent consideration net expense (benefit)17 
Contingent consideration payments and other adjustments(148)
Balance as of March 31, 2024$273 

The payments made during the first quarter of 2024 primarily related to our acquisition of Farapulse, Inc (Farapulse) following the achievement of revenue-based earnouts as a result of over-performance. The maximum amount we could be required to pay for certain contingent consideration is not determinable as it is uncapped and based on a percent of certain sales. As of March 31, 2024, the fair value of such uncapped contingent consideration is estimated at $164 million. As of March 31, 2024, the maximum amount that we could be required to pay under our other contingent consideration arrangements (undiscounted) is approximately $275 million. Refer to Note B – Acquisitions and Strategic Investments to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for additional information.

The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:
Contingent Consideration LiabilityFair Value as of March 31, 2024Valuation TechniqueUnobservable InputRange
Weighted Average(1)
Revenue-based Payments and Milestones$273 millionDiscounted Cash FlowDiscount Rate6%-11%6%
Probability of Payment100%100%
Projected Year of Payment2024-20272025
(1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

Projected contingent payment amounts related to our revenue-based payments and milestones are discounted back to the current period, primarily using a discounted cash flow model. Significant increases or decreases in projected revenues, probabilities of payment, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement as of March 31, 2024.

Strategic Investments

The aggregate carrying amount of our strategic investments was comprised of the following:

As of
(in millions)March 31, 2024December 31, 2023
Equity method investments$211 $219 
Measurement alternative investments(1, 2)
218 194 
$429 $413 
(1) Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in Other, net within our accompanying unaudited consolidated statements of operations.
(2) Includes publicly-held securities and convertible notes measured at fair value with changes in fair value recognized in Other, net within our accompanying unaudited consolidated statements of operations.

These investments are classified as Other long-term assets within our accompanying unaudited consolidated balance sheets, in accordance with GAAP and our accounting policies.

11

As of March 31, 2024, the cost of our aggregated equity method investments exceeded our share of the underlying equity in net assets by $237 million, which represents amortizable intangible assets, in-process research and development (IPR&D), goodwill and deferred tax liabilities.

NOTE C – GOODWILL AND OTHER INTANGIBLE ASSETS

The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows:
As of March 31, 2024As of December 31, 2023
(in millions)Gross Carrying AmountAccumulated Amortization/ Write-offsGross Carrying AmountAccumulated Amortization/ Write-offs
Technology-related$13,223 $(8,287)$13,207 $(8,101)
Patents480 (385)480 (387)
Other intangible assets2,159 (1,527)2,130 (1,500)
Amortizable intangible assets$15,863 $(10,198)$15,817 $(9,988)
    
Goodwill$24,261 $(9,900)$24,287 $(9,900)
IPR&D$54 $54 
Technology-related120 120 
Indefinite-lived intangible assets$174 $174 

The following represents a roll-forward of our goodwill balance by reportable segment:
(in millions)MedSurgCardiovascularTotal
As of December 31, 2023$5,347 $9,041 $14,387 
Goodwill acquired24  24 
Impact of foreign currency fluctuations and purchase price and other adjustments(29)(22)(51)
As of March 31, 2024$5,342 $9,019 $14,361 

Goodwill and Other Intangible Asset Impairments

We did not record any goodwill or intangible asset impairment charges in the first quarter of 2024 or 2023. Refer to Note A – Significant Accounting Policies to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for further discussion of our annual goodwill and intangible asset impairment testing.

12

NOTE D – HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS

Derivative Instruments and Hedging Activities

We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative and nonderivative financial instruments. We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.

Currency Hedging Instruments

Risk Management Strategy

Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities; forecasted intercompany and third-party transactions; and net investments in certain subsidiaries. We manage currency exchange rate risk at a consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative and nonderivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates.

The success of our currency risk management program depends, in part, on forecasted transactions denominated primarily in euro, Chinese renminbi, Japanese yen, British pound sterling, Australian dollar and Swiss franc. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecasted. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.

Hedge Designations and Relationships

Certain of our currency derivative instruments are designated as cash flow hedges under FASB ASC Topic 815, Derivatives and Hedging (FASB ASC Topic 815), and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in the Net change in derivative financial instruments component of Other comprehensive income (loss), net of tax (OCI) within our unaudited consolidated statements of comprehensive income (loss) until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, we recognize the gain or loss in earnings within Cost of products sold within our unaudited consolidated statements of operations. In the event the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the gains or losses within Accumulated other comprehensive income (loss), net of tax (AOCI) to earnings at that time. The cash flows related to the derivative instruments designated as cash flow hedges are reported as operating activities within our unaudited consolidated statements of cash flows.

We also designate certain forward currency contracts as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Chinese renminbi and Japanese yen. For these derivative instruments, we elected to use the spot method to assess hedge effectiveness. We also elected to exclude the spot-forward difference, referred to as the excluded component, from the assessment of hedge effectiveness and are amortizing this amount separately, as calculated at the date of designation, on a straight-line basis over the term of the currency forward contracts. As such, we defer recognition of foreign currency gains and losses within the Foreign currency translation adjustment (CTA) component of OCI, and we reclassify amortization of the excluded component from AOCI to current period earnings within Interest expense within our unaudited consolidated statements of operations.

We designate certain euro-denominated debt as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the euro. As of March 31, 2024 and December 31, 2023, we designated as a net investment hedge our €900 million in aggregate principal amount of 0.625% senior notes issued in November 2019 and due in 2027 (2027 Notes). For these nonderivative instruments, we defer recognition of the foreign currency remeasurement gains and losses within the CTA component of OCI. We reclassify these gains and losses to current period earnings within Other, net within our accompanying unaudited consolidated statements of operations only when the hedged item affects earnings, which would occur upon disposal or substantial liquidation of the underlying foreign subsidiary.

13

We also use forward currency contracts that are not part of designated hedging relationships as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings within Other, net within our accompanying unaudited consolidated statements of operations.

Interest Rate Hedging Instruments

Risk Management Strategy

Our interest rate risk relates primarily to U.S. dollar and euro-denominated borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to mitigate the risk to our earnings and cash flows associated with exposure to changes in interest rates. Under these agreements, we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges in accordance with FASB ASC Topic 815.

Hedge Designations and Relationships

We had no interest rate derivative instruments designated as cash flow hedges outstanding as of March 31, 2024 or December 31, 2023. In the event that we designate outstanding interest rate derivative instruments as cash flow hedges, we record the changes in the fair value of the derivatives within OCI until the underlying hedged transaction occurs.

We had no interest rate derivative instruments designated as fair value hedges outstanding as of March 31, 2024 or December 31, 2023. In the event that we designate outstanding interest rate derivative instruments as fair value hedges, we record the changes in the fair values of interest-rate derivatives designated as fair value hedges and of the underlying hedged debt instruments in Interest expense, which generally offset.

The following table presents the contractual amounts of our hedging instruments outstanding:
(in millions)FASB ASC Topic 815 DesignationAs of
March 31, 2024December 31, 2023
Forward currency contractsCash flow hedge$2,242 $2,284 
Forward currency contractsNet investment hedge645 333 
Foreign currency-denominated debt(1)
Net investment hedge997 997 
Forward currency contractsNon-designated3,070 3,282 
Total Notional Outstanding$6,954 $6,896 
(1) Foreign currency-denominated debt is the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge.

The remaining time to maturity as of March 31, 2024 is within 36 months for all forward currency contracts designated as cash flow hedges and generally less than one year for all non-designated forward currency contracts. The forward currency contracts designated as net investment hedges generally mature between one and two years. The euro-denominated debt principal designated as a net investment hedge has a contractual maturity of December 1, 2027.

The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 within our accompanying unaudited consolidated statements of operations. Refer to Note M – Changes in Other Comprehensive Income for the total amounts relating to derivative and nonderivative instruments presented within our accompanying unaudited consolidated statements of comprehensive income (loss).

14

Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Three Months Ended March 31, 2024
Forward currency contracts
Cash flow hedges$76 $(17)$59 Cost of products sold$1,209 $(49)$11 $(38)
Net investment hedges(2)
27 (6)21 Interest expense69 (4)1 (3)
Foreign currency-denominated debt
Net investment hedges(3)
23 (5)18 Other, net(2)   
Interest rate derivative contracts
Cash flow hedges   Interest expense69 1 (0)0 

Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Three Months Ended March 31, 2023
Forward currency contracts
Cash flow hedges$13 $(3)$10 Cost of products sold$1,040 $(69)$16 $(54)
Net investment hedges(2)
6 (1)4 Interest expense65 (3)1 (2)
Foreign currency-denominated debt
Net investment hedges(3)
(19)4 (14)Other, net43    
Interest rate derivative contracts
Cash flow hedges   Interest Expense65 1  1 
(1) In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from AOCI to earnings represent the effect of the hedging relationships on earnings.
(2) For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from AOCI to earnings as a reduction of Interest expense represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior periods, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.
(3) For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the CTA component of OCI. No amounts were reclassified from AOCI to current period earnings.

As of March 31, 2024, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below (in millions):
FASB ASC Topic 815 DesignationLocation on Unaudited Consolidated Statements of OperationsAmount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings
Designated Hedging Instrument
Forward currency contractsCash flow hedgeCost of products sold$173 
Forward currency contractsNet investment hedgeInterest expense15 
Interest rate derivative contractsCash flow hedgeInterest expense(1)

15

Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:
Location on Unaudited Consolidated Statements of OperationsThree Months Ended March 31,
(in millions)20242023
Net gain (loss) on currency hedge contractsOther, net$15 $(8)
Net gain (loss) on currency transaction exposuresOther, net(20)(6)
Net currency exchange gain (loss)$(5)$(14)

Fair Value Measurements

FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures (FASB ASC Topic 820), and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative and nonderivative assets and liabilities:

 
Location on Unaudited Consolidated Balance Sheets(1)
As of
(in millions)March 31, 2024December 31, 2023
Derivative and Nonderivative Assets:   
Designated Hedging Instruments  
Forward currency contractsOther current assets$160 $140 
Forward currency contractsOther long-term assets125 107 
  285 246 
Non-Designated Hedging Instruments   
Forward currency contractsOther current assets17 20 
Total Derivative and Nonderivative Assets $302 $266 
Derivative and Nonderivative Liabilities:   
Designated Hedging Instruments  
Forward currency contractsOther current liabilities$3 $15 
Forward currency contractsOther long-term liabilities1 9 
Foreign currency-denominated debt(2)
Long-term debt966 988 
  969 1,012 
Non-Designated Hedging Instruments   
Forward currency contractsOther current liabilities17 38 
Total Derivative and Nonderivative Liabilities $986 $1,050 
(1) We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.
(2) Foreign currency-denominated debt is the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.

16

Recurring Fair Value Measurements
On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
Level 1 – Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
Level 2 – Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
Level 3 – Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
Assets and liabilities measured at fair value on a recurring basis consist of the following:
As of
 March 31, 2024December 31, 2023
(in millions)Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets        
Money market funds and time deposits$1,979 $ $ $1,979 $454 $ $ $454 
Publicly-held equity securities20   20 18   18 
Hedging instruments 302  302  266  266 
Licensing arrangements  66 66   77 77 
 $1,999 $302 $66 $2,367 $472 $266 $77 $816 
Liabilities        
Hedging instruments$ $986 $ $986 $ $1,050 $ $1,050 
Contingent consideration liability  273 273   404 404 
Licensing arrangements  71 71   90 90 
 $ $986 $344 $1,330 $ $1,050 $494 $1,545 

Our investments in money market funds and time deposits are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as Cash and cash equivalents or Other current assets within our accompanying unaudited consolidated balance sheets, in accordance with GAAP and our accounting policies. In addition to $1.979 billion invested in money market funds and time deposits as of March 31, 2024 and $454 million as of December 31, 2023, we held $384 million in interest-bearing and non-interest-bearing bank accounts as of March 31, 2024 and $411 million as of December 31, 2023.

Our recurring fair value measurements using Level 3 inputs include those related to our contingent consideration liability. Refer to Note B – Acquisitions and Strategic Investments for a discussion of the changes in the fair value of our contingent consideration liability. In addition, our recurring fair value measurements using Level 3 inputs related to our licensing arrangements, including the contractual right to receive future royalty payments related to the Zytiga™ Drug. We maintain a financial asset and associated liability for our licensing arrangements measured at fair value within our unaudited consolidated balance sheets in accordance with FASB ASC Topic 825, Financial Instruments. We elected the fair value option to measure the financial asset and associated liability as it provides for consistency and comparability of these financial instruments with others. Refer to Note D – Hedging Activities and Fair Value Measurements to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for additional information.

The recurring Level 3 fair value measurements of our licensing arrangements recognized within our accompanying unaudited consolidated balance sheets as of March 31, 2024 include the following significant unobservable inputs:
17

Licensing ArrangementsFair Value as of March 31, 2024Valuation TechniqueUnobservable InputRange
Weighted Average (1)
Financial Asset$66 millionDiscounted Cash FlowDiscount Rate15%15%
Projected Year of Payment2024-20252025
Financial Liability$71 millionDiscounted Cash FlowDiscount Rate12 %-15%13%
Projected Year of Payment2024-20262025
(1) Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

Changes in the fair value of our licensing arrangements' financial asset were as follows:
(in millions)
Balance as of December 31, 2023$77 
Proceeds from royalty rights(14)
Fair value adjustment (expense) benefit2 
Balance as of March 31, 2024$66 

Changes in the fair value of our licensing arrangements' financial liability were as follows:
(in millions)
Balance as of December 31, 2023$90 
Payments for royalty rights(22)
Fair value adjustment expense (benefit)2 
Balance as of March 31, 2024$71 

Non-Recurring Fair Value Measurements

We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B – Acquisitions and Strategic Investments for a discussion of our strategic investments and Note C – Goodwill and Other Intangible Assets for a discussion of the fair values of our intangible assets including goodwill.

The fair value of our outstanding debt obligations, excluding finance leases, was $10.224 billion as of March 31, 2024 and $8.735 billion as of December 31, 2023. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, and face value for commercial paper, term loans and credit facility borrowings outstanding. Refer to Note E – Contractual Obligations and Commitments for a discussion of our debt obligations.

18

NOTE E – CONTRACTUAL OBLIGATIONS AND COMMITMENTS

Borrowings and Credit Arrangements

We had total debt outstanding of $10.619 billion as of March 31, 2024 and $9.102 billion as of December 31, 2023, with current obligations of $1.085 billion as of March 31, 2024 and $531 million as of December 31, 2023. The debt maturity schedule for our long-term debt obligations is presented below:
(in millions, except interest rates)Issuance DateMaturity DateAs of
Coupon Rate(1)
March 31,
2024
December 31,
2023
March 2025 Senior Notes(3)
March 2022March 2025 1,105 0.750%
June 2025 Senior NotesMay 2020June 2025500 500 1.900%
March 2026 Senior NotesFebruary 2019March 2026255 255 3.750%
December 2027 Senior Notes(3)
November 2019December 2027972 995 0.625%
March 2028 Senior Notes(3)
March 2022March 2028810 829 1.375%
March 2028 Senior NotesFebruary 2018March 2028344 344 4.000%
March 2029 Senior NotesFebruary 2019March 2029272 272 4.000%
March 2029 Senior Notes(3)
February 2024March 2029810  3.375%
June 2030 Senior NotesMay 2020June 20301,200 1,200 2.650%
March 2031 Senior Notes(3)
March 2022March 2031810 829 1.625%
March 2032 Senior Notes(3)
February 2024March 20321,349  3.500%
March 2034 Senior Notes(3)
March 2022March 2034540 553 1.875%
November 2035 Senior Notes(2)
November 2005November 2035350 350 6.500%
March 2039 Senior NotesFebruary 2019March 2039450 450 4.550%
January 2040 Senior NotesDecember 2009January 2040300 300 7.375%
March 2049 Senior NotesFebruary 2019March 2049650 650 4.700%
Unamortized Debt Issuance Discount and Deferred Financing Costs2024 - 2049(81)(65)
Finance Lease ObligationVarious4 5 
Long-term debt$9,534 $8,571 
(1) Coupon rates are semi-annual, except for the euro-denominated notes, which bear an annual coupon.
(2) Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate of 6.25% if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher.
(3) These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of March 31, 2024 and December 31, 2023, respectively.

Revolving Credit Facility

On May 10, 2021, we entered into a $2.750 billion revolving credit facility (2021 Revolving Credit Facility) with a global syndicate of commercial banks, initially scheduled to mature on May 10, 2026, with one-year extension options, subject to certain conditions. On March 1, 2023, we entered into an amendment of the 2021 Revolving Credit Facility credit agreement, which provided for an extension of the scheduled maturity date to May 10, 2027 and replaced the London Interbank Offered Rate (LIBOR) with the Secured Overnight Financing Rate (SOFR) as the Eurocurrency Rate for Dollars, including applicable credit spread adjustments and relevant SOFR benchmark provisions, among other things described under Financial Covenant below. This facility provides backing for our commercial paper program, and outstanding commercial paper directly reduces borrowing capacity under the 2021 Revolving Credit Facility. We had no amounts outstanding under the 2021 Revolving Credit Facility as of March 31, 2024 or December 31, 2023.

19

Financial Covenant

As of March 31, 2024, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility.
Covenant RequirementActual
 as of March 31, 2024as of March 31, 2024
Maximum permitted leverage ratio(1)
3.75 times2.08 times
(1) Ratio of total debt to deemed consolidated Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), as defined by the 2021 Revolving Credit Facility credit agreement, as amended.

The 2021 Revolving Credit Facility includes the financial covenant requirement for all of our credit arrangements that we maintain the maximum permitted leverage ratio of 3.75 times for the remaining term. The credit agreement provides for higher leverage ratios, at our election, for the period following a Qualified Acquisition, as defined by the agreement, for which consideration exceeds $1.000 billion. In the event of such an acquisition, for the four succeeding quarters immediately following, including the quarter in which the acquisition occurs, the maximum permitted leverage ratio is 4.75 times. It steps down for the fifth, sixth and seventh succeeding quarters to 4.50 times, 4.25 times and 4.00 times, respectively. Thereafter, a maximum leverage ratio of 3.75 times is required through the remaining term of the 2021 Revolving Credit Facility. We have elected to designate the Axonics acquisition as a Qualified Acquisition under the credit agreement, and upon closing, will increase the maximum permitted leverage ratio at that time. The agreement also provides for an exclusion of any debt incurred to fund a Qualified Acquisition, until the earlier of the acquisition close date or date of abandonment, termination or expiration of the acquisition agreement. As of March 31, 2024, we excluded $2.138 billion of debt incurred from our leverage ratio calculation in connection with the Axonics acquisition.

The financial covenant requirement, as amended on March 1, 2023, provides for an exclusion from the calculation of consolidated EBITDA, as defined by the credit agreement, through maturity, of certain charges and expenses. The credit agreement amendment reset the starting date for purposes of calculating such permitted exclusions in each case from March 31, 2021 to December 31, 2022. Permitted exclusions include any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of March 31, 2024, we had $273 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the agreement, are excluded from the calculation of consolidated EBITDA, as defined by the agreement, provided that the sum of any excluded net cash litigation payments do not exceed $1.000 billion plus all accrued legal liabilities as of December 31, 2022. As of March 31, 2024, we had $1.457 billion of the litigation exclusion remaining.

Any inability to maintain compliance with this covenant could require us to seek to renegotiate the terms of our credit arrangements or seek waivers from compliance with this covenant, both of which could result in additional borrowing costs. Further, there can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us. In this case, all 2021 Revolving Credit Facility commitments would terminate, and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our 2021 Revolving Credit Facility may negatively impact the credit ratings assigned to our commercial paper program, which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable.

Commercial Paper

Our commercial paper program is backed by the 2021 Revolving Credit Facility. We did not have any commercial paper outstanding as of March 31, 2024 and December 31, 2023.

Senior Notes

We had senior notes outstanding of $10.690 billion as of March 31, 2024 and $9.136 billion as of December 31, 2023. Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to liabilities of our subsidiaries (refer to Other Arrangements below).

In February 2024, American Medical Systems Europe B.V. (AMS Europe), an indirect, wholly owned subsidiary of Boston Scientific, completed a registered public offering (the Offering) of €2.000 billion in aggregate principal amount of euro-denominated senior notes comprised of €750 million of 3.375% Senior Notes due 2029 and €1.250 billion of 3.500% Senior Notes due 2032 (collectively, the 2024 Eurobonds). Boston Scientific has fully and unconditionally guaranteed all of AMS Europe's obligations under the 2024 Eurobonds, and no other subsidiary of Boston Scientific will guarantee these obligations.
20

AMS Europe is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of Regulation S-X. The financial condition, results of operations and cash flows of AMS Europe are consolidated in the financial statements of Boston Scientific. The Offering resulted in cash proceeds of $2.145 billion, net of investor discounts and issuance costs.

We used the net proceeds from the Offering of the 2024 Eurobonds to fund the repayment at maturity of our 3.450% Senior Notes due March 2024 and to pay accrued and unpaid interest with respect to such notes. Additionally, we plan to use the remaining net proceeds from the Offering to fund a portion of the purchase price of the Axonics acquisition and to pay related fees and expenses, and for general corporate purposes. The transaction is expected to be completed in the second half of 2024, subject to the expiration or termination of the waiting period under the HSR Act and the satisfaction (or waiver) of other customary closing conditions. If (i) the Axonics acquisition is not consummated on or before the later of (x) January 8, 2025 (as such date may be extended in accordance with the merger agreement to no later than January 8, 2026) and (y) the date that is five business days after any later date to which we and Axonics may agree to extend the "Outside Date" in the merger agreement or (ii) AMS Europe notifies the trustee that we will not pursue consummation of the Axonics Acquisition, AMS Europe will be required to redeem each series of the notes at a special mandatory redemption price equal to 101% of the aggregate principal amount of such series of notes, plus accrued and unpaid interest, if any, to, but excluding, the date on which the notes will be redeemed. Refer to Note B – Acquisitions and Strategic Investments for more information on the Axonics acquisition.

Other Arrangements

We have accounts receivable factoring programs in certain European countries and with commercial banks in China and Japan which include promissory notes discounting programs. We account for our factoring programs as sales under FASB ASC Topic 860. We have no retained interest in the transferred receivables, other than collection and administration, and once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. Amounts de-recognized for accounts and notes receivable, which are excluded from Trade accounts receivable, net within our accompanying unaudited consolidated balance sheets, are aggregated by contract denominated currency below (in millions):
Factoring ArrangementsAs of March 31, 2024As of December 31, 2023
Amount
De-recognized
Weighted Average
Interest Rate
Amount
De-recognized
Weighted Average
Interest Rate
Euro denominated$175 5.5 %$206 5.1 %
Yen denominated191 0.6 %214 0.6 %
Renminbi denominated
21 1.8 %14 2.9 %

Other Contractual Obligations and Commitments

We had outstanding letters of credit of $174 million as of March 31, 2024 and December 31, 2023, which consisted primarily of bank guarantees and collateral for workers' compensation insurance arrangements. As of March 31, 2024 and December 31, 2023 we had not recognized a related liability for our outstanding letters of credit within our accompanying unaudited consolidated balance sheets.

We have a supplier financing program offered primarily in the U.S. that enables our suppliers to opt to receive early payment at a nominal discount, while allowing us to lengthen our payment terms and optimize working capital. Our standard payment term in the U.S. is 90 days. All outstanding payables related to the supplier finance program are classified within Accounts Payable within our unaudited consolidated balance sheets and were $140 million as of March 31, 2024 and $152 million as of December 31, 2023.

Refer to Note E – Contractual Obligations and Commitments to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for additional information on our borrowings and credit agreements.

21

NOTE F – SUPPLEMENTAL BALANCE SHEET INFORMATION

Components of selected captions within our accompanying unaudited consolidated balance sheets are as follows:

Trade accounts receivable, net
 As of
(in millions)March 31, 2024December 31, 2023
Trade accounts receivable$2,413 $2,338 
Allowance for credit losses(109)(110)
 $2,304 $2,228 

The following is a roll forward of our Allowance for credit losses:
Three Months Ended March 31,
(in millions)20242023
Beginning balance$110 $109 
Credit loss expense9 16 
Write-offs(10)(6)
Ending balance$109 $118 

Inventories
 As of
(in millions)March 31, 2024December 31, 2023
Finished goods$1,555 $1,537 
Work-in-process188 174 
Raw materials818 773 
 $2,561 $2,484 
Other current assets
 As of
(in millions)March 31, 2024December 31, 2023
Restricted cash and restricted cash equivalents$93 $130 
Derivative assets177 159 
Licensing arrangements44 47 
Other357 285 
 $671 $621 
22


Property, plant and equipment, net
 As of
(in millions)March 31, 2024December 31, 2023
Land$141 $140 
Buildings and improvements1,856 1,843 
Equipment, furniture and fixtures3,550 3,503 
Capital in progress880 857 
 6,427 6,343 
Less: accumulated depreciation3,530 3,484 
 $2,897 $2,859 

Depreciation expense was $90 million for the first quarter of 2024 and $82 million for the first quarter of 2023.

Other long-term assets

 As of
(in millions)March 31, 2024December 31, 2023
Restricted cash equivalents$74 $60 
Operating lease right-of-use assets430 439 
Derivative assets125 107 
Investments429 413 
Licensing arrangements22 30 
Indemnification asset175 176 
Other341 306 
 $1,596 $1,531 
Accrued expenses
 As of
(in millions)March 31, 2024December 31, 2023
Legal reserves$129 $206 
Payroll and related liabilities749 1,051 
Rebates384 389 
Contingent consideration182 304 
Other639 696 
 $2,083 $2,646 

Other current liabilities
 As of
(in millions)March 31, 2024December 31, 2023
Deferred revenue$280 $266 
Licensing arrangements45 49 
Taxes payable257 220 
Other246 278 
 $827 $814 
23


Other long-term liabilities
 As of
(in millions)March 31, 2024December 31, 2023
Accrued income taxes$466 $470 
Legal reserves154 172 
Contingent consideration90 100 
Licensing arrangements26 41 
Operating lease liabilities382 390 
Deferred revenue314 311 
Other486 484 
 $1,919 $1,967 

NOTE G – INCOME TAXES

Our effective tax rate from continuing operations is presented below:
Three Months Ended March 31,
20242023
Effective tax rate from continuing operations18.9 %29.4 %

Our reported tax rate is affected by recurring items such as the amount of our earnings subject to differing tax rates in foreign jurisdictions and the impact of certain receipts and charges that are taxed at rates that differ from our effective tax rate.

The principal reason for the difference between the statutory rate and our reported tax rate in the first quarter of 2024 primarily relates to certain charges for acquisition expenses as well as certain discrete benefits related to unrecognized tax benefits and stock-based compensation. In the first quarter of 2023, the primary difference between the statutory tax rate and our reported tax rate relates to certain discrete charges related to provision-to-return adjustments.

As of March 31, 2024, we had $465 million of gross unrecognized tax benefits, of which a net $393 million, if recognized, would affect our effective tax rate. As of December 31, 2023, we had $467 million of gross unrecognized tax benefits, of which a net $395 million, if recognized, would affect our effective tax rate. The change in our gross unrecognized tax benefit is primarily related to current year activity and audit activities.

It is reasonably possible that within the next 12 months, we will resolve multiple issues with foreign, federal and state taxing authorities, resulting in a reduction in our balance of unrecognized tax benefits of up to $11 million.

24

NOTE H – COMMITMENTS AND CONTINGENCIES

The medical device market in which we participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These dynamics frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies.

During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters; however, there continues to be outstanding litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.

In addition, product liability, securities and commercial claims have been asserted against us and similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.

In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity. For additional information, refer to Note I – Commitments and Contingencies to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K.

In accordance with FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related net charges (credits) within our accompanying unaudited consolidated financial statements. All other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses within our accompanying unaudited consolidated statements of operations.

Our accrual for legal matters that are probable and estimable was $283 million as of March 31, 2024 and $377 million as of December 31, 2023 and includes certain estimated costs of settlement, damages and defense primarily related to product liability cases or claims related to our transvaginal surgical mesh products. A portion of this accrual is already funded through our qualified settlement fund, which is included in restricted cash and restricted cash equivalents in Other current assets of $93 million as of March 31, 2024 and $130 million as of December 31, 2023. Refer to Note F – Supplemental Balance Sheet Information for additional information. We did not record any litigation-related net charges during the first quarter of 2024 or 2023.

We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our financial covenant.

In management's opinion, we are not currently involved in any legal proceedings other than those disclosed in our most recent Annual Report on Form 10-K and those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or
25

otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be reasonably estimated.

Patent Litigation

On November 20, 2017, The Board of Regents, University of Texas System and TissueGen. Inc. (collectively, UT), served a lawsuit against us in the Western District of Texas. The complaint against the Company alleges patent infringement of two U.S. patents owned by UT, relating to “Drug Releasing Biodegradable Fiber Implant” and “Drug Releasing Biodegradable Fiber for Delivery of Therapeutics,” and affects the manufacture, use and sale of our Synergy™ Stent System. UT primarily seeks a reasonable royalty. On March 12, 2018, the District Court for the Western District of Texas dismissed the action and transferred it to the United States District Court for the District of Delaware. On September 5, 2019, the Court of Appeals for the Federal Circuit affirmed the dismissal of the District Court for the Western District of Texas. In April 2020, the United States Supreme Court denied the UT’s Petition for Certiorari. UT proceeded with its case against the Company in Delaware. In January 2023, a jury trial was held on the issue of whether the one UT patent still asserted in the case was valid and whether it was infringed by the Company. On January 31, 2023, a jury concluded that UT’s patent was valid and willfully infringed by the Company, and awarded UT $42 million in damages. Following the trial, UT has filed a motion seeking prejudgment interest and enhanced damages. The Company has filed a motion seeking judgment as a matter of law in its favor or alternatively a new trial.

Product Liability Litigation

Multiple product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us, predominantly in the United States, Canada, the United Kingdom, Scotland, Ireland, and Australia. Plaintiffs generally seek monetary damages based on allegations of personal injury associated with the use of our transvaginal surgical mesh products, including design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. We have entered into individual and master settlement agreements or are in the final stages of entering agreements with certain plaintiffs' counsel, to resolve the majority of these cases and claims. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing. In addition, in April 2021 the Company's Board of Directors received a shareholder demand under section 220 of the Delaware General Corporation Law, for inspection of books and records related to mesh settlements. The Company has notified our insurer and retained counsel to respond to the demand.

We have established a product liability accrual for remaining claims asserted against us associated with our transvaginal surgical mesh products and the costs of defense thereof. We continue to engage in discussions with plaintiffs’ counsel regarding potential resolution of pending cases and claims, which we continue to vigorously contest. The final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Trials involving our transvaginal surgical mesh products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products.

Governmental Investigations and Qui Tam Matters

On December 1, 2015, the Brazilian governmental entity known as CADE (the Administrative Council of Economic Defense), served a search warrant on the offices of our Brazilian subsidiary, as well as on the Brazilian offices of several other major medical device makers who do business in Brazil, in furtherance of an investigation into alleged anti-competitive activity with respect to certain tender offers for government contracts. On June 20, 2017, CADE, through the publication of a “technical note,” announced that it was launching a formal administrative proceeding against Boston Scientific’s Brazilian subsidiary, Boston Scientific do Brasil Ltda. (BSB), as well as against the Brazilian operations of Medtronic, Biotronik and St. Jude Medical, two Brazilian associations, ABIMED and AMBIMO and 29 individuals for alleged anti-competitive behavior. Under applicable guidance, BSB could be fined a percentage of BSB’s 2016 gross revenues. In August 2021, the investigating commissioner issued a preliminary recommendation of liability against all of the involved companies, and also recommended that CADE impose fines and penalties. However, on October 25, 2021, the CADE Attorney General's office recommended dismissal of the charges and allegations against BSB and the individual BSB employees who were still individual defendants. Subsequently, on March 30, 2022, the Federal Prosecutor’s office issued a non-binding recommendation that is contrary to the Attorney General’s recommendation. The full Commission is considering both of these recommendations but has not yet issued its decision. We continue to deny the allegations, intend to defend ourselves vigorously and will appeal any decision of liability by the full Commission to the Brazilian courts. During such an appeal, the decision would have no force and effect, and the Court would consider the case without being bound by CADE’s decision.

26

In March 2022, the Company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam. The Company has received related subpoenas for documents from the Office of the U.S. Attorney for the District of Massachusetts and the Securities and Exchange Commission. The Company is cooperating with government agencies while investigating these allegations.

On April 5, 2023, the Company received a subpoena from the U.S. Department of Justice (DOJ) that seeks documents and information relating to its ambulatory electrocardiography monitoring (AECG) business. The Company is cooperating with the DOJ in responding to this subpoena.

On December 18, 2023, the Company received a Civil Investigative Demand from the DOJ that relates to the provision of peripheral intervention services through office-based labs. The Company is cooperating with the DOJ in responding to the subpoena.

Other Proceedings

On December 4, 2020, Enrique Jevons, individually and on behalf of all others similarly situated, filed a class action complaint against the Company, Michael F. Mahoney and Daniel J. Brennan, stemming from the recall and retirement of the LOTUS Edge™ Aortic Valve System (LOTUS System) in United States District Court for the Eastern District of New York. On December 14, 2020, the parties agreed to transfer the case to the United States District Court for the District of Massachusetts. On December 16, 2020, Mariano Errichiello, individually and on behalf of all others similarly situated, filed a second, materially similar class action complaint against the Company, Michael F. Mahoney, Joseph M. Fitzgerald, and Daniel J. Brennan in the United States District Court for the District of Massachusetts. Subsequently, on March 30, 2021, the Court consolidated the two actions, and appointed Union Asset Management Holding AG as the lead plaintiff. The plaintiffs filed an Amended Complaint in June 2021 that seeks unspecified compensatory damages in favor of the alleged class as well as unspecified equitable relief. The Company filed a Motion to Dismiss in July 2021, which, in December 2022, the Court granted in part and denied in part. On October 23, 2023, the Company reached an agreement in principle with the lead plaintiff to settle the case. The Court granted the motion for preliminary approval of the proposed settlement on December 27, 2023, and approved the settlement at a hearing on April 23, 2024.

On December 15, 2020, the Securities and Exchange Commission’s Boston Regional Office (Boston SEC) notified the Company that it was conducting an investigation related to the Company’s decision to retire the LOTUS System and issued a voluntary request for documents and information related to that decision. On February 10, 2021, the Boston SEC issued a second voluntary request for additional documents and information. The Company cooperated fully with the requests, and on January 3, 2022, the SEC informed us that it was concluding its investigation and that it did not intend to recommend an enforcement action.

On February 8, 2021, the Company received a letter from The Vladimir Gusinsky Revocable Trust, a shareholder, demanding that the Company’s Board of Directors conduct an investigation into actions by the Company’s directors and executive officers regarding statements made about the effectiveness and commercial viability of the LOTUS System. The Trust subsequently agreed to stay its demand, pending the outcome of any dispositive motion against the Amended Complaint in the class action complaint described above. The Company received letters on behalf of the Union Excavators Local 731 Pension Fund, Diane Nachbaur, and Frank Tripson, three stockholders of the Company, on July 26, 2021, July 29, 2021, and February 13, 2023, respectively, each demanding access to certain books and records of the Company, pursuant to Section 220 of the Delaware General Corporation Law, regarding the business, operations, effectiveness and commercial viability of the LOTUS system, and related items. On April 7, 2023, Diane Nachbaur filed a shareholder derivative complaint in the United States District Court for the District of Massachusetts against the Company, Michael F. Mahoney, Nelda J. Connors, Charles J. Dockendorff, Yoshiaki Fujimori, Donna A. James, Edward J. Ludwig, David Roux, John E. Sununu, Ellen M. Zane, Joseph M. Fitzgerald, Daniel J. Brennan, Shawn McCarthy, Ian Meredith, Kevin Ballinger, and Susan Vissers Lisa. On May 8, 2023, the Court stayed the case until the conclusion of the consolidated class action case. On October 18, 2023, Frank Tripson filed a shareholder derivative complaint in the Court of Chancery of the State of Delaware against the Company, Michael F. Mahoney, Daniel J. Brennan, Joseph M. Fitzgerald, Shawn McCarthy, Kevin Ballinger, Ian Meredith, Susan Vissers Lisa, Nelda J. Connors, Charles J. Dockendorff, Yoshiaki Fujimori, Donna A. James, Edward J. Ludwig, Stephen P. MacMillan, David Roux, John E. Sununu, and Ellen M. Zane. On December 15, 2023, the Court stayed that case until March 31, 2024. On March 26, 2024, the Company reached an agreement in principle with all of the plaintiffs to resolve the matters.





27

NOTE I – STOCKHOLDERS' EQUITY

Preferred Stock

We are authorized to issue 50 million shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating, option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by our stockholders.

On May 27, 2020, we completed an offering of 10,062,500 shares of 5.50% Mandatory Convertible Preferred Stock, Series A (MCPS) at a price to the public and liquidation preference of $100 per share. The net proceeds from the MCPS offering were approximately $975 million after deducting underwriting discounts and commissions and offering expenses.

On June 1, 2023, (the Mandatory Conversion Date), all outstanding shares of MCPS automatically converted into shares of common stock. The conversion rate for each share of MCPS was 2.3834 shares of common stock. No action by the holders of the MCPS was required in connection with the mandatory conversion. Cash was paid in lieu of fractional shares in accordance with the terms of the MCPS. An aggregate of approximately 24 million shares of common stock, including shares of common stock issued to holders of MCPS that elected to convert prior to the Mandatory Conversion Date, were issued upon conversion of the MCPS. Following the mandatory conversion of the MCPS, there were no outstanding shares of MCPS.

Refer to Note J – Stockholders' Equity to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for information on the pertinent rights and privileges of our outstanding common stock.
NOTE J – WEIGHTED AVERAGE SHARES OUTSTANDING

Three Months Ended March 31,
(in millions)20242023
Weighted average shares outstanding — basic1,468.4 1,435.8 
Net effect of common stock equivalents13.4 10.2 
Weighted average shares outstanding - diluted1,481.7 1,446.0 

The following securities were excluded from the calculation of weighted average shares outstanding - diluted because their effect in the periods presented below would have been antidilutive:
Three Months Ended March 31,
(in millions)20242023
Stock options outstanding(1)
23
MCPS(2)
24
(1)    Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.
(2)    Represents common stock issuable upon the conversion of MCPS. Refer to Note I – Stockholders' Equity for additional information.

We base Net income (loss) per common share - diluted upon the weighted-average number of common shares and common stock equivalents outstanding during each year. Potential common stock equivalents are determined using the treasury stock method. We exclude stock options, stock awards and, prior to the Mandatory Conversion Date, our MCPS, from the calculation if the effect would be anti-dilutive. The dilutive effect of MCPS is calculated using the if-converted method. The if-converted method assumes that these securities were converted to shares of common stock at the beginning of the reporting period to the extent that the effect is dilutive.

28

For the first quarter of 2023, the effect of assuming the conversion of MCPS into shares of common stock was anti-dilutive, and therefore excluded from the calculation of earnings per share (EPS). Accordingly, Net income (loss) was reduced by cumulative Preferred stock dividends, as presented within our accompanying unaudited consolidated statements of operations, for purposes of calculating Net income attributable to Boston Scientific common stockholders. On June 1, 2023, all outstanding shares of MCPS automatically converted into shares of common stock.

We issued approximately four million shares of our common stock in the first quarter of 2024 and 2023 following the exercise of stock options, vesting of restricted stock units or purchases under our employee stock purchase plan. We did not repurchase any shares of our common stock in the first quarter of 2024 or 2023. On December 14, 2020, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock. As of March 31, 2024, we had the full amount remaining available under the authorization.

NOTE K – SEGMENT REPORTING

We aggregate our core businesses into two reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices. In accordance with FASB ASC Topic 280, Segment Reporting, we identified our reportable segments based on the nature of our products, production processes, type of customer, selling and distribution methods and regulatory environment, as well as the economic characteristics of each of our operating segments.

We measure and evaluate our reportable segments based on their respective net sales, operating income, excluding intersegment profits, and operating income as a percentage of net sales, all based on internally-derived standard currency exchange rates to exclude the impact of foreign currency, which may be updated from year to year. We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker (CODM) considers to be non-operational, such as amounts related to amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), and certain litigation-related net charges (credits) and European Union (EU) Medical Device Regulation (MDR) implementation costs. Although we exclude these amounts from operating income of reportable segments, they are included in reported Income (loss) before income taxes within our accompanying unaudited consolidated statements of operations and are included in the reconciliation below. Refer to Note L – Revenue for net sales by reportable segment presented in accordance with GAAP.

29

A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying unaudited consolidated statements of operations is as follows (in millions, except percentages). Prior period amounts have been restated at constant currency to conform to current year presentation.

Three Months Ended
March 31,
Net Sales20242023
MedSurg$1,402 $1,266
Cardiovascular2,426 2,072
Total net sales of reportable segments3,827 3,337
Impact of foreign currency fluctuations29 52
$3,856 $3,389
Income (loss) before income taxes
MedSurg$474 $409
Cardiovascular653 553
Total operating income of reportable segments1,128 963
Unallocated amounts:
Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments(115)(98)
Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs(124)(110)
Amortization expense(214)(203)
Operating income (loss)675 552
Other income (expense), net(67)(108)
Income (loss) before income taxes$608 $444

Three Months Ended March 31,
Operating income margin of reportable segments20242023
MedSurg33.8 %32.3 %
Cardiovascular26.9 %26.7 %


30

NOTE L – REVENUE

We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes within our accompanying unaudited consolidated statements of operations. Our business structure is organized into five operating segments. The following tables disaggregate our revenue from contracts with customers by business unit and geographic region (in millions). Generally, we allocate revenue from contracts with customers to geographic regions based on the location where the sale originated.

Three Months Ended March 31,
20242023
BusinessesU.S.Int'lTotalU.S.Int'lTotal
Endoscopy$395 $247 $642 $351 $226 $577 
Urology356 157 513 326 143 469 
Neuromodulation190 66 256 172 62 234 
MedSurg941 470 1,412 850 430 1,280 
   Interventional Cardiology Therapies195 457 652 183 408 591 
   Watchman311 33 344 265 25 291 
   Cardiac Rhythm Management354 221 575 345 203 548 
    Electrophysiology158 143 300 85 91 177 
Cardiology1,017 854 1,872 879 727 1,606 
Peripheral Interventions299 274 573 275 229 503 
Cardiovascular1,316 1,129 2,445 1,154 956 2,110 
Total Net Sales$2,258 $1,599 $3,856 $2,003 $1,386 $3,389 


Refer to Note K - Segment Reporting for information on our reportable segments.

Three Months Ended March 31,
Geographic Regions20242023
U.S.$2,258 $2,003 
Europe, Middle East and Africa803 712 
Asia-Pacific647 548 
Latin America and Canada149 126 
Total Net Sales$3,856 $3,389 
Emerging Markets(1)
$648 $529 
(1) Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2023, modified our list to include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada.

Deferred Revenue

Contract liabilities are classified within Other current liabilities and Other long-term liabilities within our accompanying unaudited consolidated balance sheets. Our deferred revenue balance was $593 million as of March 31, 2024 and $577 million as of December 31, 2023. Our contract liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System within our Cardiology business, for which revenue is recognized over the average service period based on device and patient longevity. Our contract liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor system, also within our Cardiology business, for which revenue is recognized over the average service period based on device longevity and usage. We recognized revenue of $62 million in the first quarter that was included in the above contract liability balance as of December 31, 2023. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.
31


Variable Consideration

For additional information on variable consideration, refer to Note A – Significant Accounting Policies to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K.

NOTE M – CHANGES IN OTHER COMPREHENSIVE INCOME

The following tables provide the reclassifications out of Other comprehensive income (loss), net of tax attributable to Boston Scientific common stockholders:
(in millions)Foreign Currency Translation AdjustmentsNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2023$(96)$154 $(8)$49 
Other comprehensive income (loss) before reclassifications65 59  124 
(Income) loss amounts reclassified from accumulated other comprehensive income(3)(38)(0)(41)
Total other comprehensive income (loss)62 22 (0)83 
Balance as of March 31, 2024$(34)$175 $(8)$132 

(in millions)Foreign Currency Translation AdjustmentsNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2022$(1)$269 $1 $269 
Other comprehensive income (loss) before reclassifications(40)10 (5)(35)
(Income) loss amounts reclassified from accumulated other comprehensive income(2)(53)(0)(56)
Total other comprehensive income (loss)(42)(43)(5)(91)
Balance as of March 31, 2023$(43)$225 $(4)$178 

Refer to Note D – Hedging Activities and Fair Value Measurements for further detail on our net investment hedges recorded in Foreign currency translation adjustment and our cash flow hedges recorded in Net change in derivative financial instruments.

NOTE N – NEW ACCOUNTING PRONOUNCEMENTS

Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our accompanying unaudited consolidated financial statements. During the first quarter of 2024, we implemented the following standard on a prospective basis, which did not have a material impact on our unaudited consolidated financial statements:

ASC Update No. 2022-03

ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities.
32


Standards to be Implemented

In November 2023, the FASB issued ASC Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. Update No. 2023-07 requires disclosure, on an annual and interim basis, of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss in addition to disclosure of amounts for other segment items and a description of its composition. Update No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. As this accounting standard update only impacts disclosures, we do not expect the adoption to have a material impact on our unaudited consolidated financial statements.

In December 2023, the FASB issued ASC Update No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. Update No. 2023-09 aims to enhance the transparency and decision usefulness of income tax disclosures. Update No. 2023-09 modifies the rules on income tax disclosures to require entities to disclose (1) specific categories in the rate reconciliation, (2) the income or loss from continuing operations before income tax expense or benefit (separated between domestic and foreign) and (3) income tax expense or benefit from continuing operations (separated by federal, state, and foreign). ASU 2023-09 also requires entities to disclose their income tax payments to international, federal, state and local jurisdictions, among other changes. Update No. 2023-09 is effective for fiscal years beginning after December 15, 2024. We expect to adopt Update No. 2023-09 prospectively. As this accounting standard update only impacts disclosures, we do not expect the adoption to have a material impact on our unaudited consolidated financial statements.

No other new accounting pronouncements issued or effective in the period had or are expected to have a material impact on our accompanying unaudited consolidated financial statements.

33

ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Introduction

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world. As a medical technology leader for more than 40 years, we have advanced the practice of less-invasive medicine by helping physicians and other medical professionals diagnose and treat a wide range of diseases and medical conditions and improve patients’ quality of life by providing alternatives to surgery and other medical procedures that are typically traumatic to the body. We advance science for life by providing a broad range of high performance solutions to address unmet patient needs and reduce the cost of health care. When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries.

Financial Summary

Three Months Ended March 31, 2024

Our net sales for the first quarter of 2024 were $3.856 billion, compared to $3.389 billion for the first quarter of 2023. This increase of $467 million, or 13.8 percent, included operational1 net sales growth of 15.0 percent and the negative impact of 120 basis points from foreign currency fluctuations. Operational net sales growth included organic2 net sales growth of 13.1 percent and the positive impact of 190 basis points from our majority stake investment in Acotec Scientific Holdings Limited (Acotec) and the acquisitions of Apollo Endosurgery, Inc. (Apollo) and Relievant Medsystems, Inc. (Relievant) during the first, second and fourth quarters of 2023, respectively, for which there is less than a full period of comparable net sales. The increase in our net sales was primarily driven by the diversity of our product portfolio and strong execution, coupled with growth in the underlying markets in which we compete. Refer to Quarterly Results and Business Overview for a discussion of our net sales by business.

Our reported net income attributable to Boston Scientific common stockholders for the first quarter of 2024 was $495 million, or $0.33 per diluted share. Our reported results for the first quarter of 2024 included certain charges and/or credits totaling $337 million (after-tax), or $0.23 per diluted share. Excluding these items, adjusted net income attributable to Boston Scientific common stockholders3 was $832 million, or $0.56 per diluted share.

Our reported net income attributable to common stockholders for the first quarter of 2023 was $300 million, or $0.21 per diluted share. Our reported results for the first quarter of 2023 included certain charges and/or credits totaling $373 million (after-tax), or $0.26 per diluted share. Excluding these items, adjusted net income attributable to Boston Scientific common stockholders3 was $673 million, or $0.47 per diluted share.















1Operational net sales growth excludes the impact of foreign currency fluctuations.
2Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales.
3Adjusted measures, including operational and organic net sales growth and adjusted net income attributable to Boston Scientific common stockholders, exclude certain items required by generally accepted accounting principles in the United States (GAAP), are not prepared in accordance with GAAP and should not be considered in isolation from, or as a replacement for, the most directly comparable GAAP measure. Refer to Additional Information for a discussion of management’s use of these non-GAAP financial measures.
34

The following is a reconciliation of our results of operations prepared in accordance with GAAP to those adjusted results considered by management. Refer to Quarterly Results and Business Overview and Additional Information for a discussion of these reconciling items:
 Three Months Ended March 31, 2024
(in millions, except per share data)Income (Loss) Before Income TaxesIncome Tax Expense (Benefit)Net Income (Loss)Preferred Stock DividendsNet Income (Loss) Attributable to Noncontrolling InterestsNet Income (Loss) Attributable to Boston Scientific Common StockholdersImpact per Share
Reported$608 $115 $493 $ $(1)$495 $0.33 
Non-GAAP adjustments:
Amortization expense214 29 184 — 182 0.12 
Acquisition/divestiture-related net charges (credits)64 (13)77770.05 
Restructuring and restructuring-related net charges (credits)46 640400.03 
Investment portfolio net losses (gains) and impairments(14)(3)(11)(11)(0.01)
European Union (EU) Medical device regulation (MDR) implementation costs14 212120.01 
Deferred tax expenses (benefits)— (37)37370.02 
Adjusted$932 $99 $833 $ $1 $832 $0.56 

 Three Months Ended March 31, 2023
(in millions, except per share data)Income (Loss) Before Income TaxesIncome Tax Expense (Benefit)Net Income (Loss)Preferred Stock DividendsNet Income (Loss) Attributable to Noncontrolling InterestsNet Income (Loss) Attributable to Boston Scientific Common Stockholders
Impact per Share(4)
Reported$444 $131 $314 $(14)$ $300 $0.21 
Non-GAAP adjustments:
Amortization expense203 28 175 — — 175 0.12 
Acquisition/divestiture-related net charges (credits)59 (7)66 — — 66 0.05 
Restructuring and restructuring-related net charges (credits)44 37 — — 37 0.03 
Investment portfolio net losses (gains) and impairments21 16 — — 16 0.01 
European Union (EU) Medical device regulation (MDR) implementation costs16 14 — — 14 0.01 
Deferred tax expenses (benefits)— (41)41 — — 41 0.03 
Discrete tax items— (25)25 — — 25 0.02 
Adjusted$787 $100 $687 $(14)$ $673 $0.47 





4 For the three months ended March 31, 2023, the effect of assuming the conversion of our 5.50% Mandatory Convertible Preferred Stock, Series A (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of Net income (loss) per common share - diluted earnings per share (EPS). Accordingly, GAAP Net income (loss) and Adjusted net income were reduced by cumulative Preferred stock dividends, as presented within our unaudited consolidated statements of operations, for purposes of calculating GAAP Net income attributable to Boston Scientific common stockholders. On June 1, 2023, all outstanding shares of MCPS automatically converted into shares of common stock.

35

Quarterly Results and Business Overview

The following section describes our net sales and results of operations by reportable segment and business. For additional information on our businesses and product offerings, refer to Item 1. Business of our most recent Annual Report on Form 10-K.
 Three Months Ended March 31,
(in millions)20242023Increase/(Decrease)
Endoscopy
$642 $577 11.4%
Urology513 469 9.3%
Neuromodulation
256 234 9.5%
MedSurg1,412 1,280 10.3%
Cardiology1,872 1,606 16.5%
Peripheral Interventions
573 503 13.9%
Cardiovascular2,445 2,110 15.9%
Net Sales$3,856 $3,389 13.8%

MedSurg

Endoscopy

Our Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with innovative, less-invasive technologies. Net sales of Endoscopy products of $642 million during the first quarter of 2024 represented 17 percent of our consolidated net sales. Endoscopy net sales increased $66 million, or 11.4 percent, during the first quarter of 2024, compared to the prior year period. During the first quarter of 2024, this increase included operational net sales growth of 12.1 percent and a negative impact of 70 basis points from foreign currency fluctuations, compared to the prior year period. Operational net sales growth included organic net sales growth of 9.8 percent during the first quarter of 2024 and the positive impact of 230 basis points from our acquisition of Apollo and divestiture of our pathology business in the second quarter of 2023.

Organic net sales growth was primarily driven by our biliary franchise led by our AXIOS Stent and Delivery System, and our hemostasis and single use imaging franchises.

Urology

Our Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia (BPH), prostate cancer, erectile dysfunction and incontinence. Net sales of Urology products of $513 million during the first quarter of 2024 represented 13 percent of our consolidated net sales. Urology net sales increased $44 million, or 9.3 percent, during the first quarter of 2024, compared to the prior year period. During the first quarter of 2024, this increase included operational net sales growth of 9.8 percent and a negative impact of 50 basis points from foreign currency fluctuations, compared to the prior year period.

Operational net sales growth during the first quarter of 2024 was primarily driven by our stone management franchise, led by our Lumenis Pulse™ Holmium Laser Systems with MOSES™ Technology, as well as our prosthetic urology franchise.

Neuromodulation

Our Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Net sales of Neuromodulation products of $256 million during the first quarter of 2024 represented 7 percent of our consolidated net sales. Neuromodulation net sales increased $22 million, or 9.5 percent during the first quarter of 2024, compared to the prior year period. During the first quarter of 2024, this increase included operational net sales growth of 9.8 percent and a negative impact of 30 basis points from foreign currency fluctuations, compared to the prior year period. Operational net sales growth included the positive impact of 1,120 basis points from our acquisition of Relievant in the fourth quarter of 2023 and a decline in organic net sales of 1.3 percent during the first quarter of 2024.

The decline in organic net sales was primarily driven by continued pressures on our U.S. spinal cord stimulation (SCS) business. This decline was partially offset by growth within our deep brain stimulation (DBS) franchise led by our Vercise Genus™ DBS System.
36


Cardiovascular

Cardiology

Our Cardiology business develops and manufactures devices and medical technologies for diagnosing and treating a variety of diseases and abnormalities of the heart. Net sales of Cardiology products of $1.872 billion during the first quarter of 2024 represented 49 percent of our consolidated net sales. Cardiology net sales increased $265 million, or 16.5 percent, during the first quarter of 2024, compared to the prior year period. During the first quarter of 2024, this increase included operational net sales growth of 17.9 percent and a negative impact of 140 basis points from foreign currency fluctuations, compared to the prior year period.

Operational net sales growth during the first quarter of 2024 was primarily driven by our continued market expansion of Left Atrial Appendage Closure (LAAC) procedures with our WATCHMAN FLX™ LAAC Device, as well as growth of our electrophysiology business, led by our Farapulse™ Pulsed Field Ablation System, our POLARx™ technologies and our access solutions portfolio, and our percutaneous coronary intervention guidance franchises.

Peripheral Interventions

Our Peripheral Interventions business develops and manufactures products to diagnose and treat peripheral arterial and venous diseases, as well as products to diagnose, treat and ease various forms of cancer. Net sales of Peripheral Interventions products of $573 million during the first quarter of 2024 represented 15 percent of our consolidated net sales. Peripheral Interventions net sales increased $70 million, or 13.9 percent, during the first quarter of 2024, compared to the prior year period. During the first quarter of 2024, this increase included operational net sales growth of 16.0 percent and a negative impact of 210 basis points from foreign currency fluctuations, compared to the prior year period. Operational net sales growth during the first quarter of 2024 included organic net sales growth of 11.3 percent and the positive impact of 460 basis points from our majority stake investment in Acotec which we acquired in the first quarter of 2023.

Organic net sales growth during the first quarter of 2024 was primarily driven by our interventional oncology franchise led by our Therasphere™ Y-90 Radioactive Glass Microspheres and EMBOLD™ Fibered Coil, as well as our drug-eluting portfolio within our vascular franchise led by our Ranger™ Drug Coated Balloon.

Emerging Markets

As part of our strategic imperative to drive global expansion, we are seeking to grow net sales and market share by expanding our global presence, including in Emerging Markets. Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2023, modified our list to include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada.

Our Emerging Markets' net sales represented 17 percent of our consolidated net sales during the first quarter of 2024 and 16 percent during the first quarter of 2023, respectively. During the first quarter of 2024, our Emerging Markets net sales grew 22.6 percent on a reported basis, which included operational net sales growth of 28.2 percent and a negative impact of 550 basis points from foreign currency fluctuations, compared to the prior year period. Operational growth was driven primarily by growth in China, fueled by the breadth of our portfolio and focus on innovation and strong commercial execution.

Economic Environment

Our business has been impacted by global supply chain disruptions, which have improved in recent quarters, however challenges still exist. In particular, we have experienced, and may continue to experience, increases in cost and limited availability of certain raw materials, components, and other inputs necessary to manufacture and distribute our products due to constraints and inflation within the global supply chain, as well as increases in wage costs and the cost and time to distribute our products. Uncertainty around inflationary pressures, interest rates, monetary policy and changes in tax laws could potentially cause new, or exacerbate existing, economic challenges that we may face, including the impact of foreign currency fluctuations on our results of operations, or result in an economic downtown or recession, which could negatively impact our business operations and results. Existing and future potential geopolitical dynamics, including matters related to the Russia/Ukraine war, Israel/Hamas war, as well as tension in the Taiwan strait, may create economic, supply chain, energy, and other challenges, including disruptions to business operations, which impact, and may in the future negatively impact our business. In particular, international conflicts could create instability, have and may further result in sanctions, tariffs, and other measures that restrict international trade and may negatively affect our business operations and results.
37


Gross Profit

Our Gross profit was $2.648 billion for the first quarter of 2024 and $2.349 billion for the first quarter of 2023. As a percentage of net sales, our Gross profit decreased to 68.7 percent during the first quarter of 2024, compared to 69.3 percent in the first quarter of 2023. The following is a reconciliation of our gross profit margin and a description of the drivers of the changes from period to period:
Percentage of Net Sales
Three Months
Gross profit margin - period ended March 31, 202369.3%
Sales pricing, volume and mix0.5
Net impact of foreign currency fluctuations(0.3)
All other, including inventory charges and other period expenses(0.9)
Gross profit margin - period ended March 31, 202468.7%

The primary factors contributing to the decrease in our gross profit margin in the first quarter of 2024, as compared to the same period in the prior year, were inventory charges, period expenses and the unfavorable impact of foreign currency. These impacts were partially offset by increased sales of higher margin products.

Operating Expenses

The following table provides a summary of our key operating expenses:
 Three Months Ended March 31,
 20242023
(in millions)$% of Net Sales$% of Net Sales
Selling, general and administrative expenses$1,364 35.4 %$1,215 35.9 %
Research and development expenses366 9.5 %337 9.9 %

Selling, General and Administrative expenses (SG&A Expenses)

During the first quarter of 2024, SG&A expenses increased $149 million, or 12 percent, compared to the prior year period and were 50 basis points lower as a percentage of net sales. The increase in SG&A expenses was primarily due to higher selling costs driven by higher global net sales and costs to support recent and upcoming product launches, including the Farapulse™ Pulsed Field Ablation System.

Research and Development expenses (R&D Expenses)

We remain committed to advancing medical technologies and investing in meaningful R&D projects across our businesses. During the first quarter of 2024, R&D expenses increased $29 million, or 9 percent, compared to the prior year period and were 40 basis points lower as a percentage of net sales. R&D expenses increased as a result of investments across our businesses in order to maintain a pipeline of new products that we believe will contribute to profitable sales growth.
38

Other Operating Expenses

The following provides a summary of certain of our other operating expenses, which are excluded by management for purposes of evaluating operating performance; refer to Additional Information for a further description.

Amortization Expense

During the first quarter of 2024, Amortization expense increased $11 million, or 5 percent, compared to the prior year period. The increase in Amortization expense was driven by the addition of amortizable intangible assets associated with our recent acquisitions.

Contingent Consideration Net Expense (Benefit)

To recognize changes in the fair value of our contingent consideration liability, we recorded net charges of $17 million in the first quarter of 2024 and $12 million in the first quarter of 2023. The net charges recorded in the first quarter of 2024 related to an increase in expected payments for achievement of revenue-based earn outs as a result of over-performance. In addition, we made payments of $123 million and $68 million associated with prior acquisitions during the first quarter of 2024 and 2023, respectively, following the achievement of revenue-based earnouts. Refer to Note B – Acquisitions and Strategic Investments to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q for additional details related to our contingent consideration arrangements.

Restructuring and Restructuring-related Net Charges (Credits)

On February 22, 2023, our Board of Directors approved, and we committed to, a new global restructuring program (the 2023 Restructuring Plan). The 2023 Restructuring Plan will advance our Global Supply Chain Optimization strategy, which is intended to simplify our manufacturing and distribution network by transferring certain production lines among facilities and drive operational efficiencies and resiliency. Key activities under the 2023 Restructuring Plan will also include optimizing certain functional capabilities to achieve cost synergies and better support business growth. For more information, refer to 2023 Restructuring Plan contained in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of our most recent Annual Report on Form 10-K.

Pursuant to the 2023 Restructuring Plan, we recorded restructuring charges in accordance with FASB ASC Topic 420, Exit or Disposal Cost Obligations of $3 million in the first quarter of 2024. The restructuring reserve balance was $35 million as of March 31, 2024. In addition, we recorded restructuring-related charges of $43 million in the first quarter of 2024 primarily within Cost of products sold and SG&A Expenses. During the first quarter of 2023, we recorded restructuring charges of $20 million and restructuring-related charges of $24 million, and the restructuring reserve balance as of December 31, 2023 was $41 million.

Litigation-related Net Charges (Credits)

We did not record any litigation-related net charges (credits) during the first quarter of 2024 or 2023. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related net charges (credits) within our accompanying unaudited consolidated financial statements. All other legal and product liability charges, credits and costs are recorded within SG&A expenses.

We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation, and therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with the financial covenant required by our credit arrangements. Refer to Note H – Commitments and Contingencies to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q for discussion of our material legal proceedings.
39


Interest Expense
The following table provides a summary of our Interest expense and average borrowing rate:
Three Months Ended March 31,
20242023
Interest expense (in millions)
$(69)$(65)
Average borrowing rate2.7 %2.8 %

Interest expense increased during the first quarter of 2024 compared to the prior year period primarily due to increased debt from the registered public offering of €2.000 billion in aggregate principal amount of euro-denominated senior notes during the quarter. Our average borrowing rate remained flat during the first quarter of 2024 compared to the prior year period. Refer to Liquidity and Capital Resources and Note E – Contractual Obligations and Commitments to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q for more information regarding our debt obligations.

Tax Rate

Our effective tax rate from continuing operations is presented below:
Three Months Ended March 31,
20242023
Effective tax rate from continuing operations18.9 %29.4 %

Our reported tax rate is affected by recurring items such as the amount of our earnings subject to differing tax rates in foreign jurisdictions and the impact of certain receipts and charges that are taxed at rates that differ from our effective tax rate.

The principal reason for the difference between the statutory rate and our reported tax rate in the first quarter of 2024 primarily relates to certain charges for acquisition expenses as well as certain discrete benefits related to unrecognized tax benefits and stock-based compensation. In the first quarter of 2023, the primary difference between the statutory tax rate and our reported tax rate relates to certain discrete charges related to provision-to-return adjustments.

Effective January 1, 2024, many countries where we do business, including the United Kingdom, Japan, South Korea, and many EU member states, adopted a global minimum effective tax rate of 15% based on the Pillar Two framework issued by the Organization for Economic Cooperation and Development (OECD). Other countries where we do business are also actively considering adopting the framework or are in various stages of enacting the framework into their country’s laws. While the Company continues to monitor legislative adoption of the Pillar Two rules by country, as well as for additional guidance from the OECD, there is significant uncertainty that exists regarding the interpretation of the detailed Pillar Two rules, whether such rules will be implemented consistently across taxing jurisdictions, how such rules interact with existing national tax laws and whether such rules are consistent with existing tax treaty obligations. Although the current impact of the adoption of a global minimum effective tax on our financial statements is not material, it is possible that the final adoption, implementation, and interpretation of Pillar Two across all jurisdictions where we do business could have a material adverse impact on our financial position, results of operations, and cash flows.

Our operations presently benefit from various tax provisions of the Tax Cuts and Jobs act which are set to expire in 2025. If future legislation is unable to extend or modify these provisions, this could have a material adverse impact on our overall effective tax rate, financial condition, results of operations, and cash flows.

Critical Accounting Policies and Estimates

Our financial results are affected by the selection and application of accounting policies and methods. During the first quarter of 2024, there were no material changes to the application of critical accounting policies previously disclosed in our most recent Annual Report on Form 10-K.

40

Liquidity and Capital Resources

Based on our current business plan, we believe our existing balance of Cash and cash equivalents, future cash generated from operations, access to capital markets and existing credit facilities will be sufficient to fund our operations, invest in our infrastructure, pay our legal-related liabilities, pay taxes due, service and repay our existing debt and fund possible acquisitions for the next 12 months and for the foreseeable future.

As of March 31, 2024, we had $2.329 billion of unrestricted Cash and cash equivalents on hand, including approximately $89 million held by Acotec, a less than wholly owned entity of which we acquired a majority stake investment during the first quarter of 2023. The balance is comprised of $1.946 billion invested in money market funds and time deposits and $384 million in interest bearing and non-interest-bearing bank accounts. We invest excess cash on hand in short-term financial instruments that earn at market interest rates while mitigating principal risk through instrument and counterparty diversification, as well as what we believe to be prudent instrument selection. We limit our direct exposure to securities in any one industry or issuer.

In 2021, we entered into our $2.750 billion revolving credit facility (2021 Revolving Credit Facility) with a global syndicate of commercial banks initially scheduled to mature on May 10, 2026, with one-year extension options, subject to certain conditions. On March 1, 2023, we entered into an amendment of the 2021 Revolving Credit Facility, which provided for an extension of the scheduled maturity date to May 10, 2027 and replaced the London Interbank Offered Rate (LIBOR) with the Secured Overnight Financing Rate (SOFR) as the Eurocurrency Rate for Dollars, including applicable credit spread adjustments and relevant SOFR benchmark provisions, as well as modification to the calculation of consolidated Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), described under Financial Covenant below. This facility provides backing for our commercial paper program, and outstanding commercial paper directly reduces borrowing capacity under the 2021 Revolving Credit Facility. There were no amounts outstanding under the 2021 Revolving Credit Facility or our commercial paper program as of March 31, 2024, resulting in an additional $2.750 billion of available liquidity.

For additional details related to our debt obligations, including our financial covenant requirement, refer to Note E – Contractual Obligations and Commitments to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q.

The following provides a summary and description of our net cash inflows (outflows):
Three Months Ended March 31,
(in millions)20242023
Cash provided by (used for) operating activities$164 $190 
Cash provided by (used for) investing activities(285)(484)
Cash provided by (used for) financing activities1,569 (69)

Operating Activities

During the first quarter of 2024, cash provided by (used for) operating activities decreased $27 million as compared to the prior year period primarily due to comparatively higher employee related payments and contingent consideration based payments, offset by higher sales and operating income.

Investing Activities

During the first quarter of 2024, cash provided by (used for) investing activities included net cash payments of $47 million for acquired businesses as well as purchases of property, plant and equipment and internal use software of $179 million. During the first quarter of 2023, cash used for investing activities included cash payments of $375 million, net of cash acquired, for the acquisition of a majority stake investment in Acotec, as well as purchases of property, plant and equipment and internal use software of $111 million. For more information on our acquisitions, refer to Note B – Acquisitions and Strategic Investments to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q.

41

Financing Activities

During the first quarter of 2024, cash provided by (used for) financing activities included a registered public offering (the Offering) of €2.000 billion in aggregate principal amount of euro-denominated senior notes (the 2024 Eurobonds). The Offering resulted in cash proceeds of $2.145 billion, net of investor discounts and issuance costs. We used the net proceeds from the Offering of the 2024 Eurobonds to fund the repayment at maturity of our 3.450% Senior Notes due March 2024 and to pay accrued and unpaid interest with respect to such notes. Additionally, we plan to use the remaining net proceeds from the Offering to fund a portion of the purchase price of our announced agreement to acquire Axonics Inc. (Axonics) and to pay related fees and expenses, and for general corporate purposes. If the Axonics acquisition is not consummated by the applicable outside date pursuant to the merger agreement or we choose to not pursue consummation of the acquisition, we will be required to redeem each series of the notes at a special mandatory redemption price equal to 101% of the aggregate principal amount of such series of notes, plus accrued and unpaid interest, if any, to, but excluding, the date on which the notes will be redeemed. For more information, refer to Note E – Contractual Obligations and Commitments to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q. Cash provided by (used for) financing activities in the first quarter of 2023 included cash used to net share settle employee equity awards of $50 million and proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans of $63 million.

Financial Covenant

As of March 31, 2024, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility.

The 2021 Revolving Credit Facility includes the financial covenant requirement for all of our credit arrangements that we maintain the maximum permitted leverage ratio of 3.75 times for the remaining term. The credit agreement provides for higher leverage ratios, at our election, for the period following a Qualified Acquisition, as defined by the agreement, for which consideration exceeds $1.000 billion. In the event of such an acquisition, for the four succeeding quarters immediately following, including the quarter in which the acquisition occurs, the maximum permitted leverage ratio is 4.75 times. It steps down for the fifth, sixth and seventh succeeding quarters to 4.50 times, 4.25 times and 4.00 times, respectively. Thereafter, a maximum leverage ratio of 3.75 times is required through the remaining term of the 2021 Revolving Credit Facility. We have elected to designate the Axonics acquisition as a Qualified Acquisition under the credit agreement, and upon closing, will increase the maximum permitted leverage ratio at that time. The agreement also provides for an exclusion of any debt incurred to fund a Qualified Acquisition, until the earlier of the acquisition close date or date of abandonment, termination or expiration of the acquisition agreement. As of March 31, 2024, we excluded $2.138 billion of debt incurred from our leverage ratio calculation in connection with the Axonics acquisition. We believe that we have the ability to comply with the financial covenant for the next 12 months.

The financial covenant requirement, as amended on March 1, 2023, provides for an exclusion from the calculation of consolidated EBITDA, as defined by the credit agreement, through maturity, of certain charges and expenses. The credit agreement amendment reset the starting date for purposes of calculating such permitted exclusions in each case from March 31, 2021 to December 31, 2022. Permitted exclusions include any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of March 31, 2024, we had $273 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the agreement, are excluded from the calculation of consolidated EBITDA, as defined by the agreement, provided that the sum of any excluded net cash litigation payments do not exceed $1.000 billion plus all accrued legal liabilities as of December 31, 2022. As of March 31, 2024, we had $1.457 billion of the litigation exclusion remaining.
Contractual Obligations and Commitments

On January 8, 2024, we announced our entry into a definitive agreement to acquire 100 percent of Axonics, a publicly traded medical technology company primarily focused on the development and commercialization of devices to treat urinary and bowel dysfunction. The purchase price is $71.00 in cash per share, or approximately $3.670 billion. On April 3, 2024, we and Axonics each received a request for additional information (Second Request) from the United States Federal Trade Commission (FTC) in connection with the FTC's review of the transaction. The issuance of the Second Request extends the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR Act), until 30 days after both we and Axonics have substantially complied with the Second Request, unless the waiting period is extended voluntarily by the parties or terminated earlier by the FTC. We and Axonics expect to promptly respond to the Second Request and to continue to work cooperatively with the FTC in its review. The transaction is expected to be completed in the second half of 2024, subject to the expiration or termination of the waiting period under the HSR Act and the satisfaction (or waiver) of other customary closing conditions. The Axonics business will be integrated into our Urology division.
42


Certain of our acquisitions involve the payment of contingent consideration. Refer to Note B – Acquisitions and Strategic Investments to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q for further details regarding the estimated potential amount of future contingent consideration we could be required to pay associated with our acquisitions. There have been no other material changes to our contractual obligations and commitments as of March 31, 2024.

Equity

On June 1, 2023, in accordance with the terms of our MCPS, all outstanding shares of MCPS automatically converted into shares of common stock. No action by the holders of the MCPS was required in connection with the mandatory conversion. The conversion rate for each share of MCPS was 2.3834 shares of common stock. Cash was paid in lieu of fractional shares in accordance with the terms of the MCPS. An aggregate of approximately 24 million shares of common stock, including shares of common stock issued to holders of MCPS that elected to convert prior to the Mandatory Conversion Date, were issued upon conversion of the MCPS. Following the mandatory conversion of the MCPS, there were no outstanding shares of MCPS, resulting in the retirement of the annualized approximately $55 million cash dividend payment on the MCPS.

We received $80 million during the first quarter of 2024 and $63 million during the first quarter of 2023 in proceeds from stock issuances related to our stock option and employee stock purchase plans. Proceeds from the exercise of employee stock options and employee stock purchases vary from period to period based upon, among other factors, fluctuations in the trading price of our common stock and in the exercise and stock purchase patterns of our employees.

We did not repurchase any shares of our common stock during the first quarter of 2024 or 2023. On December 14, 2020, our Board of Directors approved a new stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock. As of March 31, 2024, we had the full amount remaining available under the authorization.

Legal Matters

For a discussion of our material legal proceedings refer to Note H – Commitments and Contingencies to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q and Note I – Commitments and Contingencies to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K.

Recent Accounting Pronouncements
Information regarding new accounting pronouncements implemented since December 31, 2023, and relevant accounting pronouncements to be implemented in the future are included in Note N – New Accounting Pronouncements to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q.

Additional Information

Corporate Responsibility

Our sustainable environmental, social and governance (ESG) practices underpin all aspects of our global business. Our approach is aligned with the United Nations Sustainable Development Goals and our material topics and practices are informed by a broad range of internal and external stakeholders – locally, nationally and globally. Our employees around the world work with suppliers and other organizations that share our commitment to these practices that help address issues related to health inequity, economic disparity, climate change and environmental protection. Our global ESG vision and strategy is led by our ESG Executive Steering Committee and our vice president of ESG, who provides regular updates to our Board of Directors. Our ESG team works closely with subject matter experts and key advisors from across the business to implement our ESG practices and determine how we measure and share progress. These efforts are supported by our cross-functional teams, our Environmental Health and Safety teams and policies, our Global Council for Inclusion, as well as our local, regional and national employee and community engagement programs. Since 2021, our annual bonus plan has included performance measures for certain ESG goals. For additional information on our sustainability efforts, as well as our Diversity, Equity and Inclusion initiatives, refer to our most recent Annual Report on Form 10-K. For additional information on our annual bonus plan, refer to our Proxy Statement for the 2024 Annual Meeting of Shareholders.

43


Cybersecurity

We have established controls and procedures to escalate enterprise level issues, including cybersecurity matters, to the appropriate management levels within our organization and our Board of Directors, or members or committees thereof, as appropriate. Under our framework, cybersecurity issues, including those involving vulnerabilities introduced by our use of third-party software, are analyzed by subject matter experts, including a crisis committee as needed in accordance with our incident response plans, for potential financial, operational, and reputational risks, based on, among other factors, the nature of the matter and breadth of impact. Matters determined to present potential material impacts to our financial results, operations, and/or reputation are immediately reported by management to the Board of Directors, or individual members or committees thereof, as appropriate, in accordance with our established escalation framework. In addition, we have established procedures to help ensure that members of management responsible for overseeing the effectiveness of disclosure controls are informed in a timely manner of known cybersecurity risks and incidents that may materially impact our operations and that timely public disclosure is made, as appropriate. For additional information on our risk management, strategy and governance around cybersecurity, refer to Part I, Item 1C. Cybersecurity in our most recent Annual Report on Form 10-K.

Stock Trading Policy

Our directors and executive officers are subject to our Stock Trading Policy, which is designed to facilitate compliance with insider trading laws and governs transactions in our common stock and related derivative securities. Our policy designates certain regular periods, dictated by release of financial results, in which trading is restricted for individuals in information-sensitive positions, including directors and executive officers. In addition, additional periods of trading restriction may be imposed as determined by the President and Chief Executive Officer, General Counsel, or Chief Financial Officer in light of material pending developments. Further, during permitted windows, certain individuals in information-sensitive positions are required to seek pre-clearance for trades from the General Counsel, who assesses whether there are any important pending developments which need to be made public before the individual may participate in the market.

Periodically, certain of our executive officers adopt written stock trading plans in accordance with Rule 10b5-1 under the Exchange Act and our own Stock Trading Policy. A Rule 10b5-1 trading plan is a written document that pre-establishes the amount, prices and dates (or formulas for determining the amounts, prices and dates) of future purchases or sales of our stock, including shares issued upon exercise of stock options or vesting of restricted stock units. These plans are entered into at a time when the person is not in possession of material non-public information about the Company. In addition to any plans described in Part II, Item 5 of this Quarterly Report on Form 10-Q, we disclose details regarding individual Rule 10b5-1 trading plans on the Investor Relations section of our website.

44

Use of Non-GAAP Financial Measures

To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share (EPS) that exclude certain charges (credits); operational net sales, which exclude the impact of foreign currency fluctuations; and organic net sales, which exclude the impact of foreign currency fluctuations as well as the impact of acquisitions and divestitures with less than a full period of comparable net sales. These non-GAAP financial measures are not in accordance with GAAP and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.

To calculate adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share, we exclude certain charges (credits) from GAAP net income and GAAP net income attributable to Boston Scientific common stockholders, which include amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio net losses (gains) and impairments, restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), EU MDR implementation costs, debt extinguishment net charges, deferred tax expenses (benefits) and certain discrete tax items. Amounts are presented after-tax using our effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 740-270-30, “General Methodology and Use of Estimated Annual Effective Tax Rate.” Please refer to Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report filed on Form 10-K filed with the Securities and Exchange Commission for an explanation of each of these adjustments and the reasons for excluding each item.

The GAAP financial measures most directly comparable to adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share are GAAP net income (loss), GAAP net income (loss) attributable to Boston Scientific common stockholders and GAAP net income (loss) per common share – diluted, respectively.

To calculate operational net sales growth rates, which exclude the impact of foreign currency fluctuations, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior periods. To calculate organic net sales growth rates, we also remove the impact of acquisitions and divestitures with less than a full period of comparable net sales. The GAAP financial measure most directly comparable to operational net sales and organic net sales is net sales reported on a GAAP basis.

Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the relevant sections of this Quarterly Report on Form 10-Q.

Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. The adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments’ measures of net sales and profit or loss. These adjustments are excluded from the segment measures reported to our chief operating decision maker that are used to make operating decisions and assess performance.

We believe that presenting adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders, adjusted net income (loss) per share, operational net sales and organic net sales growth rates, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results “through the eyes” of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.

45

Safe Harbor for Forward-Looking Statements

Certain statements that we may make from time to time, including statements contained in this Quarterly Report on Form 10-Q and information incorporated by reference herein, constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend,” “aim,” "goal," "target," "continue," "hope," "may" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.

The forward-looking statements in this Quarterly Report on Form 10-Q are based on certain risks and uncertainties, including the risk factors described in Part I, Item 1A. Risk Factors in our most recent Annual Report on Form 10-K and the specific risk factors discussed herein and in connection with forward-looking statements throughout this Quarterly Report on Form 10-Q, which could cause actual results to vary materially from the expectations and projections expressed or implied by our forward-looking statements. These risks and uncertainties, in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this Quarterly Report on Form 10-Q. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. Risks and uncertainties that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations, future U.S. and global political, competitive, reimbursement and regulatory conditions; geopolitical events; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions and the market acceptance of those products; market competition for our products; expected pricing environment; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property rights; litigation; financial market conditions; the execution and effect of our restructuring program; the execution and effect of our business strategy, including our cost-savings and growth initiatives; our ability to achieve environmental, social and governance goals and commitments; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, refer to Part I, Item 1A. Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A. Risk Factors in subsequent Quarterly Reports on Form 10-Q that we will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this Quarterly Report.

The following are some of the important risk factors that could cause our actual results to differ materially from our expectations in any forward-looking statements. For further discussion of these and other risk factors, refer to Part I, Item 1A. Risk Factors in our most recent Annual Report on Form 10-K.

Our Business

Risks associated with challenging or uncertain domestic and international economic conditions, including those related to interest rates, inflation, supply chain disruptions and constraints, adverse developments and volatility in the banking industry, currency devaluations or economies entering into periods of recession,

The impact of disruptions in the supply of the materials and components used in manufacturing our products or the sterilization of our products,

Labor shortages and the impact of inflation on the cost of raw materials and direct labor,

The impact of any future pandemics or other public health crises on worldwide economies, financial markets, manufacturing and distribution systems, including disruption in the manufacture or supply of certain components, materials or products, and business operations,

The impact of natural disasters, climate change or other catastrophic events on our ability to manufacture, distribute and sell our products,
46


The impact of competitive offerings, value-based procurement practices, government-imposed payback provisions and changes in reimbursement practices and policies on average selling prices for our products,

The ongoing impact on our business of physician alignment to hospitals, governmental investigations and audits of hospitals and other market and economic conditions on the overall number of procedures performed,

The performance of, and physician and patient confidence in, our products and technologies or those of our competitors,

The impact and outcome of ongoing and future clinical trials and market studies undertaken by us, our competitors or other third parties or perceived product performance of our or our competitors' products,
 
Variations in clinical results, reliability or product performance of our and our competitors' products,

Our ability to acquire or develop, launch and supply new or next-generation products and technologies worldwide and in line with our commercialization strategies in a timely and successful manner and with respect to our recent acquisitions,

The effect of consolidation and competition in the markets in which we do business or plan to do business,

Our ability to achieve our projected level or mix of product sales, as some of our products are more profitable than others,

Our ability to attract and retain talent, including key personnel associated with acquisitions, and to maintain our corporate culture in a hybrid work environment,

The impact of enhanced requirements to obtain and maintain regulatory approval in the U.S. and around the world, including EU MDR and the associated timing and cost of product approval,
 
The impact of increased pressure on the availability and rate of third-party reimbursement for our products and procedures in the U.S. and around the world, including with respect to the timing and costs of creating and expanding markets for new products and technologies,

The issuance of new or revised accounting standards by the Financial Accounting Standards Board or the Securities and Exchange Commission, and

The impact of potential goodwill and intangible asset impairment charges on our results of operations.

Regulatory Compliance, Litigation and Data Protection

The impact of health care policy changes and legislative or regulatory efforts in the U.S., the EU and around the world to modify product approval or reimbursement processes, including a trend toward demonstrating clinical outcomes, comparative effectiveness and cost efficiency, as well as the impact of other health care reform legislation,

Risks associated with our regulatory compliance and quality systems and activities in the U.S., the EU and around the world, including meeting regulatory standards applicable to manufacturing and quality processes,

The effect of global legal, regulatory or market responses to climate change and sustainability matters, including increased compliance burdens and costs to meet regulatory obligations,

Our ability to minimize or avoid future field actions or FDA warning letters relating to our products and processes and the ongoing inherent risk of potential physician advisories related to our or our competitors' products,

The impact of increased scrutiny of and heightened global regulatory enforcement facing the medical device industry arising from political and regulatory changes, economic pressures or otherwise, including under U.S. Anti-Kickback Statute, U.S. False Claims Act and similar laws in other jurisdictions, U.S. Foreign Corrupt Practices Act (FCPA) and similar laws in other jurisdictions, and U.S. and foreign export control, trade embargo and customs laws,

47

Costs and risks associated with current and future asserted litigation,

The effect of our litigation and risk management practices, including self-insurance and compliance activities on our loss contingencies, legal provisions and cash flows,
 
The impact of, diversion of management attention as a result of, and costs to cooperate with, litigate and/or resolve governmental investigations and our class action, product liability, contract and other legal proceedings,

The possibility of failure to protect our intellectual property rights and the outcome of patent litigation,

Our ability to secure our information technology and operational technology systems that support our business operations and protect our data integrity and products from a cyber-attack or other breach that may have a material adverse effect on our business, reputation or results of operations including increased risks as an indirect result of the ongoing Russia/Ukraine war and Israel/Hamas war, and

The potential impact to internal control over financial reporting relating to potential restrictions to access to consigned inventory at customer locations for our inventory count procedures.

Innovation and Certain Growth Initiatives

The timing, size and nature of our strategic growth initiatives and market opportunities, including with respect to our internal research and development platforms and externally available research and development platforms and technologies and the ultimate cost and success of those initiatives and opportunities,

Our ability to complete planned clinical trials successfully, obtain regulatory approvals and launch new and next generation products in a timely manner consistent with cost estimates, including the successful completion of projects from in-process research and development,

Our ability to identify and prioritize our internal research and development project portfolio and our external investment portfolio on profitable net sales growth opportunities as well as to maintain the estimated timing and costs of such projects and expected revenue levels for the resulting products and technologies,

Our ability to develop, manufacture and market new products and technologies successfully and in a timely manner and the ability of our competitors and other third parties to develop products or technologies that render our products or technologies noncompetitive or obsolete,

Our ability to execute appropriate decisions to discontinue, write-down or reduce the funding of any of our research and development projects, including projects from in-process research and development from our acquisitions, in our growth adjacencies or otherwise,

Our dependence on acquisitions, alliances or investments to introduce new products or technologies and to enter new or adjacent growth markets and our ability to fund them or to fund contingent payments with respect to those acquisitions, alliances and investments, and

The potential failure to successfully integrate, collaborate or realize the expected benefits, including cost synergies, from strategic acquisitions, alliances and investments we have consummated or may consummate in the future.

International Markets

Our dependency on international net sales to achieve growth, and our ability to maintain or expand our worldwide market positions in the various markets in which we compete or seek to compete, including through investments in China and other Emerging Markets countries,

The timing and collectability of customer payments, as well as our ability to continue factoring customer receivables where we have factoring arrangements, or to enter new factoring arrangements with favorable terms,

The impact on pricing due to national and regional tenders, including value-based procurement practices and government-imposed payback provisions,
48


Geopolitical and economic conditions, including civil unrest, terrorist activity, governmental changes, restrictions on the ability to transfer capital across borders, tariffs and other protectionist measures,

The impact of the Russia/Ukraine war, Israel/Hamas war and tension in the Taiwan strait, and related, downstream effects thereof, including disruptions to operations or the impact of sanctions on U.S. manufacturers doing business in these regions,

Protection of our intellectual property,

Our ability to comply with established and developing U.S. and foreign legal and regulatory requirements, including FCPA, EU MDR and similar laws in other jurisdictions,

Our ability to comply with U.S. and foreign export control, trade embargo and customs laws,

The impact of significant developments or uncertainties stemming from changes in the U.S. government following the 2024 presidential and congressional elections, including changes in U.S. trade policies, tariffs and the reaction of other countries thereto, particularly China, and

The potential effect of foreign currency fluctuations and interest rate fluctuations on our net sales, operating expenses and resulting profit margins.

Liquidity

Our ability to generate sufficient cash flow to fund operations, capital expenditures, global expansion initiatives, any litigation settlements and judgments, share repurchases and strategic investments and acquisitions as well as maintaining our investment grade ratings and managing our debt levels and financial covenant compliance,

Our ability to access the public and private capital markets when desired and to issue debt or equity securities on terms reasonably acceptable to us,

The unfavorable resolution of open tax matters, exposure to additional tax liabilities and the impact of changes in U.S. and international tax laws,

The unfavorable resolution of open litigation matters, exposure to additional loss contingencies and legal provisions,

The impact of examinations and assessments by domestic and international taxing authorities on our tax provisions, financial condition or results of operations,

The possibility of counterparty default on our derivative financial instruments, and

Our ability to collect outstanding and future receivables and/or sell receivables under our factoring programs.

Cost Reduction and Optimization Initiatives

Risks associated with changes made or expected to be made to our organizational and operational structure, pursuant to our restructuring plans as well as any further restructuring or optimization plans we may undertake in the future and our ability to recognize benefits and cost reductions from such programs, and

Business disruption and employee distraction as we execute our global compliance program, restructuring and optimization plans and any divestitures of assets or businesses and implement our other strategic and cost reduction initiatives.
49

ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We develop, manufacture and sell medical devices globally and our earnings and cash flows are exposed to market risk from changes in currency exchange rates and interest rates. We address these risks through a risk management program that includes the use of derivative financial instruments. We operate the program pursuant to documented corporate risk management policies. We do not enter derivative transactions for speculative purposes. Gains and losses on derivative financial instruments substantially offset losses and gains on underlying hedged exposures. Furthermore, we manage our exposure to counterparty risk on derivative instruments by entering into contracts with a diversified group of major financial institutions and by actively monitoring outstanding positions.
Our currency risk consists primarily of foreign currency denominated firm commitments, forecasted foreign currency denominated intercompany and third-party transactions and net investments in certain subsidiaries. We use both nonderivative (primarily European manufacturing operations) and derivative instruments to manage our earnings and cash flow exposure to changes in currency exchange rates. We had currency derivative instruments outstanding in the contract amount of $5.957 billion as of March 31, 2024 and $5.899 billion as of December 31, 2023. A ten percent appreciation in the U.S. dollar’s value relative to the hedged currencies would increase the derivative instruments’ fair value by $271 million as of March 31, 2024 compared to $236 million as of December 31, 2023. A ten percent depreciation in the U.S. dollar’s value relative to the hedged currencies would decrease the derivative instruments’ fair value by $331 million as of March 31, 2024 compared to $288 million as of December 31, 2023. Any increase or decrease in the fair value of our currency exchange rate sensitive derivative instruments would be substantially offset by a corresponding decrease or increase in the fair value of the hedged underlying asset, liability or forecasted transaction, resulting in minimal impacts on our unaudited consolidated statements of operations.
Our interest rate risk relates primarily to U.S. dollar and euro-denominated borrowings partially offset by U.S. dollar cash investments. We have historically used interest rate derivative instruments to manage our earnings and cash flow exposure to changes in interest rates. We had no interest rate derivative instruments outstanding as of March 31, 2024 or December 31, 2023. As of March 31, 2024, $10.690 billion in aggregate principal amount of our outstanding debt obligations was at fixed interest rates, representing approximately 100 percent of our total debt, on an amortized cost basis. As of March 31, 2024, our outstanding debt obligations at fixed interest rates were comprised of senior notes.

Refer to Note D – Hedging Activities and Fair Value Measurements to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q for further information regarding our derivative financial instruments.

50

ITEM 4.CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer (CEO) and Executive Vice President and our Chief Financial Officer (CFO), evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2024 pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended. Disclosure controls and procedures are designed to ensure that material information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and ensure that such material information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. Based on their evaluation, our CEO and CFO concluded that, as of March 31, 2024, our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

During 2022, we began a multi-year implementation of a new global enterprise resource planning (ERP) system, which will replace our existing system. The implementation is expected to occur in phases over the next several years. The portion of the transition to the new ERP system which we have completed to date resulted in changes in our internal control over financial reporting in 2023. No changes occurred during the first quarter of 2024. As future phases are implemented, we expect the changes to have a material impact on our internal controls over financial reporting and we will evaluate whether these process changes necessitate further changes in the design of and testing for effectiveness of internal controls over financial reporting.

51

PART II
OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Refer to Note H – Commitments and Contingencies to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

ITEM 1A. RISK FACTORS

In addition to other information contained elsewhere in this report, you should carefully consider the factors discussed in Part I, Item 1A. Risk Factors in our most recent Annual Report on Form 10-K, which could materially affect our business, financial condition or future results.

ITEM 5. OTHER INFORMATION

(c)

On February 20, 2024, Vance R. Brown, our Senior Vice President, General Counsel and Corporate Secretary entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Brown’s plan covers the sale of 33,043 shares to be acquired upon exercise of stock options. Transactions under Mr. Brown’s plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Brown’s plan will terminate on the earlier of December 31, 2024, or the date all shares subject to the plan have been sold.

On February 21, 2024, Daniel Brennan, our Executive Vice President and Chief Financial Officer, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Brennan’s plan covers the sale of 112,075 shares of our common stock, including 64,454 shares to be acquired upon exercise of stock options. Transactions under Mr. Brennan’s plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Brennan’s plan will terminate on the earlier of December 31, 2024, or the date all shares subject to the plan have been sold.

On February 26, 2024, Jonathan Monson, our prior Senior Vice President, Global Controller and Chief Accounting Officer until March 1, 2024, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Monson’s plan covers the sale of 16,082 shares of our common stock, including 10,000 shares to be acquired upon exercise of stock options. Transactions under Mr. Monson’s plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Monson’s plan will terminate on the earlier of February 1, 2025, or the date all shares subject to the plan have been sold.

On February 28, 2024, Jeffrey B. Mirviss, our Senior Vice President and President, Peripheral Interventions, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Mirviss’ plan covers the sale of up to 88,888 shares of our common stock, including up to 25,086 shares to be acquired upon determination and/or vesting of performance share units and restricted share units and 33,726 shares to be acquired upon exercise of stock options. Transactions under Mr. Mirviss’ plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Mirviss’ plan will terminate on the earlier of February 21, 2025, or the date all shares subject to the plan have been sold.

On February 28, 2024, Michael F. Mahoney, our Chairman and Chief Executive Officer, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Mahoney’s plan covers the sale of 488,332 shares of our common stock, including 335,659 shares to be acquired upon exercise of stock options. Transactions under Mr. Mahoney’s plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Mahoney’s plan will terminate on the earlier of November 8, 2024, or the date all shares subject to the plan have been sold.

ITEM 6. EXHIBITS (* documents filed or furnished with this report; # compensatory plans or arrangements)
52

4.1
4.2
10.1*
10.2*
10.3*
10.4*
22*
31.1* 
 
31.2* 
 
32.1* 
 
32.2* 
 
101.SCH*
Inline XBRL Taxonomy Extension Schema Document.
101.CAL*
Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*
Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*
Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*
Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101).
53

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on May 1, 2024.

 
BOSTON SCIENTIFIC CORPORATION
 
 By:/s/ Daniel J. Brennan
   
  Name:Daniel J. Brennan
  Title:Executive Vice President and
Chief Financial Officer 
54
EX-10.1 2 exhibit101-bscx2024grantxn.htm EX-10.1 Document

Exhibit 10.1

    
Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan
Global Non-Qualified Stock Option Agreement

This Global Non-Qualified Stock Option Agreement (the “Agreement”), is between you and Boston Scientific Corporation, a Delaware corporation, (the “Company”) in connection with the Non-Qualified Stock Option Award granted to you by the Committee under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Plan”). This Agreement sets forth the terms and conditions relating to your Stock Option pursuant to the Plan. Capitalized terms used but not defined in this Agreement shall have the same meaning as assigned to them in the Plan. The applicable terms and conditions of the Plan are incorporated into and made a part of this Agreement.

    1.    Grant of Stock Option. The Committee hereby grants you a Stock Option to purchase that number of shares of Stock set forth in your Equity Award and Acceptance Summary (the “Option Shares”) at the price set forth herein (the “Grant Price”). The Grant Price is equal to the Fair Market Value of the Company’s Stock on the Grant Date.

    2.    Term and Vesting of Stock Option. Except as otherwise provided in Section 4 below, your Stock Option shall have a term of ten (10) years from date of grant until the “Expiration Date” and shall vest in accordance with the vesting schedule. If the Expiration Date falls on a date on which the New York Stock Exchange is closed for trading, the Expiration Date shall be the trading day immediately prior to the Expiration Date.

    3.    Exercise of Stock Option.

        (a)    While this Stock Option remains exercisable, you may exercise any vested portion of the Option Shares by delivering to the Company or its designee, in the form and at the location specified by the Company, notice stating your intent to exercise a specified number of Option Shares and payment of the full Grant Price for the specified number of Option Shares. Payment in full for the Option Shares being exercised may be paid in such manner as the Committee may specify from time to time, in its sole discretion, including, but not limited to the following: (i) in cash, (ii) by certified check or bank draft payable in U.S. dollars (US$) to the order of the Company, (iii) in whole or in part in shares of Stock owned by you, valued at Fair Market Value, or (iv) if available to you, via cashless exercise, by which you deliver to your securities broker instructions to sell a sufficient number of shares of Stock to cover the Grant Price for the Option Shares, any applicable tax obligations and the brokerage fees and expenses associated therewith. Notwithstanding the foregoing, if you reside in a country where the local laws and/or regulations preclude the remittance of currency out of the country for purposes of paying the Grant Price for the Option Shares being exercised, require the Company, its Affiliates and/or you to secure any legal or regulatory approvals or complete any legal or regulatory filings,

–Rev 1.2024



or undertake any additional steps for remitting currency out of the country, the Company may restrict the method of exercise to a form of cashless exercise (either a cashless “sell all” exercise and/or a cashless “sell to cover” exercise) as it shall determine in its sole discretion.

        The exercise date applicable to your exercise of the specified number of Option Shares pursuant to this Section 3 will be deemed to be the date on which the Company receives your irrevocable commitment to exercise the Option Shares in writing, subject to your payment in full of the Option Shares to be exercised within 10 (ten) days of the notice of exercise of the Option Shares to be exercised. The notice and payment in full of the Option Shares being exercised, must be received by the Company or its designee on or prior to the last day of the Stock Option term, as set forth in Section 2 above, except as provided in Section 4 below.

        Upon the Company’s determination that there has been a valid exercise of the Option Shares, the Company shall issue certificates in accordance with the terms of this Agreement or cause the Company’s transfer agent to make the necessary book entries for the shares of Stock subject to the exercised Option Shares. However, the Company shall not be liable to you, your personal representative or your successor(s)-in-interest for damages relating to any delays in issuing the certificates or in making book entries, any loss of the certificates, or any mistakes or errors in the issuance of the certificates or in making book entries, or in the certificates themselves.

        (b)    Notwithstanding Section 3(a), you acknowledge that, except as otherwise determined by the Committee, any portion of the Option that has vested and is after vested, exercisable and outstanding on the Expiration Date (or, if earlier, the last trading day of the term of the Stock Option in the event that your employment terminates due to Retirement and not for other reasons) (the “Automatic Exercise Date”) shall be deemed to have been exercised automatically by you at such time without any further action by you, provided (i) you have accepted the Option and this Agreement under the procedures specified by the Administrator from time to time, (ii) the Fair Market Value of one share of Stock exceeds the Grant Price per share of Stock by at least one dollar (or such other minimum value as the Administrator may determine from time to time upon notice to you in advance of the Automatic Exercise Date), and (iii) the Option remains outstanding on the last day of its full term. An exercise pursuant to this Section 3(b) shall be made through a “net exercise” procedure pursuant to which the Company shall deliver to you the number of shares of Stock for which the Option was deemed exercised, less the number of Shares sufficient to pay the total Grant Price and, unless otherwise determined by the Company, any withholding for Tax-Related Items (as defined in Section 10 of this Agreement).

    4.    Termination of Employment.

        (a)    In the event that your employment terminates due to death or Disability (as such term is defined in the Plan or determined under local law, as applicable), all remaining unexercised portion(s) of your Stock Option shall immediately vest and become exercisable by

–Rev 1. 2024
2


you or your appointed representative, as the case may be, until the expiration of the term of the Stock Option or such other term as the Committee may determine at or after grant, provided that such exercise period does not extend beyond the original term of the Stock Option.

        (b)    Provided that you have remained in continuous service with the Company or an Affiliate through the first anniversary of the Grant Date, in the event your employment terminates due to Retirement, all remaining unexercised portion(s) of your Stock Option shall immediately vest and become exercisable by you until the Expiration Date or such other term as the Committee may determine at or after grant, provided that such exercise period does not extend beyond the original Expiration Date of the Stock Option. For purpose of this Section 4, a “Retirement” shall not include (i) a termination of your employment for Cause (as defined in Section 5 of this Agreement), as determined in the sole discretion of the Company or (ii) a resignation by you after being notified that the entity that employs you has elected to terminate your employment for Cause.

        (c)    In the event that your employment terminates due to Retirement prior to the first anniversary of the Grant Date, the Option Shares shall immediately be forfeited in their entirety.

        (d)    Upon termination of your employment for reasons other than for Cause (as defined in Section 5 of this Agreement), death, Disability or Retirement, you shall have the shorter of (i) one (1) year from the date of termination and (ii) the remaining term of the Stock Option to exercise all vested Option Shares. Immediately upon termination of your employment for reasons other than for Cause, death, Disability or Retirement, all unvested Option Shares shall be forfeited; provided, however, that the Committee, in its sole discretion, may extend the exercise period and/or accelerate vesting of any unvested Option Shares (provided that such exercise period does not extend beyond the original term of the Stock Option). Your termination date shall be the last day of your active service with the Company or an Affiliate (if applicable).

        (e)    Any unexercised Option Shares (whether vested or unvested) shall be cancelled and forfeited immediately upon notice to you of your termination for Cause (as defined in Section 5 of this Agreement).

        (f)    The Option Shares, to the extent unexercised on the date following the end of any period described above or the term of the Stock Option set forth above in Section 2, shall thereupon be forfeited.

        (g)    Notwithstanding anything to the contrary in the Plan or the Agreement, and for purposes of clarity, any termination of employment shall be effective as of the date your active employment ceases and shall not be extended by any statutory or common law notice of termination period.


–Rev 1. 2024
3


        (h)    Any one of your permitted transferee(s) (pursuant to Section 9 below) shall receive the rights herein granted subject to the terms and conditions of this Agreement and any applicable Addendum. No transfer of this Stock Option shall be approved and effected by the Administrator unless (i) the Administrator shall have been timely furnished with written notice of such transfer and any copies of such notice as the Committee may deem, in its sole discretion, necessary to establish the validity of the transfer; (ii) the transferee or transferees shall have agreed in writing to be bound by the terms and conditions of this Agreement and any applicable Addendum; and (iii) such transfer complies with applicable laws and regulations.

        (i)    If you are a resident or employed in a country that is a member of the European Union, the grant of the Stock Option and this Agreement are intended to comply with the age discrimination provisions of the EU Equal Treatment Framework Directive, as implemented into local law (the “Age Discrimination Rules”). To the extent that a court or tribunal of competent jurisdiction determines that any provision of the Stock Option is invalid or unenforceable, in whole or in part, under the Age Discrimination Rules, the Company, in its sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full extent permitted under local law.

        (j)    If you reside or work in a country where the local foreign exchange rules and regulations require the repatriation of sale proceeds, the Company may require you to sell any Option Shares you acquire under the Plan immediately or within a specified period following your termination of employment (in which case, this Agreement shall give the Company the authority to issue sales instructions on your behalf).

5.    Definition of “Cause”.

(a)    For purposes of this Agreement, “Cause” shall mean termination of your employment by the entity that employs you as a result of the occurrence of any of the following, as determined by the Company in its sole discretion:

(i)your violation of the Company’s Code of Conduct or your violation of any written policy of the Company;

(ii)your breach of your Agreement Concerning Employment, if any, or any other written agreement between you and the Company or the entity that employs you (if different);

(iii)your commission of an act of fraud, embezzlement, dishonesty or theft in connection with your duties or in the course of your employment;

(iv)your engaging in any gross or willful misconduct that causes harm, or is likely to cause harm, to the Company’s business or its reputation;


–Rev 1. 2024
4


(v)your being charged with, convicted of, or pleading guilty or no contest to, any felony or any other crime involving dishonesty or moral turpitude; or

(vi)your failure to substantially perform the essential duties of your employment (other than such failure resulting from your Retirement, Death or Disability as set forth in Section 4 of this Agreement).

6.    Change in Control. To the extent that you have not entered into a Change in Control Agreement with the Company and except as the Administrator (as defined in the Plan) may otherwise determine, immediately prior to a Change in Control (as defined in the Plan), any unvested portion of the Stock Option shall vest and become exercisable. In addition, the Stock Option shall terminate immediately prior to the Change in Control unless the Stock Option is exercised coincident therewith or assumed in accordance with the immediately following sentence. If there is a surviving or acquiring entity, the Administrator may provide for a substitution or assumption of the Stock Option by the acquiring or surviving entity or an affiliate thereof, on such terms as the Administrator determines. If there is no surviving or acquiring entity, or if the Administrator does not provide for a substitution or assumption of the Stock Option, any unvested portion of the Stock Option shall vest and become exercisable on a basis that gives you a reasonable opportunity to participate as a stockholder in the Change in Control. If you have entered into a Change in Control agreement with the Company, the Stock Option will vest according to the provisions of the Change in Control agreement.

    7.    Recoupment Policies.

    (a)    Executive Committee Recoupment Policy. Pursuant to the Company’s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Committee Member or Former Executive Committee Member and, in the judgment of the Board, you, while serving in such capacity as a Current Executive Committee Member, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company.

        (i)    Definitions. The following terms, when used in this Section 7, shall have the meaning set forth below:

        (1)    “Current Executive Committee Member” means any individual currently designated as a corporate officer of the Company who is in an organizational job level of E-4 or E-5 (or any equivalent level under any future organizational framework).

                    (2)          “Former Executive Committee Member” means any individual previously (but not currently) designated as a corporate officer of the Company who was in an organizational job level of E-4 or E-5 (or any equivalent level under any future organizational framework).

–Rev 1. 2024
5



                 (3)          “Recovery” means the forfeiture or cancellation of unexercised Stock Options, whether vested or unvested.

                (b)          Other Compensation Recoupment Authority.   The Stock Option and any compensation associated therewith and any proceeds therefrom are subject to forfeiture, recovery by the Company or other action pursuant to any compensation recovery policy (i) in effect as of the Grant Date, as such policy may be amended from time to time, which includes but is not limited to the Company’s Dodd-Frank Clawback Policy and (ii) any other compensation recovery policy adopted after the Grant Date to facilitate compliance with applicable law, including in response to the requirements of Section 10D of the Exchange Act, the U.S. Securities and Exchange Commission’s final rules thereunder, and any applicable listing rules or other rules and regulations implementing the foregoing.

(c)     Instructions to Brokerage Firm. For purposes of Sections 7(a) and 7(b) of this Agreement, you expressly and explicitly authorize the Company to issue instructions, on your behalf, to any brokerage firm and/or third party administrator engaged by the Company to hold any shares of Stock and other amounts acquired pursuant to the Stock Option to re-convey, transfer or otherwise return such shares of Stock and/or other amounts to the Company upon the Company’s enforcement of the Company’s recoupment policy, the Company’s Dodd-Frank Clawback Policy and any other compensation recovery policy adopted by the Board or the Committee.

(d)     No Constructive Termination. No recovery of compensation as described in this Section 7 will be an event giving rise to your right to resign for “good reason” or “constructive termination” (or similar term) under any plan of, or agreement with, the Company and/or an Affiliate and you.

    8.    Restrictions on Shares; Legend on Certificate. Shares of Stock issued to you in certificate form or to your book entry account upon exercise of the Stock Option may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.

    9.    Transferability. Except as required by law, you shall not sell, transfer, assign, pledge, gift, hypothecate or otherwise dispose of the Stock Option granted under this Agreement other than by will or the laws of descent and distribution or without payment of consideration to your Family Members or to trusts or other entities for the benefit of your Family Members. During your lifetime, the Stock Option is exercisable only by you, subject to Section 4 above.

–Rev 1. 2024
6



    10.    Satisfaction of Tax Obligations. Regardless of any action the Company or the Affiliate that employs you (the “Employer”) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (“Tax-Related Items”), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and/or the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Stock Option, including the grant of the Stock Option, the vesting of the Stock Option, the exercise of the Stock Option, the subsequent sale of any shares of Stock acquired upon exercise of the Stock Option and the receipt of any dividends, and (b) do not commit to structure the terms of the grant or any aspect of the Stock Option to reduce or eliminate your liability for Tax-Related Items.

    Prior to the delivery of shares of Stock upon exercise of the Stock Option, if your country of residence (and/or the country of employment, if different) requires withholding of Tax-Related Items, the Company may withhold a sufficient whole number of shares of Stock otherwise issuable upon exercise of the Stock Option that has an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, withhold shares of Stock based on a rate of up to the maximum applicable withholding rate. If the obligation for Tax-Related Items is satisfied by withholding shares of Stock to be issued upon exercise of the Stock Option, for tax purposes, you are deemed to have been issued the full number of shares of Stock subject to the Stock Option, notwithstanding that a number of shares of Stock are withheld solely for the purpose of paying the Tax-Related Items. You will have no further rights with respect to any shares of Stock that are retained by the Company pursuant to this provision. By accepting the Stock Option, you expressly consent to the withholding of shares of Stock as provided for hereunder.

    Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon exercise resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. You agree to sign any agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the exercised Stock Option.


–Rev 1. 2024
7


    All other Tax-Related Items related to the Stock Option and any shares of Stock delivered in payment thereof are your sole responsibility. In no event, shall whole shares of Stock be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

    The Stock Option is intended to be exempt from the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.

    11.    Repatriation and Legal/Tax Compliance Requirements. If you are a resident or employed outside of the United States, you agree to repatriate all payments attributable to the shares of Stock and/or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the Stock Option) in accordance with local foreign exchange rules and regulations in your country of residence (and country of employment, if different). In addition, you agree to take any and all actions, and consent to any and all actions taken by the Company and the Employer, as may be required to allow the Company and the Employer to comply with local laws, rules and regulations in your country of residence (and country of employment, if different). Finally, you agree to take any and all actions as may be required to comply with your personal legal and tax obligations under local laws, rules and regulations in your country of residence (and country of employment, if different).

12.    Data Privacy. You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other Stock Option grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.

    You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Stock Options awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (“Data”) for the purpose of implementing, managing and administering the Plan.

–Rev 1. 2024
8



You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to Morgan Stanley Smith Barney LLC and its affiliates (“Morgan Stanley”) or any successor or any other third party that the Company or Morgan Stanley (or its successor) may engage to assist with the administration of the Plan from time to time. You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.

You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon exercise of the Stock Option. You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consent herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consent herein on a purely voluntary basis. If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Stock Options or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.

    13.    Nature of Grant. By participating in the Plan, you acknowledge, understand and agree that:
(a)the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)the grant of the Stock Option is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Stock Options, even if Stock Options have been granted in the past;


–Rev 1. 2024
9


(c)all decisions with respect to future grants of Stock Options, if any, will be at the sole discretion of the Administrator;

(d)the Stock Option grant and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any);

(e)you are voluntarily participating in the Plan;

(f)the Stock Option is not intended to replace any pension rights or compensation;

(g)the Stock Option, the shares of Stock subject to the Stock Option, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments;

(h)the future value of the shares of Stock subject to the Stock Option is unknown, indeterminable and cannot be predicted with certainty;

(i)no claim or entitlement to compensation or damages shall arise from (i) the forfeiture of the Stock Option resulting from the termination of your employment or other service relationship (for any reason and whether or not in breach of local labor laws and whether or not later found to be invalid) and/or (ii) the forfeiture or cancellation of the Stock Option and/or recoupment of any shares of Stock, cash, or other benefits acquired under the Plan resulting from the application of the Company’s recoupment policies contemplated under Section 7 of this Agreement;

(j)unless otherwise agreed with the Company in writing, the Stock Option, the shares of Stock subject to the Stock Option, and the income from and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate;
(k)for purposes of the Stock Option, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, the period (if any) during which you may exercise the Option will commence as of such date and will not be extended by any notice period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any; the Administrator shall have the exclusive discretion to

–Rev 1. 2024
10


determine when you are no longer actively providing services for purposes of the Stock Option grant (including whether you may still be considered to be providing services while on an approved leave of absence); and

(l)the following provisions apply only if you are providing services outside the United States: (A) the Stock Option, the shares of Stock subject to the Stock Option, and the income from and value of same are not part of normal or expected compensation or salary for any purpose; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Stock Option or of any amount due to you pursuant to the exercise of the Stock Option or the subsequent sale of any shares of Stock acquired upon exercise.

    14.    Securities Laws. Upon the acquisition of any shares of Stock pursuant to the exercise of the Stock Option, you will make or enter into such written representations, warranties and agreements as the Company may reasonably request in order to comply with applicable securities laws or with the Plan.

    15.    Not a Public Offering. Neither the grant of the Stock Option under the Plan nor the issuance of the underlying shares of Stock upon exercise of the Stock Option is intended to be a public offering of securities in your country of residence (and country of employment, if different). The Company has not submitted any registration statement, prospectus or other filings to the local securities authorities unless otherwise required under local law.

    16.    No Advice Regarding Grant. No Employee of the Company is permitted to advise you regarding whether you should purchase shares of Stock under the Plan. Investment in shares of Stock involves a degree of risk. Before deciding to purchase shares of Stock pursuant to the Stock Option, you should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and you should carefully review all of the materials related to the Stock Option and the Plan. You are hereby advised to consult with your own personal tax, legal and financial advisors before taking any action related to the Plan.

    17.    Insider Trading Restrictions/Market Abuse Laws. You acknowledge that, depending on your or your broker’s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws which may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Stock Options) or rights linked to the value of shares of Stock (e.g., phantom awards, futures) during such times you are considered to have “inside information” regarding the Company, as defined in the laws or regulations in your country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and

–Rev 1. 2024
11


in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to a personal advisor on this matter.

    18.    Electronic Delivery of Documents. The Company may, in its sole discretion, deliver any documents related to the Stock Option and participation in the Plan, or future grants of Stock Options that may be granted under the Plan, by electronic means unless otherwise prohibited by local law. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.

    19.    Language. If you are resident outside of the United States, you hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Stock Option, be drawn up in English. You acknowledge that you are proficient in the English language and understand the terms of this Agreement or have had the ability to consult with an advisor who is sufficiently proficient in the English language. If you have received this Agreement and any applicable Addendum, the Plan or any other documents related to the Stock Option translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

    20.    Addendum. Notwithstanding any provision of this Agreement to the contrary, the Stock Option shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable addendum to the Agreement (the “Addendum”). Further, if you transfer your residence and/or employment to another country reflected in the Addendum to this Agreement, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer). Any applicable Addendum shall constitute part of this Agreement.

    21.    Additional Requirements. The Administrator reserves the right to impose other requirements on the Stock Option, any shares of Stock acquired pursuant to the Stock Option and your participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws or to facilitate the administration of the Plan. Such requirements may include (but are not limited to) requiring you to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

    22.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its Secretary at the principal executive office of the Company and to you at the address appearing in the personnel records of the Company for you or

–Rev 1. 2024
12


to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

    23.    Choice of Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflicts of laws principles) and applicable federal laws. For purposes of litigating any dispute under the Agreement, including the Addendum, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the courts of Boston or the federal courts for the United States for the District of Massachusetts, and no other courts where the grant of the Stock Option is made and/or to be performed.

    24.    Award Subject to Plan; Conflicts.    The Stock Option granted pursuant to this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This Agreement contains terms and provisions established by the Committee specifically for the grant described herein. Unless the Committee has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the Committee retains the right to alter or modify the Stock Option granted under this Agreement as the Committee may determine are in the best interests of the Company. You hereby accept the Stock Option subject to all the terms and provisions of the Plan and this Agreement and agree that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon you and your heirs and legal representatives.

    25.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

    26.    Severability. You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable

27.     Waiver. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.

    28.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same instrument.


–Rev 1. 2024
13


    
    IN WITNESS WHEREOF, the Company, by its duly authorized officer, and the Optionee have executed and delivered this Agreement effective as of the date and year first above written.



                    BOSTON SCIENTIFIC CORPORATION        
image_0a.jpg                image_1.jpg
                    Michael F. Mahoney
President and Chief Executive Officer

























–Rev 1. 2024
14









BOSTON SCIENTIFIC CORPORATION

ADDENDUM TO THE AWARD AGREEMENT
RELATING TO NON-QUALIFIED STOCK OPTIONS GRANTED
PURSUANT TO THE
AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN

In addition to the terms of the Plan and the Agreement, the Stock Option is subject to the following additional terms and conditions. All defined terms contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement. Pursuant to Section 20 of the Agreement, if you transfer your residence and/or employment to another country reflected in an Addendum, the additional terms and conditions for such country (if any) will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).

EUROPEAN UNION (“EU”) / EUROPEAN ECONOMIC AREA (“EEA”), UNITED KINGDOM AND SWITZERLAND

Personal Data. This provision replaces Section 12 of the Agreement:

Pursuant to applicable personal data protection laws, the Company and the Employer hereby notify you of the following in relation to your Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the grant of the Stock Option and your participation in the Plan. The collection, processing and transfer of your Personal Data is necessary for the legitimate purpose of the Company and the Employer’s administration of the Plan and your participation in the Plan, and your denial and/or objection to the collection, processing and transfer of Personal Data may affect your participation in the Plan. As such, by accepting the Award, you acknowledge the collection, use, processing and transfer of Personal Data as described herein.

You understand that the Company and the Employer hold certain personally identifiable information about you, specifically, your name, home address and telephone number, date of birth, social security number or other employee identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Stock Options or

–Rev 1. 2024
15


any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (“Personal Data”). The Personal Data may be provided by you to or collected, where lawful, from third parties. The Company or the Employer each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing your participation in the Plan and meeting related legal obligations associated with these actions.

The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations. Personal Data will be accessible within the Company’s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and other aspects of the employment relationship and for participation in the Plan.

The Company and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and the Employer may each further transfer Personal Data to third parties assisting the Company or the Employer in the implementation, administration and management of the Plan, including Morgan Stanley Smith Barney LLC and its affiliates or any successor or other third party that the Company, the Employer or Morgan Stanley Smith Barney LLC and its affiliates (or its successor) may engage to assist with the administration of the Plan from time to time. These recipients may be located in the EU/EEA, the United Kingdom, Switzerland or elsewhere throughout the world, such as the United States. By participating in the Plan, you understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Personal Data as may be required for the administration of the Plan and/or the subsequent holding of shares of Stock on your behalf to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan. You further understand that you may request a list with the names and addresses of any potential recipients of your Personal Data by contacting your local Human Resources manager or the Company’s Human Resources Department. When transferring Personal Data to these potential recipients, the Company and the Employer provide appropriate safeguards in accordance with EU Standard Contractual Clauses or other legally binding and permissible arrangements. You may request a copy of such safeguards from your local human resources manager or the Company’s Human Resources Department.

To the extent provided by law, you may, at any time, have the right to request: access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data. You may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, as well

–Rev 1. 2024
16


as opt-out of the Plan herein, in any case without cost, by contacting in writing your Human Resources manager. Your provision of Personal Data is a contractual requirement. You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Stock Option to you, or grant other equity awards or administer or maintain such equity awards. For more information on the consequences of your refusal to provide Personal Data, you understand that you may contact your local human resources manager or the Company’s Human Resources Department.

When the Company and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and/or records containing the Personal Data and/or take steps to properly anonymize it so that you can longer be identified from it.

ARGENTINA

Type of Offering. Neither the grant of the Stock Option, nor the issuance of shares of Stock subject to the grant, constitutes a public offering.

AUSTRALIA

Securities Notification. You understand that the grant of the Stock Option pursuant to the Plan in Australia is being made under Division 1A of Part 7.12 of the Corporations Act 2001 (Cth). Please note that if you offer shares of Stock acquired under the Plan for sale to a person or entity resident in Australia, the offer may be subject to disclosure requirements under Australian law. You should obtain legal advice on your disclosure obligations prior to making any such offer. Participation in the Plan is subject to the terms and conditions set forth in the Australian ESS Offer Document, (which is attached hereto as Annex I), the Plan and the Agreement.

Breach of Law. Notwithstanding anything to the contrary in the Agreement or the Plan, you will not be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Plan if the provision of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.

AUSTRIA

No country-specific provisions.


–Rev 1. 2024
17


BELGIUM

Acceptance of Stock Option. In order for the Stock Option to be subject to taxation at the time of grant, you must affirmatively accept the Stock Option in writing within 60 days after the offer date by signing below and returning this original executed Addendum to:
Boston Scientific
Green Square
Lambroekstraat 5D
1831 Diegem
Belgium
Attn.: Nathalie Derue

I hereby accept ________ (number) Option Shares underlying the Stock Option granted to me by the Company on the Grant Date.

The undersigned acknowledges that he/she has been encouraged to discuss this matter with a financial and/or tax advisor and that this decision is made in full knowledge.

Employee Signature:        _______________________________

Employee Printed Name:    _______________________________

Date of Acceptance:        _______________________________

If you fail to affirmatively accept the Stock Option in writing within 60 days after the offer date, the Stock Option will not be subject to taxation at the time of grant but instead will be subject to taxation on the date you exercise the Stock Option (or such other treatment as may apply under Belgian tax law at the time of exercise).

Undertaking for Qualifying Option. If you are accepting the Stock Option in writing within 60 days after the offer date and wish to have the Stock Option subject to a lower valuation for Belgium tax purposes pursuant to the article 43, §6 of the Belgian law of 26 March 1999, you may agree and undertake to (a) not exercise the Stock Option before the end of the third calendar year following the calendar year in which the offer date falls, and (b) not transfer the Stock Option under any circumstances (except upon on rights your heir might have in the Stock Option upon your death). If you wish to make this undertaking, you must sign below and return this executed Addendum to the address listed above.
Employee Signature:        _______________________________

Employee Printed Name:    _______________________________
    

–Rev 1. 2024
18


BRAZIL

Compliance with Law. By accepting the Stock Option, you acknowledge that you agree to comply with applicable Brazilian laws and to pay any and all applicable taxes associated with the Stock Option, the receipt of any dividends, and the sale of shares of Stock acquired under the Plan.

Labor Law Policy and Acknowledgement. This provision supplements Section 13 of the Agreement:

By accepting the Stock Option, you agree that (i) the benefits provided under the Agreement and the Plan are the result of commercial transactions unrelated to your employment; (ii) the Agreement and the Plan are not a part of the terms and conditions of your employment; and (iii) the income from the Stock Option, if any, is not part of your remuneration from employment.

CANADA

Use of Previously Owned Shares. Notwithstanding any provision in Section 3 of the Agreement or the Plan to the contrary, if you are resident in Canada, you may not use previously-owned shares of Stock to pay the Grant Price or any Tax-Related Items in connection with the Stock Option.

Personal Data. This provision supplements Section 12 of the Agreement:

You hereby authorize the Company and the Company’s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan. You further authorize the Company, any Affiliate and the Administrator to disclose and discuss the Plan with their advisors. You further authorize the Company and any Affiliate to record such information and to keep such information in your employee file.

Securities Law Information. You are permitted to sell shares of Stock acquired under the Plan through the designated broker appointed under the Plan, if any, provided that the sale of shares of Stock takes place outside Canada through the facilities of a stock exchange on which the shares of Stock are listed (i.e., the New York Stock Exchange).

Tax Information. All or a portion of the shares of Stock subject to the Stock Option may be “non-qualified securities” within the meaning of the Income Tax Act (Canada).


–Rev 1. 2024
19


Nature of Grant. The following provision supplements Section 13(k) of the Agreement:

For purposes of the Stock Options, your employment or service relationship will be considered terminated as of the earliest of: (a) the date that your employment or service relationship with the Company or one of its Affiliates is terminated; (b) the date that you receive a notice of termination of employment or service; and (c) the date upon which you cease to actively provide services, regardless of any period during which notice, pay in lieu of notice or related payments or damages are provided or required to be provided under local law. You will not earn or be entitled to any pro-rated vesting for that portion of time before the date on which your right to vest terminates, nor will you be entitled to any compensation for lost vesting. The Administrator shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Stock Option grant (including whether you may still be considered to be providing services while on a leave of absence). Notwithstanding the foregoing, if applicable employment legislation
explicitly requires continued entitlement to vesting during a statutory notice period, your right to vest in the Stock Options, if any, will terminate effective as of the last date of the minimum statutory notice period, but you will not earn or be entitled to pro-rated vesting if the vesting date falls after the end of your statutory notice period, nor will you be entitled to any compensation for lost vesting.

French Language Documents. The following provision will apply if you are a resident of Quebec:

A French translation of this Agreement and certain other documents related to the Stock Option will be made available to you as soon as reasonably practicable. You understand that, from time to time, additional information related to the Stock Option may be provided in English and such information may not be immediately available in French. However, upon request, the Company will provide a translation of such information into French as soon as reasonably practicable.  Notwithstanding anything to the contrary in the Agreement, and unless you indicate otherwise, the French translation of this Agreement and certain other documents related to the Stock Option will govern your participation in the Plan.

CHILE

Securities Law Information. The offer of the Stock Option constitutes a private offering of securities in Chile effective as of the Grant Date. This offer of the Stock Option is made subject to general ruling N° 336 of the Commission for the Financial Market (Comisión para el Mercado Financiero, “CMF”). The offer refers to securities not registered at the securities registry or at the foreign securities registry of the CMF, and, therefore, such securities are not subject to oversight of the CMF. Given that the Stock Option is not registered in Chile, the Company is not required to provide public information about the Stock Option or the shares of Stock in Chile. Unless the Stock Option and/or the shares of Stock are registered with the CMF, a public offering of such securities cannot be made in Chile.

–Rev 1. 2024
20


Esta oferta de opción sobre acciones (“Opción”) constituye una oferta privada de valores en Chile y se inicia en la Fecha de la Concesión. Esta oferta de Opción se acoge a las disposiciones de la Norma de Carácter General Nº 336 (“NCG 336”) de la Comisión para el Mercado Financiero de Chile (“CMF”). Esta oferta versa sobre valores no inscritos en el Registro de Valores o en el Registro de Valores Extranjeros que lleva la CMF, por lo que tales valores no están sujetos a la fiscalización de ésta. Por tratarse los Opciónes de valores no registrados en Chile, no existe obligación por parte de la Compañía de entregar en Chile información pública respecto de los Opciónes or sus Acciones. Estos valores no podrán ser objeto de oferta pública en Chile mientras no sean inscritos en el Registro de Valores correspondiente.

CHINA

The following provisions govern your participation in the Plan if you are a national of the People’s Republic of China (“China”) resident in mainland China, as determined by the Company in its sole discretion:

Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

Limitations on Exercisability Following Termination of Employment. Notwithstanding any provision in the Agreement or the Plan to the contrary, in the event your employment terminates for any reason, your Stock Option will no longer be exercisable after the earlier of: (i) the period set forth in Section 4 of the Agreement; (ii) the last day of the 90 day period beginning on the date of termination of employment (or such earlier date as may be required by China State Administration of Foreign Exchange (“SAFE”)); and (iii) the Expiration Date specified in Section 2 of the Agreement.

Exchange Control Restrictions. You understand and agree that, pursuant to local exchange control requirements, you will be required immediately to repatriate to China the proceeds from the sale of any shares of Stock acquired under the Plan. You further understand that such repatriation of proceeds may need to be effected through a special bank account established by the Company or its Affiliate, and you hereby consent and agree that proceeds from the sale of shares of Stock acquired under the Plan may be transferred to such account by the Company on your behalf prior to being delivered to you and that no interest shall be paid with respect to funds held in such account. The proceeds may be paid to you in U.S. dollars or local currency at the Company’s discretion. If the proceeds are paid to you in U.S. dollars, you understand that a U.S. dollar bank account in China must be established and maintained so that the proceeds may be deposited into such account. If the proceeds are paid to you in local currency, you acknowledge that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the proceeds to local currency due to exchange control restrictions. You agree to bear any currency fluctuation risk between the time the shares of Stock are sold and the net proceeds are converted into local currency and distributed to you.

–Rev 1. 2024
21


You further agree to comply with any other requirements that may be imposed by the Company and its Affiliates in the future in order to facilitate compliance with exchange control requirements in China.

Administration. The Company shall not be liable for any costs, fees, lost interest or dividends or other losses you may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the Company’s operation and enforcement of the Plan, the Agreement and the Award in accordance with Chinese law including, without limitation, any applicable SAFE rules, regulations and requirements.

The above requirements will not apply to non-Chinese nationals, unless otherwise required by the Company or by SAFE.

BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

COLOMBIA

Nature of Grant. This provision supplements Section 13 of the Agreement:
You acknowledge that, pursuant to Article 128 of the Colombian Labor Code, the Plan and related benefits do not constitute a component of your “salary” for any legal purpose. Therefore, they will not be included and/or considered for purposes of calculating any and all labor benefits, such as legal/fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and/or any other labor-related amount which may be payable.

Securities Law Information. The shares of Stock are not and will not be registered with the Colombian registry of publicly held securities (Registro Nacional de Valores y Emisores) and, therefore, the shares of Stock may not be offered to the public in Colombia. Nothing in the Agreement should be construed as making a public offer of securities in Colombia.

COSTA RICA

No country-specific provisions.

CZECH REPUBLIC

No country-specific provisions.


–Rev 1. 2024
22


DENMARK

Treatment of Stock Option Upon Termination of Employment. Notwithstanding any provisions in the Agreement to the contrary, the treatment of the Stock Option upon your termination of employment shall be governed by the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in Employment Relationships (the “Stock Option Act”), as in effect at the time of your termination of employment (as determined by the Administrator, in its discretion, in consultation with legal counsel). You acknowledge having received an “Employer Information Statement” in Danish, which is being provided to comply with the Stock Option Act.

EGYPT

No country-specific provisions.

FINLAND

No country-specific provisions.

FRANCE

Nature of the Award. The Stock Option is not granted under the French specific regime provided by Articles L. 225-177 and seq. or L. 22-10-59 and L. 22-10-60 of the French commercial code, as amended.

Use of English Language. You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.

Vous reconnaissez et consentez que c’est votre souhait exprès qui cet accord, de meme que tous documents, toutes notifications et tous procédés légaux est entré dans, donné ou instituté conformément ci-annexé ou relatant directement ou indirectement ci-annexé, est formulé dans l’anglais.

GERMANY

Exchange Control Information. Cross-border payments in in excess of EUR 12,500 must be reported to the German Federal Bank (Bundesbank). If you make or receive a payment in excess of this amount (including if you acquire shares of Stock with a value in excess of this amount or sell shares of Stock via a foreign broker, bank or service provider and receive proceeds in excess of this amount) and/or if the Company withholds shares of Stock with a value in excess of EUR 12,500 to recover Tax-Related Items in connection with the Stock Option, you must report the payment and/or the value of the shares of Stock received and/or withheld to Bundesbank, either electronically using the “General Statistics Reporting Portal” (“Allgemeines Meldeportal

–Rev 1. 2024
23


Statistik”) available on the Bundesbank website (www.bundesbank.de) or via such other method (e.g., by email or telephone) as is permitted or required by Bundesbank. The report must be submitted monthly or within other such timing as is permitted or required by Bundesbank.

GREECE

No country-specific provisions.

HONG KONG

Lapse of Restrictions. If, for any reason, shares of Stock are issued to you within six months after the Grant Date, you agree that you will not sell or otherwise dispose of any such shares of Stock prior to the six-month anniversary of the Grant Date.

IMPORTANT NOTICE/WARNING. The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of the documents, you should obtain independent professional advice. The Stock Option and shares of Stock issued upon exercise do not constitute a public offering of securities under Hong Kong law and are available only to employees of the Company or its Affiliates. The Agreement, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a “prospectus” for a public offering of securities under the applicable securities legislation in Hong Kong. The Stock Option is intended only for the personal use of each eligible employee of the Employer, the Company or any Affiliate and may not be distributed to any other person.

Wages. The Stock Option and shares of Stock subject to the Stock Option do not form part of your wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.

Nature of Scheme. You understand that the Company specifically intends that the Plan will not be an occupational retirement scheme for purposes of the Occupational Retirement Schemes Ordinance (“ORSO”).

INDIA

Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

Exchange Control Information. You must repatriate any funds received in connection with the Stock Option (e.g., proceeds from the shares of Stock and the receipt of dividends) within such time as prescribed under applicable Indian exchange control laws, which may be amended from

–Rev 1. 2024
24


time to time. You should obtain a foreign inward remittance certificate (“FIRC”) from the bank in which you deposit the foreign currency and maintain the FIRC as evidence of the repatriation of funds in the event the Reserve Bank of India or the Employer requests proof of repatriation. It is the your responsibility to comply with these requirements. Neither the Company nor the Employer will be liable for any fines or penalties resulting from your failure to comply with any applicable laws. You may be required to provide information regarding funds received from participation in the Plan to the Company and/or the Employer to enable them to comply with their filing requirements under exchange control laws in India.

INDONESIA

No country-specific provisions.

IRELAND

No country-specific provisions.

ISRAEL

102 Sub-Plan. The Stock Option is granted to you pursuant to the Israeli Sub-Plan to the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Israeli Sub-Plan”), and is subject to the terms and conditions stated in the Israeli Sub-Plan, the Plan, and the Agreement, including this Addendum. By accepting the Stock Option you acknowledge and agree to be bound by the terms of the Israeli Sub-Plan and consent to the terms of the “Consent Letter - 102 Capital Gain Awards” attached hereto as Appendix A (the “Consent Letter”). If you do not affirmatively accept the Stock Option (and accordingly, the terms of the Israeli Sub-Plan, the Agreement and the Consent Letter) within ninety (90) days after the Grant Date, the Stock Option may not qualify under the capital gain tax treatment.

Until further election by the Company, the Stock Option and any shares of Stock received upon exercise of the Stock Option are intended to qualify for the tax treatment available in Israel pursuant to the provisions of the “capital gain track” under Section 102 (“Section 102”) of the Israeli Income Tax Ordinance [New Version], 1961 (the “ITO”), including the provisions of the Income Tax Rules (Tax Benefits in Shares Issuance to Employees), 2003 and any Tax Ruling. However, in the event the Stock Option does not meet the requirements of Section 102 of the ITO, such Stock Option and the underlying shares of Stock shall not qualify for the favorable tax treatment under the capital gain track. The Company makes no representations or guarantees that the Stock Option will qualify for favorable tax treatment and will not be liable or responsible if favorable tax treatment is not available under Section 102.

The Stock Option is subject to the trust (the “Trust”) established by the trust and services agreement (the “Trust Agreement”) with ESOP Management and Trust Services Ltd. (the “Trustee”). To receive the tax treatment provided for in Sections 102(b)(2) and 102(b)(3) of the

–Rev 1. 2024
25


ITO, shares of Stock acquired by you upon exercise of the Stock Option will be issued directly to the Trustee or controlled by the Trustee under a supervisory trustee arrangement, and will be held by the Trustee on your behalf or controlled by the Trustee at least until the end of the Required Holding Period (as defined in the Israeli Sub-Plan), which is currently twenty-four (24) months from the Grant Date, or any other period determined under the ITO as now in effect or as hereafter amended or by the Israeli Income Tax Authority. Subject to the conclusion of the Required Holding Period and any further period included herein, shares of Stock acquired by you upon exercise of the Stock Option will be held or controlled by the Trustee until their sale, unless you request to release the shares of Stock to your direct holding, in which case the release will be subject to the receipt by the Trustee of an acknowledgment from the Israeli Income Tax Authority that you have paid all applicable taxes due pursuant to the ITO and Section 102, or the Trustee withholds any applicable tax due pursuant to the ITO and Section 102. Notwithstanding the foregoing, in the event you elect to sell or release any shares of Stock acquired upon exercise of the Stock Option prior to the conclusion of the Required Holding Period, the tax consequences under Section 102 shall apply to and shall be borne solely by you, as further set forth in the Israeli Sub-Plan.

The Company may at its sole discretion replace the Trustee from time to time and instruct the transfer of all Stock Options and shares of Stock held and/or administered by such Trustee at such time to its successor and the provisions of your Agreement shall apply to the new Trustee mutatis mutandis.

Any and all Tax-Related Items due in relation to the Stock Option and shares of Stock shall be borne solely by you and in the event of death, by your heirs. The Company, the Employer and/or the Trustee shall withhold Tax-Related Items according to the requirements under the applicable laws, the rules, and regulations, including withholding Tax-Related Items at source. Furthermore, you hereby agree to indemnify the Company, the Employer and/or the Trustee and hold them harmless against and from any and all liability for any such Tax-Related Items or interest or penalty thereon, including without limitation, liabilities relating to the necessity to withhold, or to have withheld, any such Tax-Related Items from any payment made to you. The Company, the Employer and/or the Trustee, to the extent permitted by law, shall have the right to deduct from any payment otherwise due to you, or from proceeds of the sale of any shares of Stock, an amount equal to any Tax-Related Items required by law to be withheld with respect to such shares of Stock. You will pay to the Company, the Employer or the Trustee any Tax-Related Items that the Company, the Employer or the Trustee may be required to withhold with respect to any shares of Stock that cannot be satisfied by the means previously described. The Company may refuse to deliver any shares of Stock if you fail to comply with your obligations in connection with the Tax-Related Items as described in this section. Any fees associated with any vesting, sale, transfer or any act in relation to the Stock Option and the shares of Stock, shall be borne by you. The Trustee, the Company and/or the Employer shall be entitled to withhold or deduct such fees from payments otherwise due to/from the Company, the Employer or the Trustee.


–Rev 1. 2024
26


Securities Law Information.  The Company has obtained from the Israel Securities Authority an exemption from the requirement to file a prospectus in relation to the Plan. Copies of the Plan and the Form S-8 registration statement for the Plan filed with the U.S. Securities and Exchange Commission are available by contacting your local human resources manager.

ITALY

Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

Plan. This provision supplements Section 13 of the Agreement: You further acknowledge that you have read and specifically and expressly approve the following sections of the Agreement: Grant of Stock Option, Exercise of Stock Option, Termination of Employment, Recoupment Policy, Satisfaction of Tax Obligations, Nature of Grant, and Choice of Law and Venue.
JAPAN

No country-specific provisions.

KAZAKHSTAN

Securities Law Information. This offer is addressed only to certain eligible employees of the Company and its Affiliates in the form of Shares to be issued by the Company, subject to the terms and conditions of the Agreement and the Plan. Neither the Plan nor the Agreement has been approved, nor do they need to be approved, by the National Bank of Kazakhstan. This offer is intended only for the original recipient and is not for general circulation in the Republic of Kazakhstan.

LEBANON

Securities Law Information. The Plan does not constitute the marketing or offering of securities in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law. Offerings under the Plan are being made only to eligible employees of the Company and its Affiliates.

MALAYSIA

Award Conditioned upon Election to Pay Taxes Directly to the Malaysian Inland Revenue Board. You understand and agree that your Award is conditioned upon your completing, signing and submitting a letter to your Employer, indicating your election to pay any income tax or other tax liability arising in connection with taxable income recognized under the Plan directly to the Malaysian Inland Revenue Board. (You may contact your Employer to request a form letter for

–Rev 1. 2024
27


this purpose.) You understand that if you fail to file such an election letter with your Employer, your Award will be null and void.

Consent to Collection, Processing and Transfer of Personal Data. This provision replaces Section 12 of the Agreement in its entirety:


–Rev 1. 2024
28


You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data, as described in this Addendum and any other grant materials by and among, as applicable, the Company and Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.

You understand that the Company and Affiliates may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Stock Options or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (“Data”). The Data is supplied by the Company and also by you through information collected in connection with the Agreement and the Plan.

You understand that Data will be transferred to the current stock plan service providers or a stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan. You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that if you reside outside the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative:. You authorize the Company, the stock plan service provider and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any transfer of such Data as may be required to a broker, escrow agent or other third party with whom the shares of Stock received upon exercise of the Stock Option may be deposited. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan. You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data, limit the processing of Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consent herein on a purely voluntary basis. If you do not consent, or if you later seek to revoke your consent, your employment status or service and career with the Company will not be adversely affected; the only adverse consequence of refusing or withdrawing your consent is that the Company may not be able to grant you Stock Options or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.
Please take note that by electronically accepting this Agreement, you have confirmed that you explicitly, voluntarily and unambiguously consent to the collection, use and transfer of your personal data in accordance with the terms in this notification. However, if for any reason you do not consent to the processing of your personal data, you have the right to reject such consent by contacting your local human resources representative:.
Anda dengan ini secara eksplisit dan tanpa sebarang keraguan mengizinkan pengumpulan, penggunaan dan pemindahan, dalam bentuk elektronik atau lain-lain, data peribadi anda seperti yang diterangkan dalam Lampiran ini dan apa-apa bahan pemberian Opsyen saham terhad yang lain oleh dan di antara, seperti yang berkenaan, Syarikat dan Ahli Gabungan untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan.
Anda memahami bahawa Syarikat Ahli Gabungan mungkin memegang maklumat peribadi tertentu tentang anda, termasuk, tetapi tidak terhad kepada, nama anda, alamat rumah dan nombor telefon, tarikh lahir, nombor insurans sosial atau nombor pengenalan lain, gaji, kewarganegaraan, jawatan, apa-apa syer saham Biasa atau jawatan pengarah yang dipegang dalam Syarikat, butir-butir semua Opsyen saham terhad, atau apa-apa hak lain atas syer Biasa saham yang dianugerahkan, dibatalkan, dilaksanakan, terletak hak, tidak diletak hak ataupun yang belum dijelaskan bagi faedahanda, untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan Pelan tersebut (“Data”). Data tersebut dibekalkan oleh Syarikat dan juga oleh anda berkenaan dengan Perjanjian dan Pelan.
Anda memahami bahawa Data ini akan dipindahkan kepada pembekal perkhidmatan pelan saham semasa atau pembekal perkhidmatan pelan saham yang mungkin dipilih oleh Syarikat pada masa depan, yang membantu Syarikat dengan pelaksanaan, pentadbiran dan pengurusan Pelan. Anda memahami bahawa penerima-penerima Data mungkin berada di Amerika Syarikat atau mana-mana tempat lain, dan bahawa negara penerima-penerima (contohnya, Amerika Syarikat) mungkin mempunyai undang-undang privasi data dan perlindungan yang berbeza daripada negara anda. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh meminta satu senarai yang mengandungi nama-nama dan alamat-alamat penerima-penerima Data yang berpotensi dengan menghubungi wakil sumber manusia tempatan anda:. Anda memberi kuasa kepada Syarikat, pembekal perkhidmatan pelan saham dan mana-mana penerima-penerima kemungkinan lain yang mungkin akan membantu Syarikat (pada masa sekarang atau pada masa depan) dengan melaksanakan, mentadbir dan menguruskan Pelan untuk menerima, memiliki, menggunakan, mengekalkan dan memindahkan Data, dalam bentuk elektronik atau lain-lain, bagi tujuan melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan, termasuk segala pemindahan Data tersebut sebagaimana yang dikehendaki kepada broker, egen eskrow atau pihak ketiga dengan siapa syer Biasa saham diterima semasa peletakhakan saham terhad Opsyen mungkin didepositkan. Anda memahami bahawa Data hanya akan disimpan selagi ia adalah diperlukan untuk melaksanakan, mentadbir, dan menguruskan penyertaan anda dalam Pelan. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh, pada bila-bila masa, melihat Data, meminta maklumat tambahan mengenai penyimpanan dan pemprosesan Data, meminta bahawa pindaan-pindaan dilaksanakan ke atas Data, mengehadkan pemprosean Data atau menolak atau menarik balik persetujuan dalam ini, dalam mana-mana kes, tanpa kos, dengan menghubungi secara bertulis wakil sumber manusia tempatan. Selanjutnya, anda memahami bahawa anda memberikan persetujuan di sini secara sukarela semata-mata. Sekiranya anda tidak bersetuju, atau sekiranya anda kemudian membatalkan persetujuan anda, status pekerjaan atau perkhidmatan dan kerjaya anda dengan Syarikat tidak akan terjejas; satu-satunya akibat buruk sekiranya anda tidak bersetuju atau menarik balik persetujuan andaadalah bahawa Syarikat tidak akan dapat memberikan Opsyen saham terhad anda atau anugerah ekuiti lain atau mentadbir atau mengekalkan anugerah-anugerah tersebut. Oleh itu, anda memahami bahawa keengganan atau penarikan balik persetujuan anda boleh menjejaskan keupayaan anda untuk mengambil bahagian dalam Pelan. Untuk maklumat lebih lanjut mengenai akibat-akibat keengganan anda untuk memberikan keizinan atau penarikan balik keizinan, anda memahami bahawa anda boleh menghubungi wakil sumber manusia tempatan.
Sila ambil perhatian bahawa dengan menerima Perjanjian ini secara elektronik, anda mengesahkan bahawa anda secara eksplisit, sukarela, dan tanpa sebarang keraguan bersetuju dengan pengumpulan, penggunaan, dan pemindahan data peribadi anda mengikut terma-terma dalam notis ini. Walaubagaimanapun, jika atas apa-apa sebab-sebab tertentu anda tidak bersetuju dengan pemprosesan data peribadi anda, anda mempunyai hak untuk menolak persetujuan anda dengan menghubungi wakil sumber manusia tempatan anda:.

–Rev 1. 2024
29



MEXICO

Securities Law Information. You expressly recognize and acknowledge that the Company’s grant of the Stock Option and the underlying shares of Stock under the Plan have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico. In addition, the Plan, the Agreement and any other document relating to the Stock Option may not be publicly distributed in Mexico. These materials are addressed to you only because of your existing relationship with the Company and these materials should not be reproduced or copied in any form. The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present employees of the Employer in Mexico made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.
Acknowledgement of the Agreement. By accepting the Stock Option, you acknowledge that have received a copy of the Plan and the Agreement, including this Addendum, which you have reviewed. You further acknowledge that you accept all the provisions of the Plan and the Agreement, including this Addendum. You also acknowledge that you have read and specifically and expressly approve the terms and conditions set forth in Section 13 of the Agreement, which clearly provide as follows:
(1)    Your participation in the Plan does not constitute an acquired right;
(2)    The Plan and your participation in it are offered by the Company on a wholly discretionary basis;
(3)    Your participation in the Plan is voluntary; and
(4)    The Company and its Affiliates are not responsible for any decrease in the value of any shares of Stock acquired at exercise of the Stock Option.
Reconocimiento del Contrato. Al aceptar la Opción, Usted reconoce que ha recibido una copia del Plan y del contrato, incluyendo este Apéndice, mismos que ha revisado. Usted reconoce, además, que acepta todas las disposiciones del Plan, y del contrato, incluyendo este Apéndice. También reconoce que ha leído y aprueba de forma expresa los términos y condiciones establecidos en la sección doce 13 del contrato que claramente dispone lo siguiente:
(1)    Su participación en el Plan no constituye un derecho adquirido;
(2)    El Plan su participación en el mismo son ofrecidos por la Compañía de forma totalmente discrecional;

–Rev 1. 2024
30


(3)    Su participación en el Plan es voluntaria; y
(4)    La Compañía y sus afiliados no son responsables por cualquier disminución en el valor de las Acciones adquiridas al momento de tener derecho conforme a la Opción.
Labor Law Acknowledgement and Policy Statement. By accepting the Stock Option, you acknowledge that Boston Scientific Corporation, with registered offices at 300 Boston Scientific Way, Marlborough, Massachusetts 01752, United States of America, is solely responsible for the administration of the Plan. You further acknowledge your participation in the Plan, the grant of the Stock Option and any acquisition of shares of Stock under the Plan do not constitute an employment relationship between you and Boston Scientific Corporation because you are participating in the Plan on a wholly commercial basis and your sole employer is a Mexican legal entity (“Boston Scientific-Mexico”). Based on the foregoing, you expressly acknowledge that the Plan and the benefits that you may derive from participation in the Plan do not establish any rights between you and your Employer, Boston Scientific-Mexico, and do not form part of the employment conditions and/or benefits provided by Boston Scientific-Mexico, and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.
You further understand that your participation in the Plan is the result of a unilateral and discretionary decision of Boston Scientific Corporation, therefore, Boston Scientific Corporation reserves the absolute right to amend and/or discontinue your participation in the Plan at any time, without any liability to you.
Finally, you hereby declare that you do not reserve to yourself any action or right to bring any claim against Boston Scientific Corporation for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and that you therefore grant a full and broad release to Boston Scientific Corporation its Affiliates, branches, representation offices, shareholders, officers, agents and legal representatives, with respect to any claim that may arise.
Reconocimiento de Ley Laboral y Declaración de la Política. Al aceptar el Otorgamiento de la Opción, Usted reconoce que Boston Scientific Corporation, con oficinas registradas en 300 Boston Scientific Way, Marlborough, Massachusetts 01752, Estados Unidos de América, es únicamente responsable de la administración del Plan. Usted además reconoce que su participación en el Plan, la concesión de Opción y cualquier adquisición de acciones de conformidad con el Plan no constituyen una relación de trabajo entre Usted y Boston Scientific Corporation, ya que Usted está participando en el Plan sobre una base totalmente comercial y su único patrón es una sociedad mercantil Mexicana (“Boston Scientific-México”). Derivado de lo anterior, Usted expresamente reconoce que el Plan y los beneficios que pueden derivarle de la participación en el Plan no establecen ningún derecho entre Usted y su Patrón, Boston Scientific-México, y no forman parte de las condiciones de trabajo y/o prestaciones otorgadas por Boston Scientific-México, y cualquier modificación

–Rev 1. 2024
31


al Plan o su terminación no constituirá un cambio o perjuicio de los términos y condiciones de su trabajo.
Usted además entiende que su participación en el Plan es resultado de una decisión unilateral y discrecional de Boston Scientific Corporation, por lo tanto Boston Scientific Corporation se reserva el derecho absoluto de modificar el Plan y/o discontinuar su participación en el Plan en cualquier momento, sin responsabilidad alguna para hacia Usted.
Finalmente, Usted declara que no se reserva acción o derecho alguno para presentar una reclamación o demanda en contra de Boston Scientific Corporation por cualquier compensación o daño o perjuicio en relación con cualquier disposición del Plan o los beneficios derivados del Plan y, por lo tanto, otorga un amplio y total finiquito a Boston Scientific Corporation, sus afiliados, afiliadas, sucursales, oficinas de representación, accionistas, directores, funcionarios, agentes y representantes con respecto a cualquier reclamación o demanda que pudiera surgir.
NETHERLANDS

Waiver of Termination Rights. By accepting the Stock Option, you hereby waive any and all rights to compensation or damages as a result of the termination of employment with Boston Scientific Corporation and the Employer for any reason whatsoever, insofar as those rights result or may result from (i) the loss or diminution in value of such rights or entitlements under the Plan, or (ii) your ceasing to have rights under, or ceasing to be entitled to any awards under the Plan as a result of such termination.

PERU

Securities Law Information. The grant of the Stock Option is considered a private offering in Peru; therefore, it is not subject to registration. For more information concerning the grant, you acknowledge that you should refer to the Plan, the Agreement, and any other materials made available by the Company. For more information regarding the Company, you acknowledge that you should refer to the Company’s most recent annual report on Form 10-K and quarterly report on Form 10-Q available at www.sec.gov.

Additional Acknowledgement of Nature of Plan and the Stock Option. By accepting the Stock Option, you understand, acknowledge and agree that the Stock Option are being granted ex gratia by the

POLAND

No country-specific provisions.


–Rev 1. 2024
32


PORTUGAL

Language Consent. You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and the Agreement.
Conhecimento da Lingua. Por meio do presente, eu declaro expressamente que tem pleno conhecimento da língua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condições estabelecidas no Plano e no Acordo.

PUERTO RICO

No country-specific provisions.

ROMANIA
Language Consent. By accepting the grant of the Stock Option, you acknowledge that you are proficient in reading and understanding English and fully understand the terms of the documents related to the grant (the Agreement and the Plan), which were provided in the English language. You accept the terms of those documents accordingly.
Consimtamant cu Privire la Limba. Acceptând acordarea opțiune de stoc, recunoașteți că sunteți competenți în citirea și înțelegerea limbii engleze și înțelegeți pe deplin termenii documentelor legate de subvenție (Acordul de acordare și planul), care au fost furnizate în limba engleză. Acceptați termenii acestor documente în consecință.
RUSSIA

THE PROVISIONS BELOW ARE CURRENT AS OF DECEMBER 2022 AND MAY NOT ADDRESS THE CURRENT LEGAL AND TAX CONSIDERATIONS AND REQUIREMENTS ASSOCIATED WITH AWARDS IN RUSSIA. YOU SHOULD CONSULT WITH A LEGAL AND TAX ADVISOR TO ENSURE COMPLIANCE WITH APPLICABLE LAW AS IT RELATES TO YOUR PARTICIPATION IN THE PLAN.

U.S. Transaction. You understand that the Stock Option shall be valid and this Agreement shall be concluded and become effective only when the Agreement is received by the Company in the United States. Upon exercise of the Stock Option, any shares of Stock to be issued to you shall be delivered to you through a bank or brokerage account in the United States. In no event will shares of Stock be delivered to you in Russia; instead, all shares of Stock acquired upon exercise of the Stock Option will be maintained on your behalf in the United States. You are not permitted to sell shares of Stock acquired at vesting directly to a Russian legal entity or resident.
Securities Law Information. You acknowledge that the Stock Option, the Equity Award and Acceptance Summary, the Agreement, the Plan and all other materials that you may receive regarding participation in the Plan do not constitute advertising or an offering of securities in

–Rev 1. 2024
33


Russia. The shares of Stock acquired pursuant to the Plan have not and will not be registered in Russia and, therefore, neither the Stock Option nor the shares of Stock may be used for offering or public circulation in Russia.
Cashless Exercise Provision. Notwithstanding anything to the contrary in the Agreement, depending on the development of local regulatory requirements, the Company reserves the right to restrict exercise of your Stock Option to a cashless exercise through a licensed securities broker acceptable to the Company, such that all shares of Stock subject to the exercised Stock Option will be sold immediately upon exercise and the proceeds of sale, less the Grant Price, any Tax-Related Items and broker’s fees or commissions, will be remitted to you in accordance with any applicable exchange control laws and regulations.

Repatriation Requirements. You agree to promptly repatriate proceeds resulting from the sale of shares of Stock acquired under the Plan to a foreign currency account at an authorized bank in Russia if legally required at the time shares of Stock are sold and to comply with all applicable local foreign exchange rules and regulations. Neither the Company nor any of its Affiliates shall be liable for any fines or penalties resulting from your failure to comply with applicable laws.

The repatriation requirement may not apply with respect to cash amounts received in an account that is considered by the Central Bank of Russia to be a foreign brokerage account opened with a financial market institution other than a bank. Statutory exceptions to the repatriation requirement also may apply.

Anti-Corruption Notification. Anti-corruption laws prohibit certain public servants, their spouses and their dependent children from owning any foreign source financial instruments (e.g., shares of Stock of foreign companies such as the Company). Accordingly, you should inform the Company if you are covered by these laws because you should not hold shares of Stock acquired under the Plan.
Labor Law Information. If you continue to hold shares of Stock acquired upon exercise of the Stock Option after an involuntary termination of employment, you may not be eligible to receive unemployment benefits in Russia.
Vesting and Exercise of Stock Option. Depending on the development of local regulatory requirements, the Company reserves the right to postpone the vesting and/or the ability to exercise the Stock Option, to restrict exercise of the Stock Option to a cashless sell-all exercise and/or to pay any proceeds related to the Stock Option to you through local payroll, or to cancel the Stock Option for no consideration.

–Rev 1. 2024
34


SAUDI ARABIA

Securities Law Information. The grant of the Stock Option is not subject to the regulations concerning public offers and private placements under the Law on Capital Markets.

SINGAPORE

Private Placement. The grant of the Stock Option under the Plan is being made pursuant to the “Qualifying Person” exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (“SFA”). The Plan has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is not regulated by any financial supervisory authority pursuant to any legislation in Singapore. Accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply. You should note that the Stock Option is subject to section 257 of the SFA and you will not be able to make any subsequent sale of the shares of Stock in Singapore, or any offer of such subsequent sale of the shares of Stock subject to the Stock Option in Singapore, unless such sale or offer in is made (i) after six months from the Grant Date or (ii) pursuant to the exemptions under Part XIII Division (1) Subdivision (4) (other than section 280) of the SFA.

SOUTH AFRICA

Securities Law Information. In compliance with South African securities law, the documents listed below are available for review on the Company’s external and internal sites at the web addresses listed below:
1.    Boston Scientific Corporation’s most recent Annual Report (Form 10-K): https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.
2.    The Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.
3.    Boston Scientific Corporation Non-Qualified Stock Option Grant and Amended and Restated 2011 Long-Term Incentive Plan Q&A Summary Sheet: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.
4.    Boston Scientific Corporation Equity Award and Acceptance Summary: This
document can be accessed at https://us.etrade.com/home -> My Stock Plan ->
Holdings -> click on a grant date and select “View Grant Documents”.


–Rev 1. 2024
35


You acknowledge that you may have copies of the above documents sent to you, at no charge, on written request being mailed to Boston Scientific Corporation, attn: Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.

You understand that you are advised to carefully read the materials provided before making a decision whether to participate in the Plan and to contact your tax advisor for specific information concerning your personal tax situation with regard to Plan participation.

SOUTH KOREA

Consent to Collection, Processing and Transfer of Personal Data. By electronically accepting this Agreement:

1.You agree to the collection, use, processing and transfer of Data as described in Section 12 of the Agreement; and

2.You agree to the processing of your unique identifying information (resident registration number) as described in Section 12 of the Agreement.

Domestic Broker Requirement for Selling Shares. Residents of South Korea may not be permitted to sell foreign securities (such as shares of Stock acquired under the Plan) through non-Korean brokers (such as Morgan Stanley Smith Barney LLC and its affiliates) or deposit funds resulting from the sale of shares of Stock in an account with an overseas financial institution. For this reason, you may be restricted from using a cashless exercise method to exercise the Stock Option. If you wish to sell shares of Stock acquired under the Plan, applicable law may require you to transfer the shares of Stock to a domestic investment broker in Korea and to effect the sale through such broker. You acknowledge and agree that you are solely responsible for engaging a domestic broker, to the extent required. Non-compliance with the requirement to sell shares of Stock through a domestic broker can result in significant penalties. Because applicable law and regulations may change without notice, you should consult with a legal advisor to ensure compliance with applicable law as it relates to your participation in the Plan.

SPAIN

Acknowledgement of Discretionary Nature of the Plan; No Vested Rights. This provision supplements the terms of the Agreement.

In accepting the Stock Option grant, you acknowledge that you consent to participation in the Plan and have received a copy of the Plan.

You understand that the Company has unilaterally, gratuitously and in its sole discretion granted Stock Options under the Plan to individuals who may be employees of the Company or its Affiliates throughout the world. The decision is a limited decision that is entered into upon the

–Rev 1. 2024
36


express assumption and condition that any grant will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis. Consequently, you understand that the Stock Option is granted on the assumption and condition that the Stock Option and the shares of Stock acquired upon exercise of the Stock Option shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever. In addition, you understand that this grant would not be made to you but for the assumptions and conditions referenced above; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, the Stock Option grant shall be null and void.

You understand and agree that, as a condition of the Stock Option grant, your termination of employment for any reason (including the reasons listed below) will automatically result in the loss of the Stock Option to the extent the Stock Option has not vested as of date you cease active employment. In particular, you understand and agree that any unvested Stock Option as of the date you cease active employment and any vested portion of the Stock Option not exercised within the post-termination exercise period set out in the Agreement will be forfeited without entitlement to the underlying shares of Stock or to any amount of indemnification in the event of the termination of employment by reason of, but not limited to, resignation or retirement prior to the first anniversary of the Grant Date, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without cause, individual or collective dismissal on objective grounds, whether adjudged or recognized to be with or without cause, material modification of the terms of employment under Article 41 of the Workers’ Statute, relocation under Article 40 of the Workers’ Statute, Article 50 of the Workers’ Statute, unilateral withdrawal by the Employer and under Article 10.3 of the Royal Decree 1382/1985. You acknowledge that you have read and specifically accept the conditions referred to in the Agreement regarding the impact of a termination of employment on your Stock Option.

BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

SWEDEN

Tax Withholding. The following provision shall supplement Section 10 of the Agreement:

Without limiting the Company’s and the Employer’s authority to satisfy their withholding obligations for Tax-Related Items as set forth in the Section 10 of the Agreement, in accepting the grant of the Stock Option, you authorize the Company to sell shares of Stock otherwise deliverable to you upon exercise of the Stock Option to satisfy Tax-Related Items, regardless of whether the Company and/or the Employer have an obligation to withhold such Tax-Related Items.

–Rev 1. 2024
37



TAIWAN

Securities Law Information. This Award and the shares of Stock to be issued pursuant to the Plan are available only for Employees. The Award is not a public offer of securities by a Taiwanese company.

TURKEY

Securities Law Information. Under Turkish law, you are not permitted to sell shares of Stock acquired under the Plan in Turkey. The shares of Stock are currently traded on the New York Stock Exchange, which is located outside Turkey and the shares of Stock may be sold through this exchange.

UNITED ARAB EMIRATES

Securities Law Information. The Plan is an employee equity incentive plan and is only being offered to select employees in the United Arab Emirates. The Plan and the Agreement are intended for distribution only to such employees and must not be delivered to, or relied on by, any other person. The Emirates Securities and Commodities Authority has no responsibility for reviewing or verifying any documents in connection with the Plan. Neither the Ministry of Economy nor the Dubai Department of Economic Development have approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents. You should conduct your own due diligence on the securities offered under the Plan. If you do not understand the contents of the Agreement or the Plan, you should consult an authorized financial advisor.

UNITED KINGDOM

Income Tax and Social Insurance Contribution Withholding. The following provision shall supplement Section 10 of the Agreement:
Without limitation Section 10 of the Agreement, you agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company, the Employer or by HM Revenue and Customs (“HMRC”) (or any other tax authority or any other relevant authority). You also agree to indemnify and keep indemnified the Company and the Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay on your behalf to HMRC (or any other tax authority or any other relevant authority).

–Rev 1. 2024
38



Notwithstanding the foregoing, you understand that if you are a director or executive officer (within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the terms of the immediately foregoing provision may not apply. In the event that you are a director or executive officer and income tax due is not collected from or paid by you within 90 days after the UK tax year in which an event giving rise to the indemnification described above occurs, the amount of any uncollected tax may constitute a benefit on which additional income tax and national insurance contributions may be payable. You acknowledge that you ultimately will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for reimbursing the Company or the Employer (as applicable) for the value of any employee national insurance contributions due on this additional benefit, which the Company and/or the Employer may recover from you at any time thereafter by any of the means referred to in Section 10 of the Agreement.

Exclusion of Claim. You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Award, whether or not as a result of your termination of employment (whether the termination is in breach of contract or otherwise), or from the loss or diminution in value of the Award. Upon the grant of your Award, you shall be deemed irrevocably to have waived any such entitlement.

*    *    *    *


–Rev 1. 2024
39


APPENDIX A

CONSENT LETTER
102 CAPITAL GAIN AWARDS FOR PARTICIPANTS RESIDING IN ISRAEL
Dear Participant,
Boston Scientific Corporation (the “Company”) has elected to apply the capital gains route in accordance with the provisions of Section 102 of the Israeli Income Tax Ordinance (the “Ordinance”) on awards granted under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Incentive Plan”) to Israeli Participants (as defined in the Israeli sub-plan to the Incentive Plan (the “Israel Sub-Plan”), which was approved by the Executive Compensation and Human Resources Committee of the Company’s Board of Directors on November 14, 2022) and any future incentive plan implemented by the Company in Israel (“Awards” and “Capital Gains Route”), subject to the Company’s absolute discretion to change such election on future grants, with or without advance notice. Unless otherwise notified to you in writing by the Company, the Awards shall be granted to you under the Capital Gains Route, subject to compliance with the requirements of such tax route.
The Capital Gains Route election will enable you to enjoy lower tax rates on a portion of the income received upon disposition of the shares of Company common stock (“Shares”) issued to you from or in connection to the Awards, provided however that all the requirements under Section 102 of the Ordinance and the Income Tax (Tax Abatement on the Grant of Shares to Employees) Regulations 2003 (the “Regulations”) are met.
Below you will find a brief description of the Israeli income tax consequences of the Capital Gains Route. PLEASE NOTE THAT THE SUMMARY BELOW IS ONLY A BRIEF SUMMARY THAT DOES NOT COVER ALL THE PROVISIONS OF SECTION 102 OF THE ORDINANCE AND THE REGULATIONS AND IS NOT INTENDED TO PROVIDE ANY TAX ADVICE. IN ADDITION, THE TAX LAWS AND REGULATIONS DESCRIBED HEREIN ARE SUBJECT TO CHANGE. THEREFORE, IT IS RECOMMENDED THAT YOU CONSULT WITH A TAX ADVISER BEFORE ACCEPTING THE TERMS OF THIS CONSENT LETTER OR BEFORE ACCEPTING ANY AWARDS OR DISPOSING OF SHARES.
The main restrictions that are included under Section 102 of the Ordinance are as follows:
(1) Your Awards and the Shares issued under such Awards will be held in trust or controlled by a trustee for at least a period determined in Section 102 under the Capital Gains Route (“Required Holding Period”) (currently twenty-four months from the date in which the Awards were granted to you).

–Rev 1. 2024
40


(2) During the Required Holding Period you will not be able to sell, pledge, release from trust or otherwise perform any transaction in connection to the Awards or Shares granted to you.
Provided that all conditions set by the Ordinance under the Capital Gains Route are met, including the above conditions, you will, in general, be taxed as follows: 
The lower of (1) the difference between the fair market value of the underlying Shares on the grant date and the exercise price (plus any transactional expenses incurred in connection with the sale) and (2) the difference between the sale proceeds and the exercise price (plus any transactional expenses incurred in connection with the sale) will be treated as ordinary income subject to income tax and employee/employer social insurance contributions (to the extent the applicable contribution ceiling has not been exceeded). For tax purposes, the fair market value of the Shares at grant is deemed to be the average price of the Shares over the 30 trading days preceding the grant. 
The remainder of the gain, if any, will be treated as a capital gain and will be taxed at the capital gains tax rate of 25%.  No social insurance contributions will be due on this portion of the gain. 
In addition, a surtax may be imposed if your income is in excess of the applicable annual threshold.
If you sell your Shares, or release the Shares from trust, before the end of the Holding Period, you will immediately be subject to income tax on the gain, at your marginal income tax rate, and will be also required to pay social security and health tax contributions on all your profit.
In order to enable you to enjoy the benefits of the Capital Gains Route, please express your acceptance and confirmation of the following terms, by accepting the Award through the electronic acceptance procedures established by the Company:
1.    I undertake to comply with all the terms and conditions set under Section 102 of the Ordinance with regard to the Capital Gains Route and the Regulations.
2.    I have had the opportunity to obtain the advice of counsel prior to accepting this Consent Letter. I am familiar with and understand the provisions of Section 102 of the Ordinance in general, and the tax arrangement under the Capital Gains Route in particular, and agree to comply with such provisions, as amended from time to time.
3.    I agree that Awards granted to me, and the Shares that may be derived from such Awards, will be held or controlled by a trustee for at least the duration of the Required

–Rev 1. 2024
41


Holding Period, as determined in Section 102 under the Capital Gains Route (currently twenty-four months from the date in which the Awards were granted).
4.    I agree to the trust deed signed between the Company, my employer and the trustee available at Trust Deed RSU-Stock Option - Hebrew.pdf.
5.    I understand that any release of such Awards or Shares from trust, or any sale of the Shares prior to the termination of the Required Holding Period, will result in taxation at my marginal tax rate, in addition to deductions of appropriate social security and health tax contributions.
6.    I authorize the Company and/or my employer to provide the trustee with any information required for administrating the grant of the Awards, including without limitation information about my Awards, income tax rates, salary bank account, contact details and identification number and any reasonable information required by the trustee.
7.     I declare that I am a resident of the state of Israel for tax purposes and agree to notify the Company upon any change in the residence address and acknowledge that if I cease to be an Israeli resident or if my engagement with the Company or any affiliate is terminated, the Awards and underlying Shares shall remain subject to Section 102, the trust agreement and the applicable equity plan and grant document.
8.    I understand and agree that until the Company will determine otherwise, my acceptance of the terms of this Consent Letter will be sufficient, to apply to all potential future grants of Awards. I hereby confirm that by accepting this Consent Letter, I will be deemed to have elected to accept the terms and conditions herein in respect of any such potential future grant of Awards.
9.     I acknowledge, understand and agree that the Awards are an extraordinary, one-time benefit granted to me, and do not create any contractual or other right to receive future grant of Awards.
10.     I understand that neither the Company nor any affiliates guarantee that any Awards granted to me will be eligible for tax benefits pursuant to the Capital Gains Route and I agree that I will not hold the Company and/or any affiliate and/or the trustee liable for any tax consequences relating to my Awards, including any penalties or other negative tax consequences I could receive or be subject to if my Awards do not obtain the Capital Gains Route tax treatment, regardless of the reason for the Capital Gains Route tax treatment not being available.
*    *    *    *

415138311-v12\NA_DMS

–Rev 1. 2024
42


ANNEX 1


image_2.jpg


OFFER DOCUMENT

BOSTON SCIENTIFIC CORPORATION
AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN



OFFER TO AUSTRALIAN RESIDENT EMPLOYEES









INVESTMENT IN SHARES OF STOCK INVOLVES A DEGREE OF RISK. EMPLOYEES WHO PARTICIPATE IN THE PLAN SHOULD MONITOR THEIR PARTICIPATION AND CONSIDER ALL RISK FACTORS RELEVANT TO THE ACQUISITION OF SHARES OF STOCK UNDER THE PLAN AS SET OUT IN THIS OFFER DOCUMENT AND THE ADDITIONAL DOCUMENTS. ANY ADVICE CONTAINED IN THIS OFFER DOCUMENT IN RELATION TO THE STOCK OPTION BEING OFFERED UNDER THE PLAN DOES NOT TAKE INTO ACCOUNT THE OBJECTIVES, FINANCIAL SITUATION AND NEEDS OF ANY INDIVIDUAL EMPLOYEE. EMPLOYEES SHOULD CONSIDER OBTAINING THEIR OWN FINANCIAL PRODUCT ADVICE FROM A PERSON LICENSED BY THE AUSTRALIAN SECURITIES AND INVESTMENTS COMMISSION (“ASIC”) TO GIVE SUCH ADVICE.



OFFER TO AUSTRALIAN RESIDENT EMPLOYEES

BOSTON SCIENTIFIC CORPORATION
AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN

This ESS Offer Document sets out information about the invitation to participate in the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Plan”) for Australian resident employees of Boston Scientific Corporation (the “Company”) and its Affiliates. The offer to participate in the Plan is being made under Division 1A of Part 7.12 of the Corporations Act 2001 (the “Act”, and “Division 1A of the Act”). For purposes of Division 1A of the Act, this document is to be regarded as an ESS Offer Document.

The purpose of the Plan is to encourage ownership in the Company by key personnel whose long-term employment is considered essential to the Company’s continued progress, and thereby, encourage recipients to act in the shareowners’ interest and share in the Company’s success. We hope you will take the time to review this information carefully.

Terms defined in the Plan have the same meaning in this ESS Offer Document.

1.    OFFER OF STOCK OPTIONS

This is an offer made by the Company under the Plan to eligible employees of the Company or an Affiliate to accept stock options (an “Award”) granted under and in accordance with the terms of the Plan.

2.    TERMS OF GRANT

The specific terms of your of grant are set out in the Global Non-Qualified Stock Option Award Agreement and addendum (“Option Agreement” or “Award Agreement”).

The Award Agreement forms part of this ESS Offer Document. The rules of the Plan are incorporated into the Award Agreement and this ESS Offer Document by reference. By accepting a grant of the Award, you will be bound by the rules of the Plan and the applicable Award Agreement.

3.    ADDITIONAL DOCUMENTS

In addition to the information set out in this ESS Offer Document, the following documents (collectively “Additional Documents”) are made available to you and set out the specific terms of your grant:

(a)the Plan;
(b)the Non-Qualified Stock Option Prospectus Letter;



(c)the Plan Equity Award and Acceptance Summary;
(d)the Option Agreement;
(e)the Non-Qualified Stock Option Grant and Plan Global Q&A Summary Sheet; and
(f)the Stock Options Tax Supplement.

The Additional Documents provide further information necessary to make an informed investment decision in relation to your participation in the Plan.

4.    RELIANCE ON STATEMENTS

You should not rely upon any oral statements made to you in relation to this offer. You should only rely upon the statements contained in this ESS Offer Document and the Additional Documents when considering your participation in the Plan.

5.    WHAT IS A STOCK OPTION?

A stock option gives its holder the right, but not the obligation, to purchase a specified number of shares of Stock at a specified exercise price if certain conditions are met. A stock option is subject to a substantial risk of forfeiture and to restrictions on its sale or other transfer.

6.    HOW MANY SHARES OF STOCK WILL I RECEIVE UNDER THE STOCK OPTION AWARD AND WHAT IS THE PURCHASE PRICE OF THE SHARES OF STOCK?

The number of shares of Stock subject to the stock option award is set forth in the Option Agreement. Please note that you do not pay any monetary consideration to receive the stock options. However, you will have to pay an exercise price to receive shares of Stock upon exercise of the stock option.

7.    WHAT IS THE EXERCISE PRICE OF THE STOCK OPTION?

The exercise price for the stock option is set out in the Option Agreement. The exercise price is denominated in U.S. dollars and must be paid in U.S. dollars. The Australian dollar amount required to exercise the stock options and acquire shares of Stock will be that amount which, when converted into U.S. dollars on the date of exercise, equals the exercise price. The Australian dollar equivalent of the exercise price will change with fluctuations in the U.S./Australian dollar exchange rate. For information on how to obtain the U.S./Australian dollar exchange rate, see section 14 below.

8.    DO I HAVE RIGHTS AS A STOCKHOLDER OF THE COMPANY AS A RESULT OF AN AWARD OF STOCK OPTIONS?

6702583-v2\GESDMS
2


No. You will not have the right to receive any cash or stock dividends or to vote the shares of Stock underlying your stock options until you satisfy the terms and conditions of your Option Agreement, exercise the stock options and the Company actually delivers the underlying shares of Stock to you upon satisfaction of such terms and conditions. The terms and conditions of the stock options may include (but are not limited to) a requirement that you remain in the continuous service with the Company or an Affiliate for a specified period of time.

9.    WHO IS ELIGIBLE TO PARTICIPATE IN THE PLAN?

The following individuals may be granted an Award under the Plan:

(i)a member of the Board or of the board of directors of an Affiliate (as defined in the Plan);

(ii)an employee of the Company; or

(iii)an employee of an Affiliate (as defined in the Plan).

10.    HOW MANY SHARES OF STOCK ARE AVAILABLE FOR ISSUANCE UNDER THE PLAN?

Up to 168,450,000 shares of Common Stock may be subject to awards granted under the Plan. Shares of Common Stock delivered by the Company under the Plan may be authorized but unissued shares of Common Stock or previously issued shares of Common Stock acquired by the Company and held in treasury.

11.    HOW CAN I OBTAIN THE UPDATED AUSTRALIAN DOLLAR EQUIVALENT OF THE CURRENT MARKET VALUE OF A SHARE AND ADDITIONAL INFORMATION REGARDING THE PLAN?

You may ascertain the market price of the shares of Stock by obtaining the current trading price of the Company’s shares of Stock on the NYSE at http://www.nyse.com under the code “BSX”.

The Australian dollar equivalent of that price can be obtained at: http://www.rba.gov.au/statistics/frequency/exchange-rates.html


12.    ADDITIONAL INFORMATION RELEVANT TO AUSTRALIAN RESIDENT EMPLOYEES

Any advice given by the Company in connection with the offer under the Plan is general advice only, and employees should consider obtaining their own financial
6702583-v2\GESDMS
3


product advice from an independent person who is licensed by ASIC to give such advice.

    12.1    Who administers the Plan?

The Plan is administered by the Administrator (the Executive Compensation and Human Resources Committee of the Board) except to the extent the Administrator delegates administration pursuant to the Plan.

Subject to certain limitations, the Administrator may delegate all or a portion of the administration of the Plan to one or more executive officers of the Company, to the extent permitted by Delaware law and U.S. regulations.

In accordance with Section 7 of the Plan, the Administrator may at any time or times amend, alter, suspend, discontinue or terminate the Plan, in whole or in part.

    12.2    What is a share of Stock in the Company?

Shares of common stock in a U.S. corporation are the same as ordinary shares of an Australian corporation. Each holder of Stock is entitled to one vote for every share of Stock held in the Company.

Dividends may be paid on the Stock out of any funds of the Company legally available for dividends at the discretion of the Board.

The only issued capital of the Company is currently common stock. The shares of Stock are listed and may be traded on the NYSE.

Shares of Stock are not subject to any further calls for payment of capital or for other assessment by the Company and have no sinking fund provisions, pre-emptive rights, conversion rights or redemption provisions.

    12.3    What additional risk factors apply to Australian residents’ participation in the Plan?

You should have regard to risk factors relevant to investment in securities generally and, in particular, to the holding of shares of Stock. For example, the price at which the shares of Stock are quoted on the NYSE may increase or decrease due to a number of factors. There is no guarantee that the price of the shares of Stock will increase. Factors which may affect the price of the shares of Stock include fluctuations in the domestic and international market for the listed stocks, general economic conditions, including interest rates, inflation rates, legislation or regulation, the nature of the markets in which the Company operates and general operational and business risks.

6702583-v2\GESDMS
4


More information about potential factors that could affect the Company's business and financial results is included in the Company's most recent Annual Report on Form 10-K and the Company's Quarterly Report on Form 10-Q. Copies of these reports are available at http://sec.gov and upon request to the Company.

In addition, you should be aware that the Australian dollar value of the shares of Stock you may acquire under the Plan will be affected by the U.S./Australian dollar exchange rate. Participating in the Plan involves risks related to fluctuations in this rate of exchange.

        12.4    What are the Australian taxation consequences of participating in the Plan?

Please see the Stock Options Tax Supplement for information regarding the Australian tax treatment of your Award.

    12.5    What are the U.S. taxation consequences of participation in the Plan?

Employees will not be subject to U.S. tax consequences by reason only of the acquisition of shares of Stock and/or the sale of shares of Stock. However, liability to U.S. taxes may accrue if an employee is otherwise subject to U.S. taxes.

Again, the above is an indication only of the likely U.S. taxation consequences for Australian resident employees who accepts the stock options granted under the Plan. Employees should seek advice as to the U.S. tax consequences of participation from their personal tax advisers.

13.    OTHER RESTRICTIONS

In addition to any other limitations as identified in this ESS Offer Document, the Plan or as prescribed by the Administrator from time to time under the terms of the Plan, there is an overall restriction on the number of shares of Stock that can be issued to Australian employees.

14.    STATUTORY TERMS AND CONDITIONS

As noted above, this offer is being made under Division 1A of Part 7.12 of the Act. To comply with that Division, the following terms are included:

A.    Application period
This offer remains open until the date specified in your stock option (“Option”) documentation (the “Application Period”). You may accept this offer at any time up until then.
6702583-v2\GESDMS
5


B.    Acquisition of Options
You cannot acquire any Options and purchase any shares of Stock until at least 14 days after receiving this ESS Offer Document. Accordingly, no such acquisition will occur until the 14th day after receiving this ESS Offer Document.
C.    Terms relating to disclosure
6702583-v2\GESDMS
6


This offer is also subject to the following terms relating to disclosure:
(a) this ESS Offer Document and the terms of the offer:
(i) must not include a misleading or deceptive statement; and
(ii) must not omit any information that would result in this document or terms of the offer being misleading or deceptive;
(b) the Company must provide you with an updated ESS Offer Document as soon as practicable after becoming aware that the document that was provided has become out of date, or is otherwise not correct, in a material respect;
(c) each person mentioned in items 2, 3 and 4 of the table below must notify, in writing, the Company as soon as practicable if, during the Application Period, the person becomes aware that:
(i) a material statement in the documents mentioned in paragraph (a) is misleading or deceptive; or
(ii) information was omitted from any of those documents that has resulted in one or more of those documents being misleading or deceptive; or
(iii) a new circumstance has arisen during the Application Period which means the ESS Offer Document is out of date, or otherwise not correct, in a material respect; and
(d) if you suffer loss or damage because of a contravention of a term of the offer covered by paragraph (a), (b) or (c) above, you can recover the amount of loss or damage in accordance with the table below.
For the purposes of paragraph (d) above, an ESS participant must be able to recover loss or damage in accordance with the following table:
Item
You may recover loss or damage suffered as a result of a contravention of
from these people...

1
a term of the offer covered by any of the following paragraphs:
paragraph (a) (misleading or deceptive statements and omissions);
paragraph (b) (out of date ESS Offer Document)
the Company

2
a term of the offer covered by any of the following paragraphs:
paragraph (a) (misleading or deceptive statements and omissions);
paragraph (b) (out of date ESS Offer Document)
each director of the Company

3
a term of the offer covered by any of the following paragraphs:
paragraph (a) (misleading or deceptive statements and omissions);
paragraph (b) (out of date ESS Offer Document)
a person named, with their consent, in an ESS Offer Document or the terms of the offer as a proposed director of the Company

4
a term of the offer covered by paragraph (a) (misleading or deceptive statements and omissions)
a person named, with their consent, in the ESS Offer Document or the terms of the offer as having made:
the misleading or deceptive statement; or
a statement on which the misleading or deceptive statement is based

5
a term of the offer covered by paragraph (c) (failure to notify the Company of misleading or deceptive statement and omissions or new circumstances)
the person mentioned in item 2, 3 or 4 of this table who failed to notify the Company in accordance with the term covered by paragraph (c)

6702583-v2\GESDMS
7


D.    Exclusions from liability
A person mentioned in the table in section D above is not liable for any loss or damage suffered by you because of a contravention of a term of the offer covered by paragraph (a) or (b) of section D above if:
(a)the person:
(i)made all inquiries (if any) that were reasonable in the circumstances; and
(ii)after doing so, believed on reasonable grounds that the statement was not misleading or deceptive; or
(b)the person did not know that the statement was misleading or deceptive; or
(c)the person placed reasonable reliance on information given to the person by:
(i)if the person is a body corporate or a responsible entity of a registered scheme - someone other than a director, employee or agent of the body corporate or responsible entity; or
(ii)if the person is an individual—someone other than an employee or agent of the individual; or
(d)for a person mentioned in column 2 of item 3 or 4 of the table in section D above - the person proves that they publicly withdrew their consent to being named in the document in that way; or
(e)the contravention arose because of a new circumstance that has arisen since the ESS offer document was prepared and the person proves that they were not aware of the matter.

*    *    *    *    *
We urge you to carefully review the information contained in this Offer Document and the Additional Documents. If you have any questions, please send them to: BSCEquityCompSupport@bsci.com.

Yours sincerely,
Boston Scientific Corporation

6702583-v2\GESDMS
8
EX-10.2 3 exhibit102-bscx2024grantxr.htm EX-10.2 Document

Exhibit 10.2


EMPLOYEE COPY
PLEASE RETAIN FOR YOUR RECORDS

Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan
Global Restricted Stock Unit Award Agreement

This Global Restricted Stock Unit Award Agreement (the “Agreement”) is between you and Boston Scientific Corporation, a Delaware corporation, (the “Company”) in connection with the award of Restricted Stock Units (the “Award”) by the Committee under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Plan”). Capitalized terms used but not defined in this Agreement shall have the same meaning as assigned to them in the Plan. The applicable terms and conditions of the Plan are incorporated into and made a part of this Agreement.

1.    Grant of Units. The Committee hereby grants you that number of Restricted Stock Units as set forth in your Equity Award and Acceptance Summary (the “Units”). Each Unit represents the Company’s commitment to issue to you one share of Stock subject to the conditions set forth in this Agreement. This Award is granted pursuant to and is subject to the provisions of the Plan and the terms and conditions of this Agreement and any applicable Addendum.

    2.    Vesting. The Units shall vest and shares of Stock will be issued to you in accordance with the schedule provided in your Equity Award and Acceptance Summary. Except as otherwise provided in Sections 4, 5, 6, 7 and 8 below, the Units will vest, subject to the conditions described in Section 7 below. Shares of Stock for Units that vest in accordance with this Section 2 will be delivered to you within fifteen (15) days after the applicable vesting date but in no event later than the last day of the calendar year that includes the applicable vesting date. No shares of Stock shall otherwise be issued to you prior to the date on which the Units vest. Notwithstanding anything in the Agreement to the contrary, the Company may, in its sole discretion, settle the Units in the form of a cash payment to the extent that settlement in shares of Stock is prohibited under local law or would require the Company and/or any of its Affiliates to obtain the approval of or complete any legal or regulatory filing with any governmental and/or regulatory body in your country of residence (or country of employment, if different). Alternatively, the Company may, in its sole discretion, settle the Units in the form of shares of Stock but require you to sell such Stock immediately or within a specified time following your termination of employment (in which case, this Agreement shall give the Company the authority to issue sales instructions on your behalf).

    3.    Participant’s Rights in Stock. The shares of Stock, if and when issued to you pursuant to this Agreement, shall be registered in your name and evidenced in a
–Rev 1.2024
1


manner as determined by the Company, in its sole discretion. Under no circumstance will you be deemed, by virtue of the granting of the Units, to be a holder of any shares of Stock underlying the Units or be entitled to the rights or privileges of a holder of such shares of Stock (including the right to receive dividends or vote the shares of Stock), unless and until the Units have vested with respect to such shares of Stock and the shares of Stock have been issued to you.

    4.    Death. In the event you terminate employment by reason of death, any Units that have not vested prior to the date of your death shall immediately vest and shares of Stock shall be issued in accordance with your will or the laws of descent and distribution. Shares of Stock for Units which vest under this Section 4 will be delivered within sixty (60) days after your employment termination date.

    5.    Retirement. If you terminate employment by reason of your Retirement, any Units that have not vested prior to the date of your Retirement shall immediately vest and shares of Stock shall be issued to you, provided you have remained in continuous service with the Company or an Affiliate through the first anniversary of the Grant Date. In the event that your Retirement occurs prior to the first anniversary of the Grant Date, all unvested Units shall immediately terminate and be forfeited in their entirety. Shares of Stock for Units which vest under this Section 5 will be delivered within thirty (30) days after your employment termination date. For purpose of this Section 5, a “Retirement” shall not include (i) a termination of your employment for Cause (as defined in Section 7 of this Agreement) or (ii) a resignation by you after being notified that the entity that employs you has elected to terminate your employment for Cause.

    In this regard, if you are a local national of and employed in a country that is a member of the European Union, the grant of the Units and the terms and conditions governing the Units are intended to comply with the age discrimination provisions of the EU Equal Treatment Framework Directive, as implemented into local law (the “Age Discrimination Rules”). To the extent that a court or tribunal of competent jurisdiction determines that any provision of the Units is invalid or unenforceable, in whole or in part, under the Age Discrimination Rules, the Company, in its sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full extent permitted under local law.

    6.     Disability. If you terminate employment by reason of your Disability (as the term is defined in the Plan or determined under local law), any Units that have not vested prior to the date of your termination by reason of Disability shall immediately vest and shares of Stock shall be issued to you. Shares of Stock for Units which vest under this Section 6 will be delivered within thirty (30) days after your employment termination date.

    7.    Other Termination of Employment; Certain Vesting Conditions. If your employment terminates for any reason other than death, Retirement or Disability, any Units that have not vested prior to the date of your termination shall terminate and be forfeited on the effective date of such termination, except if your employment terminates
–Rev 1.2024
2


for Cause, in which case, all unvested Units shall be forfeited upon notice to you of your termination for Cause.

(a)    Definition of Cause. For purposes of this Agreement, “Cause” shall mean termination of your employment by the entity that employs you as a result of the occurrence of any of the following, as determined by the Company in its sole discretion:


(i)your violation of the Company’s Code of Conduct or your violation of any written policy of the Company;

(ii)your breach of your Agreement Concerning Employment, if any, or any other written agreement between you and the Company or the entity that employs you (if different);

(iii)your commission of an act of fraud, embezzlement, dishonesty or theft in connection with your duties or in the course of your employment;

(iv)your engaging in any gross or willful misconduct that causes harm, or is likely to cause harm, to the Company’s business or its reputation;

(v)your being charged with, convicted of, or pleading guilty or no contest to, any felony or any other crime involving dishonesty or moral turpitude.

(vi)your failure to substantially perform the essential duties of your employment (other than such failure resulting from your Retirement, Death or Disability as set forth in Sections 4, 5 and 6 of this Agreement).
(b)    Continuous Employment; Effective Date of Termination. Subject to Sections 4, 5 and 6 of this Agreement, the issuance of shares of Stock is conditioned on your continuous employment with the Company or an Affiliate through and on the applicable anniversary of the Grant Date as set forth in Section 2 above. For purposes of the vesting conditions set forth in this Agreement, the effective date of your termination shall be deemed to be the last day of your active service with the Company or an Affiliate (if applicable). Notwithstanding anything to the contrary in the Plan or this Agreement, and for purposes of clarity, the date of your termination of employment shall not be extended by any statutory or common law notice of termination period.

8.    Change in Control of the Company. In the event you are employed by the Company or an Affiliate at the time of a Change in Control, any Units that have not vested prior to the Change in Control shall immediately vest and shares of Stock will be issued to you immediately prior to the Change in Control; provided, however, that if you have entered into a Change in Control agreement with the Company, the Units will vest according to the provisions of the Change in Control agreement. In the event you have terminated employment with the Company or an Affiliate prior to a Change in Control as a result of death, Disability, or Retirement occurring on or after the first anniversary of
–Rev 1.2024
3


the Grant Date, and the Change in Control occurs following your termination of employment, shares of Stock for any Units that have vested under Section 4, 5 or 6 but which have not yet been issued will be issued immediately prior to the Change in Control. Notwithstanding the foregoing and unless otherwise specifically provided in any agreement of the Company or any of its Affiliates with you pertaining to the effect of a Change in Control on outstanding Awards which is in effect as of the Change in Control, if this Award is subject to and not exempt from the application of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) and provides for settlement or payment upon a Change in Control, the definition of Change in Control shall be limited to events which qualify as a change in the ownership of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(v), or a change in the ownership of a substantial portion of the assets of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(vii); provided, however, that this requirement shall not cause an event that would not otherwise be considered a Change in Control under the definition of a Change in Control under the Plan to be considered a Change in Control.

    9.    Recoupment Policies.

    (a)    Executive Committee Recoupment Policy. Pursuant to the Company’s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Committee Member or Former Executive Committee Member and, in the judgment of the Board, you, while serving in such capacity as a Current Executive Committee Member, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company.

        (i)    Definitions. The following terms, when used in this Section 9, shall have the meaning set forth below:

            (1)    “Current Executive Committee Member” means any individual currently designated as a corporate officer of the Company who is in an organizational job level of E-4 or E-5 (or any equivalent level under any future organizational framework).

            (2)    “Former Executive Committee Member” means any individual previously (but not currently) designated as a corporate officer of the Company who is in an organizational job level of E-4 or E-5 (or any equivalent level under any future organizational framework).

        (3)    “Recovery” means the forfeiture or cancellation of unvested Units.

    (b)    Other Compensation Recoupment Authority. The Units and any compensation associated therewith and any proceeds therefrom are subject to forfeiture, recovery by the Company or other action pursuant to any compensation recovery policy
–Rev 1.2024
4


(i) in effect as of the Grant Date, as such policy may be amended from time to time, which includes but is not limited to the Company’s Dodd-Frank Clawback Policy and (ii) any other compensation recovery policy adopted after the Grant Date to facilitate compliance with applicable law, including in response to the requirements of Section 10D of the Exchange Act, the U.S. Securities and Exchange Commission’s final rules thereunder, and any applicable listing rules or other rules and regulations implementing the foregoing.

(c)     Instructions to Brokerage Firm. For purposes of Sections 9(a) and 9(b) of this Agreement, you expressly and explicitly authorize the Company to issue instructions, on your behalf, to any brokerage firm and/or third party administrator engaged by the Company to hold any shares of Stock and other amounts acquired pursuant to the Units to re-convey, transfer or otherwise return such shares of Stock and/or other amounts to the Company upon the Company’s enforcement of the Company’s recoupment policy, the Company’s Dodd-Frank Clawback Policy and any other compensation recovery policy adopted by the Board or the Committee.

(d)     No Constructive Termination. No recovery of compensation as described in this Section 9 will be an event giving rise to your right to resign for “good reason” or “constructive termination” (or similar term) under any plan of, or agreement with, the Company and/or an Affiliate and you.

    10.    Consideration for Stock. The shares of Stock subject to the Units are intended to be issued for no cash consideration.

    11.    Issuance of Stock. The Company shall not be obligated to issue any shares of Stock until (a) all federal, state and local laws and regulations, as the Company may deem applicable, have been complied with; (b) the shares have been listed or authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges; and (c) all other legal matters in connection with the issuance and delivery of the shares have been approved by the Company’s legal department.

    12.    Transferability; Restrictions on Shares; Legend on Certificate. Until the vesting conditions of this Award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement and any applicable Addendum or by action of the Committee, the Units awarded under this Agreement are not transferable and you shall not sell, transfer, assign, pledge, gift, hypothecate or otherwise dispose of or encumber the Units awarded under this Agreement. Transfers of shares of Stock by you are subject to the Company’s Stock Trading Policy and applicable securities laws. Shares of Stock issued to you in certificate form or to your book entry account upon satisfaction of the vesting and other conditions of this Award may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.
–Rev 1.2024
5



    13.    Satisfaction of Tax Obligations. Regardless of any action the Company or the Affiliate that employs you (the “Employer”) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (“Tax-Related Items”), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and/or the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) do not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate your liability for Tax-Related Items.

    Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if your country of residence (and/or the country of employment, if different) requires withholding of Tax-Related Items, the Company may hold back from the total number of shares of Stock to be delivered to you, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. If the obligation for Tax-Related Items is satisfied by holding back shares of Stock to be delivered upon settlement of the Units, for tax purposes, you are deemed to have been issued the full number of shares of Stock subject to the Units, notwithstanding that a number of shares of Stock are held back solely for the purpose of paying the Tax-Related Items. You will have no further rights with respect to any shares of Stock that are retained by the Company pursuant to this provision. By accepting the grant of the Units, you expressly consent to the withholding of shares of Stock and/or cash as provided for hereunder.

    Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. You agree to sign any agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.     

    All other Tax-Related Items related to the grant of the Units and any shares of Stock delivered in settlement thereof are your sole responsibility. In no event shall whole
–Rev 1.2024
6


shares be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

    The Units are intended to comply with or be exempt from the requirements of Code Section 409A. The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.

    Notwithstanding any provision of this Agreement to the contrary, in the event that any settlement or payment of this Award occurs as a result of your termination of employment and the Company determines that you are a “specified employee” (as that term is defined under Code Section 409A) subject to Code Section 409A at the time your termination of employment, and provided further that such payment or settlement does not otherwise qualify for an applicable exemption from Code Section 409A, then no such settlement or payment shall be paid to you until the date that is the earlier to occur of: (i) your death, or (ii) six (6) months and one (1) day following your termination of employment. Any portion of this Award delayed as a result of the preceding sentence, which is (i) in whole or in part, settled in cash and (ii) based on the value of Stock, shall be based on the value of the Stock at the time the Award would have otherwise been settled or paid without application of the delay described in the preceding sentence. If this Award does not otherwise qualify for an applicable exemption from Code Section 409A, the terms “Retirement”, “terminate,” “termination,” “termination of employment,” and variations thereof as used in this agreement, are intended to mean a termination of employment that constitutes a “separation from service” as such term is defined under Code Section 409A. Notwithstanding any action or inaction by the Administrator, you are exclusively responsible for any tax consequences under Code Section 409A resulting from this Award.

    14.    Repatriation and Legal/Tax Compliance Requirements. If you are resident or employed outside of the United States, you agree to repatriate all payments attributable to the shares of Stock and/or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the Units) in accordance with local foreign exchange rules and regulations in your country of residence (and country of employment, if different). In addition, you agree to take any and all actions, and consent to any and all actions taken by the Company and the Employer, as may be required to allow the Company and the Employer to comply with local laws, rules and regulations in your country of residence (and country of employment, if different). Finally, you agree to take any and all actions as may be required to comply with your personal legal and tax obligations under local laws, rules and regulations in your country of residence (and country of employment, if different).
–Rev 1.2024
7


    
15.    Data Privacy. You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.

    You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (“Data”) for the purpose of implementing, managing and administering the Plan.

You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to Morgan Stanley Smith Barney LLC and its affiliates (“Morgan Stanley”) or any successor or any other third party that the Company or Morgan Stanley (or its successor) may engage to assist with the administration of the Plan from time to time. You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.

You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon vesting of the Units. You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consents herein on a purely voluntary basis. If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Units or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to
–Rev 1.2024
8


consent or withdrawal of consent, you understand that you may contact your local human resources representative.

    16.    Nature of Grant. By participating in the Plan, you acknowledge, understand and agree that:

(a)the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past;

(c)all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator;

(d)the grant of the Units and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any);

(e)you are voluntarily participating in the Plan;

(f)the Units are not intended to replace any pension rights or compensation;

(g)the Units, the underlying Shares, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments;

(h)the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty;

(i)no claim or entitlement to compensation or damages shall arise from (i) the forfeiture of the Units resulting from the termination of your employment or other service relationship (for any reason and whether or not in breach of local labor laws and whether or not later found to be invalid) and/or (ii) the forfeiture or cancellation of the Units and/or recoupment of any shares of Stock, cash, or other benefits acquired under the Plan resulting from the application of the Company’s recoupment policies contemplated under Section 9 of this Agreement;

(j)unless otherwise agreed with the Company in writing, the Units, the underlying shares of Stock and the income from and value of same are not granted as
–Rev 1.2024
9


consideration for, or in connection with, any service you may provide as a director of an Affiliate;

(k)for purposes of the Units, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, your right to vest in the Units under this Agreement, if any, will terminate as of such date and will not be extended by any notice period (e.g., your period of service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any); the Administrator shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Unit grant (including whether you may still be considered to be providing services while on an approved leave of absence); and

(l)the following provisions apply only if you are providing services outside the United States: (A) the Units, the underlying shares of Stock, and the income from and value of same are not part of normal or expected compensation or salary for any purpose; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Units or of any amount due to you pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.

    17.    Not a Public Offering. The grant of the Units under the Plan is not intended to be a public offering of securities in your country of residence (and country of employment, if different). The Company has not submitted any registration statement, prospectus or other filings to the local securities authorities unless otherwise required under local law, and the grant of the Units is not subject to the supervision of the local securities authorities.

    18.    No Advice Regarding Grant. No Employee of the Company is permitted to advise you regarding your participation in the Plan or your acquisition or sale of the shares of Stock subject to the Units. Investment in shares of Stock involves a degree of risk. Before deciding whether to participate in the Plan, you should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and you should carefully review all of the materials related to the Units and the Plan. You are hereby advised to consult with your own personal tax, legal and financial advisors before taking any action related to the Plan.

    19.    Investment Intent. You acknowledge that the acquisition of the shares of Stock to be issued hereunder is for investment purposes without a view to distribution thereof.

–Rev 1.2024
10


    20.    Insider Trading Restrictions/Market Abuse Laws. You acknowledge that, depending on your or your broker’s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws that may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares (e.g., phantom awards, futures) during such times you are considered to have “inside information” regarding the Company, as defined in the laws or regulations in your country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to your personal advisor on this matter.

    21.    Electronic Delivery of Documents. The Company may, in its sole discretion, deliver any documents related to the Units and participation in the Plan or future grants of Units that may be granted under the Plan, by electronic means unless otherwise prohibited by local law. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.
    
22.    Language. If you are resident outside of the United States, you hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Units, be drawn up in English. You acknowledge that you are proficient in the English language and understand the terms of this Agreement or have had the ability to consult with an advisor who is sufficiently proficient in the English language. If you have received this Agreement and any applicable Addendum, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

    23.    Addendum. Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable addendum to the Agreement (the “Addendum”). Further, if you transfer your residence and/or employment to another country reflected in the Addendum to this Agreement, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and
–Rev 1.2024
11


conditions as may be necessary or advisable to accommodate your transfer). Any applicable Addendum shall constitute part of this Agreement.

    24.    Additional Requirements. The Administrator reserves the right to impose other requirements on the Units, any shares of Stock acquired pursuant to the Units and your participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws or to facilitate the administration of the Plan. Such requirements may include (but are not limited to) requiring you to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

    25.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principle executive offices of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

    26.    Award Subject to the Plan; Conflicts. The Units granted pursuant to this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This Agreement contains terms and provisions established by the Committee specifically for the grant described herein. Unless the Committee has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the Committee retains the right to alter or modify the Units granted pursuant to this Agreement as the Committee may determine are in the best interests of the Company. You hereby accept the Units subject to all the terms and provisions of the Plan and this Agreement and agree that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon you and your heirs and legal representatives.

    27.    Governing Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For purposes of litigating any dispute under the Agreement, including the Addendum, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the courts of Boston, or the federal courts for the United States for the District of Massachusetts and no other courts where the grant of the Units is made and/or to be performed.

    28.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

–Rev 1.2024
12


    29.    Severability. You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

30.     Waiver. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.

    31.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be the one and the same instrument.

IN WITNESS WHEREOF, the Company, by its duly authorized officer, and the Participant have executed and delivered this Agreement as a sealed instrument as of the date and year first above written.

BOSTON SCIENTIFIC CORPORATION
image_0.jpg




Michael F. Mahoney
President and Chief Executive Officer

–Rev 1.2024
13


BOSTON SCIENTIFIC CORPORATION

ADDENDUM TO THE AWARD AGREEMENT
RELATING TO RESTRICTED STOCK UNITS GRANTED
PURSUANT TO THE
AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN

In addition to the terms of the Plan and the Agreement, the Units are subject to the following additional terms and conditions. All defined terms contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement. Pursuant to Section 23 of the Agreement, if you transfer your residence and/or employment to another country reflected in the Addendum, the additional terms and conditions for such country (if any) will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).

EUROPEAN UNION (“EU”) / EUROPEAN ECONOMIC AREA (“EEA”), UNITED KINGDOM AND SWITZERLAND    

Personal Data. This provision replaces Section 15 of the Agreement:

Pursuant to applicable personal data protection laws, the Company and the Employer hereby notify you of the following in relation to your Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the grant of the Units and your participation in the Plan. The collection, processing and transfer of your Personal Data is necessary for the legitimate purpose of the Company and the Employer’s administration of the Plan and your participation in the Plan, and your denial and/or objection to the collection, processing and transfer of Personal Data may affect your participation in the Plan. As such, by accepting the Award, you acknowledge the collection, use, processing and transfer of Personal Data as described herein.

You understand that the Company and the Employer hold certain personally identifiable information about you, specifically, your name, home address and telephone number, date of birth, social security number or other employee identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (“Personal Data”). The Personal Data may be provided by you to or collected, where lawful, from third parties. The Company or the Employer each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing your participation in the Plan and meeting related legal obligations associated with these actions.
–Rev 1.2024
14



The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations. Personal Data will be accessible within the Company’s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and other aspects of the employment relationship and for participation in the Plan.

The Company and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and the Employer may each further transfer Personal Data to third parties assisting the Company or the Employer in the implementation, administration and management of the Plan, including Morgan Stanley Smith Barney LLC and its affiliates or any successor or other third party that the Company, the Employer or Morgan Stanley Smith Barney LLC and its affiliates (or its successor) may engage to assist with the administration of the Plan from time to time. These recipients may be located in the EU/EEA, the United Kingdom, Switzerland or elsewhere throughout the world, such as the United States. By participating in the Plan, you understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Personal Data as may be required for the administration of the Plan and/or the subsequent holding of shares of Stock on your behalf to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan. You further understand that you may request a list with the names and addresses of any potential recipients of your Personal Data by contacting your local Human Resources manager or the Company’s Human Resources Department. When transferring Personal Data to these potential recipients, the Company and the Employer provide appropriate safeguards in accordance with EU Standard Contractual Clauses or other legally binding and permissible arrangements. You may request a copy of such safeguards from your local human resources manager or the Company’s Human Resources Department.

To the extent provided by law, you may, at any time, have the right to request: access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data. You may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting in writing your Human Resources manager. Your provision of Personal Data is a contractual requirement. You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Units to you, or grant other equity awards or administer or maintain such equity awards. For more information on the consequences of your refusal to provide Personal Data, you understand that you may contact your local human resources manager or the Company’s Human Resources Department.
–Rev 1.2024
15



When the Company and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and/or records containing the Personal Data and/or take steps to properly anonymize it so that you can longer be identified from it.

ARGENTINA

Type of Offering. Neither the grant of the Units, nor the issuance of shares of Stock subject to the grant, constitutes a public offering.

AUSTRALIA

Securities Law Information. This grant is being made under Division 1A, Part 7.12 of the Australia Corporations Act (Cth). Please note that if you offer shares of Stock for sale to a person or entity resident in Australia, the offer may be subject to disclosure requirements under Australian law. You should obtain legal advice on the relevant disclosure obligations prior to making any such offer.

Breach of Law. Notwithstanding anything to the contrary in the Agreement or the Plan, you will not be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Plan if the provision of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.

Tax Information. The Plan is a program to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) (the “Act”) applies (subject to the conditions in that Act).

AUSTRIA

No country-specific provisions.

BELGIUM

No country-specific provisions.

BRAZIL

Compliance with Law. By accepting the Units, you acknowledge that you agree to comply with applicable Brazilian laws and to pay any and all applicable taxes associated with the vesting of the Units, the receipt of any dividends, and the sale of shares of Stock acquired under the Plan.

–Rev 1.2024
16


Labor Law Policy and Acknowledgement. This provision supplements Section 16 of the Agreement:

By accepting the Units, you agree that (i) the benefits provided under the Agreement and the Plan are the result of commercial transactions unrelated to your employment; (ii) the Agreement and the Plan are not a part of the terms and conditions of your employment; and (iii) the income from the Units, if any, is not part of your remuneration from employment.

CANADA

Settlement in Shares. Notwithstanding anything to the contrary in the Agreement or the Plan, all Units shall be settled only in shares of Stock (and shall not be settled in cash).

Personal Data. This provision supplements Section 15 of the Agreement:

You hereby authorize the Company and the Company’s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan. You further authorize the Company, any Affiliate and the Administrator to disclose and discuss the Plan with their advisors. You further authorize the Company and any Affiliate to record such information and to keep such information in your employee file.

Securities Law Information. You are permitted to sell shares of Stock acquired under the Plan through the designated broker appointed under the Plan, if any, provided that the sale of shares of Stock takes place outside Canada through the facilities of a stock exchange on which the shares are listed (i.e., the New York Stock Exchange).

Nature of Grant. The following provision supplements Section 16(k) of the Agreement:

For purposes of the Units, your employment or service relationship will be considered terminated as of the earliest of: (a) the date that your employment or service relationship with the Company or one of its Affiliates is terminated; (b) the date that you receive a notice of termination of employment or service; and (c) the date upon which you cease to actively provide services, regardless of any period during which notice, pay in lieu of notice or related payments or damages are provided or required to be provided under local law. You will not earn or be entitled to any pro-rated vesting for that portion of time before the date on which your right to vest terminates, nor will you be entitled to any compensation for lost vesting. The Administrator shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Unit grant (including whether you may still be considered to be providing services while on a leave of absence). Notwithstanding the foregoing, if applicable employment legislation explicitly requires continued entitlement to vesting during a statutory notice period, your right to vest in the Units, if any, will terminate effective as of the last date of the minimum statutory notice period, but you will not earn or be entitled to pro-rated vesting
–Rev 1.2024
17


if the vesting date falls after the end of your statutory notice period, nor will you be entitled to any compensation for lost vesting.

French Language Documents. The following provision will apply if you are a resident of Quebec:

A French translation of this Agreement and certain other documents related to the Units will be made available to you as soon as reasonably practicable. You understand that, from time to time, additional information related to the Units may be provided in English and such information may not be immediately available in French. However, upon request, the Company will provide a translation of such information into French as soon as reasonably practicable.  Notwithstanding anything to the contrary in the Agreement, and unless you indicate otherwise, the French translation of this Agreement and certain other documents related to the Units will govern your participation in the Plan.

CHILE

Securities Law Information. The offer of the Units constitutes a private offering of securities in Chile effective as of the Grant Date. This offer of Units is made subject to general ruling N° 336 of the Commission for the Financial Market (Comisión para el Mercado Financiero, “CMF”). The offer refers to securities not registered at the securities registry or at the foreign securities registry of the CMF, and, therefore, such securities are not subject to oversight of the CMF. Given that the Units are not registered in Chile, the Company is not required to provide public information about the Units or the shares of Stock in Chile. Unless the Units and/or the shares of Stock are registered with the CMF, a public offering of such securities cannot be made in Chile.
Esta oferta de Unidades de Acciones Restringidas (“Units”) constituye una oferta privada de valores en Chile y se inicia en la Fecha de la Concesión. Esta oferta de Units se acoge a las disposiciones de la Norma de Carácter General Nº 336 (“NCG 336”) de la Comisión para el Mercado Financiero de Chile (“CMF”). Esta oferta versa sobre valores no inscritos en el Registro de Valores o en el Registro de Valores Extranjeros que lleva la CMF, por lo que tales valores no están sujetos a la fiscalización de ésta. Por tratarse los Units de valores no registrados en Chile, no existe obligación por parte de la Compañía de entregar en Chile información pública respecto de los Units or sus Acciones. Estos valores no podrán ser objeto de oferta pública en Chile mientras no sean inscritos en el Registro de Valores correspondiente.

CHINA

The following provisions govern your participation in the Plan if you are a national of the People’s Republic of China (“China”) resident in mainland China, as determined by the Company in its sole discretion:

Shares of Stock Must Be Held with Designated Broker. All shares of Stock issued upon settlement of your Units will be deposited into a personal brokerage account established with the Company’s designated broker, Morgan Stanley Smith Barney LLC (or any successor broker designated by the Company), on your behalf. You understand that you may sell the shares of Stock at any time after they are deposited in such account, however, you may not transfer the shares of Stock out of the brokerage account. If the
–Rev 1.2024
18


Company changes its designated broker, you acknowledge and agree that the Company may transfer any shares of Stock issued under the Plan to the new designated broker, if necessary for legal or administrative reasons. You agree to sign any documentation necessary to facilitate the transfer of shares of Stock.

Mandatory Sale of Shares Following Termination of Employment. You are required to sell all shares of Stock acquired upon vesting of the Units no later than 90 days following your termination of employment with the Company and its Affiliates (or such earlier date as may be required by the China State Administration of Foreign Exchange (“SAFE”)), in which case, this Addendum shall give the Company the authority to issue sales instructions on your behalf). If any shares remain outstanding on the 90th day following your employment termination date (or such earlier date as may be required by SAFE), you hereby direct, instruct and authorize the Company to issue sale instructions on your behalf.

You agree to sign any additional agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds and other exchange control matters noted below) and shall otherwise cooperate with the Company with respect to such matters. You acknowledge that neither the Company nor the designated brokerage firm is under any obligation to arrange for such sale of shares of Stock at any particular price (it being understood that the sale will occur in the market) and that broker’s fees and similar expenses may be incurred in any such sale. In any event, when the shares of Stock are sold, the sale proceeds, less any tax withholding, any broker’s fees or commissions, and any similar expenses of the sale will be remitted to you in accordance with applicable exchange control laws and regulations.

Exchange Control Restrictions. You understand and agree that, pursuant to local exchange control requirements, you will be required immediately to repatriate to China the proceeds from the sale of any shares of Stock acquired under the Plan. You further understand that such repatriation of proceeds may be effected through a special bank account established by the Company or its Affiliate, and you hereby consent and agree that proceeds from the sale of shares of Stock acquired under the Plan may be transferred to such account by the Company on your behalf prior to being delivered to you and that no interest shall be paid with respect to funds held in such account. The proceeds may be paid to you in U.S. dollars or local currency at the Company’s discretion. If the proceeds are paid to you in U.S. dollars, you understand that a U.S. dollar bank account in China must be established and maintained so that the proceeds may be deposited into such account. If the proceeds are paid to you in local currency, you acknowledge that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the proceeds to local currency due to exchange control restrictions. You agree to bear any currency fluctuation risk between the time the shares of Stock are sold and the net proceeds are converted into local currency and distributed to you. You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.
–Rev 1.2024
19



Administration. The Company shall not be liable for any costs, fees, lost interest or dividends or other losses you may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the Company’s operation and enforcement of the Plan, the Agreement and the Award in accordance with Chinese law including, without limitation, any applicable SAFE rules, regulations and requirements.

The above requirements will not apply to non-Chinese nationals, unless otherwise required by the Company or by SAFE.

BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

COLOMBIA

Nature of Grant. This provision supplements Section 16 of the Agreement:
You acknowledge that, pursuant to Article 128 of the Colombian Labor Code, the Plan and related benefits do not constitute a component of your “salary” for any legal purpose. Therefore, they will not be included and/or considered for purposes of calculating any and all labor benefits, such as legal/fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and/or any other labor-related amount which may be payable.

Securities Law Information. The shares of Stock are not and will not be registered with the Colombian registry of publicly held securities (Registro Nacional de Valores y Emisores) and, therefore, the shares of Stock may not be offered to the public in Colombia. Nothing in the Agreement should be construed as making a public offer of securities in Colombia.

COSTA RICA

No country-specific provisions.

CZECH REPUBLIC

No country-specific provisions.

DENMARK

Treatment of Units upon Termination of Service. Notwithstanding any provisions in the Agreement to the contrary, the treatment of the Units upon your termination of employment shall be governed by the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in Employment Relationships (the “Stock Option Act”), as in effect at the time of your termination of employment (as determined by the
–Rev 1.2024
20


Administrator, in its discretion, in consultation with legal counsel). You acknowledge having received an “Employer Information Statement” in Danish, which is provided to comply with the Stock Option Act.

EGYPT

No country-specific provisions.

FINLAND

No country-specific provisions.

FRANCE

Type of Grant. The Units are granted as French-Qualified Restricted Stock Units and are intended to qualify for the special tax and social security treatment applicable to shares of Stock granted for no consideration under Sections L. 225-197-1 to L. 225-197-5 and Sections L. 22-10-59 to L. 22-10-60 of the French Commercial Code, as amended. The Award is granted subject to the terms and conditions of the Rules of the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan French Sub-Plan (the “French Sub-Plan”).

Capitalized terms not defined herein, the Agreement or the Plan shall have the meanings ascribed to them in the French Sub-Plan.

Certain events may affect the status of the Units as French-Qualified RSUs or the underlying shares of Stock, and the Award or the underlying shares of Stock may be disqualified in the future. The Company does not make any undertaking or representation to maintain the qualified status of the French-Qualified RSUs or of the underlying shares of Stock.

(a)Restrictions on Sale or Transfer of Shares of Stock.

(1)Minimum Vesting/Issuance Period. The Award will vest according to the vesting schedule set forth in the Equity Award and Acceptance Summary, provided, however, that under no circumstances will shares of Stock underlying the Award be issued and delivered to a French Participant prior to the expiration of such period as is required to comply with the minimum mandatory period applicable to the Award under Section L. 225-197-1 of the French Commercial Code, as amended, the relevant sections of the French Tax Code and/or the relevant sections of the French Social Security Code, as amended, except in the case of your death. The minimum mandatory period is currently one (1) year from the Grant Date.

–Rev 1.2024
21


(2)Minimum Mandatory Holding Period. You may not sell or transfer the shares of Stock acquired upon vesting of the Award until such time as is required to comply with the minimum mandatory holding period applicable to the Award under Section L. 225-197-1 of the French Commercial Code, as amended, the relevant sections of the French Tax Code and/or the relevant sections of the French Social Security Code, as amended, except in the case of your death or Disability (as defined in the French Sub-Plan). The minimum mandatory holding period is currently two (2) years from the Grant Date.

Except in the case of your termination of employment due to death or Disability (as defined in the French Sub-Plan), the minimum mandatory holding period restriction will continue to apply even if you are no longer an Employee.

(3)Closed Periods. You may not sell any Stock issued upon vesting of the Award during certain Closed Periods, to the extent applicable to the Stock underlying the Award granted by the Company, as described in the French Sub-Plan.

(b)Termination of Service Due to Death. In the event of your death, your heirs may request the issuance of the Stock underlying any French-Qualified RSUs that have not vested prior to your death subject to the Award within six (6) months from the date of your death. If your heirs do not request the shares of Stock within six (6) months from the date of your death, the Award will be forfeited.

Use of English Language. You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.

Utilisation de la langue anglaise. Vous reconnaissez et acceptez qu’il est de votre volonté que le présent accord, ainsi que tous documents, toutes notifications et toutes procédures judiciaires conclues, reçues ou intentées en vertu des présentes ou s’y rapportant directement ou indirectement, soient rédigés en anglais.

GERMANY

Exchange Control Information. Cross-border payments in in excess of EUR 12,500 must be reported to the German Federal Bank (Bundesbank). If you receive a payment in excess of this amount (including if you acquire shares of Stock with a value in excess of this amount or sell shares via a foreign broker, bank or service provider and receive proceeds in excess of this amount) and/or if the Company withholds shares with a value in excess of EUR 12,500 to recover taxes due by you in connection with your Units, you must report the payment and/or the value of the shares received and/or withheld to
–Rev 1.2024
22


Bundesbank, either electronically using the “General Statistics Reporting Portal” (“Allgemeines Meldeportal Statistik”) available on the Bundesbank website (www.bundesbank.de) or via such other method (e.g., by email or telephone) as is permitted or required by Bundesbank. The report must be submitted monthly or within other such timing as is permitted or required by Bundesbank.

GREECE

No country-specific provisions.

HONG KONG

Settlement in Shares. Notwithstanding anything to the contrary in the Agreement, Addendum or the Plan, the Units shall be settled only in shares of Stock (and may not be settled in cash).

Lapse of Restrictions. If, for any reason, shares of Stock are issued to you within six months after the Grant Date, you agree that you will not sell or otherwise dispose of any such shares of Stock prior to the six-month anniversary of the Grant Date.

IMPORTANT NOTICE/WARNING. The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of the documents, you should obtain independent professional advice. The Units and shares of Stock issued at vesting do not constitute a public offering of securities under Hong Kong law and are available only to employees of the Company or its Affiliates. The Agreement, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a “prospectus” for a public offering of securities under the applicable securities legislation in Hong Kong. The Units are intended only for the personal use of each eligible employee of the Employer, the Company or any Affiliate and may not be distributed to any other person.

Wages. The Units and shares of Stock subject to the Units do not form part of your wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.

Nature of the Program. The Company specifically intends that the Plan will not be treated as an occupational retirement scheme for purposes of the Occupational Retirement Schemes Ordinance (“ORSO”). To the extent any court, tribunal or legal/regulatory body in Hong Kong determines that the Plan constitutes an occupational retirement scheme for the purposes of ORSO, the grant of the Units shall be null and void.

INDIA

Forced Sale of Shares. Due to regulatory requirements in India, the Company reserves the right to require that you sell all shares of Stock delivered to you, either immediately upon
–Rev 1.2024
23


receipt of such shares of Stock or upon your termination of employment. In this regard, you agree that the Company is authorized to instruct Morgan Stanley Smith Barney LLC and its affiliates or any successor or other third party that the Company may engage to assist with the administration of the Plan from time to time, to assist with any such mandatory sale of shares of Stock (on your behalf pursuant to this authorization), and you expressly authorize the designated broker to complete the sale of such shares of Stock. You also agree to sign any agreements, forms and/or consents that may be reasonably requested by the Company (or the designated broker) to effectuate the sale of the shares of Stock and shall otherwise cooperate with the Company with respect to such matters, provided that you shall not be permitted to exercise any influence over how, when or whether the sales occur. You acknowledge that Morgan Stanley Smith Barney LLC and its affiliates or subsequent designated broker is under no obligation to arrange for the sale of the shares of Stock at any particular price. Due to fluctuations in the Stock price and/or applicable exchange rates between the date the shares of Stock are delivered to you and (if later) the date on which the shares of Stock are sold, the amount of proceeds ultimately distributed to you may be more or less than the market value of the shares of Stock on the relevant vesting date or the date on which the shares are delivered to you.  Upon the sale of the shares of Stock, the cash proceeds from the sale of shares of Stock (less any applicable Tax-Related Items, brokerage fees or commissions) will be delivered to you in accordance with applicable laws and regulations, as determined by the Company in its sole discretion.

Alternatively, depending on applicable regulatory requirements then in effect, the Company reserves the discretion to determine whether to settle any vested Units in cash.

INDONESIA

No country-specific provisions.

IRELAND

Settlement in Shares. Notwithstanding anything to the contrary in the Agreement or the Plan, all Units shall be settled only in shares of Stock (and shall not be settled in cash).

ISRAEL

102 Sub-Plan. The Units are granted to you pursuant to the Israeli Sub-Plan to the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Israeli Sub-Plan”), and are subject to the terms and conditions stated in the Israeli Sub-Plan, the Plan, and the Agreement, including this Addendum. By accepting the Units, you acknowledge and agree to be bound by the terms of the Israeli Sub-Plan and consent to the terms of the “Consent Letter - 102 Capital Gain Awards” attached hereto as Appendix A (the “Consent Letter”). If you do not affirmatively accept the Units (and accordingly, the terms of the Israeli Sub-Plan, the Agreement and the Consent Letter) within ninety (90) days after the Grant Date, the Units may not qualify under the capital gain tax treatment.
–Rev 1.2024
24



Until further election by the Company, the Units and any shares of Stock received upon vesting of the Units are intended to qualify for the tax treatment available in Israel pursuant to the provisions of the “capital gain track” under Section 102 (“Section 102”) of the Israeli Income Tax Ordinance [New Version], 1961 (the “ITO”), including the provisions of the Income Tax Rules (Tax Benefits in Shares Issuance to Employees), 2003 and any Tax Ruling. However, in the event the Units do not meet the requirements of Section 102 of the ITO, such Units and the underlying shares of Stock shall not qualify for the favorable tax treatment under the capital gain track. The Company makes no representations or guarantees that the Units will qualify for favorable tax treatment and will not be liable or responsible if favorable tax treatment is not available under Section 102.

The Units are subject to the trust (the “Trust”) established by the trust and services agreement (the “Trust Agreement”) with ESOP Management and Trust Services Ltd. (the “Trustee”). To receive the tax treatment provided for in Sections 102(b)(2) and 102(b)(3) of the ITO, shares of Stock acquired by you upon vesting of the Units will be issued directly to the Trustee or controlled by the Trustee under a supervisory trustee arrangement, and will be held by the Trustee on your behalf or controlled by the Trustee at least until the end of the Required Holding Period (as defined in the Israeli Sub-Plan), which is currently twenty-four (24) months from the Grant Date, or any other period determined under the ITO as now in effect or as hereafter amended or by the Israeli Income Tax Authority. Subject to the conclusion of the Required Holding Period and any further period included herein, shares of Stock acquired by you upon vesting of the Units will be held or controlled by the Trustee until their sale, unless you request to release the shares of Stock to your direct holding, in which case the release will be subject to the receipt by the Trustee of an acknowledgment from the Israeli Income Tax Authority that you have paid all applicable taxes due pursuant to the ITO and Section 102, or the Trustee withholds any applicable tax due pursuant to the ITO and Section 102. You will not be permitted to elect to sell or release any shares of Stock acquired upon vesting of the Units prior to the conclusion of the Required Holding Period.

The Company may at its sole discretion replace the Trustee from time to time and instruct the transfer of all Units and shares of Stock held and/or administered by such Trustee at such time to its successor and the provisions of your Agreement shall apply to the new Trustee mutatis mutandis.

Any and all Tax-Related Items due in relation to the Units and shares of Stock shall be borne solely by you and in the event of death, by your heirs. The Company, the Employer and/or the Trustee shall withhold Tax-Related Items according to the requirements under the applicable laws, the rules, and regulations, including withholding Tax-Related Items at source. Furthermore, you hereby agree to indemnify the Company, the Employer and/or the Trustee and hold them harmless against and from any and all liability for any such Tax-Related Items or interest or penalty thereon, including without limitation, liabilities relating to the necessity to withhold, or to have withheld, any such Tax-Related Items from any payment made to you. The Company, the Employer and/or the Trustee, to the
–Rev 1.2024
25


extent permitted by law, shall have the right to deduct from any payment otherwise due to you, or from proceeds of the sale of any shares of Stock, an amount equal to any Tax-Related Items required by law to be withheld with respect to such shares of Stock. You will pay to the Company, the Employer or the Trustee any Tax-Related Items that the Company, the Employer or the Trustee may be required to withhold with respect to any shares of Stock that cannot be satisfied by the means previously described. The Company may refuse to deliver any shares of Stock if you fail to comply with your obligations in connection with the Tax-Related Items as described in this section. Any fees associated with any vesting, sale, transfer or any act in relation to the Units and the shares of Stock, shall be borne by you. The Trustee, the Company and/or the Employer shall be entitled to withhold or deduct such fees from payments otherwise due to/from the Company, the Employer or the Trustee.

Securities Law Information.  The Company has obtained from the Israel Securities Authority an exemption from the requirement to file a prospectus in relation to the Plan. Copies of the Plan and the Form S-8 registration statement for the Plan filed with the U.S. Securities and Exchange Commission are available by contacting your local human resources manager.

ITALY

Plan. This provision supplements Section 16 of the Agreement:
You further acknowledge that you have read and specifically and expressly approve the following sections of the Agreement: Vesting, Other Termination of Employment, Certain Vesting Conditions, Recoupment Policy, Issuance of Stock, Satisfaction of Tax Obligations, Nature of Grant, and Choice of Law and Venue.
JAPAN

No country-specific provisions.

KAZAKHSTAN

Securities Law Information. This offer is addressed only to certain eligible employees of the Company and its Affiliates in the form of shares of Stock to be issued by the Company, subject to the terms and conditions of the Agreement and the Plan. Neither the Plan nor the Agreement has been approved, nor do they need to be approved, by the National Bank of Kazakhstan. This offer is intended only for the original recipient and is not for general circulation in the Republic of Kazakhstan.

LEBANON

Securities Law Information. The Plan does not constitute the marketing or offering of securities in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law. Offerings under the Plan are being made only to eligible employees of the Company and its Affiliates.
–Rev 1.2024
26



MALAYSIA

Award Conditioned upon Election to Pay Taxes Directly to the Malaysian Inland Revenue Board. You understand and agree that your Award is conditioned upon your completing, signing and submitting a letter to your Employer, indicating your election to pay any income tax or other tax liability arising in connection with taxable income recognized under the Plan directly to the Malaysian Inland Revenue Board. (You may contact your Employer to request a form letter for this purpose.) You understand that if you fail to file such an election letter with your Employer, your Award will be null and void.

Consent to Collection, Processing and Transfer of Personal Data. This provision replaces Section 15 of the Agreement in its entirety:

You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data, as described in this Addendum and any other grant materials by and among, as applicable, the Company and Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.
You understand that the Company and Affiliates may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (“Data”). The Data is supplied by the Company and also by you through information collected in connection with the Agreement and the Plan.
You understand that Data will be transferred to the current stock plan service providers or a stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan. You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that if you reside outside the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative:. You authorize the Company, the stock plan service provider and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any transfer of such Data as may be required to a broker, escrow agent or other third party with whom the shares of Stock received upon vesting of the Units may be deposited. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan. You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data, limit the processing of Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consent herein on a purely voluntary basis. If you do not consent, or if you later seek to revoke your consent, your employment status or service and career with the Company will not be adversely affected; the only adverse consequence of refusing or withdrawing your consent is that the Company may not be able to grant you Units or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.
Please take note that by electronically accepting this Agreement, you have confirmed that you explicitly, voluntarily and unambiguously consent to the collection, use and transfer of your personal data in accordance with the terms in this notification. However, if for any reason you do not consent to the processing of your personal data, you have the right to reject such consent by contacting your local human resources representative:.
Anda dengan ini secara eksplisit dan tanpa sebarang keraguan mengizinkan pengumpulan, penggunaan dan pemindahan, dalam bentuk elektronik atau lain-lain, data peribadi anda seperti yang diterangkan dalam Lampiran ini dan apa-apa bahan pemberian unit saham terhad yang lain oleh dan di antara, seperti yang berkenaan, Syarikat dan Ahli Gabungan untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan.
Anda memahami bahawa Syarikat Ahli Gabungan mungkin memegang maklumat peribadi tertentu tentang anda, termasuk, tetapi tidak terhad kepada, nama anda, alamat rumah dan nombor telefon, tarikh lahir, nombor insurans sosial atau nombor pengenalan lain, gaji, kewarganegaraan, jawatan, apa-apa syer saham Biasa atau jawatan pengarah yang dipegang dalam Syarikat, butir-butir semua unit saham terhad, atau apa-apa hak lain atas syer Biasa saham yang dianugerahkan, dibatalkan, dilaksanakan, terletak hak, tidak diletak hak ataupun yang belum dijelaskan bagi faedahanda, untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan Pelan tersebut (“Data”). Data tersebut dibekalkan oleh Syarikat dan juga oleh anda berkenaan dengan Perjanjian dan Pelan.
Anda memahami bahawa Data ini akan dipindahkan kepada pembekal perkhidmatan pelan saham semasa atau pembekal perkhidmatan pelan saham yang mungkin dipilih oleh Syarikat pada masa depan, yang membantu Syarikat dengan pelaksanaan, pentadbiran dan pengurusan Pelan. Anda memahami bahawa penerima-penerima Data mungkin berada di Amerika Syarikat atau mana-mana tempat lain, dan bahawa negara penerima-penerima (contohnya, Amerika Syarikat) mungkin mempunyai undang-undang privasi data dan perlindungan yang berbeza daripada negara anda. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh meminta satu senarai yang mengandungi nama-nama dan alamat-alamat penerima-penerima Data yang berpotensi dengan menghubungi wakil sumber manusia tempatan anda:. Anda memberi kuasa kepada Syarikat, pembekal perkhidmatan pelan saham dan mana-mana penerima-penerima kemungkinan lain yang mungkin akan membantu Syarikat (pada masa sekarang atau pada masa depan) dengan melaksanakan, mentadbir dan menguruskan Pelan untuk menerima, memiliki, menggunakan, mengekalkan dan memindahkan Data, dalam bentuk elektronik atau lain-lain, bagi tujuan melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan, termasuk segala pemindahan Data tersebut sebagaimana yang dikehendaki kepada broker, egen eskrow atau pihak ketiga dengan siapa syer Biasa saham diterima semasa peletakhakan saham terhad unit mungkin didepositkan. Anda memahami bahawa Data hanya akan disimpan selagi ia adalah diperlukan untuk melaksanakan, mentadbir, dan menguruskan penyertaan anda dalam Pelan. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh, pada bila-bila masa, melihat Data, meminta maklumat tambahan mengenai penyimpanan dan pemprosesan Data, meminta bahawa pindaan-pindaan dilaksanakan ke atas Data, mengehadkan pemprosean Data atau menolak atau menarik balik persetujuan dalam ini, dalam mana-mana kes, tanpa kos, dengan menghubungi secara bertulis wakil sumber manusia tempatan. Selanjutnya, anda memahami bahawa anda memberikan persetujuan di sini secara sukarela semata-mata. Sekiranya anda tidak bersetuju, atau sekiranya anda kemudian membatalkan persetujuan anda, status pekerjaan atau perkhidmatan dan kerjaya anda dengan Syarikat tidak akan terjejas; satu-satunya akibat buruk sekiranya anda tidak bersetuju atau menarik balik persetujuan andaadalah bahawa Syarikat tidak akan dapat memberikan unit saham terhad anda atau anugerah ekuiti lain atau mentadbir atau mengekalkan anugerah-anugerah tersebut. Oleh itu, anda memahami bahawa keengganan atau penarikan balik persetujuan anda boleh menjejaskan keupayaan anda untuk mengambil bahagian dalam Pelan. Untuk maklumat lebih lanjut mengenai akibat-akibat keengganan anda untuk memberikan keizinan atau penarikan balik keizinan, anda memahami bahawa anda boleh menghubungi wakil sumber manusia tempatan.
Sila ambil perhatian bahawa dengan menerima Perjanjian ini secara elektronik, anda mengesahkan bahawa anda secara eksplisit, sukarela, dan tanpa sebarang keraguan bersetuju dengan pengumpulan, penggunaan, dan pemindahan data peribadi anda mengikut terma-terma dalam notis ini. Walaubagaimanapun, jika atas apa-apa sebab-sebab tertentu anda tidak bersetuju dengan pemprosesan data peribadi anda, anda mempunyai hak untuk menolak persetujuan anda dengan menghubungi wakil sumber manusia tempatan anda:.

MEXICO

Securities Law Information. You expressly recognize and acknowledge that the Company’s grant of the Units and the underlying shares of Stock under the Plan have not been registered with the National Register of Securities maintained by the Mexican
–Rev 1.2024
27


National Banking and Securities Commission and cannot be offered or sold publicly in Mexico. In addition, the Plan, the Agreement and any other document relating to the Units may not be publicly distributed in Mexico. These materials are addressed to you only because of your existing relationship with the Company and these materials should not be reproduced or copied in any form. The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present employees of the Employer in Mexico made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.
Acknowledgement of the Agreement. By accepting the Units, you acknowledge that you have received a copy of the Plan and the Agreement, including this Addendum, which you have reviewed. You further acknowledge that you accept all the provisions of the Plan and the Agreement, including this Addendum. You also acknowledge that you have read and specifically and expressly approve the terms and conditions set forth in the “Nature of Grant” section of the Agreement, which clearly provide as follows:
(1)    Your participation in the Plan does not constitute an acquired right;
(2)    The Plan and your participation in it are offered by the Company on a wholly discretionary basis;
(3)    Your participation in the Plan is voluntary; and
(4)    The Company and its Affiliates are not responsible for any decrease in the value of any shares of Stock acquired at vesting of the Units.
Reconocimiento del Contrato. Al aceptar los Unidades, usted reconoce que ha recibido una copia del Plan y del Contrato con inclusión de este Apéndice, que le ha examinado. Usted reconoce, además, que usted acepta todas las disposiciones del Plan y del Contrato. Usted también reconoce que ha leído y, concretamente, y aprobar de forma expresa los términos y condiciones establecidos en la “Naturaleza del Otorgamiento” que claramente dispone lo siguiente:
(1)    Su participación en el Plan no constituye un derecho adquirido;
(2)    El Plan y su participación en el Plan se ofrecen por Boston Scientific Corporation en su totalidad sobre una base discrecional;
(3)    Su participación en el Plan es voluntaria; y
(4)    Boston Scientific Corporation y sus afiliadas no son responsables de ninguna disminución en el valor de las acciones adquiridas en la adquisición de los Unidades.
Labor Law Acknowledgement and Policy Statement. By accepting the Units, you acknowledge that Boston Scientific Corporation, with registered offices at 300 Boston Scientific Way, Marlborough, Massachusetts 01752, United States of America, is solely
–Rev 1.2024
28


responsible for the administration of the Plan. You further acknowledge that your participation in the Plan, the grant of Units and any acquisition of shares of Stock under the Plan do not constitute an employment relationship between you and Boston Scientific Corporation because you are participating in the Plan on a wholly commercial basis and your sole employer is a Mexican legal entity (“Boston Scientific-Mexico”). Based on the foregoing, you expressly acknowledge that the Plan and the benefits that you may derive from participation in the Plan do not establish any rights between you and the Employer, Boston Scientific-Mexico, and do not form part of the employment conditions and/or benefits provided by Boston Scientific-Mexico, and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.
You further understand that your participation in the Plan is the result of a unilateral and discretionary decision of Boston Scientific Corporation, therefore, Boston Scientific Corporation reserves the absolute right to amend and/or discontinue your participation in the Plan at any time, without any liability to you.
Finally, you hereby declare that you do not reserve to you any action or right to bring any claim against Boston Scientific Corporation for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and that you therefore grant a full and broad release to Boston Scientific Corporation, its Affiliates, branches, representation offices, shareholders, officers, agents and legal representatives, with respect to any claim that may arise.
Reconocimiento de Ausencia de Relación Laboral y Declaración de la Política. Al aceptar los Unidades, usted reconoce que Boston Scientific Corporation, con oficians registradas on 300 Boston Scientific Way, Marlborough, Massachusetts 01752, Estados Unidos de América, es el único responsable de la administración del Plan. Además, usted acepta que su participación en el Plan, la concesión de los Unidades y cualquier adquisición de acciones en el marco del Plan no constituyen una relación laboral entre usted y Boston Scientific Corporation porque usted está participando en el Plan en su totalidad sobre una base comercial y su único empleador es una sociedad mercantil Mexicana (“Boston Scientific-Mexico”). Derivado de lo anterior, usted expresamente reconoce que el Plan y los beneficios que pueden derivarse de la participación en el Plan no establece ningún derecho entre usted y su Empleador, Boston Scientific-Mexico, y que no forman parte de las condiciones de empleo y / o prestaciones previstas por Boston Scientific-Mexico, y cualquier modificación del Plan o la terminación de su contrato no constituirá un cambio o deterioro de los términos y condiciones de su empleo.
Además, usted entiende que su participación en el Plan es causada por una decisión discrecional y unilateral de Boston Scientific Corporation, por lo que Boston Scientific Corporation se reserva el derecho absoluto a modificar y/o suspender su participación en el Plan en cualquier momento, sin responsabilidad alguna para con usted.
–Rev 1.2024
29


Finalmente, usted manifiesta que no se reserva ninguna acción o derecho que origine una demanda en contra de Boston Scientific Corporation, por cualquier compensación o daño en relación con cualquier disposición del Plan o de los beneficios derivados del mismo, y en consecuencia usted otorga un amplio y total finiquito a Boston Scientific Corporation, sus afiliadas, sucursales, oficinas de representación, sus accionistas, directores, agentes y representantes legales con respecto a cualquier demanda que pudiera surgir.
NETHERLANDS

Waiver of Termination Rights. By accepting the Units, you hereby waive any and all rights to compensation or damages as a result of the termination of employment with the Company and the Employer for any reason whatsoever, insofar as those rights result or may result from (a) the loss or diminution in value of such rights or entitlements under the Plan, or (b) your ceasing to have rights under, or ceasing to be entitled to any awards under the Plan as a result of such termination.

NEW ZEALAND

Securities Law Information.

Warning

This is an offer of Units which, upon vesting and settlement in accordance with the terms of the Plan and the Agreement, will be converted into shares of Stock. Shares of Stock give you a stake in the ownership of Boston Scientific Corporation. You may receive a return if dividends are paid.

If Boston Scientific Corporation runs into financial difficulties and is wound up, you will be paid only after all creditors and holders of preference shares have been paid. You may lose some or all of your investment.

New Zealand law normally requires people who offer financial products to give information to investors before they invest. This information is designed to help investors to make an informed decision. The usual rules do not apply to this offer because it is made under an employee share purchase scheme. As a result, you may not be given all the information usually required. You will also have fewer other legal protections for this investment.

Ask questions, read all documents carefully, and seek independent financial advice before committing.
Prior to the vesting and settlement of the Units, you will not have any rights of ownership (e.g., voting or dividend rights) with respect to the underlying shares of Stock.
No interest in any Units may be transferred (legally or beneficially), assigned, mortgaged, charged or encumbered.
–Rev 1.2024
30


The shares of Stock are quoted on the New York Stock Exchange. This means that if you acquire shares of Stock under the Plan, you may be able to sell them on the New York Stock Exchange if there are interested buyers. You may get less than you invested. The price will depend on the demand for the shares of Stock.

You also are hereby notified that the documents listed below are available for review on sites at the web addresses listed below:
1.Boston Scientific Corporation’s most recent Annual Report (Form 10-K): https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

2.Boston Scientific Corporation’s most recent published financial statements (Form 10-Q or 10-K) and the auditor’s report on those financial statements: https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

3.The Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

4.Boston Scientific Corporation Restricted Stock Unit Award Agreement and Amended and Restated 2011 Long-Term Incentive Plan Q&A Summary Sheet: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

5.Boston Scientific Corporation Equity Award and Acceptance Summary: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

A copy of the above documents will be sent to you free of charge on written request being mailed to: Boston Scientific Corporation, Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.

NORWAY

No country-specific provisions.

–Rev 1.2024
31


PAKISTAN

Forced Sale of Shares. The Company reserves the right to force the immediate sale of the shares of Stock to be issued upon vesting and settlement of the Units. If applicable, you agree that the Company is authorized to instruct its designated broker, on your behalf, to assist with the mandatory sale of such shares of Stock and you expressly authorizes the Company’s designated broker to complete the sale of such shares of Stock. You expressly acknowledge that the Company’s designated broker is under no obligation to arrange for the sale of shares of Stock at any particular price. Upon the sale of shares of Stock, you shall receive the cash proceeds from the sale of shares of Stock, less any brokerage fees or commissions and subject to any obligation to satisfy Tax-Related Items. You also acknowledge that you are unaware of any material non-public information with respect to the Company or any securities of the Company as of the date of the Agreement.

PERU

Securities Law Information. The grant of Units is considered a private offering in Peru; therefore, it is not subject to registration. For more information concerning the grant, you acknowledge that you should refer to the Plan, the Agreement, and any other materials made available by the Company. For more information regarding the Company, you acknowledge that you should refer to the Company’s most recent annual report on Form 10-K and quarterly report on Form 10-Q available at www.sec.gov.

Additional Acknowledgement of Nature of Plan and the Units. By accepting the Units, you understand, acknowledge and agree that the Units are being granted ex gratia by the Company.

PHILIPPINES

Settlement in Cash. Pursuant Section 2 of the Agreement, the Company shall settle your Units in the form of a cash payment unless, at the time of vesting, share settlement does not trigger the need for any approval from and/or filing with the Philippines Securities and Exchange Commission.

POLAND

No country-specific provisions.

PORTUGAL

Language Consent. You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and the Agreement.
–Rev 1.2024
32


Conhecimento da Lingua. Por meio do presente, eu declaro expressamente que tem pleno conhecimento da língua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condições estabelecidas no Plano e no Acordo.

PUERTO RICO

No country-specific provisions.

ROMANIA
Language Consent. By accepting the grant of Units, you acknowledge that you are proficient in reading and understanding English and fully understand the terms of the documents related to the grant (the Agreement and the Plan), which were provided in the English language. You accept the terms of those documents accordingly.
Consimtamant cu Privire la Limba. Acceptând acordarea unităților de Unit-uri, recunoașteți că sunteți competenți în citirea și înțelegerea limbii engleze și înțelegeți pe deplin termenii documentelor legate de subvenție (Acordul de acordare și planul), care au fost furnizate în limba engleză. Acceptați termenii acestor documente în consecință.
RUSSIA
THE PROVISIONS BELOW ARE CURRENT AS OF DECEMBER 2022 AND MAY NOT ADDRESS THE CURRENT LEGAL AND TAX CONSIDERATIONS AND REQUIREMENTS ASSOCIATED WITH AWARDS IN RUSSIA. YOU SHOULD CONSULT WITH A LEGAL AND TAX ADVISOR TO ENSURE COMPLIANCE WITH APPLICABLE LAW AS IT RELATES TO YOUR PARTICIPATION IN THE PLAN.
U.S. Transaction. You understand that the Units shall be valid and this Agreement shall be concluded and become effective only when the Agreement is received by the Company in the United States. Upon vesting of the Units, any shares of Stock to be issued to you shall be delivered to you through a bank or brokerage account in the United States. In no event will shares of Stock be delivered to you in Russia; instead, all shares of Stock acquired upon vesting of the Units will be maintained on your behalf in the United States. You are not permitted to sell shares of Stock acquired at vesting directly to a Russian legal entity or resident.
Securities Law Information. You acknowledge that the Units, the Equity Award and Acceptance Summary, the Agreement, the Plan and all other materials that you may receive regarding participation in the Plan do not constitute advertising or an offering of securities in Russia. The shares of Stock acquired pursuant to the Plan have not and will not be registered in Russia and, therefore, neither the Units nor the shares of Stock may be used for offering or public circulation in Russia.
Repatriation Requirements. You agree to promptly repatriate proceeds resulting from the sale of shares of Stock acquired under the Plan to a foreign currency account at an authorized bank in Russia if legally required at the time shares of Stock are sold and to comply with all applicable local foreign exchange rules and regulations. Neither the
–Rev 1.2024
33


Company nor any of its Affiliates shall be liable for any fines or penalties resulting from your failure to comply with applicable laws.
The repatriation requirement may not apply with respect to cash amounts received in an account that is considered by the Central Bank of Russia to be a foreign brokerage account opened with a financial market institution other than a bank. Statutory exceptions to the repatriation requirement also may apply.
Anti-Corruption Notification. Anti-corruption laws prohibit certain public servants, their spouses and their dependent children from owning any foreign source financial instruments (e.g., shares of Stock of foreign companies such as the Company). Accordingly, you should inform the Company if you are covered by these laws because you should not hold shares of Stock acquired under the Plan.
Labor Law Information. If you continue to hold shares of Stock acquired upon settlement of the Units after an involuntary termination of employment, you may not be eligible to receive unemployment benefits in Russia.
Settlement of Units. Depending on applicable restrictions then in effect, the Company has the sole discretion to postpone the vesting and/or settlement of any Units, to determine whether to settle any vested Units in shares of Stock or in cash, or to cancel such Units for no consideration.
SAUDI ARABIA

Securities Law Information. The grant of the Units is not subject to the regulations concerning public offers and private placements under the Law on Capital Markets.

SINGAPORE

Private Placement. The grant of the Units is being made pursuant to the “Qualifying Person” exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (“SFA”). The Plan has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is not regulated by any financial supervisory authority pursuant to any legislation in Singapore. Accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply. You should note that the Units are subject to section 257 of the SFA and you will not be able to make any subsequent sale of the shares of Stock in Singapore, or any offer of such subsequent sale of the shares of Stock subject to the grant in Singapore, unless such sale or offer is made (i) after six months from the Grant Date or (ii) pursuant to the exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the SFA.

–Rev 1.2024
34


SOUTH AFRICA

Securities Law Information. In compliance with South African securities law, the documents listed below are available for review on the Company’s external and internal sites at the web addresses listed below:
1.Boston Scientific Corporation’s most recent Annual Report (Form 10-K): https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

2.The Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

3.Boston Scientific Corporation Restricted Stock Unit Award Agreement and Amended and Restated 2011 Long-Term Incentive Plan Q&A Summary Sheet: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

4.Boston Scientific Corporation Equity Award and Acceptance Summary: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.
You acknowledge that you may have copies of the above documents sent to you, at no charge, on written request being mailed to Boston Scientific Corporation, attn: Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.

You understand that you are advised to carefully read the materials provided before making a decision whether to participate in the Plan and to contact your tax advisor for specific information concerning your personal tax situation with regard to Plan participation.

SOUTH KOREA

Consent to Collection, Processing and Transfer of Personal Data. By electronically accepting this Agreement:

1.You agree to the collection, use, processing and transfer of Data as described in Section 15 of the Agreement; and

2.You agree to the processing of your unique identifying information (resident registration number) as described in Section 15 of the Agreement.

Domestic Broker Requirement. Residents of South Korea may not be permitted to sell foreign securities (such as shares of Stock acquired under the Plan) through non-Korean brokers (such as Morgan Stanley Smith Barney LLC and its affiliates) or deposit funds
–Rev 1.2024
35


resulting from the sale of shares of Stock in an account with an overseas financial institution. If you wish to sell shares of Stock acquired under the Plan, applicable law may require you to transfer the shares of Stock to a domestic investment broker in Korea and to effect the sale through such broker. You acknowledge and agree that you are solely responsible for engaging a domestic broker, to the extent required. Non-compliance with the requirement to sell shares of Stock through a domestic broker can result in significant penalties. Because applicable law and regulations may change without notice, you should consult with a legal advisor to ensure compliance with applicable law as it relates to your participation in the Plan.

SPAIN

Acknowledgement of Discretionary Nature of the Plan; No Vested Rights. This provision supplements the terms of the Agreement.

In accepting the grant of Units, you acknowledge that you consent to participation in the Plan and have received a copy of the Plan.

You understand that the Company has unilaterally, gratuitously and in its sole discretion granted Units under the Plan to individuals who may be employees of the Company or its Affiliates throughout the world. The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis. Consequently, you understand that the Units are granted on the assumption and condition that the Units and the shares of Stock acquired upon vesting of the Units shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever. In addition, you understand that this grant would not be made to you but for the assumptions and conditions referenced above; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, the grant of the Units shall be null and void.

You understand and agree that, as a condition of the grant of the Units, your termination of employment for any reason (including the reasons listed below) will automatically result in the loss of the Units to the extent the Units have not vested as of date that you cease active employment. In particular, you understand and agree that any unvested Units as of the date you cease active employment will be forfeited without entitlement to the underlying shares of Stock or to any amount of indemnification in the event of the termination of employment by reason of, but not limited to, resignation or retirement prior to the first anniversary of the Grant Date, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without cause, individual or collective dismissal on objective grounds, whether adjudged or recognized to be with or without cause, material modification of the terms of employment under Article 41 of the Workers’ Statute, relocation under Article 40 of the Workers’ Statute, Article 50 of the Workers’ Statute, unilateral withdrawal by the Employer and under Article 10.3 of the
–Rev 1.2024
36


Royal Decree 1382/1985. You acknowledge that you have read and specifically accept the conditions referred to in the Agreement regarding the impact of a termination of employment on your Award.

BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

SWEDEN

Tax Withholding. The following provision shall supplement Section 13 of the Agreement:

Without limiting the Company’s and the Employer’s authority to satisfy their withholding obligations for Tax-Related Items as set forth in the Section 13 of the Agreement, in accepting the grant of the Units, you authorize the Company to withhold shares of Stock or to sell shares of Stock otherwise deliverable to you upon settlement of the Units to satisfy Tax-Related Items, regardless of whether the Company and/or the Employer have an obligation to withhold such Tax-Related Items.

SWITZERLAND

Securities Law Information. Neither this document nor any other materials relating to the Units (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (“FinSA”) (ii) may be publicly distributed or otherwise made publicly available in Switzerland to any person other than an employee of the Corporation or a Subsidiary or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority, FINMA.

TAIWAN

Securities Law Information. This Award and the shares of Stock to be issued pursuant to the Plan are available only for Employees. The Award is not a public offer of securities by a Taiwanese company.

THAILAND

No country-specific provisions.

TURKEY

Securities Law Information. Under Turkish law, you are not permitted to sell shares of Stock acquired under the Plan in Turkey. The shares of Stock are currently traded on the New York Stock Exchange, which is located outside Turkey and the shares of Stock may be sold through this exchange.
–Rev 1.2024
37



UNITED ARAB EMIRATES

Securities Law Information. The Plan is an employee equity incentive plan and is only being offered to select employees in the United Arab Emirates. The Plan and the Agreement are intended for distribution only to such employees and must not be delivered to, or relied on by, any other person. The Emirates Securities and Commodities Authority has no responsibility for reviewing or verifying any documents in connection with the Plan. Neither the Ministry of Economy nor the Dubai Department of Economic Development have approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents. You should conduct your own due diligence on the securities offered under the Plan. If you do not understand the contents of the Agreement or the Plan, you should consult an authorized financial advisor.

UNITED KINGDOM

Income Tax and Social Insurance Contribution Withholding. The following provision shall supplement Section 13 of the Agreement:

Without limitation Section 13 of the Agreement, you agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company, the Employer or by HM Revenue and Customs (“HMRC”) (or any other tax authority or any other relevant authority). You also agree to indemnify and keep indemnified the Company and the Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay on your behalf to HMRC (or any other tax authority or any other relevant authority).

Notwithstanding the foregoing, you understand that if you are a director or executive officer (within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the terms of the immediately foregoing provision may not apply. In the event that you are a director or executive officer and income tax due is not collected from or paid by you within 90 days after the UK tax year in which an event giving rise to the indemnification described above occurs, the amount of any uncollected tax may constitute a benefit on which additional income tax and national insurance contributions may be payable. You acknowledge that you ultimately will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for reimbursing the Company or the Employer (as applicable) for the value of any employee national insurance contributions due on this additional benefit, which the Company and/or the Employer may recover from you at any time thereafter by any of the means referred to in Section 13 of the Agreement.

Exclusion of Claim. You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Award, whether or not as a result of your termination of employment (whether the termination is in breach of contract or
–Rev 1.2024
38


otherwise), or from the loss or diminution in value of the Award. Upon the grant of your Award, you shall be deemed irrevocably to have waived any such entitlement.

*    *    *    *

–Rev 1.2024
39


APPENDIX A
CONSENT LETTER
102 CAPITAL GAIN AWARDS FOR PARTICIPANTS RESIDING IN ISRAEL
Dear Participant,
Boston Scientific Corporation (the “Company”) has elected to apply the capital gains route in accordance with the provisions of Section 102 of the Israeli Income Tax Ordinance (the “Ordinance”) on awards granted under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Incentive Plan”) to Israeli Participants (as defined in the Israeli sub-plan to the Incentive Plan (the “Israel Sub-Plan”), which was approved by the Executive Compensation and Human Resources Committee of the Company’s Board of Directors on November 14, 2022) and any future incentive plan implemented by the Company in Israel (“Awards” and “Capital Gains Route”), subject to the Company’s absolute discretion to change such election on future grants, with or without advance notice. Unless otherwise notified to you in writing by the Company, the Awards shall be granted to you under the Capital Gains Route, subject to compliance with the requirements of such tax route.
The Capital Gains Route election will enable you to enjoy lower tax rates on a portion of the income received upon disposition of the shares of Company common stock (“Shares”) issued to you from or in connection to the Awards, provided however that all the requirements under Section 102 of the Ordinance and the Income Tax (Tax Abatement on the Grant of Shares to Employees) Regulations 2003 (the “Regulations”) are met.
Below you will find a brief description of the Israeli income tax consequences of the Capital Gains Route. PLEASE NOTE THAT THE SUMMARY BELOW IS ONLY A BRIEF SUMMARY THAT DOES NOT COVER ALL THE PROVISIONS OF SECTION 102 OF THE ORDINANCE AND THE REGULATIONS AND IS NOT INTENDED TO PROVIDE ANY TAX ADVICE. IN ADDITION, THE TAX LAWS AND REGULATIONS DESCRIBED HEREIN ARE SUBJECT TO CHANGE. THEREFORE, IT IS RECOMMENDED THAT YOU CONSULT WITH A TAX ADVISER BEFORE ACCEPTING THE TERMS OF THIS CONSENT LETTER OR BEFORE ACCEPTING ANY AWARDS OR DISPOSING OF SHARES.
The main restrictions that are included under Section 102 of the Ordinance are as follows:
(1) Your Awards and the Shares issued under such Awards will be held in trust or controlled by a trustee for at least a period determined in Section 102 under the Capital Gains Route (“Required Holding Period”) (currently twenty-four months from the date in which the Awards were granted to you).
(2) During the Required Holding Period you will not be able to sell, pledge, release from trust or otherwise perform any transaction in connection to the Awards or Shares granted to you.
–Rev 1.2024
40


Provided that all conditions set by the Ordinance under the Capital Gains Route are met, including the above conditions, you will, in general, be taxed as follows: 
The fair market value of the underlying Shares at grant will be treated as ordinary income subject to income tax and employee/employer social insurance contributions (to the extent the applicable contribution ceiling has not been exceeded). For tax purposes, the fair market value of the Shares at grant is deemed to be the average price of the Shares over the 30 trading days preceding the grant. 
The remainder of the gain, if any, will be treated as a capital gain and will be taxed at the capital gains tax rate of 25%.  No social insurance contributions will be due on this portion of the gain. 
In addition, a surtax may be imposed if your income is in excess of the applicable annual threshold.
If the Company were to permit you to sell your Shares, or release the Shares from trust, before the end of the Holding Period, you will immediately be subject to income tax on the gain, at your marginal income tax rate, and will be also required to pay social security and health tax contributions on all your profit.
In order to enable you to enjoy the benefits of the Capital Gains Route, please express your acceptance and confirmation of the following terms, by accepting the Award through the electronic acceptance procedures established by the Company:
1.    I undertake to comply with all the terms and conditions set under Section 102 of the Ordinance with regard to the Capital Gains Route and the Regulations.
2.    I have had the opportunity to obtain the advice of counsel prior to accepting this Consent Letter. I am familiar with and understand the provisions of Section 102 of the Ordinance in general, and the tax arrangement under the Capital Gains Route in particular, and agree to comply with such provisions, as amended from time to time.
3.    I agree that Awards granted to me, and the Shares that may be derived from such Awards, will be held or controlled by a trustee for at least the duration of the Required Holding Period, as determined in Section 102 under the Capital Gains Route (currently twenty-four months from the date in which the Awards were granted).
4.    I agree to the trust deed signed between the Company, my employer and the trustee available at Trust Deed RSU-Stock Option - Hebrew.pdf.
5.    I understand that any release of such Awards or Shares from trust, or any sale of the Shares prior to the termination of the Required Holding Period, will result in taxation at my marginal tax rate, in addition to deductions of appropriate social security and health tax contributions.
–Rev 1.2024
41


6.    I authorize the Company and/or my employer to provide the trustee with any information required for administrating the grant of the Awards, including without limitation information about my Awards, income tax rates, salary bank account, contact details and identification number and any reasonable information required by the trustee.
7.     I declare that I am a resident of the state of Israel for tax purposes and agree to notify the Company upon any change in the residence address and acknowledge that if I cease to be an Israeli resident or if my engagement with the Company or any affiliate is terminated, the Awards and underlying Shares shall remain subject to Section 102, the trust agreement and the applicable equity plan and grant document.
8.    I understand and agree that until the Company will determine otherwise, my acceptance of the terms of this Consent Letter will be sufficient, to apply to all potential future grants of Awards. I hereby confirm that by accepting this Consent Letter, I will be deemed to have elected to accept the terms and conditions herein in respect of any such potential future grant of Awards.
9.     I acknowledge, understand and agree that the Awards are an extraordinary, one-time benefit granted to me, and do not create any contractual or other right to receive future grant of Awards.
10.     I understand that neither the Company nor any of its affiliates guarantee that any Awards granted to me will be eligible for tax benefits pursuant to the Capital Gains Route and I agree that I will not hold the Company and/or any affiliate and/or the trustee liable for any tax consequences relating to my Awards, including any penalties or other negative tax consequences I could receive or be subject to if my Awards do not obtain the Capital Gains Route tax treatment, regardless of the reason for the Capital Gains Route tax treatment not being available.
*    *    *    *



–Rev 1.2024
42
EX-10.3 4 exhibit103-bscx2024grantxt.htm EX-10.3 Document

Exhibit 10.3




Boston Scientific Corporation
Participant: %%FIRST_NAME%-% %%LAST_NAME%-%
Employee ID: %%EMPLOYEE_IDENTIFIER%-%
Award Type: Performance Share Unit Award Agreement
Plan Name: rTSR PERFORMANCE SHARE PROGRAM -
Award Date: %%OPTION_DATE,'Month DD, YYYY'%-%
Total Granted: %%TOTAL_SHARES_GRANTED%-%


BOSTON SCIENTIFIC

INTENT TO GRANT

PERFORMANCE SHARE UNIT AWARD AGREEMENT


    This Agreement, dated as of the %%OPTION_DATE,'Month DD, YYYY'%-% (the “Grant Date”), is between you and Boston Scientific Corporation, a Delaware corporation (the “Company”), in connection with the Award of Performance Share Units by the Company under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Plan”). Capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in either the Plan or in the Relative Total Shareholder Return Performance Share Program (the “Program”) for the period beginning January 1, 2024 and ending on December 31, 2026 (the “Performance Period”).
    1.    Grant and Acceptance of Award. The Company hereby indicates its award to you that number of Performance Share Units (the “Units”) set forth herein this Agreement (the “Award”). Each Unit represents the Company’s commitment to issue to you shares of the Company’s common stock, par value USD 0.01 per share (“Stock”), subject to certain eligibility, performance and other conditions set forth herein. The
-Rev. 1.2024        rTSR Program


Award is intended to be granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan and the Program.

    2.    Eligibility Conditions upon Award of the Units. You hereby acknowledge the intent of the Company to award the Units subject to certain eligibility, performance and other conditions set forth herein.

    3.    Satisfaction of Performance-Based Conditions. Subject to the eligibility conditions described in Sections 2 and 7 of this Agreement, except as otherwise provided in Sections 8 and 9 of this Agreement and Appendix B, and the satisfaction of the performance conditions set forth on Appendix A to this Agreement during the Performance Period, the Company intends to award shares of Stock hereunder to you at the end of the Performance Period. Shares of Stock shall be issued during the period January 1 to March 15 of the calendar year following the end of the Performance Period based on actual performance as determined at the first Committee meeting following the Performance Period. Except as set forth in Section 9 of this Agreement, no shares of Stock in settlement of the Units shall be issued to you prior to the end of the Performance Period.

    4.    Participant’s Rights in Stock. The shares of Stock, if and when issued hereunder, shall be registered in your name and evidenced in the manner as the Company may determine. During the period prior to the issuance of shares of Stock, you will have no rights of a stockholder of the Company with respect to the shares of Stock, including no right to receive dividends or vote the shares of Stock underlying each Award.

    5.    Death or Disability. In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to death or Disability (as the term is defined in the Plan or determined under local law), prior to the end of the Performance Period, shares of Stock shall be issued during the period January 1 to March 15 of the calendar year following the end of the Performance Period based on actual performance as determined at the first Committee meeting following the Performance Period.

    6.    Retirement. In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to Retirement after December 31, 2024, but prior to the end of the Performance Period, shares of Stock shall be issued during the period January 1 to March 15 of the calendar year following the end of the Performance Period on a prorated basis based on actual performance as determined at the first Committee meeting following the Performance Period. The number of shares of Stock to be issued under the prorated Award shall be determined by calculating (a)(i) the number of Units set forth herein multiplied by (ii) the quotient of the number of full and partial months that you worked during the Performance Period (rounded up to the nearest whole month) divided by 36, and then multiplying the product of (a)(i) and (a)(ii) by (b) the percentile performance amount, as calculated in accordance with the terms of the Program. In the event that you terminate your employment due to Retirement prior to January 1, 2025, the Award shall be forfeited in its entirety.

-Rev. 1.2024    2    rTSR Program


        For purpose of this Section 6, a “Retirement” shall not include (i) a termination of your employment for Cause (as defined in Section 7(b) of this Agreement) or (ii) a resignation by you after being notified that the Company has elected to terminate your employment for Cause.

    7.    Other Termination of Employment -- Eligibility Conditions.

(a)    If your employment with the Company and its Affiliates or subsidiaries is terminated or you separate from the Company and its Affiliates or subsidiaries for any reason other than death, Retirement or Disability, any Units that remain subject to eligibility conditions shall be void and no shares of Stock shall be issued. Except as set forth in Sections 5, 6 and 8, eligibility to be issued shares of Stock is conditioned on your continuous employment with the Company or an Affiliate through and on the last day of the Performance Period.

For purposes of the vesting conditions set forth in this Agreement, the effective date of your termination shall be deemed to be the last day of your active service with the Company or an Affiliate (if applicable). Notwithstanding anything to the contrary in the Plan or this Agreement, and for purposes of clarity, the date of your termination of employment shall not be extended by any statutory or common law notice of termination period.

(b)    Any Units not previously settled (without regard to whether the performance-based vesting condition has been satisfied) shall be cancelled and forfeited immediately upon notice to you of your termination for Cause.

For purposes of this Agreement, “Cause” shall mean termination of your employment by the Company as a result of the occurrence of any of the following, as determined by the Company in its sole discretion:

(1)your violation of the Company’s Code of Conduct or your violation of any written policy of the Company;

(2)your breach of your Agreement Concerning Employment, if any, or any other written agreement between you and the Company;

(3)your commission of an act of fraud, embezzlement, dishonesty or theft in connection with your duties or in the course of your employment;

(4)your engaging in any gross or willful misconduct that causes harm, or is likely to cause harm, to the Company’s business or its reputation;

(5)your being charged with, convicted of, or pleading guilty or no contest to, any felony or any other crime involving dishonesty or moral turpitude.

-Rev. 1.2024    3    rTSR Program


(6)your failure to substantially perform the essential duties of your employment (other than such failure resulting from your Retirement, Death or Disability as set forth in Sections 4, 5 and 6 of this Agreement).

    8.    Change in Control of the Company. Subject to the terms of any separate Change in Control or similar agreement to which you are bound, in the event you are employed by the Company or an Affiliate at the time of a Change in Control after December 31, 2024, but prior to the end of the Performance Period, shares of Stock shall be issued immediately prior to the Change in Control on a prorated basis based on actual performance using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2026, as determined by the Committee immediately prior to the consummation of the Change in Control. The number of shares of Stock to be issued under the prorated Award shall be determined by calculating (a)(i) the number of Units set forth herein multiplied by (ii) the quotient of the number of full and partial months during the Performance Period (rounded up to the nearest whole month) prior to the consummation of the Change in Control divided by 36, and then multiplying the product of (a)(i) and (a)(ii) by (b) the percentile performance amount as calculated in accordance with the terms of the Program. In the event that a Change in Control occurs prior to January 1, 2025, the Award shall be forfeited in its entirety.

    In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to death or Disability prior to a Change in Control and a Change in Control occurs after December 31, 2024, but prior to the end of the Performance Period, shares of Stock shall be issued immediately prior to the Change in Control based on actual performance using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2026, as determined by the Committee immediately prior to the consummation of the Change in Control.

    In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to Retirement prior to a Change in Control after December 31, 2024 and a Change in Control occurs after December 31, 2024, but prior to the end of the Performance Period, shares of Stock shall be issued immediately prior to the Change in Control on a prorated basis as determined under Section 6 based on actual performance using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2026, as determined by the Committee immediately prior to the consummation of the Change in Control.

    9.    Recoupment Policies.

    (a)    Executive Committee Recoupment Policy. Pursuant to the Company’s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Committee Member or Former Committee Member and if, in the judgment of
-Rev. 1.2024    4    rTSR Program


the Board, you, while serving in such capacity as a Current Executive Committee Member, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company.

        (i)    Definitions. The following terms, when used in this Section 9, shall have the meaning set forth below:

            (1)    “Current Executive Committee Member” means any individual currently designated as a corporate officer of the Company who is in an organizational job level of E-4 or E-5 (or any equivalent level under any future organizational framework).

            (2)    “Former Executive Committee Member” means any individual previously (but not currently) designated as a corporate officer of the Company who is in an organizational job level of E-4 or E-5 (or any equivalent level under any future organizational framework).

        (3)    “Recovery” means the forfeiture or cancellation of unvested Units.

    (b)    Other Compensation Recoupment Authority. The Units and any compensation associated therewith and any proceeds therefrom are subject to forfeiture, recovery by the Company or other action pursuant to any compensation recovery policy (i) in effect as of the Grant Date, as such policy may be amended from time to time, which includes but is not limited to the Company’s Dodd-Frank Clawback Policy and (ii) any other compensation recovery policy adopted after the Grant Date to facilitate compliance with applicable law, including in response to the requirements of Section 10D of the Exchange Act, the U.S. Securities and Exchange Commission’s final rules thereunder, and any applicable listing rules or other rules and regulations implementing the foregoing.

    (c)     Instructions to Brokerage Firm. For purposes of Sections 9(a) and 9(b) of this Agreement, you expressly and explicitly authorize the Company to issue instructions, on your behalf, to any brokerage firm and/or third party administrator engaged by the Company to hold any shares of Stock and other amounts acquired pursuant to the Units to re-convey, transfer or otherwise return such shares of Stock and/or other amounts to the Company upon the Company’s enforcement of the Company’s recoupment policy, the Company’s Dodd-Frank Clawback Policy and any other compensation recovery policy adopted by the Board or the Committee.

    (d)     No Constructive Termination. No recovery of compensation as described in this Section 9 will be an event giving rise to your right to resign for “good reason” or “constructive termination” (or similar term) under any plan of, or agreement with, the Company and/or an Affiliate and you.

-Rev. 1.2024    5    rTSR Program


    10.    Consideration for Stock. The shares of Stock are intended to be issued for no cash consideration.

    11.    Issuance of Stock. The Company shall not be obligated to issue any shares of Stock until (i) all United States (“U.S.”) federal, state, local and non-U.S. laws and regulations as the Company may deem applicable have been complied with; (ii) the shares of Stock have been listed or authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges; and (iii) all other legal matters in connection with the issuance and delivery of the shares of Stock have been approved by the Company’s legal department.

    12.    Satisfaction of Tax Obligations. Regardless of any action the Company or the Affiliate that employs you (the “Employer”) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (“Tax-Related Items”), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and/or the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) do not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate your liability for Tax-Related Items.

    Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if your country of residence (and/or the country of employment, if different) requires withholding of Tax-Related Items, the Company may hold back from the total number of shares of Stock to be delivered to you, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. If the obligation for Tax-Related Items is satisfied by holding back shares of Stock to be delivered upon settlement of the Units, for tax purposes, you are deemed to have been issued the full number of shares of Stock subject to the Units, notwithstanding that a number of shares of Stock are held back solely for the purpose of paying the Tax-Related Items. You will have no further rights with respect to any shares of Stock that are retained by the Company pursuant to this provision. By accepting the grant of the Units, you expressly consent to the withholding of shares of Stock and/or cash as provided for hereunder.

    Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. You agree to sign any agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s
-Rev. 1.2024    6    rTSR Program


designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.     

    All other Tax-Related Items related to the grant of the Units and any shares of Stock delivered in settlement thereof are your sole responsibility. In no event shall whole shares of Stock be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

    The Units are intended to comply with or be exempt from the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.

    Notwithstanding any provision of this Agreement to the contrary, in the event that any settlement or payment of this Award occurs as a result of your termination of employment and the Company determines that you are a “specified employee” (as that term is defined under Code Section 409A) subject to Code Section 409A at the time your termination of employment, and provided further that such payment or settlement does not otherwise qualify for an applicable exemption from Code Section 409A, then no such settlement or payment shall be paid to you until the date that is the earlier to occur of: (i) your death, or (ii) six (6) months and one (1) day following your termination of employment. Any portion of this Award delayed as a result of the preceding sentence, which is (i) in whole or in part, settled in cash and (ii) based on the value of shares of Stock, shall be based on the value of the shares of Stock at the time the Award would have otherwise been settled or paid without application of the delay described in the preceding sentence. If this Award does not otherwise qualify for an applicable exemption from Code Section 409A, the terms “Retirement”, “terminate,” “termination,” “termination of employment,” and variations thereof as used in this agreement, are intended to mean a termination of employment that constitutes a “separation from service” as such term is defined under Code Section 409A. Notwithstanding any action or inaction by the Administrator, you are exclusively responsible for any tax consequences under Code Section 409A resulting from this Award.

-Rev. 1.2024    7    rTSR Program


    13.    Investment Intent. You acknowledge that the acquisition of the shares of Stock to be issued hereunder is for investment purposes without a view to distribution thereof.

    14.    Limits on Transferability; Restrictions on Shares; Legend on Certificate. Until the eligibility conditions of this Award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement or by action of the Committee, the Units awarded hereunder are not transferable and shall not be sold, transferred, assigned, pledged, gifted, hypothecated or otherwise disposed of or encumbered by you. Transfers of shares of Stock by you are subject to the Company’s Stock Trading Policy and applicable securities laws. Shares of Stock issued to you in certificate form or to your book entry account upon satisfaction of the vesting and other conditions of this Award may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.

    15.    Award Subject to the Plan and the Program. The Award to be made pursuant to this Agreement is made subject to the Plan and the Program. The terms and provisions of the Plan and the Program, as each may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict between any term or provision contained in this Agreement and a term or provision of the Plan or the Program, the applicable terms and conditions of the Plan or Program will govern and prevail. However, no amendment of the Program after the grant date may materially and adversely impair a participant's rights under awards made pursuant to the Program without the participant's consent unless the amendment is necessary or desirable to facilitate compliance with applicable law, as determined in the sole discretion of the Committee.

    16.    No Rights to Continued Employment. The Company’s intent to issue the shares of Stock hereunder shall not confer upon you any right to continued employment or other association with the Company or any of its Affiliates or subsidiaries; and this Agreement shall not be construed in any way to limit the right of the Company or any of its subsidiaries or Affiliates to terminate your employment or other association with the Company or to change the terms of such employment or association at any time.

    17.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principle executive offices of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

    18.    Appendix. Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable
-Rev. 1.2024    8    rTSR Program


appendix to the Agreement (the “Appendix”). Further, if you transfer your residence and/or employment to another country reflected in the Appendices to these Agreements, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer). Any applicable Appendix shall constitute part of this Agreement.

    19.    Governing Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Agreement, the parties hereby submit and consent to the exclusive jurisdiction of the Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the Commonwealth of Massachusetts, or the federal courts for the United States for the District of Massachusetts, and no other courts, where this Award is made and/or to be performed.

    20.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

    21.    Severability. You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

    22.    Waiver. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.    

23.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to the one and the same instrument.

[remainder of page intentionally left blank]

-Rev. 1.2024    9    rTSR Program


APPENDIX A

PLAN: AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN


The Performance Share Units will pay out in shares of Stock in a range of 0% to 200% of the number of Performance Share Units as follows:

rTSR* Performance
Percentile Rank
Performance Share Units
as a Percent of Target
75th Percentile or above200%
55th Percentile 100%
25th Percentile30%
Below 25th Percentile
0%


*Relative Total Shareholder Return
-Rev. 1.2024        rTSR Program


BOSTON SCIENTIFIC CORPORATION

ADDENDUM TO THE AWARD AGREEMENT
RELATING TO PERFORMANCE SHARE UNITS GRANTED
PURSUANT TO THE
AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN

APPENDIX B

This Appendix B contains supplemental terms and conditions for awards of Units granted under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Plan”) to Participants who reside outside the United States or who are otherwise subject to the laws of a country other than the United States. Capitalized terms used but not defined herein shall have the same meanings ascribed to them in the Agreement.

Section I of this Appendix B contains special terms and conditions that govern the Units outside of the United States. Section II of this Appendix B includes special terms and conditions in the specific countries listed therein.

This Appendix B may also include information regarding exchange controls, taxation of awards and certain other issues of which you should be aware with respect to participation in the Plan. The information is based on the securities, exchange control, tax and other laws concerning the Units in effect as of December 2023. Such laws are often complex and change frequently; the information may be out of date at the time you vest in the Units or sell shares of Stock acquired under the Plan. As a result, the Company strongly recommends that you not rely on the information noted herein as the only source of information relating to the consequences of your participation in the Plan.

In addition, this Appendix B is general in nature, does not discuss all of the various laws, rules and regulations which may apply to your particular situation and the Company does not assure you of any particular result. Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country apply to your specific situation.

Finally, if you are a citizen or resident of a country other than the one in which you are currently working, transferred employment after the Award was granted or is considered a resident of another country for local law purposes, the information contained herein may not be applicable to you in the same manner. In addition, the Company shall, in its sole discretion, determine to what extent the terms and conditions contained herein will apply under these circumstances (or the Company may establish alternative terms and conditions as may be necessary or advisable).

-Rev. 1.2024        rTSR Program


Section I.     All Countries Outside the United States

Nature of Grant. In accepting the grant, you acknowledge that:

(a)the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past;

(c)all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator;

(d)the grant of the Units and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any);

(e)you are voluntarily participating in the Plan;

(f)the Units are not intended to replace any pension rights or compensation;

(g)the Units, the underlying shares of Stock, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments;

(h)the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty;

(i)no claim or entitlement to compensation or damages shall arise from (i) the forfeiture of the Units resulting from the termination of your employment or other service relationship by the Company or the Employer (for any reason, and whether or not in breach of local labor laws and whether or not later found to be invalid) and/or (ii) the forfeiture or cancellation of the Units and/or recoupment of any shares of Stock, cash, or other benefits acquired under the Plan resulting from the application of the Company’s recoupment policies contemplated under Section 9 of this Agreement;

(j)unless otherwise agreed with the Company in writing, the Units, the underlying shares of Stock and the income from and value of same are not granted as
-Rev. 1.2024        rTSR Program


consideration for, or in connection with, any service you may provide as a director of an Affiliate;

(k)for purposes of the Units, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, your right to vest in the Units under this Agreement, if any, will terminate as of such date and will not be extended by any notice period (e.g., your period of service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any); the Committee shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Unit grant (including whether you may still be considered to be providing services while on an approved leave of absence); and

(l)the following provisions apply only if you are providing services outside the United States: (A) the Units, the underlying shares of Stock, and the income from and value of same are not part of normal or expected compensation or salary for any purpose; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Units or of any amount due to you pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.

Electronic Delivery of Documents. The Company may, in its sole discretion, decide to deliver any documents related to the Units granted under and participation in the Plan or future Units that may be granted under the Plan by electronic means or to request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.

Language. You hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Appendix, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Units, be drawn up in English. You acknowledge that you are proficient in the English language and understand the terms of this Agreement or have had the ability to consult with an advisor who is sufficiently proficient in the English language. If you have received this Agreement and any applicable Appendix, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

-Rev. 1.2024        rTSR Program


Insider Trading Restrictions/Market Abuse Laws. You acknowledge that, depending on your or your broker’s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws that may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares (e.g., phantom awards, futures) during such times you are considered to have “inside information” regarding the Company, as defined in the laws or regulations in your country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to your personal advisor on this matter.
 
Section II.     Country-Specific Terms and Conditions

COUNTRIES OUTSIDE THE EUROPEAN UNION (“EU”) / EUROPEAN ECONOMIC AREA (“EEA”), UNITED KINGDOM AND SWITZERLAND

Data Privacy: If you do not reside and/or are not employed in the EU / EEA, the United Kingdom or Switzerland, the following provision applies:

You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other Unit grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.

You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (“Data”) for the purpose of implementing, managing and administering the Plan.

You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to Morgan Stanley Smith Barney LLC and its affiliates (“Morgan Stanley”) or any successor or any other third party that the Company or Morgan Stanley (or its successor) may engage to assist with the administration of the Plan from time to time.
-Rev. 1.2024        rTSR Program


You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.

You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon vesting of the Units. You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consents herein on a purely voluntary basis. If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Units or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.

COUNTRIES WITHIN THE EU / EEA, UNITED KINGDOM AND SWITZERLAND

Data Privacy: If you reside and/or are employed in the EU / EEA, the United Kingdom or Switzerland, the following provision applies:

Pursuant to applicable personal data protection laws, the Company and the Employer hereby notify you of the following in relation to your Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the grant of the Units and your participation in the Plan. The collection, processing and transfer of your Personal Data is necessary for the legitimate purpose of the Company and the Employer’s administration of the Plan and your participation in the Plan, and your denial and/or objection to the collection, processing and transfer of Personal Data may affect your participation in the Plan. As such, by accepting the Award, you acknowledge the collection, use, processing and transfer of Personal Data as described herein.

-Rev. 1.2024        rTSR Program


You understand that the Company and the Employer hold certain personally identifiable information about you, specifically, your name, home address and telephone number, date of birth, social security number or other employee identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (“Personal Data”). The Personal Data may be provided by you to or collected, where lawful, from third parties. The Company or the Employer each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing your participation in the Plan and meeting related legal obligations associated with these actions.

The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations. Personal Data will be accessible within the Company’s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and other aspects of the employment relationship and for participation in the Plan.

The Company and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and the Employer may each further transfer Personal Data to third parties assisting the Company or the Employer in the implementation, administration and management of the Plan, including Morgan Stanley Smith Barney LLC and its affiliates or any successor or other third party that the Company, the Employer or Morgan Stanley Smith Barney LLC (or its successor) may engage to assist with the administration of the Plan from time to time. These recipients may be located in the EU, EEA, the United Kingdom, Switzerland or elsewhere throughout the world, such as the United States. By participating in the Plan, you understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Personal Data as may be required for the administration of the Plan and/or the subsequent holding of shares of Stock on your behalf to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan. You further understand that you may request a list with the names and addresses of any potential recipients of your Personal Data by contacting your local Human Resources manager or the Company’s Human Resources Department. When transferring Personal Data to these potential recipients, the Company and the Employer provide appropriate safeguards in accordance with EU Standard Contractual Clauses or other legally binding and permissible arrangements. You may request a copy of such safeguards from your local human resources manager or the Company’s Human Resources Department.
-Rev. 1.2024        rTSR Program



To the extent provided by law, you may, at any time, have the right to request: access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data. You may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting in writing your Human Resources manager. Your provision of Personal Data is a contractual requirement. You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Units to you, or grant other equity awards or administer or maintain such equity awards. For more information on the consequences of your refusal to provide Personal Data, you understand that you may contact your local human resources manager or the Company’s Human Resources Department.

When the Company and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and/or records containing the Personal Data and/or take steps to properly anonymize it so that you can longer be identified from it.

FRANCE

Nature of the Award. The Units are not granted under the French specific regime provided by Articles L225-197-1 and seq. or L. 22-10-59 and L. 22-10-60 of the French commercial code, as amended.

Use of English Language. You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English. Vous reconnaissez et consentez que c’est votre souhait exprès qui cet accord, de meme que tous documents, toutes notifications et tous procédés légaux est entré dans, donné ou instituté conformément ci-annexé ou relatant directement ou indirectement ci-annexé, est formulé dans l’anglais.


*    *    *    *    *
415543916-v5\NA_DMS
-Rev. 1.2024        rTSR Program
EX-10.4 5 exhibit104-bscx2024grantxo.htm EX-10.4 Document

Exhibit 10.4




Boston Scientific Corporation
Participant: %%FIRST_NAME%-% %%LAST_NAME%-%
Employee ID: %%EMPLOYEE_IDENTIFIER%-%
Award Type: Performance Share Unit Award Agreement
Plan Name: ONSG PERFORMANCE SHARE PROGRAM
Award Date: %%OPTION_DATE,'Month DD, YYYY'%-%
Total Granted: %%TOTAL_SHARES_GRANTED%-%


BOSTON SCIENTIFIC

INTENT TO GRANT

PERFORMANCE SHARE UNIT AWARD AGREEMENT


    This Agreement, dated as of the %%OPTION_DATE,'Month DD, YYYY'%-% (the “Grant Date”), is between you and Boston Scientific Corporation, a Delaware corporation (the “Company”), in connection with the Award of Performance Share Units by the Company under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Plan”). Capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in either the Plan or in the Organic Net Sales Growth Performance Share Program (the “Program”) for the period beginning January 1, 2024 and ending on December 31, 2026 (the “Performance Period”).
    1.    Grant and Acceptance of Award. The Company hereby indicates its award to you that number of Performance Share Units (the “Units”) set forth herein this Agreement (the “Award”). Each Unit represents the Company’s commitment to issue to you shares of the Company’s common stock, par value USD 0.01 per share (“Stock”), subject to certain eligibility, performance and other conditions set forth herein. The Award is intended to be granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan and the Program.
-12.2022        ONSG Program



    2.    Eligibility Conditions upon Award of the Units. You hereby acknowledge the intent of the Company to award the Units subject to certain eligibility, performance and other conditions set forth herein.

    3.    Satisfaction of Performance-Based Conditions. Subject to the eligibility conditions described in Sections 2 and 7 of this Agreement, except as otherwise provided in Sections 8 and 9 of this Agreement and Appendix B, and the satisfaction of the performance conditions set forth on Appendix A to this Agreement during the Performance Period, the Company intends to award shares of Stock hereunder to you at the end of the Performance Period. Shares of Stock shall be issued during the period January 1 to March 15 of the calendar year following the end of the Performance Period based on actual performance as determined at the first Committee meeting following the Performance Period. Except as set forth in Section 9 of this Agreement, no shares of Stock in settlement of the Units shall be issued to you prior to the end of the Performance Period.

    4.    Participant’s Rights in Stock. The shares of Stock, if and when issued hereunder, shall be registered in your name and evidenced in the manner as the Company may determine. During the period prior to the issuance of shares of Stock, you will have no rights of a stockholder of the Company with respect to the shares of Stock, including no right to receive dividends or vote the shares of Stock underlying each Award.

    5.    Death or Disability. In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to death or Disability (as the term is defined in the Plan or determined under local law), prior to the end of the Performance Period, shares of Stock shall be issued during the period January 1 to March 15 of the calendar year following the end of the Performance Period based on actual performance as determined at the first Committee meeting following the Performance Period.

    6.    Retirement. In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to Retirement after December 31, 2024, but prior to the end of the Performance Period, shares of Stock shall be issued during the period January 1 to March 15 of the calendar year following the end of the Performance Period on a prorated basis based on actual performance as determined at the first Committee meeting following the Performance Period. The number of shares of Stock to be issued under the prorated Award shall be determined by calculating (a)(i) the number of Units set forth herein multiplied by (ii) the quotient of the number of full and partial months that you worked during the Performance Period (rounded up to the nearest whole month) divided by 36, and then multiplying the product of (a)(i) and (a)(ii) by (b) the percentile performance amount, as calculated in accordance with the terms of the Program. In the event that you terminate your employment due to Retirement prior to January 1, 2025, the Award shall be forfeited in its entirety.

        For purpose of this Section 6, a “Retirement” shall not include (i) a termination of your employment for Cause (as defined in Section 7(b) of this Agreement)
-1.2024    2    ONSG Program


or (ii) a resignation by you after being notified that the entity that employs you has elected to terminate your employment for Cause.

    7.    Other Termination of Employment -- Eligibility Conditions.

    (a)    If your employment with the Company and its Affiliates or subsidiaries is terminated or you separate from the Company and its Affiliates or subsidiaries for any reason other than death, Retirement or Disability, any Units that remain subject to eligibility conditions shall be void and no shares of Stock shall be issued. Except as set forth in Sections 5, 6 and 8, eligibility to be issued shares of Stock is conditioned on your continuous employment with the Company or an Affiliate through and on the last day of the Performance Period.

For purposes of the vesting conditions set forth in this Agreement, the effective date of your termination shall be deemed to be the last day of your active service with the Company or an Affiliate (if applicable). Notwithstanding anything to the contrary in the Plan or this Agreement, and for purposes of clarity, the date of your termination of employment shall not be extended by any statutory or common law notice of termination period.

(b)    Any Units not previously settled (without regard to whether the performance-based vesting condition has been satisfied) shall be cancelled and forfeited immediately upon notice to you of your termination for Cause.

For purposes of this Agreement, “Cause” shall mean termination of your employment by the entity that employs you as a result of the occurrence of any of the following, as determined by the Company in its sole discretion:

(1)your violation of the Company’s Code of Conduct or your violation of any written policy of the Company;

(2)your breach of your Agreement Concerning Employment, if any, or any other written agreement between you and the Company or the entity that employs you (if different);

(3)your commission of an act of fraud, embezzlement, dishonesty or theft in connection with your duties or in the course of your employment;

(4)your engaging in any gross or willful misconduct that causes harm, or is likely to cause harm, to the Company’s business or its reputation;

(5)your being charged with, convicted of, or pleading guilty or no contest to, any felony or any other crime involving dishonesty or moral turpitude;

-1.2024    3    ONSG Program


(6)your failure to substantially perform the essential duties of your employment (other than such failure resulting from your Retirement, Death or Disability as set forth in Sections 5 and 6 of this Agreement).

    8.    Change in Control of the Company. Subject to the terms of any separate Change in Control or similar agreement to which you are bound, in the event you are employed by the Company or an Affiliate at the time of a Change in Control after December 31, 2024, but prior to the end of the Performance Period, shares of Stock shall be issued immediately prior to the Change in Control on a prorated basis based on actual performance using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2026, as determined by the Committee immediately prior to the consummation of the Change in Control. The number of shares of Stock to be issued under the prorated Award shall be determined by calculating (a)(i) the number of Units set forth herein multiplied by (ii) the quotient of the number of full and partial months during the Performance Period (rounded up to the nearest whole month) prior to the consummation of the Change in Control divided by 36, and then multiplying the product of (a)(i) and (a)(ii) by (b) the percentile performance amount as calculated in accordance with the terms of the Program. In the event that a Change in Control occurs prior to January 1, 2025, the Award shall be forfeited in its entirety.

    In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to death or Disability prior to a Change in Control and a Change in Control occurs after December 31, 2024, but prior to the end of the Performance Period, shares of Stock shall be issued immediately prior to the Change in Control based on actual performance using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2025, as determined by the Committee immediately prior to the consummation of the Change in Control.

    In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to Retirement prior to a Change in Control after December 31, 2024 and a Change in Control occurs after December 31, 2024, but prior to the end of the Performance Period, shares of Stock shall be issued immediately prior to the Change in Control on a prorated basis as determined under Section 6 based on actual performance using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2026, as determined by the Committee immediately prior to the consummation of the Change in Control.

    9.    Recoupment Policies.

    (a)    Executive Committee Recoupment Policy. Pursuant to the Company’s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Committee Member or Former Committee Member and if, in the judgment of
-1.2024    4    ONSG Program


the Board, you, while serving in such capacity as a Current Executive Committee Member commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company.

        (i)    Definitions. The following terms, when used in this Section 9, shall have the meaning set forth below:

            (1)    “Current Executive Committee Member” means any individual currently designated as a corporate officer of the Company who is in an organizational job level of E-4 or E-5 (or any equivalent level under any future organizational framework).

            (2)    “Former Executive Committee Member” means any individual previously (but not currently) designated as a corporate officer of the Company who is in an organizational job level of E-4 or E-5 (or any equivalent level under any future organizational framework).

        (3)    “Recovery” means the forfeiture or cancellation of unvested Units.

    (b)    Other Compensation Recoupment Authority. The Units and any compensation associated therewith and any proceeds therefrom are subject to forfeiture, recovery by the Company or other action pursuant to any compensation recovery policy (i) in effect as of the Grant Date, as such policy may be amended from time to time, which includes but is not limited to the Company’s Dodd-Frank Clawback Policy and (ii) any other compensation recovery policy adopted after the Grant Date to facilitate compliance with applicable law, including in response to the requirements of Section 10D of the Exchange Act, the U.S. Securities and Exchange Commission’s final rules thereunder, and any applicable listing rules or other rules and regulations implementing the foregoing.

    (c)     Instructions to Brokerage Firm. For purposes of Sections 9(a) and 9(b) of this Agreement, you expressly and explicitly authorize the Company to issue instructions, on your behalf, to any brokerage firm and/or third party administrator engaged by the Company to hold any shares of Stock and other amounts acquired pursuant to the Units to re-convey, transfer or otherwise return such shares of Stock and/or other amounts to the Company upon the Company’s enforcement of the Company’s recoupment policy, the Company’s Dodd-Frank Clawback Policy and any other compensation recovery policy adopted by the Board or the Committee.

    (d)     No Constructive Termination. No recovery of compensation as described in this Section 9 will be an event giving rise to your right to resign for “good reason” or “constructive termination” (or similar term) under any plan of, or agreement with, the Company and/or an Affiliate and you.

-1.2024    5    ONSG Program


    10.    Consideration for Stock. The shares of Stock are intended to be issued for no cash consideration.

    11.    Issuance of Stock. The Company shall not be obligated to issue any shares of Stock until (i) all United States (“U.S.”) federal, state, local and non-U.S. laws and regulations as the Company may deem applicable have been complied with; (ii) the shares of Stock have been listed or authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges; and (iii) all other legal matters in connection with the issuance and delivery of the shares of Stock have been approved by the Company’s legal department.

    12.    Satisfaction of Tax Obligations. Regardless of any action the Company or the Affiliate that employs you (the “Employer”) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (“Tax-Related Items”), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and/or the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) do not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate your liability for Tax-Related Items.

    Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if your country of residence (and/or the country of employment, if different) requires withholding of Tax-Related Items, the Company may hold back from the total number of shares of Stock to be delivered to you, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. If the obligation for Tax-Related Items is satisfied by holding back shares of Stock to be delivered upon settlement of the Units, for tax purposes, you are deemed to have been issued the full number of shares of Stock subject to the Units, notwithstanding that a number of shares of Stock are held back solely for the purpose of paying the Tax-Related Items. You will have no further rights with respect to any shares of Stock that are retained by the Company pursuant to this provision. By accepting the grant of the Units, you expressly consent to the withholding of shares of Stock and/or cash as provided for hereunder.

    Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. You agree to sign any agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s
-1.2024    6    ONSG Program


designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.     

    All other Tax-Related Items related to the grant of the Units and any shares of Stock delivered in settlement thereof are your sole responsibility. In no event shall whole shares of Stock be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

    The Units are intended to comply with or be exempt from the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.

    Notwithstanding any provision of this Agreement to the contrary, in the event that any settlement or payment of this Award occurs as a result of your termination of employment and the Company determines that you are a “specified employee” (as that term is defined under Code Section 409A) subject to Code Section 409A at the time your termination of employment, and provided further that such payment or settlement does not otherwise qualify for an applicable exemption from Code Section 409A, then no such settlement or payment shall be paid to you until the date that is the earlier to occur of: (i) your death, or (ii) six (6) months and one (1) day following your termination of employment. Any portion of this Award delayed as a result of the preceding sentence, which is (i) in whole or in part, settled in cash and (ii) based on the value of shares of Stock, shall be based on the value of the shares of Stock at the time the Award would have otherwise been settled or paid without application of the delay described in the preceding sentence. If this Award does not otherwise qualify for an applicable exemption from Code Section 409A, the terms “Retirement”, “terminate,” “termination,” “termination of employment,” and variations thereof as used in this agreement, are intended to mean a termination of employment that constitutes a “separation from service” as such term is defined under Code Section 409A. Notwithstanding any action or inaction by the Administrator, you are exclusively responsible for any tax consequences under Code Section 409A resulting from this Award.

-1.2024    7    ONSG Program


    13.    Investment Intent. You acknowledge that the acquisition of the shares of Stock to be issued hereunder is for investment purposes without a view to distribution thereof.

    14.    Limits on Transferability; Restrictions on Shares; Legend on Certificate. Until the eligibility conditions of this Award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement or by action of the Committee, the Units awarded hereunder are not transferable and shall not be sold, transferred, assigned, pledged, gifted, hypothecated or otherwise disposed of or encumbered by you. Transfers of shares of Stock by you are subject to the Company’s Stock Trading Policy and applicable securities laws. Shares of Stock issued to you in certificate form or to your book entry account upon satisfaction of the vesting and other conditions of this Award may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.

    15.    Award Subject to the Plan and the Program. The Award to be made pursuant to this Agreement is made subject to the Plan and the Program. The terms and provisions of the Plan and the Program, as each may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict between any term or provision contained in this Agreement and a term or provision of the Plan or the Program, the applicable terms and conditions of the Plan or Program will govern and prevail. However, no amendment of the Program after the grant date may materially and adversely impair a participant's rights under awards made pursuant to the Program without the participant's consent unless the amendment is necessary or desirable to facilitate compliance with applicable law, as determined in the sole discretion of the Committee.

    16.    No Rights to Continued Employment. The Company’s intent to issue the shares of Stock hereunder shall not confer upon you any right to continued employment or other association with the Company or any of its Affiliates or subsidiaries; and this Agreement shall not be construed in any way to limit the right of the Company or any of its subsidiaries or Affiliates to terminate your employment or other association with the Company or to change the terms of such employment or association at any time.

    17.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principle executive offices of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

    18.    Appendix. Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable
-1.2024    8    ONSG Program


appendix to the Agreement (the “Appendix”). Further, if you transfer your residence and/or employment to another country reflected in the Appendices to these Agreements, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer). Any applicable Appendix shall constitute part of this Agreement.

    19.    Governing Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Agreement, the parties hereby submit and consent to the exclusive jurisdiction of the Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the Commonwealth of Massachusetts, or the federal courts for the United States for the District of Massachusetts, and no other courts, where this Award is made and/or to be performed.

    20.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

    21.    Severability. You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

    22.    Waiver. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.    

23.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to the one and the same instrument.

[remainder of page intentionally left blank]

-1.2024    9    ONSG Program


APPENDIX A

PLAN: AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN


The Performance Share Units will pay out in shares of Stock in a range of 0% to 200% of the number of Performance Share Units as follows:

ONSG* Performance
Percentile Rank
Performance Share Units
as a Percent of Target
138.2%200%
100.0%100%
61.8%50%
<61.8%0%
Linear interpolation between points


*Organic Net Sales Growth
-12.2022        ONSG Program


BOSTON SCIENTIFIC CORPORATION

ADDENDUM TO THE AWARD AGREEMENT
RELATING TO PERFORMANCE SHARE UNITS GRANTED
PURSUANT TO THE
AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN

APPENDIX B

This Appendix B contains supplemental terms and conditions for awards of Units granted under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Plan”) to Participants who reside outside the United States or who are otherwise subject to the laws of a country other than the United States. Capitalized terms used but not defined herein shall have the same meanings ascribed to them in the Agreement.

Section I of this Appendix B contains special terms and conditions that govern the Units outside of the United States. Section II of this Appendix B includes special terms and conditions in the specific countries listed therein.

This Appendix B may also include information regarding exchange controls, taxation of awards and certain other issues of which you should be aware with respect to participation in the Plan. The information is based on the securities, exchange control, tax and other laws concerning the Units in effect as of December 2023. Such laws are often complex and change frequently; the information may be out of date at the time you vest in the Units or sell shares of Stock acquired under the Plan. As a result, the Company strongly recommends that you not rely on the information noted herein as the only source of information relating to the consequences of your participation in the Plan.

In addition, this Appendix B is general in nature, does not discuss all of the various laws, rules and regulations which may apply to your particular situation and the Company does not assure you of any particular result. Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country apply to your specific situation.

Finally, if you are a citizen or resident of a country other than the one in which you are currently working, transferred employment after the Award was granted or is considered a resident of another country for local law purposes, the information contained herein may not be applicable to you in the same manner. In addition, the Company shall, in its sole discretion, determine to what extent the terms and conditions contained herein will apply under these circumstances (or the Company may establish alternative terms and conditions as may be necessary or advisable).

-1.2024        ONSG Program


Section I.     All Countries Outside the United States

Nature of Grant. In accepting the grant, you acknowledge that:

(a)the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past;

(c)all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator;

(d)the grant of the Units and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any);

(e)you are voluntarily participating in the Plan;

(f)the Units are not intended to replace any pension rights or compensation;

(g)the Units, the underlying shares of Stock, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments;

(h)the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty;

(i)no claim or entitlement to compensation or damages shall arise from (i) the forfeiture of the Units resulting from the termination of your employment or other service relationship (for any reason, and whether or not in breach of local labor laws and whether or not later found to be invalid) and/or (ii) the forfeiture or cancellation of the Units and/or recoupment of any shares of Stock, cash, or other benefits acquired under the Plan resulting from the application of the Company’s recoupment policies contemplated under Section 9 of this Agreement;

(j)unless otherwise agreed with the Company in writing, the Units, the underlying shares of Stock and the income from and value of same are not granted as
-1.2024        ONSG Program


consideration for, or in connection with, any service you may provide as a director of an Affiliate;

(k)for purposes of the Units, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, your right to vest in the Units under this Agreement, if any, will terminate as of such date and will not be extended by any notice period (e.g., your period of service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any); the Committee shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Unit grant (including whether you may still be considered to be providing services while on an approved leave of absence); and

(l)the following provisions apply only if you are providing services outside the United States: (A) the Units, the underlying shares of Stock, and the income from and value of same are not part of normal or expected compensation or salary for any purpose; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Units or of any amount due to you pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.

Electronic Delivery of Documents. The Company may, in its sole discretion, decide to deliver any documents related to the Units granted under and participation in the Plan or future Units that may be granted under the Plan by electronic means or to request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.

Language. You hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Appendix, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Units, be drawn up in English. You acknowledge that you are proficient in the English language and understand the terms of this Agreement or have had the ability to consult with an advisor who is sufficiently proficient in the English language. If you have received this Agreement and any applicable Appendix, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

-1.2024        ONSG Program


Insider Trading Restrictions/Market Abuse Laws. You acknowledge that, depending on your or your broker’s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws that may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares (e.g., phantom awards, futures) during such times you are considered to have “inside information” regarding the Company, as defined in the laws or regulations in your country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to your personal advisor on this matter.
 
Section II.     Country-Specific Terms and Conditions

COUNTRIES OUTSIDE THE EUROPEAN UNION (“EU”) / EUROPEAN ECONOMIC AREA (“EEA”), UNITED KINGDOM AND SWITZERLAND

Data Privacy: If you do not reside and/or are not employed in the EU / EEA, the United Kingdom or Switzerland, the following provision applies:

You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other Unit grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.

You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (“Data”) for the purpose of implementing, managing and administering the Plan.

You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to Morgan Stanley Smith Barney LLC and its affiliates (“Morgan Stanley”) or any successor or any other third party that the Company or Morgan Stanley (or its successor) may engage to assist with the administration of the Plan from time to time.
-1.2024        ONSG Program


You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.

You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon vesting of the Units. You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consents herein on a purely voluntary basis. If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Units or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.

COUNTRIES WITHIN THE EU / EEA, UNITED KINGDOM AND SWITZERLAND

Data Privacy: If you reside and/or are employed in the EU / EEA, the United Kingdom or Switzerland, the following provision applies:

Pursuant to applicable personal data protection laws, the Company and the Employer hereby notify you of the following in relation to your Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the grant of the Units and your participation in the Plan. The collection, processing and transfer of your Personal Data is necessary for the legitimate purpose of the Company and the Employer’s administration of the Plan and your participation in the Plan, and your denial and/or objection to the collection, processing and transfer of Personal Data may affect your participation in the Plan. As such, by accepting the Award, you acknowledge the collection, use, processing and transfer of Personal Data as described herein.

-1.2024        ONSG Program


You understand that the Company and the Employer hold certain personally identifiable information about you, specifically, your name, home address and telephone number, date of birth, social security number or other employee identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (“Personal Data”). The Personal Data may be provided by you to or collected, where lawful, from third parties. The Company or the Employer each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing your participation in the Plan and meeting related legal obligations associated with these actions.

The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations. Personal Data will be accessible within the Company’s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and other aspects of the employment relationship and for participation in the Plan.

The Company and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and the Employer may each further transfer Personal Data to third parties assisting the Company or the Employer in the implementation, administration and management of the Plan, including Morgan Stanley Smith Barney LLC and its affiliates (“Morgan Stanley”) or any successor or any other third party that the Company or Morgan Stanley (or its successor) may engage to assist with the administration of the Plan from time to time. These recipients may be located in the EU, EEA, the United Kingdom, Switzerland or elsewhere throughout the world, such as the United States. By participating in the Plan, you understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Personal Data as may be required for the administration of the Plan and/or the subsequent holding of shares of Stock on your behalf to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan. You further understand that you may request a list with the names and addresses of any potential recipients of your Personal Data by contacting your local Human Resources manager or the Company’s Human Resources Department. When transferring Personal Data to these potential recipients, the Company and the Employer provide appropriate safeguards in accordance with EU Standard Contractual Clauses or other legally binding and permissible arrangements. You may request a copy of such safeguards from your local human resources manager or the Company’s Human Resources Department.
-1.2024        ONSG Program



To the extent provided by law, you may, at any time, have the right to request: access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data. You may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting in writing your Human Resources manager. Your provision of Personal Data is a contractual requirement. You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Units to you, or grant other equity awards or administer or maintain such equity awards. For more information on the consequences of your refusal to provide Personal Data, you understand that you may contact your local human resources manager or the Company’s Human Resources Department.

When the Company and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and/or records containing the Personal Data and/or take steps to properly anonymize it so that you can longer be identified from it.

FRANCE

Nature of the Award. The Units are not granted under the French specific regime provided by Articles L225-197-1 and seq. or L. 22-10-59 and L. 22-10-60 of the French commercial code, as amended.

Use of English Language. You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English. Vous reconnaissez et consentez que c’est votre souhait exprès qui cet accord, de meme que tous documents, toutes notifications et tous procédés légaux est entré dans, donné ou instituté conformément ci-annexé ou relatant directement ou indirectement ci-annexé, est formulé dans l’anglais.


*    *    *    *    *

-1.2024        ONSG Program
EX-22 6 exhibit22-subsidiaryissuer.htm EX-22 Document

EXHIBIT 22
 
 
Subsidiary Issuer of Guaranteed Securities

Boston Scientific (the “Registrant”) is the guarantor of the senior unsecured registered notes listed below issued by American Medical Systems Europe B.V., a wholly-owned finance subsidiary of the Registrant.

American Medical Systems Europe B.V.:

0.750% Senior Notes due 2025
1.375% Senior Notes due 2028
3.375% Senior Notes due 2029
1.625% Senior Notes due 2031
3.500% Senior Notes due 2032
1.875% Senior Notes due 2034


EX-31.1 7 exhibit311-ceo302q12024.htm EX-31.1 Document

EXHIBIT 31.1
 
CERTIFICATIONS
 
I, Michael F. Mahoney, certify that:
1I have reviewed this Quarterly Report on Form 10-Q of Boston Scientific Corporation;
2Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)   
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    
 
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)    
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)    
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:May 1, 2024 /s/ Michael F. Mahoney
  Michael F. Mahoney
  Chief Executive Officer

EX-31.2 8 exhibit312-cfo302q12024.htm EX-31.2 Document

EXHIBIT 31.2
 
CERTIFICATIONS
 
I, Daniel J. Brennan, certify that:


1I have reviewed this Quarterly Report on Form 10-Q of Boston Scientific Corporation;
2Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)   
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    
 
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)    
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)    
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:May 1, 2024 /s/ Daniel J. Brennan
  Daniel J. Brennan
  Executive Vice President and Chief Financial Officer

EX-32.1 9 exhibit321-ceo906q12024.htm EX-32.1 Document

EXHIBIT 32.1
 
 
CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C.
SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Boston Scientific Corporation (the “Company”) for the period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Chief Executive Officer of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that based on his knowledge:

 (1)   the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)   the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Boston Scientific Corporation.

This certification shall not be deemed "filed" for any purpose, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934 regardless of any general incorporation language in such filing.
   
By:/s/ Michael F. Mahoney
 Michael F. Mahoney 
 Chief Executive Officer 
   
 May 1, 2024 
 


EX-32.2 10 exhibit322-cfo906q12024.htm EX-32.2 Document

EXHIBIT 32.2
 
 
CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C.
SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Boston Scientific Corporation (the “Company”) for the period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Chief Financial Officer of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that based on his knowledge:

 (1)   the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)   the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Boston Scientific Corporation.

This certification shall not be deemed "filed" for any purpose, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934 regardless of any general incorporation language in such filing.

   
By:/s/ Daniel J. Brennan
 Daniel J. Brennan 
 Executive Vice President and Chief Financial Officer 
   
 May 1, 2024 

EX-101.SCH 11 bsx-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Document link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Acquisitions, Divestitures and Strategic Investments link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Hedging Activities and Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Contractual Obligations and Commitments link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Supplemental Balance Sheet Information link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Weighted Average Shares Outstanding link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Changes in Other Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - New Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Basis of Presentation Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Hedging Activities and Fair Value Measurements (Policies) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Commitments and Contingencies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Changes in Other Comprehensive Income (Policies) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - New Accounting Pronouncements (Policies) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Acquisitions, Divestitures and Strategic Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Goodwill and Other Intangible Assets Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Hedging Activities and Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Contractual Obligations and Commitments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Supplemental Balance Sheet Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Weighted Average Shares Outstanding (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Changes in Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Acquisitions and Divestitures (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Strategic Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Goodwill and Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Hedging Activities and Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Contractual Obligations and Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Weighted Average Shares Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Weighted Average Shares Outstanding - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Segment Reporting (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Changes in Other Comprehensive Income (AOCI Rollforward with Reclassification) (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 bsx-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 13 bsx-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 14 bsx-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Net income (loss) attributable to noncontrolling interests Net income (loss) attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Amount excluded from debt in leverage ratio Amount excluded from debt in leverage ratio Amount excluded from debt in leverage ratio Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, after Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, after Tax Pay vs Performance Disclosure [Line Items] Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Accrued expenses Accrued Liabilities, Current Accrued Liabilities, Current Other Noncurrent Liabilities [Member] Other Noncurrent Liabilities [Member] Range [Domain] Statistical Measurement [Domain] Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Maximum Borrowing Capacity Preferred stock dividends Dividends, Preferred Stock, Stock Underlying Security Market Price Change Underlying Security Market Price Change, Percent Licensing Arrangements Accrued Royalties, Current Legal payments remaining to be excluded from calculation of consolidated EBITDA Legal payments remaining to be excluded from calculation of consolidated EBITDA Legal payments remaining to be excluded from calculation of consolidated EBITDA Preferred Stock, Liquidation Preference Per Share Preferred Stock, Liquidation Preference Per Share All Award Types Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Payments on short-term borrowings Repayments of Short-Term Debt Estimated Litigation Liability, Noncurrent Estimated Litigation Liability, Noncurrent the Offering the Offering - aggregate principal amount [Member] the Offering - aggregate principal amount CONTRACTUAL OBLIGATIONS AND COMMITMENTS Debt Disclosure [Text Block] Other Current Liabilities [Member] Other Current Liabilities [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Revolving Credit Facility [Member] Revolving Credit Facility [Member] Watchman Watchman [Member] Watchman Transfer of Financial Assets Accounted for as Sales, Amount Derecognized Transfer of Financial Assets Accounted for as Sales, Amount Derecognized Effect of foreign exchange rates on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Deferred income taxes Deferred Income Tax Liabilities, Net MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Segment Reporting [Abstract] Segment Reporting [Abstract] Accounts payable Accounts Payable, Current Prepaid Expenses and Other Current Assets [Member] Prepaid Expenses and Other Current Assets [Member] Restatement Determination Date: Restatement Determination Date [Axis] Derivatives Not Designated as Hedging Derivatives Not Designated as Hedging Instruments [Table Text Block] Other expense, net Nonoperating Income (Expense) Commitments and contingencies Commitments and Contingencies Insider Trading Policies and Procedures [Line Items] Capital in progress Construction in Progress, Gross Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Derivative Asset, Current Derivative Asset, Current Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Deferred Revenue, Current Deferred Revenue, Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] STOCKHOLDERS' EQUITY Equity [Text Block] Accrued expenses Accrued Liabilities, Current [Abstract] Schedule of Intangible Assets and Goodwill [Table] Schedule of Goodwill [Table] Geographical [Axis] Geographical [Axis] Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans Proceeds from Stock Plans INCOME TAXES Income Tax Disclosure [Text Block] Other Accrued Liabilities, Noncurrent Other Accrued Liabilities, Noncurrent Ownership [Axis] Ownership [Axis] Other Current Assets [Abstract] Other Current Assets [Abstract] Other Current Assets [Abstract] Other Assets, Miscellaneous, Current Other Assets, Miscellaneous, Current Number of Interest Rate Derivatives Held Number of Interest Rate Derivatives Held Restricted cash equivalents included in Other long-term assets Restricted Cash Equivalents, Noncurrent Current liabilities: Liabilities, Current [Abstract] Qualified Acquisition Consideration Qualified Acquisition Consideration Qualified Acquisition Consideration Payment of contingent consideration Payment of contingent consideration Payment of contingent consideration Goodwill, Impaired, Accumulated Impairment Loss Goodwill, Impaired, Accumulated Impairment Loss AMS Europe AMS Europe [Member] AMS Europe Preferred Stock, Par or Stated Value Per Share Preferred Stock, Par or Stated Value Per Share Preferred stock, $0.01 par value - authorized 50,000,000 shares - 0 shares issued as of March 31, 2024 and December 31, 2023 Preferred Stock, Value, Issued Business Acquisition [Line Items] Business Acquisition [Line Items] Actual, Covenant [Member] Actual, Covenant [Member] Actual Covenant. Condensed Consolidated Balance Sheet (Parenthetical) [Abstract] Condensed Consolidated Balance Sheet (Parenthetical) [Abstract] Condensed Consolidated Balance Sheet (Parenthetical) [Abstract] Inventories Inventory, Net [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] MedSurg [Member] MedSurg [Member] MedSurg [Member] Payment of contingent consideration previously established in purchase accounting Payment for Contingent Consideration Liability, Financing Activities Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Net income (loss) per common share — diluted Earnings Per Share, Diluted Derivative Liability, Fair Value, Gross Liability Derivative Liability, Subject to Master Netting Arrangement, before Offset PEO Total Compensation Amount PEO Total Compensation Amount Hedging Relationship [Axis] Hedging Relationship [Axis] Treasury stock, at cost - 263,289,848 shares as of March 31, 2024 and December 31, 2023 Treasury Stock, Value Land Land Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Goodwill [Roll Forward] Goodwill [Roll Forward] 0.625% Senior Notes due 2027 Senior Note due 2027 [Member] Senior Note due 2027 [Member] Business Acquisition, Share Price Business Acquisition, Share Price Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Treasury Stock, Common, Shares Treasury Stock, Common, Shares Other income (expense): Other Nonoperating Income (Expense) [Abstract] Trading Symbol Trading Symbol Letters of Credit Outstanding, Amount Letters of Credit Outstanding, Amount Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Schedule of Other Current Assets Schedule of Other Current Assets [Table Text Block] Effective Income Tax Rate Reconciliation, Percent [Abstract] Effective Income Tax Rate Reconciliation, Percent [Abstract] Net Income (Loss) Net Income (Loss) Total current liabilities Liabilities, Current Derivative Contract [Domain] Derivative Contract [Domain] Schedule of Notional Amounts of Outstanding Derivative Positions Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Licensing arrangements Licensing arrangements Licensing arrangements Company Selected Measure Name Company Selected Measure Name Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Total debt Debt and Lease Obligation Cardiovascular [Member] Cardiovascular [Member] Cardiovascular [Member] Beginning Balance (Shares Issued) Ending Balance (Shares Issued) Shares, Issued LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Prepaid income taxes Prepaid Taxes Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Preferred stock issuance Stockholders' Equity, Period Increase (Decrease) Stockholders’ equity Equity, Attributable to Parent [Abstract] Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Contract with Customer, Liability Contract with Customer, Liability Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Other Intangible Assets [Member] Other Intangible Assets [Member] Cost of products sold Cost of Goods and Services Sold Cost of Goods and Services Sold Euro Denominated Factoring Arrangements [Member] Euro Denominated Factoring Arrangements [Member] Euro Denominated Factoring Arrangements [Member] Derivative, Remaining Maturity Derivative, Remaining Maturity Executive Category: Executive Category [Axis] Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Foreign Exchange Contract [Member] Foreign Exchange Contract [Member] Schedule of Weighted Average Number of Shares Schedule of Weighted Average Number of Shares [Table Text Block] Urology [Member] Global Urology and Pelvic Health Reporting Unit [Member] Global Urology and Pelvic Health Reporting Unit [Member] Jonathan Monson [Member] Jonathan Monson Peripheral Interventions [Member] Global Peripheral Interventions (PI) Reporting Unit [Member] Global Peripheral Interventions (PI) Reporting Unit [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Name Measure Name Patents [Member] Patents [Member] Name Forgone Recovery, Individual Name Goodwill Goodwill Beginning Balance Goodwill Ending Balance Goodwill Property, plant and equipment, net Property, Plant and Equipment [Table Text Block] Statement, Equity Components [Axis] Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Buildings and improvements Buildings and Improvements, Gross Hedging Relationship [Domain] Hedging Relationship [Domain] Daniel Brennan Rule Trading Arrangement, Common Stock [Member] Daniel Brennan Rule Trading Arrangement, Common Stock Disaggregation of Revenue [Abstract] Disaggregation of Revenue [Abstract] Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Comprehensive Income (Loss) Note [Text Block] Comprehensive Income (Loss) Note [Text Block] Local Phone Number Local Phone Number Trade accounts receivable Increase (Decrease) in Accounts Receivable Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax Covenant [Axis] Covenant [Axis] Covenant. Legal Costs, Policy [Policy Text Block] Legal Costs, Policy [Policy Text Block] Corporate expenses and currency exchange [Member] Corporate Expenses including hedging activities [Member] Corporate Expenses including hedging activities [Member] Derivative, Notional Amount Derivative, Notional Amount Measurement Frequency [Axis] Measurement Frequency [Axis] Operating Lease, Liability, Noncurrent Operating Lease, Liability, Noncurrent Restricted cash and restricted cash equivalents included in Other current assets Restricted Cash and Cash Equivalents in Other current assets Restricted Cash and Cash Equivalents, Current March 2028 Notes [Member] March 2028 Notes [Member] March 2028 Notes [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Depreciation Depreciation Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Interventional Cardiology Therapies Interventional Cardiology Therapies [Member] Interventional Cardiology Therapies Income Statement Location [Axis] Income Statement Location [Axis] Schedule of Long-term Debt Instruments Schedule of Long-Term Debt Instruments [Table Text Block] Jeffrey B. Mirviss Rule Trading Arrangement, Common Stock [Member] Jeffrey B. Mirviss Rule Trading Arrangement, Common Stock Changes to noncontrolling ownership interest Noncontrolling Interest, Period Increase (Decrease) Research and development expenses Research and Development Expense (Excluding Acquired in Process Cost) Litigation payment exclusion from EBITDA Litigation payment exclusion from EBITDA Litigation payment exclusion from EBITDA Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Exclusion from EBITDA for Restructuring Charges Exclusion from EBITDA for Restructuring Charges Exclusion from EBITDA for Restructuring Charges Net effect of common stock equivalents Weighted Average Number of Shares Outstanding, Diluted, Adjustment Foreign Exchange Forward Foreign Exchange Forward [Member] Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax Schedule of Business Acquisitions, by Acquisition Schedule of Business Acquisitions, by Acquisition [Table Text Block] Number Of Businesses Number Of Businesses Number Of Businesses Licensing arrangement liabilities [Member] Licensing arrangement liabilities [Member] Licensing arrangement liabilities [Member] Other Assets, Noncurrent [Abstract] Other Assets, Noncurrent [Abstract] Product and Service [Domain] Product and Service [Domain] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Inventories Increase (Decrease) in Inventories Cash used to net share settle employee equity awards Payment to net share settle employee equity awards Payment to net share settle employee equity awards Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Contract with Customer, Liability [Abstract] Contract with Customer, Liability [Abstract] contingent consideration liability, probability of payment contingent consideration liability, probability of payment contingent consideration liability, probability of payment Award Type Award Type [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Document Quarterly Report Document Quarterly Report Interest expense Interest Expense Interest Expense Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Hedging Designation [Axis] Hedging Designation [Axis] Property, plant and equipment Property, Plant and Equipment, Gross Payments for Royalties Payments for Royalties Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Stockholders' Equity Note [Abstract] Trading Arrangement: Trading Arrangement [Axis] Indemnification asset Indemnification asset Indemnification asset PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Covenant [Domain] Covenant [Domain] Covenant. Cardiology [Member] Global Cardiology Reporting Unit [Member] Global Cardiology Reporting Unit [Member] Derivative, Term of Contract (less than) Derivative, Term of Contract Schedule of Other Assets Schedule of Other Assets [Table Text Block] Amortization expense Amortization expense Amortization of Intangible Assets Entity Shell Company Entity Shell Company Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Average interest rate of de-recognized receivables Receivable with Imputed Interest, Effective Yield (Interest Rate) New Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option Class of Stock Disclosures [Abstract] Class of Stock Disclosures [Abstract] Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Segment Reporting, Revenue Reconciling Item [Line Items] Segment Reporting, Revenue Reconciling Item [Line Items] Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Finite-Lived Intangible Assets, Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Axonics Axonics [Member] Axonics Debt Instrument, Fair Value Disclosure Debt Instrument, Fair Value Disclosure Subsequent Events Subsequent Events, Policy [Policy Text Block] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] foreign currency denominated in debt [Member] foreign currency denominated in debt [Member] foreign currency denominated in debt [Member] Common Stock, Shares, Issued Beginning Balance (Shares) Ending Balance (Shares) Common Stock, Shares, Issued Gross profit Gross Profit Comprehensive income (loss) attributable to noncontrolling interests Other Comprehensive Income (Loss), before Tax, Portion Attributable to Noncontrolling Interest Security Exchange Name Security Exchange Name Assets, Fair Value Disclosure Assets, Fair Value Disclosure Long-term Debt Long-Term Debt Selling, general and administrative expenses Selling, General and Administrative Expense Accumulated other comprehensive income (loss), net of tax Accumulated Other Comprehensive Income (Loss), Net of Tax Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Share-based Payment Arrangement, Option Employee Stock Option [Member] Accumulated Foreign Currency Adjustment Attributable to Parent Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Beginning balance Ending balance SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Brazil CADE - # of individuals for alleged anti-competitive behavior Brazil CADE - # of individuals for alleged anti-competitive behavior Brazil CADE - # of individuals for alleged anti-competitive behavior Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Maximum [Member] Maximum [Member] Maximum [Member] Comprehensive income attributable to Boston Scientific common stockholders Comprehensive Income (Loss), Net of Tax, Attributable to Parent Property, plant and equipment, net Property, Plant and Equipment, Net [Abstract] June 2030 Notes [Member] June 2030 Notes [Member] June 2030 Notes Document Type Document Type Goodwill acquired Goodwill, Acquired During Period Tabular List, Table Tabular List [Table Text Block] EMEA [Member] EMEA [Member] Entity Address, Address Line One Entity Address, Address Line One Repurchase of common stock Treasury Stock, Value, Acquired, Cost Method Stock-based compensation (Shares) Stock Issued During Period, Shares, Period Increase (Decrease) Intangible Assets and Goodwill [Line Items] Intangible Assets and Goodwill [Line Items] [Line Items] for Schedule of Intangible Assets and Goodwill [Table] Daniel Brennan [Member] Daniel Brennan Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Restructuring charges remaining to be excluded from calculation of consolidated EBITDA Restructuring charges remaining to be excluded from calculation of consolidated EBITDA Restructuring charges remaining to be excluded from calculation of consolidated EBITDA. Other, Other Long-term Assets Other, Other Long-term Assets Other, Other Long-term Assets Taxes Payable, Current Taxes Payable, Current Business Acquisition [Axis] Business Acquisition [Axis] Less: allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current New Accounting Pronouncements New Accounting Pronouncements [Text Block] New Accounting Pronouncements Other current liabilities Other Liabilities, Current Other Liabilities, Current Preferred Stock, Convertible, Conversion Ratio Preferred Stock, Convertible, Conversion Ratio Accounts payable, accrued expenses and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Income Statement [Abstract] Income Statement [Abstract] Inventory, Raw Materials, Net of Reserves Inventory, Raw Materials, Net of Reserves Payments for royalty rights Payments for royalty rights Payments for royalty rights Title of 12(b) Security Title of 12(b) Security Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Goodwill, Gross Goodwill, Gross Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Neuromodulation [Member] Global Neuromodulation (NM) Reporting Unit [Member] Global Neuromodulation (NM) Reporting Unit [Member] Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax Trade accounts receivable, net Accounts and Financing Receivable, after Allowance for Credit Loss, Current [Abstract] ACQUISITIONS AND STRATEGIC INVESTMENTS Business Combination Disclosure [Text Block] Derivative Liability Derivative Liability Indefinite-lived Intangible Assets (Excluding Goodwill) Indefinite-Lived Intangible Assets (Excluding Goodwill) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Subsidiary, Ownership Percentage, Noncontrolling Owner Other Assets, Current Other Assets, Current Class of Stock [Line Items] Class of Stock [Line Items] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Trade accounts receivable, net Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Entity Tax Identification Number Entity Tax Identification Number Equity method investments Equity Method Investments Inventories Inventories Inventory, Net Renminbi Denominated Factoring Arrangements [Member] Renminbi Denominated Factoring Arrangements [Member] Renminbi Denominated Factoring Arrangements Range [Axis] Statistical Measurement [Axis] Jeffrey B. Mirviss [Member] Jeffrey B. Mirviss Financial Instrument [Axis] Financial Instrument [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Total Shareholder Return Amount Total Shareholder Return Amount Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Line Items] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Segment operating income as percentage of net sales Segment operating income as percentage of net sales Segment operating income as percentage of net sales Segments [Domain] Segment [Domain] Segments [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Discount Rate, Fair Value Input Discount Rate, Fair Value Input Discount Rate, Fair Value Input Retained earnings Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Goodwill [Member] Goodwill [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Accounts receivable Accounts Receivable, before Allowance for Credit Loss, Current Business Acquisition, Contingent Consideration [Line Items] Business Acquisition, Contingent Consideration [Line Items] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Entity [Abstract] Entity [Abstract] Entity [Abstract] Cash provided by (used for) operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] PEO PEO [Member] Other, net Other Operating Activities, Cash Flow Statement AOCI attributable to Boston Scientific common stockholders, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Derivative Asset, Fair Value, Gross Asset Derivative Asset, Subject to Master Netting Arrangement, before Offset Non-cash impact of transferred royalty rights Non-cash impact of transferred royalty rights Non-cash impact of transferred royalty rights Common Stock, Par or Stated Value Per Share Common Stock, Par or Stated Value Per Share Legal reserves, current Estimated Litigation Liability, Current Cash provided by (used for) investing activities Net Cash Provided by (Used in) Investing Activities Class of Stock [Domain] Class of Stock [Domain] Equity Securities, FV-NI Equity Securities, FV-NI, Current Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Inventory Disclosure Schedule of Inventory, Current [Table Text Block] Net income (loss) attributable to Boston Scientific common stockholders Net Income (Loss) Available to Common Stockholders, Basic Payments for investments and acquisitions of certain technologies, net of investment proceeds Proceeds from (payments for) investments and acquisitions of certain technologies Proceeds from (payments for) investments and acquisitions of certain technologies Debt Instrument [Axis] Debt Instrument [Axis] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective tax rate from continuing operations Effective Income Tax Rate Reconciliation, Percent Preferred stock issuance Conversion of Stock, Shares Converted Conversion of Stock, Shares Converted Credit Facility [Axis] Credit Facility [Axis] Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value Requirement, fifth quarter following qualified acquisition [Member] Requirement, fifth quarter following qualified acquisition [Member] Requirement, fifth quarter following qualified acquisition [Member] BASIS OF PRESENTATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Deferred and prepaid income taxes Cash flow impact of deferred income tax expense (benefit) Cash flow impact of deferred income tax expense (benefit) Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Accumulated other comprehensive income (loss), net of tax AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Charges to expenses SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] Impact of Foreign Currency Fluctuations on Net Sales Impact of Foreign Currency Fluctuations on Net Sales Impact of Foreign Currency Fluctuations on Net Sales Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Net Change in Defined Benefit Pensions and Other Items Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] BSX Reportable Segments [Member] BSX Reportable Segments [Member] BSX Reportable Segments [Member] Debt Instrument, Extension Option, Term Debt Instrument, Extension Option, Term Debt Instrument, Extension Option, Term Debt Disclosure [Abstract] Debt Disclosure [Abstract] Number of reportable segments Number of Reportable Segments Earnings Per Share [Abstract] Earnings Per Share [Abstract] November 2035 Notes [Member] November 2035 Notes [Member] November 2035 Notes [Member] Proceeds from long-term borrowings, net of debt issuance costs Proceeds from Issuance of Senior Long-Term Debt Proceeds from Issuance of Senior Long-Term Debt Decrease in Unrecognized Tax Benefits is Reasonably Possible Decrease in Unrecognized Tax Benefits is Reasonably Possible Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,733,293,885 shares as of March 31, 2024 and 1,729,000,224 shares as of December 31, 2023 Common Stock, Value, Issued Debt Instrument, Redemption Price, Percentage Debt Instrument, Redemption Price, Percentage Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Senior Notes [Member] Senior Notes [Member] Total current assets Assets, Current Preferred stock Preferred Stock [Member] Payments for finance leases Finance Lease, Principal Payments Business Combination, Contingent Consideration, Liability Beginning Balance Business Combination, Contingent Consideration, Liability Ending Balance Business Combination, Contingent Consideration, Liability Business Combination, Contingent Consideration, Liability All Business Acquisitions All Business Acquisitions [Member] All Business Acquisitions Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] Credit Rating A- or A3 Or Higher Credit Rating A- or A3 Or Higher [Member] Credit Rating A- or A3 Or Higher Supplemental Information Supplemental Cash Flow Information [Abstract] Other, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Supplemental Balance Sheet Information [Abstract] Supplemental Balance Sheet Information [Abstract] Supplemental Balance Sheet Information. Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] Requirement, seventh quarter following qualified acquisition Requirement, seventh quarter following qualified acquisition [Member] Requirement, seventh quarter following qualified acquisition Statement [Table] Statement [Table] Business Combination, Contingent Consideration, Liability, Noncurrent Business Combination, Contingent Consideration, Liability, Noncurrent Current Fiscal Year End Date Current Fiscal Year End Date Stock Repurchase Program, Authorized Amount Stock Repurchase Program, Authorized Amount Requirement, four succeeding quarters following qualified acquisition Requirement, four succeeding quarters following qualified acquisition [Member] Requirement, four succeeding quarters following qualified acquisition GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Unrecognized Tax Benefits Unrecognized Tax Benefits PEO Name PEO Name Other Other Sundry Liabilities, Current APAC [Member] Asia Pacific [Member] Changes in Other Comprehensive Income Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Preferred Stock, Shares Authorized Preferred Stock, Shares Authorized Investments Investments Investments Schedule of Goodwill Schedule of Goodwill [Table Text Block] Impact of foreign currency fluctuations and purchase price and other adjustments Goodwill, Translation and Purchase Accounting Adjustments Cash provided by (used for) operating activities Net Cash Provided by (Used in) Operating Activities Utilization of allowances SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Business Combination, Contingent Consideration, Liability, Current Business Combination, Contingent Consideration, Liability, Current Class of Stock [Axis] Class of Stock [Axis] Entities [Table] Entities [Table] Licensing arrangements, asset Licensing arrangements, asset Licensing arrangements, asset Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Cardiac Rhythm Management [Member] Cardiac Rhythm Management [Member] Cardiac Rhythm Management Other Other Accrued Liabilities, Current Depreciation and amortization Depreciation, Depletion and Amortization Litigation Settlement, Amount Awarded to Other Party Litigation Settlement, Amount Awarded to Other Party Other Operating Income (Expense), Net Other Operating Income (Expense), Net Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Information [Line Items] Entity Information [Line Items] Conditional Rating [Domain] Conditional Rating [Domain] Conditional Rating [Domain] Total stockholders’ equity Total stockholders’ equity Beginning Stockholders' Equity Ending Stockholders' Equity Equity, Attributable to Parent Business Combination, Contingent Consideration Arrangements [Abstract] Business Combination, Contingent Consideration Arrangements [Abstract] Commercial Paper [Member] Commercial Paper [Member] Unrecognized Tax Benefits that Would Impact Effective Tax Rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value Conditional Rating [Axis] Conditional Rating [Axis] Conditional Rating Forward Currency Contracts, Time to Maturity Forward Currency Contracts, Time to Maturity Forward Currency Contracts, Time to Maturity in Months Fair Value Measurement Inputs and Valuation Techniques Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Contract with Customer, Liability, Revenue Recognized Contract with Customer, Liability, Revenue Recognized March 2049 Notes [Member] March 2049 Notes [Member] March 2049 Notes [Member] March 2039 Notes [Member] March 2039 Notes [Member] March 2039 Notes [Member] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Net Change in Derivative Financial Instruments Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] March 2028 Senior Notes March 2028 Senior Notes [Member] March 2028 Senior Notes Long-term debt Long-term Debt and Capital Lease Obligations Long-Term Debt and Lease Obligation Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Measurement alternative investments(1, 2) Equity Securities without Readily Determinable Fair Value, Amount Fair Value Measurement, Policy [Policy Text Block] Fair Value Measurement, Policy [Policy Text Block] Not Designated as Hedging Instrument [Member] Not Designated as Hedging Instrument [Member] Preferred Stock, Shares Issued Preferred Stock, Shares Issued Preferred Stock, Shares Issued Operating Income Unallocated to Segment Operating Income Unallocated to Segment Operating Income Unallocated to Segment Hedging Designation [Domain] Hedging Designation [Domain] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Accounting Standards Update and Change in Accounting Principle [Abstract] Jeffrey B. Mirviss Rule Trading Arrangement, Stock Options [Member] Jeffrey B. Mirviss Rule Trading Arrangement, Stock Options Emerging Markets [Member] Emerging Markets [Member] Emerging Markets [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Equity Method Investment, Difference Between Carrying Amount and Underlying Equity Equity Method Investment, Difference Between Carrying Amount and Underlying Equity Net Investment Hedging [Member] Net Investment Hedging [Member] Entity Emerging Growth Company Entity Emerging Growth Company Requirement, as of December 31, 2021 and through remaining term of facility Requirement, as of December 31, 2021 and through remaining term of facility [Member] Requirement, as of December 31, 2021 and through remaining term of facility Other intangible assets, net Intangible Assets, Net (Excluding Goodwill) Other Noncurrent Assets [Member] Other Noncurrent Assets [Member] Impact of stock-based compensation plans Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture Operating Income Allocated to Reportable Segments Operating Income Allocated to Reportable Segments Operating Income Allocated to Reportable Segments Derivative Instruments, Gain (Loss) Derivative Instruments, Gain (Loss) [Table Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Document Fiscal Period Focus Document Fiscal Period Focus Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis] Antidilutive Securities [Axis] Title Trading Arrangement, Individual Title Stock-based compensation expense Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Weighted Average [Member] Weighted Average [Member] Requirement, sixth quarter following qualified acquisition Requirement, sixth quarter following qualified acquisition [Member] Requirement, sixth quarter following qualified acquisition Common Stock, par value $0.01 per share Common stock Common Stock [Member] Accrued income taxes Accrued Income Taxes, Noncurrent Net change in defined benefit pensions and other items Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Individual: Individual [Axis] Net proceeds from issuance of preferred stock in connection with public offering Proceeds from Issuance of Convertible Preferred Stock City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service [Axis] Product and Service [Axis] Weighted Average Number Of Shares Outstanding [Text Block] Earnings Per Share [Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Revenues from contracts with customers, disaggregated - performance measurement Revenues from contracts with customers, disaggregated - performance measurement Revenues from contracts with customers, disaggregated - performance measurement - measures used by CODM to make business decisions, excludes impact of foreign currency fluctuations Valuation Technique, Discounted Cash Flow [Member] Valuation Technique, Discounted Cash Flow [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Total equity Beginning Balance, Equity Ending Balance, Equity Equity, Including Portion Attributable to Noncontrolling Interest Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax Minimum [Member] Minimum [Member] Minimum [Member] Licensing arrangement assets [Member] Licensing arrangement assets [Member] Licensing arrangement assets [Member] Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block] Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block] Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Weighted-average shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Cash Cash Other comprehensive income (loss) Changes in other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Supplier Finance Program Obligation. current Supplier Finance Program, Obligation, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] ASSETS Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Financial and Nonfinancial Liabilities, Fair Value Disclosure Liabilities, Fair Value Disclosure Foreign Currency Transaction Gain (Loss), before Tax Gain (Loss), Foreign Currency Transaction, before Tax Schedule of Derivative Instruments in Statement of Financial Position, Fair Value Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Net income (loss) Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Cash provided by (used for) financing activities Net Cash Provided by (Used in) Financing Activities Deferred tax assets Deferred Income Tax Assets, Net COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Proceeds from royalty rights Payments for (Proceeds from) Other Investing Activities December 2027 Notes [Member] December 2027 Notes [Member] December 2027 Notes [Member] Business Acquisition, Percentage of Voting Interests Acquired Business Acquisition, Percentage of Voting Interests Acquired Retained earnings/(Accumulated deficit) Retained Earnings [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Reconciliation of Operating Profit (Loss) from Segments to Consolidated Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] TOTAL LIABILITIES AND EQUITY Liabilities and Equity Other long-term assets Other Assets, Noncurrent Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Ownership [Domain] Ownership [Domain] Operating Lease, Right-of-Use Asset Operating Lease, Right-of-Use Asset Net change in derivative financial instruments Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Net income (loss) per common share — basic Earnings Per Share, Basic Debt Instrument [Table] Schedule of Long-Term Debt Instruments [Table] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] March 2026 Notes [Member] March 2026 Notes [Member] March 2026 Notes [Member] Arrangement Duration Trading Arrangement Duration In Process Research and Development [Member] In Process Research and Development [Member] In Process Research and Development [Member] Yen Denominated Factoring Arrangements [Member] Yen Denominated Factoring Arrangements [Member] Yen denominated factoring arrangements. Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net (charges) credits, restructuring- and restructuring-related net (charges) credits, EU MDR implementation costs and litigation-related net (charges) credits Special Charges [Member] Intangible asset impairment charges, acquisition/divestiture-related net (charges) credits, restructuring- and restructuring-related net (charges) credits, EU MDR implementation costs and litigation-related net (charges) credits Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value SUPPLEMENTAL BALANCE SHEET INFORMATION Supplemental Balance Sheet Disclosures [Text Block] Restructuring net charges (credits) Restructuring Charges Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] June 2025 Notes [Member] June 2025 Notes [Member] June 2025 Notes Interest Expense [Member] Interest Expense [Member] Schedule of Business Acquisitions, by Acquisition [Table] Schedule Of Business Acquisitions By Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Combinations [Abstract] Business Combinations [Abstract] Technology-Based Intangible Assets [Member] Technology-Based Intangible Assets [Member] Termination Date Trading Arrangement Termination Date Derivative Instruments in Hedges, Assets, at Fair Value Derivative Instruments in Hedges, Assets, at Fair Value Common Stock, Shares Authorized Common Stock, Shares Authorized Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax March 2024 Notes [Member] March 2024 Notes [Member] March 2024 Notes [Member] Jonathan Monson Rule Trading Arrangement, Stock Options [Member] Jonathan Monson Rule Trading Arrangement, Stock Options Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets by Major Class [Axis] Indefinite-Lived Intangible Assets [Axis] Derivative Instrument [Axis] Derivative Instrument [Axis] Daniel Brennan Rule Trading Arrangement, Stock Options [Member] Daniel Brennan Rule Trading Arrangement, Stock Options All Trading Arrangements All Trading Arrangements [Member] Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Investment Investment Holdings, Schedule of Investments [Table Text Block] Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] All Adjustments to Compensation All Adjustments to Compensation [Member] Acotec Acotec [Member] Acotec Award Timing Disclosures [Line Items] March 2031 Notes March 2031 Notes [Member] March 2031 Notes Compensation Amount Outstanding Recovery Compensation Amount Royalty expense Royalty Expense Net loss (gain) on investments and notes receivable Gain (Loss) on Investments Other long-term liabilities Other Liabilities, Noncurrent [Abstract] Derivative Asset Derivative Asset Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Change in Contract with Customer, Liability [Abstract] Change in Contract with Customer, Liability [Abstract] Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract] Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract] Current debt obligations Debt, Current Debt, Current Other current assets Prepaid Expense and Other Assets, Current Electrophysiology [Member] Electrophysiology (EP) [Member] Electrophysiology (EP) Latin America and Canada [Member] Latin America and Canada [Member] Latin America and Canada [Member] Finance Lease Obligation Capital Lease Obligations [Member] Jonathan Monson Rule Trading Arrangement, Common Stock [Member] Jonathan Monson Rule Trading Arrangement, Common Stock Insider Trading Arrangements [Line Items] Deferred Revenue Deferred Revenue Net currency exchange gain (loss) Net currency exchange gain (loss) Net currency exchange gain (loss) Schedule of Intangible Assets and Goodwill Schedule of Intangible Assets and Goodwill [Table Text Block] Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Other Liabilities, Current [Abstract] Other Liabilities, Current [Abstract] Entity Registrant Name Entity Registrant Name Award Timing Method Award Timing Method [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Other assets Increase (Decrease) in Other Operating Assets Adjustment to Compensation, Amount Adjustment to Compensation Amount Proceeds from sale of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Michael F. Mahoney [Member] Michael F. Mahoney Cost of Sales [Member] Cost of Sales [Member] Contingent consideration net expense (benefit) Contingent consideration net expense (benefit) Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Noncontrolling interests Equity, Attributable to Noncontrolling Interest Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block] Summary of term loan and revolving credit facility agreement compliance with debt covenants. Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Adoption Date Trading Arrangement Adoption Date Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Preferred Stock, Dividend Rate, Percentage Preferred Stock, Dividend Rate, Percentage Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Reconciliation of Revenue from Segments to Consolidated [Table] Reconciliation of Revenue from Segments to Consolidated [Table] Michael F. Mahoney Rule Trading Arrangement, Common Stock [Member] Michael F. Mahoney Rule Trading Arrangement, Common Stock Treasury stock Treasury Stock, Common [Member] Entity Central Index Key Entity Central Index Key Accrual for legal matters that are probable and estimable Loss Contingency Accrual Transfer of Financial Assets Accounted for as Sales Transfer of Financial Assets Accounted for as Sales [Table Text Block] Maximum Leverage Ratio Maximum Leverage Ratio Maximum leverage ratio permitted by revolving credit facility agreement. Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Gross Income tax expense (benefit) Income Tax Expense (Benefit) International [Member] Non-US [Member] Inventory, Finished Goods, Net of Reserves Inventory, Finished Goods, Net of Reserves Designated as Hedging Instrument [Member] Designated as Hedging Instrument [Member] Endoscopy [Member] Global Endoscopy (Endo) Reporting Unit [Member] Global Endoscopy (Endo) Reporting Unit [Member] Payroll and related liabilities Employee-related Liabilities, Current Requirement, eighth quarter following qualified acquisition and through remaining term of facility Requirement, eighth quarter following qualified acquisition and through remaining term of facility [Member] Requirement, eighth quarter following qualified acquisition and through remaining term of facility Entity Listing, Par Value Per Share Entity Listing, Par Value Per Share Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Preferred stock dividends Dividends, Preferred Stock, Cash Proceeds from Royalties Received Proceeds from Royalties Received revenue-based payments [Member] revenue-based payments [Member] revenue-based payments [Member] Name Trading Arrangement, Individual Name (Income) loss amounts reclassified from accumulated other comprehensive income Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Net sales Revenue from Contract with Customer, Excluding Assessed Tax Revenue from Contract with Customer, Excluding Assessed Tax Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag March 2032 Euro Senior Notes March 2032 Euro Senior Notes [Member] March 2032 Euro Senior Notes Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Payments for acquisitions of businesses, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Payments to Acquire Businesses, Net of Cash Acquired Allowance for doubtful accounts SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Credit Facility [Domain] Credit Facility [Domain] Equipment, furniture and fixtures Equipment, furniture and fixtures Gross Equipment, furniture and fixtures Gross. Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Diluted Weighted average shares outstanding - diluted Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Total allocated to reportable segments [Member] Total allocated to reportable segments [Member] Total allocated to reportable segments [Member] Current Requirement [Member] Current Requirement [Member] Current Requirement. Interest Rate Contract [Member] Interest Rate Contract [Member] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Other long-term liabilities Other Noncurrent Liabilities [Table Text Block] Licensing arrangements, liability Licensing arrangements, liability Licensing arrangements, liability Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax Money Market Funds, at Carrying Value Money Market Funds, at Carrying Value Accrued Rebates, Current Accrued Rebates, Current Accrued Rebates, Current Operating expenses: Operating Expenses [Abstract] Jeffrey B. Mirviss Rule Trading Arrangement, Vesting of Performance Units And Restricted Units [Member] Jeffrey B. Mirviss Rule Trading Arrangement, Vesting of Performance Units And Restricted Units Revenue from Contract with Customer [Text Block] Revenue from Contract with Customer [Text Block] Purchases of property, plant and equipment and internal use software Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional paid-in capital Additional Paid in Capital, Common Stock March 2029 Notes [Member] March 2029 Notes [Member] March 2029 Notes [Member] Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Additional paid-in capital Additional Paid-in Capital [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] TOTAL ASSETS Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Uncapped Contingent Considertation Uncapped Contingent Considertation Uncapped Contingent Considertation United States UNITED STATES Fair Value, Measurements, Recurring [Member] Fair Value, Recurring [Member] Other Current Liabilities Other Current Liabilities [Table Text Block] Cash dividends paid on preferred stock Payments of Dividends Other long-term liabilities Other long-term liabilities Other Liabilities, Noncurrent Non-NEOs Non-NEOs [Member] Michael F. MahoneyRule Trading Arrangement, Stock Options [Member] Michael F. MahoneyRule Trading Arrangement, Stock Options Other Nonoperating Income (Expense) [Member] Other Nonoperating Income (Expense) [Member] 5.50% MCPS, Series A [Member] 5.50% MCPS, Series A [Member] 5.50% MCPS, Series A Cash Flow Hedging [Member] Cash Flow Hedging [Member] Operating expenses Operating Expenses Segment Reporting Segment Reporting Disclosure [Text Block] Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Other Comprehensive Income (Loss) Net of Tax, Period Change [Abstract] Other Comprehensive Income (Loss), Net of Tax, Period Change [Abstract] Non-PEO NEO Non-PEO NEO [Member] Derivative Instruments in Hedges, Liabilities, at Fair Value Derivative Instruments in Hedges, Liabilities, at Fair Value Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Inventory, Work in Process, Net of Reserves Inventory, Work in Process, Net of Reserves Trade accounts receivable, net Trade accounts receivable, net Accounts and Financing Receivable, after Allowance for Credit Loss, Current Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Basic Weighted average shares outstanding — basic Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract] Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract] Operating income (loss) Operating income (loss) Operating Income (Loss) January 2040 Notes [Member] January 2040 Notes [Member] January 2040 Notes [Member] March 2025 Notes March 2025 Notes [Member] March 2025 Notes Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement, Business Segments [Axis] Segments [Axis] Segments [Axis] Statement [Line Items] Statement [Line Items] Vance R. Brown [Member] Vance R. Brown March 2029 Euro Senior Notes March 2029 Euro Senior Notes [Member] March 2029 Euro Senior Notes Other comprehensive income (loss), net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] March 2034 Notes March 2034 Notes [Member] March 2034 Notes Customer Relationships Customer Relationships [Member] Noncontrolling interests Noncontrolling Interest [Member] Schedule of Effective Income Tax Rate from Continuing Operations Schedule of Effective Income Tax Rate from Continuing Operations [Table Text Block] Schedule of Effective Income Tax Rate from Continuing Operations [Table Text Block] EX-101.PRE 15 bsx-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 16 image_0a.jpg begin 644 image_0a.jpg MB5!.1PT*&@H -24A$4@ =4 !]" 8 #T@?G 7-21T( KLX< MZ0 1G04U! "QCPO\804 )<$A9

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end GRAPHIC 17 image_1.jpg begin 644 image_1.jpg MB5!.1PT*&@H -24A$4@ !K8 &*" 8 !)BG$E "7!(67, $SE M !,Y0%USO"5 *5DE$051XG.W! 0$ ""(/^O;DA 0 M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M 8 "_!E1A &P%:>H $E%3D2N0F"" end GRAPHIC 18 image_2.jpg begin 644 image_2.jpg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image_0.jpg begin 644 image_0.jpg MB5!.1PT*&@H -24A$4@ =4 !]" 8 #T@?G 7-21T( KLX< MZ0 1G04U! "QCPO\804 )<$A9

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end XML 21 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover Document - $ / shares
3 Months Ended
Mar. 31, 2024
Apr. 29, 2024
Entity Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2024  
Document Transition Report false  
Entity File Number 1-11083  
Entity Registrant Name BOSTON SCIENTIFIC CORPORATION  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 04-2695240  
Entity Address, Address Line One 300 Boston Scientific Way  
Entity Address, City or Town Marlborough  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 01752-1234  
City Area Code 508  
Local Phone Number 683-4000  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Listing, Par Value Per Share $ 0.01  
Entity Common Stock, Shares Outstanding   1,470,179,843
Entity Central Index Key 0000885725  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Common Stock, par value $0.01 per share    
Entity Information [Line Items]    
Title of 12(b) Security Common Stock, par value $0.01 per share  
Trading Symbol BSX  
Security Exchange Name NYSE  
0.625% Senior Notes due 2027    
Entity Information [Line Items]    
Title of 12(b) Security 0.625% Senior Notes due 2027  
Trading Symbol BSX27  
Security Exchange Name NYSE  

XML 22 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Net sales $ 3,856 $ 3,389
Cost of products sold 1,209 1,040
Gross profit 2,648 2,349
Operating expenses:    
Selling, general and administrative expenses 1,364 1,215
Research and development expenses 366 337
Royalty expense 10 11
Amortization expense 214 203
Contingent consideration net expense (benefit) 17 12
Restructuring net charges (credits) 3 20
Operating expenses 1,973 1,797
Operating income (loss) 675 552
Other income (expense):    
Interest expense (69) (65)
Other, net 2 (43)
Income (loss) before income taxes 608 444
Income tax expense (benefit) 115 131
Net income (loss) 493 314
Preferred stock dividends 0 (14)
Net income (loss) attributable to noncontrolling interests (1) 0
Net income (loss) attributable to Boston Scientific common stockholders $ 495 $ 300
Net income (loss) per common share — basic $ 0.34 $ 0.21
Net income (loss) per common share — diluted $ 0.33 $ 0.21
Weighted-average shares outstanding    
Basic 1,468.4 1,435.8
Diluted 1,481.7 1,446.0
XML 23 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Comprehensive Income (Loss) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Statement of Comprehensive Income [Abstract]    
Net income (loss) $ 493 $ 314
Other comprehensive income (loss), net of tax:    
Foreign currency translation adjustment 57 (42)
Net change in derivative financial instruments 22 (43)
Net change in defined benefit pensions and other items 0 (5)
Other comprehensive income (loss) 78 (91)
Comprehensive income (loss) 572 223
Comprehensive income (loss) attributable to noncontrolling interests (6) 0
Comprehensive income attributable to Boston Scientific common stockholders $ 578 $ 223
XML 24 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 2,329 $ 865
Trade accounts receivable, net 2,304 2,228
Inventories 2,561 2,484
Prepaid income taxes 319 315
Other current assets 671 621
Total current assets 8,185 6,514
Property, plant and equipment, net 2,897 2,859
Goodwill 14,361 14,387
Other intangible assets, net 5,839 6,003
Deferred tax assets 3,792 3,841
Other long-term assets 1,596 1,531
TOTAL ASSETS 36,669 35,136
Current liabilities:    
Current debt obligations 1,085 531
Accounts payable 921 942
Accrued expenses 2,083 2,646
Other current liabilities 827 814
Total current liabilities 4,916 4,933
Long-term debt 9,534 8,571
Deferred income taxes 132 134
Other long-term liabilities 1,919 1,967
Commitments and contingencies
Stockholders’ equity    
Preferred stock, $0.01 par value - authorized 50,000,000 shares - 0 shares issued as of March 31, 2024 and December 31, 2023 0 0
Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,733,293,885 shares as of March 31, 2024 and 1,729,000,224 shares as of December 31, 2023 17 17
Treasury stock, at cost - 263,289,848 shares as of March 31, 2024 and December 31, 2023 (2,251) (2,251)
Additional paid-in capital 20,713 20,647
Retained earnings 1,314 819
Accumulated other comprehensive income (loss), net of tax 132 49
Total stockholders’ equity 19,926 19,282
Noncontrolling interests 242 248
Total equity 20,168 19,530
TOTAL LIABILITIES AND EQUITY $ 36,669 $ 35,136
Preferred Stock, Shares Issued 0 0
XML 25 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2024
Dec. 31, 2023
Condensed Consolidated Balance Sheet (Parenthetical) [Abstract]    
Preferred Stock, Par or Stated Value Per Share $ 0.01 $ 0.01
Preferred Stock, Shares Authorized 50,000,000 50,000,000
Preferred Stock, Shares Issued 0 0
Common Stock, Par or Stated Value Per Share $ 0.01 $ 0.01
Common Stock, Shares Authorized 2,000,000,000 2,000,000,000
Common Stock, Shares, Issued   1,729,000,224
Treasury Stock, Common, Shares 263,289,848 263,289,848
XML 26 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Millions
Total
Preferred stock
Common stock
Treasury stock
Additional paid-in capital
Retained earnings/(Accumulated deficit)
Accumulated other comprehensive income (loss), net of tax
Noncontrolling interests
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Total stockholders’ equity             $ 269  
Beginning Balance (Shares Issued) at Dec. 31, 2022   10,062,500            
Beginning Balance (Shares) at Dec. 31, 2022     1,696,633,993          
Beginning Balance, Equity at Dec. 31, 2022   $ 0 $ 17 $ (2,251) $ 20,289 $ (750) 269 $ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Stock-based compensation (Shares)     4,194,880          
Preferred stock issuance   $ 0            
Repurchase of common stock       0        
Impact of stock-based compensation plans     $ 0   68      
Net income (loss) $ 314         314    
Preferred stock dividends           (14)    
Preferred stock issuance   0            
Net income (loss) attributable to noncontrolling interests 0         0   0
Changes in other comprehensive income (loss) (91)           (91) 0
Changes to noncontrolling ownership interest               259
Ending Balance (Shares Issued) at Mar. 31, 2023   10,062,500            
Ending Balance (Shares) at Mar. 31, 2023     1,700,828,873          
Ending Balance, Equity at Mar. 31, 2023 18,109 $ 0 $ 17 (2,251) 20,356 (450) 178 259
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Total stockholders’ equity 17,850           178  
Total stockholders’ equity $ 19,282           49  
Beginning Balance (Shares Issued) at Dec. 31, 2023   0            
Beginning Balance (Shares) at Dec. 31, 2023 1,729,000,224   1,729,000,224          
Beginning Balance, Equity at Dec. 31, 2023 $ 19,530 $ 0 $ 17 (2,251) 20,647 819 49 248
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Stock-based compensation (Shares)     4,293,661          
Preferred stock issuance   $ 0            
Repurchase of common stock       0        
Impact of stock-based compensation plans     $ 0   66      
Net income (loss) 493         493    
Preferred stock dividends           0    
Preferred stock issuance   0            
Net income (loss) attributable to noncontrolling interests 1         1   (1)
Changes in other comprehensive income (loss) 78           83 (5)
Changes to noncontrolling ownership interest               0
Ending Balance (Shares Issued) at Mar. 31, 2024   0            
Ending Balance (Shares) at Mar. 31, 2024     1,733,293,885          
Ending Balance, Equity at Mar. 31, 2024 20,168 $ 0 $ 17 $ (2,251) $ 20,713 $ 1,314 132 $ 242
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Total stockholders’ equity $ 19,926           $ 132  
XML 27 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash provided by (used for) operating activities    
Net income (loss) $ 493 $ 314
Depreciation and amortization 304 285
Deferred and prepaid income taxes 31 19
Stock-based compensation expense 63 55
Net loss (gain) on investments and notes receivable 2 31
Contingent consideration net expense (benefit) 17 12
Other, net (4) (2)
Trade accounts receivable (114) (86)
Inventories (124) (185)
Other assets (55) (41)
Accounts payable, accrued expenses and other liabilities (450) (211)
Cash provided by (used for) operating activities 164 190
Investing activities:    
Purchases of property, plant and equipment and internal use software (179) (111)
Proceeds from sale of property, plant and equipment 1 3
Payments for acquisitions of businesses, net of cash acquired (47) (375)
Payments for investments and acquisitions of certain technologies, net of investment proceeds (66) (10)
Proceeds from royalty rights 7 9
Cash provided by (used for) investing activities (285) (484)
Financing activities:    
Payment of contingent consideration previously established in purchase accounting (34) (34)
Payments for royalty rights (15) (34)
Payments for finance leases (25) 0
Payments on short-term borrowings (504) 0
Proceeds from long-term borrowings, net of debt issuance costs 2,145 0
Cash dividends paid on preferred stock 0 (14)
Cash used to net share settle employee equity awards (78) (50)
Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans 80 63
Cash provided by (used for) financing activities 1,569 (69)
Effect of foreign exchange rates on cash (7) 0
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents 1,441 (363)
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period 1,055 1,126
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period 2,496 763
Supplemental Information    
Stock-based compensation expense 63 55
Non-cash impact of transferred royalty rights (7) (9)
Cash and cash equivalents 2,329 570
Restricted cash and restricted cash equivalents included in Other current assets 93 135
Restricted cash equivalents included in Other long-term assets 74 57
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period $ 2,496 $ 763
XML 28 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Basis of Presentation
3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BASIS OF PRESENTATION
NOTE A – BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements of Boston Scientific Corporation have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and with the instructions to Form 10-Q and Article 10 of Regulation S-X, and they do not include all of the information and footnotes required by GAAP for complete financial statements. When used in this report, the terms, "we," "us," "our," and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for fair presentation have been included. Operating results for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. Accordingly, our unaudited consolidated financial statements and footnotes thereto should be read in conjunction with our audited consolidated financial statements and footnotes thereto included in Item 8 of our most recent Annual Report on Form 10-K.

The accompanying unaudited consolidated financial statements include the accounts of the Company's wholly owned- subsidiaries and entities for which the Company has a controlling financial interest. All intercompany balances and transactions have been eliminated in consolidation.

Amounts reported in millions within this Quarterly Report on Form 10-Q are computed based on the amounts in thousands. As a result, the sum of the components may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.
Subsequent Events
We evaluate events occurring after the date of our accompanying unaudited consolidated balance sheet for potential recognition or disclosure within our financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly.
Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note H – Commitments and Contingencies for further details.
XML 29 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Acquisitions, Divestitures and Strategic Investments
3 Months Ended
Mar. 31, 2024
Business Combinations [Abstract]  
ACQUISITIONS AND STRATEGIC INVESTMENTS
NOTE B – ACQUISITIONS AND STRATEGIC INVESTMENTS

Our accompanying unaudited consolidated financial statements include the operating results for acquired entities from the respective dates of acquisition. We have not presented supplemental pro forma financial information for completed acquisitions or divestitures given their results are not material to our accompanying unaudited consolidated financial statements. Further, transaction costs were immaterial to our accompanying unaudited consolidated financial statements and were expensed as incurred.

On January 8, 2024, we announced our entry into a definitive agreement to acquire 100 percent of Axonics, Inc. (Axonics), a publicly traded medical technology company primarily focused on the development and commercialization of devices to treat urinary and bowel dysfunction. The purchase price is $71.00 in cash per share, or approximately $3.670 billion for 100% of the fully diluted equity. On April 3, 2024, we and Axonics each received a request for additional information (Second Request) from the United States Federal Trade Commission (FTC) in connection with the FTC's review of the transaction. The issuance of the Second Request extends the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR Act), until 30 days after both we and Axonics have substantially complied with the Second Request, unless the waiting period is extended voluntarily by the parties or terminated earlier by the FTC. We and Axonics expect to promptly respond to the Second Request and to continue to work cooperatively with the FTC in its review. The transaction is expected to be completed in the second half of 2024, subject to the expiration or termination of the waiting period under the HSR Act and the satisfaction (or waiver) of other customary closing conditions. The Axonics business will be integrated into our Urology division.

2023 Acquisition

On February 20, 2023, we completed the acquisition of a majority stake investment in Acotec Scientific Holdings Limited (Acotec), a publicly traded Chinese manufacturer of drug-coated balloons and other products used in the treatment of vascular and other diseases. We consolidated this majority stake investment in Acotec based on the conclusion we control the entity, and
recorded a noncontrolling interest for the portion we do not own. We acquired approximately 65 percent of the outstanding shares of Acotec, for an upfront cash payment of HK$20.00 per share, or $519 million at foreign currency exchange rates at closing. The Acotec portfolio complements our existing Peripheral Interventions portfolio.

Purchase Price Allocation

We accounted for our majority stake investment in Acotec as a business combination in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 805, Business Combinations (FASB ASC Topic 805). The final purchase price was comprised of the amount presented below:

(in millions)
Acotec(1)
Payment for majority stake investment$381 
$381 
(1) Excludes approximately $140 million of cash on hand at the closing of the transaction

We recorded the assets acquired, liabilities assumed and the noncontrolling interest at their respective fair values as of the closing date of the transaction. The final purchase price allocation was comprised of the components presented below, with the excess of the purchase price over the fair value of net assets acquired recorded to goodwill:

(in millions)Acotec
Goodwill$337 
Amortizable intangible assets334 
Other assets acquired93 
Liabilities assumed(48)
Net deferred tax liabilities(76)
Fair value of noncontrolling interest(259)
$381 

The fair value of Acotec's noncontrolling interest was based on the publicly traded market value of the remaining 35 percent of the outstanding shares we did not acquire as of the transaction date and is presented in Stockholders' equity within our accompanying unaudited consolidated balance sheets. Goodwill was primarily established for Acotec due to opportunities for collaboration in research and development, manufacturing and commercial strategies and was not deductible for tax purposes.

We allocated a portion of the purchase price to the specific intangible asset categories as follows:

Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
Technology-related$308 1114%
Customer relationships15 1114%
Other intangible assets11 1314%
$334 
Contingent Consideration
Changes in the fair value of our contingent consideration liability during the first quarter of 2024 associated with prior period acquisitions were as follows:

(in millions)
Balance as of December 31, 2023$404 
Contingent consideration net expense (benefit)17 
Contingent consideration payments and other adjustments(148)
Balance as of March 31, 2024$273 

The payments made during the first quarter of 2024 primarily related to our acquisition of Farapulse, Inc (Farapulse) following the achievement of revenue-based earnouts as a result of over-performance. The maximum amount we could be required to pay for certain contingent consideration is not determinable as it is uncapped and based on a percent of certain sales. As of March 31, 2024, the fair value of such uncapped contingent consideration is estimated at $164 million. As of March 31, 2024, the maximum amount that we could be required to pay under our other contingent consideration arrangements (undiscounted) is approximately $275 million. Refer to Note B – Acquisitions and Strategic Investments to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for additional information.

The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:
Contingent Consideration LiabilityFair Value as of March 31, 2024Valuation TechniqueUnobservable InputRange
Weighted Average(1)
Revenue-based Payments and Milestones$273 millionDiscounted Cash FlowDiscount Rate6%-11%6%
Probability of Payment100%100%
Projected Year of Payment2024-20272025
(1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

Projected contingent payment amounts related to our revenue-based payments and milestones are discounted back to the current period, primarily using a discounted cash flow model. Significant increases or decreases in projected revenues, probabilities of payment, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement as of March 31, 2024.

Strategic Investments

The aggregate carrying amount of our strategic investments was comprised of the following:

As of
(in millions)March 31, 2024December 31, 2023
Equity method investments$211 $219 
Measurement alternative investments(1, 2)
218 194 
$429 $413 
(1) Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in Other, net within our accompanying unaudited consolidated statements of operations.
(2) Includes publicly-held securities and convertible notes measured at fair value with changes in fair value recognized in Other, net within our accompanying unaudited consolidated statements of operations.

These investments are classified as Other long-term assets within our accompanying unaudited consolidated balance sheets, in accordance with GAAP and our accounting policies.
As of March 31, 2024, the cost of our aggregated equity method investments exceeded our share of the underlying equity in net assets by $237 million, which represents amortizable intangible assets, in-process research and development (IPR&D), goodwill and deferred tax liabilities.
XML 30 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Goodwill and Other Intangible Assets
3 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS
NOTE C – GOODWILL AND OTHER INTANGIBLE ASSETS

The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows:
As of March 31, 2024As of December 31, 2023
(in millions)Gross Carrying AmountAccumulated Amortization/ Write-offsGross Carrying AmountAccumulated Amortization/ Write-offs
Technology-related$13,223 $(8,287)$13,207 $(8,101)
Patents480 (385)480 (387)
Other intangible assets2,159 (1,527)2,130 (1,500)
Amortizable intangible assets$15,863 $(10,198)$15,817 $(9,988)
    
Goodwill$24,261 $(9,900)$24,287 $(9,900)
IPR&D$54 $54 
Technology-related120 120 
Indefinite-lived intangible assets$174 $174 

The following represents a roll-forward of our goodwill balance by reportable segment:
(in millions)MedSurgCardiovascularTotal
As of December 31, 2023$5,347 $9,041 $14,387 
Goodwill acquired24 — 24 
Impact of foreign currency fluctuations and purchase price and other adjustments(29)(22)(51)
As of March 31, 2024$5,342 $9,019 $14,361 

Goodwill and Other Intangible Asset Impairments
We did not record any goodwill or intangible asset impairment charges in the first quarter of 2024 or 2023. Refer to Note A – Significant Accounting Policies to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for further discussion of our annual goodwill and intangible asset impairment testing.
XML 31 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Hedging Activities and Fair Value Measurements
3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS
NOTE D – HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS

Derivative Instruments and Hedging Activities

We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative and nonderivative financial instruments. We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.

Currency Hedging Instruments

Risk Management Strategy

Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities; forecasted intercompany and third-party transactions; and net investments in certain subsidiaries. We manage currency exchange rate risk at a consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative and nonderivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates.

The success of our currency risk management program depends, in part, on forecasted transactions denominated primarily in euro, Chinese renminbi, Japanese yen, British pound sterling, Australian dollar and Swiss franc. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecasted. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.

Hedge Designations and Relationships

Certain of our currency derivative instruments are designated as cash flow hedges under FASB ASC Topic 815, Derivatives and Hedging (FASB ASC Topic 815), and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in the Net change in derivative financial instruments component of Other comprehensive income (loss), net of tax (OCI) within our unaudited consolidated statements of comprehensive income (loss) until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, we recognize the gain or loss in earnings within Cost of products sold within our unaudited consolidated statements of operations. In the event the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the gains or losses within Accumulated other comprehensive income (loss), net of tax (AOCI) to earnings at that time. The cash flows related to the derivative instruments designated as cash flow hedges are reported as operating activities within our unaudited consolidated statements of cash flows.

We also designate certain forward currency contracts as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Chinese renminbi and Japanese yen. For these derivative instruments, we elected to use the spot method to assess hedge effectiveness. We also elected to exclude the spot-forward difference, referred to as the excluded component, from the assessment of hedge effectiveness and are amortizing this amount separately, as calculated at the date of designation, on a straight-line basis over the term of the currency forward contracts. As such, we defer recognition of foreign currency gains and losses within the Foreign currency translation adjustment (CTA) component of OCI, and we reclassify amortization of the excluded component from AOCI to current period earnings within Interest expense within our unaudited consolidated statements of operations.

We designate certain euro-denominated debt as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the euro. As of March 31, 2024 and December 31, 2023, we designated as a net investment hedge our €900 million in aggregate principal amount of 0.625% senior notes issued in November 2019 and due in 2027 (2027 Notes). For these nonderivative instruments, we defer recognition of the foreign currency remeasurement gains and losses within the CTA component of OCI. We reclassify these gains and losses to current period earnings within Other, net within our accompanying unaudited consolidated statements of operations only when the hedged item affects earnings, which would occur upon disposal or substantial liquidation of the underlying foreign subsidiary.
We also use forward currency contracts that are not part of designated hedging relationships as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings within Other, net within our accompanying unaudited consolidated statements of operations.

Interest Rate Hedging Instruments

Risk Management Strategy

Our interest rate risk relates primarily to U.S. dollar and euro-denominated borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to mitigate the risk to our earnings and cash flows associated with exposure to changes in interest rates. Under these agreements, we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges in accordance with FASB ASC Topic 815.

Hedge Designations and Relationships

We had no interest rate derivative instruments designated as cash flow hedges outstanding as of March 31, 2024 or December 31, 2023. In the event that we designate outstanding interest rate derivative instruments as cash flow hedges, we record the changes in the fair value of the derivatives within OCI until the underlying hedged transaction occurs.

We had no interest rate derivative instruments designated as fair value hedges outstanding as of March 31, 2024 or December 31, 2023. In the event that we designate outstanding interest rate derivative instruments as fair value hedges, we record the changes in the fair values of interest-rate derivatives designated as fair value hedges and of the underlying hedged debt instruments in Interest expense, which generally offset.

The following table presents the contractual amounts of our hedging instruments outstanding:
(in millions)FASB ASC Topic 815 DesignationAs of
March 31, 2024December 31, 2023
Forward currency contractsCash flow hedge$2,242 $2,284 
Forward currency contractsNet investment hedge645 333 
Foreign currency-denominated debt(1)
Net investment hedge997 997 
Forward currency contractsNon-designated3,070 3,282 
Total Notional Outstanding$6,954 $6,896 
(1) Foreign currency-denominated debt is the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge.

The remaining time to maturity as of March 31, 2024 is within 36 months for all forward currency contracts designated as cash flow hedges and generally less than one year for all non-designated forward currency contracts. The forward currency contracts designated as net investment hedges generally mature between one and two years. The euro-denominated debt principal designated as a net investment hedge has a contractual maturity of December 1, 2027.

The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 within our accompanying unaudited consolidated statements of operations. Refer to Note M – Changes in Other Comprehensive Income for the total amounts relating to derivative and nonderivative instruments presented within our accompanying unaudited consolidated statements of comprehensive income (loss).
Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Three Months Ended March 31, 2024
Forward currency contracts
Cash flow hedges$76 $(17)$59 Cost of products sold$1,209 $(49)$11 $(38)
Net investment hedges(2)
27 (6)21 Interest expense69 (4)(3)
Foreign currency-denominated debt
Net investment hedges(3)
23 (5)18 Other, net(2)— — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest expense69 (0)

Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Three Months Ended March 31, 2023
Forward currency contracts
Cash flow hedges$13 $(3)$10 Cost of products sold$1,040 $(69)$16 $(54)
Net investment hedges(2)
(1)Interest expense65 (3)(2)
Foreign currency-denominated debt
Net investment hedges(3)
(19)(14)Other, net43 — — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest Expense65 — 
(1) In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from AOCI to earnings represent the effect of the hedging relationships on earnings.
(2) For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from AOCI to earnings as a reduction of Interest expense represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior periods, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.
(3) For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the CTA component of OCI. No amounts were reclassified from AOCI to current period earnings.

As of March 31, 2024, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below (in millions):
FASB ASC Topic 815 DesignationLocation on Unaudited Consolidated Statements of OperationsAmount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings
Designated Hedging Instrument
Forward currency contractsCash flow hedgeCost of products sold$173 
Forward currency contractsNet investment hedgeInterest expense15 
Interest rate derivative contractsCash flow hedgeInterest expense(1)
Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:
Location on Unaudited Consolidated Statements of OperationsThree Months Ended March 31,
(in millions)20242023
Net gain (loss) on currency hedge contractsOther, net$15 $(8)
Net gain (loss) on currency transaction exposuresOther, net(20)(6)
Net currency exchange gain (loss)$(5)$(14)

Fair Value Measurements

FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures (FASB ASC Topic 820), and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative and nonderivative assets and liabilities:

 
Location on Unaudited Consolidated Balance Sheets(1)
As of
(in millions)March 31, 2024December 31, 2023
Derivative and Nonderivative Assets:   
Designated Hedging Instruments  
Forward currency contractsOther current assets$160 $140 
Forward currency contractsOther long-term assets125 107 
  285 246 
Non-Designated Hedging Instruments   
Forward currency contractsOther current assets17 20 
Total Derivative and Nonderivative Assets $302 $266 
Derivative and Nonderivative Liabilities:   
Designated Hedging Instruments  
Forward currency contractsOther current liabilities$$15 
Forward currency contractsOther long-term liabilities
Foreign currency-denominated debt(2)
Long-term debt966 988 
  969 1,012 
Non-Designated Hedging Instruments   
Forward currency contractsOther current liabilities17 38 
Total Derivative and Nonderivative Liabilities $986 $1,050 
(1) We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.
(2) Foreign currency-denominated debt is the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.
Recurring Fair Value Measurements
On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
Level 1 – Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
Level 2 – Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
Level 3 – Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
Assets and liabilities measured at fair value on a recurring basis consist of the following:
As of
 March 31, 2024December 31, 2023
(in millions)Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets        
Money market funds and time deposits$1,979 $— $— $1,979 $454 $— $— $454 
Publicly-held equity securities20 — — 20 18 — — 18 
Hedging instruments— 302 — 302 — 266 — 266 
Licensing arrangements— — 66 66 — — 77 77 
 $1,999 $302 $66 $2,367 $472 $266 $77 $816 
Liabilities        
Hedging instruments$— $986 $— $986 $— $1,050 $— $1,050 
Contingent consideration liability— — 273 273 — — 404 404 
Licensing arrangements— — 71 71 — — 90 90 
 $ $986 $344 $1,330 $ $1,050 $494 $1,545 

Our investments in money market funds and time deposits are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as Cash and cash equivalents or Other current assets within our accompanying unaudited consolidated balance sheets, in accordance with GAAP and our accounting policies. In addition to $1.979 billion invested in money market funds and time deposits as of March 31, 2024 and $454 million as of December 31, 2023, we held $384 million in interest-bearing and non-interest-bearing bank accounts as of March 31, 2024 and $411 million as of December 31, 2023.

Our recurring fair value measurements using Level 3 inputs include those related to our contingent consideration liability. Refer to Note B – Acquisitions and Strategic Investments for a discussion of the changes in the fair value of our contingent consideration liability. In addition, our recurring fair value measurements using Level 3 inputs related to our licensing arrangements, including the contractual right to receive future royalty payments related to the Zytiga™ Drug. We maintain a financial asset and associated liability for our licensing arrangements measured at fair value within our unaudited consolidated balance sheets in accordance with FASB ASC Topic 825, Financial Instruments. We elected the fair value option to measure the financial asset and associated liability as it provides for consistency and comparability of these financial instruments with others. Refer to Note D – Hedging Activities and Fair Value Measurements to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for additional information.

The recurring Level 3 fair value measurements of our licensing arrangements recognized within our accompanying unaudited consolidated balance sheets as of March 31, 2024 include the following significant unobservable inputs:
Licensing ArrangementsFair Value as of March 31, 2024Valuation TechniqueUnobservable InputRange
Weighted Average (1)
Financial Asset$66 millionDiscounted Cash FlowDiscount Rate15%15%
Projected Year of Payment2024-20252025
Financial Liability$71 millionDiscounted Cash FlowDiscount Rate12 %-15%13%
Projected Year of Payment2024-20262025
(1) Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

Changes in the fair value of our licensing arrangements' financial asset were as follows:
(in millions)
Balance as of December 31, 2023$77 
Proceeds from royalty rights(14)
Fair value adjustment (expense) benefit
Balance as of March 31, 2024$66 

Changes in the fair value of our licensing arrangements' financial liability were as follows:
(in millions)
Balance as of December 31, 2023$90 
Payments for royalty rights(22)
Fair value adjustment expense (benefit)
Balance as of March 31, 2024$71 

Non-Recurring Fair Value Measurements

We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B – Acquisitions and Strategic Investments for a discussion of our strategic investments and Note C – Goodwill and Other Intangible Assets for a discussion of the fair values of our intangible assets including goodwill.

The fair value of our outstanding debt obligations, excluding finance leases, was $10.224 billion as of March 31, 2024 and $8.735 billion as of December 31, 2023. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, and face value for commercial paper, term loans and credit facility borrowings outstanding. Refer to Note E – Contractual Obligations and Commitments for a discussion of our debt obligations.
XML 32 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Contractual Obligations and Commitments
3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
CONTRACTUAL OBLIGATIONS AND COMMITMENTS
NOTE E – CONTRACTUAL OBLIGATIONS AND COMMITMENTS

Borrowings and Credit Arrangements

We had total debt outstanding of $10.619 billion as of March 31, 2024 and $9.102 billion as of December 31, 2023, with current obligations of $1.085 billion as of March 31, 2024 and $531 million as of December 31, 2023. The debt maturity schedule for our long-term debt obligations is presented below:
(in millions, except interest rates)Issuance DateMaturity DateAs of
Coupon Rate(1)
March 31,
2024
December 31,
2023
March 2025 Senior Notes(3)
March 2022March 2025— 1,105 0.750%
June 2025 Senior NotesMay 2020June 2025500 500 1.900%
March 2026 Senior NotesFebruary 2019March 2026255 255 3.750%
December 2027 Senior Notes(3)
November 2019December 2027972 995 0.625%
March 2028 Senior Notes(3)
March 2022March 2028810 829 1.375%
March 2028 Senior NotesFebruary 2018March 2028344 344 4.000%
March 2029 Senior NotesFebruary 2019March 2029272 272 4.000%
March 2029 Senior Notes(3)
February 2024March 2029810 — 3.375%
June 2030 Senior NotesMay 2020June 20301,200 1,200 2.650%
March 2031 Senior Notes(3)
March 2022March 2031810 829 1.625%
March 2032 Senior Notes(3)
February 2024March 20321,349 — 3.500%
March 2034 Senior Notes(3)
March 2022March 2034540 553 1.875%
November 2035 Senior Notes(2)
November 2005November 2035350 350 6.500%
March 2039 Senior NotesFebruary 2019March 2039450 450 4.550%
January 2040 Senior NotesDecember 2009January 2040300 300 7.375%
March 2049 Senior NotesFebruary 2019March 2049650 650 4.700%
Unamortized Debt Issuance Discount and Deferred Financing Costs2024 - 2049(81)(65)
Finance Lease ObligationVarious
Long-term debt$9,534 $8,571 
(1) Coupon rates are semi-annual, except for the euro-denominated notes, which bear an annual coupon.
(2) Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate of 6.25% if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher.
(3) These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of March 31, 2024 and December 31, 2023, respectively.

Revolving Credit Facility

On May 10, 2021, we entered into a $2.750 billion revolving credit facility (2021 Revolving Credit Facility) with a global syndicate of commercial banks, initially scheduled to mature on May 10, 2026, with one-year extension options, subject to certain conditions. On March 1, 2023, we entered into an amendment of the 2021 Revolving Credit Facility credit agreement, which provided for an extension of the scheduled maturity date to May 10, 2027 and replaced the London Interbank Offered Rate (LIBOR) with the Secured Overnight Financing Rate (SOFR) as the Eurocurrency Rate for Dollars, including applicable credit spread adjustments and relevant SOFR benchmark provisions, among other things described under Financial Covenant below. This facility provides backing for our commercial paper program, and outstanding commercial paper directly reduces borrowing capacity under the 2021 Revolving Credit Facility. We had no amounts outstanding under the 2021 Revolving Credit Facility as of March 31, 2024 or December 31, 2023.
Financial Covenant

As of March 31, 2024, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility.
Covenant RequirementActual
 as of March 31, 2024as of March 31, 2024
Maximum permitted leverage ratio(1)
3.75 times2.08 times
(1) Ratio of total debt to deemed consolidated Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), as defined by the 2021 Revolving Credit Facility credit agreement, as amended.

The 2021 Revolving Credit Facility includes the financial covenant requirement for all of our credit arrangements that we maintain the maximum permitted leverage ratio of 3.75 times for the remaining term. The credit agreement provides for higher leverage ratios, at our election, for the period following a Qualified Acquisition, as defined by the agreement, for which consideration exceeds $1.000 billion. In the event of such an acquisition, for the four succeeding quarters immediately following, including the quarter in which the acquisition occurs, the maximum permitted leverage ratio is 4.75 times. It steps down for the fifth, sixth and seventh succeeding quarters to 4.50 times, 4.25 times and 4.00 times, respectively. Thereafter, a maximum leverage ratio of 3.75 times is required through the remaining term of the 2021 Revolving Credit Facility. We have elected to designate the Axonics acquisition as a Qualified Acquisition under the credit agreement, and upon closing, will increase the maximum permitted leverage ratio at that time. The agreement also provides for an exclusion of any debt incurred to fund a Qualified Acquisition, until the earlier of the acquisition close date or date of abandonment, termination or expiration of the acquisition agreement. As of March 31, 2024, we excluded $2.138 billion of debt incurred from our leverage ratio calculation in connection with the Axonics acquisition.

The financial covenant requirement, as amended on March 1, 2023, provides for an exclusion from the calculation of consolidated EBITDA, as defined by the credit agreement, through maturity, of certain charges and expenses. The credit agreement amendment reset the starting date for purposes of calculating such permitted exclusions in each case from March 31, 2021 to December 31, 2022. Permitted exclusions include any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of March 31, 2024, we had $273 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the agreement, are excluded from the calculation of consolidated EBITDA, as defined by the agreement, provided that the sum of any excluded net cash litigation payments do not exceed $1.000 billion plus all accrued legal liabilities as of December 31, 2022. As of March 31, 2024, we had $1.457 billion of the litigation exclusion remaining.

Any inability to maintain compliance with this covenant could require us to seek to renegotiate the terms of our credit arrangements or seek waivers from compliance with this covenant, both of which could result in additional borrowing costs. Further, there can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us. In this case, all 2021 Revolving Credit Facility commitments would terminate, and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our 2021 Revolving Credit Facility may negatively impact the credit ratings assigned to our commercial paper program, which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable.

Commercial Paper

Our commercial paper program is backed by the 2021 Revolving Credit Facility. We did not have any commercial paper outstanding as of March 31, 2024 and December 31, 2023.

Senior Notes

We had senior notes outstanding of $10.690 billion as of March 31, 2024 and $9.136 billion as of December 31, 2023. Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to liabilities of our subsidiaries (refer to Other Arrangements below).

In February 2024, American Medical Systems Europe B.V. (AMS Europe), an indirect, wholly owned subsidiary of Boston Scientific, completed a registered public offering (the Offering) of €2.000 billion in aggregate principal amount of euro-denominated senior notes comprised of €750 million of 3.375% Senior Notes due 2029 and €1.250 billion of 3.500% Senior Notes due 2032 (collectively, the 2024 Eurobonds). Boston Scientific has fully and unconditionally guaranteed all of AMS Europe's obligations under the 2024 Eurobonds, and no other subsidiary of Boston Scientific will guarantee these obligations.
AMS Europe is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of Regulation S-X. The financial condition, results of operations and cash flows of AMS Europe are consolidated in the financial statements of Boston Scientific. The Offering resulted in cash proceeds of $2.145 billion, net of investor discounts and issuance costs.

We used the net proceeds from the Offering of the 2024 Eurobonds to fund the repayment at maturity of our 3.450% Senior Notes due March 2024 and to pay accrued and unpaid interest with respect to such notes. Additionally, we plan to use the remaining net proceeds from the Offering to fund a portion of the purchase price of the Axonics acquisition and to pay related fees and expenses, and for general corporate purposes. The transaction is expected to be completed in the second half of 2024, subject to the expiration or termination of the waiting period under the HSR Act and the satisfaction (or waiver) of other customary closing conditions. If (i) the Axonics acquisition is not consummated on or before the later of (x) January 8, 2025 (as such date may be extended in accordance with the merger agreement to no later than January 8, 2026) and (y) the date that is five business days after any later date to which we and Axonics may agree to extend the "Outside Date" in the merger agreement or (ii) AMS Europe notifies the trustee that we will not pursue consummation of the Axonics Acquisition, AMS Europe will be required to redeem each series of the notes at a special mandatory redemption price equal to 101% of the aggregate principal amount of such series of notes, plus accrued and unpaid interest, if any, to, but excluding, the date on which the notes will be redeemed. Refer to Note B – Acquisitions and Strategic Investments for more information on the Axonics acquisition.

Other Arrangements

We have accounts receivable factoring programs in certain European countries and with commercial banks in China and Japan which include promissory notes discounting programs. We account for our factoring programs as sales under FASB ASC Topic 860. We have no retained interest in the transferred receivables, other than collection and administration, and once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. Amounts de-recognized for accounts and notes receivable, which are excluded from Trade accounts receivable, net within our accompanying unaudited consolidated balance sheets, are aggregated by contract denominated currency below (in millions):
Factoring ArrangementsAs of March 31, 2024As of December 31, 2023
Amount
De-recognized
Weighted Average
Interest Rate
Amount
De-recognized
Weighted Average
Interest Rate
Euro denominated$175 5.5 %$206 5.1 %
Yen denominated191 0.6 %214 0.6 %
Renminbi denominated
21 1.8 %14 2.9 %

Other Contractual Obligations and Commitments

We had outstanding letters of credit of $174 million as of March 31, 2024 and December 31, 2023, which consisted primarily of bank guarantees and collateral for workers' compensation insurance arrangements. As of March 31, 2024 and December 31, 2023 we had not recognized a related liability for our outstanding letters of credit within our accompanying unaudited consolidated balance sheets.

We have a supplier financing program offered primarily in the U.S. that enables our suppliers to opt to receive early payment at a nominal discount, while allowing us to lengthen our payment terms and optimize working capital. Our standard payment term in the U.S. is 90 days. All outstanding payables related to the supplier finance program are classified within Accounts Payable within our unaudited consolidated balance sheets and were $140 million as of March 31, 2024 and $152 million as of December 31, 2023.

Refer to Note E – Contractual Obligations and Commitments to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for additional information on our borrowings and credit agreements.
XML 33 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Supplemental Balance Sheet Information
3 Months Ended
Mar. 31, 2024
Supplemental Balance Sheet Information [Abstract]  
SUPPLEMENTAL BALANCE SHEET INFORMATION
NOTE F – SUPPLEMENTAL BALANCE SHEET INFORMATION

Components of selected captions within our accompanying unaudited consolidated balance sheets are as follows:

Trade accounts receivable, net
 As of
(in millions)March 31, 2024December 31, 2023
Trade accounts receivable$2,413 $2,338 
Allowance for credit losses(109)(110)
 $2,304 $2,228 

The following is a roll forward of our Allowance for credit losses:
Three Months Ended March 31,
(in millions)20242023
Beginning balance$110 $109 
Credit loss expense16 
Write-offs(10)(6)
Ending balance$109 $118 

Inventories
 As of
(in millions)March 31, 2024December 31, 2023
Finished goods$1,555 $1,537 
Work-in-process188 174 
Raw materials818 773 
 $2,561 $2,484 
Other current assets
 As of
(in millions)March 31, 2024December 31, 2023
Restricted cash and restricted cash equivalents$93 $130 
Derivative assets177 159 
Licensing arrangements44 47 
Other357 285 
 $671 $621 
Property, plant and equipment, net
 As of
(in millions)March 31, 2024December 31, 2023
Land$141 $140 
Buildings and improvements1,856 1,843 
Equipment, furniture and fixtures3,550 3,503 
Capital in progress880 857 
 6,427 6,343 
Less: accumulated depreciation3,530 3,484 
 $2,897 $2,859 

Depreciation expense was $90 million for the first quarter of 2024 and $82 million for the first quarter of 2023.

Other long-term assets

 As of
(in millions)March 31, 2024December 31, 2023
Restricted cash equivalents$74 $60 
Operating lease right-of-use assets430 439 
Derivative assets125 107 
Investments429 413 
Licensing arrangements22 30 
Indemnification asset175 176 
Other341 306 
 $1,596 $1,531 
Accrued expenses
 As of
(in millions)March 31, 2024December 31, 2023
Legal reserves$129 $206 
Payroll and related liabilities749 1,051 
Rebates384 389 
Contingent consideration182 304 
Other639 696 
 $2,083 $2,646 

Other current liabilities
 As of
(in millions)March 31, 2024December 31, 2023
Deferred revenue$280 $266 
Licensing arrangements45 49 
Taxes payable257 220 
Other246 278 
 $827 $814 
Other long-term liabilities
 As of
(in millions)March 31, 2024December 31, 2023
Accrued income taxes$466 $470 
Legal reserves154 172 
Contingent consideration90 100 
Licensing arrangements26 41 
Operating lease liabilities382 390 
Deferred revenue314 311 
Other486 484 
 $1,919 $1,967 
XML 34 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes
3 Months Ended
Mar. 31, 2024
Income Tax Disclosure [Abstract]  
INCOME TAXES
NOTE G – INCOME TAXES

Our effective tax rate from continuing operations is presented below:
Three Months Ended March 31,
20242023
Effective tax rate from continuing operations18.9 %29.4 %

Our reported tax rate is affected by recurring items such as the amount of our earnings subject to differing tax rates in foreign jurisdictions and the impact of certain receipts and charges that are taxed at rates that differ from our effective tax rate.

The principal reason for the difference between the statutory rate and our reported tax rate in the first quarter of 2024 primarily relates to certain charges for acquisition expenses as well as certain discrete benefits related to unrecognized tax benefits and stock-based compensation. In the first quarter of 2023, the primary difference between the statutory tax rate and our reported tax rate relates to certain discrete charges related to provision-to-return adjustments.

As of March 31, 2024, we had $465 million of gross unrecognized tax benefits, of which a net $393 million, if recognized, would affect our effective tax rate. As of December 31, 2023, we had $467 million of gross unrecognized tax benefits, of which a net $395 million, if recognized, would affect our effective tax rate. The change in our gross unrecognized tax benefit is primarily related to current year activity and audit activities.

It is reasonably possible that within the next 12 months, we will resolve multiple issues with foreign, federal and state taxing authorities, resulting in a reduction in our balance of unrecognized tax benefits of up to $11 million.
XML 35 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES
NOTE H – COMMITMENTS AND CONTINGENCIES

The medical device market in which we participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These dynamics frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies.

During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters; however, there continues to be outstanding litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.

In addition, product liability, securities and commercial claims have been asserted against us and similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.

In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity. For additional information, refer to Note I – Commitments and Contingencies to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K.

In accordance with FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related net charges (credits) within our accompanying unaudited consolidated financial statements. All other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses within our accompanying unaudited consolidated statements of operations.

Our accrual for legal matters that are probable and estimable was $283 million as of March 31, 2024 and $377 million as of December 31, 2023 and includes certain estimated costs of settlement, damages and defense primarily related to product liability cases or claims related to our transvaginal surgical mesh products. A portion of this accrual is already funded through our qualified settlement fund, which is included in restricted cash and restricted cash equivalents in Other current assets of $93 million as of March 31, 2024 and $130 million as of December 31, 2023. Refer to Note F – Supplemental Balance Sheet Information for additional information. We did not record any litigation-related net charges during the first quarter of 2024 or 2023.

We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our financial covenant.

In management's opinion, we are not currently involved in any legal proceedings other than those disclosed in our most recent Annual Report on Form 10-K and those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or
otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be reasonably estimated.

Patent Litigation

On November 20, 2017, The Board of Regents, University of Texas System and TissueGen. Inc. (collectively, UT), served a lawsuit against us in the Western District of Texas. The complaint against the Company alleges patent infringement of two U.S. patents owned by UT, relating to “Drug Releasing Biodegradable Fiber Implant” and “Drug Releasing Biodegradable Fiber for Delivery of Therapeutics,” and affects the manufacture, use and sale of our Synergy™ Stent System. UT primarily seeks a reasonable royalty. On March 12, 2018, the District Court for the Western District of Texas dismissed the action and transferred it to the United States District Court for the District of Delaware. On September 5, 2019, the Court of Appeals for the Federal Circuit affirmed the dismissal of the District Court for the Western District of Texas. In April 2020, the United States Supreme Court denied the UT’s Petition for Certiorari. UT proceeded with its case against the Company in Delaware. In January 2023, a jury trial was held on the issue of whether the one UT patent still asserted in the case was valid and whether it was infringed by the Company. On January 31, 2023, a jury concluded that UT’s patent was valid and willfully infringed by the Company, and awarded UT $42 million in damages. Following the trial, UT has filed a motion seeking prejudgment interest and enhanced damages. The Company has filed a motion seeking judgment as a matter of law in its favor or alternatively a new trial.

Product Liability Litigation

Multiple product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us, predominantly in the United States, Canada, the United Kingdom, Scotland, Ireland, and Australia. Plaintiffs generally seek monetary damages based on allegations of personal injury associated with the use of our transvaginal surgical mesh products, including design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. We have entered into individual and master settlement agreements or are in the final stages of entering agreements with certain plaintiffs' counsel, to resolve the majority of these cases and claims. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing. In addition, in April 2021 the Company's Board of Directors received a shareholder demand under section 220 of the Delaware General Corporation Law, for inspection of books and records related to mesh settlements. The Company has notified our insurer and retained counsel to respond to the demand.

We have established a product liability accrual for remaining claims asserted against us associated with our transvaginal surgical mesh products and the costs of defense thereof. We continue to engage in discussions with plaintiffs’ counsel regarding potential resolution of pending cases and claims, which we continue to vigorously contest. The final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Trials involving our transvaginal surgical mesh products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products.

Governmental Investigations and Qui Tam Matters

On December 1, 2015, the Brazilian governmental entity known as CADE (the Administrative Council of Economic Defense), served a search warrant on the offices of our Brazilian subsidiary, as well as on the Brazilian offices of several other major medical device makers who do business in Brazil, in furtherance of an investigation into alleged anti-competitive activity with respect to certain tender offers for government contracts. On June 20, 2017, CADE, through the publication of a “technical note,” announced that it was launching a formal administrative proceeding against Boston Scientific’s Brazilian subsidiary, Boston Scientific do Brasil Ltda. (BSB), as well as against the Brazilian operations of Medtronic, Biotronik and St. Jude Medical, two Brazilian associations, ABIMED and AMBIMO and 29 individuals for alleged anti-competitive behavior. Under applicable guidance, BSB could be fined a percentage of BSB’s 2016 gross revenues. In August 2021, the investigating commissioner issued a preliminary recommendation of liability against all of the involved companies, and also recommended that CADE impose fines and penalties. However, on October 25, 2021, the CADE Attorney General's office recommended dismissal of the charges and allegations against BSB and the individual BSB employees who were still individual defendants. Subsequently, on March 30, 2022, the Federal Prosecutor’s office issued a non-binding recommendation that is contrary to the Attorney General’s recommendation. The full Commission is considering both of these recommendations but has not yet issued its decision. We continue to deny the allegations, intend to defend ourselves vigorously and will appeal any decision of liability by the full Commission to the Brazilian courts. During such an appeal, the decision would have no force and effect, and the Court would consider the case without being bound by CADE’s decision.
In March 2022, the Company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam. The Company has received related subpoenas for documents from the Office of the U.S. Attorney for the District of Massachusetts and the Securities and Exchange Commission. The Company is cooperating with government agencies while investigating these allegations.

On April 5, 2023, the Company received a subpoena from the U.S. Department of Justice (DOJ) that seeks documents and information relating to its ambulatory electrocardiography monitoring (AECG) business. The Company is cooperating with the DOJ in responding to this subpoena.

On December 18, 2023, the Company received a Civil Investigative Demand from the DOJ that relates to the provision of peripheral intervention services through office-based labs. The Company is cooperating with the DOJ in responding to the subpoena.

Other Proceedings

On December 4, 2020, Enrique Jevons, individually and on behalf of all others similarly situated, filed a class action complaint against the Company, Michael F. Mahoney and Daniel J. Brennan, stemming from the recall and retirement of the LOTUS Edge™ Aortic Valve System (LOTUS System) in United States District Court for the Eastern District of New York. On December 14, 2020, the parties agreed to transfer the case to the United States District Court for the District of Massachusetts. On December 16, 2020, Mariano Errichiello, individually and on behalf of all others similarly situated, filed a second, materially similar class action complaint against the Company, Michael F. Mahoney, Joseph M. Fitzgerald, and Daniel J. Brennan in the United States District Court for the District of Massachusetts. Subsequently, on March 30, 2021, the Court consolidated the two actions, and appointed Union Asset Management Holding AG as the lead plaintiff. The plaintiffs filed an Amended Complaint in June 2021 that seeks unspecified compensatory damages in favor of the alleged class as well as unspecified equitable relief. The Company filed a Motion to Dismiss in July 2021, which, in December 2022, the Court granted in part and denied in part. On October 23, 2023, the Company reached an agreement in principle with the lead plaintiff to settle the case. The Court granted the motion for preliminary approval of the proposed settlement on December 27, 2023, and approved the settlement at a hearing on April 23, 2024.

On December 15, 2020, the Securities and Exchange Commission’s Boston Regional Office (Boston SEC) notified the Company that it was conducting an investigation related to the Company’s decision to retire the LOTUS System and issued a voluntary request for documents and information related to that decision. On February 10, 2021, the Boston SEC issued a second voluntary request for additional documents and information. The Company cooperated fully with the requests, and on January 3, 2022, the SEC informed us that it was concluding its investigation and that it did not intend to recommend an enforcement action.

On February 8, 2021, the Company received a letter from The Vladimir Gusinsky Revocable Trust, a shareholder, demanding that the Company’s Board of Directors conduct an investigation into actions by the Company’s directors and executive officers regarding statements made about the effectiveness and commercial viability of the LOTUS System. The Trust subsequently agreed to stay its demand, pending the outcome of any dispositive motion against the Amended Complaint in the class action complaint described above. The Company received letters on behalf of the Union Excavators Local 731 Pension Fund, Diane Nachbaur, and Frank Tripson, three stockholders of the Company, on July 26, 2021, July 29, 2021, and February 13, 2023, respectively, each demanding access to certain books and records of the Company, pursuant to Section 220 of the Delaware General Corporation Law, regarding the business, operations, effectiveness and commercial viability of the LOTUS system, and related items. On April 7, 2023, Diane Nachbaur filed a shareholder derivative complaint in the United States District Court for the District of Massachusetts against the Company, Michael F. Mahoney, Nelda J. Connors, Charles J. Dockendorff, Yoshiaki Fujimori, Donna A. James, Edward J. Ludwig, David Roux, John E. Sununu, Ellen M. Zane, Joseph M. Fitzgerald, Daniel J. Brennan, Shawn McCarthy, Ian Meredith, Kevin Ballinger, and Susan Vissers Lisa. On May 8, 2023, the Court stayed the case until the conclusion of the consolidated class action case. On October 18, 2023, Frank Tripson filed a shareholder derivative complaint in the Court of Chancery of the State of Delaware against the Company, Michael F. Mahoney, Daniel J. Brennan, Joseph M. Fitzgerald, Shawn McCarthy, Kevin Ballinger, Ian Meredith, Susan Vissers Lisa, Nelda J. Connors, Charles J. Dockendorff, Yoshiaki Fujimori, Donna A. James, Edward J. Ludwig, Stephen P. MacMillan, David Roux, John E. Sununu, and Ellen M. Zane. On December 15, 2023, the Court stayed that case until March 31, 2024. On March 26, 2024, the Company reached an agreement in principle with all of the plaintiffs to resolve the matters.
XML 36 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stockholders' Equity
3 Months Ended
Mar. 31, 2024
Stockholders' Equity Note [Abstract]  
STOCKHOLDERS' EQUITY
NOTE I – STOCKHOLDERS' EQUITY

Preferred Stock

We are authorized to issue 50 million shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating, option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by our stockholders.

On May 27, 2020, we completed an offering of 10,062,500 shares of 5.50% Mandatory Convertible Preferred Stock, Series A (MCPS) at a price to the public and liquidation preference of $100 per share. The net proceeds from the MCPS offering were approximately $975 million after deducting underwriting discounts and commissions and offering expenses.

On June 1, 2023, (the Mandatory Conversion Date), all outstanding shares of MCPS automatically converted into shares of common stock. The conversion rate for each share of MCPS was 2.3834 shares of common stock. No action by the holders of the MCPS was required in connection with the mandatory conversion. Cash was paid in lieu of fractional shares in accordance with the terms of the MCPS. An aggregate of approximately 24 million shares of common stock, including shares of common stock issued to holders of MCPS that elected to convert prior to the Mandatory Conversion Date, were issued upon conversion of the MCPS. Following the mandatory conversion of the MCPS, there were no outstanding shares of MCPS.

Refer to Note J – Stockholders' Equity to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for information on the pertinent rights and privileges of our outstanding common stock.
XML 37 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Weighted Average Shares Outstanding
3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Weighted Average Number Of Shares Outstanding [Text Block]
NOTE J – WEIGHTED AVERAGE SHARES OUTSTANDING

Three Months Ended March 31,
(in millions)20242023
Weighted average shares outstanding — basic1,468.4 1,435.8 
Net effect of common stock equivalents13.4 10.2 
Weighted average shares outstanding - diluted1,481.7 1,446.0 

The following securities were excluded from the calculation of weighted average shares outstanding - diluted because their effect in the periods presented below would have been antidilutive:
Three Months Ended March 31,
(in millions)20242023
Stock options outstanding(1)
23
MCPS(2)
24
(1)    Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.
(2)    Represents common stock issuable upon the conversion of MCPS. Refer to Note I – Stockholders' Equity for additional information.

We base Net income (loss) per common share - diluted upon the weighted-average number of common shares and common stock equivalents outstanding during each year. Potential common stock equivalents are determined using the treasury stock method. We exclude stock options, stock awards and, prior to the Mandatory Conversion Date, our MCPS, from the calculation if the effect would be anti-dilutive. The dilutive effect of MCPS is calculated using the if-converted method. The if-converted method assumes that these securities were converted to shares of common stock at the beginning of the reporting period to the extent that the effect is dilutive.
For the first quarter of 2023, the effect of assuming the conversion of MCPS into shares of common stock was anti-dilutive, and therefore excluded from the calculation of earnings per share (EPS). Accordingly, Net income (loss) was reduced by cumulative Preferred stock dividends, as presented within our accompanying unaudited consolidated statements of operations, for purposes of calculating Net income attributable to Boston Scientific common stockholders. On June 1, 2023, all outstanding shares of MCPS automatically converted into shares of common stock.

We issued approximately four million shares of our common stock in the first quarter of 2024 and 2023 following the exercise of stock options, vesting of restricted stock units or purchases under our employee stock purchase plan. We did not repurchase any shares of our common stock in the first quarter of 2024 or 2023. On December 14, 2020, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock. As of March 31, 2024, we had the full amount remaining available under the authorization.
XML 38 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Reporting
3 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
Segment Reporting
NOTE K – SEGMENT REPORTING

We aggregate our core businesses into two reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices. In accordance with FASB ASC Topic 280, Segment Reporting, we identified our reportable segments based on the nature of our products, production processes, type of customer, selling and distribution methods and regulatory environment, as well as the economic characteristics of each of our operating segments.

We measure and evaluate our reportable segments based on their respective net sales, operating income, excluding intersegment profits, and operating income as a percentage of net sales, all based on internally-derived standard currency exchange rates to exclude the impact of foreign currency, which may be updated from year to year. We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker (CODM) considers to be non-operational, such as amounts related to amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), and certain litigation-related net charges (credits) and European Union (EU) Medical Device Regulation (MDR) implementation costs. Although we exclude these amounts from operating income of reportable segments, they are included in reported Income (loss) before income taxes within our accompanying unaudited consolidated statements of operations and are included in the reconciliation below. Refer to Note L – Revenue for net sales by reportable segment presented in accordance with GAAP.
A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying unaudited consolidated statements of operations is as follows (in millions, except percentages). Prior period amounts have been restated at constant currency to conform to current year presentation.

Three Months Ended
March 31,
Net Sales20242023
MedSurg$1,402 $1,266
Cardiovascular2,426 2,072
Total net sales of reportable segments3,827 3,337
Impact of foreign currency fluctuations29 52
$3,856 $3,389
Income (loss) before income taxes
MedSurg$474 $409
Cardiovascular653 553
Total operating income of reportable segments1,128 963
Unallocated amounts:
Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments(115)(98)
Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs(124)(110)
Amortization expense(214)(203)
Operating income (loss)675 552
Other income (expense), net(67)(108)
Income (loss) before income taxes$608 $444

Three Months Ended March 31,
Operating income margin of reportable segments20242023
MedSurg33.8 %32.3 %
Cardiovascular26.9 %26.7 %
XML 39 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue
3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
Revenue from Contract with Customer [Text Block]
NOTE L – REVENUE

We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes within our accompanying unaudited consolidated statements of operations. Our business structure is organized into five operating segments. The following tables disaggregate our revenue from contracts with customers by business unit and geographic region (in millions). Generally, we allocate revenue from contracts with customers to geographic regions based on the location where the sale originated.

Three Months Ended March 31,
20242023
BusinessesU.S.Int'lTotalU.S.Int'lTotal
Endoscopy$395 $247 $642 $351 $226 $577 
Urology356 157 513 326 143 469 
Neuromodulation190 66 256 172 62 234 
MedSurg941 470 1,412 850 430 1,280 
   Interventional Cardiology Therapies195 457 652 183 408 591 
   Watchman311 33 344 265 25 291 
   Cardiac Rhythm Management354 221 575 345 203 548 
    Electrophysiology158 143 300 85 91 177 
Cardiology1,017 854 1,872 879 727 1,606 
Peripheral Interventions299 274 573 275 229 503 
Cardiovascular1,316 1,129 2,445 1,154 956 2,110 
Total Net Sales$2,258 $1,599 $3,856 $2,003 $1,386 $3,389 


Refer to Note K - Segment Reporting for information on our reportable segments.

Three Months Ended March 31,
Geographic Regions20242023
U.S.$2,258 $2,003 
Europe, Middle East and Africa803 712 
Asia-Pacific647 548 
Latin America and Canada149 126 
Total Net Sales$3,856 $3,389 
Emerging Markets(1)
$648 $529 
(1) Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2023, modified our list to include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada.

Deferred Revenue

Contract liabilities are classified within Other current liabilities and Other long-term liabilities within our accompanying unaudited consolidated balance sheets. Our deferred revenue balance was $593 million as of March 31, 2024 and $577 million as of December 31, 2023. Our contract liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System within our Cardiology business, for which revenue is recognized over the average service period based on device and patient longevity. Our contract liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor system, also within our Cardiology business, for which revenue is recognized over the average service period based on device longevity and usage. We recognized revenue of $62 million in the first quarter that was included in the above contract liability balance as of December 31, 2023. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.
Variable Consideration
For additional information on variable consideration, refer to Note A – Significant Accounting Policies to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K.
XML 40 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Changes in Other Comprehensive Income
3 Months Ended
Mar. 31, 2024
Other Comprehensive Income (Loss), Net of Tax, Period Change [Abstract]  
Comprehensive Income (Loss) Note [Text Block]
NOTE M – CHANGES IN OTHER COMPREHENSIVE INCOME

The following tables provide the reclassifications out of Other comprehensive income (loss), net of tax attributable to Boston Scientific common stockholders:
(in millions)Foreign Currency Translation AdjustmentsNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2023$(96)$154 $(8)$49 
Other comprehensive income (loss) before reclassifications65 59 — 124 
(Income) loss amounts reclassified from accumulated other comprehensive income(3)(38)(0)(41)
Total other comprehensive income (loss)62 22 (0)83 
Balance as of March 31, 2024$(34)$175 $(8)$132 

(in millions)Foreign Currency Translation AdjustmentsNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2022$(1)$269 $1 $269 
Other comprehensive income (loss) before reclassifications(40)10 (5)(35)
(Income) loss amounts reclassified from accumulated other comprehensive income(2)(53)(0)(56)
Total other comprehensive income (loss)(42)(43)(5)(91)
Balance as of March 31, 2023$(43)$225 $(4)$178 

Refer to Note D – Hedging Activities and Fair Value Measurements for further detail on our net investment hedges recorded in Foreign currency translation adjustment and our cash flow hedges recorded in Net change in derivative financial instruments.
XML 41 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
New Accounting Pronouncements
3 Months Ended
Mar. 31, 2024
Accounting Standards Update and Change in Accounting Principle [Abstract]  
New Accounting Pronouncements
NOTE N – NEW ACCOUNTING PRONOUNCEMENTS

Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our accompanying unaudited consolidated financial statements. During the first quarter of 2024, we implemented the following standard on a prospective basis, which did not have a material impact on our unaudited consolidated financial statements:

ASC Update No. 2022-03

ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities.
Standards to be Implemented

In November 2023, the FASB issued ASC Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. Update No. 2023-07 requires disclosure, on an annual and interim basis, of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss in addition to disclosure of amounts for other segment items and a description of its composition. Update No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. As this accounting standard update only impacts disclosures, we do not expect the adoption to have a material impact on our unaudited consolidated financial statements.

In December 2023, the FASB issued ASC Update No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. Update No. 2023-09 aims to enhance the transparency and decision usefulness of income tax disclosures. Update No. 2023-09 modifies the rules on income tax disclosures to require entities to disclose (1) specific categories in the rate reconciliation, (2) the income or loss from continuing operations before income tax expense or benefit (separated between domestic and foreign) and (3) income tax expense or benefit from continuing operations (separated by federal, state, and foreign). ASU 2023-09 also requires entities to disclose their income tax payments to international, federal, state and local jurisdictions, among other changes. Update No. 2023-09 is effective for fiscal years beginning after December 15, 2024. We expect to adopt Update No. 2023-09 prospectively. As this accounting standard update only impacts disclosures, we do not expect the adoption to have a material impact on our unaudited consolidated financial statements.

No other new accounting pronouncements issued or effective in the period had or are expected to have a material impact on our accompanying unaudited consolidated financial statements.
XML 42 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Insider Trading Arrangements
3 Months Ended
Mar. 31, 2024
shares
Vance R. Brown [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
On February 20, 2024, Vance R. Brown, our Senior Vice President, General Counsel and Corporate Secretary entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Brown’s plan covers the sale of 33,043 shares to be acquired upon exercise of stock options. Transactions under Mr. Brown’s plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Brown’s plan will terminate on the earlier of December 31, 2024, or the date all shares subject to the plan have been sold.
Name Vance R. Brown
Title Senior Vice President, General Counsel and Corporate Secretary
Rule 10b5-1 Arrangement Adopted true
Adoption Date February 20, 2024
Arrangement Duration 315 days
Aggregate Available 33,043
Daniel Brennan [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
On February 21, 2024, Daniel Brennan, our Executive Vice President and Chief Financial Officer, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Brennan’s plan covers the sale of 112,075 shares of our common stock, including 64,454 shares to be acquired upon exercise of stock options. Transactions under Mr. Brennan’s plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Brennan’s plan will terminate on the earlier of December 31, 2024, or the date all shares subject to the plan have been sold.
Name Daniel Brennan
Title Executive Vice President and Chief Financial Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date February 21, 2024
Arrangement Duration 314 days
Jonathan Monson [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
On February 26, 2024, Jonathan Monson, our prior Senior Vice President, Global Controller and Chief Accounting Officer until March 1, 2024, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Monson’s plan covers the sale of 16,082 shares of our common stock, including 10,000 shares to be acquired upon exercise of stock options. Transactions under Mr. Monson’s plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Monson’s plan will terminate on the earlier of February 1, 2025, or the date all shares subject to the plan have been sold.
Name Jonathan Monson
Title prior Senior Vice President, Global Controller and Chief Accounting Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date February 26, 2024
Arrangement Duration 341 days
Jeffrey B. Mirviss [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
On February 28, 2024, Jeffrey B. Mirviss, our Senior Vice President and President, Peripheral Interventions, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Mirviss’ plan covers the sale of up to 88,888 shares of our common stock, including up to 25,086 shares to be acquired upon determination and/or vesting of performance share units and restricted share units and 33,726 shares to be acquired upon exercise of stock options. Transactions under Mr. Mirviss’ plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Mirviss’ plan will terminate on the earlier of February 21, 2025, or the date all shares subject to the plan have been sold.
Name Jeffrey B. Mirviss
Title Senior Vice President and President, Peripheral Interventions
Rule 10b5-1 Arrangement Adopted true
Adoption Date February 28, 2024
Arrangement Duration 359 days
Michael F. Mahoney [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
On February 28, 2024, Michael F. Mahoney, our Chairman and Chief Executive Officer, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Mahoney’s plan covers the sale of 488,332 shares of our common stock, including 335,659 shares to be acquired upon exercise of stock options. Transactions under Mr. Mahoney’s plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Mahoney’s plan will terminate on the earlier of November 8, 2024, or the date all shares subject to the plan have been sold.
Name Michael F. Mahoney
Title Chairman and Chief Executive Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date February 28, 2024
Arrangement Duration 254 days
Daniel Brennan Rule Trading Arrangement, Common Stock [Member] | Daniel Brennan [Member]  
Trading Arrangements, by Individual  
Aggregate Available 112,075
Daniel Brennan Rule Trading Arrangement, Stock Options [Member] | Daniel Brennan [Member]  
Trading Arrangements, by Individual  
Aggregate Available 64,454
Jonathan Monson Rule Trading Arrangement, Common Stock [Member] | Jonathan Monson [Member]  
Trading Arrangements, by Individual  
Aggregate Available 16,082
Jonathan Monson Rule Trading Arrangement, Stock Options [Member] | Jonathan Monson [Member]  
Trading Arrangements, by Individual  
Aggregate Available 10,000
Jeffrey B. Mirviss Rule Trading Arrangement, Common Stock [Member] | Jeffrey B. Mirviss [Member]  
Trading Arrangements, by Individual  
Aggregate Available 88,888
Jeffrey B. Mirviss Rule Trading Arrangement, Vesting of Performance Units And Restricted Units [Member] | Jeffrey B. Mirviss [Member]  
Trading Arrangements, by Individual  
Aggregate Available 25,086
Jeffrey B. Mirviss Rule Trading Arrangement, Stock Options [Member] | Jeffrey B. Mirviss [Member]  
Trading Arrangements, by Individual  
Aggregate Available 33,726
Michael F. Mahoney Rule Trading Arrangement, Common Stock [Member] | Michael F. Mahoney [Member]  
Trading Arrangements, by Individual  
Aggregate Available 488,332
Michael F. MahoneyRule Trading Arrangement, Stock Options [Member] | Michael F. Mahoney [Member]  
Trading Arrangements, by Individual  
Aggregate Available 335,659
XML 43 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Basis of Presentation Basis of Presentation (Policies)
3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Subsequent Events
Subsequent Events
We evaluate events occurring after the date of our accompanying unaudited consolidated balance sheet for potential recognition or disclosure within our financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly.
Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note H – Commitments and Contingencies for further details.
XML 44 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Hedging Activities and Fair Value Measurements (Policies)
3 Months Ended
Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Fair Value Measurement, Policy [Policy Text Block] FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures
XML 45 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies (Policies)
3 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Legal Costs, Policy [Policy Text Block] In accordance with FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related net charges (credits) within our accompanying unaudited consolidated financial statements. All other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses within our accompanying unaudited consolidated statements of operations.
XML 46 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
New Accounting Pronouncements (Policies)
3 Months Ended
Mar. 31, 2024
Accounting Standards Update and Change in Accounting Principle [Abstract]  
New Accounting Pronouncements
NOTE N – NEW ACCOUNTING PRONOUNCEMENTS

Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our accompanying unaudited consolidated financial statements. During the first quarter of 2024, we implemented the following standard on a prospective basis, which did not have a material impact on our unaudited consolidated financial statements:

ASC Update No. 2022-03

ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities.
Standards to be Implemented

In November 2023, the FASB issued ASC Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. Update No. 2023-07 requires disclosure, on an annual and interim basis, of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss in addition to disclosure of amounts for other segment items and a description of its composition. Update No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. As this accounting standard update only impacts disclosures, we do not expect the adoption to have a material impact on our unaudited consolidated financial statements.

In December 2023, the FASB issued ASC Update No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. Update No. 2023-09 aims to enhance the transparency and decision usefulness of income tax disclosures. Update No. 2023-09 modifies the rules on income tax disclosures to require entities to disclose (1) specific categories in the rate reconciliation, (2) the income or loss from continuing operations before income tax expense or benefit (separated between domestic and foreign) and (3) income tax expense or benefit from continuing operations (separated by federal, state, and foreign). ASU 2023-09 also requires entities to disclose their income tax payments to international, federal, state and local jurisdictions, among other changes. Update No. 2023-09 is effective for fiscal years beginning after December 15, 2024. We expect to adopt Update No. 2023-09 prospectively. As this accounting standard update only impacts disclosures, we do not expect the adoption to have a material impact on our unaudited consolidated financial statements.

No other new accounting pronouncements issued or effective in the period had or are expected to have a material impact on our accompanying unaudited consolidated financial statements.
XML 47 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Acquisitions, Divestitures and Strategic Investments (Tables)
3 Months Ended
Mar. 31, 2024
Business Acquisition [Line Items]  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
Changes in the fair value of our contingent consideration liability during the first quarter of 2024 associated with prior period acquisitions were as follows:

(in millions)
Balance as of December 31, 2023$404 
Contingent consideration net expense (benefit)17 
Contingent consideration payments and other adjustments(148)
Balance as of March 31, 2024$273 
Fair Value Measurement Inputs and Valuation Techniques
The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:
Contingent Consideration LiabilityFair Value as of March 31, 2024Valuation TechniqueUnobservable InputRange
Weighted Average(1)
Revenue-based Payments and Milestones$273 millionDiscounted Cash FlowDiscount Rate6%-11%6%
Probability of Payment100%100%
Projected Year of Payment2024-20272025
(1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.
Investment
The aggregate carrying amount of our strategic investments was comprised of the following:

As of
(in millions)March 31, 2024December 31, 2023
Equity method investments$211 $219 
Measurement alternative investments(1, 2)
218 194 
$429 $413 
(1) Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in Other, net within our accompanying unaudited consolidated statements of operations.
(2) Includes publicly-held securities and convertible notes measured at fair value with changes in fair value recognized in Other, net within our accompanying unaudited consolidated statements of operations.
Acotec  
Business Acquisition [Line Items]  
Schedule of Business Acquisitions, by Acquisition
(in millions)
Acotec(1)
Payment for majority stake investment$381 
$381 
(1) Excludes approximately $140 million of cash on hand at the closing of the transaction
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
(in millions)Acotec
Goodwill$337 
Amortizable intangible assets334 
Other assets acquired93 
Liabilities assumed(48)
Net deferred tax liabilities(76)
Fair value of noncontrolling interest(259)
$381 
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination
We allocated a portion of the purchase price to the specific intangible asset categories as follows:

Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
Technology-related$308 1114%
Customer relationships15 1114%
Other intangible assets11 1314%
$334 
XML 48 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Goodwill and Other Intangible Assets Goodwill (Tables)
3 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets and Goodwill
The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows:
As of March 31, 2024As of December 31, 2023
(in millions)Gross Carrying AmountAccumulated Amortization/ Write-offsGross Carrying AmountAccumulated Amortization/ Write-offs
Technology-related$13,223 $(8,287)$13,207 $(8,101)
Patents480 (385)480 (387)
Other intangible assets2,159 (1,527)2,130 (1,500)
Amortizable intangible assets$15,863 $(10,198)$15,817 $(9,988)
    
Goodwill$24,261 $(9,900)$24,287 $(9,900)
IPR&D$54 $54 
Technology-related120 120 
Indefinite-lived intangible assets$174 $174 
Schedule of Goodwill
The following represents a roll-forward of our goodwill balance by reportable segment:
(in millions)MedSurgCardiovascularTotal
As of December 31, 2023$5,347 $9,041 $14,387 
Goodwill acquired24 — 24 
Impact of foreign currency fluctuations and purchase price and other adjustments(29)(22)(51)
As of March 31, 2024$5,342 $9,019 $14,361 
XML 49 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Hedging Activities and Fair Value Measurements (Tables)
3 Months Ended
Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Notional Amounts of Outstanding Derivative Positions
The following table presents the contractual amounts of our hedging instruments outstanding:
(in millions)FASB ASC Topic 815 DesignationAs of
March 31, 2024December 31, 2023
Forward currency contractsCash flow hedge$2,242 $2,284 
Forward currency contractsNet investment hedge645 333 
Foreign currency-denominated debt(1)
Net investment hedge997 997 
Forward currency contractsNon-designated3,070 3,282 
Total Notional Outstanding$6,954 $6,896 
(1) Foreign currency-denominated debt is the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge.
Derivative Instruments, Gain (Loss)
Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Three Months Ended March 31, 2024
Forward currency contracts
Cash flow hedges$76 $(17)$59 Cost of products sold$1,209 $(49)$11 $(38)
Net investment hedges(2)
27 (6)21 Interest expense69 (4)(3)
Foreign currency-denominated debt
Net investment hedges(3)
23 (5)18 Other, net(2)— — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest expense69 (0)

Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Three Months Ended March 31, 2023
Forward currency contracts
Cash flow hedges$13 $(3)$10 Cost of products sold$1,040 $(69)$16 $(54)
Net investment hedges(2)
(1)Interest expense65 (3)(2)
Foreign currency-denominated debt
Net investment hedges(3)
(19)(14)Other, net43 — — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest Expense65 — 
(1) In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from AOCI to earnings represent the effect of the hedging relationships on earnings.
(2) For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from AOCI to earnings as a reduction of Interest expense represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior periods, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.
(3) For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the CTA component of OCI. No amounts were reclassified from AOCI to current period earnings.
Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months
As of March 31, 2024, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below (in millions):
FASB ASC Topic 815 DesignationLocation on Unaudited Consolidated Statements of OperationsAmount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings
Designated Hedging Instrument
Forward currency contractsCash flow hedgeCost of products sold$173 
Forward currency contractsNet investment hedgeInterest expense15 
Interest rate derivative contractsCash flow hedgeInterest expense(1)
Derivatives Not Designated as Hedging
Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:
Location on Unaudited Consolidated Statements of OperationsThree Months Ended March 31,
(in millions)20242023
Net gain (loss) on currency hedge contractsOther, net$15 $(8)
Net gain (loss) on currency transaction exposuresOther, net(20)(6)
Net currency exchange gain (loss)$(5)$(14)
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value The following are the balances of our derivative and nonderivative assets and liabilities:
 
Location on Unaudited Consolidated Balance Sheets(1)
As of
(in millions)March 31, 2024December 31, 2023
Derivative and Nonderivative Assets:   
Designated Hedging Instruments  
Forward currency contractsOther current assets$160 $140 
Forward currency contractsOther long-term assets125 107 
  285 246 
Non-Designated Hedging Instruments   
Forward currency contractsOther current assets17 20 
Total Derivative and Nonderivative Assets $302 $266 
Derivative and Nonderivative Liabilities:   
Designated Hedging Instruments  
Forward currency contractsOther current liabilities$$15 
Forward currency contractsOther long-term liabilities
Foreign currency-denominated debt(2)
Long-term debt966 988 
  969 1,012 
Non-Designated Hedging Instruments   
Forward currency contractsOther current liabilities17 38 
Total Derivative and Nonderivative Liabilities $986 $1,050 
(1) We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.
(2) Foreign currency-denominated debt is the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
Assets and liabilities measured at fair value on a recurring basis consist of the following:
As of
 March 31, 2024December 31, 2023
(in millions)Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets        
Money market funds and time deposits$1,979 $— $— $1,979 $454 $— $— $454 
Publicly-held equity securities20 — — 20 18 — — 18 
Hedging instruments— 302 — 302 — 266 — 266 
Licensing arrangements— — 66 66 — — 77 77 
 $1,999 $302 $66 $2,367 $472 $266 $77 $816 
Liabilities        
Hedging instruments$— $986 $— $986 $— $1,050 $— $1,050 
Contingent consideration liability— — 273 273 — — 404 404 
Licensing arrangements— — 71 71 — — 90 90 
 $ $986 $344 $1,330 $ $1,050 $494 $1,545 
The recurring Level 3 fair value measurements of our licensing arrangements recognized within our accompanying unaudited consolidated balance sheets as of March 31, 2024 include the following significant unobservable inputs:
Licensing ArrangementsFair Value as of March 31, 2024Valuation TechniqueUnobservable InputRange
Weighted Average (1)
Financial Asset$66 millionDiscounted Cash FlowDiscount Rate15%15%
Projected Year of Payment2024-20252025
Financial Liability$71 millionDiscounted Cash FlowDiscount Rate12 %-15%13%
Projected Year of Payment2024-20262025
(1) Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

Changes in the fair value of our licensing arrangements' financial asset were as follows:
(in millions)
Balance as of December 31, 2023$77 
Proceeds from royalty rights(14)
Fair value adjustment (expense) benefit
Balance as of March 31, 2024$66 

Changes in the fair value of our licensing arrangements' financial liability were as follows:
(in millions)
Balance as of December 31, 2023$90 
Payments for royalty rights(22)
Fair value adjustment expense (benefit)
Balance as of March 31, 2024$71 
XML 50 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Contractual Obligations and Commitments (Tables)
3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Instruments The debt maturity schedule for our long-term debt obligations is presented below:
(in millions, except interest rates)Issuance DateMaturity DateAs of
Coupon Rate(1)
March 31,
2024
December 31,
2023
March 2025 Senior Notes(3)
March 2022March 2025— 1,105 0.750%
June 2025 Senior NotesMay 2020June 2025500 500 1.900%
March 2026 Senior NotesFebruary 2019March 2026255 255 3.750%
December 2027 Senior Notes(3)
November 2019December 2027972 995 0.625%
March 2028 Senior Notes(3)
March 2022March 2028810 829 1.375%
March 2028 Senior NotesFebruary 2018March 2028344 344 4.000%
March 2029 Senior NotesFebruary 2019March 2029272 272 4.000%
March 2029 Senior Notes(3)
February 2024March 2029810 — 3.375%
June 2030 Senior NotesMay 2020June 20301,200 1,200 2.650%
March 2031 Senior Notes(3)
March 2022March 2031810 829 1.625%
March 2032 Senior Notes(3)
February 2024March 20321,349 — 3.500%
March 2034 Senior Notes(3)
March 2022March 2034540 553 1.875%
November 2035 Senior Notes(2)
November 2005November 2035350 350 6.500%
March 2039 Senior NotesFebruary 2019March 2039450 450 4.550%
January 2040 Senior NotesDecember 2009January 2040300 300 7.375%
March 2049 Senior NotesFebruary 2019March 2049650 650 4.700%
Unamortized Debt Issuance Discount and Deferred Financing Costs2024 - 2049(81)(65)
Finance Lease ObligationVarious
Long-term debt$9,534 $8,571 
(1) Coupon rates are semi-annual, except for the euro-denominated notes, which bear an annual coupon.
(2) Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate of 6.25% if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher.
(3) These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of March 31, 2024 and December 31, 2023, respectively.
Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants
As of March 31, 2024, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility.
Covenant RequirementActual
 as of March 31, 2024as of March 31, 2024
Maximum permitted leverage ratio(1)
3.75 times2.08 times
(1) Ratio of total debt to deemed consolidated Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), as defined by the 2021 Revolving Credit Facility credit agreement, as amended.
Transfer of Financial Assets Accounted for as Sales Amounts de-recognized for accounts and notes receivable, which are excluded from Trade accounts receivable, net within our accompanying unaudited consolidated balance sheets, are aggregated by contract denominated currency below (in millions):
Factoring ArrangementsAs of March 31, 2024As of December 31, 2023
Amount
De-recognized
Weighted Average
Interest Rate
Amount
De-recognized
Weighted Average
Interest Rate
Euro denominated$175 5.5 %$206 5.1 %
Yen denominated191 0.6 %214 0.6 %
Renminbi denominated
21 1.8 %14 2.9 %
XML 51 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Supplemental Balance Sheet Information (Tables)
3 Months Ended
Mar. 31, 2024
Supplemental Balance Sheet Information [Abstract]  
Trade accounts receivable, net
Trade accounts receivable, net
 As of
(in millions)March 31, 2024December 31, 2023
Trade accounts receivable$2,413 $2,338 
Allowance for credit losses(109)(110)
 $2,304 $2,228 

The following is a roll forward of our Allowance for credit losses:
Three Months Ended March 31,
(in millions)20242023
Beginning balance$110 $109 
Credit loss expense16 
Write-offs(10)(6)
Ending balance$109 $118 
Inventory Disclosure
Inventories
 As of
(in millions)March 31, 2024December 31, 2023
Finished goods$1,555 $1,537 
Work-in-process188 174 
Raw materials818 773 
 $2,561 $2,484 
Schedule of Other Current Assets
Other current assets
 As of
(in millions)March 31, 2024December 31, 2023
Restricted cash and restricted cash equivalents$93 $130 
Derivative assets177 159 
Licensing arrangements44 47 
Other357 285 
 $671 $621 
Property, plant and equipment, net
Property, plant and equipment, net
 As of
(in millions)March 31, 2024December 31, 2023
Land$141 $140 
Buildings and improvements1,856 1,843 
Equipment, furniture and fixtures3,550 3,503 
Capital in progress880 857 
 6,427 6,343 
Less: accumulated depreciation3,530 3,484 
 $2,897 $2,859 
Schedule of Other Assets
Other long-term assets

 As of
(in millions)March 31, 2024December 31, 2023
Restricted cash equivalents$74 $60 
Operating lease right-of-use assets430 439 
Derivative assets125 107 
Investments429 413 
Licensing arrangements22 30 
Indemnification asset175 176 
Other341 306 
 $1,596 $1,531 
Schedule of Accrued Liabilities
Accrued expenses
 As of
(in millions)March 31, 2024December 31, 2023
Legal reserves$129 $206 
Payroll and related liabilities749 1,051 
Rebates384 389 
Contingent consideration182 304 
Other639 696 
 $2,083 $2,646 
Other Current Liabilities
Other current liabilities
 As of
(in millions)March 31, 2024December 31, 2023
Deferred revenue$280 $266 
Licensing arrangements45 49 
Taxes payable257 220 
Other246 278 
 $827 $814 
Other long-term liabilities
Other long-term liabilities
 As of
(in millions)March 31, 2024December 31, 2023
Accrued income taxes$466 $470 
Legal reserves154 172 
Contingent consideration90 100 
Licensing arrangements26 41 
Operating lease liabilities382 390 
Deferred revenue314 311 
Other486 484 
 $1,919 $1,967 
XML 52 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes (Tables)
3 Months Ended
Mar. 31, 2024
Income Tax Disclosure [Abstract]  
Schedule of Effective Income Tax Rate from Continuing Operations
Our effective tax rate from continuing operations is presented below:
Three Months Ended March 31,
20242023
Effective tax rate from continuing operations18.9 %29.4 %
XML 53 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Weighted Average Shares Outstanding (Tables)
3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Schedule of Weighted Average Number of Shares
NOTE J – WEIGHTED AVERAGE SHARES OUTSTANDING

Three Months Ended March 31,
(in millions)20242023
Weighted average shares outstanding — basic1,468.4 1,435.8 
Net effect of common stock equivalents13.4 10.2 
Weighted average shares outstanding - diluted1,481.7 1,446.0 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following securities were excluded from the calculation of weighted average shares outstanding - diluted because their effect in the periods presented below would have been antidilutive:
Three Months Ended March 31,
(in millions)20242023
Stock options outstanding(1)
23
MCPS(2)
24
(1)    Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.
(2)    Represents common stock issuable upon the conversion of MCPS. Refer to Note I – Stockholders' Equity for additional information.
XML 54 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Reporting (Tables)
3 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
Reconciliation of Operating Profit (Loss) from Segments to Consolidated
A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying unaudited consolidated statements of operations is as follows (in millions, except percentages). Prior period amounts have been restated at constant currency to conform to current year presentation.

Three Months Ended
March 31,
Net Sales20242023
MedSurg$1,402 $1,266
Cardiovascular2,426 2,072
Total net sales of reportable segments3,827 3,337
Impact of foreign currency fluctuations29 52
$3,856 $3,389
Income (loss) before income taxes
MedSurg$474 $409
Cardiovascular653 553
Total operating income of reportable segments1,128 963
Unallocated amounts:
Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments(115)(98)
Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs(124)(110)
Amortization expense(214)(203)
Operating income (loss)675 552
Other income (expense), net(67)(108)
Income (loss) before income taxes$608 $444

Three Months Ended March 31,
Operating income margin of reportable segments20242023
MedSurg33.8 %32.3 %
Cardiovascular26.9 %26.7 %
XML 55 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue (Tables)
3 Months Ended
Mar. 31, 2024
Disaggregation of Revenue [Abstract]  
Disaggregation of Revenue The following tables disaggregate our revenue from contracts with customers by business unit and geographic region (in millions). Generally, we allocate revenue from contracts with customers to geographic regions based on the location where the sale originated.
Three Months Ended March 31,
20242023
BusinessesU.S.Int'lTotalU.S.Int'lTotal
Endoscopy$395 $247 $642 $351 $226 $577 
Urology356 157 513 326 143 469 
Neuromodulation190 66 256 172 62 234 
MedSurg941 470 1,412 850 430 1,280 
   Interventional Cardiology Therapies195 457 652 183 408 591 
   Watchman311 33 344 265 25 291 
   Cardiac Rhythm Management354 221 575 345 203 548 
    Electrophysiology158 143 300 85 91 177 
Cardiology1,017 854 1,872 879 727 1,606 
Peripheral Interventions299 274 573 275 229 503 
Cardiovascular1,316 1,129 2,445 1,154 956 2,110 
Total Net Sales$2,258 $1,599 $3,856 $2,003 $1,386 $3,389 


Refer to Note K - Segment Reporting for information on our reportable segments.

Three Months Ended March 31,
Geographic Regions20242023
U.S.$2,258 $2,003 
Europe, Middle East and Africa803 712 
Asia-Pacific647 548 
Latin America and Canada149 126 
Total Net Sales$3,856 $3,389 
Emerging Markets(1)
$648 $529 
XML 56 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Changes in Other Comprehensive Income (Tables)
3 Months Ended
Mar. 31, 2024
Other Comprehensive Income (Loss), Net of Tax, Period Change [Abstract]  
Changes in Other Comprehensive Income
The following tables provide the reclassifications out of Other comprehensive income (loss), net of tax attributable to Boston Scientific common stockholders:
(in millions)Foreign Currency Translation AdjustmentsNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2023$(96)$154 $(8)$49 
Other comprehensive income (loss) before reclassifications65 59 — 124 
(Income) loss amounts reclassified from accumulated other comprehensive income(3)(38)(0)(41)
Total other comprehensive income (loss)62 22 (0)83 
Balance as of March 31, 2024$(34)$175 $(8)$132 

(in millions)Foreign Currency Translation AdjustmentsNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2022$(1)$269 $1 $269 
Other comprehensive income (loss) before reclassifications(40)10 (5)(35)
(Income) loss amounts reclassified from accumulated other comprehensive income(2)(53)(0)(56)
Total other comprehensive income (loss)(42)(43)(5)(91)
Balance as of March 31, 2023$(43)$225 $(4)$178 
XML 57 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Acquisitions, Divestitures and Strategic Investments - Acquisitions and Divestitures (Details)
$ / shares in Units, $ in Millions
3 Months Ended
Jan. 08, 2024
USD ($)
$ / shares
Feb. 20, 2023
USD ($)
Feb. 20, 2023
HKD ($)
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Business Acquisition [Line Items]            
Payments to Acquire Businesses, Net of Cash Acquired       $ 47 $ 375  
Goodwill       14,361   $ 14,387
Cash       384   $ 411
Acotec            
Business Acquisition [Line Items]            
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners   35.00%        
Acotec            
Business Acquisition [Line Items]            
Business Acquisition, Percentage of Voting Interests Acquired   65.00%        
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value   $ 519 $ 20.00      
Payments to Acquire Businesses, Net of Cash Acquired       381    
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination       381    
Goodwill       337    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets       93    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities       (48)    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities       (76)    
Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value       (259)    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill       334    
Cash   $ 140        
Acotec | Technology-Based Intangible Assets [Member]            
Business Acquisition [Line Items]            
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles       $ 308    
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life       11 years    
Acotec | Other Intangible Assets [Member]            
Business Acquisition [Line Items]            
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles       $ 11    
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life       13 years    
Acotec | Customer Relationships            
Business Acquisition [Line Items]            
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles       $ 15    
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life       11 years    
Acotec | Weighted Average [Member] | Technology-Based Intangible Assets [Member]            
Business Acquisition [Line Items]            
Discount Rate, Fair Value Input       14.00%    
Acotec | Weighted Average [Member] | Other Intangible Assets [Member]            
Business Acquisition [Line Items]            
Discount Rate, Fair Value Input       14.00%    
Acotec | Weighted Average [Member] | Customer Relationships            
Business Acquisition [Line Items]            
Discount Rate, Fair Value Input       14.00%    
Axonics            
Business Acquisition [Line Items]            
Business Acquisition, Percentage of Voting Interests Acquired 100.00%          
Business Acquisition, Share Price | $ / shares $ 71.00          
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value $ 3,670          
XML 58 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Acquisitions, Divestitures and Strategic Investments - Contingent Consideration (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]    
Business Combination, Contingent Consideration, Liability Beginning Balance $ 404  
Contingent consideration net expense (benefit) 17 $ 12
Payment of contingent consideration (148)  
Business Combination, Contingent Consideration, Liability Ending Balance 273  
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]    
Business Combination, Contingent Consideration, Liability 273  
Uncapped Contingent Considertation 164  
All Business Acquisitions    
Business Combination, Contingent Consideration Arrangements [Abstract]    
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 275  
Valuation Technique, Discounted Cash Flow [Member] | revenue-based payments [Member]    
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]    
Business Combination, Contingent Consideration, Liability Ending Balance 273  
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]    
Business Combination, Contingent Consideration, Liability $ 273  
contingent consideration liability, probability of payment 100.00%  
Minimum [Member] | Valuation Technique, Discounted Cash Flow [Member] | revenue-based payments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]    
Discount Rate, Fair Value Input 6.00%  
Maximum [Member] | Valuation Technique, Discounted Cash Flow [Member] | revenue-based payments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]    
Discount Rate, Fair Value Input 11.00%  
Weighted Average [Member] | Valuation Technique, Discounted Cash Flow [Member] | revenue-based payments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]    
contingent consideration liability, probability of payment 100.00%  
Discount Rate, Fair Value Input 6.00%  
XML 59 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Acquisitions, Divestitures and Strategic Investments - Strategic Investments (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Business Combinations [Abstract]    
Equity method investments $ 211 $ 219
Measurement alternative investments(1, 2) 218 194
Investments 429 $ 413
Equity Method Investment, Difference Between Carrying Amount and Underlying Equity $ 237  
XML 60 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Goodwill and Other Intangible Assets (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Intangible Assets and Goodwill [Line Items]    
Finite-Lived Intangible Assets, Gross $ 15,863 $ 15,817
Finite-Lived Intangible Assets, Accumulated Amortization (10,198) (9,988)
Indefinite-lived Intangible Assets (Excluding Goodwill) 174 174
Goodwill [Roll Forward]    
Goodwill Beginning Balance 14,387  
Goodwill acquired 24  
Impact of foreign currency fluctuations and purchase price and other adjustments (51)  
Goodwill Ending Balance 14,361  
MedSurg [Member]    
Goodwill [Roll Forward]    
Goodwill Beginning Balance 5,347  
Goodwill acquired 24  
Impact of foreign currency fluctuations and purchase price and other adjustments (29)  
Goodwill Ending Balance 5,342  
Cardiovascular [Member]    
Goodwill [Roll Forward]    
Goodwill Beginning Balance 9,041  
Goodwill acquired 0  
Impact of foreign currency fluctuations and purchase price and other adjustments (22)  
Goodwill Ending Balance 9,019  
Goodwill [Member]    
Intangible Assets and Goodwill [Line Items]    
Goodwill, Gross 24,261 24,287
Goodwill, Impaired, Accumulated Impairment Loss (9,900) (9,900)
In Process Research and Development [Member]    
Intangible Assets and Goodwill [Line Items]    
Indefinite-lived Intangible Assets (Excluding Goodwill) 54 54
Technology-Based Intangible Assets [Member]    
Intangible Assets and Goodwill [Line Items]    
Indefinite-lived Intangible Assets (Excluding Goodwill) 120 120
Technology-Based Intangible Assets [Member]    
Intangible Assets and Goodwill [Line Items]    
Finite-Lived Intangible Assets, Gross 13,223 13,207
Finite-Lived Intangible Assets, Accumulated Amortization (8,287) (8,101)
Patents [Member]    
Intangible Assets and Goodwill [Line Items]    
Finite-Lived Intangible Assets, Gross 480 480
Finite-Lived Intangible Assets, Accumulated Amortization (385) (387)
Other Intangible Assets [Member]    
Intangible Assets and Goodwill [Line Items]    
Finite-Lived Intangible Assets, Gross 2,159 2,130
Finite-Lived Intangible Assets, Accumulated Amortization $ (1,527) $ (1,500)
XML 61 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Hedging Activities and Fair Value Measurements (Details)
€ in Millions
3 Months Ended
Mar. 31, 2024
USD ($)
units
derivative_instrument
Mar. 31, 2023
USD ($)
Mar. 31, 2024
EUR (€)
units
derivative_instrument
Dec. 31, 2023
USD ($)
derivative_instrument
Dec. 31, 2023
EUR (€)
derivative_instrument
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative, Notional Amount $ 6,954,000,000     $ 6,896,000,000  
Cost of Goods and Services Sold 1,209,000,000 $ 1,040,000,000      
Interest Expense 69,000,000 65,000,000      
Other Operating Income (Expense), Net (2,000,000) 43,000,000      
Derivative Asset, Fair Value, Gross Asset 302,000,000     266,000,000  
Derivative Liability, Fair Value, Gross Liability 986,000,000     1,050,000,000  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Derivative Asset 125,000,000     107,000,000  
Licensing arrangements, asset 22,000,000     30,000,000  
Business Combination, Contingent Consideration, Liability 273,000,000     404,000,000  
Licensing arrangements, liability 26,000,000     41,000,000  
Cash 384,000,000     411,000,000  
Debt Instrument, Fair Value Disclosure 10,224,000,000     8,735,000,000  
Accumulated Foreign Currency Adjustment Attributable to Parent          
Derivative Instruments, Gain (Loss) [Line Items]          
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent 0 0      
December 2027 Notes [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Long-term Debt $ 972,000,000   € 900 995,000,000 € 900
Debt Instrument, Interest Rate, Stated Percentage 0.625%   0.625%    
Licensing arrangement assets [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Discount Rate, Fair Value Input 15.00%   15.00%    
Proceeds from Royalties Received $ (14,000,000)        
Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option 2,000,000        
Licensing arrangement liabilities [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Payments for Royalties (22,000,000)        
Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option 2,000,000        
Fair Value, Inputs, Level 3 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Licensing arrangements, asset 66,000,000        
Licensing arrangements, liability 71,000,000        
Fair Value, Measurements, Recurring [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Money Market Funds, at Carrying Value 1,979,000,000     454,000,000  
Equity Securities, FV-NI 20,000,000     18,000,000  
Derivative Asset 302,000,000     266,000,000  
Licensing arrangements, asset 66,000,000     77,000,000  
Assets, Fair Value Disclosure 2,367,000,000     816,000,000  
Derivative Liability 986,000,000     1,050,000,000  
Business Combination, Contingent Consideration, Liability 273,000,000     404,000,000  
Licensing arrangements, liability 71,000,000     90,000,000  
Financial and Nonfinancial Liabilities, Fair Value Disclosure 1,330,000,000     1,545,000,000  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Money Market Funds, at Carrying Value 1,979,000,000     454,000,000  
Equity Securities, FV-NI 20,000,000     18,000,000  
Derivative Asset 0     0  
Licensing arrangements, asset 0     0  
Assets, Fair Value Disclosure 1,999,000,000     472,000,000  
Derivative Liability 0     0  
Business Combination, Contingent Consideration, Liability 0     0  
Licensing arrangements, liability 0     0  
Financial and Nonfinancial Liabilities, Fair Value Disclosure 0     0  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Money Market Funds, at Carrying Value 0     0  
Equity Securities, FV-NI 0     0  
Derivative Asset 302,000,000     266,000,000  
Licensing arrangements, asset 0     0  
Assets, Fair Value Disclosure 302,000,000     266,000,000  
Derivative Liability 986,000,000     1,050,000,000  
Business Combination, Contingent Consideration, Liability 0     0  
Licensing arrangements, liability 0     0  
Financial and Nonfinancial Liabilities, Fair Value Disclosure 986,000,000     1,050,000,000  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Money Market Funds, at Carrying Value 0     0  
Equity Securities, FV-NI 0     0  
Derivative Asset 0     0  
Licensing arrangements, asset 66,000,000     77,000,000  
Assets, Fair Value Disclosure 66,000,000     77,000,000  
Derivative Liability 0     0  
Business Combination, Contingent Consideration, Liability 273,000,000     404,000,000  
Licensing arrangements, liability 71,000,000     90,000,000  
Financial and Nonfinancial Liabilities, Fair Value Disclosure 344,000,000     494,000,000  
Designated as Hedging Instrument [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative Instruments in Hedges, Assets, at Fair Value 285,000,000     246,000,000  
Derivative Instruments in Hedges, Liabilities, at Fair Value 969,000,000     1,012,000,000  
Designated as Hedging Instrument [Member] | Other Noncurrent Liabilities [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative Instruments in Hedges, Liabilities, at Fair Value $ 966,000,000     988,000,000  
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Forward Currency Contracts, Time to Maturity | units 36   36    
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Prepaid Expenses and Other Current Assets [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative Instruments in Hedges, Assets, at Fair Value $ 160,000,000     140,000,000  
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other Noncurrent Assets [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative Instruments in Hedges, Assets, at Fair Value 125,000,000     107,000,000  
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other Current Liabilities [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative Instruments in Hedges, Liabilities, at Fair Value 3,000,000     15,000,000  
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other Noncurrent Liabilities [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative Instruments in Hedges, Liabilities, at Fair Value 1,000,000     9,000,000  
Not Designated as Hedging Instrument [Member] | Other Nonoperating Income (Expense) [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments 15,000,000 (8,000,000)      
Foreign Currency Transaction Gain (Loss), before Tax (20,000,000) (6,000,000)      
Net currency exchange gain (loss) (5,000,000) (14,000,000)      
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative, Notional Amount 3,070,000,000     3,282,000,000  
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Prepaid Expenses and Other Current Assets [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value 17,000,000     20,000,000  
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other Current Liabilities [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value $ 17,000,000     $ 38,000,000  
Not Designated as Hedging Instrument [Member] | Foreign Exchange Forward          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative, Term of Contract (less than) 1 year        
Derivative, Remaining Maturity 1 year   1 year    
Weighted Average [Member] | Licensing arrangement assets [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Discount Rate, Fair Value Input 15.00%   15.00%    
Weighted Average [Member] | Licensing arrangement liabilities [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Discount Rate, Fair Value Input 13.00%   13.00%    
Minimum [Member] | Licensing arrangement liabilities [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Discount Rate, Fair Value Input 12.00%   12.00%    
Maximum [Member] | Licensing arrangement liabilities [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Discount Rate, Fair Value Input 15.00%   15.00%    
Cash Flow Hedging [Member] | Foreign Exchange Contract [Member] | Cost of Sales [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months $ 173,000,000        
Cash Flow Hedging [Member] | Interest Rate Contract [Member] | Interest Expense [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net $ (1,000,000)        
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Number of Interest Rate Derivatives Held | derivative_instrument 0   0 0 0
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative, Notional Amount $ 2,242,000,000     $ 2,284,000,000  
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Cost of Sales [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 76,000,000 13,000,000      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax (17,000,000) (3,000,000)      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 59,000,000 10,000,000      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax (49,000,000) (69,000,000)      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax 11,000,000 16,000,000      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax (38,000,000) (54,000,000)      
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Interest Rate Contract [Member] | Interest Expense [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 0 0      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax 0 0      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 0 0      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax 1,000,000 1,000,000      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax 0 0      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax 0 1,000,000      
Net Investment Hedging [Member] | Foreign Exchange Contract [Member] | Interest Expense [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net 15,000,000        
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative, Notional Amount 645,000,000     333,000,000  
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Interest Expense [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax 27,000,000 6,000,000      
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax (6,000,000) (1,000,000)      
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax 21,000,000 4,000,000      
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax (4,000,000) (3,000,000)      
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax 1,000,000 1,000,000      
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, after Tax (3,000,000) (2,000,000)      
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | foreign currency denominated in debt [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative, Notional Amount 997,000,000     $ 997,000,000  
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | foreign currency denominated in debt [Member] | Interest Expense [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax 23,000,000 (19,000,000)      
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax (5,000,000) 4,000,000      
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax 18,000,000 (14,000,000)      
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax 0 0      
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax 0 0      
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, after Tax $ 0 $ 0      
XML 62 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Contractual Obligations and Commitments (Details)
€ in Millions
3 Months Ended 12 Months Ended
May 10, 2021
USD ($)
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Mar. 31, 2024
EUR (€)
Mar. 31, 2024
Mar. 31, 2024
Rate
Feb. 22, 2024
EUR (€)
Dec. 31, 2023
EUR (€)
Debt Instrument [Line Items]                  
Total debt   $ 10,619,000,000   $ 9,102,000,000          
Debt, Current   1,085,000,000.000   531,000,000          
Long-term Debt and Capital Lease Obligations   9,534,000,000   8,571,000,000          
Exclusion from EBITDA for Restructuring Charges   500,000,000              
Restructuring charges remaining to be excluded from calculation of consolidated EBITDA   273,000,000              
Amount excluded from debt in leverage ratio   2,138,000,000              
Legal payments remaining to be excluded from calculation of consolidated EBITDA   1,457,000,000              
Letters of Credit Outstanding, Amount   174,000,000   174,000,000          
Qualified Acquisition Consideration   1,000,000,000              
Proceeds from Issuance of Senior Long-Term Debt   2,145,000,000 $ 0            
Supplier Finance Program Obligation. current   140,000,000   152,000,000          
Litigation payment exclusion from EBITDA   $ 1,000,000,000              
AMS Europe                  
Debt Instrument [Line Items]                  
Debt Instrument, Redemption Price, Percentage   101.00%              
Commercial Paper [Member]                  
Debt Instrument [Line Items]                  
Debt, Current   $ 0   0          
Current Requirement [Member]                  
Debt Instrument [Line Items]                  
Maximum Leverage Ratio           3.75      
Actual, Covenant [Member]                  
Debt Instrument [Line Items]                  
Maximum Leverage Ratio           2.08      
Requirement, as of December 31, 2021 and through remaining term of facility                  
Debt Instrument [Line Items]                  
Maximum Leverage Ratio           3.75      
Requirement, four succeeding quarters following qualified acquisition                  
Debt Instrument [Line Items]                  
Maximum Leverage Ratio           4.75      
Requirement, fifth quarter following qualified acquisition [Member]                  
Debt Instrument [Line Items]                  
Maximum Leverage Ratio           4.50      
Requirement, sixth quarter following qualified acquisition                  
Debt Instrument [Line Items]                  
Maximum Leverage Ratio           4.25      
Requirement, seventh quarter following qualified acquisition                  
Debt Instrument [Line Items]                  
Maximum Leverage Ratio           4.00      
Requirement, eighth quarter following qualified acquisition and through remaining term of facility                  
Debt Instrument [Line Items]                  
Maximum Leverage Ratio           3.75      
Revolving Credit Facility [Member]                  
Debt Instrument [Line Items]                  
Long-term Debt   0   0          
Line of Credit Facility, Maximum Borrowing Capacity $ 2,750,000,000                
Debt Instrument, Extension Option, Term 1 year                
March 2024 Notes [Member]                  
Debt Instrument [Line Items]                  
Debt Instrument, Interest Rate, Stated Percentage           3.45%      
March 2025 Notes                  
Debt Instrument [Line Items]                  
Long-term Debt   0   1,105,000,000          
Debt Instrument, Interest Rate, Stated Percentage           0.75%      
June 2025 Notes [Member]                  
Debt Instrument [Line Items]                  
Long-term Debt   500,000,000   500,000,000          
Debt Instrument, Interest Rate, Stated Percentage           1.90%      
March 2026 Notes [Member]                  
Debt Instrument [Line Items]                  
Long-term Debt   255,000,000   255,000,000          
Debt Instrument, Interest Rate, Stated Percentage           3.75%      
December 2027 Notes [Member]                  
Debt Instrument [Line Items]                  
Long-term Debt   972,000,000   995,000,000 € 900       € 900
Debt Instrument, Interest Rate, Stated Percentage           0.625%      
March 2028 Senior Notes                  
Debt Instrument [Line Items]                  
Long-term Debt   810,000,000   829,000,000          
Debt Instrument, Interest Rate, Stated Percentage           1.375%      
March 2028 Notes [Member]                  
Debt Instrument [Line Items]                  
Long-term Debt   344,000,000   344,000,000          
Debt Instrument, Interest Rate, Stated Percentage           4.00%      
March 2029 Notes [Member]                  
Debt Instrument [Line Items]                  
Long-term Debt   272,000,000   272,000,000          
Debt Instrument, Interest Rate, Stated Percentage           4.00%      
June 2030 Notes [Member]                  
Debt Instrument [Line Items]                  
Long-term Debt   1,200,000,000   1,200,000,000          
Debt Instrument, Interest Rate, Stated Percentage           2.65%      
March 2031 Notes                  
Debt Instrument [Line Items]                  
Long-term Debt   810,000,000   829,000,000          
Debt Instrument, Interest Rate, Stated Percentage           1.625%      
March 2034 Notes                  
Debt Instrument [Line Items]                  
Long-term Debt   540,000,000   553,000,000          
Debt Instrument, Interest Rate, Stated Percentage           1.875%      
November 2035 Notes [Member]                  
Debt Instrument [Line Items]                  
Long-term Debt   350,000,000   350,000,000          
Debt Instrument, Interest Rate, Stated Percentage           6.50%      
November 2035 Notes [Member] | Credit Rating A- or A3 Or Higher                  
Debt Instrument [Line Items]                  
Debt Instrument, Interest Rate, Stated Percentage           6.25%      
March 2039 Notes [Member]                  
Debt Instrument [Line Items]                  
Long-term Debt   450,000,000   450,000,000          
Debt Instrument, Interest Rate, Stated Percentage           4.55%      
January 2040 Notes [Member]                  
Debt Instrument [Line Items]                  
Long-term Debt   300,000,000   300,000,000          
Debt Instrument, Interest Rate, Stated Percentage           7.375%      
March 2049 Notes [Member]                  
Debt Instrument [Line Items]                  
Long-term Debt   650,000,000   650,000,000          
Debt Instrument, Interest Rate, Stated Percentage           4.70%      
Senior Notes [Member]                  
Debt Instrument [Line Items]                  
Long-term Debt   10,690,000,000   9,136,000,000          
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net   (81,000,000)   (65,000,000)          
Finance Lease Obligation                  
Debt Instrument [Line Items]                  
Long-term Debt   4,000,000   5,000,000          
the Offering                  
Debt Instrument [Line Items]                  
Long-term Debt | €               € 2,000  
March 2029 Euro Senior Notes                  
Debt Instrument [Line Items]                  
Long-term Debt   810,000,000   0       750  
Debt Instrument, Interest Rate, Stated Percentage           3.375% 3.375%    
March 2032 Euro Senior Notes                  
Debt Instrument [Line Items]                  
Long-term Debt   1,349,000,000   0       € 1,250  
Debt Instrument, Interest Rate, Stated Percentage           3.50% 3.50%    
Euro Denominated Factoring Arrangements [Member]                  
Debt Instrument [Line Items]                  
Transfer of Financial Assets Accounted for as Sales, Amount Derecognized   $ 175,000,000   $ 206,000,000          
Average interest rate of de-recognized receivables   5.50%   5.10%          
Yen Denominated Factoring Arrangements [Member]                  
Debt Instrument [Line Items]                  
Transfer of Financial Assets Accounted for as Sales, Amount Derecognized   $ 191,000,000   $ 214,000,000          
Average interest rate of de-recognized receivables   0.60%   0.60%          
Renminbi Denominated Factoring Arrangements [Member]                  
Debt Instrument [Line Items]                  
Transfer of Financial Assets Accounted for as Sales, Amount Derecognized   $ 21,000,000   $ 14,000,000          
Average interest rate of de-recognized receivables   1.80%   2.90%          
XML 63 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Supplemental Balance Sheet Information (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Line Items]      
Depreciation $ 90 $ 82  
Trade accounts receivable, net      
Accounts receivable 2,413   $ 2,338
Less: allowance for doubtful accounts (109)   (110)
Trade accounts receivable, net 2,304   2,228
Allowance for doubtful accounts      
Beginning balance 110 109  
Charges to expenses 9 16  
Utilization of allowances (10) (6)  
Ending balance 109 118  
Inventories      
Inventory, Finished Goods, Net of Reserves 1,555   1,537
Inventory, Work in Process, Net of Reserves 188   174
Inventory, Raw Materials, Net of Reserves 818   773
Inventories 2,561   2,484
Other Current Assets [Abstract]      
Restricted Cash and Cash Equivalents in Other current assets 93 135 130
Derivative Asset, Current 177   159
Licensing arrangements 44   47
Other Assets, Miscellaneous, Current 357   285
Other Assets, Current 671   621
Property, plant and equipment, net      
Land 141   140
Buildings and improvements 1,856   1,843
Equipment, furniture and fixtures 3,550   3,503
Capital in progress 880   857
Property, plant and equipment 6,427   6,343
Less: accumulated depreciation 3,530   3,484
Property, plant and equipment, net 2,897   2,859
Other Assets, Noncurrent [Abstract]      
Restricted cash equivalents included in Other long-term assets 74 $ 57 60
Operating Lease, Right-of-Use Asset 430   439
Derivative Asset 125   107
Investments 429   413
Licensing arrangements, asset 22   30
Indemnification asset 175   176
Other, Other Long-term Assets 341   306
Other Assets, Noncurrent 1,596   1,531
Accrued expenses      
Legal reserves, current 129   206
Payroll and related liabilities 749   1,051
Accrued Rebates, Current 384   389
Business Combination, Contingent Consideration, Liability, Current 182   304
Other 639   696
Accrued Liabilities, Current 2,083   2,646
Other Liabilities, Current [Abstract]      
Deferred Revenue, Current 280   266
Licensing Arrangements 45   49
Taxes Payable, Current 257   220
Other 246   278
Other Liabilities, Current 827   814
Other long-term liabilities      
Accrued income taxes 466   470
Estimated Litigation Liability, Noncurrent 154   172
Business Combination, Contingent Consideration, Liability, Noncurrent 90   100
Licensing arrangements, liability 26   41
Operating Lease, Liability, Noncurrent 382   390
Deferred Revenue 314   311
Other Accrued Liabilities, Noncurrent 486   484
Other long-term liabilities $ 1,919   $ 1,967
XML 64 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Effective Income Tax Rate Reconciliation, Percent [Abstract]      
Effective tax rate from continuing operations 18.90% 29.40%  
Unrecognized Tax Benefits $ 465   $ 467
Unrecognized Tax Benefits that Would Impact Effective Tax Rate 393   $ 395
Decrease in Unrecognized Tax Benefits is Reasonably Possible $ 11    
XML 65 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies (Details)
$ in Millions
Jan. 31, 2023
USD ($)
Mar. 31, 2024
USD ($)
units
Dec. 31, 2023
USD ($)
Mar. 31, 2023
USD ($)
Commitments and Contingencies Disclosure [Abstract]        
Accrual for legal matters that are probable and estimable   $ 283 $ 377  
Restricted Cash and Cash Equivalents in Other current assets   $ 93 $ 130 $ 135
Litigation Settlement, Amount Awarded to Other Party $ 42      
Brazil CADE - # of individuals for alleged anti-competitive behavior | units   29    
XML 66 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stockholders' Equity (Details)
$ / shares in Units, $ in Millions
3 Months Ended
May 27, 2020
USD ($)
$ / shares
shares
Mar. 31, 2024
shares
Dec. 31, 2023
shares
Jun. 01, 2023
Class of Stock [Line Items]        
Preferred Stock, Shares Authorized   50,000,000 50,000,000  
Preferred Stock, Shares Issued   0 0  
5.50% MCPS, Series A [Member]        
Class of Stock [Line Items]        
Preferred Stock, Shares Issued 10,062,500      
Preferred Stock, Dividend Rate, Percentage 5.50%      
Preferred Stock, Liquidation Preference Per Share | $ / shares $ 100      
Net proceeds from issuance of preferred stock in connection with public offering | $ $ 975      
Preferred Stock, Convertible, Conversion Ratio       2.3834
Common Stock, par value $0.01 per share        
Class of Stock [Line Items]        
Conversion of Stock, Shares Converted   24,000,000    
XML 67 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Weighted Average Shares Outstanding (Details) - shares
shares in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Weighted average shares outstanding — basic 1,468.4 1,435.8
Net effect of common stock equivalents 13.4 10.2
Weighted average shares outstanding - diluted 1,481.7 1,446.0
Share-based Payment Arrangement, Option    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 2.0 3.0
5.50% MCPS, Series A [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 0.0 24.0
XML 68 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Weighted Average Shares Outstanding - Narrative (Details) - USD ($)
shares in Millions, $ in Billions
3 Months Ended
Mar. 31, 2024
Dec. 14, 2020
Earnings Per Share [Abstract]    
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture 4,000,000  
Stock Repurchase Program, Authorized Amount   $ 1.0
XML 69 R49.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Reporting (Details)
$ in Millions
3 Months Ended
Mar. 31, 2024
USD ($)
reportablesegments
Mar. 31, 2023
USD ($)
Segment Reporting [Abstract]    
Number of reportable segments | reportablesegments 2  
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]    
Amortization expense $ (214) $ (203)
Operating income (loss) 675 552
Other expense, net (67) (108)
Income (loss) before income taxes 608 444
Impact of Foreign Currency Fluctuations on Net Sales 29 52
Net sales 3,856 3,389
MedSurg [Member]    
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]    
Operating Income Allocated to Reportable Segments 474 409
Revenues from contracts with customers, disaggregated - performance measurement $ 1,402 $ 1,266
Segment operating income as percentage of net sales 33.80% 32.30%
Net sales $ 1,412 $ 1,280
Cardiovascular [Member]    
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]    
Operating Income Allocated to Reportable Segments 653 553
Revenues from contracts with customers, disaggregated - performance measurement $ 2,426 $ 2,072
Segment operating income as percentage of net sales 26.90% 26.70%
Net sales $ 2,445 $ 2,110
BSX Reportable Segments [Member]    
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]    
Revenues from contracts with customers, disaggregated - performance measurement 3,827 3,337
Total allocated to reportable segments [Member]    
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]    
Operating income (loss) 1,128 963
Corporate expenses and currency exchange [Member]    
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]    
Operating Income Unallocated to Segment (115) (98)
Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net (charges) credits, restructuring- and restructuring-related net (charges) credits, EU MDR implementation costs and litigation-related net (charges) credits    
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]    
Operating Income Unallocated to Segment $ (124) $ (110)
XML 70 R50.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue (Details)
$ in Millions
3 Months Ended
Mar. 31, 2024
USD ($)
business
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax $ 3,856 $ 3,389  
Number Of Businesses | business 5    
Contract with Customer, Liability [Abstract]      
Contract with Customer, Liability $ 593   $ 577
Change in Contract with Customer, Liability [Abstract]      
Contract with Customer, Liability, Revenue Recognized 62    
United States      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 2,258 2,003  
International [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,599 1,386  
Emerging Markets [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 648 529  
Endoscopy [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 642 577  
Endoscopy [Member] | United States      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 395 351  
Endoscopy [Member] | International [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 247 226  
Urology [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 513 469  
Urology [Member] | United States      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 356 326  
Urology [Member] | International [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 157 143  
Neuromodulation [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 256 234  
Neuromodulation [Member] | United States      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 190 172  
Neuromodulation [Member] | International [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 66 62  
Interventional Cardiology Therapies      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 652 591  
Interventional Cardiology Therapies | United States      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 195 183  
Interventional Cardiology Therapies | International [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 457 408  
Watchman      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 344 291  
Watchman | United States      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 311 265  
Watchman | International [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 33 25  
Cardiac Rhythm Management [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 575 548  
Cardiac Rhythm Management [Member] | United States      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 354 345  
Cardiac Rhythm Management [Member] | International [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 221 203  
Electrophysiology [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 300 177  
Electrophysiology [Member] | United States      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 158 85  
Electrophysiology [Member] | International [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 143 91  
Cardiology [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,872 1,606  
Cardiology [Member] | United States      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,017 879  
Cardiology [Member] | International [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 854 727  
Peripheral Interventions [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 573 503  
Peripheral Interventions [Member] | United States      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 299 275  
Peripheral Interventions [Member] | International [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 274 229  
BSX Reportable Segments [Member] | United States      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 2,258 2,003  
BSX Reportable Segments [Member] | EMEA [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 803 712  
BSX Reportable Segments [Member] | APAC [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 647 548  
BSX Reportable Segments [Member] | Latin America and Canada [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 149 126  
MedSurg [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,412 1,280  
MedSurg [Member] | United States      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 941 850  
MedSurg [Member] | International [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 470 430  
Cardiovascular [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 2,445 2,110  
Cardiovascular [Member] | United States      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,316 1,154  
Cardiovascular [Member] | International [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax $ 1,129 $ 956  
XML 71 R51.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Changes in Other Comprehensive Income (AOCI Rollforward with Reclassification) (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
AOCI attributable to Boston Scientific common stockholders, Net of Tax [Roll Forward]    
Beginning Stockholders' Equity $ 19,282  
Other comprehensive income (loss) 78 $ (91)
Ending Stockholders' Equity 19,926 17,850
Accumulated other comprehensive income (loss), net of tax    
AOCI attributable to Boston Scientific common stockholders, Net of Tax [Roll Forward]    
Beginning Stockholders' Equity 49 269
Other comprehensive income (loss) before reclassifications 124 (35)
(Income) loss amounts reclassified from accumulated other comprehensive income (41) (56)
Other comprehensive income (loss) 83 (91)
Ending Stockholders' Equity 132 178
Accumulated Foreign Currency Adjustment Attributable to Parent    
AOCI attributable to Boston Scientific common stockholders, Net of Tax [Roll Forward]    
Beginning Stockholders' Equity (96) (1)
Other comprehensive income (loss) before reclassifications 65 (40)
(Income) loss amounts reclassified from accumulated other comprehensive income (3) (2)
Other comprehensive income (loss) 62 (42)
Ending Stockholders' Equity (34) (43)
Net Change in Derivative Financial Instruments    
AOCI attributable to Boston Scientific common stockholders, Net of Tax [Roll Forward]    
Beginning Stockholders' Equity 154 269
Other comprehensive income (loss) before reclassifications 59 10
(Income) loss amounts reclassified from accumulated other comprehensive income (38) (53)
Other comprehensive income (loss) 22 (43)
Ending Stockholders' Equity 175 225
Net Change in Defined Benefit Pensions and Other Items    
AOCI attributable to Boston Scientific common stockholders, Net of Tax [Roll Forward]    
Beginning Stockholders' Equity (8) 1
Other comprehensive income (loss) before reclassifications 0 (5)
(Income) loss amounts reclassified from accumulated other comprehensive income 0 0
Other comprehensive income (loss) 0 (5)
Ending Stockholders' Equity $ (8) $ (4)
EXCEL 72 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( +. H5@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "S@*%8OT@*5^X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M3L,P#(9?!>7>.NT80E&7"X@32$A, G&+'&^+:-HH,6KW]J1EZX3@ 3C&_O/Y ML^0&@\(^TG/L T5VE*Y&WW9)8=B( W-0 D/Y$TJ'\C'L(!C_, MGJ"6\@8\L;&S (BQ$H1N+"B,9[N,);W'!A\_8SC"+0"UYZCA!558@]#0Q M',>V@0M@@C%%G[X+9!?B7/T3.W= G))CL2 MFPXI_TI.\3'01IPGOZ[N[KROB[DNI#5MI9*KE5U^SZY_O"["/O>NIW[ MQ\9G0=W K[O07U!+ P04 " "S@*%8F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M +. H5B)!M?^GP8 (HF 8 >&PO=V]R:W-H965T&UL MM9KK%9:Z/4]F.G$]H;[K/P6&QY M )^LA/29@DVY[H1;R9F3%/E>AQI&O^,S-VB-3I/WYG)T*B+EN0&?2Q)&OL_D M\X1[XO&L9;9V;]RZZXV*W^B,3K=LS1=<_;F=2]CJY"F.Z_,@=$5 )%^=M<;F MQVG7B N2/;ZX_#'<>TUBE#LA[N.-F7/6,N(CXAZW51S!X-\#GW+/BY/@./[- M0EOY=\:%^Z]WZ1<)/,#O6.2I6_'X.\^ >G&>+;PP M^4L>TWV[W1:QHU )/RN&(_#=(/W/GK(3L5]@E!30K("^*C#+OL'*"JP$-#VR M!.L34VQT*L4CD?'>D!:_2,Y-4@TT;A WXT))^-2%.C6:B@*EX^W4$Y/=.4O#L?*3Y:5Y%DE>>>!Z'_^A.6!K8U0?&8_1CN&4V/VO!( RY?."MT4\_F'WC5QWM.X6] M8._F[%TL?91WD>7SENM(\7+3:'_6(:%5-9%Z.5*O&M+GB$G%I?=,;OE62*7# MPZ.4C'0G98I6U<3KYWC]:GAS+EWAQ(.2P!RA;3P\*1^&I>,0K:_).<@Y!Q5[ MIF2PO"3#LKP=\:P5\T)M0Z)E-0&'.> 0/:ALVKEP/4ZN(_^.2QT8GF&V3=,8 M6CHTM+ FVDF.=E(%[9:OW5!!\RERS7QM#\5S)C>+Y MM+@N+RUX:17>L>- >GBT>T$27[@)].V*1UJ&028"E# @"]O-SB'YRIZU^&A6 M7?S"E$Q41OZ'/XVWH&LOQ6.@1+>DW3:,5P=E]/A 3UCJ,5J0I?,PI=,7'(NA0V--M^( /.) R'] MH=7N&H9^ZFW"ELQ"E\Q*OC2-I(RU,'5!-U@GXS+27]?BB=^U5\-3O*HN9^%. M9B5YF@5P[9+>#HG]GNW M9QX8AEG$[9$"UNBE6PI]E]P(YA:UT+JUKS)@9Q+ M)M>4K MY(A6DJ-SG\MU/#!_@P2U@5G6W[) W[1X8#EH$QI$"PVBE31HL>'0D!@>'E.. MUX3XT$)\:"7QN82+-VA&\ $FR1?F13R^YP#43&I7S2RUEZ3&-YH?1L:Q89YV M'EZP->$ZM' =6LEUH-'\6+B5L.^/4J20W$0*Q"=P %K+]T[:DIV'-*V_=[;, M[@#$Z638M?)S]I*R4!R*&\J.$M8+"5(P"QS^1/[@^DZ*1X$,&,-A;T![6HHF MG(<6SD-Q7=G)P(4;QO+SG4-/Q6Z('8AK@[*V+5,+VH3\T$)^**XJ^=VP?=(+ M>%._?N!AI;?=FQ ?6H@/Q37E-6-V@[.<$H_[K&_')J3'*J3'PF5E#(!."NDQ M[2QS(*!TS<#KZH(5;F/A3O)R0MU"[WQ(5HP/\1) MK!NA&7K!I[\YE]3FG @ MJW @B[[[CTGO)#,9?Q-J9.W]EH8[S=)5'B=B14SZ\]TO9,'M2,()T7+C2?5[ MU!1/KGL."G^R<']:2N8D%Z;/_IWPM.AXP&3Q38O5A#I9A3I9N#KMVI*%E=OD*:K .F<]RGO1^ARP:ND.1:*%!"!SH<+)<# M+>4[N4\&WX1)685)68-WG[?>28DR_B8$RRH$R\*=Z"WS%I[TQFXTQ>/J@A?6 M9>&:5&&R.O CW>);"5@3JM4M5*N+FU+UZ>I 4-ETA9>]E:^S][1/? ,E>0@J M)';\HV'ZX$_^;OZ@U3AYO*A3[)X^I77%XOLO(?'X"DJ-XP',JS)]\"G=4&*; M/#MT)Y02?O)RPYG#9;P#?+X2T&NSC?@+\L?/1O\!4$L#!!0 ( +. H5C% M X9(K@4 '47 8 >&PO=V]R:W-H965T&ULK5AM;^(X M$/XK%KM:M5(+L1,"="E2R]Y+/_2N:M7;#Z?[8!(#5I.8LPUM[]??.(&$QHZ[ M*_4+Y&5F\LQX9IZQI\]"/JDU8QJ]Y%FA+GMKK3<7@X%*UBRGJB\VK( W2R%S MJN%6K@9J(QE-2Z4\&Y @B #VDK*%OQ^8LRXPEP/'OWFBO_J91/+X^ M6/^U=!Z<65#%YB+[SE.]ONR->RAE2[K-]+UX_IWM'1H:>XG(5/F+GO>R00\E M6Z5%OE<&!#DOJG_ZL@_$D0+8<2N0O0)I*T0="N%>(2P=K9"5;GVCFLZF4CPC M::3!FKDH8U-J@S>\,,OXH"6\Y:"G9W-1*)'QE&J6H@<-?[!&6B&Q1']NF*0F MU@J=/!9TFW*0.47GZ/'A&SKY?(K4FDJF$"_0+<\R(WB&/A_?3@<:()H/#9(] MG.L*#NF $Z);4>BU0K\4*4O?Z@_ M=H_Q%^)L42AE\2ZY=P&+KFR2.QBU@#J$PZ@C=J 8V\B;ROCD4*\1> M@%(44QD0R8<'NI74)!V &1-!#).PVM,#5IECH%1R<+2&'H)Z=. M\,2.W*B-W2%#.J WQ(B]_&/R5$MHPEMIFHK!F\!XL8+YXB21#&8/Y<8;VFG8 MAFN+D(ZVC!L^PWY"L_N?$UUD1VHRL@ ZI$:3KEIJR W[V:V!R*NIXR0#,G%' MT>:N>#1LP[2%AL.N=6\(#L=^(M%K)FN$^V">.LD$>[GR9]GDHZR]];OA3^RE M*Y@$-0.[VMM)1E;$S^/VV.$4ZB -W- =]O-=N2QGI@Z=P&RF(FU8MLAYU-7@ M&C+#?C:[.<[D:C46##:S[)!!FKYTE*+-5W'0GI0<0E$4N4&3AM2(G]1N:F@_ MUH.)B[W:U>@2"CLXCC0<1_P<9^;T=[L%L;DKFK2;FD,HQ%VA; B.^ GN#C;Y M3 (?(-@9)T\HY3L@N2)U+CFQ>:H]*#A$SCM1-EQ&_%QF11%1K25?;#5=9) ( M A4"7A=:BG*J!.&J&;C=L/GK'+?]L&4Z*(XT%$?>W[/YO;B&_1,,%P\)AXF# M+WD"4T>>PY-R<=:PF6+2[9*]FXLF5H8[MGQ!EU<-*Q(_*UI>55T$N+(&;XXU MT)=/8X+)5W-&Q!.G#]5WAL5'V7M M;0P:JB5^JKWNS+!*;WSZD:+37E,NA!:B[R\7#,*'R%O%<%(1H]E(RK MJ5=HO;GT?945I,3J0FP(AR\K(4NLX56N?;61!.?6J61^% 0#O\24>^G$KMW( M="*VFE%.;B12V[+$\N>,,+&?>J'WN'!+UX4V"WXZV> U61!]M[F1\.8W*#DM M"5=4<"3):NI=A9?S,#(.UN)?2O;JX!D9*4LA[LW+QWSJ!8818233!@+#WX[, M"6,&"7C\J$&]9D_C>/C\B/Z7%0]BEEB1N6!?:*Z+J3?R4$Y6>,OTK=C_36I! M?8.7":;L+]I7ML.QA[*MTJ*LG8%!27GUCQ_J0!PX ([;(:H=HK9#+#^C-J[?H%:(<75/&("EJ MXFO@9)#]K-Y_5NT?G=@_1M>"ZT*A/WE.\F-_'[0T@J)'0;/H+. UEA/S]")F_C&%B\^@=>$]&1$OUXME990SM]Z.>.7:H,S M,O4 6!&Y(U[Z^H]P$+QW27\AL*- )$T@DG/HZ2=H2;2N(69JR*6V@AA:"-. M=FDRABSL#D5T;>(P:6R.N/4;;OVS2?JL"R)1=I2=(Z[O$"A]4A)>/8306ERQ7#5<_/OT)%,-;MB4 $/#A+3 M'[9RUS7I)9$[=\.&\/"7=945F*]-RJ"!2[K#YF9 *\HQSRAFL X';&O[FHOW ML$,JBEJ\NR:])';S'C6\1\_B#72A R\)AR>--M5%J1#F.1*V/"GT$2?_48=< MT*+?M>CUW>S'#?OQ6?:_/#$NHN,.C>&HQ;1KTAN';JIA\'3%!6?)SI]'LT8[ M+N1V13B,HNA$280'EW'XNTP1UEK2Y5;C)2-("\0%?.9:"KAZ^1J,-8%VX"[Q M>MNCN [:BKHVP0D]T9.>Z/EZVD)F J8&PO=V]R:W-H M965T&ULK5G;;MLX$/T5PBV*%G!BD91D*4T,Y-+=-9"VV3K9 MQ3XR%F,+E417I'/9K]^A9$N61-$.-@^)=1D.SPPY/(?4Z9/(?\HEYPH]ITDF MSP9+I58GHY&<+WG*Y+%8\0S>/(@\90IN\\5(KG+.HJ)1FHR(X_BCE,798'): M/+O))Z=BK9(XXS29CD:&#JD_=G M =DT((6'R.*AX@XQ#4TO[0WO^+SJCEM-A]!Z%7\ MI(J?%/YH7_SK/.>90DQ*"/G$%$_IP#4[T&5V(E=LSL\&4$>2YX]\,/GP#OO. M9U-T;^2L$2NM8J4V[Y-+)I>(91&:ZPO^:QT_L@2"-XYBZ6I.$4!*> MCAYWH^D:!;Y7V31 NA5(UPKR-F<1A^J>BS4@@Y5BS@'F?<*'*./*A+3TYS>0 M.FX+J<&(D, ,U:N@>E:HT^P1LB?RF!LSZ'6[]'SV KONUKR'-:VW<(SP1MWNO;' M[?09; @VPPLJ>(%] @K%D@/@!9VN QQX+7Q=(]_#/<,;5@##/<,+))ZKER%: MP7*MBHK6Q;P"=E6]51)V)UH0CEMP349>:(:+G9IB'"O@WX6(GH PC&3A=+K$ M+NV4B=DL&/= VV$_?,!L#55 M82L[ /<]<)B5D:YHR\3<>&G4[#@D;8P&J\#MJ1U<4PRVV#69,,WL,RWV_/K]'Y;/;E=F8$U^4+ZOM^9Z -9AZF?@^\ MFEBP=Y J26)V'R>Q H8Q2A-L):C7:I.W\M8,NF8M;*>M;= 1OU=(W"?Q@JE> MC=GE)>QT5E^#5?_D+V_GK?*M-5NQ%"Q,COBXQA:2SJ!F,7-(#KZ8O;.O89'@S[#5DV;FQUU>(DY V_@,5K[;-[EK^L)V_FKR_\X4-R+M4E) VK1E M,NIC65+3%K'35E,([,%)N@3EAKB]FAFM: \QD)K%B)W%KJOE5M>.$5Z7D4*/ MMD6RP2KPQCT%0W:V6 ?RUCY!2KJ="]*H78\!ORHMOY:T9>LV+9.]V;E,_4B=AB-X[ MQPX&]LD1[-_7'!TAME9+V(?^"S:>,W2>$6-:>[RJ],N 9M),R$U 1,[ >OY+[*#LD&VR6@F M9),'/!Q3.B0A'0:!MWUK3PXT(6'AD,"31I-7Y*U+_+C-:7:;9N9J;4#V[&US MSN0Z?]GFCBE8/*2"C! ?$A&$P\ -#DO$*Z+MRH@C0KRV&MIKUHRYEAO$+C?. MHRC6.A*X7)^*',49FK-5#-QN!&O8 CMCW)9&1C/?[1D@6FL.:M<84C: M&L]H1H(>74]W#F_M"N6;R#31YR*!-PM]9L&A2GL.;[O"@[B=Q)J,>HY$:2U. MZ)Z==9%92Q8-)[$.]H,VN*X9!L7:PQVTUA'4?F9;;OROI^<7T^OI[?3+#)U_ MNT)?_KR;WOYCA.MUCKA-!P$FL_Z# %IS/SV4^V?EBCTKU^9I06!&P/LYV6I2 M AWM?%'2G_. !19Q)E'"'Z"-//R"UEYH\2J^,AT+Y02:7&YY P*2QO M^PJOE-._@-02P,$% @ LX"A6.G-@]C> @ E D !@ !X M;"]W;W)KW#)%2V[F':@TDN)*H3,]N!=K]^UPY$4$(*U7@@MG//\3DWUQ_AFHM'F0(H M\I2S0HZL5*GEI6W+.(6\O^U7A'+S,J8RK VP \8[12 M9FS=4$6C4/ U$3H:V73#Y,:@T4U6Z*\X50+?9HA3T9@7DK,LH0H2#/3=363>V2F;U1TB->] M(*[C]AK@XW;X#<0UW-N'V^BY-N[6QEW#YQTWGF QHNOC*3C(P*^KF50"2^]W MD_]JPE[SA'HY7LHEC6%DX7J3(%9@11_>=7WG2U,V_A/97FZ\.C=>&WLTP:4$ M0F ZIHK'CQ<$TT"XP)[)T0-E)9 )X("NA:945/Q]PZ\WDE7D=)QN:*]V+;X2 MM">]5TOOG2?=2)3DJE0I%]E?2)KD5IS^CI*^4_U>2#XA<$]VOY;=?Y/L.RG+ M9LG] R4OM;9%[(GT:Y%^J\@QSW/<>=]:$_XI-?%*T)[N0:U[<(;NDPIB<) [ MUW&:2^*DT#W=0:T[.%OW14M)M+*=N_\$![:Z W>(GER]>S?9&M:VAJVVON-M M0Y;B>6NLLKDUV&1L>)ABWW.#8= +7GR,4R(KT?;.F:GO*W@\+;)"$@9SQ#J= M =:@J.X 54?QI3E&9USAH6R:*5Z;0.@ ?#_G7&T[^F2N+V+1/U!+ P04 M" "S@*%8U^^%]PL* #C;@ & 'AL+W=OSA:O+9^$0M4E?8E_A/PI[+D\]:O2OW>?ZMWJ"KJXE>MXBE M;%G5B)C_>F(+EJ8UB;?CKP8Z.<:L*YY^_DD/]CO/=^8^+MDB3_^;K*KUU<29 M:"OV$._2ZC9_CEBS0[.:M\S3V[*ZA-MN2NK?--4YBW8)-GA=_R]Z8B3 M"H8Y4($T%8A8P1ZH8#85S)=&L)H*EEAA-E!AUE28"17(?*""W52PA0K64"_- MFPISH<+,&:C@-!4_?I>^U5+,NV/)$VY?LO+:<4;5N.G MRZ81-X=&D(%&_#NOXE12;:&N]H6?%ZPH>,/+NJD2@*<&+/+-AI]P0[7],ZWF M@TNY*WX,U@_4]3^O>#_R#HM3;1LGJPO>A$RPNLB1[ M+*?O/B^7N\TNW1]8?O8GRZ1Z+P%'9QIY0LFK-2NT9;[AP^JZ'N^>&#_N?)MI M[]*\+-]_T#(^/'/I5/%W22BJ#O5GSEE95>1<1MDC)U>L8&4EZ&G*!7Y4.3FJ MG.S1Y@":9LOZ8/%V>NSPZ7VM6*G"_W?+&Z#QD?0Y+E;_EXGY$,N2QZIGIT_E M-EZRJPGOIY(53VQR_=LOAJW_+I,X$N8A83X2%B!A(1(6(6$4!.N(W#R*W%31 M#Z/H83!J-/W;+PXQYK]K;*]LF925Q+%21L(\),Q'P@(D+$3"H@-LOH?55[E/ MU\1V+Z=/IPH%!>PHU#HJU%(J](8])ED]/6DW<1IG2SX>WZUC'D>C9;FK+RGB M2N,C]$?--#YH1"=$IEEEC+&:/<#LDRXS^&T"F>EZM]\\9%0?"0N0L! )BY P M"H)UA#L["G?VSX3[,L4JX6,5BX1YL[[\;=>V3=-US>X)X"/C!DA8B(1%2!@% MP3J:M8^:M<=I]L//*]R72%;)'BM9NS M.L(D&$I8\YG0ILCNG1O]V52U9YVC-C\>M?D;WJG,D4<1"?.0,!\)"Y"P$ F+ MD# *@G5$[AQ%[BB'IKV:+^IGE*O]XP26E?'^T>?/656F925RK):1,,_I#126 MX5J.(PPH/C)H@(2%2%B$A%$0K"-3]RA35RE3X?FBEO";E'HBE:E321JK3O?L M?(D,YR-A 1(6(F$1$D9!L(XN#;U]:*\KE7G+MKMBN:ZO$_*'>@A5/<:^4+ ME.C1BD72O(:F&)U]:,"@H9V*VG:$&QIHQ A*HRA:5X>M]6,H'[I?_\FJKDLE M%1SI'533L+J=O% '&JTCJ%D#I0506MC0;%7G1M"0%$7K:JYU8@RU%2->.:Z2 MIV3%LI5\L(.:,%":!Z7Y4%H I84-[52D%WV1(D-2%*TKTM:,,=1NS)C;&S5J MM$;[KHMX@P,-Z$-I 9060FD1E$91M*Y"6]?%4-LNO:E;BZNJ2.YW57R?,JW* MM>Q%:T8:#??-#EV[]H(&I J W;5UOHEAMHP6:SC[)&5 M]>/VLRN=I/KJ&P87KB$J#&FL>%":#Z4%4%H(I44O.5144FA(8ZV[8RB?JQ\U MUA^Z\N>,%>4ZV1X',:G&H(X.E.9!:3Z4%D!I(90606FTH75LRYD[H-O6L#'4 MCHV?K%PH5Z.U":U] ZI\%HC: MZ^E*]W01SUGEDKX=8CB&+BQB633%5'ZCI$AO@8XDFFR%CJ08T4YD%I/I060&DAE!9!:11%Z\J] MM5&(VD;Y)]D%I/_@GY^=XDF\4$<>K59L$@PV"P:;!H/-@Y$>+'$H?0U?A;2^ M"L&GN)!^5H3A$H>((H3Z)E":#Z4%4%H(I46D[\)8XII;5,2N!EO;A*AMD]%) M+/)+,ZBA0LX;*M" /I060&DAE!9!:11%ZVJW-50(*H]%+EI)NLBK>Z$O] =JLK22'1;6LNWNKVBSF&*][I]@OU9T9)/,L9N-%M/0OREBDI!.I@ M0&D>E.9#:0&4%D)I$91&4;2NW%NK@[Q"-&$%I%$7KZK#U64Q NHK9?U9OB2_L6*@#C=81U%:!T@(H M+7Q)YT;0D!1%ZVKNY,5AP'05-6OT8(=]:1CVK6'8UX9AWQO6-TK$M1'0@!1% MZTJT=5U,M>LRYB9'C1JMT//>"C2@#Z4%4%H(I450&D71N@IMO17S+9-53(GA M(<[O4(<%2O.AM !*"\]W;00-2"4!+PSY4WFSM4O,U\U6,?M>@;C:8Z%NPFB% M09-5H+0 2@NAM$ARI!SAUWJW! M8R%R5*3*M63I((;X@J.%=3Y'15*DMW!'4D:V<$=2C.AS0[CJ"F41^V^VD>RA M80K+CZDLHD7D6;_<OKT4CG*UXQ_4ZN>0V_+*2JF(%;M1SIM>*L<(VJ"F?;@?)8/_@JUBNC'TPNKM9LR5_Y.;; M^D'!W>C02R$J7FLA:Z+XXG;P/KF^SZAMX"S^$/Q)'UT3Z\I\+&U/@..OMM/!84S;\/AZW_LGYSPX,V>:W\OR3U&8U>W@ M2"W#.](I\@SIJD=H.Y?WIQ&X-##U%+7'PU-K9V_M9); >Z1 M^8Z<;31P6O]9KEO/; >QAS=66#^Y^ M^2F9CO^#N?]&G9U,1G:8C"S6^]WOD)%$G=MT,7-=V/RSO"-7FE+@BKI#+B;_< P]ET-SW&,,YZ M.'V;]'*"XYP><$Z?P;G@2L$2LA@!\IJ)8C^IAOW 5]#4QYKTH/HFR16.='9 M.HLB?30R_SZTZ;4@ \X1S>SRW_8:XX!G7DHIOW8^R:3P)1>'H!>/KLL[7(D M9TN@/-B7-4SHEFO39$$[T;4T7 -CY5QLV;Q$L5_ZP>Y!]RV.PG "_>H _2H* M'3*W32" $Z88:+5P&04K 1DQ2'G8P[QAE' M@?_7K+BZL#!1SAA[0P[[>PNS"<$Z(L(D"NM_BA417;.=#>N%C;7:0(9J-TNSW:7SH!1L+LH@ M+;=#G2*@KQ&L489NX.U$;KFI6$@@MT7)AGIC"$Y'/B<-D=M6/)&857(D=>29Q]GQ0,N>\ MT&2A9$4T*_FSWJ$^^.38ERB("0V@[_@SB1/H ]LU+ \[!]8B(-3"$J@+T7RC MP1SRF'9,91_E=M\Y.]4O5UH_?+8<9GU&Q8SH+)!XTXY4TSBIGCC3ES!]YW(( M#\@=8GB^JF4IE^+(S:ZQC:2++^9LBG#P=-IS%C-* ADD[9@ZC3/UZ;)37P0,$V\!(D9! MI)U22./U[@G2A5N,G)3 M%9E+!5W! L#1(I0\\4X1$*L0W(ZUT]>P=BGK91_O@0L*/C=$:+UQ4Y]+'5@C M2/V;9-[4^U8A7SH.3Y\I@FV.+81-L75AI;TH2+,_VZ,2;4\B4,P^#_?U.V(R M#)TUT8ZI:9RI'63'!$:Z>=8KT'8$*B8#^HE7ZU+N.'>*"38F ^&'$S!%N'5V MV7,!,YH$9IUV!$Q?0\#[]=%("UE5=AO8:;?)T/YDK*<'QYJ?3DZ%W'G6/G%: MT8@[['/T93]DB,TT(!1I1^3TWQ/Y N%(%+Q/TP\%< [$1X#/N\I85MRANI!;OBR?$)K3$.A:F+SHO5C;; MD[."-U?G#<^+!N]%(\GM3ME"[0$9^(* (C!*Y/9M1J/786GUGQTU0%WV:3?) MLGY%@E@-:7"M=>Q,GR_NW\ OP@R9\Z6H:[LT;5'&E9!HU4*1*G_LGO7P-O%VA4;;SZI<\;]7;J>"NJ4E*I@2ES&- C9JM<3S8IDBBL'+EHA-(,5GG:C(7B J["9Y28++?%&0 MTK3/18C59!;(ZUDG';*X=/CZRHT-'%!NBJ:V:@Z7\PT$PQXK!0^9,Z28]UXC M^C8)#2R@K%,*65PI]+V+>]))[X@OOB*8]8L$Q&8R"[C2B88L+AK^GYFYA3*+ M9V;$RL_,HZ-/(2JNENX+$4U<+=Y\27!X>O@*Y;W[]J+W_$-R?=]\2])UTWS: M\H4I(%8-E>@"NAR_FP$UJN9KD>;&R+7[X&(NC9&5NUQQ5G!E#>#WA91F?V,' M.'RS<_&PO=V]R:W-H M965T&ULI5=M;]LV$/XKA IT+>#8CI-V19L8<-)T#88F:9RN M X9]H*6SQ98B59**X_[Z/4=*MH,Y68=^L47Q[KF[YUY('2VM^^I+HB#N*FW\ M<5:&4+\>#'Q>4B5]W]9DL#.WKI(!2[<8^-J1+*)2I0>CX?#EH)+*9..C^.[* MC8]L$[0R=.6$;ZI*NM4):;L\SO:S[L6U6I2!7PS&1[5A8Y6)@N:RT>':+M]3&\\+ MQLNM]O%7+%O982;RQ@=;M*M5(5-EF.)>^$S'.V6DR9748HJ7A#(,7OPUF?G@ M4$A_[V(H.7"XVP%NKM>^ECD=9S7;4C9\^V7\Y?/-(>(?K\ X?0Q^?3*;G M4W'Y3EQ=GTW/+FXF-^>7%[NO1OO[;\1.5'%3$IHIMU4M MS4J9A6B,; H5J!#YFEO%S/'H$2C$GM["KX MJTRA4,B#V%3P0=%?C[.%.:(VM2#HVPHZ\!5PU([36.38 MU*N>0,+^5V/=+RI8PFP,=&8M\A MPG\3_#%6,?O4, 1?8PK>CX2U!B*.;3P<14-/.-I4U&FHX-;64V9%%T M&&P08Y =BW \'AKN*D1PA23P4%A M1T0V(X\2)WS_.9RLPCGVNK6\<=3RQD=WGQ4UIP1+,5=UYDV;A!K ])W>V MUZ926<-%9I"BU@%>;0;70[:VO'UFK-EK;7^G=)*TY"8FG_^@-P\X<$US9M^* M"U GWJ]O,^CD2H7-&,,ED(\$@H6VZ^>-XXF&6SWJ4?O^KHO98.NN79%;Q"\* M+^+02=?N]=OU1\LDW=4WXNF+!P?- M<.H6D.U6'_UQ>9<.DK(BV"K>/-?68# MO@/B8XDQ3HX%L,^#N%NP@?6GW/@?4$L#!!0 ( +. H5B23]N&V0T !0D M 8 >&PO=V]R:W-H965T&ULM5IM<]LV$OXK&#?I23.R MK!>_-_&,[-B-KXWCLYQV;F[N T1"$F*28 #2LOKK[]D%2%&R[.:F=U]L2006 M^_+LL[N0WBV,?7!SI0KQE":9>[\S+XK\=&_/17.52M<%OVFU M<(W7@BR9&/- ;Z[C]SL]4D@E*BI(@L2_1W6ADH0$08UO0>9.?21M;+ZNI%^Q M[;!E(IVZ,,GO.B[F[W>.=T2LIK),BCNS^*B"/0#'=$5+K" MI&$S-$AUYO_+I^"'QH;CW@L;!F'#@/7V![&6'V0AS]Y9LQ"65D,:O6!3>3>4 MTQD%95Q8/-785YR-HF^E=IH\Y#KB SSD"EV45CDALUA@J2S43$?B.J-'"$?A MWNT5.)GV[T7AE'-_RN"%4X;BD\F*N1.76:SB]?U[T+A6>U"I?3YX5> G:;MB MV.^(06^P_XJ\8>V&(YO)7N+^ M=HF43*D7?_5K?_=>DGXTN_O'E>GQ]?_WY M9BQ&-Q_$^/YN='_Y\_6%N+[Y[7)\_^GRYGZ\3>M7Y6[7^N;S_:4X%S_^<#SH M]W\2WW>V^%Q:Y%QDTEQF2YW-1)G),M:%BD4$YYI$QY+>3.'N+-(R$:[ !XPP MH;,H*6,EBKD2("" D"1 (R2;$^ BB 9P+?9C/> +O$ZM27D#EN6*LUW0$4Z8 MJ5_N<=X5ORLQEWB:F4*PF1DIXLH\3_A\Z));(YCR&OKIS),@L0FI0+8EBK8V MI.,T*^)F'LWP)B/%M*TMD-:?#FG*DNS""/,7'-855Z7%$;8C -C,2<]YD7$X M;*%PFD[_5V682,UN*8#0BK%&&--9.#8B6].(H09M' MU*J/FM!')]AL4Q(WH#^:VQ D1B<>>7ME=Y]R5C (T+3KHK%2-O$W%/D2!> M3;7C4MZZNK]HL\TFRT)Q7NABSC+P[&\.:CQ200^V-1#M'0E!)6"IJ@7K&@&6 MA1*8K=.Q/KS(@1$8E%R177*3S_&- ^ MBAAT_9.CPPX!7>)C@E;KX_B.'@)W)7;"QSW0S1(+IL@S8 6;7B;2<>5*"H2 M.R1%C#E$0USM@75C2'A"A6F+,0"0-Q7;'TT"+3R>)TM>G<-"XD6$$@JE5-4( M&M+B/%LM@K^9#]= \43T2="&&]*\@$BB5-**X/[J ;9:I^FSNLPE\F4XN/A#>=^#;K3&LC0 M-N3LR@LAA5^'AP^N-XU.PS8W#=JU( P['Y5MDR!#Q!N:-:* *#&.A))^OB9X M RO_3JIF8X%D)MM @VIFI3*$U="%)VOQH(?B-,?Z/2JLR/7CI 2*A+C2%-AG:+S^V@2Y,?, MB5]UR@G>\FNV$N[%G$Q3.",KR5VH@);YTI:SW*UL%7, Z'O,I(:^)GZ(0-?!',5. M1(E"/\XX(FI8=OALL*6Q,;-EA@U^54+QIC#:BCTY XTM@K38<+TW"]]^U-W+ M.LD?'C3K'#<_94%L00'PI8&[&:]]Q]-T)LH<'(P]OHC(9>6SC[^\&?2ZOG@V M"LN;@_X)9@E?2"2KB^$%?$P%/(N62!O4J6R&3HJ9'$L"I ..O>_(NBE<;@+> M/%UR<7_2CM/J%FF5S[D,7)-S'LF1%/EZ;U?<5E7QEJOB"-B(?(ZRGR(T#=R) M0'&2_3U1)99>95FT:NEI#8FT,9_N*"Y0/Y$FHCJ,QBMN]R9$XQ[V#CM@^6; \@;6KI6WO7.JXDLU682'9#+QA MN'IHR)1T:32P$QJQ3T4+1H;HNG;EDE:_+6X#,LB5+[OQC1@>]\-?VG7YQ*VX MV^Q'^ON]&D30B+&'EW/*$2"&$RH0X?,Z3K&M$XF-<4Y1:QGRHB,2+='K^,X> M#\N4DB60\4MYYX_U;78U 4PEWC_*I&0YE2J59D07+[896T,A5_C<&A7ZP&2< M"AN1Z:PJ(!*,(!&V;)R SL/3QTIU6IFI8M-+#1<:,3,FIH+R @!^#H\ILL,C M,4J)F_Z0DX3+#[)=T\MPP'"X+SXSQVZ>>#)$&7@>F=;^<5O<0$.T\HK& %'( MI[48MHX.V^)JW:(7PM@:')RT P+OG_G!VX,F\:7M%)8U7G\V%$C[ %5KB7YF MI!LLDC/\'@XF1MYBBMRKJ_A8:= 8)G MWSN=H9 RC_'U#\I@'6-RP6J^@5,09XU5GD8#(F+?J9F9)S?5I2;AP>13NDD@IYSIW*)I %B9F!YWSNH^ @#=TI@9^8M<2YG>^ MR([QV+?E_T]]^*"VXG%7%9XHO&7.=.] ^J!3X_G^VL\AK=J0\\[]<6R?<-W6CA6S[J MR$DI S 4U82#P"'FH=U>NS;A&X5FE-:C9V#-<5XC61&5JJC&Z]H]>WA'ZJ&:7*CG(_M-6GRAO7:M/G"35M214&AP- M_>1?R4II%OY3IZU2MX)&?66SULI?22OS,G&*KT+05%3OV\&+U3&8\K7R RWM MP]2E,*?M>I8$BC.B.-\V^1LJA@#@OXM(\>@/(WU13"5:@#*MN@]NE,N$2AQ? M'G"1H,E1+CV7*%M(/^MO=[.N2"%,9Q[)& [I29E%Z#I"Y:\Y738)NCK R83X M8[0E$)TM^'8E%M3B7]..+O)23T=HCOJ'^Q4H7SMLPTO%7+[N*C]X4HC#,/F2 M0M):RMJ 06P+=*/B-BF[T:,-C@Y6VMY1::8#;T#_S?O<9A:^>.E?0S 4HJTW M@Z0V@N$KW#4^%^3U< M8_2WDJ[F&F==TUGBCB>\9\6.6OZ[-7ZX;1+A)XTT*]#@.D+7L)X /M0X%!DLO;JV95/; @FHRX1M-_H,%7_WUSS_!3\TU;.,N M_3NB/P>L\9?GOO0%95'9%^Z[?#5]W*2#,/[_2?"[A#VZJPBJ+8-J@=X[S;', MJM#N^:L[NHB6=1\3- Q](7>1*TVECT2WX8.&:M5X[X]QFQ5BG=K7:EBZ"AU] M_;!B#C!K]% U4_X2H @ENM.H125/3+*YD8>^*84Z-;%*NF+X!$(!E7;]6- MK5N'R9HX3D.M6>^)-A+_>5-TZ<>*5!5SNB]N'(?>I-_GOR?B4]-:>,MF/D6: MZULDLHWE:%!/J+79'YS07[2:E'_?(X) !_,>N3;MSE52?4]!5[EHB3CPU"2B M&1'T P,"W5I?T)SEF8=)9(@5EV?ZODOP=;G&[*2M!Y"> O]T>U?UZ(!Z(]C^ M$@T\M&(0/UY$JP:9IFSK)\AJM'/U-1^8 CBDKYE($E"&"$G;O%,)X70R]5]> MT/=T-+L#CG]X<'[V7]Y1F_I?#H&-\DL RP-KH1=J(6#76;B]J89@[_B&Q_W0 M!EVMG\G 1OBTZ=6&K[B';_BE\>C_;P^RRSV'5)1@QD!6^Z\A_524F&RV2\"I MAJ*_-%AWMET;_CP:W?K1(,@,]X(YA$2:6M%M7_/O-7ZI@>%NQK]'H<3';O^C MC?K3^B=W! $PH M !D !X;"]W;W)K&ULI59M;^(X$/XKHVQ5%8DV M+X066D"B+]M%:@LJW/7#Z3Z8Q$F\Z\34=LIRO_[&3@CL+:TJW0>"/9Z79Q[/ MV!ZLA?RA,DHU_,QYH89.IO7JTG55E-&ZW8X#4:FTR&MC1)"SHOHG/VL>]@QZWCL& M06T06-Q5((OREF@R&DBQ!FFTT9L9V%2M-8)CA=F4N9:XRM!.C^Z%B->,0W>\=J!1U'H3,%=$=/X5WL7 M$38P@RW,Z^!#AX]$GD'';T/@!>$'_CI-VAWKK_.9M']+&&Z9BKA0I:3PUWBI MM,3B^?L0#564\' 4TU"7:D4B.G2P8Q25;]09'7_QS[VK#W((FQS"C[R/[J?3 MVY?)PP.,GVYANOAV]PR3I\7XZ7YR_7 'X_G\;C$_A/ECKT_3Q1W

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 74 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 76 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 344 348 1 false 122 0 false 11 false false R1.htm 0000001 - Document - Cover Document Sheet http://www.bostonscientific.com/role/CoverDocument Cover Document Cover 1 false false R2.htm 0000002 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited Consolidated Statements of Operations (Unaudited) Statements 2 false false R3.htm 0000003 - Statement - Consolidated Statements of Comprehensive Income (Loss) Sheet http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss Consolidated Statements of Comprehensive Income (Loss) Statements 3 false false R4.htm 0000004 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited Consolidated Balance Sheets (Unaudited) Statements 4 false false R5.htm 0000005 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 0000006 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited Consolidated Statements of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 0000007 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 0000008 - Disclosure - Basis of Presentation Sheet http://www.bostonscientific.com/role/BasisofPresentation Basis of Presentation Notes 8 false false R9.htm 0000009 - Disclosure - Acquisitions, Divestitures and Strategic Investments Sheet http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestments Acquisitions, Divestitures and Strategic Investments Notes 9 false false R10.htm 0000010 - Disclosure - Goodwill and Other Intangible Assets Sheet http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssets Goodwill and Other Intangible Assets Notes 10 false false R11.htm 0000011 - Disclosure - Hedging Activities and Fair Value Measurements Sheet http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements Hedging Activities and Fair Value Measurements Notes 11 false false R12.htm 0000012 - Disclosure - Contractual Obligations and Commitments Sheet http://www.bostonscientific.com/role/ContractualObligationsandCommitments Contractual Obligations and Commitments Notes 12 false false R13.htm 0000013 - Disclosure - Supplemental Balance Sheet Information Sheet http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation Supplemental Balance Sheet Information Notes 13 false false R14.htm 0000014 - Disclosure - Income Taxes Sheet http://www.bostonscientific.com/role/IncomeTaxes Income Taxes Notes 14 false false R15.htm 0000015 - Disclosure - Commitments and Contingencies Sheet http://www.bostonscientific.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 15 false false R16.htm 0000016 - Disclosure - Stockholders' Equity Sheet http://www.bostonscientific.com/role/StockholdersEquity Stockholders' Equity Notes 16 false false R17.htm 0000017 - Disclosure - Weighted Average Shares Outstanding Sheet http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding Weighted Average Shares Outstanding Notes 17 false false R18.htm 0000018 - Disclosure - Segment Reporting Sheet http://www.bostonscientific.com/role/SegmentReporting Segment Reporting Notes 18 false false R19.htm 0000019 - Disclosure - Revenue Sheet http://www.bostonscientific.com/role/Revenue Revenue Notes 19 false false R20.htm 0000020 - Disclosure - Changes in Other Comprehensive Income Sheet http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncome Changes in Other Comprehensive Income Notes 20 false false R21.htm 0000021 - Disclosure - New Accounting Pronouncements Sheet http://www.bostonscientific.com/role/NewAccountingPronouncements New Accounting Pronouncements Notes 21 false false R22.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 22 false false R23.htm 9954471 - Disclosure - Basis of Presentation Basis of Presentation (Policies) Sheet http://www.bostonscientific.com/role/BasisofPresentationBasisofPresentationPolicies Basis of Presentation Basis of Presentation (Policies) Policies http://www.bostonscientific.com/role/NewAccountingPronouncements 23 false false R24.htm 9954472 - Disclosure - Hedging Activities and Fair Value Measurements (Policies) Sheet http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsPolicies Hedging Activities and Fair Value Measurements (Policies) Policies http://www.bostonscientific.com/role/NewAccountingPronouncements 24 false false R25.htm 9954473 - Disclosure - Commitments and Contingencies (Policies) Sheet http://www.bostonscientific.com/role/CommitmentsandContingenciesPolicies Commitments and Contingencies (Policies) Policies http://www.bostonscientific.com/role/NewAccountingPronouncements 25 false false R26.htm 9954475 - Disclosure - New Accounting Pronouncements (Policies) Sheet http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies New Accounting Pronouncements (Policies) Policies http://www.bostonscientific.com/role/NewAccountingPronouncements 26 false false R27.htm 9954476 - Disclosure - Acquisitions, Divestitures and Strategic Investments (Tables) Sheet http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables Acquisitions, Divestitures and Strategic Investments (Tables) Tables http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestments 27 false false R28.htm 9954477 - Disclosure - Goodwill and Other Intangible Assets Goodwill (Tables) Sheet http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillTables Goodwill and Other Intangible Assets Goodwill (Tables) Tables http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssets 28 false false R29.htm 9954478 - Disclosure - Hedging Activities and Fair Value Measurements (Tables) Sheet http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables Hedging Activities and Fair Value Measurements (Tables) Tables http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements 29 false false R30.htm 9954479 - Disclosure - Contractual Obligations and Commitments (Tables) Sheet http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables Contractual Obligations and Commitments (Tables) Tables http://www.bostonscientific.com/role/ContractualObligationsandCommitments 30 false false R31.htm 9954480 - Disclosure - Supplemental Balance Sheet Information (Tables) Sheet http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables Supplemental Balance Sheet Information (Tables) Tables http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation 31 false false R32.htm 9954481 - Disclosure - Income Taxes (Tables) Sheet http://www.bostonscientific.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.bostonscientific.com/role/IncomeTaxes 32 false false R33.htm 9954482 - Disclosure - Weighted Average Shares Outstanding (Tables) Sheet http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables Weighted Average Shares Outstanding (Tables) Tables http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding 33 false false R34.htm 9954483 - Disclosure - Segment Reporting (Tables) Sheet http://www.bostonscientific.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.bostonscientific.com/role/SegmentReporting 34 false false R35.htm 9954484 - Disclosure - Revenue (Tables) Sheet http://www.bostonscientific.com/role/RevenueTables Revenue (Tables) Tables http://www.bostonscientific.com/role/Revenue 35 false false R36.htm 9954485 - Disclosure - Changes in Other Comprehensive Income (Tables) Sheet http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeTables Changes in Other Comprehensive Income (Tables) Tables http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncome 36 false false R37.htm 9954486 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Acquisitions and Divestitures (Details) Sheet http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails Acquisitions, Divestitures and Strategic Investments - Acquisitions and Divestitures (Details) Details 37 false false R38.htm 9954487 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Contingent Consideration (Details) Sheet http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails Acquisitions, Divestitures and Strategic Investments - Contingent Consideration (Details) Details 38 false false R39.htm 9954488 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Strategic Investments (Details) Sheet http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsStrategicInvestmentsDetails Acquisitions, Divestitures and Strategic Investments - Strategic Investments (Details) Details 39 false false R40.htm 9954489 - Disclosure - Goodwill and Other Intangible Assets (Details) Sheet http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails Goodwill and Other Intangible Assets (Details) Details http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillTables 40 false false R41.htm 9954490 - Disclosure - Hedging Activities and Fair Value Measurements (Details) Sheet http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails Hedging Activities and Fair Value Measurements (Details) Details http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables 41 false false R42.htm 9954491 - Disclosure - Contractual Obligations and Commitments (Details) Sheet http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails Contractual Obligations and Commitments (Details) Details http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables 42 false false R43.htm 9954492 - Disclosure - Supplemental Balance Sheet Information (Details) Sheet http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails Supplemental Balance Sheet Information (Details) Details http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables 43 false false R44.htm 9954493 - Disclosure - Income Taxes (Details) Sheet http://www.bostonscientific.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.bostonscientific.com/role/IncomeTaxesTables 44 false false R45.htm 9954494 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.bostonscientific.com/role/CommitmentsandContingenciesPolicies 45 false false R46.htm 9954495 - Disclosure - Stockholders' Equity (Details) Sheet http://www.bostonscientific.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://www.bostonscientific.com/role/StockholdersEquity 46 false false R47.htm 9954496 - Disclosure - Weighted Average Shares Outstanding (Details) Sheet http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails Weighted Average Shares Outstanding (Details) Details http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables 47 false false R48.htm 9954497 - Disclosure - Weighted Average Shares Outstanding - Narrative (Details) Sheet http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingNarrativeDetails Weighted Average Shares Outstanding - Narrative (Details) Details 48 false false R49.htm 9954498 - Disclosure - Segment Reporting (Details) Sheet http://www.bostonscientific.com/role/SegmentReportingDetails Segment Reporting (Details) Details http://www.bostonscientific.com/role/SegmentReportingTables 49 false false R50.htm 9954499 - Disclosure - Revenue (Details) Sheet http://www.bostonscientific.com/role/RevenueDetails Revenue (Details) Details http://www.bostonscientific.com/role/RevenueTables 50 false false R51.htm 9954500 - Disclosure - Changes in Other Comprehensive Income (AOCI Rollforward with Reclassification) (Details) Sheet http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails Changes in Other Comprehensive Income (AOCI Rollforward with Reclassification) (Details) Details http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeTables 51 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 5 fact(s) appearing in ix:hidden were eligible for transformation: ecd:TrdArrDuration - bsx-20240331.htm 4 bsx-20240331.htm bsx-20240331.xsd bsx-20240331_cal.xml bsx-20240331_def.xml bsx-20240331_lab.xml bsx-20240331_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 79 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bsx-20240331.htm": { "nsprefix": "bsx", "nsuri": "http://www.bostonscientific.com/20240331", "dts": { "inline": { "local": [ "bsx-20240331.htm" ] }, "schema": { "local": [ "bsx-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "bsx-20240331_cal.xml" ] }, "definitionLink": { "local": [ "bsx-20240331_def.xml" ] }, "labelLink": { "local": [ "bsx-20240331_lab.xml" ] }, "presentationLink": { "local": [ "bsx-20240331_pre.xml" ] } }, "keyStandard": 310, "keyCustom": 38, "axisStandard": 28, "axisCustom": 2, "memberStandard": 47, "memberCustom": 71, "hidden": { "total": 10, "http://xbrl.sec.gov/dei/2023": 5, "http://xbrl.sec.gov/ecd/2023": 5 }, "contextCount": 344, "entityCount": 1, "segmentCount": 122, "elementCount": 690, "unitCount": 11, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 912, "http://xbrl.sec.gov/ecd/2023": 40, "http://xbrl.sec.gov/dei/2023": 33 }, "report": { "R1": { "role": "http://www.bostonscientific.com/role/CoverDocument", "longName": "0000001 - Document - Cover Document", "shortName": "Cover Document", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "longName": "0000002 - Statement - Consolidated Statements of Operations (Unaudited)", "shortName": "Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GrossProfit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "unique": true } }, "R3": { "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "longName": "0000003 - Statement - Consolidated Statements of Comprehensive Income (Loss)", "shortName": "Consolidated Statements of Comprehensive Income (Loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "unique": true } }, "R4": { "role": "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "longName": "0000004 - Statement - Consolidated Balance Sheets (Unaudited)", "shortName": "Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:PrepaidTaxes", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "unique": true } }, "R5": { "role": "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsParenthetical", "longName": "0000005 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "longName": "0000006 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited)", "shortName": "Consolidated Statements of Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-39", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:SharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "unique": true } }, "R7": { "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "longName": "0000007 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "unique": true } }, "R8": { "role": "http://www.bostonscientific.com/role/BasisofPresentation", "longName": "0000008 - Disclosure - Basis of Presentation", "shortName": "Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestments", "longName": "0000009 - Disclosure - Acquisitions, Divestitures and Strategic Investments", "shortName": "Acquisitions, Divestitures and Strategic Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssets", "longName": "0000010 - Disclosure - Goodwill and Other Intangible Assets", "shortName": "Goodwill and Other Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements", "longName": "0000011 - Disclosure - Hedging Activities and Fair Value Measurements", "shortName": "Hedging Activities and Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.bostonscientific.com/role/ContractualObligationsandCommitments", "longName": "0000012 - Disclosure - Contractual Obligations and Commitments", "shortName": "Contractual Obligations and Commitments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation", "longName": "0000013 - Disclosure - Supplemental Balance Sheet Information", "shortName": "Supplemental Balance Sheet Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.bostonscientific.com/role/IncomeTaxes", "longName": "0000014 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.bostonscientific.com/role/CommitmentsandContingencies", "longName": "0000015 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.bostonscientific.com/role/StockholdersEquity", "longName": "0000016 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding", "longName": "0000017 - Disclosure - Weighted Average Shares Outstanding", "shortName": "Weighted Average Shares Outstanding", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.bostonscientific.com/role/SegmentReporting", "longName": "0000018 - Disclosure - Segment Reporting", "shortName": "Segment Reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.bostonscientific.com/role/Revenue", "longName": "0000019 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncome", "longName": "0000020 - Disclosure - Changes in Other Comprehensive Income", "shortName": "Changes in Other Comprehensive Income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.bostonscientific.com/role/NewAccountingPronouncements", "longName": "0000021 - Disclosure - New Accounting Pronouncements", "shortName": "New Accounting Pronouncements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "bsx:NewAccountingPronouncementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "bsx:NewAccountingPronouncementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-330", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-330", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.bostonscientific.com/role/BasisofPresentationBasisofPresentationPolicies", "longName": "9954471 - Disclosure - Basis of Presentation Basis of Presentation (Policies)", "shortName": "Basis of Presentation Basis of Presentation (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsPolicies", "longName": "9954472 - Disclosure - Hedging Activities and Fair Value Measurements (Policies)", "shortName": "Hedging Activities and Fair Value Measurements (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.bostonscientific.com/role/CommitmentsandContingenciesPolicies", "longName": "9954473 - Disclosure - Commitments and Contingencies (Policies)", "shortName": "Commitments and Contingencies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LegalCostsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LegalCostsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies", "longName": "9954475 - Disclosure - New Accounting Pronouncements (Policies)", "shortName": "New Accounting Pronouncements (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "bsx:NewAccountingPronouncementsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "bsx:NewAccountingPronouncementsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables", "longName": "9954476 - Disclosure - Acquisitions, Divestitures and Strategic Investments (Tables)", "shortName": "Acquisitions, Divestitures and Strategic Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillTables", "longName": "9954477 - Disclosure - Goodwill and Other Intangible Assets Goodwill (Tables)", "shortName": "Goodwill and Other Intangible Assets Goodwill (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables", "longName": "9954478 - Disclosure - Hedging Activities and Fair Value Measurements (Tables)", "shortName": "Hedging Activities and Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables", "longName": "9954479 - Disclosure - Contractual Obligations and Commitments (Tables)", "shortName": "Contractual Obligations and Commitments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables", "longName": "9954480 - Disclosure - Supplemental Balance Sheet Information (Tables)", "shortName": "Supplemental Balance Sheet Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.bostonscientific.com/role/IncomeTaxesTables", "longName": "9954481 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "bsx:ScheduleofEffectiveIncomeTaxRatefromContinuingOperationsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "bsx:ScheduleofEffectiveIncomeTaxRatefromContinuingOperationsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables", "longName": "9954482 - Disclosure - Weighted Average Shares Outstanding (Tables)", "shortName": "Weighted Average Shares Outstanding (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.bostonscientific.com/role/SegmentReportingTables", "longName": "9954483 - Disclosure - Segment Reporting (Tables)", "shortName": "Segment Reporting (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.bostonscientific.com/role/RevenueTables", "longName": "9954484 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeTables", "longName": "9954485 - Disclosure - Changes in Other Comprehensive Income (Tables)", "shortName": "Changes in Other Comprehensive Income (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails", "longName": "9954486 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Acquisitions and Divestitures (Details)", "shortName": "Acquisitions, Divestitures and Strategic Investments - Acquisitions and Divestitures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-58", "name": "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "unique": true } }, "R38": { "role": "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails", "longName": "9954487 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Contingent Consideration (Details)", "shortName": "Acquisitions, Divestitures and Strategic Investments - Contingent Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "bsx:PaymentOfContingentConsideration", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "unique": true } }, "R39": { "role": "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsStrategicInvestmentsDetails", "longName": "9954488 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Strategic Investments (Details)", "shortName": "Acquisitions, Divestitures and Strategic Investments - Strategic Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "longName": "9954489 - Disclosure - Goodwill and Other Intangible Assets (Details)", "shortName": "Goodwill and Other Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "longName": "9954490 - Disclosure - Hedging Activities and Fair Value Measurements (Details)", "shortName": "Hedging Activities and Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "longName": "9954491 - Disclosure - Contractual Obligations and Commitments (Details)", "shortName": "Contractual Obligations and Commitments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:DebtAndCapitalLeaseObligations", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:DebtAndCapitalLeaseObligations", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails", "longName": "9954492 - Disclosure - Supplemental Balance Sheet Information (Details)", "shortName": "Supplemental Balance Sheet Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.bostonscientific.com/role/IncomeTaxesDetails", "longName": "9954493 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "bsx:ScheduleofEffectiveIncomeTaxRatefromContinuingOperationsTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "bsx:ScheduleofEffectiveIncomeTaxRatefromContinuingOperationsTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails", "longName": "9954494 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.bostonscientific.com/role/StockholdersEquityDetails", "longName": "9954495 - Disclosure - Stockholders' Equity (Details)", "shortName": "Stockholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-220", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "unique": true } }, "R47": { "role": "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails", "longName": "9954496 - Disclosure - Weighted Average Shares Outstanding (Details)", "shortName": "Weighted Average Shares Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "unique": true } }, "R48": { "role": "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingNarrativeDetails", "longName": "9954497 - Disclosure - Weighted Average Shares Outstanding - Narrative (Details)", "shortName": "Weighted Average Shares Outstanding - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.bostonscientific.com/role/SegmentReportingDetails", "longName": "9954498 - Disclosure - Segment Reporting (Details)", "shortName": "Segment Reporting (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "reportablesegments", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "reportablesegments", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.bostonscientific.com/role/RevenueDetails", "longName": "9954499 - Disclosure - Revenue (Details)", "shortName": "Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "bsx:NumberOfBusinesses", "unitRef": "business", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "unique": true } }, "R51": { "role": "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails", "longName": "9954500 - Disclosure - Changes in Other Comprehensive Income (AOCI Rollforward with Reclassification) (Details)", "shortName": "Changes in Other Comprehensive Income (AOCI Rollforward with Reclassification) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-40", "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240331.htm", "unique": true } } }, "tag": { "bsx_A550MCPSSeriesAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "A550MCPSSeriesAMember", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails", "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.50% MCPS, Series A [Member]", "label": "5.50% MCPS, Series A [Member]", "documentation": "5.50% MCPS, Series A" } } }, "auth_ref": [] }, "bsx_AMSEuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "AMSEuropeMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AMS Europe", "label": "AMS Europe [Member]", "documentation": "AMS Europe" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesAndLoansReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsNotesAndLoansReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Trade accounts receivable, net", "totalLabel": "Trade accounts receivable, net", "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable." } } }, "auth_ref": [ "r324", "r836" ] }, "us-gaap_AccountsNotesAndLoansReceivableNetCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsNotesAndLoansReceivableNetCurrentAbstract", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Trade accounts receivable, net", "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r34", "r863" ] }, "us-gaap_AccountsReceivableGrossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableGrossCurrent", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_AccountsNotesAndLoansReceivableNetCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Accounts Receivable, before Allowance for Credit Loss, Current", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r216", "r324", "r325", "r823" ] }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxesNoncurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued income taxes", "label": "Accrued Income Taxes, Noncurrent", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent." } } }, "auth_ref": [ "r131", "r182" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses", "totalLabel": "Accrued Liabilities, Current", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r38" ] }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrentAbstract", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses", "label": "Accrued Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "bsx_AccruedRebatesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "AccruedRebatesCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Rebates, Current", "label": "Accrued Rebates, Current", "documentation": "Accrued Rebates, Current" } } }, "auth_ref": [] }, "us-gaap_AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing Arrangements", "label": "Accrued Royalties, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r38", "r826" ] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Change in Defined Benefit Pensions and Other Items", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": [ "r8", "r19", "r49", "r974", "r975", "r976" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r74", "r206", "r647" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Change in Derivative Financial Instruments", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r229", "r237", "r238", "r543", "r833", "r974" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r236", "r237", "r579", "r581", "r582", "r583", "r584", "r585" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated other comprehensive income (loss), net of tax", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r48", "r49", "r144", "r217", "r643", "r681", "r682" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r236", "r237", "r579", "r581", "r582", "r583", "r584", "r585" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income (loss), net of tax", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r5", "r19", "r49", "r554", "r557", "r592", "r677", "r678", "r974", "r975", "r976", "r984", "r985", "r986" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Foreign Currency Adjustment Attributable to Parent", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r7", "r19", "r49", "r237", "r238", "r581", "r582", "r583", "r584", "r585", "r974" ] }, "bsx_AcotecMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "AcotecMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Acotec", "label": "Acotec [Member]", "documentation": "Acotec" } } }, "auth_ref": [] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r162" ] }, "bsx_ActualCovenantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "ActualCovenantMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actual, Covenant [Member]", "label": "Actual, Covenant [Member]", "documentation": "Actual Covenant." } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r914" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r134" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r513", "r514", "r515", "r694", "r984", "r985", "r986", "r1022", "r1046" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r920" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r920" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r920" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r920" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r885", "r896", "r906", "r931" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r888", "r899", "r909", "r934" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r920" ] }, "bsx_AllBusinessAcquisitionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "AllBusinessAcquisitionsMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All Business Acquisitions", "label": "All Business Acquisitions [Member]", "documentation": "All Business Acquisitions" } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r927" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r892", "r900", "r910", "r927", "r935", "r939", "r947" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r945" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_AccountsNotesAndLoansReceivableNetCurrent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r218", "r326", "r363" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense", "negatedLabel": "Amortization expense", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r16", "r67", "r72" ] }, "bsx_AmountExcludedFromDebtInLeverageRatio": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "AmountExcludedFromDebtInLeverageRatio", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount excluded from debt in leverage ratio", "label": "Amount excluded from debt in leverage ratio", "documentation": "Amount excluded from debt in leverage ratio" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r283" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r61" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r61" ] }, "srt_AsiaPacificMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AsiaPacificMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "APAC [Member]", "label": "Asia Pacific [Member]" } } }, "auth_ref": [ "r1048", "r1049", "r1050", "r1051" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r180", "r210", "r250", "r294", "r309", "r315", "r360", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r539", "r544", "r573", "r636", "r738", "r863", "r876", "r1014", "r1015", "r1027" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r202", "r221", "r250", "r360", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r539", "r544", "r573", "r863", "r1014", "r1015", "r1027" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets, Fair Value Disclosure", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r120" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r942" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r943" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r938" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r938" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r938" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r938" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r938" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r938" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r941" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r940" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r939" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r939" ] }, "bsx_AxonicsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "AxonicsMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Axonics", "label": "Axonics [Member]", "documentation": "Axonics" } } }, "auth_ref": [] }, "bsx_BSXReportableSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "BSXReportableSegmentsMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSX Reportable Segments [Member]", "label": "BSX Reportable Segments [Member]", "documentation": "BSX Reportable Segments [Member]" } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r107", "r113" ] }, "bsx_BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior": { "xbrltype": "integerItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Brazil CADE - # of individuals for alleged anti-competitive behavior", "label": "Brazil CADE - # of individuals for alleged anti-competitive behavior", "documentation": "Brazil CADE - # of individuals for alleged anti-competitive behavior" } } }, "auth_ref": [] }, "us-gaap_BuildingsAndImprovementsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingsAndImprovementsGross", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings and improvements", "label": "Buildings and Improvements, Gross", "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [ "r165" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r534", "r857", "r858" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r89", "r91", "r534", "r857", "r858" ] }, "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionContingentConsiderationLineItems", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]", "label": "Business Acquisition, Contingent Consideration [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r534" ] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Percentage of Voting Interests Acquired", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": [ "r90" ] }, "us-gaap_BusinessAcquisitionSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionSharePrice", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Share Price", "label": "Business Acquisition, Share Price", "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value", "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value", "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date." } } }, "auth_ref": [ "r94" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsAbstract", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Contingent Consideration Arrangements [Abstract]", "label": "Business Combination, Contingent Consideration Arrangements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 }, "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Contingent consideration net expense (benefit)", "terseLabel": "Contingent consideration net expense (benefit)", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r537", "r978" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid." } } }, "auth_ref": [ "r97" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Business Combination, Contingent Consideration, Liability Beginning Balance", "periodEndLabel": "Business Combination, Contingent Consideration, Liability Ending Balance", "verboseLabel": "Business Combination, Contingent Consideration, Liability", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r2", "r96", "r536" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Contingent Consideration, Liability, Current", "label": "Business Combination, Contingent Consideration, Liability, Current", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r96" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Contingent Consideration, Liability, Noncurrent", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r96" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestments" ], "lang": { "en-us": { "role": { "verboseLabel": "ACQUISITIONS AND STRATEGIC INVESTMENTS", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r173", "r535" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } }, "auth_ref": [ "r93" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": [ "r93" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r92", "r93" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": [ "r93" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r93" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r93" ] }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value", "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages." } } }, "auth_ref": [ "r24" ] }, "us-gaap_BusinessCombinationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Business Combinations [Abstract]", "label": "Business Combinations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CapitalLeaseObligationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalLeaseObligationsMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease Obligation", "label": "Capital Lease Obligations [Member]", "documentation": "A borrowing recorded for a lease meeting the criteria for capitalization. A lease is defined as an agreement conveying the right to use property, plant, or equipment (land or depreciable assets) usually for a stated period of time." } } }, "auth_ref": [ "r190" ] }, "bsx_CardiacRhythmManagementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "CardiacRhythmManagementMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cardiac Rhythm Management [Member]", "label": "Cardiac Rhythm Management [Member]", "documentation": "Cardiac Rhythm Management" } } }, "auth_ref": [] }, "bsx_CardiovascularMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "CardiovascularMember", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cardiovascular [Member]", "label": "Cardiovascular [Member]", "documentation": "Cardiovascular [Member]" } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r192", "r640", "r705", "r733", "r863", "r876", "r967" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r56", "r204", "r821" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period", "periodEndLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period", "terseLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r56", "r156", "r247" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Line Items]", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease)\u00a0in cash, cash equivalents, restricted cash and restricted cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r4", "r156" ] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowHedgingMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow Hedging [Member]", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r105" ] }, "bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "CashFlowImpactOfDeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred and prepaid income taxes", "label": "Cash flow impact of deferred income tax expense (benefit)", "documentation": "Cash flow impact of deferred income tax expense (benefit)" } } }, "auth_ref": [] }, "us-gaap_ChangeInContractWithCustomerLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ChangeInContractWithCustomerLiabilityAbstract", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Contract with Customer, Liability [Abstract]", "label": "Change in Contract with Customer, Liability [Abstract]" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r918" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDisclosuresAbstract", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock Disclosures [Abstract]", "label": "Class of Stock Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r197", "r213", "r214", "r215", "r250", "r276", "r277", "r280", "r282", "r288", "r289", "r360", "r408", "r410", "r411", "r412", "r415", "r416", "r447", "r448", "r452", "r455", "r462", "r573", "r686", "r687", "r688", "r689", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r706", "r725", "r747", "r767", "r796", "r797", "r798", "r799", "r800", "r954", "r980", "r987" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r213", "r214", "r215", "r288", "r447", "r448", "r450", "r452", "r455", "r460", "r462", "r686", "r687", "r688", "r689", "r846", "r954", "r980" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r919" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r919" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial Paper [Member]", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r168", "r870", "r871", "r872", "r873" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r43", "r126", "r639", "r724" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "verboseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r166", "r400", "r401", "r806", "r1010" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.bostonscientific.com/role/CoverDocument", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, par value $0.01 per share", "verboseLabel": "Common stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r866", "r867", "r868", "r870", "r871", "r872", "r873", "r984", "r985", "r1022", "r1038", "r1046" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Par or Stated Value Per Share", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r133" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Shares Authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r133", "r725" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Shares, Issued", "periodStartLabel": "Beginning Balance (Shares)", "periodEndLabel": "Ending Balance (Shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r133" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,733,293,885 shares as of March\u00a031, 2024 and 1,729,000,224 shares as of December\u00a031, 2023", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r133", "r642", "r863" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r924" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r923" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r925" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r922" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income attributable to Boston Scientific common stockholders", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r50", "r233", "r235", "r242", "r631", "r656" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r102", "r178", "r233", "r235", "r241", "r630", "r655" ] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive Income (Loss) Note [Text Block]", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": [ "r143", "r240", "r629", "r653" ] }, "bsx_CondensedConsolidatedBalanceSheetParentheticalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "CondensedConsolidatedBalanceSheetParentheticalAbstract", "lang": { "en-us": { "role": { "terseLabel": "Condensed Consolidated Balance Sheet (Parenthetical) [Abstract]", "label": "Condensed Consolidated Balance Sheet (Parenthetical) [Abstract]", "documentation": "Condensed Consolidated Balance Sheet (Parenthetical) [Abstract]" } } }, "auth_ref": [] }, "bsx_ConditionalRatingAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "ConditionalRatingAxis", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conditional Rating [Axis]", "label": "Conditional Rating [Axis]", "documentation": "Conditional Rating" } } }, "auth_ref": [] }, "bsx_ConditionalRatingDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "ConditionalRatingDomain", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conditional Rating [Domain]", "label": "Conditional Rating [Domain]", "documentation": "Conditional Rating [Domain]" } } }, "auth_ref": [] }, "us-gaap_ConstructionInProgressGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressGross", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital in progress", "label": "Construction in Progress, Gross", "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [ "r165" ] }, "us-gaap_ContingentConsiderationByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationByTypeAxis", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration by Type [Axis]", "label": "Contingent Consideration by Type [Axis]", "documentation": "Information by type of contingent consideration." } } }, "auth_ref": [] }, "bsx_ContingentConsiderationLiabilityProbabilityOfPayment": { "xbrltype": "percentItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "ContingentConsiderationLiabilityProbabilityOfPayment", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "contingent consideration liability, probability of payment", "label": "contingent consideration liability, probability of payment", "documentation": "contingent consideration liability, probability of payment" } } }, "auth_ref": [] }, "us-gaap_ContingentConsiderationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationTypeDomain", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration Type [Domain]", "label": "Contingent Consideration Type [Domain]", "documentation": "Description of contingent payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Liability", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r464", "r465", "r476" ] }, "us-gaap_ContractWithCustomerLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityAbstract", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Liability [Abstract]", "label": "Contract with Customer, Liability [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Liability, Revenue Recognized", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r477" ] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockSharesConverted1", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock issuance", "verboseLabel": "Conversion of Stock, Shares Converted", "label": "Conversion of Stock, Shares Converted", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r57", "r58", "r59" ] }, "bsx_CorporateExpensesincludinghedgingactivitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "CorporateExpensesincludinghedgingactivitiesMember", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Corporate expenses and currency exchange [Member]", "label": "Corporate Expenses including hedging activities [Member]", "documentation": "Corporate Expenses including hedging activities [Member]" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of products sold", "verboseLabel": "Cost of Goods and Services Sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r148", "r625" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Sales [Member]", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r252", "r253", "r421", "r450", "r593", "r830", "r832" ] }, "bsx_CovenantAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "CovenantAxis", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Covenant [Axis]", "label": "Covenant [Axis]", "documentation": "Covenant." } } }, "auth_ref": [] }, "bsx_CovenantDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "CovenantDomain", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Covenant [Domain]", "label": "Covenant [Domain]", "documentation": "Covenant." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "bsx_CreditRatingAOrA3OrHigherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "CreditRatingAOrA3OrHigherMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Rating A- or A3 Or Higher", "label": "Credit Rating A- or A3 Or Higher [Member]", "documentation": "Credit Rating A- or A3 Or Higher" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "bsx_CurrentRequirementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "CurrentRequirementMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current Requirement [Member]", "label": "Current Requirement [Member]", "documentation": "Current Requirement." } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRelationshipsMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r95" ] }, "bsx_DanielBrennanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "DanielBrennanMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Daniel Brennan [Member]", "documentation": "Daniel Brennan" } } }, "auth_ref": [] }, "bsx_DanielBrennanRuleTradingArrangementCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "DanielBrennanRuleTradingArrangementCommonStockMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Daniel Brennan Rule Trading Arrangement, Common Stock [Member]", "documentation": "Daniel Brennan Rule Trading Arrangement, Common Stock" } } }, "auth_ref": [] }, "bsx_DanielBrennanRuleTradingArrangementStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "DanielBrennanRuleTradingArrangementStockOptionsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Daniel Brennan Rule Trading Arrangement, Stock Options [Member]", "documentation": "Daniel Brennan Rule Trading Arrangement, Stock Options" } } }, "auth_ref": [] }, "us-gaap_DebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtAndCapitalLeaseObligations", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total debt", "label": "Debt and Lease Obligation", "documentation": "Amount of short-term and long-term debt and lease obligation." } } }, "auth_ref": [ "r186" ] }, "us-gaap_DebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Current debt obligations", "terseLabel": "Debt, Current", "label": "Debt, Current", "documentation": "Amount of debt and lease obligation, classified as current." } } }, "auth_ref": [ "r212" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitments" ], "lang": { "en-us": { "role": { "verboseLabel": "CONTRACTUAL OBLIGATIONS AND COMMITMENTS", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r167", "r248", "r417", "r423", "r424", "r425", "r426", "r427", "r428", "r433", "r440", "r441", "r443" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r32", "r129", "r130", "r181", "r183", "r254", "r418", "r419", "r420", "r421", "r422", "r424", "r429", "r430", "r431", "r432", "r434", "r435", "r436", "r437", "r438", "r439", "r587", "r841", "r842", "r843", "r844", "r845", "r981" ] }, "bsx_DebtInstrumentExtensionOptionTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "DebtInstrumentExtensionOptionTerm", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Extension Option, Term", "label": "Debt Instrument, Extension Option, Term", "documentation": "Debt Instrument, Extension Option, Term" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Fair Value Disclosure", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r431", "r572", "r842", "r843" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r40", "r419" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r254", "r418", "r419", "r420", "r421", "r422", "r424", "r429", "r430", "r431", "r432", "r434", "r435", "r436", "r437", "r438", "r439", "r442", "r587", "r841", "r842", "r843", "r844", "r845", "r981" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r41", "r254", "r418", "r419", "r420", "r421", "r422", "r424", "r429", "r430", "r431", "r432", "r434", "r435", "r436", "r437", "r438", "r439", "r587", "r841", "r842", "r843", "r844", "r845", "r981" ] }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Redemption Price, Percentage", "label": "Debt Instrument, Redemption Price, Percentage", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": [ "r25" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r41", "r80", "r83", "r122", "r123", "r125", "r127", "r170", "r171", "r254", "r418", "r419", "r420", "r421", "r422", "r424", "r429", "r430", "r431", "r432", "r434", "r435", "r436", "r437", "r438", "r439", "r442", "r587", "r841", "r842", "r843", "r844", "r845", "r981" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r124", "r429", "r444", "r842", "r843" ] }, "bsx_December2027NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "December2027NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "December 2027 Notes [Member]", "label": "December 2027 Notes [Member]", "documentation": "December 2027 Notes [Member]" } } }, "auth_ref": [] }, "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit." } } }, "auth_ref": [ "r88" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r518", "r519" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r518", "r519", "r637" ] }, "us-gaap_DeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenue", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Revenue", "label": "Deferred Revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r972" ] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Revenue, Current", "label": "Deferred Revenue, Current", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r971" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r16", "r73" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r16", "r299" ] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssets", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Asset", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r223", "r224", "r572", "r707", "r708", "r709", "r710", "r711", "r713", "r714", "r715", "r716", "r717", "r731", "r732", "r783", "r786", "r789", "r790", "r791", "r792", "r832", "r868", "r1042" ] }, "us-gaap_DerivativeAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetsCurrent", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Asset, Current", "label": "Derivative Asset, Current", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r223" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r715", "r717", "r730", "r731", "r732", "r734", "r735", "r736", "r737", "r739", "r740", "r741", "r742", "r754", "r755", "r756", "r757", "r760", "r761", "r762", "r763", "r783", "r784", "r789", "r791", "r866", "r868" ] }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Asset, Fair Value, Gross Asset", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": [ "r29", "r110", "r142", "r222", "r832" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Liability, Fair Value, Gross Liability", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [ "r29", "r110", "r142", "r222", "r832" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r108", "r111", "r114", "r116", "r715", "r717", "r730", "r731", "r732", "r734", "r735", "r736", "r737", "r739", "r740", "r741", "r742", "r754", "r755", "r756", "r757", "r760", "r761", "r762", "r763", "r783", "r784", "r789", "r791", "r832", "r866", "r868" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r21", "r108", "r114" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r21", "r108", "r114", "r116", "r117", "r118", "r551" ] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r551" ] }, "bsx_DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months", "label": "Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]", "documentation": "Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsInHedgesAssetsAtFairValue", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments in Hedges, Assets, at Fair Value", "label": "Derivative Instruments in Hedges, Assets, at Fair Value", "documentation": "Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsInHedgesLiabilitiesAtFairValue", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments in Hedges, Liabilities, at Fair Value", "label": "Derivative Instruments in Hedges, Liabilities, at Fair Value", "documentation": "Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value", "label": "Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value", "documentation": "Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as an asset." } } }, "auth_ref": [ "r112" ] }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value", "label": "Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value", "documentation": "Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as a liability." } } }, "auth_ref": [ "r112" ] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilities", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Liability", "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r223", "r224", "r572", "r707", "r708", "r709", "r710", "r713", "r714", "r715", "r716", "r717", "r739", "r741", "r742", "r784", "r785", "r786", "r789", "r790", "r791", "r792", "r832", "r1042" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Notional Amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r1020", "r1021" ] }, "us-gaap_DerivativeRemainingMaturity1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeRemainingMaturity1", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Remaining Maturity", "label": "Derivative, Remaining Maturity", "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DerivativeTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTermOfContract", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Term of Contract (less than)", "label": "Derivative, Term of Contract", "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "bsx_DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "label": "Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "documentation": "Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net" } } }, "auth_ref": [] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Designated as Hedging Instrument [Member]", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r21" ] }, "us-gaap_DisaggregationOfRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueAbstract", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Abstract]", "label": "Disaggregation of Revenue [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r475", "r847", "r848", "r849", "r850", "r851", "r852", "r853" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r475", "r847", "r848", "r849", "r850", "r851", "r852", "r853" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r1018" ] }, "bsx_DiscountRateFairValueInput": { "xbrltype": "percentItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "DiscountRateFairValueInput", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount Rate, Fair Value Input", "label": "Discount Rate, Fair Value Input", "documentation": "Discount Rate, Fair Value Input" } } }, "auth_ref": [] }, "us-gaap_DividendsPreferredStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPreferredStockCash", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Preferred stock dividends", "label": "Dividends, Preferred Stock, Cash", "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash." } } }, "auth_ref": [ "r12", "r172" ] }, "us-gaap_DividendsPreferredStockStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPreferredStockStock", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Preferred stock dividends", "label": "Dividends, Preferred Stock, Stock", "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock." } } }, "auth_ref": [ "r12", "r172" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r880" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r913" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EMEAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EMEAMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "EMEA [Member]", "label": "EMEA [Member]", "documentation": "Regions of Europe, Middle East and Africa." } } }, "auth_ref": [ "r1048", "r1049", "r1050", "r1051" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss)\u00a0per common share \u2014 basic", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r243", "r264", "r265", "r266", "r267", "r268", "r273", "r276", "r280", "r281", "r282", "r286", "r562", "r563", "r632", "r657", "r834" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss)\u00a0per common share \u2014 diluted", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r243", "r264", "r265", "r266", "r267", "r268", "r276", "r280", "r281", "r282", "r286", "r562", "r563", "r632", "r657", "r834" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Number Of Shares Outstanding [Text Block]", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r272", "r283", "r284", "r285" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of foreign exchange rates on cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r578" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective tax rate from continuing operations", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r521" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective Income Tax Rate Reconciliation, Percent [Abstract]", "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]" } } }, "auth_ref": [] }, "bsx_ElectrophysiologyEPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "ElectrophysiologyEPMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Electrophysiology [Member]", "label": "Electrophysiology (EP) [Member]", "documentation": "Electrophysiology (EP)" } } }, "auth_ref": [] }, "bsx_EmergingMarketsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "EmergingMarketsMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Emerging Markets [Member]", "label": "Emerging Markets [Member]", "documentation": "Emerging Markets [Member]" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payroll and related liabilities", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r38" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Option", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitiesTable", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entities [Table]", "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "bsx_EntityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "EntityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Entity [Abstract]", "label": "Entity [Abstract]", "documentation": "Entity [Abstract]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r878" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r878" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r878" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationLineItems", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Information [Line Items]", "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r952" ] }, "dei_EntityListingParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityListingParValuePerShare", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Listing, Par Value Per Share", "label": "Entity Listing, Par Value Per Share", "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r878" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r878" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r878" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r878" ] }, "bsx_EquipmentFurnitureAndFixturesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "EquipmentFurnitureAndFixturesGross", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equipment, furniture and fixtures", "label": "Equipment, furniture and fixtures Gross", "documentation": "Equipment, furniture and fixtures Gross." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r20", "r198", "r236", "r237", "r238", "r259", "r260", "r261", "r263", "r269", "r271", "r287", "r361", "r362", "r463", "r513", "r514", "r515", "r527", "r528", "r553", "r554", "r555", "r556", "r557", "r558", "r561", "r579", "r581", "r582", "r583", "r584", "r585", "r592", "r677", "r678", "r679", "r694", "r767" ] }, "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsStrategicInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity", "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity", "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee." } } }, "auth_ref": [ "r359" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsStrategicInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investments", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r304", "r358", "r968", "r994" ] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Securities, FV-NI", "label": "Equity Securities, FV-NI, Current", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": [ "r211", "r571", "r824" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsStrategicInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement alternative investments(1, 2)", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r357" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r921" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r885", "r896", "r906", "r931" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r882", "r893", "r903", "r928" ] }, "bsx_EuroDenominatedFactoringArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "EuroDenominatedFactoringArrangementsMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Euro Denominated Factoring Arrangements [Member]", "label": "Euro Denominated Factoring Arrangements [Member]", "documentation": "Euro Denominated Factoring Arrangements [Member]" } } }, "auth_ref": [] }, "bsx_ExclusionFromEbitdaForRestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "ExclusionFromEbitdaForRestructuringCharges", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exclusion from EBITDA for Restructuring Charges", "label": "Exclusion from EBITDA for Restructuring Charges", "documentation": "Exclusion from EBITDA for Restructuring Charges" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r927" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r565", "r566", "r569" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r565", "r566", "r569" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r22" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]", "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r431", "r480", "r481", "r482", "r483", "r484", "r485", "r566", "r597", "r598", "r599", "r842", "r843", "r854", "r855", "r856" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r565", "r566", "r567", "r568", "r570" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r564" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 1 [Member]", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r431", "r480", "r485", "r566", "r597", "r854", "r855", "r856" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 2 [Member]", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r431", "r480", "r485", "r566", "r598", "r842", "r843", "r854", "r855", "r856" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 3 [Member]", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r431", "r480", "r481", "r482", "r483", "r484", "r485", "r566", "r599", "r842", "r843", "r854", "r855", "r856" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r23", "r121" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement, Policy [Policy Text Block]", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r431", "r480", "r481", "r482", "r483", "r484", "r485", "r597", "r598", "r599", "r842", "r843", "r854", "r855", "r856" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Recurring [Member]", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r564", "r570" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for finance leases", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r590", "r591" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r442", "r460", "r559", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r654", "r838", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r990", "r991", "r992", "r993" ] }, "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination", "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Finite-Lived Intangible Assets, Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r208", "r387" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "verboseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r384", "r386", "r387", "r389", "r626", "r627" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Gross", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r163", "r627" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r68", "r71" ] }, "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months", "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months", "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months." } } }, "auth_ref": [ "r119" ] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Transaction Gain (Loss), before Tax", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r574", "r575", "r576", "r577", "r764" ] }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeContractMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Exchange Contract [Member]", "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": [ "r832", "r854", "r862" ] }, "us-gaap_ForeignExchangeForwardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeForwardMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Exchange Forward", "label": "Foreign Exchange Forward [Member]", "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate." } } }, "auth_ref": [ "r731", "r736", "r741", "r756", "r762", "r787", "r788", "r789", "r868" ] }, "bsx_ForeigncurrencydenominatedindebtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "ForeigncurrencydenominatedindebtMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "foreign currency denominated in debt [Member]", "label": "foreign currency denominated in debt [Member]", "documentation": "foreign currency denominated in debt [Member]" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r889", "r900", "r910", "r935" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r889", "r900", "r910", "r935" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r889", "r900", "r910", "r935" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r889", "r900", "r910", "r935" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r889", "r900", "r910", "r935" ] }, "bsx_ForwardCurrencyContractsTimetoMaturity": { "xbrltype": "integerItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "ForwardCurrencyContractsTimetoMaturity", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forward Currency Contracts, Time to Maturity", "label": "Forward Currency Contracts, Time to Maturity", "documentation": "Forward Currency Contracts, Time to Maturity in Months" } } }, "auth_ref": [] }, "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments", "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments", "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments." } } }, "auth_ref": [ "r108", "r115" ] }, "us-gaap_GainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnInvestments", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net loss (gain) on investments and notes receivable", "label": "Gain (Loss) on Investments", "documentation": "Amount of realized and unrealized gain (loss) on investment." } } }, "auth_ref": [ "r151", "r953" ] }, "bsx_GlobalCardiologyReportingUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "GlobalCardiologyReportingUnitMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cardiology [Member]", "label": "Global Cardiology Reporting Unit [Member]", "documentation": "Global Cardiology Reporting Unit [Member]" } } }, "auth_ref": [] }, "bsx_GlobalEndoscopyEndoReportingUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "GlobalEndoscopyEndoReportingUnitMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Endoscopy [Member]", "label": "Global Endoscopy (Endo) Reporting Unit [Member]", "documentation": "Global Endoscopy (Endo) Reporting Unit [Member]" } } }, "auth_ref": [] }, "bsx_GlobalNeuromodulationNmReportingUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "GlobalNeuromodulationNmReportingUnitMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Neuromodulation [Member]", "label": "Global Neuromodulation (NM) Reporting Unit [Member]", "documentation": "Global Neuromodulation (NM) Reporting Unit [Member]" } } }, "auth_ref": [] }, "bsx_GlobalPeripheralInterventionsPiReportingUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "GlobalPeripheralInterventionsPiReportingUnitMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Peripheral Interventions [Member]", "label": "Global Peripheral Interventions (PI) Reporting Unit [Member]", "documentation": "Global Peripheral Interventions (PI) Reporting Unit [Member]" } } }, "auth_ref": [] }, "bsx_GlobalUrologyandPelvicHealthReportingUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "GlobalUrologyandPelvicHealthReportingUnitMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Urology [Member]", "label": "Global Urology and Pelvic Health Reporting Unit [Member]", "documentation": "Global Urology and Pelvic Health Reporting Unit [Member]" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Goodwill Beginning Balance", "periodEndLabel": "Goodwill Ending Balance", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r207", "r372", "r628", "r840", "r863", "r998", "r1005" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill acquired", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r375", "r840" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssets" ], "lang": { "en-us": { "role": { "verboseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r161" ] }, "us-gaap_GoodwillGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillGross", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, Gross", "label": "Goodwill, Gross", "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r374", "r381", "r840" ] }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Goodwill, Impaired, Accumulated Impairment Loss", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r374", "r381", "r840" ] }, "us-gaap_GoodwillMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillMember", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Member]", "label": "Goodwill [Member]", "documentation": "Asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillRollForward", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillTranslationAndPurchaseAccountingAdjustments", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of foreign currency fluctuations and purchase price and other adjustments", "label": "Goodwill, Translation and Purchase Accounting Adjustments", "documentation": "Amount of increase (decrease) from foreign currency translation adjustments and purchase accounting adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r1", "r997" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r147", "r250", "r294", "r308", "r314", "r317", "r360", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r573", "r835", "r1014" ] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r21", "r551" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r21" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingRelationshipDomain", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r21" ] }, "bsx_ImpactOfForeignCurrencyFluctuationsOnNetSales": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "ImpactOfForeignCurrencyFluctuationsOnNetSales", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of Foreign Currency Fluctuations on Net Sales", "label": "Impact of Foreign Currency Fluctuations on Net Sales", "documentation": "Impact of Foreign Currency Fluctuations on Net Sales" } } }, "auth_ref": [] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InProcessResearchAndDevelopmentMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "In Process Research and Development [Member]", "verboseLabel": "In Process Research and Development [Member]", "label": "In Process Research and Development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 }, "http://www.bostonscientific.com/role/SegmentReportingDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income (loss)\u00a0before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r145", "r187", "r294", "r308", "r314", "r317", "r633", "r649", "r835" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r390", "r395", "r750" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r395", "r750" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "verboseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r251", "r516", "r522", "r525", "r526", "r529", "r531", "r532", "r533", "r691" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax expense (benefit)", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r191", "r195", "r270", "r271", "r302", "r520", "r530", "r658" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable, accrued expenses and other liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r15" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Trade accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r15" ] }, "us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option", "label": "Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option", "documentation": "Amount of increase (decrease) in fair value adjustment on other assets (liabilities) carried at fair value under the fair value option on the statement of cash flows of Federal Home Loan Banks (FHLBanks)." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r15" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r15" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "verboseLabel": "Indefinite-lived Intangible Assets by Major Class [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r385", "r388" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r164" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "verboseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r69", "r164" ] }, "bsx_IndemnificationAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "IndemnificationAsset", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indemnification asset", "label": "Indemnification asset", "documentation": "Indemnification asset" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r892", "r900", "r910", "r927", "r935", "r939", "r947" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r945" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r881", "r951" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r881", "r951" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r881", "r951" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Other intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r66", "r70" ] }, "bsx_IntangibleAssetsandGoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "IntangibleAssetsandGoodwillLineItems", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets and Goodwill [Line Items]", "label": "Intangible Assets and Goodwill [Line Items]", "documentation": "[Line Items] for Schedule of Intangible Assets and Goodwill [Table]" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "verboseLabel": "Interest Expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r124", "r189", "r239", "r298", "r586", "r751", "r874", "r1045" ] }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Expense [Member]", "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": [ "r28" ] }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months." } } }, "auth_ref": [ "r119" ] }, "us-gaap_InterestRateContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateContractMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Contract [Member]", "label": "Interest Rate Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate." } } }, "auth_ref": [ "r818", "r832", "r854" ] }, "bsx_InterventionalCardiologyTherapiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "InterventionalCardiologyTherapiesMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interventional Cardiology Therapies", "label": "Interventional Cardiology Therapies [Member]", "documentation": "Interventional Cardiology Therapies" } } }, "auth_ref": [] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory, Finished Goods, Net of Reserves", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r160", "r827" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "totalLabel": "Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r219", "r822", "r863" ] }, "us-gaap_InventoryNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNetAbstract", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "label": "Inventory, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory, Raw Materials, Net of Reserves", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r160", "r829" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory, Work in Process, Net of Reserves", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r160", "r828" ] }, "us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Investment", "label": "Investment Holdings, Schedule of Investments [Table Text Block]", "documentation": "Tabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments." } } }, "auth_ref": [ "r1039", "r1040", "r1041", "r1042", "r1043", "r1044" ] }, "us-gaap_Investments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Investments", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "verboseLabel": "Investments", "label": "Investments", "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments." } } }, "auth_ref": [ "r635" ] }, "bsx_January2040NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "January2040NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "January 2040 Notes [Member]", "label": "January 2040 Notes [Member]", "documentation": "January 2040 Notes [Member]" } } }, "auth_ref": [] }, "bsx_JeffreyB.MirvissRuleTradingArrangementCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "JeffreyB.MirvissRuleTradingArrangementCommonStockMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Jeffrey B. Mirviss Rule Trading Arrangement, Common Stock [Member]", "documentation": "Jeffrey B. Mirviss Rule Trading Arrangement, Common Stock" } } }, "auth_ref": [] }, "bsx_JeffreyB.MirvissRuleTradingArrangementStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "JeffreyB.MirvissRuleTradingArrangementStockOptionsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Jeffrey B. Mirviss Rule Trading Arrangement, Stock Options [Member]", "documentation": "Jeffrey B. Mirviss Rule Trading Arrangement, Stock Options" } } }, "auth_ref": [] }, "bsx_JeffreyB.MirvissRuleTradingArrangementVestingOfPerformanceUnitsAndRestrictedUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "JeffreyB.MirvissRuleTradingArrangementVestingOfPerformanceUnitsAndRestrictedUnitsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Jeffrey B. Mirviss Rule Trading Arrangement, Vesting of Performance Units And Restricted Units [Member]", "documentation": "Jeffrey B. Mirviss Rule Trading Arrangement, Vesting of Performance Units And Restricted Units" } } }, "auth_ref": [] }, "bsx_JeffreyBMirvissMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "JeffreyBMirvissMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Jeffrey B. Mirviss [Member]", "documentation": "Jeffrey B. Mirviss" } } }, "auth_ref": [] }, "bsx_JonathanMonsonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "JonathanMonsonMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Jonathan Monson [Member]", "documentation": "Jonathan Monson" } } }, "auth_ref": [] }, "bsx_JonathanMonsonRuleTradingArrangementCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "JonathanMonsonRuleTradingArrangementCommonStockMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Jonathan Monson Rule Trading Arrangement, Common Stock [Member]", "documentation": "Jonathan Monson Rule Trading Arrangement, Common Stock" } } }, "auth_ref": [] }, "bsx_JonathanMonsonRuleTradingArrangementStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "JonathanMonsonRuleTradingArrangementStockOptionsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Jonathan Monson Rule Trading Arrangement, Stock Options [Member]", "documentation": "Jonathan Monson Rule Trading Arrangement, Stock Options" } } }, "auth_ref": [] }, "bsx_June2025NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "June2025NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "June 2025 Notes [Member]", "label": "June 2025 Notes [Member]", "documentation": "June 2025 Notes" } } }, "auth_ref": [] }, "bsx_June2030NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "June2030NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "June 2030 Notes [Member]", "label": "June 2030 Notes [Member]", "documentation": "June 2030 Notes" } } }, "auth_ref": [] }, "us-gaap_Land": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Land", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land", "label": "Land", "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale." } } }, "auth_ref": [ "r969" ] }, "bsx_LatinAmericaandCanadaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "LatinAmericaandCanadaMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Latin America and Canada [Member]", "label": "Latin America and Canada [Member]", "documentation": "Latin America and Canada [Member]" } } }, "auth_ref": [] }, "us-gaap_LegalCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LegalCostsPolicyTextBlock", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Costs, Policy [Policy Text Block]", "label": "Legal Costs, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights." } } }, "auth_ref": [ "r407" ] }, "bsx_LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal payments remaining to be excluded from calculation of consolidated EBITDA", "label": "Legal payments remaining to be excluded from calculation of consolidated EBITDA", "documentation": "Legal payments remaining to be excluded from calculation of consolidated EBITDA" } } }, "auth_ref": [] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letters of Credit Outstanding, Amount", "label": "Letters of Credit Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND EQUITY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r138", "r185", "r646", "r863", "r982", "r995", "r1024" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r39", "r203", "r250", "r360", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r540", "r544", "r545", "r573", "r863", "r1014", "r1027", "r1028" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r120" ] }, "bsx_LicensingarrangementassetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "LicensingarrangementassetsMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing arrangement assets [Member]", "label": "Licensing arrangement assets [Member]", "documentation": "Licensing arrangement assets [Member]" } } }, "auth_ref": [] }, "bsx_LicensingarrangementliabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "LicensingarrangementliabilitiesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing arrangement liabilities [Member]", "label": "Licensing arrangement liabilities [Member]", "documentation": "Licensing arrangement liabilities [Member]" } } }, "auth_ref": [] }, "bsx_Licensingarrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "Licensingarrangements", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing arrangements", "label": "Licensing arrangements", "documentation": "Licensing arrangements" } } }, "auth_ref": [] }, "bsx_Licensingarrangementsasset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "Licensingarrangementsasset", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing arrangements, asset", "label": "Licensing arrangements, asset", "documentation": "Licensing arrangements, asset" } } }, "auth_ref": [] }, "bsx_Licensingarrangementsliability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "Licensingarrangementsliability", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing arrangements, liability", "label": "Licensing arrangements, liability", "documentation": "Licensing arrangements, liability" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r35" ] }, "bsx_LitigationPaymentExclusionFromEBITDA": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "LitigationPaymentExclusionFromEBITDA", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation payment exclusion from EBITDA", "label": "Litigation payment exclusion from EBITDA", "documentation": "Litigation payment exclusion from EBITDA" } } }, "auth_ref": [] }, "us-gaap_LitigationReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationReserveCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal reserves, current", "label": "Estimated Litigation Liability, Current", "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position." } } }, "auth_ref": [ "r43", "r1011" ] }, "us-gaap_LitigationReserveNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationReserveNoncurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Litigation Liability, Noncurrent", "label": "Estimated Litigation Liability, Noncurrent", "documentation": "Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r43", "r1011" ] }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationSettlementAmountAwardedToOtherParty", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Settlement, Amount Awarded to Other Party", "label": "Litigation Settlement, Amount Awarded to Other Party", "documentation": "Amount awarded to other party in judgment or settlement of litigation." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r32", "r183", "r430", "r445", "r842", "r843", "r1035" ] }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtAndCapitalLeaseObligations", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Long-term debt", "terseLabel": "Long-term Debt and Capital Lease Obligations", "label": "Long-Term Debt and Lease Obligation", "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent." } } }, "auth_ref": [ "r32", "r638" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r41" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r41", "r76" ] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrual for legal matters that are probable and estimable", "label": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": [ "r402", "r955" ] }, "bsx_March2024NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "March2024NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2024 Notes [Member]", "label": "March 2024 Notes [Member]", "documentation": "March 2024 Notes [Member]" } } }, "auth_ref": [] }, "bsx_March2025NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "March2025NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2025 Notes", "label": "March 2025 Notes [Member]", "documentation": "March 2025 Notes" } } }, "auth_ref": [] }, "bsx_March2026NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "March2026NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2026 Notes [Member]", "label": "March 2026 Notes [Member]", "documentation": "March 2026 Notes [Member]" } } }, "auth_ref": [] }, "bsx_March2028NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "March2028NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "March 2028 Notes [Member]", "label": "March 2028 Notes [Member]", "documentation": "March 2028 Notes [Member]" } } }, "auth_ref": [] }, "bsx_March2028SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "March2028SeniorNotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2028 Senior Notes", "label": "March 2028 Senior Notes [Member]", "documentation": "March 2028 Senior Notes" } } }, "auth_ref": [] }, "bsx_March2029EuroSeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "March2029EuroSeniorNotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2029 Euro Senior Notes", "label": "March 2029 Euro Senior Notes [Member]", "documentation": "March 2029 Euro Senior Notes" } } }, "auth_ref": [] }, "bsx_March2029NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "March2029NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2029 Notes [Member]", "label": "March 2029 Notes [Member]", "documentation": "March 2029 Notes [Member]" } } }, "auth_ref": [] }, "bsx_March2031NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "March2031NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2031 Notes", "label": "March 2031 Notes [Member]", "documentation": "March 2031 Notes" } } }, "auth_ref": [] }, "bsx_March2032EuroSeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "March2032EuroSeniorNotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2032 Euro Senior Notes", "label": "March 2032 Euro Senior Notes [Member]", "documentation": "March 2032 Euro Senior Notes" } } }, "auth_ref": [] }, "bsx_March2034NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "March2034NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2034 Notes", "label": "March 2034 Notes [Member]", "documentation": "March 2034 Notes" } } }, "auth_ref": [] }, "bsx_March2039NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "March2039NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2039 Notes [Member]", "label": "March 2039 Notes [Member]", "documentation": "March 2039 Notes [Member]" } } }, "auth_ref": [] }, "bsx_March2049NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "March2049NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2049 Notes [Member]", "label": "March 2049 Notes [Member]", "documentation": "March 2049 Notes [Member]" } } }, "auth_ref": [] }, "bsx_MaximumLeverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "MaximumLeverageRatio", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum Leverage Ratio", "label": "Maximum Leverage Ratio", "documentation": "Maximum leverage ratio permitted by revolving credit facility agreement." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Maximum [Member]", "terseLabel": "Maximum [Member]", "label": "Maximum [Member]" } } }, "auth_ref": [ "r403", "r404", "r405", "r406", "r486", "r624", "r676", "r716", "r717", "r773", "r776", "r780", "r781", "r793", "r816", "r817", "r837", "r846", "r859", "r865", "r1016", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r919" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r919" ] }, "bsx_MedsurgMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "MedsurgMember", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MedSurg [Member]", "label": "MedSurg [Member]", "documentation": "MedSurg [Member]" } } }, "auth_ref": [] }, "bsx_MichaelF.MahoneyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "MichaelF.MahoneyMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Michael F. Mahoney [Member]", "documentation": "Michael F. Mahoney" } } }, "auth_ref": [] }, "bsx_MichaelF.MahoneyRuleTradingArrangementCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "MichaelF.MahoneyRuleTradingArrangementCommonStockMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Michael F. Mahoney Rule Trading Arrangement, Common Stock [Member]", "documentation": "Michael F. Mahoney Rule Trading Arrangement, Common Stock" } } }, "auth_ref": [] }, "bsx_MichaelF.MahoneyRuleTradingArrangementStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "MichaelF.MahoneyRuleTradingArrangementStockOptionsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Michael F. MahoneyRule Trading Arrangement, Stock Options [Member]", "documentation": "Michael F. MahoneyRule Trading Arrangement, Stock Options" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Minimum [Member]", "terseLabel": "Minimum [Member]", "label": "Minimum [Member]" } } }, "auth_ref": [ "r403", "r404", "r405", "r406", "r486", "r624", "r676", "r716", "r717", "r773", "r776", "r780", "r781", "r793", "r816", "r817", "r837", "r846", "r859", "r865", "r1016", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r47", "r184", "r250", "r360", "r408", "r410", "r411", "r412", "r415", "r416", "r573", "r645", "r727" ] }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner", "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestPeriodIncreaseDecrease", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Changes to noncontrolling ownership interest", "label": "Noncontrolling Interest, Period Increase (Decrease)", "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period." } } }, "auth_ref": [ "r99" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r938" ] }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money Market Funds, at Carrying Value", "label": "Money Market Funds, at Carrying Value", "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MovementInValuationAllowancesAndReservesRollForward", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Allowance for doubtful accounts", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r946" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r920" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Cash provided by (used for) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r246" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Cash provided by (used for) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r246" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Cash provided by (used for) operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r156", "r157", "r158" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash provided by (used for) operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Net Income (Loss)", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r146", "r158", "r188", "r201", "r231", "r234", "r238", "r250", "r262", "r264", "r265", "r266", "r267", "r270", "r271", "r278", "r294", "r308", "r314", "r317", "r360", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r563", "r573", "r652", "r746", "r765", "r766", "r835", "r874", "r1014" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net income (loss) attributable to noncontrolling interests", "terseLabel": "Net income (loss) attributable to noncontrolling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r101", "r179", "r231", "r234", "r270", "r271", "r651", "r976" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) attributable to Boston Scientific common stockholders", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r244", "r264", "r265", "r266", "r267", "r273", "r274", "r279", "r282", "r294", "r308", "r314", "r317", "r835" ] }, "us-gaap_NetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetInvestmentHedgingMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Investment Hedging [Member]", "label": "Net Investment Hedging [Member]", "documentation": "Hedges of a net investment in a foreign operation." } } }, "auth_ref": [ "r106" ] }, "bsx_Netcurrencyexchangegainloss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "Netcurrencyexchangegainloss", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net currency exchange gain (loss)", "label": "Net currency exchange gain (loss)", "documentation": "Net currency exchange gain (loss)" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]", "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "bsx_NewAccountingPronouncementsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "NewAccountingPronouncementsTextBlock", "presentation": [ "http://www.bostonscientific.com/role/NewAccountingPronouncements" ], "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements", "label": "New Accounting Pronouncements [Text Block]", "documentation": "New Accounting Pronouncements" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r919" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r889", "r900", "r910", "r927", "r935" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r917" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r916" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r927" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r946" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r946" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonUsMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International [Member]", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r1048", "r1049", "r1050", "r1051" ] }, "bsx_Noncashimpactoftransferredroyaltyrights": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "Noncashimpactoftransferredroyaltyrights", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash impact of transferred royalty rights", "label": "Non-cash impact of transferred royalty rights", "documentation": "Non-cash impact of transferred royalty rights" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r98", "r463", "r984", "r985", "r986", "r1046" ] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NondesignatedMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Not Designated as Hedging Instrument [Member]", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r21" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SegmentReportingDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other expense, net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r152" ] }, "bsx_November2035NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "November2035NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "November 2035 Notes [Member]", "label": "November 2035 Notes [Member]", "documentation": "November 2035 Notes [Member]" } } }, "auth_ref": [] }, "bsx_NumberOfBusinesses": { "xbrltype": "integerItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "NumberOfBusinesses", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number Of Businesses", "label": "Number Of Businesses", "documentation": "Number Of Businesses" } } }, "auth_ref": [] }, "us-gaap_NumberOfInterestRateDerivativesHeld": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfInterestRateDerivativesHeld", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Interest Rate Derivatives Held", "label": "Number of Interest Rate Derivatives Held", "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date." } } }, "auth_ref": [ "r103", "r104" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r989" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "bsx_OperatingIncomeAllocatedToReportableSegments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "OperatingIncomeAllocatedToReportableSegments", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Income Allocated to Reportable Segments", "label": "Operating Income Allocated to Reportable Segments", "documentation": "Operating Income Allocated to Reportable Segments" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.bostonscientific.com/role/SegmentReportingDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating income (loss)", "terseLabel": "Operating income (loss)", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r294", "r308", "r314", "r317", "r835" ] }, "bsx_OperatingIncomeUnallocatedToSegment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "OperatingIncomeUnallocatedToSegment", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Operating Income Unallocated to Segment", "label": "Operating Income Unallocated to Segment", "documentation": "Operating Income Unallocated to Segment" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Noncurrent", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r589" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Right-of-Use Asset", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r588" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.bostonscientific.com/role/BasisofPresentation" ], "lang": { "en-us": { "role": { "verboseLabel": "BASIS OF PRESENTATION", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r128", "r177", "r683", "r684" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r38" ] }, "us-gaap_OtherAccruedLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Accrued Liabilities, Noncurrent", "label": "Other Accrued Liabilities, Noncurrent", "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r42" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Other Assets, Current", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r220", "r863" ] }, "us-gaap_OtherAssetsMiscellaneousCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsMiscellaneousCurrent", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Assets, Miscellaneous, Current", "label": "Other Assets, Miscellaneous, Current", "documentation": "Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other long-term assets", "totalLabel": "Other Assets, Noncurrent", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r209" ] }, "us-gaap_OtherAssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrentAbstract", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Assets, Noncurrent [Abstract]", "label": "Other Assets, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss) before reclassifications", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r31", "r49", "r237", "r579", "r582", "r585", "r974" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive income (loss) attributable to noncontrolling interests", "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Noncontrolling Interest", "documentation": "Amount before tax of other comprehensive income (loss) attributable to noncontrolling interests." } } }, "auth_ref": [ "r13", "r18", "r178" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "Net change in derivative financial instruments", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r225", "r227" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r225", "r227" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r225", "r227", "r546", "r547", "r552" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax", "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r228" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r227", "r230" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r194", "r227", "r230" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax", "documentation": "Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r228" ] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, after Tax", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, after Tax", "documentation": "Amount, after tax, of adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": [ "r226", "r227", "r230", "r549" ] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax", "documentation": "Amount, before tax, of adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": [ "r226", "r227", "r230", "r549" ] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsTax", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax", "documentation": "Amount of tax expense (benefit) for adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": [ "r226", "r227", "r230" ] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax", "documentation": "Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": [ "r226", "r227", "r548", "r552" ] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax", "documentation": "Amount, before adjustments, of tax expense (benefit) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": [ "r226", "r227", "r548", "r552" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r6" ] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": [ "r550" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss)", "terseLabel": "Changes in other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r20", "r31", "r232", "r235", "r240", "r579", "r580", "r585", "r629", "r653", "r974", "r975" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss) Net of Tax, Period Change [Abstract]", "label": "Other Comprehensive Income (Loss), Net of Tax, Period Change [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), net of tax:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net change in defined benefit pensions and other items", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan." } } }, "auth_ref": [ "r9", "r144" ] }, "bsx_OtherCurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "OtherCurrentAssetsAbstract", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Current Assets [Abstract]", "label": "Other Current Assets [Abstract]", "documentation": "Other Current Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCurrentLiabilitiesMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Current Liabilities [Member]", "label": "Other Current Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCurrentLiabilitiesTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Other Current Liabilities", "label": "Other Current Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIntangibleAssetsMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Intangible Assets [Member]", "label": "Other Intangible Assets [Member]", "documentation": "Intangible assets classified as other." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other current liabilities", "totalLabel": "Other Liabilities, Current", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r38", "r863" ] }, "us-gaap_OtherLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrentAbstract", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Liabilities, Current [Abstract]", "label": "Other Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other long-term liabilities", "totalLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r42" ] }, "us-gaap_OtherLiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrentAbstract", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentAssetsMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Noncurrent Assets [Member]", "label": "Other Noncurrent Assets [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Noncurrent Liabilities [Member]", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentLiabilitiesTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Other long-term liabilities", "label": "Other Noncurrent Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Other, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r153" ] }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Other income (expense):", "label": "Other Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Nonoperating Income (Expense) [Member]", "label": "Other Nonoperating Income (Expense) [Member]", "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)." } } }, "auth_ref": [] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other, net", "label": "Other Operating Activities, Cash Flow Statement", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": [] }, "us-gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Operating Income (Expense), Net", "label": "Other Operating Income (Expense), Net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "bsx_OtherOtherLongtermAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "OtherOtherLongtermAssets", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other, Other Long-term Assets", "label": "Other, Other Long-term Assets", "documentation": "Other, Other Long-term Assets" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r919" ] }, "us-gaap_OtherSundryLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherSundryLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Sundry Liabilities, Current", "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date." } } }, "auth_ref": [ "r38", "r75" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r887", "r898", "r908", "r933" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r890", "r901", "r911", "r936" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r890", "r901", "r911", "r936" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipDomain", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PatentsMember", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patents [Member]", "label": "Patents [Member]", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": [ "r175" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r915" ] }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of contingent consideration previously established in purchase accounting", "label": "Payment for Contingent Consideration Liability, Financing Activities", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date." } } }, "auth_ref": [ "r11" ] }, "bsx_PaymentOfContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "PaymentOfContingentConsideration", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Payment of contingent consideration", "label": "Payment of contingent consideration", "documentation": "Payment of contingent consideration" } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Proceeds from royalty rights", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r956", "r977" ] }, "us-gaap_PaymentsForRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRoyalties", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for Royalties", "label": "Payments for Royalties", "documentation": "The amount of cash paid for royalties during the current period." } } }, "auth_ref": [ "r14" ] }, "bsx_PaymentsForRoyaltyRights": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "PaymentsForRoyaltyRights", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for royalty rights", "label": "Payments for royalty rights", "documentation": "Payments for royalty rights" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividends", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash dividends paid on preferred stock", "label": "Payments of Dividends", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": [ "r53" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments for acquisitions of businesses, net of cash acquired", "terseLabel": "Payments to Acquire Businesses, Net of Cash Acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r51" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property, plant and equipment and internal use software", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r155" ] }, "bsx_Paymenttonetsharesettleemployeeequityawards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "Paymenttonetsharesettleemployeeequityawards", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash used to net share settle employee equity awards", "label": "Payment to net share settle employee equity awards", "documentation": "Payment to net share settle employee equity awards" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r918" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r918" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r917" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r927" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r920" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r916" ] }, "us-gaap_PreferredStockConvertibleConversionRatio": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockConvertibleConversionRatio", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Convertible, Conversion Ratio", "label": "Preferred Stock, Convertible, Conversion Ratio", "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted." } } }, "auth_ref": [ "r449" ] }, "us-gaap_PreferredStockDividendRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockDividendRatePercentage", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Dividend Rate, Percentage", "label": "Preferred Stock, Dividend Rate, Percentage", "documentation": "The percentage rate used to calculate dividend payments on preferred stock." } } }, "auth_ref": [ "r448", "r774", "r777", "r779", "r794" ] }, "us-gaap_PreferredStockLiquidationPreference": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockLiquidationPreference", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Liquidation Preference Per Share", "label": "Preferred Stock, Liquidation Preference Per Share", "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share." } } }, "auth_ref": [ "r80", "r81", "r132", "r980", "r1017" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock", "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r866", "r867", "r870", "r871", "r872", "r873", "r1038", "r1046" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Par or Stated Value Per Share", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r132", "r447" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Shares Authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r132", "r725" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Shares Issued", "verboseLabel": "Preferred Stock, Shares Issued", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r132", "r447" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.01 par value - authorized 50,000,000 shares - 0 shares issued as of March\u00a031, 2024 and December\u00a031, 2023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r132", "r641", "r863" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r973" ] }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expenses and Other Current Assets [Member]", "label": "Prepaid Expenses and Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets." } } }, "auth_ref": [] }, "us-gaap_PrepaidTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidTaxes", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid income taxes", "label": "Prepaid Taxes", "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r825", "r839", "r996" ] }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net proceeds from issuance of preferred stock in connection with public offering", "label": "Proceeds from Issuance of Convertible Preferred Stock", "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from long-term borrowings, net of debt issuance costs", "verboseLabel": "Proceeds from Issuance of Senior Long-Term Debt", "label": "Proceeds from Issuance of Senior Long-Term Debt", "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer)." } } }, "auth_ref": [ "r52" ] }, "bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for investments and acquisitions of certain technologies, net of investment proceeds", "label": "Proceeds from (payments for) investments and acquisitions of certain technologies", "documentation": "Proceeds from (payments for) investments and acquisitions of certain technologies" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromRoyaltiesReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRoyaltiesReceived", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Proceeds from Royalties Received", "label": "Proceeds from Royalties Received", "documentation": "Cash received for royalties during the current period." } } }, "auth_ref": [ "r55" ] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of property, plant and equipment", "label": "Proceeds from Sale of Property, Plant, and Equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r154" ] }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockPlans", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans", "label": "Proceeds from Stock Plans", "documentation": "The cash inflow associated with the amount received from the stock plan during the period." } } }, "auth_ref": [ "r10" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r319", "r625", "r670", "r671", "r672", "r673", "r674", "r675", "r819", "r847", "r864", "r958", "r1012", "r1013", "r1018", "r1036" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r319", "r625", "r670", "r671", "r672", "r673", "r674", "r675", "r819", "r847", "r864", "r958", "r1012", "r1013", "r1018", "r1036" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss)", "terseLabel": "Net income (loss)", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r201", "r231", "r234", "r245", "r250", "r262", "r270", "r271", "r294", "r308", "r314", "r317", "r360", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r538", "r541", "r542", "r563", "r573", "r633", "r650", "r693", "r746", "r765", "r766", "r835", "r860", "r861", "r875", "r976", "r1014" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r165", "r205", "r648" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r17", "r634", "r648", "r863" ] }, "us-gaap_PropertyPlantAndEquipmentNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNetAbstract", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r17" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r915" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r915" ] }, "bsx_QualifiedAcquisitionConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "QualifiedAcquisitionConsideration", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Qualified Acquisition Consideration", "label": "Qualified Acquisition Consideration", "documentation": "Qualified Acquisition Consideration" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r403", "r404", "r405", "r406", "r479", "r486", "r509", "r510", "r511", "r600", "r624", "r676", "r716", "r717", "r773", "r776", "r780", "r781", "r793", "r816", "r817", "r837", "r846", "r859", "r865", "r868", "r1008", "r1016", "r1030", "r1031", "r1032", "r1033", "r1034" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r403", "r404", "r405", "r406", "r479", "r486", "r509", "r510", "r511", "r600", "r624", "r676", "r716", "r717", "r773", "r776", "r780", "r781", "r793", "r816", "r817", "r837", "r846", "r859", "r865", "r868", "r1008", "r1016", "r1030", "r1031", "r1032", "r1033", "r1034" ] }, "us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivableWithImputedInterestEffectiveYieldInterestRate", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Average interest rate of de-recognized receivables", "label": "Receivable with Imputed Interest, Effective Yield (Interest Rate)", "documentation": "Yield on the receivable, on which interest has been imputed, as calculated from its issuance value or purchase price. The calculated effective interest rate considers factors such as the issued face value or price paid for the receivable, the time period between payments, and the time until maturity [full receipt] of the receivable." } } }, "auth_ref": [ "r123", "r587" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "(Income) loss amounts reclassified from accumulated other comprehensive income", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r31", "r49", "r237", "r579", "r584", "r585", "r974" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI attributable to Boston Scientific common stockholders, Net of Tax [Roll Forward]", "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent." } } }, "auth_ref": [ "r31", "r49" ] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r63", "r64" ] }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]", "label": "Reconciliation of Revenue from Segments to Consolidated [Table]", "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues." } } }, "auth_ref": [ "r62", "r64" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r882", "r893", "r903", "r928" ] }, "bsx_RenminbiDenominatedFactoringArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "RenminbiDenominatedFactoringArrangementsMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Renminbi Denominated Factoring Arrangements [Member]", "label": "Renminbi Denominated Factoring Arrangements [Member]", "documentation": "Renminbi Denominated Factoring Arrangements" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfShortTermDebt", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments on short-term borrowings", "label": "Repayments of Short-Term Debt", "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r54" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r252", "r253", "r421", "r450", "r593", "r831", "r832" ] }, "bsx_RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Requirement, as of December 31, 2021 and through remaining term of facility", "label": "Requirement, as of December 31, 2021 and through remaining term of facility [Member]", "documentation": "Requirement, as of December 31, 2021 and through remaining term of facility" } } }, "auth_ref": [] }, "bsx_RequirementEighthQuarterFollowingQualifiedAcquisitionAndThroughRemainingTermOfFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "RequirementEighthQuarterFollowingQualifiedAcquisitionAndThroughRemainingTermOfFacilityMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Requirement, eighth quarter following qualified acquisition and through remaining term of facility", "label": "Requirement, eighth quarter following qualified acquisition and through remaining term of facility [Member]", "documentation": "Requirement, eighth quarter following qualified acquisition and through remaining term of facility" } } }, "auth_ref": [] }, "bsx_RequirementFourSucceedingQuartersFollowingQualifiedAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "RequirementFourSucceedingQuartersFollowingQualifiedAcquisitionMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Requirement, four succeeding quarters following qualified acquisition", "label": "Requirement, four succeeding quarters following qualified acquisition [Member]", "documentation": "Requirement, four succeeding quarters following qualified acquisition" } } }, "auth_ref": [] }, "bsx_RequirementSeventhQuarterFollowingQualifiedAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "RequirementSeventhQuarterFollowingQualifiedAcquisitionMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Requirement, seventh quarter following qualified acquisition", "label": "Requirement, seventh quarter following qualified acquisition [Member]", "documentation": "Requirement, seventh quarter following qualified acquisition" } } }, "auth_ref": [] }, "bsx_RequirementSixthQuarterFollowingQualifiedAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "RequirementSixthQuarterFollowingQualifiedAcquisitionMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Requirement, sixth quarter following qualified acquisition", "label": "Requirement, sixth quarter following qualified acquisition [Member]", "documentation": "Requirement, sixth quarter following qualified acquisition" } } }, "auth_ref": [] }, "bsx_RequirementfifthquarterfollowingqualifiedacquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "RequirementfifthquarterfollowingqualifiedacquisitionMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Requirement, fifth quarter following qualified acquisition [Member]", "label": "Requirement, fifth quarter following qualified acquisition [Member]", "documentation": "Requirement, fifth quarter following qualified acquisition [Member]" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept." } } }, "auth_ref": [ "r1019" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r883", "r894", "r904", "r929" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r884", "r895", "r905", "r930" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r891", "r902", "r912", "r937" ] }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Restricted cash and restricted cash equivalents included in Other current assets", "terseLabel": "Restricted Cash and Cash Equivalents in Other current assets", "label": "Restricted Cash and Cash Equivalents, Current", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r56", "r204", "r247" ] }, "us-gaap_RestrictedCashEquivalentsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashEquivalentsNoncurrent", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash equivalents included in Other long-term assets", "label": "Restricted Cash Equivalents, Noncurrent", "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r193", "r804", "r805", "r970", "r979" ] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Restructuring net charges (credits)", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r16", "r397", "r398", "r1009" ] }, "bsx_RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring charges remaining to be excluded from calculation of consolidated EBITDA", "label": "Restructuring charges remaining to be excluded from calculation of consolidated EBITDA", "documentation": "Restructuring charges remaining to be excluded from calculation of consolidated EBITDA." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r135", "r172", "r644", "r680", "r682", "r690", "r726", "r863" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings/(Accumulated deficit)", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r198", "r259", "r260", "r261", "r263", "r269", "r271", "r361", "r362", "r513", "r514", "r515", "r527", "r528", "r553", "r555", "r556", "r558", "r561", "r677", "r679", "r694", "r1046" ] }, "bsx_RevenueBasedPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "RevenueBasedPaymentsMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "revenue-based payments [Member]", "label": "revenue-based payments [Member]", "documentation": "revenue-based payments [Member]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales", "verboseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r295", "r296", "r307", "r312", "r313", "r319", "r321", "r323", "r474", "r475", "r625" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.bostonscientific.com/role/Revenue" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Text Block]", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r196", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r478" ] }, "bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues from contracts with customers, disaggregated - performance measurement", "label": "Revenues from contracts with customers, disaggregated - performance measurement", "documentation": "Revenues from contracts with customers, disaggregated - performance measurement - measures used by CODM to make business decisions, excludes impact of foreign currency fluctuations" } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility [Member]", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RoyaltyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RoyaltyExpense", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty expense", "label": "Royalty Expense", "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property." } } }, "auth_ref": [ "r149" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r946" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r946" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Trade accounts receivable, net", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r46" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Accrued Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in Other Comprehensive Income", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r49", "r1025", "r1026" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r61" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r61" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]", "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments." } } }, "auth_ref": [ "r176" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "verboseLabel": "Schedule Of Business Acquisitions By Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r89", "r91", "r534" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts." } } }, "auth_ref": [ "r89", "r91" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Long-term Debt Instruments", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r41", "r80", "r83", "r122", "r123", "r125", "r127", "r170", "r171", "r842", "r844", "r983" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Derivative Instruments, Gain (Loss)", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r108", "r114", "r551" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r109" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r565", "r566" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets and Goodwill [Table]", "label": "Schedule of Goodwill [Table]", "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons." } } }, "auth_ref": [ "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r840" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r840", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007" ] }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets and Goodwill", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class." } } }, "auth_ref": [ "r65" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r33", "r139", "r140", "r141" ] }, "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Notional Amounts of Outstanding Derivative Positions", "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]", "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions." } } }, "auth_ref": [ "r103" ] }, "us-gaap_ScheduleOfOtherAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherAssetsTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Assets", "label": "Schedule of Other Assets [Table Text Block]", "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Current Assets", "label": "Schedule of Other Current Assets [Table Text Block]", "documentation": "Tabular disclosure of the carrying amounts of other current assets." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives Not Designated as Hedging", "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument." } } }, "auth_ref": [ "r115", "r957" ] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r174" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r77", "r78", "r79", "r80", "r81", "r82", "r83", "r170", "r171", "r172", "r213", "r214", "r215", "r288", "r447", "r448", "r450", "r452", "r455", "r460", "r462", "r686", "r687", "r688", "r689", "r846", "r954", "r980" ] }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Weighted Average Number of Shares", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)." } } }, "auth_ref": [ "r60" ] }, "bsx_ScheduleofEffectiveIncomeTaxRatefromContinuingOperationsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "ScheduleofEffectiveIncomeTaxRatefromContinuingOperationsTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Effective Income Tax Rate from Continuing Operations", "label": "Schedule of Effective Income Tax Rate from Continuing Operations [Table Text Block]", "documentation": "Schedule of Effective Income Tax Rate from Continuing Operations [Table Text Block]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r877" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r879" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "verboseLabel": "Segment [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r291", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r317", "r323", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r396", "r399", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r840", "r958", "r1036" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r321", "r322", "r709", "r712", "r714", "r775", "r778", "r782", "r795", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r820", "r848", "r868", "r1018", "r1036" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SegmentReporting" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r290", "r291", "r292", "r293", "r294", "r306", "r311", "r315", "r316", "r317", "r318", "r319", "r320", "r323" ] }, "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingRevenueReconcilingItemLineItems", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]", "label": "Segment Reporting, Revenue Reconciling Item [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "bsx_Segmentoperatingincomeaspercentageofnetsales": { "xbrltype": "percentItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "Segmentoperatingincomeaspercentageofnetsales", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment operating income as percentage of net sales", "label": "Segment operating income as percentage of net sales", "documentation": "Segment operating income as percentage of net sales" } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expenses", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r150" ] }, "bsx_SeniorNotedue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "SeniorNotedue2027Member", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "0.625% Senior Notes due 2027", "label": "Senior Note due 2027 [Member]", "documentation": "Senior Note due 2027 [Member]" } } }, "auth_ref": [] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes [Member]", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "verboseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r15" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Award Types", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512" ] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssued", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance (Shares Issued)", "periodEndLabel": "Ending Balance (Shares Issued)", "label": "Shares, Issued", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [ "r20" ] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeAxis", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt, Type [Axis]", "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r36" ] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeDomain", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt, Type [Domain]", "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r34" ] }, "bsx_SpecialChargesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "SpecialChargesMember", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net (charges) credits, restructuring- and restructuring-related net (charges) credits, EU MDR implementation costs and litigation-related net (charges) credits", "label": "Special Charges [Member]", "documentation": "Intangible asset impairment charges, acquisition/divestiture-related net (charges) credits, restructuring- and restructuring-related net (charges) credits, EU MDR implementation costs and litigation-related net (charges) credits" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Statement, Business Segments [Axis]", "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r200", "r291", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r317", "r323", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r391", "r396", "r399", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r840", "r958", "r1036" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r197", "r213", "r214", "r215", "r250", "r276", "r277", "r280", "r282", "r288", "r289", "r360", "r408", "r410", "r411", "r412", "r415", "r416", "r447", "r448", "r452", "r455", "r462", "r573", "r686", "r687", "r688", "r689", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r706", "r725", "r747", "r767", "r796", "r797", "r798", "r799", "r800", "r954", "r980", "r987" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement, Equity Components [Axis]", "verboseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r20", "r45", "r198", "r236", "r237", "r238", "r259", "r260", "r261", "r263", "r269", "r271", "r287", "r361", "r362", "r463", "r513", "r514", "r515", "r527", "r528", "r553", "r554", "r555", "r556", "r557", "r558", "r561", "r579", "r581", "r582", "r583", "r584", "r585", "r592", "r677", "r678", "r679", "r694", "r767" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r321", "r322", "r709", "r712", "r714", "r775", "r778", "r782", "r795", "r803", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r820", "r848", "r868", "r1018", "r1036" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r259", "r260", "r261", "r287", "r625", "r685", "r706", "r718", "r719", "r720", "r721", "r722", "r723", "r725", "r728", "r729", "r730", "r731", "r732", "r734", "r735", "r736", "r737", "r739", "r740", "r741", "r742", "r743", "r745", "r748", "r749", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r767", "r869" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r259", "r260", "r261", "r287", "r625", "r685", "r706", "r718", "r719", "r720", "r721", "r722", "r723", "r725", "r728", "r729", "r730", "r731", "r732", "r734", "r735", "r736", "r737", "r739", "r740", "r741", "r742", "r743", "r745", "r748", "r749", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r767", "r869" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r886", "r897", "r907", "r932" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockGrantedDuringPeriodValueSharebasedCompensation", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of stock-based compensation plans", "label": "Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r86", "r87" ] }, "us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesPeriodIncreaseDecrease", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation (Shares)", "label": "Stock Issued During Period, Shares, Period Increase (Decrease)", "documentation": "The increase (decrease) during the period in the number of shares issued." } } }, "auth_ref": [ "r20", "r1046", "r1047" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r20", "r132", "r133", "r172" ] }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Repurchase Program, Authorized Amount", "label": "Stock Repurchase Program, Authorized Amount", "documentation": "Amount of stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "terseLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning Stockholders' Equity", "periodEndLabel": "Ending Stockholders' Equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r133", "r136", "r137", "r159", "r727", "r744", "r769", "r770", "r863", "r876", "r982", "r995", "r1024", "r1046" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Beginning Balance, Equity", "periodEndLabel": "Ending Balance, Equity", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r98", "r99", "r100", "r198", "r199", "r237", "r259", "r260", "r261", "r263", "r269", "r361", "r362", "r463", "r513", "r514", "r515", "r527", "r528", "r553", "r554", "r555", "r556", "r557", "r558", "r561", "r579", "r581", "r585", "r592", "r678", "r679", "r692", "r727", "r744", "r769", "r770", "r801", "r875", "r982", "r995", "r1024", "r1046" ] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "STOCKHOLDERS' EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r169", "r249", "r446", "r448", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r461", "r463", "r560", "r771", "r772", "r802" ] }, "us-gaap_StockholdersEquityPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityPeriodIncreaseDecrease", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock issuance", "label": "Stockholders' Equity, Period Increase (Decrease)", "documentation": "The increase (decrease) in stockholders' equity during the period." } } }, "auth_ref": [ "r20", "r172", "r768", "r800", "r875", "r1037" ] }, "us-gaap_SubsequentEventsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsPolicyPolicyTextBlock", "presentation": [ "http://www.bostonscientific.com/role/BasisofPresentationBasisofPresentationPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for reporting subsequent events." } } }, "auth_ref": [] }, "bsx_SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants", "label": "Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block]", "documentation": "Summary of term loan and revolving credit facility agreement compliance with debt covenants." } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation" ], "lang": { "en-us": { "role": { "verboseLabel": "SUPPLEMENTAL BALANCE SHEET INFORMATION", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": [ "r966" ] }, "bsx_SupplementalBalanceSheetInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "SupplementalBalanceSheetInformationAbstract", "lang": { "en-us": { "role": { "terseLabel": "Supplemental Balance Sheet Information [Abstract]", "label": "Supplemental Balance Sheet Information [Abstract]", "documentation": "Supplemental Balance Sheet Information." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Supplemental Information", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplierFinanceProgramObligationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplierFinanceProgramObligationCurrent", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier Finance Program Obligation. current", "label": "Supplier Finance Program, Obligation, Current", "documentation": "Amount of obligation for supplier finance program, classified as current." } } }, "auth_ref": [ "r392", "r393", "r394" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r926" ] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Taxes Payable, Current", "label": "Taxes Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r37" ] }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TechnologyBasedIntangibleAssetsMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Technology-Based Intangible Assets [Member]", "label": "Technology-Based Intangible Assets [Member]", "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights." } } }, "auth_ref": [ "r30" ] }, "bsx_TheOfferingAggregatePrincipalAmountMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "TheOfferingAggregatePrincipalAmountMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "the Offering", "label": "the Offering - aggregate principal amount [Member]", "documentation": "the Offering - aggregate principal amount" } } }, "auth_ref": [] }, "bsx_TotalAllocatedToReportableSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "TotalAllocatedToReportableSegmentsMember", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total allocated to reportable segments [Member]", "label": "Total allocated to reportable segments [Member]", "documentation": "Total allocated to reportable segments [Member]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r918" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r925" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r945" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r947" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Transfer of Financial Assets Accounted for as Sales, Amount Derecognized", "label": "Transfer of Financial Assets Accounted for as Sales, Amount Derecognized", "documentation": "Amount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition." } } }, "auth_ref": [ "r27" ] }, "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer of Financial Assets Accounted for as Sales", "label": "Transfer of Financial Assets Accounted for as Sales [Table Text Block]", "documentation": "Tabular disclosure of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction." } } }, "auth_ref": [ "r26" ] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r442", "r460", "r559", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r654", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r990", "r991", "r992", "r993" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r948" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r949" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r947" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r947" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r950" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r948" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r84" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock, Common, Shares", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r84" ] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock, at cost - 263,289,848 shares as of March\u00a031, 2024 and December\u00a031, 2023", "label": "Treasury Stock, Value", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": [ "r44", "r84", "r85" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchase of common stock", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r20", "r84", "r172" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "bsx_UncappedContingentConsidertation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "UncappedContingentConsidertation", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Uncapped Contingent Considertation", "label": "Uncapped Contingent Considertation", "documentation": "Uncapped Contingent Considertation" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r944" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized Tax Benefits", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r517", "r523" ] }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate." } } }, "auth_ref": [ "r524" ] }, "us-gaap_ValuationAllowancesAndReservesBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesBalance", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "documentation": "Amount of valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r255", "r258" ] }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Charges to expenses", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense." } } }, "auth_ref": [ "r256" ] }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesDeductions", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Utilization of allowances", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "documentation": "Amount of decrease in valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r257" ] }, "us-gaap_ValuationTechniqueAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueAxis", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Approach and Technique [Axis]", "label": "Valuation Approach and Technique [Axis]", "documentation": "Information by valuation approach and technique." } } }, "auth_ref": [ "r22" ] }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueDiscountedCashFlowMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Technique, Discounted Cash Flow [Member]", "label": "Valuation Technique, Discounted Cash Flow [Member]", "documentation": "Valuation technique calculating present value of future cash flows." } } }, "auth_ref": [ "r1023" ] }, "us-gaap_ValuationTechniqueDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueDomain", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Approach and Technique [Domain]", "label": "Valuation Approach and Technique [Domain]", "documentation": "Valuation approach and technique." } } }, "auth_ref": [ "r22" ] }, "bsx_VanceRBrownMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "VanceRBrownMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Vance R. Brown [Member]", "documentation": "Vance R. Brown" } } }, "auth_ref": [] }, "bsx_WatchmanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "WatchmanMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Watchman", "label": "Watchman [Member]", "documentation": "Watchman" } } }, "auth_ref": [] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "WeightedAverageMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average [Member]", "label": "Weighted Average [Member]" } } }, "auth_ref": [ "r816", "r817", "r1029", "r1031", "r1034" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net effect of common stock equivalents", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r988" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Diluted", "totalLabel": "Weighted average shares outstanding - diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r275", "r282" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-average shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic", "terseLabel": "Weighted average shares outstanding \u2014 basic", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r273", "r282" ] }, "bsx_YenDenominatedFactoringArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240331", "localname": "YenDenominatedFactoringArrangementsMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Yen Denominated Factoring Arrangements [Member]", "label": "Yen Denominated Factoring Arrangements [Member]", "documentation": "Yen denominated factoring arrangements." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-16" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "b", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a),(b),(c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i),(j),(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i-k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(1)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "e", "SubTopic": "470", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-13" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29,30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.3,4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(a),(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-10" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "30", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480513/718-10-30-3" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "30", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480843/718-30-35-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a),(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480870/815-30-50-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-7" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//220/tableOfContent" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "c", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.13,16)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481161/840-30-50-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(dd)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479468/405-50-50-3" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479468/405-50-50-3" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479468/405-50-50-4" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480627/815-20-45-3" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(h))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-4" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480602/954-210-50-2" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r868": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r869": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r870": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r871": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r872": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r873": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r874": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r875": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r876": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r896": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r897": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r898": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r899": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r900": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r911": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r939": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r940": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r941": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r942": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r943": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r944": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r945": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r946": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r947": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r948": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r949": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r953": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r954": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r955": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CC" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//210/tableOfContent" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 80 0000885725-24-000046-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000885725-24-000046-xbrl.zip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�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�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�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

VGQ"T[#@A* M'"0/+E8RZ&,K+99T<]%*DS MPM#S*(W#X'_Q=NJE<+B>C)8G0\VMIP:HAP6F"U*]FN&9J4$M-PAD;'*?=3IS M2\Z>ZVYWP=&S I/"Q:3%LJC)$S=+[U/#N>JT_VIVF^U6UWG?N&A_<=Q.PZE= M=SJ-5L]QNT[[@U-OU!J7[QL=C+0<.VZK[ERZ7YU6&[ZOUSN-;M?!&ZEK+AK@ MX].O>NZ_G!K/0(_[C3^O&YV&I?P8_B@VVW7FFZO47>^-'N?'/>+ MVZEWG6;+X26H.E_;UT[W4_OZHDXWN[[HR2]S3W+K\![MC@/F8 -^AF_1OKRZ M:+JM6D.NN()_UMSW%PWGPOV"+]?LP6@NX.E=O R>U'&NW$ZO66M>T8!Q'#1) M%V[K!0RM3;!?KJO=JM-#N$MNV5EQ(401T?5QSQ->?E3V M$E_%.L5D]!0+*V9B0R;^HA&!#-WYC-C+=5Z,5NO)RV5[E)E]'//DF]FX^8QP MVR^6G.*%+6IISNX@LO69_]O%"AS:U&+$(%AP-YW PCS,E0QD(F\HO/G:@4R/ MM.Q\JRY@::>TW3$\)"Y?Q2;NA67XR\&N0V$+\D G:Y0'6G_E!)8XJ5S$&(0M M5*JQIVF,NIC-$PZAK4!5]8CE41V"5,85^0)M^[C0*I3TX/QA4 M!7#S%.$8L,#1;.-8(:L/@GB0CK56T.^V3@[1D^,#7G([]I/$::@C_$H%)U=L M&[:B&>9;=.P)["DP^PP1 %?*Q]I$LPX \+M]ODB -89@"8VCJ:J?8>9YD"-< MS2C&,X DD>)#E8S]E\$5L!CND6-@D 5T)8LF(VM<*:YF6/_6V'4@57Y(T/H6 M4#_9>!+)HBJP;-%912I-\0PKLLRLLCW"VI"G#HN-,B)M""83?XCMZAC0R]AS M*B@WC:.![P_I,5AQ7W'HE?"KCQ3,NXH)W12GK.=]/^A(P*\Y\R51QJ^E*^9& M1 U G0M"+$'M[#PH6 EMZXEAFN<(H++_?\7%GE MGQ)LWX#]W?&QX360XG=+S-? \Y,R+TS9@6C/N!J21VM)'%=8XV:F>G'2W2"! M18A*QBG)5FK3/L1S 5;*@8T6^^'@0;M0A._A>.GL-HKA)8;L;9FC)1BQQS#6 M>H)\#(HQPZS,CR*6;46;A^OTT>\DL45,"2.VK(C4R+00QRG"\N6E%U2B=:@I M!15*,3X\/H=@K1U+Q"FQT*M'0_=$C2!MK]UB'A":>P=EXF(/A0)7O>!.4+BNR0$PO6NI(?V>KM%7H =NR MA8H'EU7$D&,'1H[G8P$1L@=+E8*'RPSJ$EO@)TR3$HC30DT@(D=T& MXR$H5M8@T7VH0'J4O":@5.#T-F*)\AA+3F[/K]Y4*W.J%/ZBU3;I.U169/YX MB:T%]RFYH;)Z%;MNGTO_LS&]D4Y\#J([:^LEK-,R>'D6A1-"]#SVS-FV6)(! M-EV;!ABGR>NH<;RPNVOQ$BV-59*_[A#=J*;)*.^>J^@@DKBF/JQA(":[BBNE MH=5NIT&IC/^X98+REX1>44G^:$^L_V#J=1,B.F N(&,?.AL.<8HDXC MQUE^X5P$M,35G)/;K*>)\?$#-/YL/TX_';O2'Q1^FK*Q,_49^5O;R0B>';@# M>%ECZITD@P<KE$8=#4E!EWWNMYTW([[ MOJ#08(/\G WL?/UE8867=OSFNG;9<=,!!+M%U^8*97M^C@;4[G?'Y8='U+PI M5J<([^83FYY6M$^;K8_N5;O3V-9->B7K=J76;<5&^6(AS07F@D1Z.:F;.Y\& M$NB]/U-8@1$Q)%^!M$:AP.VA=3.Q;YL(D>7QVT?[>:%\/P6*S!5'_D&+[ M++)8S)R]VJTW19O_^/QM!4[?PS=.8UC=U[A_W0^NA>ZG:0MOO<10,><35.-H M>,/$LE:JRF.NW8B"1&EB>DDNP5(D-\/E".2,8GE=>%UOBKWKQ$V7"/PN;6;V M5R64)\YTDD[!$@T2M%<]?2-[1@FQ&,=C,ECZ(3GW.=&1( -Q;%8.IH2KA.5& M5CY&+&CSFC#+]]I_YA 1A7Z-5UW6YXNH_D:5Z:5]?:87%88AB.29V5[7X8!P0AU_?' MT3WSSFN CQ$=$L@YK8(1>6@16"JPV01'/PCE'^#E,I<,7G+O]S5+>_9I?X^= M^:Q89M>&W/6H6L:%M1#0JA"UQ674E@[#L>PI,);/^\PPN:8P++>SV90IN"FZ M0_^QH%GHWX.;X*"/)?SP]WX+??WMS\J[6_ Q_'KWK)]]__^WD M_%UT'V*2'C[QOU,E+7W*M<+T\8T_&R@)A6\^!!A8@L^[OA#M[E(?"'UT!WL-47=<'QX=.1<1/#^"(T'Z@VW ,:JT;85@>]AB;72 M81C@(]MJ,$ E0_GO(ME+DZJ/*/-^%82$/KG%"NP#$)'C=\[E@]A"9$++AY^B M,:Y$HOX] +_T&_,0L1LQ]&9L!"?8)3M37L%?J#/%^%&:5BSU[96$DQ_3>$XK M"@_8C0KRA4 \A519^V11"J2ERG>^O[LVT6H#GHOA4)PND/"L(CRJEY M^7#U'C<+9R_18UP\"S]?NM9^"E8G_=9+[U".MB.M\WJ-TCIK%H)E&)K"!GK, M_U.Q^B":!K[N?O?ZT9WM!2)<@"13*ZB@,"]Z"_8(!IM"YS[&BE>NK8*S5X=% M X&A70*2[?1M#LN<^U4G.ON5H1WRE>S@.:.W?/A'15, M4V([]AGH $$1:%U-&Y$A)V3FL(GWC3+]AN#N_M;G$%ID-17Y\^A E"*?@9O% MI9E+HS3RT>.#/&%TFV^"T#6N\ M*(3WN=UIK%4O^$MU=C!""2YZ+1J/.7Y;P?8.-))4B0[U DN,^TI)4-V;K12^ MDB'2R5Z)(V33,H!?, MD!&_-('S;IJ5P9DE@RAZ#M$X)(,XZ'/9=->7 !2!*!^K$]86@;?O\%8_#W)] M(P7C>,T%PY(#U3^5(B\(G)!#LE >&*G<''I[JE<[ TGNA.FD[\?[98+C%,C, M-AQ[3ST2ZN#MPL@&SGON,;/Z@$#/5+T?ULTND67_J1AWJ/9:$&(),%=_\[:#R6/9$=N? 4K, M?*L%I\7E:ZISF DYG'3ENR31V"=OA=BY I5C],,;[T:<$S4POG/%5 G,6*_R MI%0I:)Q/>W))F=$:95-K6EQSCZ-0G9"FP#PDL#NH-2:&C!R"Y'K MB*.%D98YQ?5',US .;&4CV9@O.5R^!<+-UIZ.I%M>?I@2\KV M3G 96)=JAL&:2$. B76$2(2!)'\I(G9S_0I9(7A("3VF69Q<8G*.;@M6!ERJ MX"X8IAA\N[^-E.G _56^";VJ$8%^S_5$R[F$)P55SD3Q>"AUG3IH%R2$S# ) MA/>1/U7]NA2@)^\"!D0-97BC7?)CXY,?;W;)C_+9$?QTL(*25&JN,^CW D<" M>XZSCKH@ERC.)Q+"P^I6C(??H\W>#P1;Q-JMQ4 &]##X[TV$JKWO)0&"(5!\ MDXIQ540:X MP1IU@7W0%OBR&=OGA*_UI"P9'+&34GVW]*-6T/% RT=A1$S3&-0.NJL!(2KB MQ"=(\4CVL??%+U=FLR?_01B#6:1CBWS:,1K4/.+\'&CN1<%"ZB4M\RRR+JV%6Z=,%NS M:%<9\RY>0'::(RZU9)O]6OPT6T"[SYK,2^$HACL.! 5&N:]X&1.7%O?D6G[U MW->JA>2./0J/;D+5&F2/PF"PH(5JKM *E\C3J'"DEG"GN@#>V6TDIR"S$18G@(Z,)W-H7EI M4"A8O)%/-IGR]2T26#79[.51V'@.2R+6=*X3ADM!X-&A/PDU-H=Z...F+N7. M[6M)BD85TE#X^LIR1/YKC%;?J&NQTGNF B=3>&E-)SD*8/60.!+Q6!/4P_)L MT]Q1(7LY0#QQ_![^@;!9%,CX=TKM1HP/0V<$!4^67T$C&D0W(:$>F>MQ;N46 MQN)FL"Y.Y-SYUNWPU:C?!3^^ ?,Z'"*4EV2^ESX,O\@]5&78-8N]+6[:K;46 M@CT%%S<%.!:G1^JW7Z(8PZ12\"T -SXN"W:Q6YUC_BK /UH0F5-M*#O?'18/5'W[D0/F)/U![BKCT[.CZER[>CM^>MJ M"92JYD.BH@6R!:2"P,JDYH\I.CH%#7AN$V9)4P,P/P9LLBS8'@KD-Q.8W>28 MTJL_WG]U&A>-6J_3;C5K[L7%5\>MU1I7O6;KH]/[U.PZ[L=.@[#1*X1\[M8^ MM]I?+AKUCXV*<]VJ-SK='B*>T__C3Q&X'"'*>XW.)>.KU]JM>I/AUML?-'QY MA?ZF[\ZPZ?3 >KW1JE]?;H-Q4!**_-* 5]R"UWMJF++G?7>^@-*XY1+/50<; M\00>@TE$[>,FZDBFJHD]FI3KX5SL\:=4:JS)0K[ZXXL<8G3^Y^BE=MR*E$V4&X6!?;6[H M$Y=.1PPJZ/G$1ZF9YLS;W -WR#6;'^4[VZ0HW]IION(3NN]>=SXVO6_!ZV[(OKLG'[J7Q-Z8/O*_HNIDG M(]6F38;X&-3#C ?5$.N#@[X 7H?, D66O7D8WF8"BZ^2-#8G5H5CEN. -VO_ MH6+EN;C;A@>DAI?'F0(G!".8]&\#[L1Q?U.AQ_!*!@A$.$?N<&T>%(BR:2,+ MJ/,G%(].IP2I]"0#$'\9A#@!%$MN4!;V09.?U-.^%R 0JA?/5 E40S*U\+&! M0V4_:8K^OF_H61VYC9E\NC%EPY*9/Z7Z.'X!CA=:%=PJSH_C!%FHF**:XDFA M!=.OGT&/PN!EJGJFHOO0&:88F(8=C1E I6 M T2)70ZJ616+"KM3CM)6<*WP M:HX/PX?\%_/ZD5T]6E!ZF.47,-6Q4H6X"4!ZHG8_-UL?Z^W+7P@1J1E2FAZC M<2@2W8A6KHE%HY0,KV&:7JF9M8G7K3)@M]+(&VN9A1&O!].'8I=.VS09,$7% M-#:HM<"/0=SXT%/U@@],Q%,8-.+T-2($WIKVWCF>R4HV/(54CP_.ITNG@ZG( ME&L5:C#)$0Q#01-^NNS4%#:ALY>IPJ &4@,GF"G0@//VCB _U/?[*HV$5 ZZ M/T>E1MG0_.;[4Y,M]8?Y(%LNGW7C8=U_"1N0*JUYH%G7E"HRDY$)>.+?Z628 M>L&0OQB/^4=9_DBX%"?C[TW"+KBW\<&]\U\HN-?W!M\XVWX@\SNB_WGW4EHW MS\]&A0Q1[%.57G&AET6\X0DW:T3*SO\.1AI3](Y&P0!VZ)Y5.S+QO5!Z!+5> M/]G[IG$HB=38LKV5#TT K_";H[%HOS)?(&]3H.FWL([-#.$/5^&8 M2I$L>L"2-^,Z:+(I4$.AS2K!,RFO4!U0R-"$B@]. FYEH@EY>^@,05P%$91> M_S/=Z,'WJ+6(XP;HE='8;H([?).8VJ0B,<>S52^F99(Q*Z(!3*4P'9A:&2XE M,F/$9U(#CD6&JNH)"=&"QR&5?]0*IE\:YX!K!KA%+%5UA<:42E0@ _0]GLOS M'5!ZUK%I;<)+9QCDLOU/,>'ZJ89CN*5RK'(K03X#.K5FV.J5;"YA.FV,%P$^ M[.C 0_3%1%5+(#$8%1C2PX-)'V8TEQ1T\DFI/111W76TK^L=[[QQZF<+1.&, M7CI_B]]'!9@>DRT3FEQL[],$88Y4EQ$%&CES+)&"3"S;"K?N7&G) N-L&X+! M3W4P&HBTF$C]3&WL!9-UX.9;W&I(^TQY[;DZ/+LZF)I,O0D5;$ NH\,V$+Z?9C&AQ(2I1",J MDAD7DTH%IVHZ+Z]AVK.3RO;/ HK$H!D!;P+7Z&)MN\9]GT)(NIF6*T4Q, 6W M257!H=[=>LR*7SZ3C*>!RBOE:.-A"N%(@0UV%Z'F>-#S=.]QDQ*!8&=GO#K? MLO+$[?233+W'2>E_E<'?_< 7/S01.Z=@4YR"M^OM%+S0-BH*ZBWLD;VZ:K3J MS7\YCX).RKS$WPD"KG V7OU1:[>Z6%QYT>CU&IU-?(.CPV.GYEXU>^Z%\]%M MMASWB]NI=YT/[8YSY79ZS5KSRFWUNDZGT6W6L6H5?M/L=MS&Q1->=T4ZOXX. MSI5JS@UGE0T,-+_Z8S$^ZQZ>^1+?LVH'*<2'B2-?.5^14,]2AD)H>2CJYL11 MRA!S>FZ0ZLQ0\OC5,AZ8(_4VEM0DY&8-?61!'JIDH_I=DO8/IM)L3)\O>"A= M@IP9!_93E5MUS[XG2&9S?+ROFW=&1'J33\T&$TD#S$6D<6KD'57 MF:Q/A1)+-U:2*@+XD02P@P)HYB/'AC)7$2O&C]T//HL4K >;K8(>AF\HKT$2 M1HSQV0X2;WA'DLHP(%CQP=6AN@HU)"K>#+4\0F]28VE!1)Y?V1C;2K)5 :L6 M\((IR+SZ$B"51'/,8"2"MG"!A;X)^JU7/!EF$ MHO:Q;OO--YM)N$;C+U %,4B.LJ7G*7F4. \P&8_I::R1T>Q.]#.M,:0:3A97 M!>&R&7?;N4PJ!@/T%D9_QVPY,TH'S:TP"TN!SC4*5F52+.V[A_]Q^S CJJG& M-(:A"N<7A5'INKQ]T",&(^?X\/ DH[BL+_6+8]QRXB^(OJRSQ+TG7A4=E1AA M7[D'KGG@CR2T.;5%0^EZ*_(W4*WD PM#8EZ&J\[51I_<'G7E M=*\O+]W.5^=]XZ+]!:PII]W"QB#G?:?9^*"_I9_7VXTN7NW4VG\U.HY[<<$= M/IWV7\VNZOGI-FK8_T,2(BU [0X8:VZKUI#&GP88XQXK8B_/+"_<(WLF]<;W1KG>9[ MN-VG1J>!UW7P==__/Q@A/J'VR6U]A#OV\&NP,1L5I]G#H70:M?;EI8P$7QR; MH="\OK[H.5^:2*RDA]2%B7A/5V>:J51/%,T W#)KG,.,S%^$+RH&+WQ=;W:O MVDC_1W/Z"8;>W6"5.O&(Y<#NN2\(3W ZPX*10/; +\[QB, MH0PEG;O#LB)K1&?EB HJE@6C)QA70K?V+>/DYPQ'F30ST/@*2(:V5ZRK&ZPX M1*X(0U434-K?5_G^)%+8O86%!7OSR#866*K]6P?<=$*4SO E^]]Q7OSAOB " MPU@4WE1E\>++BH-NX=5&AC%.?W(*F(:"3<8W:I*S%T9WHFQ.#JD-!X=&U313 MC"@,,QW0U9V66)F6B'WT=X:L*6A%/&P5"*@$IE(D\EXF"FXHNBI9M 75ON\8F%ZK")_R(#*W-89[!;?- B<2JY*M/$# 10CP% M4ID@>H7+(G"#&U L2S=XS+(ZNX7-B!6^FQEPDG81ZA!DA!O2+JI?B(Q$2^D8 M>[&BF()(>X9#-4-9<]18,YFJQ'Z9'E?G'VT13]IA>/ZR57#Z*\!,FAC/D"P*7N$H4/U0IM+ZXR"YGO'(BZ";;B]B:IK,P#X+O+C%Z M+@/.X4BBK_*(<%J.7*O4C1$#T J]_SA'[;I-?CD[<9.KT&Z%."V:X@F9A@)R M$_5GGJ1?L0V.;37DDP"]:N#Q.QOD;8L)_IN9KG4." ] M]&'B$7.6 (Q-0$H7M4QT!TELSC?1?P;L![3@DK# :+227HD>O64=W[+3O3[( M8,4=.)]\V*OWU>EPM-(.BJT1OM?+[&JKMX]QM=GY4;5,]7^S2/D4PD!:'62VIL'( J>&,@I'[/6'#$"(#D>0.3:<,(R)5PQ/ MJ4P\DQ^ZGP<#L._N]?%+&)MUI1T?23050M\+ORF&NXKF9X;S#90D^XM"4JG: M*)F$4A=<,C0XJ=/"UQ.'7.9B>X3FK.J42PUH];$7BXE/SALU8S&EIZK=FTE$ M5LI/1[D<0=:EHH+.;.4J%052S1\7D8J7*<_!(,QPR&PF>*-\1VD #Q8H?$XJ M>*&N&3-#C?%W*.)(K*> ZHOI.33G(D9'E3KSAYD"4^VT9C);7';*P7 [^&>9 M517K\/<,%I*<[%;H5:"9-""3I,L$6&=[Q._\<6=6KJ<1]G@PSBP>G27:FC5I M?C*AK'!;'I:^($RA'= DQ1[P@$!(3 5_1*&H:83)-#QD,B7.>$N6$0QV:/01 M"B#RT/MSU-C9IU?@.IVNT,DRBLS8W00&$[XP(,9H30X7H4W]@6X)YS!&X>"M ML3]W$FU%PO5VD6ZS-$EE@:C9NSXF[0)O%WLJ9PN&$3R58C^J\[P@!B)050-* M@+&NB[@!5:@:;#:>6:0*IK=\>8X.%ZU/WF(-+; TM>O#O,Y.G)O4H_FW&%6* M8E-ZC\$Y<:-Q!_#1+GSE(Q8W661-)C"NBAE(TK4;,0O^&@EOS=VQB1'<\U/*'P$;9/-;(/$E) MM149+IHB? AE?AG-*0L"S@<]D;(H^(2E]Y#*!'I!Y0(_"HA@>UN@UQYUX?R1 M4;[71R?G)T='!W='Q[__]O;X7_/FS>O3T:#_MM_O'[T^.8)_G[QYGV][-WBK MU?B7<_1DJ7A**SA:$O+)+)K^\[!ZI"NCGGJ;;%W1V7GU^#7=*YB AA_/0#(0 MD>1_CJO_GMZ\%#H^/4V[5KY#AZ_$0\];7?5N?LV+M[N]=LOIUIHP/\T/S9I3:W>NVAUJUUHC@Z5X]*XTA'&7 M6;?G(IXL=WFW6Q\/L-W+:;9J^&I_,>O5SQ&!E[QJ@;@52ML:"1OOQE[;<:^[ MO8Y[T71;#!N!77B-RZN+]M=& ?+ZQBW1[JKG$7.D+,S+^?F@V\CV+M@QNVKR_JSF6[U>RU._AYTP)BH2Y?X?S#?<4-P7A_YX-;@PNPD?:B M\9?;ZBF>0+?VYW6S2[V[IJW5#)@H!LWCW:[3;?2<]G6/1X6]R9DS5K<3JX9@ M]T)_UZUR0RUU#>,0>VZS!1J[Y$Y-U [<.*P&RV-J7]%G[QOWTXZCV&-VE]:UH.N.NWZ=:VGYN)#IWT)(G'5 MZ'3AV1?P4:L+[_3^*T^E49?=1NVZ _/:D!YM+6S8SGQYV>QBS[>!U^@V#9XS MS,!'/ :[U[5/JG-[F==Z^G853NN/>5YGS^%Y/4NU#1O"AZ\+SNCSLZ)#^OSL M94]INN,_,805#%9P;F?=C!_P,@Y+)K=P;M?( -I9VW_+-%B;,Y[(T!I=.!N( MDZPN*4^L\4Z$J@( :(P1!:J;SR3^ :>4\ =4J@V6%L6PWQ3H( M!!$R>6C#9!.-E@QH$;0853/ ;+@Z[<',-LSB5OSZBO^' ^<3;ZB:>>N!8&8? MN3@JQ-YRSJI'NMC:&E1"$-W'AX='F>'!AS*TB@TSE;LQ)=+T+Y'% +L)=94 M86,575#A+*E*?5-6/F+0:,PD2#]96" R\(C-BY0_ 61$YD[-E5IA:H(91"FU M54;WH1\GM\%4R8%*1O4?'*0E8V*DT!\[][=XKS'*.J:4;5A=N"FFB4"&L1+& M3Q+)'I=@A&%N,PB)J#".;K!T0U>"8SZ\8@TO]D%* \);XK3V3(V3(*%X](JF M'>FB$%.%*=)O&4RE< 1).L"6MJKSQ7=NHZEO6K2XM023;%*NSRQ.+&.V9AG M[4?I>+P5A(M/4?=$ZVR\A8EMM>T M"\?NTH\QVJUQ:IX.86:+XT.%#HPP,A=B9&;X((@Y[W$*'! MGRF\&B%29HK9N=O3S53TPF36[.2FZ/F(U8, M+).I.N_M&CZOH,39Z@D'0[6/M#]*>1:,<+[Z,S>T-2$.='#7H5#7:;S M?O*8GCA'18'<;;,EFMFN#7;6YQE&RZW+2J[EWK"K[@F_$7CDXP>M1 UYCKI# M#CH5;1G3/27XL>14&+;3LG."-GMQ/_Z3U^GLF&-MRX[,DS?TNU6ALGG[ZP(Z MJYE>8/A)U*_3BBSM MN#Y_O>K_<[#>Z287,)%;AK.CVZZ63BQ0];IB&&Z[08 M1D/,NS9;->O^.LWZV2/4,@/.XXZ@?2(.[)^__W9R_LY56\/IWOH^+Q7^='N6 M:[0^RW5:/3Q1ZV6O4$)L 5W-Z_TT%V\#K'YRY LL<=U9/$ICZD:Q?8'0Q[ ] MBB:VM&"HWE/]P.2YW_D)MX ,P39/!*V730=V+AC83&>_Y!?E$O1)](?4G8^1.CJZ=[AJ,8^_QGPK>1L&]GR&)LV2#O MDJ+93$XK]XS"\8-U4]W2S/>C1G*3'RF.#JD(3J&\$Y&\2I^A^[J-,EH./?$% M^22:6)-G)TQ^_^W-R3,XT.LEJ&XFAX%4SH@*#"* G8"2*:&$0L7II]S&1D!K M?1B[Q[B=F+M/X\$MMK-[*@0!PB=@!8C4H:ER^#C!'D?KASG0XF#D#!!/CR&) M57>PXH]Q.$B^X5-!%X_\@-I22>RC+,T%W@7>F&%" M5,,A 2;COGML!J8Z7\GUIGK^ SF8)5+S,L;*$_=2.8S'I_87YQ+K)?.%I%^: M%Q=.$WE<&E@>9,HU,S6=1+9"%49J4U)%YW6G]@EI=X2JH-0)G )VNT7(+*VSB-^*I]@D"OT9 MFCWJG-"'ENK$S0\AJ3J?F,*JDF-X%EA8:E3/Z +K;OEWI9-/_UP#>YC';>:I M=+;T5$)1;_RKT:DUYS; MI]6O7F(>]6"/7<"_">@\C04_!2Z^K MW2H(_GCLQ8Q7,4$4E#Y'WL[2H@&9@L%WB;4YC.<73_K*[L6I[0Y: U]38EWLZ1#+ M]U/[HLZ50ZA>:NW+*^K7P._AI$6F-6J&D%,Z7V#TXRKH)2+NBTJ/9Y1DT_=$ MU.X#3-MYT\3_I_K+.R2%''L/_PQ"FFZZZ(>Z>%]73\Y/<5@SF)/94#U8OJW2 MB/\Q&\Y_]_:\^O:P_.O#ZI'^[A]T;[X_O$$R]<+_?G7R*B?*_SR>?G>.LBH? MI3O_$CS^PHGD>ORSN7K\GU!!<_8XB+FSP^/7YR<'=PS/\+'1G8-G,#/T#UK% MEY: X^KK-ULC &5]'6=YB3A96;0UC^PPM_SKFGM;+W.L%7%4RL 'J1K<.50H MPH_R$F)29GL'7A$;#!B\$WYYQ\Y&@:%O0.LH#)4UEQA6C<@RX&A(!*>O$&!, ME4/D;<'*,G,L XA$^%?C![ 4Q_!B,1M.UACSPU<\SNBN\!"%M$W3,1>,E4VO MLK>8'R4"E M)I[.'@1H,E^"*$$8EV9S[A(.HR8*-7R?@?V)'22%\E*()'=\% M=GEJ64$LH3U9 1VAL,21(K#\1OIA;Q?X86UTPQH7S8_-]Q<-XL$M;L[=6A_, MU#6!K8O[F#P(0*C'-UEPOY@5YIN+0567Q@G7*XKUYBQ/A.1-?Q8NX MIPS7)-+_[O._1Z"005G/HIB1B>W]O><5MESL/R%COH%+N49K>53EF< F70I MY)H4.",>Q=N[&NNS'$?GDB#/+<>C]LQ/B30:4L59*(>M/%6OIV@H'KTYKYR^/JS LRP[$K;X!)MNR>*3 M0];.>66A0K.G;57S4N;N(^;K'&U7OD-*GJ>QV(>4!TQ#X3\O&25VR6*7(IB1 M8"HO_JT$.^<&P@#XBD3=]Y(T?BB@W?@Y'3]K%;L[*F_MP^U4 _+]W.YT;/@2^O*9_@\@:E MU)M5\=]LP(E*2Z.4"G=LA@(V[_J!0'.$ M6A$+" .-)H;-7#W7$)R[FP3P6U^[C?5E3[F=S:9"@'UZQO^YO[^OA@^)7QU$ MD]4-^M4?RV;LIPJ1T:J#:*A1"-YW_R5='D]HEWNV>H)55MDM32IY:F\-X#=] M7S82L>R2?&V6_,=]KWH3W56]E#["8JT 5FZ0T#]',:-9/S!'MJ2K#H@LI'H[ MFXR?R:K?MIS647F;<.F19<#.G@9>M#&'6$G3'AI4S(&)-5YAWM@JX7_G1OJ< M21@DBL!2TVJ&XX=*ANT]4:6*JCHD>Q(&,:)\.".BQ,12K5TJ<)<*W*4"=ZG ME^>*W:4"G^-\F<81$MNI X%8^*@/8NA/?;(=!+8),9OP!($3W@\3]OH1EA(C M&3=4YX6!R?4A@0XM]%:8Q\,!A;"F8S$R&GA,<^5H$1 M_50D%6LS3H+F'S?TQT@UXR<98D!X5IY:YPGP/-L D^+P!XD-U4;&_DW*S38+"*JV;BF;\^!3BN[OS%Z!LD45BBI" MH\/:#1H;\!A@[90!LL&Y-I5@PEV(2B/V[0.! MSO!?:*X)&3[S@AH9UZC#.+VDLM3DS?#D7\GGI&%=X"$TDQFCTR>$C$>D_Q7E*$7#,#^ MCK7ECBY/IV&?#E--#GG1 %29@<3?_)XUF6?6FJF5C:G(D MGT_^/DP9W=5JL927)(4:4XL8;-L<8:L934DBF JDU1/A563B>.!D4H]&I&V6 MW4C5^!8U5 TC6'J840&8!5,[]$32)5FM>N7D#*"3 O2*"N;[H&"B"=S 5!O; MS*P:REI([(-P)$ %\@&<[D$B'Y%F4LX5KQ>,)HWUF_&0$K;^U?KI N.I'[,/ MCC3B,CS^D%\(/^^GH#V1DQ6%\=G]MUW>87/#SKN\PR[OL.YYA]-=WN$YIO$R MBK/0K,RN,HUFPO>@C!0ZJ)DIW#ILY<#YOXDY3?!H,7EI./#2\8QPY>7LS4< MX-I)A*>BCSPKCAN&*5S7\3'0B58'V"T3Y^CPX'.^E0@N_!/LB!DV#A7\_L\J M_' ::.#E!.TO_!%CH1@7&MZKH.H$3"^L.*&'4N\1U9@DAAG^EXM?6)B^C#\A MIBU6M]YS>$ELN?GJI#MOG)8:90^J0%"Z]G/E$JIIG\7.I#D>WP!_9;P.16FA M,BCA731&R!ZR@1@ZBJ-9\Q8BB'"LF__Y_C]U]<_>YLE&"RMM^6=K[U@N<#A/ M%SN<$KBT5GGF?1?"%E@<+OUB>9J6+?16NI>",I/X/$'K6="W" !QE06EY,S9 M!Q\[YZK2."MM5#\_4_$J:H*EUKP?BQ.]I ]7UCH]:-V*>4='K,_?X'P3T/7 M\ND&[VSGB9JL[#P1[X27$% +6#8JT8N'(SO$A9!PX9#.0H7F0UAL!5$@#2 % MHMT/QHBD; W$3^0@'L0I :N3K2>&T^*:JC+Q$ M6;/%DCBW8ZDLB'@*KP?3.03X^;KHO2.7HJUI%B4-H.UI-W[U.@0 M36FG6=M*_K,<9PG%42D59=7IX):AC>T,D29K-W6C-\W(9-T! M,K+V(DRN8WI0&B- ]-25>:(?P6QA!B^*%SV=>.?%H_^'A]5#C@NN+OK;]P;? M;F*D'3L08?'>X/^^D])QL'04<(DW_.67? #S2Z>^SH7=G;PSY/J MV=GR"#3<\>7+K6FVW?+&)V9DXX( PN'1XO681>"I4CFL\LE\J=5X]B3 FWP* MX#B;*.*!'R]ASWSY>B"MQABN*<%T:"CH5QK7TT PP MQ-L6IBL2)HL*6_=%,Q>JI6GM M%T:@:9KY#KP08^XJK8PF5=M")36D M*^%# 6@JVEQ@B&&.;88XYT/03 ZI*0%EY511"3$ULA)2B\4-=O9CI3*U95K2 M1#F!:#!(8\L*/3H%_WA(!8V/>U"9^OUQQ; ^OLM&J(Y:J>KH422##6U\L^!<_*=_L+/@UM>#7[3PN*D5;P3D\)\:'N0@? M9L7&291G\\KG&(I/9LXV@"CN>?ME5I>N1,TDYNCAYO)@G\F.T 15;2>>,PD2 ML"BY28<:9WSN4=/TDX::EVYBWR6:!!P8M,N6*)ER3ZE]KK7524D5EE1]X]F! MJEQ.\7@8F1I'T-_/=);08!2=*Y.0@<7JA4XZ'5+I9-%L)2!76%J,65 $[Q]P MW2V9N'U_@(11-_D:4CUZ?D%/D\AB+U7"E_FJ879(Q$11G*U1P3D#(QQ1N2O< M%0US!M+%9<[#O^-CC+" K^&2870X$![ RB7-<<4YHX4_5/+).(OXC MO4BP)[@C']NVPIM*MG.Q>"*"4<49IK$N/9L+&DN_%@^-WSRQYBLC<]9+:IDR M'4Z*H#3S?E,O]FYB;WKKH,S#%"X2"L3(5I)IRR&N4"1X$8)>(^4O46(_F983 M5Y"EE4=@XU047+-<5,VH: I"T"F#((;K$R:&QP=Z,0A%N'BF54N9#YJ(?E(@ MSBAC.;%[LLSI#3[A-X&S%U?92YN?SB%LB]NYX[?@C MW-C9?3V(-"QQ9F$K#NYE!(0!69?L[@-[R>AGXE5=B+W"ZH MXBM]D!(T<*_!\=!51&H@0_UP>"[.KJXP@H-Q)+P>,-]+9H MPB[ /U7"I>2NO "8^DZ(ZH.4:>&\X\U4*122MOG1=.Q7JU7;@K'/P)]WZI4] M\:5.W2,IJP:VEMZ4G(4!W1.0CW;^UJ96S<"B=^S-FO! M=M['*RPE_>NMX?%VK"$=WXJ#(P?T\.LMZLEV+*JGK)[0F_A@!RE='\1>G>J1$W+ M+[7+/\[O8C/2LTSGR.ZO7WH7*I+S0*A^/>%Y_33A 2-T;^0%8X0TF$7B.F5! M#$:/F.^,<.&/\J9_H@_X,M>./3NX5!P[6$*V:;'B'H?(I;$%(RRSB'$*RMYZ MM8*QRS?L\@V[?,,NW[#"?,/9+M^PIOF&7<70X]/^]=*T?^/[8)RR.4(Q(MUH MN:LCW_RR(K?0BC1A4,9LHS!AW32&,I&PQNLD),^2V".8BQB4?;ZP+T5\,? [ MFA_9:#&7[!/7[_!)"Y@%L3@Z7QTUIK$Z_LIR5%:[/JE9C?6A*3ZIO M3W$YJ-W-(P!"+"1$1*$]:HU_V)?D)+9B(T\[#"(,*253!S%7@WS'"I;6(; DE)B%M8@Z8ZD25OBPA^8OKU?[:+/UI M]? XJUB=(9@ZN(;?PNB^;(UWZ[MP?0=KM+ZY<],!KVS@#^W]'/O8U4Y<:YFZ M!69SDQ(A56+QL#MXU^#@#4;VHA#)0S\:/FAF I\94;"N DGR<)6)C^"!;>08 MX729&"<9W,*V=@Y X4]\*C8A8 ?8]UBAH?(_%8N-'&Y\H[DT_8+GSC]UM7IA M=\+K$WY>;AB8YRX8IMZ8H,B/WQ5)0E@N /;U._6/"S]]9X+L?V(*$]8>^,0C!ST[[XV @J!;#V+_/YC#Q4.'*-4IS MYHOP^-]4V[ABU;$^,N6OD4QIDR(;?O%BK$W,Q&?FJ@UUC:.4'"8!?\KI;([7 M:#'@TE9_ZL5"*[)(Y,C5I*:V>\_&@I_!.?=T<("B]%M):'RA+&9S36]E[E8B M0O]5%I9]SB]^?)NNS;G]Q7?2^(9+N)&2#J1IE"*[1.S?!:S),F8R;@+F#U?E MY24E\:[A!U'?)56GR36NQ(*!X4^"4A:F%H5BRC>8P'#6F:#\?;?6^$\*YAX6 M 2"4:13/?O_MS>F[?C((JH-HLDHHN7*HKI^RU5=W4GR-TCAAO0J.W4-EV1MP MEN-P+C'^4]^ [OAXP+'W43*#G=8=!(PO-W!JAH+M,6"RB)_NQX]:V%V1Q^;F M^'=%'KLBCW4O\CA_>I''/S#& G_ 97AH:6)I=#$P,BUB'(N:'1M[+UK M4QO7UB[Z_?R*/EEUUH:JAA?P+8[7FRH,..'$!F_ *R?OEUU3ZBFI3:M;JR]@ MY=>?<9NW[I8 QS$2\-;>6492SY[7,9C__:Z)5\O/_]:__>VLK M.BR&S53G=30LM:IU$C55FH^CWQ-=749;6_*K@V(V+]/QI([V=O:>1[\7Y65Z MI?C[.JTS_;-IYU__Q7__Z[_H)?\:%,G\YW\EZ564)O_]0_I\[]G>X,7HQ4OU M8_)\-]D;_*CTZ]%7D-'2FA8?XG MM]]]BRK'\**ZF/WT$E[A-45#EY;,KX=%5I0__6.'_N\-?K,U4M,TF__TOR[2 MJ:ZB$WT=G153E?^ON%)YM57I,AWQ#ZOT3_W3[AZ\A/Z\YJ&]@G:R--=FJ+M[ M.+JC+Y-TD-;1[L[V7C@ ^L^"P=UJ6#?-T-T;^1LFAUK\*:WA;'C^]/ M_S@ZB@Y./_ZQ_L/Y^/YH__PH.CNZV#\^B=Z=GD5_G'XZ@[\/3L\.SQ>.[^L6 M^3M.P])!ORVJNLBC\V$*O4A'Z1#D3SDK2E6G\/$^B)D$!)7*D^A,5S5)K;V= MW=WH?9&/MRYT.8V.J6CCYG*5W[ OV3%0&4TFC(=XGC.ZV)X&7W*X>#O M7ZLRB?;'I=8L8&\>S.>F@GF;\[Y.8;;R^J=GL-'ON@MN:.?OFZ;GO=-T,4FK MZ"YS%6W4$QW]\Q\_[NWMO+&?TM^[;S8C:&V@ZVNM\VA>-+2AEFZ].%+1HH>JX/]5L/>PT0*_GW(+ MW!]X[07.W6P&XE,-,BUOQA'!)",#4Y5 4]%, ME34_X?=R^P[G8\V/U>[V/_^Q^W+G3?>_9C#?OU<\-XD>RM[]B?8X_@JD9:ER M6C$Z*/?7QQ]^ENWH3N)$EQJ.YQA[6)%0J2<*SD,S'< )77S88=M7NHY&10G2 M(25Q5$9'_VG2>BXR#3?L_G"H9[6"$QJ=-U/08>;!^:2FO -ZI(83%HNEGI6Z MTM@GD1Q&0NV^>E/!R<'^T]F$HY%65:/Q']C](M=X7N$,0>>YQU4S^ S"3(ZG M?^R"(;2.$\X4?D"#@7_0%,$LS)JR:A2_&<<(7[5>,"N+J[3JGFOX,?ZQ6 $ M0@=_ &/V1<=^ B MT5:C,U.Y0W.=PK<#S8LB5?0\CE[$TD6-_0@]S(KKF#K!PZ)^XZCB)><^ MT=6P3 =!X] D-;8=G;>F B2$-$ZRD::L=R+@_)K&]NP$)CH#Y:1TJ#*::U5RYT&QR!H8_K+7P(*<%)T-P?O%K4]G;\S*%"9*)INZ MB]KC)!U.O.7!]U#[-4X#:'2P)JA%Y7.T)@M6&/DJ\#O5"DTF8%S#FLPW4$4W%=-%D"5QD<@5('_891__,?SU^]@1_A MG] D]F]_-$JS%":NPLX4@UI)CV&=X#! P_!#> 1NOUFF87[QV4R/\8L2WC-N M8#\4<,=B,S"7M"OQ-^,"-F".XX"?>N_V'D&OESVTPZ*!V:9^P8CA$.(>WRB" M+S3TH:"9@Q48P<2/1K#)\QKO\?T,MF6N4"G/ON6*M5< CX.97E)=8-=JV*15 M WM.%FDZU0G.:3:G)>&SIZ)JIH=@;N#N!0D+;\C@Z..DT03@%9WF;(,$8XTV M4K.G8?/HN-]2&*=7X7K3(C;UI"A1&%J5I8+SB8,$#:L1 5?($@PTM#3:_ Y* M_8I=Z\_6[%K_",98.DQAF6NKGI[AD[1[:1.NP)7?.CET9/$"O9[ #=02XYY^ M&^[N6+8W2'Z0'&E5TZUFA$:.5C&VJ:]88M!7:K&F*OU\A0.9%15=S3^5.B.Y ML=!?/BCJNIC^M.,>40,0)$W=?>0;S_CKFR9\=Y?V-6R"W3=G^BK:W<;8PSWZ M\G9N9TWW11GXOY/2=&:FQGIK4&IUN45JRD\JNP:=Y8<[1CUN']M8&4$%#>1P MLRO4&OE>0)_1W)?OBVXT.'R?2"T A6V8EL-F6M6B+\(QPL-&^B$XJ!86"&_)?03=J^QT;K$R:=W"X#1HM]5#C#0BKB9(@H;:O MBEJ\9V$KFS'T%:Y!MHA!O4@SK\?DTRF$=^F]+SMU>S[.\> Y4:)M%3E&(O7E?_9O\][[%]1OJOT"RC!&R]W K.7.N?-IJ^"BU'Z MZ,[JBS4[JV=PZY5!S.^^#NSHEL>4=IWK]E\XL*Z1OW)J^5:*G?,+AT&=@+:5 M"4^A,R3-FZ)!#W9YE?JN.&-RDFO!N13@N[)HQOR;45I2?W(\F)4JK<.( Q6' M?-P"J4>ST1YH,1R"L1!.RBW:AEF&03>YS*GOCO0GS:T>SMR W CG=8F1*?3 MDG09T+7F?T%2O5@LJ> _)8JJ9W<65>]0FVI*L%&T=>W;%V)45B(@;C(E#"+S M@%M.7'6@9FW" RV71+L/.-H#U<#K-DA3M:%,Y]WLA!@V<9-LI-0\^GG&TCR< M$(HNTV '&O4[Z(]X2W ?T+9 +7+.?W,_*MFL5:0S30$CW!)V$1?V^/'I8,<2 M; (K6I4)&>,TX27J]>Q"Y*5@EQ\9U31QQJ8V?CAVZ<*^C*;:!.QP<8Z:LIAI M./]P -"Q9LV)P)98'I%BIV%H0'!HNN:@/*PN>2+G'D1@+.9/:O=J-QAV] FC M C"T"P3PT5YX5ZJIOB[*R^@0CL,0'0 Q6EPI.CKQ%R8*[ORK(5!"PX/!:\\: ML"F\T.)%U[M+TXB1=! (J/'(;..8-/WJ3]!,A*_@WQC+CST\Q**A!%[4)1[4$*DP*Z[1 M=,5(HN]]+/45>O +M.[+]%*S*>5&(Z(<>I!.FZF9M!S,NHHD.GP_5?!8"OBAWL2#4 1:*>WZ]B=S>]SO6: M+D4CZ?!\!E@?B<\7I>_A:>W2S;^@&OI7=]!+KX-_66?\"QK0RV^O 3VZ,_UJ MS4RU4XSC1A>A4GED5_2?_WCQ^DUTH$N*00IT :X?HQVLA'W7NP7A/2,)JYJ# M1D.E(+EX97P3QA<3W^B,\P%=8KX48EF-1JSKV*;H'O::BN'V)&1$NG3 3R&6 MU0VQT%3M/858EIUH:PJ*>NS"ZPL=!<%Y:F9%3B;JT,$ >\ZELSB_@RMQ5;"R M&VISO6ZF0U3-4G,ET7K=[VWC^7)Z<)JQ1=%C3T,O#F+$;W+<2"1QD3L%X>7H MG&DR:[N3UZTD3(X$_^0+"V*)ET8K%QB/<.7_^.8;;/!O=5"6MS-3"08>MS(] MXJ?>K/ 13#?O\:@%,[7W?/OE:YP(VH97:9'9C=F'LSXH$MIDJ/@U0]*6N@_B MEKHNT;;/HUF1I<-YISE0)O^6E7Q(>V2%-LGN-L\$(]% (X'[V(@NAW6#33$4 M#^%1" 8D%Y7!-I+V;?:'LD^W\YA:L8ME,G$CP!L^[:Y;[:[5V5Z[/V[O/+/; MBU(YJLK*DD@-Z:8;E:I)P/Z9#O2??V9RU<)M-2ERT ;-'AG5?=EJ'$%OZE17 MXF9E"'%35KKG#G[:0;?905>KM(&\2TSG8S46Z#B!G"OY3OQ,YO7XH#)!S0_ [4HTH]:VHE*M33 M1KII(ZW./MK;V][9<_<M&-%>F65:$>!MW*092R'$ M]L%KT;=:%^Q!&NFL,"%X#9U=%=D6)%H$HFX(AE$4U6!EIW21+_*=/ MFX@WT4I=9YXT&JDT:TK-^,0!PCWK%$S!.<:_*(V!%)L*4QOAW"#<]M M26Y!TS(;@[B%1F4Q[2)8"# 7^C4[V9I!/A6I7R][X %W\>*ORL[X%HF1WWTW M#];,10.:O\$?M4,&1]:G?2@^;2_&<+]^G'.7#GBK_<\A=PRR*?&U]&2 6< $ MN_5%I;73XQWH6R.TL#N%3?PR"7I+$56+#GBT%ZE!<=5")%DDADGZNUU&=+P@ M:+$@_F&A[8)8;RW.U1T@#PN2T;U'E[^+[R8#JHVC27$-LU+& J ;.9@M10DMYTI/KYT' MJRVL>K/0!83O":0N(&[)2_I6D=%=)OJ;W.F.L=/4.[0PUB#!TYT M) 861W!=\[Q:+)4IM%$'G$ >PP@.'R=[UO4\/;Y M-HAYXDQ GCB0](VVL;?=US^^I("N$C*TD+HMT99F#;L@<\P@*(^_ C5;(;H@ MM$3O?4YJ;AA^7W!KPP[*TFDJ('^ZF\QT(K0;#BG?)D/[/$6NKW.X#B;I3.@W M/*8WBS=TS&IH.R*$JX'KXXR9*O"79@9WMW$.MYYMI)L;+S8WKC8YY+3\E9Y/ M)H)W^[%/5<%T57]'S])T<[D"(LD 1&31,B+8'PUWN)>&P[PB^&W Q@*6#G)U MH/;2=P08J MT6TWA7\M^1$,)S:WW>#YED3*$)V1C\!IN5%:>O39&V#*_@ $=DM#]OF214BZF)I$7F M-85F6VO]^"3)0@F3KIF$<6#/^TXIN/ !E)P1&3,]$I$$&V^XT?%>=W+MC'+H M/.A$)WA76.7?$ZO=ND>O[ETW\<+-O;MP249_,X&V3=Y^/>K[EP$'!!X^H=^ MAU55%<.41!*.1@N3;&)8#X9:)Q5_18Y.M&@\7ZC;T3'97V08=>.-C'!2K%"% MM.JM_MA&Q#9X"B6M>"CI^5,HZ8:,H-Z80Q!>JH26@[<\>AJ0]U&" !Q?P. \ MVL+PO[&)9AB";^(*KTC9\%SU?2Z2PR))MM[!JR^C@TQ=#]3P4GP[=.:9(<@! M69<=3)44,U)D;"C8 RFA9%!##"7C7\0=DSIV.@_K1(X71RZ9YD3["#:B91;Q MG.65'U;9W3FT-#-?)!*P/Q3H$L59X)<-R%]$7>+@[*\.;!Z"G1$=9G8[CP7H]6\V(_]GFZ M81^^+8M+72+ET;NTG*Y6CJH%.+[>4!P8? V*5!_&$1V2^@M66T'[A(A\ON"V M3M$.%M:@/UMLYH:_W&T,IR^'6/K$KA$D] ?#%SNOX:P3X'66W3#KYCDTJ MGK5W[Y0Z_]#*N6TDZR:S3@J,S\HIO=*K \8^*=S^,Z1KSOH("[2$CE<+8;%! M\7%*(8TRK0S]0^F34:-WA> 08HF/BR(1;AACC+LOA_YL>8@=\TOTHU2@3F6* M 3V;G@-E1M!B3A0*88)A#8R@^H4%61#& 95=BD+(FV5_" M &L!D/X*SXXT;L4LIAP*EI66G*]C8I'U[(MV8SXVQ 4GA(]<]AK@=+1&VAK/[!_*<\A"-]1EC%=-M M;)/>X\.ZM.%QQ^DJ.?G4U6G@OI*5/N1Y8D6/JT)-%:AL9;6HH*M-;2+>=Z;^ MLP"&SKBY"%5'*;=**+\RT:C/"W3]\"%FCR#\>3N9DI^F(!7S2O)W M[V'7<7X:D@,2**.^9WXFN-1,T9">A+8BP.RZ[8RZ9D64UGT))YUR(0L*'S)S ML7E:\DZJPS(W;VQE^;%_Y2214<-G"O=MO*!G@7=L5S*P&Z8E;K(?FK-M8 M:A7'F,B>H-P9IZ,:).%\AG)C2$%'WP!.TLIPF)-9/N2ZL+?K(]X!\N*JMWS; MW,*A6FI*6[;P[R]$_/FFK9O?RCGV\$KHX4/ME+(9*:T ,BN(2LX'* M.2U\8X#3O&_"U3/;SOD@%FY <>.6KJHN>W(]]P-6A6M[/L*Z6@/,)"QF6_:I MH(0<=7/1&*CJGWUW1J=YHX*K ^ZK+T+J[68EK,#7NE.%_@+;A5U&(S/%^-JE M>EI'H6P)&!HQT7#S>!8KFT_QG=6([[Q8K_C.NJL5ZU84\;PE)"_4E^B4M?X5 M@/J=4=D%SE1B^CKI:0\'F9^>WZ8A\_)PF ;!XH VVXGJ4:TN3?Y22RZB(8%Y ML#D8(? 6F"FOKAJ%K!::/O!C#B\9=U)>Y%OT"'VS"4\49(3 _="4J+G$F 54 M%AD]&]N4H"+W+PAA'E%?MDBRBEF$GG?LTH8,&=9TZTR^/Z[UU%9;X)B"&E[F MQ35I&7Q3HU80V?(A2&&",&"PF@Q)R4AFHM,PFQ8(RVNT41I28_-A59Q*?'X< M)$P-Z4GNE2OI\;U1D%#6+;+8?"ILD!>N KT$[:B20X)I9YRH[B!ZC##J$&^&H("$=*Y+-T'Z"]WO1N4(:P.2(0B&:U(PR(RAVLA%0^I! M(V6(/:W5(-4-/JRG.YOL1DV:(5W2.DO]BB[A^G6&_?C\1I],O&<9K-L3A_26=6Z?A-N6=C8Y7!4*!97RX])W"SQR\H^B4 M38^L"ZQ)G3>F>DW_N-HUU&-CM(&XX PYX1@1!;+L@!UBJ;K2:=_FUB+UX'B, MQQJV]CN5EM$'55[J.OJWRK!6'Q8Q MCES^K62FI'ZVGZ3FHRF:8%Z]-D*;I)"10'>HM^W6HV.:J8H);50D2%00.[8N MC/I"=6$\C=[?"R65P#H6LF)[Z_?+!\JBM:;X@/<(MM+;K?9N8(O,RW(-I"&^ M$.]3$QB/K;GIB&FZ=4$G4K=F\9[L\ZG'N$*M[&BJ,;2X&>P(;0T>*BQ.QD*4 M6")<\3#8:^::Z8K7Z \8$D7$).4;.E\R]@1E5;_*T7L(%'&+U:J/,;I3$]J2 M6( Z]9:L2SVS<)9NI:DVS !#"]H%Y%N29$FDG0(3JG*IY#A?5MP]1I?C?D9Y MXVC_9G.>9YR/P2+PQD8(TV#=3$K[)5Q\JX7&I 4WC=%1)HW IPY +Q-E5UL9 MR=)VR>8WX(Q FW'<=JEX!2S8]"_*7]@:>%)$"RTHI2PD(6"!,0WT:=FGE^=C1#3 M&(M&8'Y2-T19'(IS+8UI&)ZQT+GO#^:>O9_GWD7T5& M!/":$)(F+#BV>,4=#2(,394MWDV#RH'G36DR3H=$N0CB\@;98_QQW:_HMO:= M7E29BF@?4>E6+*N,A>7E7H^?= VHV<+'238,VKROHGC+7AN!-1IP\,#B,WH0]84+)UU2-N M<)JGHVY$I<4NI,;H2^+2GB00X+P:]T:*YD.BIK#D%>; 5R(T0*?5>:6K7D]3 M^P5D \/L,#H>;O &;DM4;#CP,]#!%8 W7I_HMTZ[LGUY]<[HX_/ >,E-2^K5 M\H2WZ9K:B07$PN23-@FPA7AQV,,8A&4M/9(!-#-?3DZ,@KH$ Z@V17QA_#F' M"BO\G:/OH]S.6MC_PM3/=A5:,5)VN.X]H6E.=9J24[B_DVYX&>DK: MNH.# 5]HM%-#C5LQW2KFL;0GS_+OL]/2[U1W,-WUZZ[5H]OZ/6RX[2K%[1EG MQQ^3Y%HB$8]MBM2B7B*Q,+(MI'<%8__]";Z/H]X+;'^%^H+9W Y@>U-9%+HJD7B9:C3 MF/[/]Z_Q-B M&(^?S6XST##4W*3*AX710+@.=<(<'"@_ARXIKHHDY:Y;>YOGBF0R>Y=,RIOU M@1+$@YS SO:S<]G_*_Q#'!W>/G+A%G;J]H']3'=HW5(G/EL\@K1@.!5MJ'S? M-)A[Q$WB-]][$E.RR>Z&)%9.IZV29WEK8W-N6U_@O;'XJ];),S_$-;M292JQ M.FN=52%YB_+HOEN: 97J4TLD%9>.P>R %-10U!:M2$+(HW(3)&3FMF^5*^MZ M"[%TQ]CX/O(H_>6(^'T&Y/NN+&,DX#&5?XN#;=_/$W,.?3 9LJ8B'ZBSPC-M MB5319"#=XS\-'HAJT>RWJVNX,_/X=(G=YVN&.CF#@UB+$""1\!YQ ^3+10#* M@4LX/O/4V^\SEE?+.1#O8]U-&6V)_%!0F/0%2Q&/E+EIHGU7&7QZCB@4$TPS M1G9IYEZ3V2PJ!TC)&CX=-+7QO?;YLCOQ'1L;"&E(?9^WX=%QJ>U8'8X0DHES MYUDW-[237EFPY0V^]>6)HYM]6&#&XV >-\85M$DJ7Y#_G=\0D[]5()[=BTBA MP[96L!P(-PK\&,IDZ7+S-OS6\QMZ..]#H/J>? HQ>&$0X[50J.,M?;)MVKDT MCOCOGK!WF-%OPF0W3M:"$?I]IV[-=%D15Q*G0-!X0=ZXT+>Y;K[;2)_\RRON M7W[UY%_^&I5D#7/&=U_X0-7?SO9[ISZ3 MZ?*' SSXQ!54C$!-!^FX8>:]%N0$^IP9=R8SK"=>E@P&(?#KLLC3H8/$(CX@ MMEXM)_<3G*#>K/5N1A"WQ"%(PX-;<7VH!(/54KW=SU,,K]T;8@P&0&0M(A]* MY#//Q)Z+VB2OP!)Q+56^UU19PWS.6*'VZF>MM2UTQRVVZ/#^0;XS."-DN/:' M?]K(!P;<#;EVA=L^*1*!3,5L&8BOW"= VNAJN^* @RV.B:R(' =-$-%56#)9 MI9GYD_L!FWF&U48%D!/;8F:#M$0'7A],O*K0 >$'15HSX;>'F_' MSGP 98:M<_<;A*$3,"../_^P IUY82ZV43AHW8[R>:N MFB$&SHLRW.T^S5)'3,$O6_W9D+P^V]HF32A3,M%$TK2Y>6K-BS<1798ZN;"# M94/K"FZ9U,4:=;".:#5)T-2WC6RL*G!+<(9"I:]1)S UFF3,[C6"Q[/&%,EF M=,9;&XKO]!DK/8YC8%86M:'6HM*\?H_Z!@>O)OEC@&)4$HZH MP$HA 7GP4+ M;6T3DV8%QH%1-B^8HP%I-C5:K.;:9BMSTL#F1+D,'Z'#T\]GH8*@WT0*K#"3 MTU=(DW[$;*BY@;QFU[*W(!QDPB66LQ% 067>L[F$G1AACLDXF[P';JV5V7-% M#K>AAH6,J4-T[X,:&PN".U!G[6:Y0:\UEQ)%\;]&:<2';U <^T\([61#ZT37 M?)%G5)(B*_ EE"40H$%MG_P.>2+YAG[X$AK7B-P[55J':%D*VQR*;M_GZA(, MKYH'1/EAQP23*6^)(8O9,"GJ5PH'A MQ;?B1UR&O9HG;0!0N92D[9$'%38U]\$UA(!7?(M;%4)T6)6*IHV2S4=H7@E6 M*2G5M0$<,+ :Q71*ZT'-#56E;<@3459Q2\)A"!>S_.\H["PV>;Y@YM 'SB%\ MLY-;7>1D&#@65*BTR$#BXZ@'"@[\MG6EV\0[@;G@B>=O$)&%TW$%.Z:%A6F7 M?B>D6\5P@59=9&M-T&D1/AW)!L(30P!RG3!7!^7?Y,;VY<@7>Q1A36A%W:K8 M"35VBS*8M#M,F+HF7#+L$T3*ZUARJ).ZD$G4YSDE5TS/A7 M#*Z"_A5X>?>MU:WZ3I*8N76YRK1D*!*HSH@$W1),2*$Y+2@L[ Z%Q/6#T*&Q M_ZDKF(5;/.%Y5]W?^N.C][?>41TR1\D[9BICID8GM1;=049@WT%$K[-'Z>NB MZR_7++I^HKA$Q8@IO>^9P^'MW-?N6#%PVEV+@"#V-VI(1L" MD=$NZTV[W%[ M!15?]O:V7^$\6*L&5 [03T&O2*L)*,!&R8)>M(+1,0*$4S^!#%4QV $Y[U&V M TA?GQ8)P45CPYR/@/MJQKBOHO3KJ/DG50#,(UKR^16D_0U2%8(VPGD9?98":'F&G/U@_CIC%E,_-( M_QWU,)GHIK 2=:!BW'JN1RE70\Q2W6"O)$\:@==H,G '77:ZJ21I,)ZJJI^V MVL9PE;8:"3,,0,#]27C[;O)]:R?854_)VQ<[:NO:>6*_^"E%BD*_4_9HM7YJW A&7#E_@KU0 M ^<"/!*RDKM>T2O11>[Y_\6Z#FL8=)M$@6F;[0:Y"W<7=SPBWAC8>(;#A37= M-_C@;#Z)P@V]2J> 1*%QJ_EZW$*=_6D%-T:KLX+/MW>>&3GF,BG-^3G=7U;RE10/"?;.L3UQ SYYKPJ3;DA)QF M(RE.E<)/9%O@N<8/<_2<>ME!Q$67(_AZCICO"LMVH?8.^W*K&&V9B\) T.-H4.0-T3]A-,E^SQYG M(L%*,3MMAK$3LXTIYVWW M+M$B?(O>(PI,F9Q4R[ ]5+G$0$#W2IA)F;0A078)C_JCW@CIZFR$Y]LO7^-$ M8%V33*539C*W"# #Z;J^BRD*$9<$L4MI07LU>7\/OI(_I=DIA MCVK+;H-^!=(,8OA!%LW&08#K$=A0"NM!S@2.2J: MW!9_R>%DI,FFGXE#*;#MH7;+$P?&C7G6*ULF.)8.=Q(F^L1N\%:L+LK]Z9G8 MGHS8F^JG(>H+C2"FH/ESA>J/L8UQP8M$]QX)NW][W&@5\_^CCPTK,>E/Q"R1\+ M9JW%7"V(;;FQ3-17*#"8FL%@M_D&<(Z?)X&Z<;DZ M4HR6V[S).5=U-8C ?; M["3T%+@0FZMTG8B;3Z0HF692#)Z2^!T62U[3H:K$?N0,4 PS8#;*@-^?D;^D M/>$H+1>#T$^- ]N%J%#Y-N!<$(>0*:3/8SD5B$DI,8BU^A*T9()Q%H$F=\TX8+FQ- MM&?7D*D!B@D>>91I=66).GR+GG\/9RWQU,3ONM@.PA<&I-DDH:>\X*V_0VF_KL2PLK; QQ>5D>*47WVY&.9C($UV&8C6(@.7M$)CC MD$*228^LIDLC007*LH:XH8D,1]?76N<^OF[8E"6<%Y=X2'5@$E@?)5QD'BJV M;G-5.>CNR&=@QH(KDD#7YL)8P+IO*ULT T;,UI9JXV:TNVOS$>(!7ZT;'K# M3*:/S2!+A]$IIDW!J5R!DK,]6+RFM.J$LQ%S %J>Q%#(6UCML4<%O1D)R MX2FQR,))91J)-)Q49'+V>4FT5/2)6P(12E"2QD/9HS#!>D1R+%D8>-V6G";Z M=T=UM-DL+7X2)TS[45/29;\*1M7,4*Q7GC=N65^Z!_QAG.(?U^X4@WY)JO69 M+6BU"OA>Z)?U+4I^QT;CY!ENRB)^%Y?>9=V,-QNL8-03L8&K]1]8ZDIKXSJ M31N6;D-ET2+;=\BG5A(@E[_A2B6T@D*NE!.EIV-7*JX]J@2J6N=HED9@<>9$ M74!-X) '/*MH M3U#TEV)#L34B]Y$=J36Q+<-H7,S[PZV!0[EXJ#^P/,F7ZOKN^[4FZ?&(PQ?5TSU8VI M)6;4*2N;3M!VJG!7,0N-CZ)F*N:&4.+["40RX85H>-^$N0CJ1?XFT[%+G9L M"X=H80OTP<1?.K7$.:OX<7EJ-@$M#OU9 EIC0!.TDS1DJG)4@U;?^-M"#RPY MC,7YS5/HYSD;%WA8U-:1+#G6:M%&:4()Z;&0NQ*VSWLR -LK9G$I_L,2/YRD M@Y0OVA!H4CIZ 9RE949DZZ<]?E%D(.'7$&*N$-D)G/-:\&GB@SY\0@L.EHYPWI M>3J;P4O-KT+F(@+B-*934V^'HO+1S!DPG_G&-PS\-ZUGN$IP25A6'+]5$U(9 M:>)P-046*N'C#TZ:-16J_LV .U"(T3U7;.H(:\VT!:W:(SH@^J6BLJX)4N0= M)[W#=X1[BU ^\T4*'&<-]M6*;M&Z=CI&2:.E]BV5:@97L7A'/0Y8,428.2#% MC0UV:OGX_)E[NVMV.1\Y8IQ#KF)%%]=A,6R^(T_X4M?FK6KN2 DNVL.)Z?QB MJWRICZ0_7RTXI@;]U/8=#.8^U1"65^CQ/WH"%VMW&?=C2.OI,7>:C$H.+MO! MA>]*S.IYF=X+72KPC[)HQGCDXU$*L%C%-,M2:/C-1T64#X'U/-\5)=YU@#'63'43Y&0;#=KV1X\6Y3 ML%CDC3P'$HY77. \ 16B18AT\3NDPD]4$B1=MEVF*K<:R/6DX(IPIG R@SUN MZ-2VV0GT.A&XG4IMMUNG@(;RAKN(B-X6SR. M-*\AI,6B6ZWRB!VI'7_D\JNX[T,&+A&^J,B6D28:B 09=3]MT;E[L*K=LS43 ML69KWGM,ZR\6YW.GQ4)'/,\(X2NP/)[*1(Q(K0\VN-C]_ U"V(3O+0FN@N25 MN9^,02E2,MNF_VY &_BGV+=F30R)K4_2)Z@AR\5H+#;IJ>?E\0MTX0RPJ#"C M*/4H8TB/]'(_Z%J(9B1WU$W31XJG:9YD X.=!"03$L3X2J$K;+A8)*3F_A,NW5=*>&2V-4@S7 M,70PI\B!U]6GT,.JAQYVGT(/-R1$F+/F.& 7'#EV(1?3:9%8#@LCPC;%A]:C M+XDL=Z4%+30QE% ]QN*#]R&M6P6Z?4>M^_U+S"UU'84@+!&60LD1!O?/ M'E?#8A54@/:2 ?JK-2ROF78;YIONW1GV^=8W*%V7/8,@Y.]7WI;57:]+F/9S M[$?0 Y0?QLE.-3T,&-FOZ\%/"(:)',V(!29CRX@"Z@UM.X:YA!ZY@"B;)-*, MKFC&:Y=Z7, CC] A?6^%F+[6,40.C!-V:=RS",&[BQTJDE_C-EE?;I"S3TQ% M VOM>YFYB"O3UHNLT!/R[Q2[$)@VNWJHR/)<7LGW*&$R_HNY1*F9::O!=4"_TB[#V15:<8?>[KC1_W M<=$;0A^+OP!+8B$HUM3/8,B\JP7'G8#W?N+P5]@$9@#8XE)<]T=0\O-VW@** M(FMPFU<[CS%F6>/F\NNQ^W/)LF5<7(&A3NI)L"JD@DCPOM)UZ-WAD%[8<:XT MTE(AR0U [/[(NSOW-,#;;*/VW+ 4-8F,7+*=?C+@#%5TYU=U6WJ'T4-&]?BN M,\]CAGFKM]J&>;\'W(4Y0MY/6CAQ4AN.1IG;8A0O;;>_SKF;$]ED;PL4(_:Z M0"!T%D>#U'@6R4UD4D/I[J"+T:CA<-Q+/TP2LK'W9&<\^'MDW=*O?J%SC(O] M7EW32OY;Y\U]1Q$O)KJUXY%3K22PE+AN(XW8J:&7.MBO.;*@7YTNEJ))PD;L\IE910JAF%YU]A( M)Z26XN^E1HB?& VF()5X%F<^P@/1@>/DMI\M;Y.F?4\T"P.#P!*9Q=E@[-$. MJG770<9WD'A^JYEI"2W2/,T8BMS-/;J]&G*<*"!EKVG0,M7B;-URV0[)P9;1N>L0O:&N^W9GQ;:-QW)Q@2\ANF4N6B8 M9TFJH_D\'Y2]:DF%).\M8XLBR)MHX\%<%Z?AL9SM:K[/QNT)@[OV>BD5UVZ^I;VTL M;[N A\!G,**BI)KB32@>IQ(4,TWI$%R\@0*^9<.L:,J\7QJ46K.+FXT]LA:/ M:\4QDZEE3]_EE"S:[FNN)S];M_P$C(R@\@C"\OYUY6"'BWN6(S2L,Q.O6S,= M\(X>>EV/([-#N6IR.^(A9"P8D$W'J2F^)$P#_$A=C)DIH?]9BJ_DVG(.$.U3 M2H?M85,+'9]$OQ]?G!R=GT>__WIT=G3Z+O:%&>5DH-F<-&BMF%K7B0342D?Z M\M$$Z6$,! .V2TN%L#B_H@<4C'*LTBKCU#N9[S;I(_D@M4+FFA*K$0\*> && MQVJ=_YUK0S[J>UJ9MZ?G%ZS+V^FJH3SM"6FW0OH-RI4&+N0 M=]#K^&NQ*)X]VYE]^>'VT_I5:['B#WWOK?(!))S26?1N._J@)B#'YJO>XX\V M7P2/]L$DU:/HR$;K3UFX?!7/RI/S8D6<%\]6W7GQ-TU/^P#TUTJ^FW2_HRRZ MUY'M'QX>G1Q^^A!=G$87OQY%^[_OGQU&^[^<'1U]@+&N?/_/CM[#(IS\@OT_ M.SJ_.#L^N#@ZC&"Y#GZ+/IT<7YQ'OYSMG\!G*S^4CY_.SC]!5\U2X/[9AT4X MA/'LGQS2\/9Q<'L[N[O1^].37[8NCLX^1,;&M)EO MEW7P &S=?G%X].GL]./1_@E*<;A[-R2K[.B3R2>+:)=']G='!Z8=R(>Q54^D[=(V(S5HXW4IE5C:V'/4%0=,9P;-!R;4D$ M%]-K59[LY-'A-D?V0^:_PW]9='A,E7GP?YN<_T5#;FK+*& H^$;J"E'#1KAX M$@5VD1J;@V$D!]/=.Y55E*/@K'AY^BC^ND?'DR) 'T(B\\&R;LD,B#7I^8DPV*@GY MI;;SY2"6_6(YA0[1"E)=P7 6F1M*)OF&E$?ZK=8U\U@R9XF@)\ \&!LJO8KV MNZTR6Q/I'K-:+T%J/SE/5\1Y^GS5G:(QLL#P$9$O4:2Z(W*N272) M0!09A96CBWS$EQ7=1HPE-=>;#[GR_4:#(..JCU85G4?AZZ4\%^I6,$WX'+X_ MO,:L9EF48Y6G?XI>B1A7@L>@%.3+O_*RE;G)WMIA5EY*1D!+8\5.,S:F3W^5 M1$N"X-@6/==54'Z0B@(4RW3,1Z3>72Q3Y?AX&,VX=75.BWQB3?NXC5FR5!70^Q2/_5I4Y_/'^_0%#+='X=$4L16<$8P@GO?"4 M6Y]GN*VQMTJ.P3-?\6KT6'*BG+Q[D^4E!F@G59,U/"H] M!.N>6EJ$ 9<+\MS-Z,H#,_3H:-\Y\.';WV!"DV(:1^?P_C]UF9&,0,;.2IMD M$1+T:'@0L*\H,U ]R2,@&89!8@I68IG[.]'EB;N:*SU64G<,0I87&P9JL48Y M43*T1#L70[S,H]'1Y*MOJ(7Z&Y5YC[G"A0[LYAZ'BG--VS)2IIO+71(V5V<2 MU(E#X]*4W6H;7V+7#/1$92/:@\(UWW\N:&M>@V%I2>1I:KDP)FFV=R,Q\'1*T=24!2[+U*XL>+6J^^?T-U>\[8CK<&I5_L[ < MFOBU@>7&@@+P$;H_62B541A]L#=[^^>'2-5=<[SI=RP8:M:>=E./0,7MW]?O M&_R&MD0TEON>T(.DNI%X%J:NZ-/)+P23.0[*%R=UX-,-97V M"J&1X80JB@<,ISI1HN>HLL1BBL2?(FL9KM>PF,WM5ODB08C/=Q10N3DY/3'2:Q"9?DJ>(1,[M?GELEI<'U0T3OBX)4K13>.\/FVO M7QR!JEDUS#W2>=*2ON.WGCG1_2UM,%#$#15K^Q?>)E-95?2,AOVK,8JW<8G5 MI@-N5"4RN\$*GB"R&E%!C+FQM&]5=(W\_XB]G-5;>!?Z0IA=G;%!Z@Y5I6T1 MHF%1U7%+T'@$)G00%D@;'G$+M]YQ?JN@7K-'D"03YB0K^@:O,>_#"_*2&4(I ML7AK, 0?RY)58JT9"=-Y;<>[B0LC):E-))4# BX:P'$+PMI+K(!]>-!E--*H M& >'8\WE2WDR0@W.DB3XL>004R:-[R[ 6AT&&9?,+A^#<7<1[** MWUF /3F?5L3Y].+)^?1=[C=6FI:I/J[TNJD"@Y6)0C'54?,9'8^QAX)DE7E4 M;(JTEE1DFY!DRY?8+#QQ!Q6EK5PM*1C.008KCYU (0@R;%;Q&Z;XZE;_V&.O MTU+*(@0EEPR9EF"B;$RA[9:W^C^^V[X0%4*L[8U I'P^A=7 X56%$V=#$$,R MA0,7VS&$0.EZZU/+<9AGOR"([V3_ 8SPKF"3B_F,+OD5*3%]XA5Z[^('8BKS M3HZC"BW(85^ML#8"D9J)/0;8JEN,>AGW_!W7_IZV\*?SB[/]]\?=+?Q ]NFY MJW.-C#S'3KM;!804;]444Z=1+A-M"M/4'*:BJ^_NQY3Y%;W:WMVSH*D&O3AP MN<#%QK1J%(?8A]V[<5!/,!S\,=-H/\#U9$I^C 01-.(>N]@C<;O;=[%3@]KH5 :5"6U/J*&!;Y>'91G*N+/2'JV=<#.@2E7+" M7 5;%'%;.-EKW(_)SLJ4@:!35V>8:2&QDP_A(KKK]G]K,X]A]]^WC.X66L 8 MU]C!F+BB@D4V^V560L4Y4^\R*&?K[NRWI?HS-=IP94C39QBC$*>5DNPL M>:!67W0O!I' J%[=->D9:\],4R[Q3;PR,'6LS4 W1G="1^IL#6=GWUW[E'+NG>-,YA#7G\UM@X+O;=PQ+L&'@(*B/,MR AL;XG$2E-IY@, MH 2ZIVPU=B]NS+56+4"2ZPI0:?D;WD6TI5[UJ04IJ28NV7Z%5+"7]Z1L$9B( M@9D=3@*.*0D*7F=>)H'.:9,;&"@]Z%ZQ#LK1P?[)_N$#]F_6)F\%K+%SNK@? MAI_'9>JXLIHT6$=_W=93-D+WC_<$U;6I)@\B]?H!Y07WWDL/,#5XZ;3X93$, M_5MOT+H- 6F5AS!>]Z:J3,#9>M/Q2%CON0]Q(8&.W]KJ2Y2H.4(,$VV: F/D M1)1_5617#@A\VVR!%D"S=X3L[=PW8&='MQ&4FG-!!?Z%&:N]+8T-E):FVG9U MF[?;0CFN Q1IQ[ Y>T*#W$FVS2ZUGG6_-)E^-M41&GRPY9_6,.SV?5[>KX>X M4/%]"1G4)@E[6XM.6B$8\9;&OLW4P@]L$;7$ +[5;%:D5$HH?,SIEE;#MI"_ M1>X&1*!4DA^&>;2(K3M0N4I4T EA>TD%L@TSB@_K+\,)(HHC&^Z@5_$K< 80 M Z]V/B;5V,A4JE_?=)M_9UV9__[V46$C?U1E)>R$$P1D+L1-6" M1_X%X_3WKCKY/!XWV?8;EYN/3(UJ5P$*C?^ 5PO!#KHD9$&0IVCR,!'S T*G M%#ZQE"6=8\S5JL30&-K(C'D'RX/MZT35SNU[RW>*X]9+>2-F?Z[ N>\RP-+* MZXWX#P8]KS493R 2I7XE=EN>%.VLMV.>PV"XR31*MG$J5L;RE$!_!"XAEBO4 M/;.Y!4%+6U4L=9ZH,H!)J8&5+4!Q:RA_A5OC+L;D[$;81ZJ)M<;TO+38>_B! MK;*;**3597EN[Y7"5A8VG-,MIXZE"V.\B041P'+F0O_N@0D,A?P6%RTT?G4& M@\),8Y*!T74QE6Z@L8RO6PY_ODJ778#MN'44:!IU!>>UIPL8,M!Y)>IZ@<. M%J0[VSUEI%L,=XXVP=&S<%WC2C9N2@(#A#;6EH9AI&R:8PV %BV(V0.R@95@+1#$*_N5=WCB!'CYLM7D_DH6CT%6V MH (>1YN$8HPAAXE9WZC%N,).>Z-+DD!QE[D@]BEO?5=<;Z?:C%@PF*-\S)RO>8^SSTM&3*=3G: BCKDP=CC0 M $_?=O2K28J4FO"4$ALF7AOB*TZV;L]XCS<1.B^K<_.$L<+^]=$7AH$T7 T; MUP@SMH>D=M12,8Q'\S?N%ZXN>Q,AX3H$'7\]?G_TK65&6"N$>O(=Q,CNFKF" M;]-?ZU#A[(6 :[25\%.F5ZQZ<\8/'50W(MB6!V2C]"GNY#7"J)O>YL"7?5M8 M*-<#V(YU3C5[RR;#EYW H7[U\DWT[)D%:U#-<0K.V+S$=V [Y 0_^*#*2XTY M( 7\)OWG/_:>/WM#E?Q4I.%;70Y54IC?Z[*(#?#WX,,[1R7H)J;4(V3R(U>Q M'3,*Q!)-J)J,-^/,=3_@+X42N[9F&6S2_E_)P#Z\(Q%$0J8D8UKX8;R'#"#" MFS(4&1596JZA[>@76(K!14Z"(@&EIIR_;L384D(!\+HB:K55DAQU4EZY,$ MXQ(1!=/E=D%,K_V"9U%RS]PK9L)QI]T*S!1^N?L&7_WJ#:TKZ$#D&G4;2X2) MUQ#\X\7.&SS6RA2ZI!ES/:5"#I7=\;1.13 WLR(I[>1HYHWF5LQ>]]]B.S-% MQJ!241.5QJ236ZPN\2["7@:5$;TCW\S^O3?MK2>I>]7,NCN*S06&<'4[I3LT MD@U%L^/X+6:9ML"4,VVO)-Q4(%VM9,&_K)SRTTJ1GB634F4Y<^5X58Q;!6#[ MBXZL/7QUJ1K=T@D^0#^CMSKZ%0FO22,X=$'YMQ24O^> Y7X/N #S[S$>@R9R MY:"+QAL7N@Z$%(ZT-"\O&;8=@P[0RX3$9 VT8(NW!/I1"S#5@2W$-S(Q;G0H M'P7PX+<5;,[-N$6,UR%0"JF "(31J_4YTBWGO)Q+?6\W,\*AR//@<3.9]E'O M"Q@..S1^CH:J,Z_;T3%_\Q086/7 P(]/@8%E LE<'8QHJ;CD;E<>M%.X"!OH M\@;\2P@/ESU8?<251MBU<%3L]U^678 M'F=WB;=-2BS8)KM5L@(^T7 $CS&,\0%9+2D@="[P-+EYWUG=Z2+$4AS9R/(] M7[@&X^>[+>AV44MA?G@7]V4-$A1 \;T#^_;U3I2 J/!T2*YJMA!8TD&V&%;C M_9#5F/GX"%)32C'J+H>MN6-)FR2*8!_U("]_)UXF@UNS:N?Y_KLCHW5N$L$B M0S.08C&.^@H$$HN#WWG"/#-\N*9C1*>;,(R5U-66M)_P]D?LW/'(EP^EGI)7 MW*L0(OPFKW=@QF"2VW/LEP3TIIOFZBXSB-.PR3). .=>M4?@[S1C&8((M2!V#E5V&*I]Z%=[,_86Y7B@4FN9KF/OR0.9F#-' MM'S?680MDSG4P^. "YYQG9U5]FG'/-HH_T[T@_J4\S-3=6DR@%C7J">>@+-Y ML^;4+^6K;[$E+&>JIQ-I.^ S7>.+Y1BS3*<<"LZ#4%S #5TB*K_L]8:T+A,I M(V%U,%MJT*@$XPPS8O?TL\KK?S?A'N!8WVPDZ?H,<1-Y&T. MKDB1FFK9AM>U[AEYRQO7FJM;C"*88@3[".T:3!&FYRQU@!V,E3%V89.&1$2/S'$"U%AD1F$<@(;. MT$'3RBAKAD(@CXQQE_"3^EK+_U-R[B3T<]"X M.[2=*=G+6&/YY@)*1YI:HVA,$1/>Y[ G&$!#&35^/6_/&]$F3%XJT>V^?J([ M7WG7Y.OUD96(&_-B(& FR'CPK0CB;!@A0LTFS4FQ1"8VM[A5.55 MV*J\TC)4S\G&.0GX52=HS&HC'./@R*@C&7BL4O&B>0>0F9I/;Y M3B4^F_".,K6G=1X4&T3_#M%^'%\\DMT\>OQ>;3_R]G1T8>C MDXLX^N/T$WS[V\GI[^^/#G\YBJ-/)X='9^<7^R>'$?U__&ET<0H/PO\'AZ=''[ZL!80X-/WIQ_> M?B6S^OU ?1]:PO2WXT!;N;/9Y^T,O2+[:!?!I;"[]Z/##F?%=( TDTQA=U D M GRU=5T--M\2HTF)$X>*IDI1H.7G/G!#XBQ3ZX4 M5R;#Y$S8TM.G.)N,$32ESU9IN.VN)>K-EIE9- MR2[G")1U*\PIB>.!WB6KE!]P)\6US_8F/<*4L9=MVXO.MJ?-A[HS,@Z4$'(Z M>1#M%2,DL2C/$S7DX)8']YQ'1U/D5[I?KKG-3KI G[O$R^$BA+Q?&ER@_':I MF+UNXA6;=7J[E*>0S/6Z;)@2PI2:"%#X/5DBY@UKH;F WA:=@X;^,X_]IPJJ;_!] M=3JC3GJE. B @87(*?IG@DH4'S#Z]^+A;?0"Z9]\YC>?[GOUF>_MK)?/_+O3 M%OB41[%)"'&!U5CB>>@#EMI'J)>S*8JW5Z6SS2YH:**H!)(P:*$5:@ZGK1CJ M&2@,1&2O 9N\\%(6&['8=ZE'+=Z*IN$Y;!_Y=;@\CW[YX^/%2O7SH:HI[XY/ MWN^?'*ZSFO(@EN%L_^2@R^:P1JMPFTJN*^"RO0@R]8E*CHULIAS9^M\-3"75 M%C9 -?@GBU";1T^/8N0P%Y'['WIH;MD2#& *D8H$F62'GICKB!BRK9.2+P;&K8B;N8K>;T=[>R^V=E^_VMK%MKR_7T34"^^G3.2RM[>U MN[/UXK7].?[Y:/MT55XXTW3+G \] O7QCM\SNI(5P;SN1N^+?+R%A@=6H\-'K\3; M+", M7F+_O8UX=9W+AG]@?I'?_CY0,W(-?>G<(XR 46B1Z2UHX4V-/M6;XH3J>86*%A(C@S0QF4VQ'D3! ^K>0+K9? MWIQ_LKP>+#OG1%09RH2X%=R_\0&+K4NK_]AW!5BI%H B*82 98I5VO$3:KQF M)R0QH+J: (R5,_ ^:M2])1SYP@'+]XN'\,UWS@SS*4!F9'HD=FBW(?X(PS1Y M_=/6LY>S^IYVUX;:O+\K\TTP57M[VZ_,9/7?]#ZZ&UT:G.!61A=>4D M?4/WOK?N%+[:O!$KKM1,$+.6<6$XO41\,K M.\@\P=^^S%*7+$DA<6'D5D1&YN>-MAT5AG-X:M-CS:.!DNQZ&FC H0)\:Q76 MU*V4NC65T9'#!K"\,3[99M&ZZ;ES5OS/C>+??;O^@DMK5GZH*N=P3[4Y\*L>Y%@[?W95T M^*[5C;FWCC>F(QSXE7,F5^.Z_,.CCR$2 29,6TPCLY10P-P)=9KQQ<.L-E]Q M[4ABZ=/U S,$;SI,*S7 !)JY1/K88=!OY6\NNK!:DQI<7/5U$<')HHNK6J6; M:YU$T]'BI5PCK(*(^/[Z)52 8/+B/T?'49Y7HO'2G68LC(PW'%SC:JNRY_ M%Z'M-<:,2SU,#1'J0N-W7>!O_7M=&[C+5R5A #;^8)TV?C](*CIDB7B(POB> M3\,Q;RGR:(<:@10>PA*H[.H63AGZ?6K<,7(\.CL;#U6_(YB<%Q1)J$*6WDV]7'(W\DDH/@#Z:M?=[Y M'7'004: C8IRI#'%_7'6.Q1XFZF(82JYK(#L7\+(E]:HKC)-UA>,?: [K9J8 M?'^_* 5)YFNZ/BK*$K$E*6*I_L.14,E7X8QZBJ*18T#2Z6/B!J-R6JG)B4E< MY@V&ZI"57@K7$5$%D6QES+V1V[_XES'%?TIUG<,=YA4D>1A;L ]0L70+@H&8 M2E$EYM#.'?_VDD M,QB,7)132"9>U$B5#AU$C!BRCS/!.9)+"!LYJ1WDAX;]"3LJ9:9S?).W/^'O MFD-_&'N7O%Y=F\]QLW)[H.[ WY^;!&GJ33F[8=9P3C#^9O=-@Y*S892$=(MY M[I$UHD'E)>@>_[J2P<&E@L5^09M"$X4VLX2C&[N[Y;A5!8(%(FDJ2 #C^\NT4BN3TW6?TN->RW\?E$55;0V8=<564DV) MXAW=3%RC]>C36;2[%[_8V;%D0:7&H^YRIGX![1C!.SJA:A1OD6EHXRTN?H6L M0YM&=?.*T,KKPE?1S2R9D%ZU4.-E8%]BKY8'+5XID&>+VZ.*MBZB=I4J>,94 MH#%$N\21Y!7EE9!=*5FPW'G+JK/H79N^UR\=^7:@I<&K3$<6]]Z;>*(A&V(J M F>-<]QD\EO.2>Y#2 ?I@9[M;VD, MF*@(W7H*(:UZ"&EO)4-(*W)C_?"S$U-Q)+R@.H/#5!8YJ%09J.1-93P\ D0T M57<0Z)]"WX=4W*)@CK"/J 1E!OION(97*XUW/\O&H(TAT4GT 0XR==X;T+TB M?&PA$%=043*MW%*!P39 VKEHX_KZ>GM@/]].]";*;Y3N%%'B5/NIKB=%$FWH M[?%VC'(3R98Y> 5K/9L4.3S&<:<9.GJ(1=2O' Z/N)=SO$3$J;D2JV8@SY&7 M@>TZ\3]P)TR$BYPJMW[7 ] 4%VC"9T='/?CY]1O>MTEP6+]Q]R_KKZP CO3EIA:]? J6?0Y.KET=ZV\*M/>Q;2EDG5.I,BRR5[0(CE&;73(1)G M/E%+N&!^CXJKJB:;#^$PW'6KO%'7+EXU%LV7F8B#[NI3J1X)IPN'H^ M=O&ONYKJ#@X@Q*[.0VN9EWTHB6-8XQJ(CDV9F,E;?0E@C/#^+7H__#Y/J22A MJR+JP1(>X5X[_O#Q].QB_^0B.CF].#XX(C/N]_VSDV,GI>]IRZV66GPA I'< M(,:D-^Y6%^D:(!EOJ:]2?C+2Q+R/12L2=( $V7=(LHS"M)=7,76D!IQCIYF@^IUB"E?T^G M32Y>="P@ 7U56=5:]AF2L9N2">WB M)I_+&?:QC,A=B#,-=$-]Y4 2_:K:8* MQ^%!$KSO,Z1GRFR91F_OA4F4MGS+M) M?8_;JX#_8U-RF6L++1]EF)#*9SP\T460^SYPONDQ<*DBRZU/,M?GQ:-D:L[AAF^PILW,E(Y%GHY2J-6&$_A'A]P16SSU M'SESCYS3(U5TBND[))B-_^WT[/S4)0Q'%R&^BXBFFQ+O"!1..=?6<[20WN4^ M*)+P7G<\.NTA.[E_VW&V#PSVFN4KHM+P'=*1-2>.?=/J"AH_,QE@Q$XP9LZ*HZI4FMJL"05*KM4]#_QNT& MK!?,Y6PL*K6UT:Z0Y?%_,TI!YHGZL>EJ?0E4,INWBGUV:B+:I"S=JB/9M]A" M74/>CZPJ^FIEWKY IJV*:>MDWE@@L]/[NQ;"_(8%*6./]\W>%W[Y$Q<2]+U# M7"QIE#6:D-H( YD4UU*6$>.,$UV;@I9<>Y8*1?HSWRZI]76' BS!"N<;07Z= M3;&X,I=?'_/&V>XOD;EML/9>>2S+ VK]P<,@X:ZOVF-)0_%+:B5V#_3XNGO+ MR6VD(ZZ!O.G!R$WUX$4MN2J9!I#D5?+#FC135@"Z1;C,II\6I6:[I*+3X%CM5L_=--B^#O+N+PV:%\I4,G@:7.F>K7,R"@K,NU7\GN@ MS@J$D,!,Y*1W9O,X8B^R5*WV9G*1AEVCY++LM4OT;#>7G/4H\^]$7B'Q1-HL MDH3"!K+$%]>!3!#LWM.3H_,[VK[K@6Q8P=D^.UIW!LW' D,(P0>H*'T-^"!0 ML6Z&'ZS@CCT_VS]Z_U W[.[.GLV!746N4=$90CM*1\=5J4"O<&25\ODW)\7T M23#;+_7HX"7\>!LN3WFMG+9VF[%_Y QWH8NC.F!^4!YQ.WH[E[0G@Y?U(.@+ MDO6P &XT@.O$*E1>[<6>*99Q5![GO__ :N$)S)H=2(??:S0"HZT(-[QP>T:_ M8!B>,DYM*/@^SP#8J0IISDS*(BB]]YBFO:R3F_7I2)[D_+B)>9RAK+#NFBVJ;A]&P:Y%@.?43R MDM<[FV"$SA?AQUR7#)S <#@[5,10SM28F$W5%T?;_+VRO!;LDB>'_JH[])^O MET-_+72^'W[^1-Q>IGP\Y=6@#M3F1G%GFZ0-UX0.U'B;AM9'Z=(#;.JA> _D M@8+W[!I?CW[K$OL#?S][$T>[KE[NA8GAQZG1!7T7K&X?W)N9SW\!_ MOC7E/:W9&%FV5I@20^I4P0OV=G:>V<629E($FOUJJ$U3GX^D QN::EV+3]+S M"A&SBILZT]F+4ZG5Z?8(?KZ$0=L9?.U=,%)7H$P0E4^P'Q9=(KBXVP'8!4FV M,>>^Q:I-SL=QH\AF\+$@W&GR1/J=6=21=A%)*8A.&4+5#.L)T*8=+6P@92YP MM\$[>_+A>B5#^ZUM"968J^6?F0O\Q)Y&-,8&R++AO+O\"+D0.".XG'Y'148V=0L0/G)M6W]?)=K=!K4/,DLE [HHS&U8:$9V(JQP! MR[TQV$2J/GRK_/5L,SQ;BT@;)<-XL^-<+N;>P][U(1^9IN4"58"/F\P(.35+!X M:)^!7>T5@L.G*[+>6(\6XDBI3;_@NMDWD/5M'(A_:)@GI/("UHLFQ]P&YK8W MM)&F=K,I5_'7=QLM_@U[2E8U+2G$%,,G%%%B$@)AC"HH(H:TBWU!,\MA19O: M,"32Q<8K/#1/FE9,_UIRQX AVML54UL\OPB=8[LAEBV2BQT3.'VF4JYO[?/4 M69: CM<*-XVK+8,B(39>5M,U1U+0BL"AT+EEHYSOX-]D86P[,^%QR?TQD]BG M_2UED>6]$20#W7K3/NR;T(>E$"E6)SZ).DRFACI8_0X8A<$ !D[#]Z(K#N&< M\GW8<3JK?DQ>0#!:3CSI=9Y4=CS ".'!'EL,CM'[0G66SJA?D-F>1P?9.>,9#J MC)*I(C5JIG.5T6T+'W'Q4'\N,.TN2^%&4UQ:U+PF)=8<27.Q(@AE&%W=A9U( MOG8+OL0-ITZ\K(-V:(; 9ZH2;2 Y=]Y1EN;VR3NYZM[)%^OEG?S>$E[R>)R" M"=(&1%O<+H!G0?M@CZ JTSE/7@)Z8PX6'5/ZI86O&:";@-=Z5-:8='L&^FET M^YALQ^ZA]HE?,/>58Z*68ZL73MJ&V#I=&T9BCG6_+.@(U+X^M9'-R]NPH%Q7 MLL%>4^WN]ZGW]+:AR@U W4BHAD6BPGK%J*&KZ_2HD%XLB72;GOF$#PVPO15 M6F/"_/6^41CE1L@"U"HP07>T@Z]6??QJ-/CN%=AA^ ;53NH\;$>HA1!&4554 M7!2?L\AN,6EB,5:=>LW=5\-ZN8[2"[ML*2JL?_",N1O F[[6+6%7V[:#F 2" MSO@+7)3F--'.I"'R:3%)G.U#12^QANYM=MC=(#HK)IZ60[5L[O9[./JK0HDI MZ%[_;$U@=S-G@$[:7HK(&X9S4BCD,M13KF)NG_!T4D)SIQDQ!-AT^+Y]SMSX M!\4L=2F@%@V"?[S#).3SK1]1=74)%I6IPVZ=_YQKD6;FZ-$AVC[?]@> ;7I< MI09,W*(C&,S)^P0'$[4\DAE9,00Q/VF0"1,.(BG#&*Q&MV^Y%B"SB_WW76;: MVYRTJ2K'H%>(XK?;7W%CY0[?_/'C MFS5F0K \@> 5 <_%T1ELIV9&DN5C :8T7%['7AD% MN7[/28U10],ZA76=7A%'+JN?O/]L?!],BI2;>2\\*/_6>;/P!OS>,N+_W?^X M?[)2LNRA@M1_V_^?_=]^/;^XXW0_*3_? 2<5LS 0TFE28(BQT#,T5HPQO*>V/B3<&H;)G,;9&];\%D=B96H$TDYM]I0+JJ1 M>P U/>(Z$A&;Q/2CA%XZCW+-!L! >S^0GIX8>@MB (>N_*;^5)<$^V]/:S\% M$6B.<'<1/\8PG:6F_P)IP%^-A7N7:N4ZJB..\5CV)/_%:W#6WQ^]W3\Y[1[T MA^&!7T,9\&B),9C7AR1#4NBJS>5&WAA*.*4 ;+F(J Q.Y'L]4#D<3C]4C$M\ M4FR#3KL;;6#.@]0C-%CX#]0T;050CD^E;3]VP68?:$T#C6\E_[>EAOL*>;PX MZO7D^UX1W_?+E?)]K][E\6'__?X?=TT=7:,K@JNQ6?O+H$".#)@83OY'14YL MZ,UA"X'V066P#5*%A#X9IUQ=H3T5O2V@U14H8D8#I;S(=@TS!C;0X-/*J7AF M_/2UD'"PZQ@6D7,K$\-&3W]&&:<=&3R3(V[$PDQ#Y3Q8VIM2C"-P7COACQ#X MXSA0X \75%5E2@42^OSDZHM K*D1+&$"??PS +'Q77.G98.IVS#%/\4+%P[- M\#)A(%>QKBV3P(HF.EV89FU[L[,,7$ N#!"0FY+\V^C5--,D;;JP@9M:;_$, M*NSN-&T/3-<[<'E[!XC:&W+<_"-&U:K*;-T+#UKTT3"2'JI:K9:K3H!3GI_N M1=?V$E((C)N4NIXO]]O=<>%__E?-]*]&\< J3ELP(1E2B_]D_O$&F;3A,/V4 MYC0L>NA-Z"-\ 7. 1=[0T28]H,[PU^Z2W-[AB[*&[M2)>;-\O4U?_5>==+][ M_N/VJ[V7"[_>V=Y=^-W29E]O[[QZ?JMF_XNZS-V&F:E &_SO'Y[]T)H\H[QM MPX2 ^DN19+.WY"=4+W;9#^IBUO^]5)S]:6_V)=H-?;+8:&XG,%LG,#3'UIB.$'@BR:%K@K8L< MIA9/U8FG^IX?X^/07PB;>F6I/K&3Z50<_W25.Y"DD8H41K(7-9,CI;/ _7%# M!6DY\K@_:?T>RGYJW]Q+5@#U!8I9&P^>W16I\SL(H3H!/RS@*XX&\!D:PX3X M(@^87/*P<6'=)ZC?B*N0]ZF!BRQRR"XIZ!M>TFC?/[0S_'+!&:85,7JSD?2EJS>)] MP_5M5VSDG;OL%RBZ!;E4:5F\+JD7.>L;#-1YB3U,S&CV5T#\AQ_8W2G(T!;Q MH]V@PG S\K?#(I%F'>+6J463) - [(%'Z(%'%YF&:\/;I[-*7^/-:P@].JU* M'5\3-3.UTCJM;;(4Q3!MDJ*#CK@ L2NS,KU2P[DC3X.)KDT\ENCJQ&2E%VPO M,[M JJ3HV /I@/_;Z41L:?& MEM@=?1^TJ&P=6-0-B^L(CBA34'6Y7VDZKR>&QO NZ>H>C051$Y*K&+&,O4;F?2GT9,Z-^J0W^1HQH;)D^ELL5J.; U[ M9A/V:/7J7W)4B-I1A(GQ$L TNH:0>AO?XF: $AZ%9;"07Y+69I*'6NUP\AFA M1J5D8U(B#)?SR)A[UN0N2N6=(6?[<0[ L*CJN"4T,$<00R%WD1\P[Y(YP7/8 M7@!3_8>EA3FDQE3B'A+[(AXK3$FY*C(0M3@E P6RHL/\(H\2OEE6EUA-02[I M2S[X5W PEOUG(0[Y_+2Y\;/2DY9 M. O=4^ MOZ7"^_(!*+AHI'Z4%&-U2:6AQ+N/+I"PS+!/G8;>"$>X9H%Q,-=(UN2S1SL_ M2FP/?/I7G2K];I,^TER'0S%>%!BB-5I].I!1J[9@CR3R>%<\&=WGO[$S$F1U ME)K@,70D39-_29EKQ0#%R_CW.A!Y6]^+B[$'.?H0#N!^GBA0LW+D.P<1CC@% M5:I(7U9P=$#U@CV%;&'Y#,Q%/4 "EW%$I-(-? XG<)S^F>:7"MU%^;B9SAI2 M,_&/,9PPC%[1=W ])&J"7R4J4U.X9?*ZN<13?DFG'*G-%5ZQ,,7XGUC,)ACF M0"4I'D#LP P7*9IC)T ]TMB;2WH'MOE>36=I*>/ UZJ9VH+_#S?\A#LQ0"]E M#DII>"O( #%;P7VKC4.+(X.I^#.+E4/$?[ MDRR-?E&#AJ:RH>'5S6><)IC,2W33C* GXQ1F+5.7L(KJ$ALA4S@9I"6U@C/: ME$TE,SI'7QQC^17VB ?Z4=_*F_D@M^I43W'A4EK4:^76()S_*?S/98KS.=5C M16 86 *X^MV6@J5'6[>)\+^*#2DL:@,"6U4-,K.##3>#WZ6)NC0;Y5+#K"ET M,$Z5/(!+@NH+M,X[)R^F ZF>/L(+!"^=RPEL+["08O.MN#:1=*!"ED]:*TGNIS03Z !N)GX&F%8H7 MM_*\N#.SZ>2BY#UG;TK>=7;5H]YIF"'0-YVJ+?,/<7A*/V%#*;XP]J<:7^XZ M0<-&5\<6_@?V*UA_=62NW-R\@(5,SWLV4&$L)ODQ#\D++3-_3K0?^*W94HS*UW!D[)@-BI]B1,XYQ_AR47) MCP:RF)^RV2^:17D,3?$L&_ M8"W,8,BCBD/FU<=6)\V 6KU6EVD&&CF%MF Y0#"9%9$[7]RF9M2HOT27#6XU MV>YN3#=O99)J=N6[W;[4LGQR[X1[GPY<=U-ON-T/R\#Z(1^M\%1LN@FXB\QE MZ3V5+L:T7%EZF=*3I&*:9L9&W')#4RL8V,EU6[63[@6Y+;Y646MI:DZG@"D: MP^>>/MRZ-5#%'JN4%DBNS4L]T?#;R]0LN77#@HX0Z>J2?+$TXRE>CP@_'F,? M>+IA2QG%P+^327O&11=I"/L$+]@)K7*@&M/E[P2@>&0OR;&R6$1/^#BRD*Y2 M=#%A( DG%_:XPMF9D I29LVEM\Z]$Q[?K!K[>O&WEA$Q[^4!:"E;^!_:U=@] MN K$!QU;.6+US%I-V>Z8LC:74J=I)IQ5A*F]NK*;U#1BI#QN$I5OR?\&>A*L M,ZM;YDEX"2S7I=>NV5TL\G5>9*(]X1\X3'@/G"5R'VC9\CR1<,&:$^,$QB7Z MK]D2O"RJN$^@B?$(8JINP'I<+N!@_YSC@GUN:KI-5-^R*4_R\=B\OL(+/9,5 MSI=""#IMZ1H[72M,7@[6G=7)@6E%%-G6YD!!B/HJBSO64H,WLV8ISMV9OD1U M3>5&I?#$;T(+!=^:IF72K/CD_M""PGG[K#^KBOV\>!]MX7_X'*&V#)IY23)D MV8AN6F!\1HY?VX+R^I(HU J\>>^:S/1R-@-$L0?MNDG!3#:F0..)3/.GE=+F MH2W[M!&"V]$I7LQIW2S8$Y<:13\=(YEQ&BPI+WW#M3=]3O/+AZ>9P9J8']A; M9HP^P8Q>-$[M<1"Y\HE_90YXI@ M74Z=D_L7E.8>]S0!7?^+0+[? F)\+_DL1__?\<'I=^.A&*CAY;C$"C1;,L(1 M_=^;^P?,+TZ.[$U0O.>1_/ SX08<18--]V!<2YONP8O,"OBHZBMS?PNV]U8R M"06&.,ZKF-B9,H!"V1SL?--N7J*TBRX70FZ"-GABX<";I4F#7;J>%()5HI!Z-R/;9NK9->%<[@40@VX%$R.0O>W(V>-X M5<9VWY *;Q+("1A@)R0H"HEHRG'.2^$!CN]D2JQ!"MZ^NX1][+$];_><8W?; M H)MNB@!6RH\1?->AKB;RQ<:>+?7+&(6+2YS*6V5E$W##=6_7>_8&0,CQJR# M;\>3U5\*4A.Q"H*#&2XFD;\6.Y4I<"0,6YV=8Z9OF&D%:IK!-",^E>FYJCNS ME@6F^;.7O2>,/T)"Z;S^:0M_=$_,9AN[F\R:V/WO'TOAMOWB.WWL+9N_!/3S]R.:WILC%:1RN)@R"Q<"%EK U(Y0,+BWWH,_OL:_$:+@G^*3-[I;)F$6>T._(@Y/N* MG-P-#W4/ZDB?0V>9.H)$BGDQ3*>8W$*,ST)$KNN([^ ZLY492A,TB3 B&WI,HK&@R=HWDP+I3R?.M7Z3__ ML??\V1N$Q&#M,;A,9_#),_@D28Y\Z"6)Y@H@NG.:84^AB$RB%2+.@<#Y_8QLI=*9SJ#S31^\^H-#'<> M4ZT=3 5")0!A[Z!QE,5 (2LTF3%*E!%%$UESHTB["7_-61&13G']-9C)I$#. M!.AVH(NHC# 3T-W3NBC'BC>-T4NP;\-,E=P/'FZ.B7'(B]+@3QG3^Q $6/^N M7:*!G#=.S@_MML/8>F98 *WV,4=7&TPSK#H:<0F*)%@1O@$>\.PMUD".[%FI M;II'\A.@/9)',[@!EE>"UY@] D<4PSP@7:*J&)2:),@ ;PS658;D@:'9?[AS MOUA'N7'G:J>EI(HWZ?SA3M1B'67Y5L.MBX6U465)J&1@5!&)#6DL*'7Q3L!2 MW!B&PZT' KII3S@H+\3V3Q<*F+PLMHV(4$9HTP=XU7CWFW^)/C2GRGN%B&:, MT+3=*Z@L,D,T9T=^/Q?+ L5FM+K9<- M<8_^[V\_X[)N1]4F<&V12(+_*.JU'#25+H&TV9G]]6+O?M+NI7$Z!Z:7(QZ$R@:ZOL; O"F7N%QS,>$WF_WNAL-Y M]K83OI]O6$RG2#RD,G;R.>*V>$C(7;7XX(X+.8!&J(7_Q"$!08ZUR-_VA/NQ]_B[O3+ #F&)NT2A2:^W6P_;W&]6()70!>EZ!>) MH[SR8R>83X93XU7L< &\(/ II7OP@>E,8;JT"W0MHLQOD1JLHX8:%E?IR=:_ MP=?+=$!5D]%D448>@"*>FO/(-JE'M*!&6GW0,%9=7FGMB[EZ7 MW$VT'OX.PQX52!?3W,1H$C*1&-X._,2QV$H1S;5<^'=8,@$) +QBJ[!"&CI2S=9 ]*PY\#K:136U]U^0H:IS>R$NN\4J;91$WADL<4 M^[$J+3./XU)MG?- %K+X:Q,&>S16S,@F>TRN,P7G0,AV!V6A$E?GO;AINX:^ M_1B>5_]_>U__VS:2;/NO$'/Q+NP'Q2_.QVR" ,HEI+HQI:]DCS9[&^4U+*Y MD4@M*=KQ_O6O3E7U!ZDO.W8">V+)+=S>[JZJI3YZ2C2_P4$@1PH]G% M5SU[T K2@FOHQ_B)R8/$V,C.4F48*!HKM1%EO+EG3 22)X5Y_''_J$E[?#KB ML'D$544?/.#3-8W>3=3B*1U7XPHQ#M@2CP:WP0-*&VR9B".>8V3/4$%M=>T0 M9,G2GW2F7-W+G3]3KFYV(VK3=CC6EY)QN*LYTVP$GRR1@9A&],GKY^]2 )*" MZ)A.->^*AY-P:IWQ9IB+J>1A\+ZW!8\;> *R*:98%SE#PJ2,I^2:P]U?$69S M03FY+5F'4>:3/94H?\J1YKRRUJ:ZUNBMYC:3M,)KJQA]^L&GG6]A@ MZ+XRUB#$H ] 0*H]DN259)4JZ]>GT/"*9,.BT2_XC_/2C$TJNU<,#BN90%NS M,#8')K%8[;[+QE3?"XU/VP[*)C_^AEM$-^=T7,J-,#:,&R;@QN+7&W(-(O:R MHHP1?(M8O\ 2O 4**%9F-X(G^FEJ/?KE%4-WG\;6HZ],8^K9R.9+@TF;Y#JY MRC0:(4.917AM\L(RNU@VI1CEWM+)7??U5MNQ%38&HP\MK5M9&:P>G*B92"#+ M>26)-^_&/\@[T? %YX#QUDT+=Z1%M'5[0Z),/%'4'OELHWC]8&*TTR:/;L3A M1P9C;A3'N:V/:64"8O%F$,@(,AZ)F)]XR@F/.8J:L./RB#Z) NU\:/'M4VCQ MCH:##XD*TA"[0;>D)0;S;C>(8%7:5" \"KO",K=0\7W1ZC-J069%8'\>ZXXO,)A94LQXRY*V M ^HN)Q$9I(RQ)MAQ8MHU$FR-[+Q$$_($P1$)8[6EIY7<*WX=E3F$WOFX2&U* M68X@.!^ZCNBU[-7QQMMP1.[&'C'9+?37\@=\X#2\N]L#)MH9C)B^,/%5QO01 MJLMI]JY5JO[9\[7;'GQJ]XZ;W5;_L2I;?8EIU^#:LU"(N,=1VQU&XFN$Z1JM MCSQ!_M3&FQGDMCH"!-Q $&6T(=E @SD(+*^KJ?'%(S5&R>O+>%%DRC>9%MDD M9I+WQ254 [1Q]N&YTH?S;QQYD+0I13 &PL82'7"3BTCT9EE%$J&N M4\C$NGO#?:5WI39JQ9* ]X/*%/YF\(6AL?<=V[B0$M'6E1"KX\EM"P;T5BI3 ME8U\EPJ!N^TOT3_;39B QVH!=ES^] &+DZV>4E_B'([-(^C?ZC?'(F6<[M3" M09?8Y>J<1I6/GDN'S,(JNFRD]]U2QV0)ZLGA ,LL%RHN*\0<1/U:(OD">P@G M(L U\\WAY+/KU+!6S=8,DPA)B#'G.C"VB(LR3\$YS"6)=&HL-'G\>)7W?OFM MLV6DHKQ,"WDO$U"N<)@-(A[)B/:/1/4RP&F$FF.:*K+=VU>+P5->]@D+"M#' MH]R,$Z@*\:6:!,$K(V^4M4%&3AN!-SVNR.>W$+G7-L7N7$ _*9.;VGQLPD)! MF_.Q#_V=X3;_-#%K7$YI!TAA_Z?3&ZMM .ZE;#XU7%$K2]J_.ZD?%H^+%U)( M_LX5N1A O)VA9,<6$'"73ZVB87A)PJIH4@<+-\5,Y\$]%BC1_<;0#KF(OF7S MP*JD5!8E\EPEPTDEWPAQ-)7U=/+O%M.1,$T_U_V*7^-0(T:G#:0,1I<(#!>C M2S(U"+)[E\?+P&@5+P8A=5688=>X97Y8[?SCN6G-("V++]@V0>D7F\:NKF8;Z@+ M-QRXHP;[N1N/62M")R;P.J)7N^M1V34<_XA 6S*"-=MK6,D56%9,79Y\ 6*' MONHW0%5BNLJLYKK=T_3;^TMYY,UT*3N?35YC*6'/@*XM%I8EH:*C$\J$[?'B M%1DD&_C![_L-5^C?@%S&XH).I="KHQ&ZD.)_VK*8=^DI"KS[4>"7SWC&-3#[;7K'B#"\H;,8N ]7AC0%!9>84YW9][B!\S%D/!I!OL4 M[T/VT1("=3#;NI7\*VWLGFLB-S:\)SHN)A +]-L\M/;P,LP4Q+QX2U=Q,HTM M:EF8,S#.$#;C*@A(_-U!!W+]$Z?'-O9>2'?W:-S:9(4V6DWF(, M-AX('>W:C+[%QV=J<3--2V9&HV\MHKT/0/X>/G_V>5_*9[>5[$PF]Q)(NUPL MYL(PPMEB_L_U]?5!848'%]D5_SZZ2)X-DY1_'N;9=6&>F?%%G/_W?_WZ\MU1 MYS/]>_AN6'S_[_]Z^>8=^U_\"0O0C@U_*E!)_I@,S\BRU]%?/B1 IM+G?1/3 MD66]^;C-;+Z507E0R^+%0U\63*=57)+%\F>8PM;T%7Z=_!U.)*\7%R:+2XZ1 MN-OFLK1X&T+L8]4-GQ;;TV+[\;*_W5IL\,(V!R:;P/8;X;+J&5X%X^C%\\/# MZ#BC6R$[&G52K$-$N>!=ZOI@#]6Q HZ8:)@3E\Q0M[GZ\A[3/JL64%D<&"!\ MS0'-=/X$FO+WF0:*GM$:>_$N.KE1[YR#__KAIVR*UUS8WT?3!$+SJ,$2##[+ MW4L(!#J#ELKC=WB&S"@6M:P_J6C,#8&)O^8Z?K5;ZWCS&L:ZI:.6E.UBMB Z M$S61MJ[Q>=Y]M4=_9[/?C/KE;(;ZH_ZE,8LG&_ (;<"3":B,_^N'9 +:HIDL M:YY7.D.(.)VL*U?6[-.2_4LLV8>>G&U6^&3C(7A4?1#,YL6M@7Z>]+\VO.]70M5FI45:FB_SFF27A#=A_[S;43^FE'4LO'>Y4>NE^ M5N)9\W.G/VAV'RL"\T.6@X&_'T_9< L^[7[!UR'=;(44P97G3]!HP;C,9F:, M4O6HT!ZLR&4II#@IBA*5]!L@@%6VV'-2PE-878)F59L2XJ5&C-+K;& ]:E9R*!N>MY!3>3F5K(VRX],+)0[S:)L M2"O$@;;B/.<,J,M+VL;4^RT,%E((5T[C7#*=!]'Y7!.<:ZZ4%RGD*18RB:^/ MXN(2>]?(F'$AD/B-=^&L*YH@78K19E9XR 7.4Q26$X8&AJ<.4'[A-VDNL,^ _!KSIK]\X?J;O^ &'V;.EK!%P)%VT5R9AY!+T> MBY,M25@[O12JTX!<1\"40),%J\WR1@A0^@.J7K*\BHQDQ@%&Q7L^L V*&ZIA MP_!>NX)6"/=X1B=!4WJU&H9[>KQ E:S_0,A,5S;4L\<$%]RQI77#'&;X8DE\ M^^P<4GK2'N3SN$/_+E$[GS.0-/R:9/Y\K[:',.XI=1>DZ9XJ3'ZR]HZ*7=$< M6R'#X^56*B46;!3NUTAM*@7T-&.-RB+DQ5]U%95?,#<: F%#8\9_=JCOCI2T MYCL:MDA^$I'0F@A>S2@^!,?B4^>X\CW7Z)Z5>5'" M>>BK)M.+%:I,H0,K/K\<]^3XI3Z'HZZ<"?>?' 5B*<,M4WCZ#8OB XD>OJ4G M2.4_"P^13M!H00?6"X6$IL:,7;VNB%*AB!ZGC(#3#T7R9!O<&?#LDCZ8SQ-P MMP1.',R+@XIZ%<+'L*NL65ZG*ZM@'U[W_I@HZ@_V^[[>76]P_K%Y_-,4C>_? M5![3PBQC7IMI<=^R@O?).G>_#/=?/5F##U@M$8-*Y1OX,KW_9E4ZTPLF$Y[: M]\E5GE9ZL&'=ORR3="]7?JFSJ/@.=@+']6+B&@&O8RUV^J9KZHR?2G)V/F?R MHMK$OVY)SETY4P*10@_%C M$_=900"X@\[#>;LW.(UZG:/3G6KMS\N&+WM ]^2#]TY/FMU.\\E5^YFQIFIT M?$.T5]3&F4Y-3^AP46R*T\>I\(EU:[S/4J'+KU&>>,1/KMDI#29+V_8J'HKS M66!M]JTH\K7)C1="4!>G[EP=.%56*R==:PIJ17QCA*H%=G1%@&A'YN2=@F]; M-L7*%$M0I]LG9\,_>)N\81#Q0X"-X6G]]!R^8675H0H)- M%1^_?DL;U>N7;]\EJJB&Z?VLS!.P*HS*-(.4'2C-C7XM&LE545&FP8= @RU, M:G_'%O@&[(CDS.)I02VEBQ%?_';/BRO?T<1;/S*>:O M@:P&76SGHT$_4'4OS,)%.;QRS3+1'F^XY50HJF4LW//FM #**:V5$5>2EM$$ M29E)F:?)?W [VRDT-];6RF#8<8YM UVSR&D :8EOGA\:IGA,M&UZGP>P^9SW M^S]O[VDB5;?MY'+'13'XU([.>J>_=_J=TVX_>M\^/OT2-7OMZ.B\UVMW!U&S M'YU^B%KMH_;)^W8OHN/.BZC9;44GS:]1]Y3^WFKUVOU^A!O9:X[;'YO'_*U! M\Q_1$=VXTVKWF@-^!#[NM?]^WNFU3^C+]$&_?WK4:0[:K>A+9_ I:GYI]EK] MJ-.-9'@/HJ^GYU'_T^GY<8MO=GX\T&_6GM1L43].>Q&Y9FWZ&GIQ>G)VW&EV MC]IZQ1G]>M1\?]R.CIM?T+G.@%IS3$_OXS)Z4B\Z:_8&G:/.&3<8[>!!.FYV M-P4M)I/_]:'SCJ_N(1*&;-I-S@_Z!]$ ?"%28GC/;*N M2D6.#R+1(82LRFNS2M>\ C]3I+1K]-A,P8+J_[*X9-1R!$6 ]!M3N#B $9R> M4MR[5>WJ"(?^E;"'(M=1:\FJY]&]>F516/58(-&Y4%^323-NHQ4OU,!"MQ5KIVJR9LS. '3) MPQ2Y^C&0SSW6T" $_'75F258,GP8V%XZLX2PJ<1)F3BO!K6IZ,A9J)^'T6Q5 MDPMEU<:@=4P*I:"R_)(Z^P/,G%M-2K^R=M[.;?8R !%);)EIX]*QI\<:FE!; MU3TA8MA! (%*3<(CX!=CNIK8 M0_2FZ'B9@[CRQFTVC+0-\6&9OR%H9%7$[K0B4B6[GBIYN9.IDMTU8P@# MB5N:*HZ$EE15K\^[E5!V5#HJ?'/"$!)8=Y/&0G9;LQOLH4WB9 H87GU5!BLR MOGZ0 O9"PY&'UC[WUMZ1J I=:QTFSWB@> 9K&)P5F(7164EAB*N@E^UA K)5 M9,;>LSL_L6933@7>[BY[^1F]+)L\C@.:'!KE;V;!GCJ\$U8.4+N'!K%])FL( MS[KD A(RG(@I(]>LWL;:@>!R U9>Q$@\Q#>]$8-*IX!G1UF>ESP<49=)WD8[ M (6/N&DCWS0L-&SRE\DP(5>4O$\Z3%GGC#5J4G6>$S*6\ZPL=$N43SSG[.@R MF8YI1Y=EGEVG5H#43KR"5OXHI&&2XB4E=A+VU?H>3C\X?X&-$BP*UPO%E:JC M?8Y1VD!](P2F"[:]>MR>N%S&*+L*UE AAJ>BAJVW8?Y8>!.W='8>VY1F?=#= M*NM X1S>D),G!IGVYEVIF$MSPDET$;3_["ZQIP[Y#.C)3L8UR&7PR576$H[!&J>9^\BS]YGFK$S5[ MS?72'[K!\3GT3CB6)*V*+]^;3 M>+0D$86QSU!(,$$21S3XNDT_W8/#OMM1_K"CG3]W9FW]L][Q;K M9Z>EDQF;I8"J,O?\O:2QGK 0P!G-2Z$W?7'XC@Y%Y .(.(:HJMHJDK^]W#O< MWYOLVX?5"B\^E*A4HU,W+8B]H\MX#N_DQ9NWC>C%\^>_1NWQP;[37^Y_: 92 MRP,?YBW4.S'I4JAWFHV5BS\(^K+0&9T&^$A:%AY0?$(;'3M$38G/+3@JT*?N MQG-4D*JD#>ZMRU:<:@T*6.+54O/Q"W?N M1! BF>)6?MG3D @Z:>HJX+GZGN:![LB^FX:U>-3)EP,I!T:]Z[^RP"XP5^ZE MOOZ;>YW4 $N:$(Z[Y6A7D1?H2P\+L!9ARF\@EPA'HA&YR(RJ3PF'PNWN5#.S M,N.KMY=B)+TKWTJ#]TY)9B_95X^Y2+Y',QK6RX#-0"FLN*(ZI^_2E^OKQJT+ M:ZS/XGP1_:/3Z42M1*",T6'4+X=C^]O>*YKQ003"#?J;Y_O!J#^Q 3WH<.VK MG0S7[@BRG9R"TW/ 7C[T.D?K<4J/3COA ;)._&5]?,!#.*J?>('#?D:[?=2< MT)E;#+=]8]/XNO&CJA>KF"9HFM Q <)7Z5@$3?#+DS[&3UVL3_H83Y3]N[DL M=DP?XXFR_XG[]XFN^^[COV/*&T^,_4\FX!&8@!7'OP=E%1Z4CL<3B?_3*M[! M=(V*5*XJ_076@8'CHVP>T+;6^?H#GGXFLT(*FFGZ&[?@Z=_&T!\O%NK@_LE< M_8^%\FE5T9/%/D$;O)!A=X+BHC8NO-"VOL%55*N*^"S^QE ')TL?@AA\M8-9 M)IEA-,*"3J\" UW$WZ41H"0#8L*2&:PA3N6+YIQ=BZ=\=9$LR@KE,(HN\!Q^ M9J7RXC&\XTTAX<^GO?8?'A'>D7F\K69=3'FX.1?X=2W8S'-2NF,Y);] M]"L+VN_FU3FX".8@IAZR[6-3C/)D*#!O2S!Y^'J)85**)NDN3Y& 70[H+9,X]AQ[OK;M"B P6U M;!2]%P&(H-1NU\A+[C5)U]-))K 0SLY]SL!6$B":EZNC'93?)_#V+!K_EKCX M?5=X#NT(?J:M20EN=I+E%_1YGYS6J:&SV0S>W?LX3^F7X^,CR>XQ9MN6).U' MS/#".(QH0L\LGDKS=A[K\?H)Z[%ID=ZAY+9:)":E7&F$XI;"T'JJ%MUH-=>! M+:"X!C_65@:$ZCINU*KUM/B=ORO\$IEW>-:()=$)TIKK) 7D7>HD5+HG58ND M)T=!Y_M!L&:$389<<[#$ 5 CR+ M:Y52[474ZI7YQ6A!,UI'MAX&/AF92ID4R@3P.*T"%#8+>SC'\-.?N5ZJVM7Z MLPL(I B!6Z%1H'P] \)C\%#6G,G/FIUE,;>'U[L[5SXN2VZT7-4,$E1>@,-. M CG:=+/H=REZZ>%!]ZX-EQ2>4A.XY?E4*PN6B L?O;_]RV^=]$?Y(D<^.K.> M!R6@N]::Y[@B"?M83,7M0[3U$C0Z,\*DYH@0-5@ZI4P66 QT8V^X7J1F MM5\$LKY,QD'G]^0J&9<(\EY?9I:N16H6C5E29D/5694'0'J)"9R^5HD\Q$![ G MHY1F,PVE ;2.N#3Y-R8:)DH96A.B6R8WX(?1?R\R3/=A7"0@_> X(X/K;8'Q M>C(Q^!AV\+5'FWL27*JM_ %*+"%ED,,;>SP)E)H6+**2^K#%>N,'_,>$N[@@OG2FO4U;+C"RJIR=)CT;J$NO#-I/A6 M>,W$EK#8-MG>F(4;7O*8BTQEXE;4,CGBCA1*!&CG59:,_S+&M7H>:$B]DU^+ M.E3+X];0A-6Z:O#:\(=S6PX#^+0*-MX7HQ67BPR1OY$2&UF?'Y=-LZ*HOK[J M*<1_[@B]M'!8-#0Y/^VW8FH$D ,,'O)-EV7D]4V7%E+M#(5>EFFE0+FFV+GA M88ZVC\9K8GA'L&<29LZ;N@,3[B9^)4=(5Q1 :[68\*6PI:*OSU)'M&%'47@* MM8'KW^#0O;QLTF"C@/&T^]8B:S"CWX6]%D#TA3W@S?,D<^*'DX0&#C*'X#\L M8/KTV;XHJL&[= *.7_R=?H&T$A^X_E5R69ZPMK!9YD/>]BNX1:.,3HK_J5R/ ML=5;^/U>U&,E77%E@MNA:UP=AH\O:'-/QT7#Y7>W/@Q_J#W4:<7.LK%_-\'K M*&HO0OR4)N8CN3.O#NUWOV0Y@H2*%E?:&8/7 OJNH,)2+Q6>[U?/MUUOG_1Z MZS>]%\:='.?Q-?VH]#MM\9IR3X3N[GSX_."EO?=34'+7@Y*_/@4E-V8.LAND MSLT(.\+ARSP_*M C2'C771MVMW*K?\U:A^WCP:]TV[GJ'E\_#5J'AVUSP:=[L=H M\*G3CYH?>VTFZFXP#7?SZ'/W],MQN_6QW8C.NZUVKS\ _3;_'U\%BS;XL@?M MWHF0?1^==EL=X?X^_>"XM!O\D[N[<'CS UNM=K=U?O)C=;F[$]'[TJ9^/-)Y MLRFD-XB_1U]HN[L4..1]!^;@.T[)?V8J$!^A$\U-%Z?S>?&72W&Z/P5)LR,O M\I??OJC[Q9YK3<;;5=K9*(-U6OP?'"L#DA8T%XK)C5*]7?LY0#XB]53S"SCZ MT!QYUE/9EL["S/A,4,BQE+Q"-> ;WDF#,UBK8XS54YAGB*T$+*BYMH%K#@LK M4S ^/J2$Y9:>@0]!F^C"@O%9ZGU#=R@F4:"K'#XR:'# %%5Q'WFG1/S)#7&U M;TAW+3WP,>QGZ\QN9_#/=N\1Z[(^P-KVD (YK$Y(*P$[CR"68PS6=1:L(%"( M>.[S&O.,TUWB<[XN(C$IA_GW@"#]H\1;1!S/F8QG(_YLO2 <.B!?H? M>FN:K.9 )\-,*Y2IJ8NM^]"Z+PG!X('PI$C&"8<-F#F%&H@, '/X\.E: RB, MF(=9:*C.L[364NQX^AT9(2F;YX!V-KY9.;S1Z\.(A\?&7>V5G$NNY_;71]"]QV+PSCG\/"CS;Z)\>=UPT+<[RA[50 /D MZ>"NYN9@M>H,$&*LZ\'R2"CU= EP=.YKEG_3K[959,-J=Y+!Y# ^+B@72"CK MD]9:;'7;6.+#(NG8';7Z'4\RYCL?:__;3L7:=X\"]KS;@8PBB)*C]DFG!UG# MAQ)&?2S&U/.I LD4'.&,E/ GCI%C;L%L22'^H50WL^_GC"U S!YA516I:^;Q MD!S*)!>M.O=@:P(#NI#<,+T9\X7 #76'5CY)IJ).Q\$B_S#<9D9OW^)&0HV^ MAN1TIXE8[.%-(SC)RU%6&F2;5^>K/SKDV MCM=6G!A]?&6FV9P_E]";/4R[34]OXP>?;\P G6)AYAP*E Y(.BHHYD((5,%Q M.T2!G,Q_U_732._)!WTJ4FDDH/*EY!7%*NS7T MC_S?]RW& ?)5KM#7 L_DK/+-F+G'HIDJZ+B>>*.;Q"C)XJ#\-.7QS >?1,TVC,GSXW_O?MY MH9T%AIHW2AOT1C4L8\178X\#E:E8-8,SGJ[F.VW2(A4]F20C&N,]W%M=P9F) M4X5V^Y6Y]\TQG+.J=N![V8.TY#XFT>';EZ]D(0F;W'YCN60EFC>FDIT3SW/O/?*,;$W.%H,0.X)1SVRZ2*W0D1[)&0[=U4*@OGA?BHFQ$ M(ZGJP!Y**B!7WT8\D^OH JE>BW!G6B-IAV+1N'&>J*!_<= O\J MGI:F6K) 1G;K^&WNCPTRW2;_KB+.*)UUBI61XIY99Y9]>9F1FF'35865NP1< MV["[/AA U%V]QS:HB@N%X!U-XV1VSW[A+3'9DUD-BQX6I3#-0#R++_CP M7F03,D2Q*F6$E\4P0BR%RBJ7;)*\ "K@\9I\%60DUSSJ*A.X"@JQY'YC:\LX MM>31V*SOM9 :!BTR$6)?Q:PJ=MA-FH)W2-JQ&BQSP%4G<]D/IF MIP*I.V:K?OG-83CV.<[EZ!2DP@;1,^IV::M&W![D%AW9D'-;F^AP:1Y.;,,@ M6ELUAGTGQX>V@:L,^]N-6^C7L=2WLNY/U63\F5[UGS0Y;S?X_U<"2,O__8$_ M/&G[/&0K]78GK=1FV9N?M'16Q2$W$BV#-J]A]B#P^BLV1MTCCIGS>Z@ M'_7:_4X+U1?TG4Z_UVP?WZ&[]V2Q6SA>GUF^AG31>("24=L(N/>PEVMX,(#' M2*4I=:D1;0^-D>U-,&L*/N2/ MZ0">"E=AV.NB'#Z;*P\%?[[AH7P)D+'/PJ?:0_VU1!(D:6>+,5TD*F2'YEY_ M*FEBH>\L1U]PWA)@F "26ZV5>)\!T,=$-A+J8H:(+CT.C(S1X2LH0+V, ']>-2$'9>* M/M1]J>E8:_A0W%$E,$4/M1L\PU #7"OOC<=7/%.%2PJ8(ZEV<&AI_$'BWU)- MD0C[-T.05P3TIB;8SV]9BN F^8@@J7=_"QE4XN4S$P7@)'ZP_X.ZR?1NL M'@S_$CFF85).U2@EFTG_E=W0L>=:@_ZY8SR).&CH2[,U6.@H>;@8AF:.]8:7 MU47M=!X!"8#<.%!:3J*6O^8LA@)M]>7:$' UW1]&/8J&IR&_I-9?":9^P=FD MI3.AGEB)AI8GX=3P]KZ(.X\LBPZ MHX!>:'D.'T1GQ^UFOQUU3P?M:/"I.>#JTO[YR4FS]S5ZWSX^_4+>5'3:18%K M]+[7:7]P?^6OMT[;?5P='9W^WNY%S>-CJ53MG?[>Z=O:U7[["'6L/$.TE/6T M1\Y:LWO4U@+6-CEP'\^/FU+OBL\Z+N%^EB^:PN7T-.;Y).W?N\< MM0_@\C5;4BLKY;'XXW'SB]PHO'&KW3_J==[3[3ZU>VUNVCTY,3;0DZCJ)>N-?GQX/H2P=:H:Y)?1J(]WQU MI2C8UO;R"- MJ\XYCBH.KSTYU:G?W8*M7(>TT_4]/X#-JFSF'6C1;2) M%[88&MG2H<$WOI6!07JL4#A"L1E5L,M#LG>XC_AY;C=H:SC5'*HA5VUS;*OZ M/9N=NC13/)N@LW5!Z['J6?@\DNVFR>N^RH;\ M^$Z_:')A6V5N$W=K!FZMGCEPY+1)'Z_#EP1NK'#N)$V27N=*VDK(*>-/48-(,"H@R\2YIE5FB.)Y N8.' M!$?I&HK%PC$8-V$L8*+(++'X2F3&WC)G74 :'7XWHI/F%(T6T/A":I[-]Y$Q MP#$=1!\R.;1:"DD)'*P=AGK?4:DNF3E)KW-30/EP@6A=,JI?F%WI"H.GM;!O:T#.O7'B2 GE+\Q!M0^80Q18]64CRN!7(& D>\^+U_[&OO)MM6P+VWB%(J19MP1-^9 [MS'95H6*-R8CD%C,W M9(:N#(P$B2;-U:X(Y 0+W/-G&U:-CVUK.K;C5_76_6Y>P7P.UUEY"W'@!11K ML8F,;A74F#.+9;AP&!)=1RCKPM"JE!N%APR]!;/E.JV2G M!__%AL%G^-2EBI-F<^R?9:I$9=EP$6M^$45FXLF!BH'LJB?GK2DK6N'(8[-8 M@$V\$\6SB+N5Q+F5T!G7"^2VIG7]&PV/3_9R=J7S'!FW@.QVW:XC WP_&//_ 6.;^(YHFK[9/$S&X M$JBD0^*8-9>8JIU&TJ35=/7,52;D?F'KB_<,0=NEV2>3>X'G#[B7+?2RUS]_ M)FP:IY*Y>Q9],L/<7!_,QY-[!>T_FLGW>IM#$92,B8* >'T6I; 4_ [/ %JI M9U7A G-6H:2OE0-LM#]LX0(=@OB[8F<6F/?N+. / 8D_^>%YM.>4FC=#%0^ M.=06F)R[' :>N%MV/J1_^%!"^CMM'G[=M#>M9+H-"M?"C0@G;DD95/8C]6-O M*K04[IC.;LIX)N09\6KJ7>OZ^+S!]7(1>7CW>(@_4MN"*\.X0>$T@89Q^LV* M5C;8 *#@B-P?VD/E'*4JR;9Z4U20'=).!#N4@W-%]_2@JF/Q>/:4OQU$ZV<- M;?K3.%?7EP\U7!XFFM(6M+70.*;B#B>UR'KUJ,%(OBIDD=%@#/82]*">OO0Y M"$Z,QZ+@A1O5"UD3>K!*Q$@H/DX=6,@W-YV M9EQ!%KK#7"4S(GA#"2&'0;' ZVX$OF'L&7C4\0L"EDH(Y&B 9!E9.I?',_W> MW,ZEJ559TAI/IM58*%P-=]CQZ #VL(,P5%TL9L7QW1W,BA*EYPF35WCH=L8A MFGF&%!1\D JV%;>4.8(@@&.MX,":-+T60%MZ>H.N: M-*#HLJO>D81/:A+NT449\VL(E,96A6[<4J/MXL*Q'F#[;&HV =;M"@AQ G.K0UY 1O>HIJ8\E#.*J]>QG6VHN^*"S M?,<. I[3L9N&X,6IIGDF_DEV<@>!TU5#A(=PVE3(@*JB!K+?LV*:)6_8>@]- MZW,';:#DQU<&TN'NDUPFZ9M[J1&[A\+7/XMRYT^Y[.G0OB.']A?K#^W_#\( M],_E8C;][?\#4$L#!!0 ( +2 H5@@ P]U]ST *J4 0 > 97AH:6)I M=#$P,RUB'0N:'1M[7U9<]M&]N_[_12X3LV,]"]*T6+9 MEIU)%2W1B>[8DDN2)W?N2ZH)-$G$(,#!HB6?_IZM%RRDI%@V*4MYB$42:#2Z MSSE]UM_Y:5).DY]_FF@5_?R_?OK?&QO!81964YV609AK5>HHJ(HX'0>_1;KX M'&QLR%4'V>PZC\>3,MC9VGD>_);EG^,+Q;^7<9GHG\TX/_W(GW_ZD1[RTS"+ MKG_^*8HO@CCZY[-X;S]\$>YLA=NO7D3/1]'N4._LOE"CO>&KK1=Z]\7N[]O/ MX%:XG.\IRNM$__/9-$XW)AJ?__KYJ\V=Y[/RS64#O?SGSQ,:[!27Y4;*HG'Z6MZI6=\J_DYS)(L?_W#%OWW!G_9&*EIG%R_ M_L=Y/-5%<*PO@]-LJM)_] J5%AN%SN,17UC$?^K7VSLP/?IXR5-^">,D<:K- M*VSOX*0'5Y-X&)?!]M;F;GW&W7,-87%U_FSN>R[IKIF*(B"8C42/8'.V-U_N MSG!%2S5,M+EFF.61SC=@91,U*_1K\\>;*"YFB;I^':>T/G33FZG*Q[#?PZPL ML^GK/5C,"YV7<:@2F1U-E'\6,GBUM?ER9Q\IH82IEI%YL!#))A')CV74_FW_ MU>;^UOR?MS:W[6\_TM@\/KQ!,5/I/Y_M/FLLQ.N=V56P#9/VEA/7IOD2//]G M7W'?OAY!/^\DZ+=9469IJ<^*IQJ#"]8_OV'O5=O@N!O?WMW='IV_OMQ_\/@;QM_ M@\_O^^[C_,U[!(LUF,Z2[%KKX.C0+M;@P\?W)_\9#'X_.AP?4CC0^++^ M.->:%0)9E<=%-A\3E0;':BIK%>3G9Z?!Q\'INY/3#_WC@T%P]FO_=!!\/#WY MY;3_P2S2,A218..[%LXKRTB'H&Y;B7+R\?SHY/CWP_[YH/>/#S#")#@\[ 7_ M@?_^X8N6[VMO'AI3GV>E2H)?$@NO:>DL*U::I#NO0RAEGBY7P8P[MTJ[,PM6NZ3L8+B&+HFX5S M#/JP6A$N%+S-J2Y*6K6=K>WMX'V6CC?.=3X-CE+DA?A"!Z0N^M/'+\S<-X/@ M0,UB.'M@.Z, F&=:!&E6!AGZE!/A_#P7?[]1?TAWE0^TL!V]5:?]6YUXJZF=-C>G/?+M[%I[BKE6?X@ M9?7#4,]*(AC@?A(#RYORLY^!R<\],8,,"I(G!O(/0704 8HB1;(*^!;%9#E1 M99!6Q!(+Q)?/)/2-Y<-"E\B+( =%:I0U25^[DY;'DT<#%4[8W,_U+-<%7%_X M8A(OW7[YI@"1.YW&)8V'\J8H*FU>H,!9VF.DZT;@>A"QX>=>,%-Y<*$2N/G3 MV6&PM;FUC>*#APC69))G>*T3^$4U_ .D/3XN!!M#H; #3HJ'<1*7UST;P?8FRN1YS#[O_^SVX .@*R[#_Y_DSE@41,[%7C:[R SM\\NX@+=Y$H .9GV34@^KN?3@]T^,%(^@V^*D6(CK:[6;+Q5!'2*#+ATQ5>WO\S598:H$614Y6C%DUK1,M1[-6G/ MVD_AI+XS$TB_)X$M3ABV(\ ,(OY+[3'7?@:R:V,<]I& @D5&2>3/43P3UA^! M3_J@\G B-N^>>5"H$G@LV";7&OXWRI(DNS2#+)Q/,"19!I0$M%>II'YBH=1 M98Y<.O)ZHS@O2EPE,*=*C3X=7>*CZ@_M?/.!E2B.AIT@Z9(@O2#-6@N/?B5= ME@EOJ:]1M-92=F8&$\BM?%RX/X].QWS^P [F6M*(V.BG>&=!M(04L@+NDP;- M]H)X1++^9Z'!? .[:%Z1RVY$F-'7 RQOG4FC4RSV5L7+C BSFO-%RAV"4BCMB&JDQ> M;1AJYNDE[25)PZ0BKZH9&"_-=:C1V0L\A*\+$ACF>I&5NFL0]H(GUSB(1E<0 M61F/CXGW'A@3'VJ%^DL>',:%8EUUR4Q[Q"RE+\A#B"Y-8CY-65=TT-A(C2%R MC%"P#5C$4:SR6!.M]D"'VE18!\R$%72)V.4;M=P_6A(?Q:KS+A%&$T4U MQ#N-6?-(,CCY@T1=KO?N<,CU6FST5W20X&&I'X].)KQX8#+A%#8RKZ7J??>B MP+UR0%[F5FSQ>2\85N7#9&UD:G08Y/3&P.@87O^&U@:J82XLU5P6]FG+FKA8 MNIUOW]A\O'C>S(;7N"AAA>$4>/Z:6E^+U^EF]S2Q1IJ!K6F5E/$LB7F4M5CN M^V^5E;%GR[AQ1A4\'G6_&6J]L&!3(.!)8:DRN,SRS_5-[=B)M3RKR)%?S0P1 MI1J7 R@9]#?-HZZ+RD5SVWUA?1-VVM>6;O(LJD*:KKP]7DI_PM_X9L-U0V"4 M6)#4G1EJ"O,!VPYVW*PDGW4J!,$0T366Q3B88,C,Q@(ZF=2Q6(MEVQQGF:H> M[M_K>>D8=O]A[B,=RS1Q;_&U;]Y[5.(11^]VGL)W7TT=N(LR,%3AYS$) MC0V9]HC^>_.M7N(=<.:LRH&6M74*&3<12B:3#N#86<+MPK&8E,3FI0Y(/EG) M(/[5IGC 7* #5<'CUE1-_39/?8DRK>6?6L=3GJ2>0G,7=I^? #*0/()TJ \U MV[B8FT4Y3W*VV10+>*).X#GLL)HOP^PDV\KL=Z&QOGQ@&NL)1?/.ZY0U?J6,(@WZ&G+P*,^F=QT1N1POA=.K0)*2M$B5LN>@Y^LP-2]" MCVYCU9.$#%R$$6DO2#TG-FC5G(LLYDS1#K=[PY#8O,&=7P2@2;V@P5[U:@^N MJ=XMYW[A)L:F NT2? ?:=I55Q4UV&*R375SX#4ZQ\81C[ZPQ)@K4WDA=+XK1 MW .E?Q''H.[W;'6/9*N.7X )@6=;9W2REC9! T,.+.V3.8O]\]JPN MN-'D'S4WCVY3/!2\TT7L6PWS"&(-_? S,,%"+'[!#,+CK,2[BE)QAB_KYO$_=*)%Y2WU5,MGOW>RQ.2=2%A:D)PG>H6 M"Y9&W&2D-"I 8&/)ZJ@2ZSG*PK#*RM[=+)5[(I>[D<0-$2I.\S-0>VM M*!VQVSR$K1^#GHIBI(=R!>Q\\K2-B%9FB59DMH^K.&$AE&9DLV-TL\S8)S;2 M26:< >9 "W-X#:#1BRRYP 'JDFR:Y2H)2E#EX[**%M@T7X^('G$<\J$ ) M-B.SV4R9).BBI_N<7[T7="0HSG=T/^\%>Z0"O^B($#Z^Q+-7#RR,=P#4,<:C M VB,L^2AO&[6N5=-A^&_,$FT-3Q#B $8YB1RCV;C?R'<3AAHPWX8(A.V9Y1 MR#F;QOS&?-3V$35]ZA+.+O$\I<3P]F2^67:;[[BLC=NQ0'?,3V- XJX0$J5/ MH?LVU)&YAKW]J2QW]PPXUE54TZF!LI$5('U$P@5SRN&?73\NO_ #,Q3^+::$==_Q.@J"(NEVI2/CF 6I(&N)L4, MKG1846:;DQ)-*EJV7^*CAP/6%9;)W7PEIX L&CEUK@AA:88RL2Q9*(ZS"XE& M)^J2;8.W&=@&/6,)N(24'E6Y%UI_IF6!^ZST9W/"@)5)PE(\LEX-.#0I1:8, MNA;Y XMN$,'O0,+#7ZV?*(-W9%TF?U31V.!0/+GR.^ E'JXK?V7$FL<)0,4] M5&(2R7GE,"NYMD,U4Z'XJ6]#Y#W!Q/3CL>C:DX MR"(-7&M4CZC"S&W.*D?7 M.:%MJ !5I1R=)[5\(J,E>WPO05XLD4&(8I0;&-1M"(_'=S3-/;+B!W9D'6+- MU$J4MYS[^8[LP.HQ\$I5&$P%KYYLW\"OM&"JG8]QJ&&TU[Z)?E9,,J^(VE\G* MI"1R))D\Z2G6PWH35D61A3'):'P;30$ <^4LST*MHX)_H@0B]"QX=;:.HGOD M!R$'13N-@K.3!/6UCJO>F(\=1$PJ:QX@XC155'J=<%QO&W(]DW4H]Z';9(@A M8"XKY/ID3-Q .PS^[8F'7, 3"HH7Q%R?EL33V& 4=/A[#K,HVG@'C_X<'"3J M$L\P<51Q?#HV4_9R,!>]HHJR&9V1%,JHOQ>M,5B[28S];&B<)':!:U?AR:XD MAS08IP1+"$:*-N^1XVG$01F.GJ9M !U">'F?PZ1$*RG"NH%Q1G.2CM"CS2K((@1S?YMEGG2L@H7=Q/EVN M@&R6,MILQ_TUQ1DG^YV0* P:JJ^P&PMJP(1<>H74':,]IEC\_ZEKLM"V9(F] M%>G9ZO^A!@-]U#.2<6B7:03+A$_X^P_/7[[AHNR<$WI0?DSC%'@)ECV3JH1V M+AN,B BFG$S7"'4ZP'[.F 'N"TE4U'M@E/8D(?32#X7)';)8)U"NP?UG"1;_3*]_Z*,+^C")=%)Q^FU DY MB^H1)ARL10]-4AUG&&X6WL16;*Y2>;EBZCAS5(>("W4EKM[UH.[V8V!C5(92 M2?T8Q^10S^/"5+KG/BXQ6NU4YBX&S3C+(D%I,3:-^S'T5\NKZS97KGGYN?CS MNF<#SPAB@@M<7.XN5\#4"L"=O*@GY *'PN3O70-XQ&&LO:B76&..N,TPKVH2\,=9R6E49J>BFAPN\ZM&JDUZ1$> MDNX)##KCEJ4;9)N#TMJVECL[)>BI;WU3$)#PAAE]Y-').>XRP*>B*G M[N-"YUP/.\M!F4GT6!<\=7'!6!\,+#0K\' -UCXH4,7S8EYS8MLD H>)=!+[ M&3?SUP'6-0?5K&EU62N#GQUA$1.UYGR$LN>AM?AK]D4[5U?!";/Y"H3^3PDF M*R$P *Z0DYDV'*^4*.:A!*I2LKT+\E[X'6<9&<5&_-:;$')!J3[#.S0[GIA" M.>"S. 51 D^!E5ISGDB24G5!1MS%L@PN9F^?4?"M8*-?L*ML1K(C3HLJ1];$ MWK37>9;0O?2!W0 L&RH&BY1R6'6U06J["#?T@%"YE;PR[.G&J?Q^5.IIX7K9 M4A:=URV1G %HH@06UA:KE3 M"(2=*209R4JT!F8)@&%Z.!H$-#>T7Z)#:#(^%Q%#K4&53*Z->LFU[19^DNMKNA0[BD8%&!>;FTQA]%-0B"HB^S@W>1;H.]13% MHY'."8PA18NDD^AVS:Z\@AM.?0;NOAD D6 %]B=N!T J42+&X74+^)DM74&8>X@@GK M*M$NC>(+!;#T\A8U-*,<<]9XC.^<)<:TIE +G5JH='3C@\"S*1+X,,X[:G#, MF@M@U8S9)[=Y^_\OGMSF7RP=O'31>N";6)63?RIE^F,B8\WQRSCCLQ<87&G* MZ5&L,R@;:':AZY$;U64]U:/1R'%TS-^1;1%\_1V?:'7%IFG ^8J.K^.8HX5Y MG4$MP B#8P@Q)A9*$@?Z!*^F\@8TG F[P_VD AG-E Y<.(=O.-.RW&Y#EQJ( M\D66A'M6$<@56G.*ST!CNGM9LK+D7Z:3V MWF/S()K;[W38>J-J2OM"2S 7^YJ4]KIG@Y%5@,0X(,UF4+=YX^_V\)J[@WJF ME,]0<=IICG8Z,O15*-XSWQYP?0=0ZZZ9!(8 80Z)NFR>Q5@U,$WC40.YO-T% M18W1VU,&YF=\<>. B%'!C]04!%^!56N%K#XHG3HM=-'I"VH^@*Q46!U.)P11 M6&'?Y6HD&3I#7>,E%!U=/&3=:GE3"G2NZ./SD7AYM8W8(\539%5YP?65GLY* MYS&8DXG) S_?VN];!D1'Z%%*VG$2G"*S5-I"G6_OOV+,!9/EZKMS\2+CSI30 M%77T8)>BG\CFH"Y,)AGQ%I$6/AH,'H.;9#IQ4R"U*#W$$*J0P"^0L^L%%!81 MPJ-?]_"X\(U1>C63N4(K85V@<4DM'A#8L+W.7:M*=\E8=_ H4/=RT1I,2YZ" M.Y_@,C<7ST+WLI?2GU3[9=KDT+KF(7+2]N;>%_'2,H,I'6UQG&N@G?79[);3 M@!1D-T1Z7?/HY$Z:FN'(86T@;.KM+6YHF]- H&]QERO_%T& 8IT;\@G.H6W( MP/MY!1ICE!W\6$ M_UL!98\D\)+Z[CQF,G+:=?(9201203A%M7._K&2,>7CI8VUXGM!]7XKMX M54'R]JD6/2]KI$NT!CJ3NC:UH?5>*@Y ",6(AA&I1/^MD"&*>:O?A)YV//.4KWM_CL>73X['KY>SM/O 5B8S"D^RAVA??2$9/W]@9/P>??4%JH3GXI^7_!S.\#S5N*M2I <7G1'E M\&_O]5AS"]P#G9<$P%3J)7/!)VLOS.E*7-?473C?)15(JLB<[%.#4'HCL'7- MD$5?A%,/K,N&:]5ZOO\7IU5C0E034.4M[?8DVDMGD:1H.$NCGI_/@KXJ#/'@ M7S.2"/#'.(;3!OZ=7,]0@PY->VFG3@,7(X,3>BL5.(84D657+);_!)9.BJXP MA>E17Z]<[XIL\O7GDEGLEP$Z%;YPM="8>HU]"[ISW PB']A'CA0I/"LY,AS! MSK+/B/R=7]OT15:L1ZHT2B^$O>=6Y7"V%NT.HWD=4$@ MQG$+G=2B2EV)(=Y6Y0U!P<&JW*["(SP*]A[84<#4W.@,XOFQ=5/%79*,/[?N M"-9;IBK2[024FM>;+BEN?C,9G<6X]9L5CNF[;Z/ /7#O D*0[*X*-\&4[@% M#RDR#2>&R'"4.LGN#]_?B9X!E$(C1%"TG3+)3-0LZ)PO%5VFG)K5ZI@N*-_M M>_P7E'"Y?3]2)!VWNP5J2D5WO]S+V68,PRI+JB]4C T_?LTNXD2CU#,OGA@8O8X"TZ9%,FSC^FXJ,*X9KDK(%Z;RAJ'&UW!79<1Z516IYFB MM((OC/I"PLH6OX?VW3U_I8.I$+"D6LE8K5L4)9XW O*H:WGM$UR96F<85I1G M*:L7M1YAZ!2E^E >$X<[:/G 9,-[JET\IM+-99>]87R+:RFEE-2=:J;]UKS,A@C3 MMCM3AD+4?X1C?M$IUJG!SVQMB+]JEH-B%,\X@B-(F0P7630Y4+#?2;*(LXN? MC8>I5KDD!M.HH!Q@.55"R!YX]C?&&G$3>^$T'1-/"NB/1$J%3\TCBOI57/@K M:944QT/3%5/<>17H;EE7&DZ6U6M91E4&G'R);TUB$Z-B\HD5:1;Y,7+U M0^L%V0=B!"WY:LD,_<79%\Y-96G6LZDH$P/S'[#2M,L^$ Y;4%QVNXHRQ6E@ MMF5JPS9YBERU___J*7+UY?#%PL6&+QRC^*F AM>]=$";CRX-0ZR+SU0A"P=X M=21^ !\YRW@@F3MR/4IT6#JK4!X::I-'7WC3D\+*&UF3^SW((\AH1Z:Z-@=L MO="P.RMJ?J*?BT;5\T%LBD%K2DTS&NQ[;"*8T-&*L!1Y,P60B]S!=I8SW+.U M^<2T(?BFMZ-1?4-'N08Y.4QBS+9Q%5/=4U6%\?O,F3'N88C5U5ED30!#!>NB M$G@2S-"0J5BUV1ND:;0E]?>K LPM*]A^:.VZ?K%]B-X#@2(!_1OSBU? UK=Y MQU*Q4^OJBC&*)OYCM];/'CY7V498.5CG+>ZI++W4P$D3_.X#6*@JG%28-%8$ M:\;1QA@)GM[!GDZX@0:SAH'-E%IO!HP$^L)$BYIPHYCV/U:E47XPV%69K$*% M"'V%E#0F' I)[2VUL::E0 MBD0-=2A7?\G$%6YJE5BN^J6^-D,J^*."'8KB5@QU/F$U<$3HK#$D@"$J0[K2 MJ(@R(Y-K6@H@[]JBK$A\)$IK(X5L6& M7D#XQVE,>C(Q:3T#0C%:/56729\EDM_^R?:8]*:Y]/K04 G/,$ H&4FKD&!7 M1Z5J1H=;I%OP]"5C)^:"/JPWP)+=+*^-P$ C-N G.7D)NV!K23I5*CH9CMSK M+AE@7071KABXSSY&F 8G!M=0_!(+ V+C$[(*'P[^"#GDH6'G_::P/G>YO/$? MJM2!*9%OT?'')C^11[8T\7P9D MW6K!L*34R<48SJ.L^S) =UL@E&"(=@8A(5/H9KM^]%;-3-L%3LZ-T7N[\_?W8/88[]S1>OOBC,8;KV$6V\WMC9 MKO?M^SI\\.61S8\?!\>'1_\WZ,\EX;N\6#,?!8= _ M/@Q.!V?G_7/XL+.UO1V\/SG^9>-\NMTJL3 M?H7G!::D>XG\4F (@4S081NG;=!9QH#$-"7X;NMO>'[L #\8CYT[P.8] 7$G MJ J[Z.Z-?.<>F/M[F\]))2JYJ, (28PA82O41,T*_=K\\0:]PHFZ?AVGM#)T MTYNIRN'@W!#)B@@,:#_%H4J$CHFD^6>1 B]?;.YL[Z$@*&&F960>+#)BDV3$ MCV74_NWYJ\W=W?D_;VUNS_UMX;#[F\]?WF[8'VG*/&U8F +T]G\^VWW66#M: MW2W$H\" 7QP%AC3E]S*;=?XLN_-Z9W85-,0!#ME5I'&I"5G^=8OA- MOY2D]KN6J<6PV>Q;K=R6K%R7N$,Q1K:JK"Q#(^>@C+M$EJ5RY#VLWGT=3K2. M+_?*2>"1(0;:A]F%KJW6"A#A:J\B'LE/]-6U,GL-^GJBJ[NLWO837_WW?VNGZ/Z?",\$Y-5$A(P2Q9G4>G%(#Z2Z)?WX(6F_;F7 M3/MO=-!T^QC>GIR=GQP'9P='Z%)]=W00')R_#H+^;_W3PZ#_R^E@\ '>=>7G?SIX#YMP_ O._^/@]-W)Z8?^ M\<$@./NU?SH(/AT?G9\%OYSVC\\'ARO_+A\_G9Y]@JF:O4 "N@=/_TVON6J$ M^IB?C4(U!,<"#0(IIKT!4T$AT9 +@(,8;+,8)W/$UNS8+K0&G8O+]E2OB,T## M:7O(S2 X4#/*9<:0M&@_>\BM5)U"#7X)HB"TG3KUCR^/'>4%T7%X")7[ M-;#:"5K.+(%MX$H=T>8W/;,G!:]9WR&+U[LM%+ HZ9C0A+'>$"C"@ZKGII!8 MVY2VY@V_.6$KJ'"4:%]D5QZ8ARM@>^DN93)TW?U,B]\,DGN.>46(G#'2?\^7 M2H76G[EM_"RGWMSPUT@7!:7P49DNECI2[?0DNS1E?OH",<%((L1I';B@OHSV M<+*+^#CHNWL3WL64%VFKW;D_1@@$_Z=.!:L2"Q/+AHF/26E"4_H(2=\EE%4=I5[-I MZ<#1@,OOSC?]2]NQ^J=W]XJMJ?4E5NK48^([FR]Q'2Q*"YS:]K0!KKL 60VG M6 ZS:%28]; _7.SW=<6CQBK4="[)233-(NK7U3.0O=B^L9BQORUS#: FU0*=A)V57P>OP3PG9#Y2E445421,HN) Q MU2/Q622QKJSGN$=(T*A9\P1=6P*CW!JT0U643Z2V%JX2J9$P0\L=CDVIQ6YZ MR1J48'>="\=[K*4/K4=I#AAT34(1%3QJ(HA6B0@6RAN2(XL]9SZVLL@9)U#J M*,!##]J)"Z+16.4B_\:ETOK-RJL6_C";H[9YN@]OW$#BH$NM9M[-X(HFW>H 32M,>>L/\G"-;U*;$"RT+AU?$7.(WR'W?ND M.-$.CE9G!Y]O;NT:0>8:Z.5V=W_6-*-!#\DVW\:^K0VNPP:Z(&V--DJJ6QJ6E'JZ3O"=*'0;!,T7%* M6K&^FC&8J4\0Y';UH?M"E815XK#[&%F'^N?F KK-;E.O'RO\$L&DX2HX;4!/ MFL9%@7H\$.A&-MHP)X8T((:W'&9I1<[=!/,JS.\<".T%$TR052BCKGN6GLFA M;;K&4J*$3D;XLE:)Q[,IABU3MM5Q\43N:Y/5)'?1P&NMD>?3/5J(58I.I!2] M\\8/;P&?0I5*! "4L(C[+[Y8A\7(LV",%'QE#O@ ME;%I5BYXPU9&87,?-55C;5"U"$.4L4*QES<15 ;:<&P\HNZ\;#7LU ?UNR'J.Z+\WWVIS&\!/$CXR.O]2BS+63(MEL*(*/"M6 M<@%1B%Q.&)@'YLL*E@=(90*3PTQ27^"&I2YK8[()]N@"'JA2"VB7@FR-.R>Y M]-5>]W%5U^(.#LY1I(\:$"I>YQF^S9Y$YEAATT,8*&1CV)%N114$P3;;Z.:/1U0?ZS> 25]YUPN M+N%21NVV4:X+C=>]XR9MOJG,$\'-U^B-ZUD53ZTWOI\(_8H$FI_];!)UK%G8 M$YS3$-LYA;9=6D_,0M:-T+>$(3[":XPTPT$RFKO!>'2^QB=S;.WSZ@@Y8XXU M/0">_+J;:FRB)E[*EQ?6579PTYM#)!LY ;#?%S7C2@PMD<#DQYAN*[Z"2^"^ MK;:$:YQUS5)[)!F&J'>ZSBN^]M^A]LW5I(0;G$[HK8M)7L3GU>#S&5C>O"O? M(0%OO[=@$&DC(=)!"=!HE6%UK*=6J^([X>>"WR-+=ONMDN MX]WVFVW6Y;AV#5Y<$O;/I2C";-([=[S%,(T1_R!DV[S/#1/: MC[F<$)X0LA]G"U]0.W5UP9#$PP*SV]=M2]%OD2C4&.KYYE[G6"MSC"2K\AN4Z]NZRU%0J$1) MOC+)%V88UP%W[>UZD$K'ROEQV+09B'6 P/"1>NS(%? O+'[J2G((AWN45*$I M)3 MRDFRL*N"4[C#:[L,GS;/-H,(L1=S+E2A,@77SJ'FB;75,F)5JRFF9091 M9?.JF[V\L;M*XO4N\L:@GQW*-RR?GF.M>T8Y=N1T8\[/\Z_1(DF 6[+R?8J% ME4L-'6#;NCQ+XS XU EBLU-6P&$6$I#TDB&XS^NI[8OR[4.2!WBLT5MP-RGS M%JQ].NCLKJ)?)/_Y21Y G1*(X'LM8PQU1_$PW0**BW:KBY6QA;3!HX*UHC05 M++:[DGN\KCV\8R3I?B'-FKPQ3 H;:U9V >I#1&:KX:5)EY 98;(E=L;CGAKS M)U1.\JP:3PB_/-W G2,YZ!Y07,-@TUIR**=XQJ;*H>V(-F4>H$#FD73PM=U[ MFS,XPLND(I-N\>H M=9R)CH'H_+FZ3.$\0DX9I&,D>^[#T4QJ]S6;44P X:[Y#ZP''C_Q);S^GAX MYD';>".E?Z*B6I(7QX1>V0Y X* #%]3-_S89Y]UKD-SG6V02A#V6)2QE"7-O"?T(Y9174M%*DN>H:7S1C#VISE54 M/6,+]0*&+*@U)D/H?+ YR8IMVKV2^$ W]XE[CCG/8 M&34#6A46K48.,0;#R6M5^(TBOW2RQC$D\C-DNKL>A.[>F8RD(#[6$F +>:'!>6 MAV@<)2#G96':"\A=S*]KVO::=XRBT\TL?ZIY2Y"OS,(/51$7W.V7XO)R:1G/ M9O!0/SF5U)W401W"(21R7%B'$&QJP(WRU8;U3<&XRGRFS,J:PJ0 M"P+7"8PR :Y-1\.FNNCIQUB9@ESBJW:NW7IK8J2#87D=ZGN\A\4,SCR'-P%$ M:2$7"@J6L!X'1 *GXGVI,]]:D[BAR]NJG,8WU#\?S6W=)L7/UQMG!NCBW);W M']CR_N58R+NKM)8')Y^.ST^/!F?!R:?SLZ/# 0$+#CZ=GGP<](\1'_'D.%@3 MV37X9#'9Z%!VUPT.3HY//AP=!/W30=]=/^B;&WH$M3@X#/YU=/S+XT?-^GL^)0E0IT]_A"A4OM*,O! V/<1IF@,]')Z2EJ)A!@ MPW;&3/YDR&;0=[D]\/N_8%.BC')7ST!._PGO37ZW.7$0/C#TG%Y+WZ67BT9\ M3=B#X2VXVG,KZ2L\7.-2^D]7J9H.XW&551CI;C2NQWY2+%M["&S( 0]!JR'7 MLN? M/D+J##U;##6'9@1$BVIF0;IL*-5MKA >"0O/CK%U(%8)05'MR,,FV!" M6+/ S@L#U>%G2"NI)S28CO8NWBOQ)DI^F HH)N6=*2E'U;EI, R;I,;XX:^B MA#UVMO5BVBAZHBPGQ;%#]+5;Z"KH8(60<;T@M<.'W-@'$F\31F#]DZ M;QI0OL:*& Q51A%Z47L!=LI,S$>>!]#X;((I,=SVK:9J0*4SMS+Z2%D)E0[!*B.&\B)X6>1FT"OYI)G=PVT%?V3#@)+Z>YW!/DQ+D40Q3!\J@/D3*W:=S8L4$9 FW['N^MR?6'?ZEKW0>HCK=HQP8_+=*^2]:HJHD.I!J2=J; MD;K _&71&_"\LYJ&8=NYS&I9D^1$C7,M6W:@-#TQ9C=CDK(AMIH/5=8RA]&T M!,J'Q6YX%UQ.K]TH*6Y3KLS?Y(S1[M6BW;AA/D>W&3KXD.5C,,'/8-:)O@[. MIOC MRI/X8KR^M,X/L 6M(+KFS,!T'' M* IK1EMGW+%TC*YX7$A:-J_3W_L;2PR* M;\6S6 O\!W[CBQ#,H1&4%]^5V/,S(VNHW3HI-+F33=Z1L)M[C'BCK3.:M 5% M^7LF0$7*YXPM)N>=! NBU,XEU7)N=HE#X[,V*0F*O-F.=5&K$#\2:Q%\.%(Z M4T9-MT%9F+-$G)A08AZAT2PYY6A23;E^AH!L,=J'45^6HQ<+)1:,I==V>TZ4\*MS0>7(6(S47K& MO4U&%^J'I/+ZQIQA80UJUO-?4%$=TZ^'9((S@GCA3Y3 M"&A\)]([305[.&3VP=ZD%*&5^WL\5S,0\KX#03_%';RXPV]'Y[\>'4O8P7<0 M+PX8W$$%NL^(P9(6\?N(&'2'"E8L3/ %U++"NO%'+RO3B[?7O?7./I+># N= MM!)@P'S1T;7IL5#?B]ATW>"\ )*0'\TCB4;73!;*$%NUKMNG^*$(3XFI*<4+ M5&&K_]6?UI@//J@#T_!F2$/I '.;29KCIC$17R$V6GNBQZ :3:G;@]/=%^V! MSV3XVQ"JF,=!YL: M(W3A8+="5W>86BU$)9V9[L[A3_FHWY=?;H5%^9VC:9V1-"PAE"@5G01S FNF M40SW1YD31[M3X$Q2UZY-5,P9')*7UAT]^YJ!L*M66RK2KF^B&4K/!ZA'1)\A2GS;F]H!",JJ1GH'R\() W35.7 M1)M"\4*$"'F8I2,61B1M&#;:B"^_++O EM\ MPTK"6T=F5& \,T'F\PTBE< M2*YI?'Y=3%E=CV*-\9_&PV%:22"9LW OQ,5'E$U#=L(1W"(XF\WT'(V2Q:(B M&'@[HN<$JZ&9X TT@_MHKO<],,3]#''GS9D$S<-$)G,O>05_(8F@*TO@Y@R!-FS\ M38_^V@D$YW0:>>&O=K"6/3&]>4Z8GN^"J85MC4@WX8C++$^H10VJ 44[Y@O3 M>;L 1+W;]UIVO< =XVDU@KQE8,V7H?>D4-PAF-4R7)M1+3/-Q>X 8]I3L,BA M2:"9((&BEAHM&NI03U0R^OK!LV8-L1=\-'+E&\3I._PV$&[*I5_B@#MF)]-\U\1N<=A9I$B"+8BN_/6U?G+8?/\.FX>K*-9;LWEF.A@5MIBV MD3!@4.M.6T^'O]8S#AK7 MDD@ *\EKKU.[PA,+U R^_3;LCN[AB<2XRS4H!-79']IVN5L\MP+[("2$NSU&KEH,Z+D@V.LDKQ[V<%G5W(#KF+K'/1,^IH0N3 M"#"H+F="Z[$MUZ+?'[B6/^"")QSFH=0)":WPW=FH,/E_< M=+:B.FVCV^!=S;=Y$I MNKB]^VG_^&#PJ!;BKS= MG'6)2-CG4^:;;K:*'+O$)=Q8F-45% UK4QO;^R\WML6-^]]-E 3O-X.=G8WMK8V]??K>?GZQ959#G@("98HA M'42$S")I]L<->!\7D]V5MCZQ+]*@0JT0\MK=(-@;;HM? ] M+@A%BT*?P$56(MY(5DT4; ANQ-]_V-G= 0T+-,0@1#0@\E9@"#>8PF[0""4^ MQ-L$^%QRHV-KX13X7+H.]P,'W7T3\3]%D/ ?8U5=(4 C;E/.7P41O#L\#*8O M7P 5F>V2;S!H!$HJ?R+_ M;'"VM%[ 5@FLZ5)D$:+%WK?<>76[[CU_88IW>K7]^B*%Q+/+>=?_F>>:N<\? M5G_+GV_O[3W?W=]^L7&Q]_'/=_/_QP]N3+NV]?WH_#++J&?R;E-/GY M_P-02P,$% @ M("A6"#-(@6P/0 )Y(! !X !E>&AI8FET,3 T+6)S M8W@R,#(T9W)A;G1X;RYH=&WM??M7V\;V[^_WK]!-5\^![Q(4R).DIVLYX*3< MDT 6D--[[B]=8VELJY$E5P\(_>OO?LU##QMH2#"!_M!@6QJ-9O;>LY^?_?.T MFJ6__#S5*O[E?_W\OSK*[\US!%X]'NU'\_$FD7CP?_;[]"&Z%R_F>LKI( M];\>S9)L8ZKQ^2^?O-C<>3*O7ITG<35]N;VU]>,CNO27G\=Y5L'S"KB?_^1A M.H-5^G.UH=)DDKVD5WK$MYJ?HSS-BY<_;-%_K_"7C;&:)>G%RW^>)C-=!H?Z M/#C.9RK[9UBJK-PH=9&,^<(R^4N_W-Z!Z=''XHI4:I=I< M,\J+6!<;L+*IFI?ZI?GC59R4\U1=O$PR6A^ZZ=5,%1/8[U%>5?GLY5-8S#-= M5$FD4ID=391_%C)XL;7Y?&<7*:&"J5:Q>; 0R281R4]5W/UM]\7F[M;BG[/7[46HB7._//P39,VEM.7)OV2_#\'WW%??MZ!/VD MEZ!?YV659\%)E, LDG$2@=0HYGFAJB3/6CSIK:>9IAGK.=//TC7>PA5^]'7& MN87]_=8[]4'A5!-XP>H?/SQ]\2H(?OSQS<'QR>GOAX/WPQ\W?H3/[P;NX^+- MNP>+-9S-T_Q"Z^!@WR[6\/V'=T?_'0Y_/]@?'IX>O#D8'M_T,O$[MQ=JEL1Q MJK_]2I"(')RK(@Y.+^::%^*#+L9Y <-&.CB9JD(''S,XT/BRP:30FA4"697[ M138?4I4%AVHF:Q4<'9Z\#3X,C]\<';\?'.X-@Y-?!\?#X,/QT=OCP?OO6CRN M+"GO@\)K>?KHP^G!T>'O^X/38?C/]S#"--C?#X/_PG__])G[^]J;N\96IWFE MTN!M 4>7CNW>G1Z=#M[]3AQU\COPT^'I<'^)0/Z)%,V54*7Z;8-@)53[5=GS MUT'P 1^V>]WEN3NOP\P7ZT@4XY=U!K817O7HEP.@V\/3X/0H(!K^ M+K=SV?MWC\>/AP>GP>"WP?%^,'A[/!R^'_8LR[*7O^;"_%&78+I$5K.%E__CAQ<[.UBL2GG+VP1?; MK];# ,8?Z>I\;#]K+9W 077A/R>#: M+-,177J>P"SQQ'L.&Q@%\UO"BY52E:3!5,#*..=,J0[^:*J,B&>$0>%V5XYKH M!#_0932)O,!O\>-1,8';(J"O*CA1*5#:VR(_AV7KKM2'(I\4:M9\ _[.O$0 MM]"PK_J*Q6Q46P';)_#U<,U@Y_@G7C6"&C_GW9\V' M>%/Y0 /;15M]CKO20;N:0F%[<]$OYIU62[BSV$'*&D21GE=$,,#TQ/VW-^5' MOP!OGWK2!?D2!$X"Y!^!Q"@#E$"*1!2P*TK':JJJ(*N))99(+9])Z!O+AR6P M,]P"?"S"HFH(^,:=M#R>&!JJ:,IV=J'GA2[A^M*7CGCI]O-7)4C:V2RI:#P4 M,V59:_,")<[2GAY]-P+7@V2-/H7!7!7!F4KAYH\G^\'6YM8VB@\>(EB329[@ MM4[.E_7H#Q#R^+@(3 N%,@XX*1DE:5)=A#B 73$D"!*B>#3$"5)-V5D@V2(^ M*&"I$E!?2+3#$T8ZF+ Y$,SKHJP5OS"."U=Z4\%W9<&-OWE/HW5H; !>0(*R MR,^2TETD MK\+/(59K=0C BE/4=2G.\O=HD9E MGM95]Y:;YIFM*_',QO;.)IP$.XM$T*+_LQ>$EZTO3,/_GQ;.ZG2Y>:'52LH6N8G%9X5'K\B M2U=\=0>WN;K,$ V"C.L"[6/2 SLF<-B0]JRNED[J.P6<-&<2V.+58 T=# SB MO\P><]UG(+NVQF&G VC$I.['_AS%YK>6/C[IO2K F-A^:IX1J12>" K_A8;_ MC?,TS<_-_4NG$HQ(C $1 =G5*FT>5B@P4/$F]XB\V3@IR@H7"&R42J-_1%?X MJ.9#>U]Z:(6)(U\G0_J$1QAD>6?-T4>CJRKEW?25BG*]!N$61JQGJCQE,72#4V3D:8; :21S7<"/#MA6-;F,Y^1Y0TV $G M8SPZG5DC\YPGQAT*O%CP2L,5BOT,TSR-V9OBSX$\Q##4W%-)NDN216E-KDHS M,%Y:Z$BC5Q=X"%\7A"_,]2RO=-\@[%%.+W 0C?X5,C#N'Q,_O6-,O*\5JBY% ML)^4BM746V;: V8I?49N-_03$O-IRB&B@\9&/0R1H[>?S;\RB1-5))IH=3 > MPPNQ [(,F \I@!&S'R_NOGNP)CR,5^-=)B0AC&Z""]YIS$I'FL/)'Z3J?#V\ MQB$7=MCH'J@?]TXF/+MC,N$8-K)H))Y]]Z+ O7) 3M).P.Y)&(SJZFZR-C(U M^@H*>F-@= Q5?T-K ]4P%^MI+PO''V1-7%S:SG=@S#U>/&]FHPM=5XMDR;IQQ#8]'W6^.6B\L MV P(>%I:J@S.\^)3/[-N M"3OM"TLW11[7$4U7WAXOI3_A;WRST;HA, K2ITT_AIK!?,"V@QTW*\EGG8I M,,1TC64Q#OP8,K-QFUXF=2S68=DNQUFF:L;0GX9>:H/=?YC[6"C3A'9T0X3BF/Y[==L'SJ+_OX%EGM?%/"^UM?"-S8]D9@*F;F\D M("G+C]D:;"OH@(C-;K/XR=I[C=D2>ZJ&QZVIABYEGOH<";3C;%B_A\% C 4^ M61AY^@Z#@2O#14"C)"X5VLDP3Z9F$)[D121M8*39.,8$*4H\LL[%"HT&^LQD M7])=4Z!VG0*-L^=KL3"T#-*57M^%ZOO\CJF^1Q01/&U*M:';KXV-H#^J>LN: M\KVSJ4#'6?330?<.W#)/-2\(#90":V3,:[$78>'!#E>\$"THW,38]:)?@.]#>Z[PN+[/K8)WL MXL)O<&1,IAS&9PTT5:!&Q^IBE6(*MWZX>2J?U=W/P-[ \ZPWBME)I6,M7(_' MN/OH#L;E-[J>K_]Y)AK<:!++VCM#MRD>"M[I+/%-C$6[O89.^SG8:Q%6G6 . MWV%>X5UEI3C'%NZ"::-9Q&85DE6!MD3+<==^-Z2?<6N-HA3X%;D.;USXNO"= M1[!.089W!JK@W#I,9H'7P;SINLH+>C')#4S5.2D4[._W!YY_*UKE@S"!F6;5 MR\?/YNTR_ELG7C .%@GY@16(N.;S0I\E($+2"PE(@A&,Y)'7*"LGDGAZ/M4V M2]RS@C?8%]+A"M+B1IC/S^D H/FM.R*/\-8TE=QXSRJ= >TCT<)<*--*-ED" MH'V4M$0)O/[F?1$1H%FU:D30E6!-#C:5$KB 37,5"P8NLU"E+F*1(@\40&9! MG5J?4!Y%=5%H"=21M.(?K"+=-,\WD"60 M2%Y=7PI\,V;?7N]3HF^9_EXUEG!G9W.+6(3("$1.JOP4H78:^%X>$Y&@F4!N MNB+HWDA1V@*=JB#Z@NL=W MC>JHHJ4LK>A!39S"&X6J8S#F9B/]UU^IJ9%,RBG8:O!60CKCJJ_^D :.ZTI" M;:)P1_!MJ7N.W ?"N@)A/;EKA*6SB9J@S,+@$<@:F&9)Y(!)2^,:E#'0=.08 M),D3H;Y6@HY=S$BH@5*7)I]0:\;L?8H9\&]BT+7/UA&"K&E^!JI3A9[7E1)- MZH' +B.PIW>-P-@%'P%-3$"E1L$3HB0Z2\C)GH^)B.:I5N0.F-1)RF(KR\D7 M@"'6*F='VEBGN7$RF),T*N U@'C/\O0,!VC*OEE>J#2HP I)JCK6UZ P"E3] M3>W]?L:Z'M_=6->=D@#/[IH$&*LDK0ORI*!;O5(9)F+ @2&^'%9N2RSGQ00- MHY%T;?XUS_->UJ"$FY'9T*>L%G3OTWW.)Q\&/, K;&JR-.62;Y:)68V,8=\S29"U?,.(!H3F)$J/(.1_*))-&6+ M$9A@A,P?&C6>TWK,;\Q$79=6VU\OX?$*SU3*4.].YINEV?D.V<:X/0MTS40Y MQOGMBSU1'A>ZI2,=FVLXDI#)]W>>Y'P^U61]A]ZY7H0')+]GP5!?YW(=R??G7A_L!EWZ+P8#ES-;A'+.7M4-)# M#>#8'6._/GVK2^#8;^Z-G;O^'7WCMF7Q_!M/2>N_X A7Q 6MVI2 MWCN"69(^NIH4,_RLHYJ2YIR4:%/1;;LE/GC8<7TAF\+-5Q(=R*"14^=<'&D8;36R-3=N M,7YX72)>2-S;"XG;9/9>*KU,VB]N5AEPCBVY3M%$Y&S=*D4L'B[O8U-.6=!U M-.- #O6 YTQSALH-J'@ @<3_(F*'8?_(1T&JSS2%AH8;3U!>#C>>!FN25J#_ MK),S+-FOY#(V92G_H*XPVM@:< QGG\8J\B7QP0:%;&^]N *)T%4/Y+>0_'8N M(S]1^_XF]7F5"6OH:<%J!4N1ZRV27,& _*-?5I=/OBN3^2K<=T=X;>WQ93QE M3+0FZW 1!05[>-]-D8U5)NL,JW2 62CB=_\TQ"4%4:NI"7(]-00,OG0,ZR@]2:LRC*/$I+1^#::7/_FRGF11UK')?]$ M:4/H4_ JGUM7*<: M1QOO(%'?PKV4G6.9YBXJ#@PG9@I>PF8RUY1Q?FXT M-$Z:N)"U*QME)Y+#.DPR D8$(T6;]RCP-.)P#$S'S9--O+(&2L:H#[ZAO6K/)MS;Q0';"(ZQHL9>-)4'/6E(RI]QPC6)?+&E M$OZ(UQ=Z4K-XA.,77IRF;D(<0'EZDL.G>R@HHX6"A>"^B$1%LV-*94\2PD_=P 1U MC87D(*W*,;N1'7Q[H>%4$(==SP/-BS2?VY2X7&+<)X)U!NP?-9"9+_7'AW]' MF%]3A,NBDPO35*19B^H>IAJLQ7=-4AWF&&@6W@1[V$/+N5TQ=9@[JD,8AZ82 MUVRYT'3[,;0R*D.9)'U,$O*G%TEI2O<+'QD9K7:JVQ>#9I+GL>"Z&)O&_1CY MJ^75HYLKU[S$7/QYW;.!YX1;P=4M+FF7RU]\.>#)BV8F+G H3/[&-8#[&+M-7O39*UQE(AI\HIY1;9][E_)L/V M7>L&>>#U"U@5RC/'40,.*1_!MBMQ%[!NWZ=CUYB7SKBB<"^JT7#'246YDZ9+ M(MK:KA>K1FI-0\)7TJ%@L#/(6;9!9CGHJUU#N;=-@Y[YAC?%_PC[A_T)4G)* MA9^>^Z+J839W*UKO#!UG+1WF.&/6D_)./G4,FSN@(!P6]^6_>?%)1C4.A1#; M[6[BF/0<9TS0$SE?'Q>ZX#K8>0%Z3*HGNN2IB_?%NE]@H5EWAVNPWD&!%EZ4 MB[H,VPX5.$RLT\1/LUF\#K"N!6AE;8/+&AC\[!@+EZC9YCV4/7>MM6"[']NI M^AP<,9NO0-3_F""_4D('X*HXF6D/&HH/*=@&1,'?1? P%(L-]JVW(>F"2GV" M=VBW6S'%<^D#>P!8-M2,+"GUK^KS!FGL(MS0^4$E5O+*L*<;Q_+[ M0:5GI>M.2ZES7I=&\@.@=1)8:%RL4,*,(!!VIGID+"O1&9@E $;HX6@0X-W$ MR&U$NBS% &-WK8&;Y'(H>5Z/(43N6MFWP&9\SF"CJ,^-Z?TKIP+<0 0.&PFK M4 ING/&E5J"K5\:9@L_IOD2/T*0),3$TNF/)Y+H0F5P?A\>"@:/S[V,?,;K: MXIPCR9RUA1719&!2>72[1HOS'TV\M6-SGV'5MSU" 9&QQ58&X^C=$]0?VI@.B;W.!= MI)O84@[XR01!RH908!G?W/JPHT:1_Y0PJEV+(S/@H(TD40[6@R0;8&TGZCD@);;'S25? ?ZLU=UJ2( M24TT"$X:O -F\&!P"': M4[]?/E '<8.?B<+=C-([K38UD"A6IB$Z'-Z780M$X--9T(,3*& MA;Z+:;+5\5R>EK4@9Z7(=?$P.!$B#7Y5V)R4A2A5XKH^#$!KYICIBE=JC-SH M_#:N"XX"HJSJ5SEZF4 1P@5V1>[&/II!C*1T;=M!G7J-^A,B0IM94BY]:R^: MD1[T)6@7$VE)DB7!#O)$J-*UML7ULN+N/E;\#E(XS3/RJZ87O,ZF3W9O_&RM M&2ECW4P*&&,07-T, ]IP,QBQ,FD$?A%:J;$RWI>1+&V7$+^)CS6T&8>P@IGJ M*M4N@>(+Y:^T$!A3P%$ MT2)+PJVR",\*[3C%QY\QVKW46%GR+]-&.6DR""YS-=VCH]6X/_L6-E5>AEM7 MY;')#^WM=]IKLS\VY7JA#5B(94WJ>M.GP4 J0&(H).LU1'M=&/IS)'XSWQ)P'0Q0WVX8 X8 80ZI.F\?PU@J,,N2BG[WFD"U,^ACQ%I$6/AIL'0.39!J 4PBUK#R $"J+P"^0LYM5$Q8 MPJ-?]_"D],U0>C63KD(K89V?246-*A##L+O.?:M*=\E8U_ E4--TT1I,YYZ2 M>ZC@,K<7SZ+XLG_2GU3W9;KDT+GF+G+2]N;3+^*EVPRC]#38<4Z!;JIGN^]. M"T"0'1#91<.74SAI:H8C5[5!K&GVWKBD 4\;[+[-7:[:7P0!BG5NYR>HAK9[ M"/< 1XYL-0'GM*P.::Y?PJD>&.+REV F:L?!<- M_K,&RAY+R"7S'7G,9.2NZ^4SD@BD@G!>:N]^6FRIH7>T"NR>X#9IIR%@FGX.U9^L&A8];?>E@;7N=P'U<7>_R M507).Z "]*)JD"[1&NA,ZL(4A#8;O3B\(!1SFH)K4A%14II"DHEJQJCW&+X. M;?\AC :1+TOJ'9S'%<<^(Y=SGX%@E[;_^CZ[SBM;83D 79"@U#MW[ XVSQ3RV6-!?B M/IZI(I%HH57FRV8EN?):B[7T'VI'U&F9ZXDPQL7'9-$$E&W4B:VL8E!7NT#2 M.,W.30I[KBBOKGFL#!#4X<8Z5*[*669,(61=^5MJ(AA&I1'_6R!#EHM5OHTP[GGE(TKT1G^/S!Y_CUTM4>GS'$I4.J&*8 MQ.L!V6&WG)KTWU;FC+7\*%["_+;HG.]/ 4"!/R8Q9M_4UFK9DSTX2^ 5$-45 M!5LRJDTZ%!YB=]&T^D(R?G+'R/@=NNE+U 9/Q34O23FE* \N.B'* MX=_>Z8GF)KE[NJ@(<*G2M\P%'ZVIL*!O<5-)=S%\ETD@^2$+4DX-%NFE$-8- M&Q;=$$XSL-X:KDT+?=U)M9?#(IG0<(S&H9_$@FXJC.[@ M7W.2"/#')('3!OZ=7LQ1>8Y, VJG20,7(X,33BL5-$84AV4O+);[!)9.RKX( MA6ENWZQ4[XMG\O6GDD[LE_TY[;UTM<^8;XT-"OH3VPSV'IA&CA0I*"N),1RW MSO-/B/%=7-B<14X#:;FPR2Z2N+*KSUQ(1#:BRZQB*]Z]TDR*VHRZKFI]QOE4 MM+QEE<\W[%U^D2I/<]$[Y(7_[)2XWK&C@*FYU0+$&TK:QQI=%5V?4:D4UF=9HK2 M"KXPZ@L)*UOL'MEW]UR5#I9"P)$:=6*-ME"4;=Z*Q:.NY35*<+5IO1%849ZE MC%[4>H2=4Y3E0RE,'.FD.;? Z9J36-*? >6*<1UW^CU<^85QQ1CZIV%ID'^V M.9X_DD3'\.RYA[+A^1V3#>^H8/&0ZC5ON]8-0UM<0"GUH^Y4,WVV%B4UQ)BL MW9LM%*'^(QSS5F=8G 8_L[4A_JIY 8I1,N?@C2!C,CQDV>9 07DGR2+.+GXV M'J9:%9(.3*.">#9WQH+/5TX$'.:3H@G!>1'@J3"I^819?,JKO:5 MC$H*X:'IBHGMO ITMZPK#2?+ZO4FH]("SKO$MR:QB0&Q9.Z2O,2*-(M\'[GZ MKC5]' Q@I;\^989^HL3+YR;RM*L9U-1$@:F/F!Y:9]](!RVI*+L:F5DBC/ M;&/4EFWR$+1J_/_%0]#JRY&*A8$-2S@>\1, #9M[28 V"UVZ@ECOGJDZ%N+W M"D?\L#TRE7$^,F,4>ISJJ'(&H3PTTB9[OO2F)X64EW(E=W:01Y"]COQT8<[6 M9F%A?R[4XO0^%XAJ9H'8Q(+.E-H6-)CVV"DPI5,582B*=N(?%[6#V2S'MV=F M\V%I ^]M1T>KW(9.<0TB@*Z>_W]%]83+!]UWIRO;7-AMX!@2(!_0>SBE? S+?9 MQE*GT^CVU8Z591 M$XD:FJBM_I*)%]Q4*+%<]6M[;5Y4\$<-.Q0GG?#I8L)JX8;066-( *-3AG2E M)Q'E0Z87YE!=.G9HG..&XN#@+*K2UE\W\:7,M_L)Q\=ZAF-<*1MEQ,&HE0Q! M;M@HHXEB^, +%/X0IOU:F[W]T.BO]ZS9N6NH@K]J"K7?MEL)#X6I3&5YF(IM MO("@CK.$]&1BTF;R@V)@>JHIDY9*)+_]D^T^Z4T+Z?6NH1">8&Q0DI%6(;>N MB4+5#@QW2+?DZ4NR3L)E?%AE@(6Z>=$8@8%%;*Q/TO%2]KXV\G/J3'0R'#GL M+Q1@7071K1BHSSY&F 8G!M=0Z!++ 1+C#K(*'PY^#SGDKF'E_::P*O=V>>._ M5)\#4R*WHN./IG40D[D ;")=JUV5>22?Y\[EFA*&B&<2CBAMYO@S( MNM6284FIDXLQDD>Y]E6 [JYHRID72^Z^E&Z^'@\U^J;=8MNTG;N6OXU1)]01 M0&3>ODK4H'!Q*''TRP6E'2).Y$T]# R%<@59.YK$9PEEY"03Z@]C:N#M+54^ MT<0?/?=2X"K3-N&I5#/3/^-KJU$1%H 5-TW.NU<\(G:W7_$9&O.:H_=;TB"H M6UR*P=$Q2(A499_@\L=7XG7*(WBHL%D8K-C]LF %KD02_^M1,E9;+[:BW=V= M9\^VGNSN/%?PQ>/1;A0_?Q*I%\]'OS]Y= ,!CMW-9R^^*,!A6O,16;S',#Q^&A_L'_S<8+*3>Z[Q8/Q__&<8X'T+7F'9ZZW2JQ-> MA>?_I4Q["?=22 B!2]!5FV1=>%E&>\3<)/ANZT<\.7: 'XROSAU=BYZ .!-4 M=5WV-T"^=J/+W:>;3T@9JKB2P,A'C!YAO]-4S4O]TOSQ"OW!J;IXF62T,G33 MJYDJX,C<$*&*B MH.2612H6.B:3Y9Y$"SY]M[FP_14%0P4RKV#Q89,0FR8B? MJKC[VY,7FX\?+_YY:W-[X6]+A]W=?/+\:L/^1%/F:MM:/5 MW4+\"0SU)7%@2%-^K_)Y[\^R.R]WYI^#ECC (=M+.TOB.-6/%F_PSN9SW)&F MI)$OOT"&7JLF^7DO)^%9]3\^I5^-8E?WA>!5\*D)\-$Q:#NM0TW(ZN]3#+_I MEY+4;M\R=1@VGW^KE=N2E>L3=RC&R$J5E640Y +4<)>]0.K=U.'$ZWC M]N,7FSL_-M9F!4ANM=<,#^ ':NJEIJVMS:T':KKNFCU04^_*/-O>?/% 3-=: MLJ,_>#EO8=?*-,R#WG M'"E;GCK/X?NRN_8_D8E]N>MH^\7\:@[3F[_O6_M&_^>HF*@LB6"\*CA1F.SV MMLC/J^G]XWP7P^NCD].@P.-D[ M0(_GFX.]8._H^,/1\>#TX.AZGL]5>[/!_O[P# MM\?#X7MXUY6?__'P'6S"X5N<_X?A\9NCX_>#P[UAVXV.5!Q\9:0C&:RCA;[!];N^#N8V+ON3!!HJ$8:XCH2T"Z>*^ MQ!73Q[W>X+9XPJ0>E9:Y66/XER(#M!NN(ZB6;LQ<=0N&:8CPKS:)6:06;0@V M%,5Z..)H@N4H74X/ENV54P)JQO2?<]6#X&4Q;6ATV5443+8ZR,T07J8!&^V0 MV<+.G&G*'G :22'X+9(J*$>LV!6$T[<5S7U?1YHBQ:#]/T9JI;(-ZK1-L &5 M:9NM>7QY[KC@=+U40 NKUN0EH0J#U_ 0JL-K0:<3W)M9 MM)E7J3+6X_9D\* M7K.! _IN-C\H85&R"8'[8B$@4(2'',_=&;'H*.O,&WYSPE:0VB@#OLSK@K,E MFU24*A]PH($9;'#N%V_Z/6;6 ^R+R>(M[ I%4 X$J0*6*U/8"S=T*.18ZEHC M' 2GU!%VH"J2O&;,PC H:K3DVZWBF4U)*GBEMF9_X#(@OP2[;Q&(2[L%@7FX M K:79D\F==;=S[3XS1"R%YA7A)*9(/V'OE0JM?[$_=OG!37)AK_&NBPIN8[J M9[$&D8J:I_FYJ;_39XC311(AR9I@ LUEM(>37<3[0=_]F_ FH8Q%6X;.[2HB M(/B_=";XD5@Q6"U5%C$/E H.S &#P\ Q4)#H#<[SXA-U@/-;Z?I]-"R0F[01 M4$[KS@ELF)K)$(4^4U GWPT.XL>ZM18 M:KO#"'R^:/"D.BJ_BZO>;3D'CGY.#>!=^7RO6M69K%>(;\\:T/&CI(CJ&:;; MHUS_RO7KZWV-41_R5[^.9_+6O(S?P@=^-4EE[9/-A?7_V%MOSYH<1XL,Y&\1 M*'C5%?DKYQPZ)(4%I>A;%+:W7.IPD/5U?)9>&"WT^OY,T+^U':M_OV)I: MO\7JF69ZXL[F,I879J. M)#F$9GE,G;-"@Z"+C13+.;O:*R6%--'JJ^&B'80NV9HZW5MZ=[()#>_%J M^9E(!M\AA8U6B<*V=@R)];1%18+[3+(#;8304AQ7A.=1I(SUD'E=HH#DR.#/ M+@3)#'L:NZI:!T=*0'N@)XUKHDJ:0,G%A9D>B[LB371MG<8A 3.C4LT3=%T" MC%YKP =563V0VEJT2J1&P@R-=C@VI3ZZ[2!K48+==2[F#EE!'UEGT@)LYH:$ M(BJXUT00KQ(1+)4W*$:6^\Q\I&,1,TZ>-#%Y1Q[:$MM2Z4'FQ57 M'31@-D1M%W,?;+@%CD&/1-Q$-X8@*K3@3[M#HL"TPW+36VLQAY="&IMW:& F MK3'CK#^(PC6]2EQ HM X='P]SB-\AZ3[H#?1#HY79P>?;&X]-G+,=<@V_&^Z M1!9ZGJJ(-2'L;DXA QR2E!P,J\"7BMMBW_O=G:S.[OJGE"@@^">;^!?4*K7= MZM7$"[##R$Q+AU'3%U9)%Q*D#P,JF:'+E)1B['Q/>&@^09##U4?3BU0:U:F# MTV.P&VID6P@$-CM,O<:H\$L,DX:KX+0!-6F6E"6J\4"@&_EXPYP8T@D8WG*4 M9S6Y=5/,J#"_S*8$M4[;G M\?E+"8NV616B2A M=.EY=Z\)(5D=0GBR^6P7%R++@RA5R8S[T56)Z1HN$,!61F&K'353$VV K@C6 MD^$[L:DV$50.VG!B'*+NO.QTSM7M;LH+VW;T:[JF=R]8!27*OKY5':GHTZ3( M@: W9('']-^K;P9K#4QQ/F7L%Y@O*PP>YI$)L8UR2>* &VX54;0UV10[0,&> MUIG%3,M 5B2]D[SUU5[WH3NI<7N;(@L449%.TP9,M35&S;V81E+/9S8V>M%5 M +!!?.AHU)Y^"Y)7^NB_IV=[NRN0-Y$Y]F_$> P:K<@FRB53FIC.;A95*!">$38IBFP3L%#,*]8QT$>#D3*"(HPU(QTR4+F! M+W0^NP>S9NW3ZL@W8]:T+6E/=%U/Q33!!R]IRHN.*CNX:3LA0HV,:>QB12VF M4D-+)"OY,::1B-][CG!K.\WVUCAOF07V6'+T4-]U345\+;I'W5RHP0DW.%W4 M6Q>3_H?/:R##,V:Z>5>^0^+&?L>\]CHK!P(J#FKVH'2.(OUYCCVW[*+UPE93 MQT\+Y=N.A'/?%Q,BZ&8=]W56:P6;,B/Y"D<36CNG+$TV"3AAO1U!;8XF]HX;2 I=D$!T%J1:G6DI M>&GX8/AZX+78TQB_Z6:[G'';1;5=V>(Z$7CA/=@_E^0'L\FNR66+)(&$HM9X MW?$6PS1&_(.0[?(^]P+H/N9\BKA-Q'Z<;WM&3<+5&:/MCDK,#U^WC3*_1;Y- M:Z@GFT][QUJ98R1=G6/$J,EL.B)@7@OCF_-%N9F%2_;MH8N%E66,?[@V6+^Z M6MWQ.%^B5U_5[8R"0J5*,GY)OC##N+ZN:Z_7@TSZ,"Z.9V;M@*;#NH6/U#Y& MKH!_8?$S5]1"$-/CM(Y,,KY!-B#)PBX23H*.+NPR?-P\V0QB!!HQL8AJ=>6QQN#?G8 UK!\>H&7P',&8)]) M-^;B3/D&+9($N"(KWZ186+D,RR%V9"MR1&[8URG"CE-T?3^/""/YEM&E3YO) MX1,R<34 M";3 ]4F"F9J-I(BE+ZWM2=N^84E]Y@-;/_KE'8C_6DUNNT^;1Z)^@G2KP15G MV+*RRU:*[=G.'1F:_4GPYO[&@Z&C4 L43R1E^2 4S9\3I+A'">@7D=;<+=9[!>82<,LPF2/;<8J*=&^YK-N.$ M2O0-=\E]8#GP_HDMY[6H\,R#KO%&2O]4Q8UD*>Y6CSYR=D3BZF")C!3A)X@Z M,)9YL+9_R:0V@P/6SNAQ(G Z7>JOMD^F#WUSF_KE-=5F\?>X/X%RR^15>\EL M0].ZIO*;*_%';R"0@J74"-LNO:YJS+RY7!7V?G#;WB&W M[5T]0@[8/ ]."^IW1D A!?LO2HKFO5?%)UT%@U%=:NP.>LNZ8I^D1<601 [R MOE@]II'WJ,@_Z<+& WO[>I.(Y%Z&NFN"%%I (T+KW6AV%4]D"2M9PL);0C\H M.N.55+22Y#1JVUTT8T^@K$VR7]L6KZ3.D73%:]JO M)NXU$KOKE)C$-\"Z?W)2V=G'?+O<-0?I6:$)+0K\PUCCB'.Y$PW16I45ZD>.+@62*1@5[JP ;5)5W9 RW=\QD M#C1NEBC&-!DE;!$W(]\%U_\8"Y>@$OE5*8<102W04.=O\K($?8:TQDD8'%,!. 6TV6"(M#-(M2D/"R,-T%-/WN?3U[S3M T=UFEC_3O"7( M5F;A1ZI,2FYA2YD XI'79JAS&EQ00 M'RSL1R;5PQ<;)P8DXM26QN_9TOC;L8T?K]):[AU]/#P]/AB>!$'ST83@X1&S!H\-@3637\*/%,Z,SV5TWW#LZ/'I_L!<,CH<#=_UP8&X( M":9PN!_\^^#P[?[1>\+Z._GMX/3_#8_?P=\WM'S?IYMB7U4*5/?D3$6WVB:5 MPP;&K(US03:BD]/3TTP(P ;LC('\T9#-<. 2>N#W?\.FQ#EE?YZ G/X+WIL\ M;@LB('Q@Z 5MA+Y+_Q:-V-<2_HR':U))4^4Z4[-1,JGS&F/ZY+F[F "E/HL*?,>1DCS9*6:4 ">]H_B^^#!_(" MHS/,&4A46G)8.\9X"2:!M2O4O/A/$[F%E))F)H/ITNX"O1)HHJR'F>!)4JZ9 MDG).79BFN;!':H(?_B[ UGVGQK[^L?YF-4)YJ"E.\]0!X%FJ\O5S-4*T-]B0 M,'!Q]#6#8YDFLX1=8^N\:4#X&DM*,$89Q^@^#0/L_IB:CSP/(/'Y%'-AN*%9 MR&D70"*CI,! MPWJF#!@*9H3D':,%RLHOH8SYOD8O&Y\,X8YUS_>&8MSA7_JS+B+4ID-*?L%_ MZXS_HB6J*Z(#*3>DO1FK,TR8%K4!CSNK:!BV7Y(K1YC6BW+A?/D-W^3EX MGR.(/J8R9*F^"$YF^,#7JLC@P[MW>U;X*R^-34BK>:LE,B'YLHX0("LOFCS@ M>P ZP@NN;,T'X;HH^FI&6V?$KFR"+GA<2%HVKUR[N2[>0DBJ/B)8XA$-__9A M=3WXNQ_\W=]>6%!(*YDG6H S\!M?>F#:C."C^#[$T$^&;$!=Z[34Y$8VJ4;" M:>XQXH6V3FC2$Q2E[)F8%*F=EF$ MGBUE_OM^D*FZFN8%#--1+9T@1S=R@FY&;UL\D%86R_[M:[+ZZ84D*[N*U76F MA"L;#BXIQ":?A,:O3=86:H:D[/I6ER692\POHR51QL]7L&OZ681HV22ID\Y) M28E@I6%N+/X+YIX#G<10CYF//QE/$[AD'KYBP+[,X@V'_1_DPQ!V1IE*7-P R4%9WF[7;%1&-+O:=G(YS]&#P!& M]F ],&=#/ 3D,"@%OY2HDI+&5UA8T];/W5'$F_P/FY9B2Q@BNCXPC0F:.Y%8EI5<$( 2<@/YI%$HVLF_62DX9YU M^Q0_!N$I,0VE>(DJ;/6_YM-:\ZG^+AJ@M$VYRB3-<=.:B*\0&ZT]U1-0C6;4 M(L'I[LOVP.9C+?$=7?XVH;LFUEG"L*J&0W/*S_(6[(HOW7S?]I&^;&4'Y#.; MDNK81)"F;@)]"-*=F-4UIM8(3DD[H^MS^$,*ZG?CDEMA*7[M$%IO^ P+!B4T M18? @FB:::S"_406!,^N%2V3=+4+$PISMH;DHO6'S+YF-*PW$K8H]/65(U]A M7Y3K"G$M&]9H"#83U>"ZL*XXMC7$7"V$0A5>C_ A293BM#F=%W2!<9V&!C#( M"_W(.>@%01K41Q7]BGM^2D/N+[Y6ZXJSD[DD@JMB\A'("Y,;61*Y6\PYSJ)4['>^\:-EA:45DH9W##.D M@?JD.;,W,&5QG@Z'"YSEV4:G$E"9WE)(HVD^2:+2^;=B3)@&HBA:=3"VY'Y, MF>GHX.W2U#G1IE"\$"$"!>;9F(4121L&6S;BRR_"+K&<%I\ -XT:2:Q]V=# M,*W'&V!Q"A*25QJ?WQ135LVC"&/REW%NF/X+2.8LW$OQ[A%ETY"]X -7",GF M<[U F62QJ @[W8[H^;\:V"5X \W@)IK1?0\,L?"H9O8P:FI+-F+>$PR("1?Y8$+? ].(VAJQ;J(1YWF14F\75 7*;L@7IO-Z"?QXO^NU MZGN!:X;3&D1YQ;B:+T=O2*FX1BRK8[>V@UIFFLN] <:RIUB1PX] 4T'B1!U5 M6K34D9ZJ=/SU8V?MJF$O]FADRS<(T_>X;18&['\EA_^Q=?BS""J,$&N?X^W+ M][&4IN)6V<%O"#!DDZ[P03WR$^F_;^*7^.PLG)S7CK-48U!0*,J39*)IH2W# MBS?\2&(IQCZ.>[G#A-I+55UJ+UY$BC!J)$D6&QZ@3DRBUJBB0)05"C'*9C8W M+,KG%Y;6O4F1!%L27/G[:_W@K_FN_35W5T]LMC/SK'2P*6SY;"M5P$*8>6VN MB+4X!B/6 'S=.OC01>(\+FWW:!B &5 *BG;G3EM"A[\VF5^: MX[#@;. W+KQX5<#HJF-Q#]>+E\X6,>>%!9@+ MV6AUWBD&-B4J!R*=E_R$&3ZZ-3\!4$\*07#J8+F3MZC8#.9 E'SG%N"MR3*V"[?1& M]VHA_G[38!MAO648K--IN[=5%S+N#8(P3FV(BHJH9LV Q@#5@11F]FYGY^G& M]N[SC6WQXOZYB9+@W6:PL[.QO;7Q=)>^MY^?;9G5D*> 0)EA1 ?A'_-8.N1Q MT]K[Q637I:V/[(HT$% K!+-V/7RU[X"&!1IB$"'^#SDJ,((;S& W:(0*'^)M GRNN#FP MM7!*?"Y=A_N!@SY^%?,_99#R'Q-5?T8T1MRF@K\*8GAW>!A,7[X *C+;)=]@ MS B45/Y$[N&AI8FET,C(M6ESO,*FV@;1D M^=&L79I%8F."/;"'=6*\(3>^M,<^T3N6R5CA? M&!+ZX9!<2W6#M[1;-V@X9&L_Z4$GIP?M)NE,LCI+&=X29,<.SA@4PRCRBR"G M0W84T3@*@E$11G$.P=$H^A@XUM2J=S;:U!R.G1*%NX!F_V08>J-X:28K9&:1 M!+Z_X[2J65I(8>Q^RMIWKYV;!\X,?#8NY3@721N2TYFNEW/)I4H&?GM-FA6W MH"7R.MF[PA(TN8 5N90E%7O[F@KM:E!8=(H:OX#%9.&UXJJ#/+)^. I8AQ"$ M_LZD1<$@EXH:E"*I! /5:#G9V8>WYR?G5R0,OX^D/X9/E398U'\]BF%/%$ZV M.P@._*30(^M=CZ2F. M;X7SA.<1A#;.$ZF-%&2:H^T96&!.7I@%D-W!. S]R27,49LFYO9#,'E)4)-& M8=Y1(5M>F@\:!%JI$KIAQC*D6EMH7H4T%C%O1$9FP.7*NK&D6J$FKTJ+/*>" MO -FGYQ,:ZM7:G)6*;D$/ZRR[8R_/S%]^WOQ=VR=M6EUT680 MJZ#Y[\5;#S[PHE'<#WZ\]>"CS>"/MAY\X!V&_>"C8.O!1U[L]^=\]*@1Y!\S M/]Z0-M&0_%8K^F'27$J-;2]4P&U3O(4'L^?:<":-D67BWYO0F9:\,IM--K&X M<9"]NW=C]4$[SG\%4$L#!!0 ( +2 H5A/P69HP@@ #M1 ; 97AH M:6)I=#,Q,2UC96\S,#)Q,3(P,C0N:'1M[5Q;;QNW$G[OKV!E-!= DG6Q%%MV M#.3BX/@A+9H::-\*:G?68LU=;DFN9)U?WQER9=W6MI38T0I9 U&TXI S')+? M7$CNVEN!?_9,:*:/KL_3@JZ$?M_,5!N]\Z+9.<1?JNG7^X^')U^>GRP[NK MR]]^_:-,\NZ+7HOEO*RSSR(8<9#L4Y-]YB.5P+3. M D%+,C;E\<]([WH"=L M$Q$#Q#C0**'E0PDS@J'2N'P;**GDJ8'![,MI*$PJ^70@$L?/53J-N;Y&1!LJ M:U4\(#0;D[8"+G,FCI\OSH'NI-WL]_N$=18!SH8SQCD,-AT,'MIPO:S3[/6/ M[RUM-=OWECW4:K?9:?6?O-635O.DLUFSATX/7A>H;9/RY&VM6YM52'D8HAT; M=-);UD8%KT^R-9VK]/GFG6MQ("RR"AZ>B*V.QX(] X+H5D0C0E=%I;G01ETY.EU2=SZI9!^_@ M(24OH7BFY7J6$#VDYA8IN?84 WH/HT>&.R_&,=Q4R$<6V$;2/,RN)%-OR[79 M>;JU^8Q#61+=/JC)]]S@8L;5&4_93:(F$L)KJ/O5K?V:#A6R2Q1&)]@:%PGC MR91EB=49F5Z,5USH@NNY '$01"8YR#9 E69\YI9Y,1^C_,9/0QKS\!#7DCU(%8 M&(D!$<56$V%'V$&30N $I'93%$W17,+10:4,IXMJ^ XXM3T^E'7F5R"VP=+K M5B#VW" &+!()P@0ASAP6ZHA@2([%>J%<)!%Z+LXGP>^!S$)L$Z%G 0/J"%N" MO)T4D8- C\!0RCFJY8!B5E@C<(:"&JX312:1 *%,(=XX=L;)$W S8I%4$S/# M.0W7PEC-D1&G'[W<*&5] :[,3)@U:2O$JA#K:1'K:'/$^L$1Z6II^;XT.=KD M"1ER0%2$@1#^1$OZDG$-#CP0# 2E-'"1,S"4J1!F1.1$%J/S10X8/8?"!%*9 M#.N16Z9Q(!Q-JE4 (?YLV"L$C1 0A3PR7-P&(YY< WN''L^73(+)H[0N;[1[ MK^"UJ]_NA?[)/PI*M"0>PH@)(]]H =D\TI! VW&+EKA%R(UZO IZ2$%!YW+J MJH1 5DHN^P2'WT>S![0#F_I!<_5[9]=CF%]\%, M? 2# B!BNL#U<4RO4TP=\,QL7H6"VR$@-.>-H>!#(86=4KZFB"T98F>EG 'R M-G2)="%3[0*^V[Q#::93-(#&Y9>" ?>">!RUM>0@.82[2"60$H&EDBRQ'I; MAX98I"[TJ:U< 0,$>6+O*BCRBQHLQEYF++PAB(8H@L&*,X&@*\NWX1DP]E.A[. X'4P M.T5!#"K$KQ"_0OQ5L @KQ-]_Q/_H(74=FND\2K[;X$I6D'^+.(%27RH(,DW0 MNY!G6FHO5L;B+W0(%5LQJ!KVKS\'QUZM$4=H-]!K7Z'+Q0P0S=W!&3I3DV1W MLKSVDHRXN4O$D;_O[ R$+A!RO<^#E"F3X@9D?HIFA;[^#0JIK,K]7*J]ZG+O M5?>JO>IGVJMVYX##&1C7YSXIN+:>=:A0)E<]5<(GNAC&_+A\7_:W9BA//R;"139X7J6!.YH MSNMJ\[GRJBNO>B\VGRNO^BO4^$Y*1GEQNI=!AV[H# ]=U,!_)C]UE&\%3X#? M4(K#YZ5=DL-EU-TY[]E9QJV0/M^U]8>?"IQ9'F)% W>^;(%5R#/P2*SI'B>: M(Y=A,:;.3!;'7*,J7#?R6*'PO&?EY^X+SG^;UUT.W_^'LQ/[L+M\CJ@.+H) N^!NW>0&I.ZS&B(9*SD&2FTD_#J_/*3SH /B5*HI8.ED MI'RDP9?,$YJ3;\SR--=!_M!="=[FH$'!.PY*=549QZ39\N]EV/:N[3RYLN]G;4 4[2>H4F1D_J7:5\$7@ M6 ^_RVZ9=ZJRSWS*VG7W@IC-E?9]DH,[US/NIT0\C 1&[ MN(4@H^-G[#>_3;=%?+OR/K]4&7=-?>!O^HQA[0U_\S%R@].:5^%#U&5F[Z]2 M%!3?$THO??J7%QZZER;^!U!+ P04 " "T@*%8[Q;P.LX( =40 &P M &5X:&EB:70S,3(M8V9O,S R<3$R,#(T+FAT;>U<;7/B.!+^?K]"1VKGI0J( M(4 F)).J>2(=ROWV[)! (D@4PR@1I3%8*M MEKK5EIY^D>23H'+ZMY._-QKLLXZ+#)1CL0'N(&&%%>J2_9& O6*- M1DGU2><3(RZ'CK6C=H?]HR8G YU,3D\2,6(B M>5\3@VX[/NBVTVYT$'72=X>\%Q]THKA[=)"VNYTT_6^KAE61/-2Q;B+A?2T3 MJC$$XM_OM)N'W=P=CT7BAOU6%/U4\Z2G)ZE6#OD9K!]^AF:6&G-P[1IOZY8KV[!@1!H( MK?@_H$PHGK\%.:-4O5 *&J&JG9__YQ_G' M\PMVT&JV;_=E=2_^5U@GTLFS]Z.SHA^UTU=[K5YTO$URKM)W[?33V=>+\R_G MGSY7R@N$>NHU>SU>@1:#N5TR91QB6=-CV?[+EDN M:S>[O7=WED;-UIUE][5ZT&Q'O2=O]2AJ'K77:W;?ZR'H K5MUPYJTPHY M3Q(T2/UV?LU:J.#EX;*DW M)4-OP[G9?KJY^8R/Z\F/W*+DQEG9S9A5TJ/)2274 ^SVX0YG6ADIS2& M&=@:%XIQ-6&%<#G1+! IBL):; M"9%D_ J0[UR;%N\E* RRE#Z 01Y$$ N# 0N2*:S.O/?-QD,1#YDMZ&M6?PP& MRD:H YFP$B,;"I+&P@VQ@S:'V M([>8HFJ:QA$\'E3*8S*OA.^#4YOBPK2._ M K$UIMY!!6+/#6+ 4H$Q34R(,X.%.B(8DF.QF2L7*D7/Q?LD^#N618)M(O3, M84 =84N0MY,C%K$ZZR/6#XY(%[>F M[VM;HDV96B$'1*<8".$MFM+GC!OPX(%@("BE@9.<@:5,A;!#(B>R#)TO0X&W+WB!H)( H%)#A[#H>AMA#(MI+++L'A]]'L"N"@YE:CQ@OE:S=$9/YV.B]> N7"E)[_7EB_ M>N#V-ZG6+JF!=V_2H4W X H;GD%,)E72!X%NA!CH3U M?BE2@?+M4-I_YM'.>\4&)/=87\;+,ZBNEQXS%0KT;E$6_U#\JJ0M!E8D@AM! M'1 AJO=^NJ*6"DN1MK>/UH?EWHO5%AAE"YVOE'-Z8(7DY'QCM[P0LX@=:X3X M?SYM@;\&0(3H'V-]2+;>']Y*+I49^0',R&#+S,@.+*!&=RWT5D9O(Z.W=H2Q M9/O6CTW6-H%H-D[#K 6M769$'U'@VXK+P\05!+*0IQ$Z, M$!SMBOSY:[M.I!0N5R?3O;G BACEV)"R'^C"WD#R]"LL%T MI<-;0 @ZF.ZB( 85XE>(7R'^(E@D%>+O/N)_#I"Z#,VT'Z5<;? E"\B_09Q MJ2\=QX4AZ)W+,]UJ+]/6X1W:A(JM6%0-^S/L@V-OEHA3M!OHM2_0E6+&B.9^ MXPSMJ5'%C2QO@R1#;F\2<>3O>SL#B0^$?._+(&7"I+@"6>ZB6:"O?X-"*JMR M-Y=JK7J[UZJ[U5KU,ZU5^WW R12,ZS.?E%SD>7"I;6%U H7B3" M:6-OLBK^!C:69<(Y@)5._T!SXSWK1*!,OOH;!$_TL2WY\/B?5C>F* ]_%@)% M]KA>J-AOS7E;+3Y77G7E5>_$XG/E53]"C1^D9)07IW,9M.F&]O#000W\L^6N MHW(I> S\BE(<(2_MDQP^H^[W>4_W,FZ$].6J;=C\M,*9Y0E6M'#CRZZP"F4& M'HD-']&&2NLW.]9^;F[@O/?YG5OA^__P]F)75A= MWNJ ;R?LB)JPU*!37D=4!Q]!H%WPIVY* U(/60VA1EJ.@%(;BE^6AX=,&71 MEDL] 2P=#W6(-/@M\X3FY!NS/,UED-_W1X*?]X#S=SZJ?-0\C X?=52YUXS6 M//[[G9J]KZS=;'6>7MA.U.QVVD\N;*O9[=W-=(.#U<]C9CQ$+0ZM,*I>*N.+ MR+$P?K=!X+OPQKY<6W]^O1^. (U@ MZ1U^LZ?G'ULTJ\('J.7"W5UE@]>!W?H.KR?<]Z]%_ M02P,$% @ M("A M6)51&@V\!0 K2H !L !E>&AI8FET,S(Q+6-E;SDP-G$Q,C R-"YH=&WM M6NUOVC@8_WY_A8]J72=!FI! >1L2951#NI:MT-ONT\G$#O$MB3/;:7WXQZ80JCKJ=D&+2_:WS>Z6"WG _BVFBD"\H5I2@ M3+)DACX0*C^A2J58U>?I7+!9J%#5KGKH Q>?V#G.Z8JIB'87?#K[^75GWPCI M3#F9=SN$G2-&7I=8;4IJ>.HX5:?>\&SB8X_XCMMLNE/LPO7T;Z<$6V%YOD>J M>41?EV*65$*JY;>\JG502U7[@A$5MAS;?E$R2[N=@"<*Y G8GW_-V=QBINBE MJN"(S9*6,:F4;UV0?1YQT=JQS:NM*94 QRR:MUY.6$PE.J$7Z)3'.'E9ECB1 M%4D%"_*%DOU+02=0SUQ>Y"H? )^()71A@E.U7[2-%H3Z7&#%>-+*$D*%7E7J M#CZ^'1X.)\BM6LY-6^ZVXI],*A;,']T.[PX[2MW=':=NM[=Z/DQ>E+K]P>ED M>#3L]R;#T0D:':'^V^'@" T^#OIGD^&? _@)J(-3].[L='S6.YF@R0@Y#71F MC:V^M?GVC0=]8YGCUFS4&Z/>F]&[R>#-#7,6:YIV77M@\G;P!.SJG1[V3@;C MRNCC'X._4*\_T:I7;;OZ_;K?T<8VL:2&"?)YDE!?=S!TP52(5$C1^PP+!